Veterinary drug residues. Residues in food producing
animals and their products: Reference materials and methods. Second edition. EUR 15127 EN by Heitzman, R.J.
Directorate 
General 
for Agriculture 
EC Brussels 
Published on behalf of 
Commission of the European Communities 
VETERINARY 
DRUG 
RESIDUES 
Residues in food producing 
animals and their products: 
Reference Materials and Methods 
Second Edition 
Edited by R.J.Heitzman 
REPORT 
Eur 15127-EN 
Measurements and 
Testing (BCR) 
Directorate General 
Science, Research and 
Development 
EC Brussels 
BLACKWELL  SCIENTIFIC  PUBLICATIONS 3§1. 779 
Published on behalf of 
•***• 
*  * 
Commission of the European Communities 
*•••* 
VETERINARY DRUG RESIDUES  -
Residues in food producing animals and their products: 
Reference Materials and Methods. 
/ 
Second Edition 
Edited by 
R.J.I-Jeitzman 
1, Churn Road 
Compton 
Newbury 
Berkshire RG 16 OPP 
United Kingdom 
Contract Numbers  5464/1/5/272/91/04-BCR-UK(10) & 5326/1/5/272/90/3-BCR-UK(10) 
Final Report 
Measurements and Testing Programme (BCR) 
Directorate General for Science, Research and Development 
Directorate for Agriculture. 
OXFORD 
BLACKWELL SCIENTIFIC PUBLICATIONS 
LONDON  EDINBURGH  BOSTON 
MELBOURNE  PARIS  BERLIN  VIENNA 
1994  EUR 15127-EN 
<26'6:. : YJ / r 5 Published on behalf of the 
COMMISSION OF THE EUROPEAN COMMUNITIES 
Directorate General 
Telecommunications, Information Industries and Innovation 
L-2920 Luxembourg 
by 
Blackwell Scientific Publications 
Osney Mead, Oxford OX2 OEL 
Publication no. EUR 15127-EN of the 
Commission of the European Communities, 
Dissemination of Scientific and Technical Knowledge Unit 
Directorate-General Information Technologies and Industries 
and Telecommunications, 
Luxembourg 
© ECSC-EEC-EAEC, Brussels-Luxembourg, 1994 
LEGAL NOTICE 
Neither the Commission of the European Communities nor any person acting 
on behalf of the Commission is responsible for the use which might be made 
of the following information. 
All rights reserved. No part of this publication may be reproduced, stored 
in a retrieval system, or transmitted, in any form or by any means, 
electronic, mechanical, photocopying, recording or otherwise without 
prior permission of the publisher. 
Cataloging in Publication Data can be found at the end of the publication. 
First edition published 1992 
Second edition published 1994 
Luxembourg: Office for Official Publications of the European Communities 1994 
ISBN 0-632-03786-5 
ECSC-EEC-EAEC, Brussels- Luxembourg, 1994 
Printed in Great Britain by 
the University Press, Cambridge PREFACE 
Food  quality,  especially public  concern  about  residues  in  meat,  is one  of 
the  important  issues  in  Europe.  This  is the first revision  of  a  book  whose 
purpose  is to bring  together  and  update  the  activities  in  residues  of 
veterinary drugs  within  the  Community.  The  increasing  vigilance  and 
control  of  residues  of  veterinary drugs  in  farm  animals  and  their primary 
products  relies on  effective control  of  residues.  This  is only  made 
possible  by  having  adequate  technical  resources  to  carry out  relevant 
legislation.  The  analytical  methodology  used  must  have  an  acceptable 
quality assurance  supported  by  good  quality control  criteria,  sufficient 
reference materials  and  technical  data. 
This  book  addresses  each  of  these  needs  in  detail.  There  is a  summary  of 
relevant  EEC  legislation  including  a section  on  Maximum  Residue  Limits 
(MRLs).  The  methods  used  in  each  Member  State for  the  examination  of 
residues  of  a  large  number  of  drugs  is summarised  and  a selection of  the 
methods  are  described  in  detail.  There  is supporting  information  on 
residues  and  chemical/physical  data  of  the  most  important  veterinary drugs. 
Also  one  section of  the  book  covers  quality assurance  and  gives  the 
criteria for  the  methods  to  be  used  in  routine analysis  of  residues. 
The  project to  produce  this  book  was  supported  by  funds  from  the 
Directorate General  for  Science,  Research  and  Development  (Measurements  and 
Testing  Programme,  BCR)  and  from  the  Directorate General  for  Agriculture 
(Division  of  Veterinary  and  Animal  Husbandry  Legislation  and  the  Division 
for  the  Coordination  of  Agricultural  Research). 
The  Commission  wishes  to  thank  all  those  who  contributed  to the  successful 
completion  of  this book  and  in  particular the  editor,  Doctor  R.J.Heitzman. RESIDUES  IN  FOOD-PRODUCING  ANIMALS  AND  THEIR  PRODUCTS: 
REFERENCE  MATERIALS  AND  METHODS. 
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[Note:  The  pages  are  numbered  separately for  each  section,  e.g.  section  3 
page  5 is  3/5.  The  analytical  methods  in  section  6 are  numbered  separately 
for  each  method,  e.g.  page  3 of  routine  method  Cy  1.2  is  Cy  1.2/3.] SECTION  6.  ROUTINE  METHODS  FOR  DETECTING  RESIDUES. 
THE  METHODS  CHOSEN  FOR  INCLUSION  IN  THIS  MANUAL  ARE  A SELECTION  OF  METHODS 
USED  IN  VARIOUS  MEMBER  STATES.  THEY  DO  NOT  HAVE  OFFICIAL  STATUS  FROM  THE 
EUROPEAN  COMMISSION  AND  AT  THIS  STAGE  CANNOT  BE  TREATED  AS  OFFICIAL 
COMMUNITY  REFERENCE  METHODS. 
SCREENING  METHODS  (Sg) 
Sg  1.0 
Sg  1.1 
Sg  1.2 
Sg  1.3 
Sg  1.4 
Sg  2.0 
Sg  2.1 
Sg  2.2 
Sg  2.3 
Sg  2.4. 
Sg  3.0 
Sg  3.1. 
Sg  3.2. 
Sg  3.3. 
Sg  3.4. 
Sg  3.5. 
Sg  3.6. 
METHODS  FOR  ANABOLICS 
Anabolics  - A routine method  for  the  determination  of  residues 
of  anabolics  in  perirenal  fat using  HPLC-HPTLC.  [Origin, 
Belgium] 
Anabolics  - a routine method  for  the  detection of  residues of 
anabolics  in  bovine  urine  using  GC-MS  in  the  electron  impact 
mode.  [Origin,  France] 
Diethylstilboestrol  - method  for  the  detection of  residues  of 
diethylstilboestrol  in  bovine  urine  using  radioimmunoassay 
(RIA).  [Origin,  Ireland]  · 
Thyreostats  - method  for  the  measurement  of  residues  of 
thyreostatic substances  in  animals  and  animal  tissues on  the 
basis  of  high  performance  thin  layer  chromatography  (HPTLC). 
[Origin,  Belgium] 
METHODS  FOR  B-AGONISTS 
B-agonists  - a  screening  method  for  the  detection of  B-agonists 
in  bovine  urine  by  GC-MS  in  the  electron  impact  mode  for  the 
trimethylsilyl  derivatives.  [Origin,  France] 
B-agonists  - An  ELISA  screening  method  using  a commercially 
available kit for  the  detection of  B-agonists  in  bovine  urine. 
[Origin,  Italy] 
B-agonists  - an  EIA  screening  method  for  the  detection  of  B-
agonists  in  bovine  urine.  [Origin  Belgium] 
B-agonists  - a screening  method  for  the  detection of  B-agonists 
in  bovine  liver,  kidney  and  meat  by  GC-MS  in  the  electron 
impact  mode  for  the  trimethylsilyl  derivatives.  [Origin, 
France] 
METHODS  FOR  ANTIBIOTICS 
Antibacterial  substances.  A screening  method  for  the  detection 
of  antibacterial  substances  in  fresh  meat  using  a modified  four 
plate test.  [Origin,  France] 
Sulphonamides  - Screening  method  using  HPTLC  for  the  detection 
of  sulphonamides  and  dapsone  in  the  meat  of  farm  animals. 
[Origin  - the  Netherlands] 
Chloramphenicol  - RIA  screening method  for  the  detection of 
chloramphenicol  in  meat,  milk  and  eggs.  [Origin,  Germany] 
Nitroimidazoles  and  Nitrofurans  - Analysis  with  dialysis  and 
on-line  HPLC  for  determining  residues  of  nitroimidazoles  and 
nitrofurans  in  poultry  (chickens,  ducks  and  turkeys)  meat. 
[Origin,  The  Netherlands] 
Ciprofloxacin  and  Enrofloxacin  - Routine  screening  method  for 
the  determination  by  HPLC  after cation-exchange  column 
chromatography  in  pig  muscle,  bacon  and  bovine  muscle.  [Origin, 
UK] 
Gentamicin  and  Neomycin  - routine  screening method  for  the 
determination  by  HPLC  in  muscle  of  cattle,  sheep  and  pigs  and 
in  muscle,  liver,  kidney  and  fat of  veal  calves.  [Origin, 
France] Sg  4.0 
Sg  4.1. 
Sg  4.2. 
Sg  4.3 
Sg  4.4 
Sg  4.5 
METHODS  FOR  OTHER  SUBSTANCES. 
Tranquillizers  -An  HPLC  method  with  on-line  UV  spectrum 
identification  by  diode-array for  residues  in  pig  kidneys. 
[Origin,  The  Netherlands] 
Carbadox  as  QCA  - routine  screening  method  for  the 
determination  by  HPLC  of  quinoxaline  carboxylic  acid  (QCA)  in 
pig  kidney  tissue.  [Origin,  UK] 
Carbadox  as  Oesoxycarbadox  - routine  screening method  for the 
determination  by  HPLC  of  Carbadox  and  Desoxycarbadox  in  pig 
meat,  liver and  kidney  tissue.  [Origin,  The  Netherlands] 
Ionophores  - a  routine method  for  the determination  of  residues 
of  ionophores  in  chicken  meat,  liver and  kidney  using  HPTLC. 
[Origin,  The  Netherlands] 
Levamisole  - a  routine method  for  the  determination  of residues 
of  levamisole  in  liver tissue by  GC-MS.  [Origin,  UK] 
CONFIRMING  METHODS  (Cy) 
Cy  1.0 
Cy  1.1. 
Cy  1.2. 
Cy  1.3. 
Cy  1.4. 
Cy  1.5. 
Cy  1.6  * 
Cy  1.7 * 
Cy  1.8. 
Cy  1.9. 
Cy  2.0 
Cy  2.1 
Cy  2.2. 
Cy  2.3. 
METHODS  FOR  ANABOLIC  AGENTS. 
Anabolic  Agents  - A modular  method  for  the  analysis of 
biological  materials for  residues  of  anabolic  agents.  [Origin; 
The  Nether lands  and  Italy] 
Anabolic  Agents  - A multi-residue method  for determining 
residues  of  anabolic  agents  in  animal  tissues.  [Origin; 
Germany] 
Stilbenes - Confirmation  of  stilbenes  in  bile by  gas 
chromatography-mass  spectrometry.  [Origin;  UK] 
Trenbolone  - Confirmation  of  trenbolone  in  bile by  gas 
chromatography-mass  spectrometry  [Origin;  UK] 
Zeranol  - Confirmation  of  zeranol  in  bile by  gas 
chromatography-mass  spectrometry.  [Origin;  UK] 
Zeranol  - Method  for measurement  of  residues  of zeranol  in 
animals  and  animal  tissues using  HPLC/radioimmunoassay  (RIA). 
[Origin;  The  Netherlands  and  UK] 
Stilbenes - Method  for  the measurement  of  residues  of the 
stilbenes,  diethylstilboestrol,  hexoestrol  and  dienoestrol  in 
animals  and  animal  tissues on  the  basis of  HPLC/RIA.  [Origin; 
The  Netherlands  and  UK] 
Ethinyloestradiol  - Method  for  the measurement  of  residues  of 
ethinyloestradiol  in  cattle urine  by  GC-MS  [Origin;  Belgium] 
Thyreostats  - method  for  the measurement  of residues  of 
thyreostatic substances  in  animals  and  animal  tissues  on  the 
basis of  high  performance  thin  layer chromatography  and  gas 
chromatography  - mass  spectrometry  (GC-MS).  [Origin,  Belgium] 
METHODS  FOR  8-AGONISTS 
B-agonists  - a  method  for  the  detection  and  identification of 
B-agonists  in  biological  samples  and  animal  feed.[Origin;  The 
Netherlands] 
Clenbuterol  - Determination  of  clenbuterol  at residue  levels  in 
bovine  plasma  and  tissues  by  GC-MS.  [Origin;  France] 
B-Agonists  - a  method  for  confirming  the detection of  B-
agonists  in  bovine  urine  by  GC-MS  in  the  positive chemical 
ionisation mode  for  the  trimethylsilyl  derivatives.  [Origin, 
*  France] 
[Note;  The  use  of spectroscopic methods  for the  confirmation  of the 
stilbenes and  zeranol  is preferred]. Cy  3.0 
Cy  3.1. 
Cy  3.2 
Cy  3.3. 
Cy  3.4. 
Cy  3.5. 
Cy  3.6. 
Cy  3.7. 
Cy  3.8. 
Cy  3.9. 
Cy  4.0 
Cy  4.1. 
Cy  4.2. 
Cy  4.3. 
Cy  4.4. 
Cy  4.5. 
Cy  4.6. 
METHODS  FOR  ANTIBIOTICS 
Sulphonamides  - Confirmation  of  sulphonamides  by  GC-MS. 
[Origin;  UK] 
Sulphadimidine.  Determination  of sulphadimidine  in  pig  kidney 
and  diaphragm  muscle  tissue by  high  performance  liquid 
chromatography.  [Origin  UK-NI] 
Sulphadimidine  - HPLC  analysis of  sulphadimidine  in  porcine 
kidney.  [Origin;  UK] 
Sulphadimidine.  Determination  of  sulphadimidine  in  reference 
material  and  fresh  tissues  by  high  performance  liquid 
chromatography.  [Origin  UK-NI] 
Chloramphenicol  - Confirmation  of  chloramphenicol  in  meat, 
eggs,  milk  and  urine  by  GC-MS.  [Origin;  The  Netherlands] 
Chloramphenicol  - Confirmation  of  chloramphenicol  in  meat  by 
GC-MS  [Origin;  Germany] 
Chloramphenicol  - HPLC  analysis of  chloramphenicol  in  milk. 
[Origin;  France] 
Tetracyclines  - Determination  by  HPLC  of  tetracyclines at 
residue  levels  in  animal  tissues.  [Origin;  UK] 
Nitrofurans  - HPLC  combined  with  dialysis for  determining 
residues of  nitrofurans  in  eggs,  milk  and  meat.  [Origin;  The 
Netherlands] 
METHODS  FOR  OTHER  SUBSTANCES. 
Benzimidazoles  - Determination  by  HPLC  of  Benzimidazole  type 
anthelmintics at residue  levels  in  animal  tissues  and  milk. 
[Origin;  UK] 
Lasalocid  - Determination  by  HPLC  of  Lasalocid  at residue 
levels  in  poultry muscle  and  eggs.  [Origin;  UK] 
Carbadox  - Determination  by  GC-MS  of  quinoxaline  carboxylic 
acid  (QCA)  at residue  levels  in  kidney  tissue.  [Origin;  UK] 
Ivermectin  - Determination  by  HPLC  of  Ivermectin  at residue 
levels  in  animal  tissues.[Origin;  UK] 
Tranquillizers  and  carazolol  -an HPLC  method  with  on-line  UV 
spectrum  identification and  off-line TLC  confirmation for 
residues  in  pig  kidneys.  [Origin;  The  Netherlands] 
Tranquillizers  - Identification using  GC-MS  confirmation  for 
residues of  tranquillizers  in  pig  kidneys.  [Origin;  The 
Netherlands] !.INTRODUCTION 
The  Council  Directive  (86/469/EEC)  concerning  the  examination  of  animals 
and  fresh  meat  for  the  presence  of  residues  requires  that samples  are 
analyzed 
11 in  accordance  with  methods  which  are  applied  by  Member  States  and 
have  been  submitted  to  the  Commission  under  their  inspection  plans...  These 
methods  are  routine methods  of  analysis  for screening  and  confirmation 
purposes.  All  positive findings  must,  if challenged,  be  confirmed  by  a 
laboratory officially approved  for  that purpose  by  the  competent 
authorities,  using  the  reference methods  established pursuant  to Article 
4(1)(b)  of  Directive 64/433/EEC. 
This  manual  brings  together  those  parts of  EEC  legislation concerned  with 
residues,  the  National  Surveillance  programmes  for  residues,  and  the  latest 
progress  and  developments  in  routine methods  and  Reference  Materials  (RMs). 
More  specifically the  purpose  of  the  manual  is to  provide  a reference 
manual  describing  the  methods  and  materials  (standards  and  reference 
materials)  for  use  in  the  identification,  measurement  and  confirmation  of 
residues  in  food  of  animal  origin. 
Analytical  technology  is continually changing  and  progressing.  Thus  in  the 
first edition  in  1991  methods  were  reported  at various  advanced  stages  of 
development  and  with  special  emphasis  on  multi-residue  and  modular  methods. 
In  this edition there  are  more  methods,  including  a  new  section  describing 
a selection of  routine  screening  methods  used  by  Member  States.  The 
routine methods  used  throughout  the  Community  are  summarised  in  table form 
for  each  analyte.  Where  possible  the  routine  methods  are  differentiated as 
screening  or  confirmatory methods. 
For  many  analytes  there  are  excellent confirmatory  methods  used  by  one  or 
more  Member  States which  for  a variety of  reasons  have  not  yet  been  raised 
to  the  status of  Reference  Methods.  Until  such  time  as  a reference  method 
is available a  selection of  these  routine confirming  methods  is detailed. 
Many  of  these methods  are  probable  candidates  for  Reference  Methods. 
This  edition  includes  a section  on  quality assurance  which  complements  the 
criteria for  methods  set out  in  EEC  Decision  93/256  and  reproduced  in 
section  5. 
The  book  is aimed  primarily for  use  in  reference  laboratories or  other 
laboratories  performing  residue  analysis.  Many  international  and  national 
authorities may  also find  the  book  helpful  as  a reference  work  for  problems 
associated with  residues. 
1/1 REFERENCE  METHODS  AND  ROUTINE  CONFIRMING  METHODS. 
The  routine confirming  methods  as  defined  in  EEC  93/256  and  used  by  Member 
States may  in  the  future  be  approved  by  the  Commission  and  given  the  status 
of  Community  Reference  Methods.  Reference  methods  could  be  used  to settle 
disputes  (e.g  between  Member  States)  by  providing  an  approved  analytical 
tool  for  the  means  of  controlling residues  in  food  through  the  specific and 
accurate  determination  of  the  residue  content  in  food.  The  routine 
confirming  methods  when  fully developed  meet  the  criteria in  EEC  93/256 
(see  section 5)  and  are  suitable for 
(i)  being  performed  in  EEC  reference  laboratories. 
(ii)  identifying  unambiguously  an  analyte  (residue) 
(iii)  measuring  the  concentration  of  analytes  accurately. 
REFERENCE  MATERIALS  (RMs). 
The  purpose  of  the  RMs  is the  quality control  of  analytical  methods  by;-
(i)  use  in  development  of  a method 
(ii)  determination  of  accuracy  and  precision 
(iii)  quality assurance 
(iv)  providing  RMs  with  concentrations of  analytes  at or  near  the 
tolerance  limits  (MRL)  set by  the  EEC  or  when  MRL  are  zero  at or 
close to  the  lower  limit of  detection of  the  method. 
(v)  a  standard  for  traceability 
The  RMs  will  be  available commercially  through  the Measurement  and  Testing 
Programme  of  DG12.  Certified  RMs  are  now  available for  the  stilbenes  in 
bovine  urine. 
RMs  are  stable materials of  animal  origin containing  residues  at known 
concentrations.  They  are  prepared  by  collecting samples  (muscle,  liver, 
kidney,  fat,  bile,  urine,  blood  or  faeces)  from  animals  administered 
veterinary drugs  or  other  substances.  The  samples  are  prepared  as 
lyophilised material  which  are  stable and  have  stated residue 
concentrations. 
1/2 2.  RESIDUE  GROUPS;  TESTS  AND  MRLs. 
2.1  ANNEX  I,  DIRECTIVE  86/469/EEC,  lists the  groups  of  residues which  will 
require  tests. 
The  list is:-
A.  GROUPS  COMMON  TO  ALL  MEMBER  STATES. 
Group  I. 
(a)  Stilbenes,  stilbene derivatives,  their salts and  esters. 
(b)  Thyreostatic  substances. 
(c)  Other  substances  with  oestrogenic,  androgenic  or  gestagenic 
action. 
Group  II  Authorised  Substances 
Natural  (endogenous)  hormones. 
Group  III 
(a)  Inhibitors:  Antibiotics,  sulphonamides  and  similar antimicrobial 
substances. 
(b)  Chloramphenicol. 
B.  SPECIFIC  GROUPS. 
Group  1:  Other  medicines. 
(a)  Endo- and  ectoparasitic substances. 
(b)  Tranquillizers  and  beta-blockers. 
(c)  Beta-agonists 
(d)  Other  veterinary medicines. 
Group  II:  Other  residues. 
(a)  Contaminants  present  in  feeding  stuffs. 
(b)  Contaminants  present  in  the  environment. 
(c)  Other  substances 
2/1 2.2.  MAXIMUM  RESIDUE  LIMITS,  (MRL) 
A summary  of  the  MRLs  allocated  by  the  Committee  on  Veterinary Medicinal 
Products  (CVMP)  of  DG3/EEC  and  the  WHO/FAO  Joint Expert  Committee  on  Feed 
Additives  (JECFA)  is given  for  compounds  of  interest  in  table 1.  More 
detailed  information  on  the  MRls  allocated  by  the  CVMP  and  published  as 
Commission  Regulation  (EEC)  ~675/92 is given  in  table 2. 
Table  1;  MRls  allocated  by  CVMP  and  JECFA. 
MRL  in  ~g per  kg  tissue or  fluid 
Group  and  Compound 
Group  A I; 
Dienoestrol  (DEN), 
Diethylstilboestrol  (DES), 
Hexoestrol  (HEX), 
Medroxyprogesterone  acetate 
Methyltestosterone  (MT), 
19-Nortestosterone  (NT), 
Tapazole  (TAP), 
Trenbolone  (TB), 
2-Thiouracil  (2-TU), 
Zerano 1  ( Z) , 
Group  A II; 
17B-Oestradiol  (BE2), 
Progesterone  (P), 
Testosterone  (T), 
Group  A III 
Ampicillin, 
Amoxicillin 
Benzylpenicillin, 
Chloramphenicol  (CAP), 
Chlortetracycline, 
Cloxacillin 
Dicloxacillin 
Dihydrostreptomycin, 
Furazolidone 
Nitrofurans 
Nitrofurazone 
Oxacillin 
Oxytetracyline, 
Sulphadimidine, 
EEC 
ol 
ol 
ol 
0 
0 
01 
0 
ol 
0.043 
? 
io  & 303 
4 &  502 
4 &  502 
4 &  502 
102 
100  to  6002 
30  &  3002 
30  &  300
2 
52 
52 
52 
30  &  3002 
100  to  6002 
1002 
2/2 
JECFA 
0 
0 
0 
2  (BTB,  M)c, 
10  (<lTB,  l)c 
2(M)c,  lO(L)c 
unnecessary 
unnecessary 
unnecessary 
50(M,L,K),  4(Mk) 
not  allocated 
1000  (M),  200  (Mk), 
500  (Eg) 
not  allocated 
not  allocated 
100  (M,Mk),  300  (L) 
600(K),10(F),200  (Eg) 
300  as  total  (M,L,K,F) 
100  as  parent  (M,L,K,F) 
50  as  total  (Mk) 
25  as  parent  (Mk) Group  and  compound 
Sulphaquinoxaline, 
Sulphathiazole 
Tetracycline 
Trimethoprim 
Group  B 
Albendazole, 
Azaperone 
Carazolol, 
Carbadox, 
Chlorpromazine, 
Clenbuterol, 
Closantel 
Cimatero l, 
Dapsone 
Dimetridazole, 
Diminazene 
Febante l, 
Fenbendazole, 
Flubendazole 
Isometamidium 
Ivermectin, 
Ipronidazole, 
Lasalocid, 
Levamisole, 
Metronidazole, 
Monensin, 
Narasin, 
Olaquindox 
Oxfendazole 
Propionylpromazine, 
Ractopamine 
Ronidazole, 
Sa 1  butamo l, 
Salinomycin, 
Spiramycin 
Thiabendazole, 
Triclabendazole 
Tylosin 
MRL  in  ~g per  kg  tissue or  fluid 
EEC  JECFA 
1002 
1002 
100  to  6002 
502 
under  evaluation 
50  &  1002 
5 &  30
2 
$ 
10  or  1000
2 
$ 
10  or  10002 
50(M),  300(L)C,P 
200(K), c ,P 
100(Mk)c 
2/3 
not  allocated 
100  (M,F,Mk)  as  sulphone 
SOOO(L,K) 
not  allocated 
5(F),  30(L,K~C,P 
30  as  QCA(L)  5 as  QCA(M)P 
not  allocated 
1500(M,L),5000(K),  2000(F) 5 
1000(M,L),  3000(K,F)c 
not  allocated 
not  allocated 
100(M,F  K),  500(L)C,P,S 
lOO(Mk)c  N.B. 4 
as  Febantel 
10(M,L)P  200(M),  500(L)PY 
400  (Eggs)c 
100  (M,FcMk),  500(L)  , 
lOOO(K) 
100(L),  40(F)c, 
15(L),  20(F)  other  species 
not  allocated 
10  (all) Temporary 
not  allocated 
not  allocate~ 
as  febantel 
not  allocated 
not  allocated 
not  allocated 
50(M),  300(L)C,P 
200(K), c ,P 
100(Mk)c 
100  (M,L,K,F)C,P,S,G,S 
100(Mk)C,G,S 
200(M),  300(L,K),  100(F)C,G 
100(M,L,K,F)
5
'
6 
not  allocated Specific species  are  indicated  by  superscripts,  C is cattle,  P is Pig.  S 
is sheep,  G is goats. 
Superscript  1  indicates that these  compounds  are  prohibited from  use  in  EC 
Member  States. 
Superscripts  2 and  3 refer to  data  in  tables 2 and  3 respectively. 
Superscript 4 refers to three benzimidazoles  which  have  a group  MRL.  The 
MRL  is the  sum  of  the  concentrations of  fenbendazole,  oxfendazole,  and 
oxfendazole  sulphone,  calculated as  oxfendazole  sulphone  equivalents. 
Superscipt  5,  the  MRL  is  the  sum  of  thiabendazole  and  5-
hydroxythiabendazole. 
Superscript  6,  the  MRL  is expressed  as  the marker  residue,  5-chloro-6-
(2' ,3'-dichlorophenoxy)-benzimidazole-2-one. 
$  indicates  that these  compounds  are  classed as  feed  additives  and  as  such 
are  not  covered  by  EEC  Directives 81/851  and  81/852.  They  are  covered  by 
EC  Directive  70/524. 
Note;  The  JECFA  values  are  those  recommended  to  the  Codex  Alimentarius 
Commission,  they  may  not  yet  be  officially adopted  by  Codex.  "Not 
allocated"  means  there was  insufficient  information  to  allocate an  MRL. 
A full  list of  the  status of  ADI  and  MRL  evaluated  by  JECFA  (32nd-40th 
meetings)  may  be  found  in  the  FAO  Monograph,  Food  and  Nutrition  Paper  41/5, 
Residues  of  some  veterinary drugs  in  animals  and  foods.  (1993). 
2/4 Table  2.  MRLs  recommended  by  the  Committee  for Veterinary Medicinal 
Products  for  residues of  certain active substances  used  in  veterinary 
medicine.  The  MRLs  are  published  in  the  Commission  Regulation~ 675/92 
.. amending  Annexes  I  and  III  of  Council  Regulation  (EEC)  N9  2377/90  laying 
down  a  Community  procedure  for  the  establishment  of  maximum  residue  limits 
of  veterinary medicinal  products  in  foodstuffs  of  animal  origin ... 
Compound 
GROUP  A III 
B-LACTAMS. 
Ampicillin 
Amoxicillin 
Species  MRL(s)  Marker 
J,Lg/kg  Residue 
All 
All 
50 
4 
50 
4 
parent  drug 
parent  drug 
Benzylpenicillin All  50 
4 
parent  drug 
Cloxacillin 
Dicloxacillin 
Oxacillin 
A  11 
All 
All 
300 
30 
300 
30 
300 
30 
Chloramphenicolm  All  10 
Spiramycin 
Sulphonamides 
Tetracyclines 
Trimethoprim 
C,P  300 
C,P  200 
C,P  50 
c  150 
All  100 
C,S,G  100 
All  600 
300 
200 
100 
All  50 
parent  drug 
parent  drug 
parent  drug 
parent  drug 
parent  drug 
parent  drug 
parent  drug 
parent  drug 
parent  drug 
parent  drug 
parent  drug 
parent  drug 
2/5 
Target  food 
Commodity 
Status 
meat,  all  tissues  Final 
milk  Final 
meat,  all  tissues  Final 
milk  Final 
meat,  all  tissues  Final 
milk  Final 
meat,  all  tissues  Final 
milk  Final 
meat,  all  tissues  Final 
milk  Final 
meat,  all  tissues  Final 
milk  Final 
meat,  all  tissues  1.1.94P 
1  iver 
kidney 
muscle 
milk 
meat,  all  tissues 
milk 
kidney 
liver 
eggs 
muse le,  milk 
meat,  all  tissues 
milk 
1.7.95p 
1.7.95p 
1.7.9SP 
1.7.95P 
Final 
1.1.94p 
1.1.94p 
1.1.94p 
1.1.94p 
1.1.94p 
1.1.96p B GROUP 
Azaperone  A  11  100  azaperol  kidney  1.1.96P 
50  azaperol  muscle,  liver  1.1.96p 
kidney 
Carazolol  A  11  30  parent  drug  liver,  kidney  1.7.95P 
5  muscle,  fat  1.7.95p 
Dapsone  A  11  25  parent  drug  meat,  all  tissues,  1.1.94p 
milk 
Dimetridazole  All  10  all  residues  meat,  all  tissues  1.1.94p 
with  intact 
nitro-imidazole  structure 
Febantel
8  A  11  1000  oxfendazole  +  liver  1.7.95p 
10  oxfendazole- muscle,  kidney,  1.7.95P 
sulphone  +  fat,  milk 
fenbendazole 
Fenbendazole
8  A  11  1000  oxfendazole  +  liver  1.7.95p 
10  oxfendazole- muscle,  kidney,  1.7.95p 
sulphone  +  fat,  milk 
fenbendazole 
Ivermectin  C,P,S,H  15  H 2B 1a  Liver  Final 
20  metabolite  fat  Final 
Levamisole  All  10  parent  drug  meat,  all  tissues  1.1.95p 
milk 
Nitrofurans  group  All  5  all  residues  meat,  all  tissues,  1.7.93p 
with  intact  eggs 
5-nitro structure 
Oxfendazole  A  11  1000  oxfendazole  +  liver  1.7.95p 
10  oxfendazole- muscle,  kidney,  1.7.95p 
sulphone  +  fat,  milk 
fenbendazole 
Ronidazole  A  11  2  all  residues  meat,  all  tissues  1.1.94p 
with  intact 
nitro-imidazole  structure 
Superscripts;  a;  The  CVMP  was  agreed  that there  is  no  need  to  establish 
separate ADis  for  febantel  and  fenbendazole  because  these  are metabolised 
into oxfendazole  which  is the  more  toxic metabolite. 
p;  provisional  date. 
m;  no  MRLs  are  allocated for  residues  in  milk  or  eggs  because  the  CVMP 
specifically recommends  that chloramphenicol  not  be  authorised  for  use  in 
lactating animals  or  laying  birds. 
Species  are  C,  cattle;  P,  pigs;  S,  sheep;  G,  goats,  H,  horses. 
2/6 2.3.  Amendments  to Directive 86/469/EEC 
There  are  some  amendments  to  the  National  Plans  for  examinations  for 
residues  provided  for  in  Article 4 of  Directive 86/469/EEC.  They  include; 
2.3.1.  Naturally Occurring  Steroid Residues. 
- Until  the  Scientific Veterinary Committee  makes  its report  on  the 
physiological  levels  of 
11natural
11  sex  hormones  in  plasma  the 
following  provisional  procedures  for  dealing with  the  illegal  use  of 
11natural
11  sex  hormones  for fattening  purposes  in  bovine  animals  for 
the  year  1991  shall  be  adopted. 
If,  in  the  course  of  testing for 
11natural
11  sex  hormones  in  accordance 
with  Directive 86/469/EEC  (live bovine  animals  at the  farm  or at the 
slaughterhouse)  or  in  the  course  of  any  other testing,  levels of 
oestradiol  or  testosterone exceeding  the  level  given  in  the  table 
below,  are  found  in  the  blood  plasma  of  at  least one  bovine  animal, 
the  investigations  and  measures  foreseen  in  Article 6,  paragraphs  1 
,2  and  3 of  Directive 85/358/EEC  should  immediately  be  carried out. 
AGE 
(months) 
free oestradiol-17B  < 6 
~ 18 
free  testosterone-17B  <6 
6  - 18 
~ 18 
Maximum  Plasma  Concentrations 
Male  Bovine  Non-pregnant 
female  bovine 
(~g per  L)  (~g per  L) 
0.04 
10 
30 
0.04 
0.5 
2.3.2.  Xenobiotic  Anabolic  Agents  with  Hormonal  Activity. 
In  order  to  detect the  presence  of  residues  of  stilbenes,  trenbolone 
or  zeranol  in  urine,  bile or  faeces,  a routine method  with  a decision 
limit  less  than  or  equal  to  2 ppb  (~g per  kg  or  L)  shall  be  used. 
- Testing  shall  include  the  substances,  19-nortestosterone, 
melengestrol  acetate,  chlormadinone  acetate and  megestrol  acetate. 
2/7 3.  REFERENCE  LABORATORIES. 
The  Community  has  two  levels  of  Reference  Laboratories.  There  are  four 
Community  Reference  laboratories  (CRL)  and  thirty  six  National  Reference 
Laboratories  (NRL). 
(a)  COMMUNITY  Reference  Laboratories. 
The  role of  the  Community  Reference  Laboratories  is delineated  in  Articles 1 
and  2  of  the  Council  Decision,  89/187/EEC, 
11determining  the  powers  and 
conditions of  operation of  the Community  Reference  Laboratories provided  for 
by  Directive 86/469/EEC  concerning  the examination  of  animals  and  fresh meat 
for the  presence  of  residues". 
The  Community  Reference  Laboratories  are;-
Robert  Von  Osterag  Institut des  Bundesgesundheitsamt 
Diederdorfer  Weg  1 
D-1000  Berlin  48,  Germany 
Istituto Superiore  di  Sanita 
Viale  Regina  Elena  299 
00161  Roma,  Italy 
Rijksinstitut voor  Volksgezondheid  en  Milieuhygiene 
Antonie  van  Leeuwenhoeklaan  9 
NL-3720  BA  Bilthoven,  The  Netherlands 
Laboratoire  des  Medicaments  Veterinaires 
La  Haute  Marche 
Javene 
F-35133  Fougeres,  France 
(b)  NATIONAL  Reference  Laboratories 
(BGA) 
(ISS) 
(RIVM) 
(LMV)-(CNEVA) 
The  list  of  National  Reference  Laboratories  is  given  in  Annex  II  in  the 
Commission  Decision  93/257/EEC  "laying  down  the  reference methods  and  the 
list of  National  Reference  Laboratories for detecting residues  ..  and  revoking 
Decision  89/610/EEC
11  (see  list  below).  A major  difference  from  the  first 
edition of this book  is that laboratories  in  Germany  are regrouped  because  of 
the  unification  of  Germany.  Each  Reference  Laboratory  is  responsible  for 
certain groups  of  compounds  as  described  in  section  2. 
Member  State. Reference Laboratories and  Residue  groups  measured  (in italics) 
Belgium 
Denmark 
Institut d'Hygiene  et d'Epidemiologie 
Rue  J.  Wijtsman,  14 
1050-Brussels  ALL 
Veterinaerdirektoratets Laboratorium 
Odinsvej  4 
Postboke  93 
DK  4100-Ringsted  ALL 
Levnedsmiddelstyrelsens  Centrallabatorium 
Morkhoj  Bygade  19 
DK-2860  Soborg  8 
3/1 Germany 
Greece 
Robert  Von  Osterag  Institut des  Bundesgesundheitsamt 
Diederdorfer  Weg  1 
D-1000  Berlin  48  8-agonists,  CAP,  Sulphonamides 
Landesuntersuchungsamt  fur  das  Gesundheits- und  Veterinarwesen 
InstitUt Chemnitz 
Hohe  StraBe  27/29 
D-9005  Chemnitz  Stilbenes 
Staaliches Medizinal-,  Lebens- Mittel- und  Veterinarsuchungs-
DruselteistraBe  63 
D-3500  Kassel  Trenbolone,  19-Nortestosterone 
Staaliches Medizinal-,  Lebens- Mittel- und  Veterinarsuchungs-
Amt  Mittelmessen 
Marburger  StaB3  54 
D-6300  GieBen  Gestagogenic  substances 
Chemisches  Landesuntersuchungsamstalt  Freiburg 
BifflerstraBe 5 
D-7800  Freiburg  1  Organochlorine  PCBs 
Landesuntersuchungsamt  fur  das  Gesundheitswesen 
Sudbayern 
VeterinarstraBe  2 
D-8042  OberschleiBheim  Natural  Hormones 
Staatliches Veterinarsuchungsamt  Arnsberg 
Zur  Traubeneiche  10/12 
D-5760  Arnsberg  2  Zeranol,  Ethynyloestradiol,  Thyreostats 
Chemische  Landesuntersuchungsanstalt  Stuttgart 
BreidscheidstraBe  4 
D-7000  Stuttgart 1  Nitrofurans 
Chemische  Landesuntersuchungsanstalt  - Karlsruhe 
HoffstraBe  3 
D-7500  Karlsruhe  Avermectin 
Chemische  Landesuntersuchungsanstalt  - Nordrhein-Westphalien 
SperlichstraBe  19 
D-4400  MUnster  Tranquillizers &  8-blockers 
Staatliches Veterinar- und Lebelsmitteluntersuchungsamt- Potsdam 
Pappelallee  2 
D-1572  Potsdam  Heavy  metals 
Staatliches Veterinarsuchungsamt  - Hannover 
Eintrechtweg  17 
D-3000  Hannover  1  Penicillins,  Tetracyclines,  Quinolone 
Institute of  Biochemistry,  Toxicology  and  Nourishment  of Animals 
25,  Neapoleos  Street 
GR-153  10  Aghia  Paraskevi  Athens  AI,a,c; All; AIII,b; Bll,a,b 
3/2 Institute of  Food  Hygiene 
Dept.  Residue  Analysis  Thyreostats,  Antimocrobials 
75,  Iera  Idos,  Botanikos  Parasiticides,  Tranquillizers, 
GR-118  55  Athens  8-blockers,  8-agonists,  PC8s,  8/I,c. 
Spain  Centro  Nacional  de  Alimentacion  Y Nutrition 
c/Pozuelo-Majadahonda  Km  6.2 
France 
Ireland 
28023  - Majadahonda  (Madrid)  AI,a,c; All; AIII,a,b; 8-agonists 
Laboratorio  de  Sanidad  y  Produccion  Animal 
18320  Santa  Fe  (Granada)  AI,b; 8/,a,b,c 
Laboratorio  de  Sanidad  y  Produccion  Animal 
28806  Algete  (Madrid)  Al,b; BI,b 
Laboratorio  Arbitral  del  Ministerio  de  Agricultura,  Pesca  y 
Alimentacion 
Ctra.  de  la  Coruno,  Km  10.7 
28032  Madrid  Pesticides,  Heavy  metals 
Laboratoire  Central  d'Hygiene  Alimentaire 
43,  rue  de  Dantzig 
75015  Paris  8/,a; 8/I,a,b,c 
Laboratoire  des  Medicaments  Veterinaires  (LMV) 
La  Haute  Marche 
Javene 
F-35133  Fougeres,  8/,b,c;  Alll,a,b 
Laboratoire  de  dosages  hormonaux  Ecole  nationale  veterinaire de 
Nantes 
CP  3028 
F-44087  Nantes  Cedex  03  AI;  All 
Central  Meat  Control  Laboratory 
Abbots town 
Castleknock 
Dublin  15  AI,  All,  Alii,  81,  811  (not  pesticides) 
State Laboratory 
Abbots town 
Castleknock 
Dublin  15  AI,  All,  Alii,  81,  811 
Italy  Istituto Superiore  di  Sanita 
Viale  Regina  Elena  299 
Luxembourg 
1-00161  Roma  ALL 
RIVM  Bilthoven  ALL 
Institut d'hygiene  et d'epidemiologie 
Rue  J.  Wijtsman,  14 
1050-Brussels  ALL 
3/3 Netherlands 
Rijksinstitut voor  Volksgezondheid 
en  Milieuhygiene  (RIVM) 
Antonie  van  Leeuwenhoeklaan  9 
NL-3720  Bilthoven  ALL 
Rijkskwaliteitsinstituut voor  Land- en  Tuinbouwprodukten  (RIKILT) 
Bornesteeg  45 
NL-6708  Wageningen  ALL 
Portugal  Laboratorio  Nacional  de  Investigacao 
Veterinaria 
Estrada  de  Benfica  701 
1500  Lisboa  ALL 
United 
Kingdom  Central  Veterinary  Laboratory  (CVL) 
New  Haw 
Addles tone 
Surrey  KT15  3NB  AI,  All,  Alii,  81 
Food  Science  Laboratory 
Colney  Lane 
Norwich  NR4  7UA  Alii,  81,  811 
Veterinary Research  Laboratories  (VRL-NI) 
Stormont 
Belfast  BT4  3SD  AI,a,c;  All,  Alii,  81,  811 
Food  and  Agric.  Chern.  Res.  Division 
Dept.  Agriculture  for  N.I. 
Newforge  Lane, 
Belfast  BT9  5PX  AI,b;  Alii,  81,  811 
3/4 4.0.  ROUTINE  METHODS 
4.1.  The  purpose  of  this section  is to  summarise  the  routine methods  used 
by  the  Member  States of  the  European  Community  for  the  control  of  residues 
in  food-producing  animals  and  their products  in  accordance  with  the 
Directive 86/469. 
The  definitions  and  criteria for  ROUTINE  methods  are  given  in  Section  5 and 
are  in  the  Commission  Decision  93/256/EEC.  Routine  methods  are  used  for 
surveillance or regulatory purposes  and  are  divided  into  two  types. 
1.  SCREENING  METHODS. 
Methods  used  to detect  the  presence  of  an  analyte  (residue)  or  class of 
analytes  at the  level  of  interest.  They  have  a  high  sample  throughput 
capacity and  are  used  to sift large  numbers  of  samples  for  potential 
positives  and  aim  to reduce  the  number  of  false negative  results. 
2.  CONFIRMATORY  METHODS. 
These  methods  are  applied  to  positive samples  identified  in  the  screening 
methods.  They  are methods  which  provide  unequivocal  identification of  the 
analyte at the  level  of  interest.  They  are  aimed  to  prevent  false positive 
results and  an  acceptable  probability of  false negative  results. 
4.2.  A selection of  screening  and  confirmatory methods  are  described  in 
ISO  format  in  this edition  (see  section 6). 
4.3.  For  the first edition,  a  survey of  routine methods  used  throughout 
the  Member  States was  carried out  by  the  Commission  (DGVI)  in  the  period 
May-July  1990  and  updated  during  the  period  April-June,  1991.  In  this 
edition the  survey  covers  the  period  April-August,  1993.  Responses  were 
received  from  the  National  Reference  Laboratories  in  Belgium,  Denmark, 
France,  Germany,  Greece,  Ireland,  Netherlands  and  UK. 
The  results are  summarised  below  giving  the  methods  used  for each  analyte 
or  group  of  analytes.  LLD  in  the  tables  is either the  limit of  detection 
or  the  limit of  determination  and  is that claimed  by  the  member  nation  and 
is not  necessarily as  defined  in  EEC  Directive 89/610.  The  methods  may  not 
have  been  validated  by  another  laboratory. 
The  procedures  for  some  of  the  methods  are  published  in  Section  6 following 
selection  by  the  editor  in  consultation with  the  CRL. 
4/1 STILBENES 
-----Procedures-------- --Sample----
Method  Type  Ext.  Purif.  Det.  Type  Size  LLD  Member 
Sg,Cy  ml  or  g  J..LQ/kg  or/L  State 
TLC  Sg,Cy  Sv  cc  uv  U,M  50  1-5  p 
HPTLC  Sg  no  C18,HPLC  Fl  u  15  2  s 
Sg  Sv  C-Si  uv  U,M(i.s)  2  5  F 
Sg,Cy  Sv  C18,HPLC  UV  U,F  20(U),25(F)  2  B 
Sg  Sv  C18,HPLC  UV  Fe  30  2  B 
HPLC  Sg  Sv  C18  ECD  M  10  1  s 
Cy  Sv  C18,HPLC  RIA  u  0.05-1  0.02-0.05  Gr 
RIA  Sg  Sv  C18  RIA  Bi  0.05  2  UK 
Sg  Sv  C18  RIA  Fe  1.0  2  UK 
Sg  Sv  C18  RIA  u  0.1  2  B 
Sg  Sv  C18  RIA  u  0.05  0.5-1  Gr 
Sg  Sv  C18  RIA  M  1  0.02-0.05  Gr 
Sg  Sv  C18  RIA  u  0.1  2  p 
Sg  Sv  Cl8/HPLC  RIA  Fe  1  2  B 
Sg  Sv  no  RIA  Se  0.5  0.05  UK 
Sg  Sv  no  RIA  u  0.1  2  UK 
Sg  Sv  no  RIA  Fe  1.0  2  D 
Sg  Sv  no  RIA  u  0.05  2  It 
Sg  Sv  no  RIA  u  0.2  0.5  Ir 
Sg  Sv  no  RIA  u  0.5  1  F 
Sg  Sv  no  RIA  u  0.5  0.4  UK-NI 
Sg  Sv  no  RIA  M  1  0.2  UK-NI 
Sg  Sv  Sv  RIA  M  1.0  0.3  It 
EIA  Sg  no  Cl8  EIA  u  0.5  0.2  G 
GC-MS  Sg,Cy  Sv  C18,HPLC  MS  u  10  1  s 
Cy  Sv  C18  MS  u  10  1  G 
Sg  Sv  C18,HPLC  MS  Fe  30  2  B 
Sg  Sv  C18,HPLC  MS  u  10  1  It 
Cy  IAC  HPLC  MS  u  10  0.1  NL* 
Cy  Sv  lAC  MS  M  5  0.1  NL* 
Sg,Cy  no  C18,C-Si  MS  U,L,K  20  0.5  F 
Cy  Sv  cc  MS  M  30  0.3  It 
Cy  Sv  SPE  MS  Bi  5  5  UK-NI 
Sg,Cy  Sv  cc  MS  U,Bi  25(U),  0.5-1  NL 
Cy  Sv  HPLC  MS  Bi,Fc  5(Bi),  2(Fc)  5  UK 
Cy  Sv  HPLC  MS  u  3  2  UK 
Abbreviations  are  at the  end  of  this section. 
4/2 19-NORTESTOSTERONE 
-----Procedures------- ---Sample----
Method  Type  Ext.  Purif.  Det.  Type  Size  LLD  Member 
Sg,Cy  ml  or  g  f.LQ/kg  or/L  State 
TLC  Sg,Cy  Sv  cc  uv  U,M  50  0.5-2  p 
HPTLC  Sg  Sv  C-Si  uv  U,M(i.s.)  2  5  F 
Sg,Cy  Sv  C18,HPLC  UV  U,F  20(U),25(F)  2  B 
Sg  Sv  C18,HPLC  UV  Fe  30  2  B 
HPLC  Cy  Sv  C18  uv  u  5  2  Ir 
EIA  Sg  Sv  no  EIA  u  0.5  1.5  0 
Sg  Sv  lAC  EIA  Se,Pl,U,Bi  0.25-0.5  0.2-1  UK-NI 
Sg  Sv  lAC  EIA  u  0.5  1  G 
RIA  Sg  Sv  C18  RIA  u  0.1  5  It 
Sg  Sv  C18  RIA  u  0.1  2  B 
Sv  C18  RIA  M  1  0.5  It 
Sg  Sv  C18  RIA  u  0.2  1  p 
Sg  Sv  IAC  RIA  M  4  0.5  G 
Sg  Sv  C18/HPLC  RIA  Fe  1  2  B 
Sg  no  C18  RIA  u  0.5  1  F 
Sg  Sv  no  RIA  Se  0.5  2  UK 
Sg  Sv  no  RIA  u  0.2  0.5  Ir 
Sg  Sv  no  RIA  u  0.1  2  UK 
Sg  Sv  HPLC  RIA  u  1  0.2  NL* 
Sg  Sv  IAC  RIA  Bi  0.25  0.2  NL* 
Sg,Cy  Sv  lAC  RIA  u  0.1  0.2  Gr 
GC-MS  Cy  Sv  cc  MS  u  20  2  G 
Sg,Cy  Sv  cc  MS  u  25  0.5-1  NL 
Cy  Sv  cc  MS  M  30  0.5  It 
Sg  Sv  C18,HPLC  MS  Fe  30  2  B 
Cy  Sv  C18,HPLC  MS  u  10  1  It 
Cy  Sv  HPLC  MS  u  3  5  UK 
Cy  Sv  IAC  MS  U,M  5  0.2  NL* 
Cy  Sv  lAC  MS  Bi  1  0.2  NL* 
Sg,Cy  no  C18,C-Si  MS  U,L,K  20  0.5  F 
Sg,Cy  no  C18,HPLC  MS  u  10  1.2  s 
Cy  Sv  lAC  MS  Bi  5  0.2  UK-NI 
Abbreviations  are  at the  end  of  this section. 
4/3 TRENBOLONE 
------Procedures------- ---Sample----
Method  Type  Ext.  Purif.  Det.  Type  Size  LLD  Member 
Sg,Cy  ml  or  g  ).Lg/kg  or/L  State 
TLC  Sg,Cy  Sv  cc  uv  U,M  50  0.5  p 
HPTLC  Sv  C1S  uv  u  10  0.5  It 
Sg  no  C1S,HPLC  Fl  u  15  1  s 
Sg  Sv  C-Si  uv  U,M(i.s.)  2  5  F 
Sg,Cy  Sv  C1S,HPLC  UV  U,F  20(U),25(F)  2  B 
Sg  Sv  C1S,HPLC  UV  Fe  30  2  B 
Cy  no  lAC  Fl  u  5  2  s 
HPLC  Sv  C1S,CC  uv  u  9  2  It 
Cy  Sv  CIS  uv  u  5  2  Ir 
HPLC/EIA  Sg  Sv  HPLC  EIA  Bi  I  I  UK-NI 
EIA  Sg  Sv  no  EIA  Pl  0.5  0.43  D 
Sg  Sv  no  EIA  u  0.5  2.4  D 
Sg  Sv  lAC  EIA  Se  0.5  O.I  UK-NI 
Sg  Sv  no  EIA  Bi  0.04  2  UK 
Sg  Sv  no  EIA  u  0.08  2  UK 
Sg  Sv  lAC  EIA  M  5  0.2  UK-NI 
Sg  Sv  lAC  EIA  Fe  3  0.4  UK-NI 
Sg,Cy  Sv  lAC  EIA  u  O.I  O.I  Gr 
Sg  Sv  CIS  EIA  u  0.5  I  G 
Sg  Sv  CIS  EIA  M  IO  I  G 
RIA  Sg  Sv  CIS  RIA  u  O.I  2  8 
Sg  Sv  CIS  RIA  u  O.I  0.2  p 
Sg  Sv  CIS  RIA  ·Fe  I  2  UK 
Sg  Sv  CI8/HPLC  RIA  Fe  I  2  B 
Sg  Sv  no  RIA  Se  0.5  0.02  UK 
Sg  Sv  no  RIA  u  0.2  0.5  Ir 
GC-MS  Sg,Cy  Sv  cc  MS  u  25  1-2  NL 
Cy  Sv  lAC  MS  U,M  5  0.5(M),0.3  NL* 
Cy  Sv  lAC  MS  B"?  1 •  5  I  NL 
Sg,Cy  no  CI8,C-Si  MS  U,K,L  20  2  F 
Sg  Sv  CIB,HPLC  MS  Fe  30  2  B 
Cy  Sv  CIS,HPLC  MS  Bi,Fc,U  5(Bi),2(Fc),3(U)  I  UK 
Cy  no  CIB,HPLC  MS  u  5  2  s 
Abbreviations  are  at the  end  of  this section. 
4/4 ZERANOL 
----Procedures-------- ---Sample----
Method  Type  Ext.  Purif.  Det.  Type  Size  LLD  Member 
Sg,Cy  ml  or  g  p.g/kg  or/L  State 
TLC  Sg,Cy  Sv  cc  uv  u  50  5  p 
HPTLC  Sg,Cy  Sv  CIS,HPLC  uv  U,F  20(U),25(F)  2  B 
Sg  Sv  CIS,HPLC  uv  Fe  30  2  B 
EIA  Sg  Sv  no  EIA  Bi,U  o.os  2  UK 
Sg  Sv  lAC  EIA  u  0.25  0.5  Gr 
Sg  Sv  CIS  EIA  u  0.5  0.125  G 
HPLC/RIA  Sg  Sv  no  RIA  Bi  1  2  UK-NI 
RIA  Sg  no  CIS  RIA  u  0.5  2  D 
Sg  Sv  no  RIA  u  0.2  2  Ir 
Sg  Sv  CIS  RIA  u  O.I  2  lt,B 
Sg  Sv  CIS  RIA  u  O.I  2  p 
Sg  Sv  CIS  RIA  F  I  5  p 
Sg,Cy  Sv  lAC  RIA  u  O.I  0.5  Gr 
Sg  Sv  CIS/HPLC  RIA  Fe  1  2  B 
Sg  Sv  no  RIA  U,Fc  0.5(U),1(Fc)  1  G 
Sg  Sv  no  RIA  Pl,Se  0.5  0.2  UK-NI 
Sg  Sv  no  RIA  u  0.5  1  UK-NI 
Sg  Sv  no  RIA  M  3  0.5  UK-NI 
GC-MS  Cy  Sv  no  MS  u  3  0.2  G 
Sg,Cy  Sv  cc  MS  u  25  0.5-I  NL 
Sg  Sv  C1S,HPLC  MS  Fe  30  2  B 
Cy  Sv  HPLC  MS  Bi,Fc,U  5(Bi),2(Fc),3(U)  2  UK 
Cy  Sv  lAC  MS  U,M  5  0.3  NL* 
Sg,Cy  no  ClS,C-Si  MS  U,K,L  20  2  F 
Sg,Cy  no  C1S,HPLC  MS  u  10  2  s 
Abrreviations  are  at the  end  of  this section. 
4/5 ETHINYLOESTRADIOL 
----Procedures--------
Method  Type  Ext.  Purif.  Det. 
---Sample----
Type  Size  LLD  Member 
Sg,Cy  ml  or  g  ~g/kg or/L  State 
EIA 
GC-MS 
Sg  Sv  C18  EIA 
Cy  Sv  Cl8,CC  MS 
Sg,Cy  C18  C-Si  MS 
ACETYL-GESTAGENS 
u 
U,Fc 
u 
------Procedures------
Substance.  Method  Type  Ext.  Purif.  Det. 
Sg,Cy 
MPA,MGA  RIA  Sg  no  C18  RIA 
CMA  RIA  Sg  no  C18  RIA 
MLA  RIA  Sg  no  C18  RIA 
Various  EIA  Sg  Sv  C18  EIA 
Various  HPLC/EIA  Sg  Sv  C18  EIA 
Various  HPLC  Sg  Sv  HPLC  uv 
Various  GC-MS  Cy  Sv  cc  MS 
0.5  0.2 
10(U),  2(Fc)  1 
20  2 
--Sample--
Type  size 
ml  or  g 
Pl  2 
Pl  2 
Pl  4 
Fat  2 
I.S  actual 
Fat  50 
I.S.  actual 
MPA  is medroxyprogesterone  acetate,  MGA  is megestrol  acetate, 
chlormadinone  acetate and  MLA  is melengestrol  acetate. 
Other  abbreviations  are  at the  end  of  this section. 
4/6 
LLD 
G 
G 
F 
Member 
State 
~g/L or/kg 
1  D 
1.5  D 
2.5  D 
0.1  G 
various  UK-NI 
5  UK-NI 
various  UK-NI 
CMA  is NATURAL  STEROIDS 
-----Procedures------- ---Sample----
Method  Type  Ext.  Purif.  Det.  Type  Size  LLD  Member 
Sg,Cy  ml  or  g  J.LQ/kg  or/L  State 
TLC  Sg  Sv  cc  uv  U,M  50  <2  p 
HPTLC  Sg  no  C18,HPLC  Fl  u  15  2  s 
Sg  Sv  C-Si  uv  u  20  2  F 
EIA  Sg  Sv  no  EIA  Pl,Se  0.5  0.1(T)  UK-NI 
RIA  Sg  Sv  C18  RIA  Pl  1  0.04- B 
Sg  Sv  no  RIA  Pl  0.5  0.2(P,T)  D 
Sv  no  RIA  Pl  0.5  0.002(E2B)  D 
Sg  Sv  no  RIA  Pl  0.1  0.01  Gr 
Sg  Sv  no  RIA  Se  0.5-1  0.008-0.1  G 
Sg  Sv  no  RIA  Se  0.15-0.5  0.01-0.5  UK 
Sg  Sv  no  RIA  Pl,Se  0.05-0.1  0.02-0.2  It 
Sg  Sv  no  RIA  Pl  1-2  0.02-0.09  F 
Sg  Sv  cc  RIA  Pl,  0.1-1  0.01-0.1  Ir 
Sg  no  no  RIA  Pl  0.05-0.2  0.008-0.05  p 
Sg  Sv  no  RIA  Se  0.05-0.1  0.02-0.2  NL 
Sg  Sv  no  RIA  Pl, Se  0.5  0.01(E2B)  UK-NI 
0.1(P)  UK-NI 
GC-MS  Sg,Cy  Sv  cc  MS  u  25  0.5-1  NL 
Cy  Sv  lAC  MS  U,M  5  0.2  NL* 
Cy  Sv  lAC  MS  Pl, Se  10  0.01  NL* 
Cy  Sv  HPLC  MS  Imp.  all  10J.LQ  total  UK 
Sg,Cy  no  C18,HPLC  MS  u  10  1-2  s 
Abbreviations  are  at the  end  of  this section. 
4/7 THYREOSTATS 
-----Procedures------- ---Sample----
Method  Type  Ext.  Purif.  Det.  Type  Size  LLD  Member 
Sg,Cy  mL  or  g  J.LQ/kg  or/L  State 
Grav  Sg  no  no  Grav  Th  whole  >55g  UK,  UK-NI 
Grav  Sg  no  no  Grav  Th  whole  >50g  B 
HPTLC  Cy  Sv  C-Si  Fl  Th  2  200  UK, 
Sg  Sv  cc  Fl  Th  2-5  100-200  s 
Sg  Sv  C-Si  Fl  M  2  100  D 
Sg,Cy  Sv  cc  Fl  M,U  2  50-100  Gr 
Sg  Sv  no  Fl  Pl  2  100  D 
Sg,Cy  Sv  cc  Fl  u  2  50-100  NL 
Sg,Cy  Sv  cc  uv  u  2  50-100  It 
Sg,Cy  Sv  cc  uv  u  2  100  p 
Sg,Cy  Sv  cc  uv  Th,M  2  100  p 
Sg,Cy  Sv  cc  uv  Th,U  2  10-50  B 
Sg  Sv  cc  uv  M  2  25-100  Ir 
Sg,Cy  Sv  CIS  uv  M,Th  2  50-100  It 
TLC  Sg  Sv  no  uv  M,Th  5  20  G 
Sg  Sv  no  uv  Se  1  100  G 
Cy  Sv  cc  Fl  Th  2  25  UK-NI 
HPLC  Cy  Sv  cc  Di .A  Th  2-5  100-200  s 
Sg  Sv  cc  uv  Th  5  50-100  F 
GC-MS  Cy  Sv  no  MS  M,Th  5  50-100  G 
Abbreviations  are  at the  end  of  this section. 
4/8 8-AGONISTS 
------Procedures------ --Sample--
Member 
Substance.  Method  Type  Ext.  Purif.  Det.  Type  size  LLD  State 
Sg,Cy  ml  J.LQ/kg 
or  g  or  J.LQ/L 
Cl  TLC  Sg,Cy  Sv  C18  Vis  u  20  1  p 
Cl  I Ci  HPTLC  Sg  no  C18  Vis  u  10  1  s 
Cl  I Ci  HPTLC  Sg  no  C18  Vis  L  5  2  s 
Unspec.  Sg,Cy  Sv  cc  Vis  u  16  1  Gr 
Cl,Sa,T  Cy  Sv  C18  uv  u  22.5  2  Ir 
Cl,  Mab  Sg  Sv  C-Si  ECD,UV  u  20  1  F 
Sa,  T  Sg  Sv  CB  ECD,UV  u  20  1  F 
Cl  Sg  acid  cc  uv  u  10  <5  Ir 
Cl,Ci  Cy  no  C18  Di .A  u  20  1-2  s 
Cl.Ci  Cy  Sv  C18  Di .A  L  10  2  s 
Cl  HPLC  Sg  Sv  C18  uv  L  5  1  Ir 
Cl ,Ci ,Mab  Sg,Cy  Sv  C18  Di .A  U,L  10  1-2  B 
Sa  Sg,Cy  Sv  lAC  Fl  U,L  5  1-2  B 
Unspec  GC  Cy  Sv  cc  ECD  M  5  2  Ir 
Cl,Sa,T  RIA  Sg  Sv  no  RIA  u  1  0.05  Ir 
Cl  Sg  Sv  no  RIA  L  1.25  0.5  Ir 
Cl  Sg  Sv  no  RIA  u  0.1  0.8  Gr 
Cl  Sg  Sv  no  RIA  u  0.5  1  p 
Various  (>8)  EIA  Sg  no  no  EIA  u  10  1-2  NL 
Mab,Ci,Sa  Sg  Sv  C18  EIA  L  1  1-5  D 
Cl  Sg  Sv  C18  EIA  L  1  0.25  D 
Cl,Ci,Sa,Mab,Terb,Carb  Sg  no  C18  EIA  u  1  0.1-2.6  G 
Cl  Sg  Sv  EIA  M,L,K,U  5  0.25  UK 
Sa  Sg  Sv  C18  EIA  L  10  1  UK 
Cl ,Mab  Sg  Sv  no  EIA  Bi,U,R  0.5  0.5-2  UK-NI 
Cl ,Mab  Sg  Sv  no  EIA  K,M,L  5  0.2-4  UK-NI 
Cl,Ci,Sa  Sg  Sv  no  EIA  u  0.5  0.1-1  Gr 
Unspec.  GC-MS  Cy  Sv  lAC  MS  u  10  0.5  NL* 
Various  (>8)  Sg,Cy  C18  lAC  MS  U,L  5  0.5-1  NL 
Various  (9)  Sg,Cy  Sv  C8/CS03H  MS  U,L,K  10  0.2-1  G 
Cl  Cy  cc  C18  MS  u  10  1  Ir 
Unspec  Sg,Cy  Sv  cc  MS  U,L,K  20  0.5-2  F 
Cl  Cy  Sv  HPLC  MS  l  5  0.5  UK 
Sa  Cy  Sv  HPLC  MS  l  5  0.5  UK 
Cl ,Mab  Cy  Sv  Sv  MS  U,Bi,L,K,M  10  0.2-4  UK-NI 
Cl ,Mab  Cy  Sv  Sv  MS  R  0.5  0.5  UK-NI 
Cl  is Clenbuterol,  Ci,  Cimaterol;  Sa,  Salbutamol;  T is Terbutaline,  Mab 
is Marbuterol 
Unspec.  is unspecified.  Other  abbreviations  are  at the  end  of  this 
section. 
4/9 CHLORAMPHENICOL 
------Procedures------ ---Sample----
Method  Type  Ext.  Purif.  Det.  Type  Size  LLD  Member 
Sg,Cy  ml  or  g  J.LQ/kg  or/L  State 
HPLC  Cy  Sv  Sv  Di .A  u  25  2  B 
Cy  Sv  Sv  Di.A  M,Eg,Fish  10  2  B 
Cy  Sv  Sv  Di .A  K,  Mk  10  2  B 
Sv  Sv  uv  M,L,K,Mk  5  2,1(Mk)  F 
Sg  Sv  C18  uv  M,Mk  5  10  UK-NI 
Sv  CC,C18  uv  M,Eg  5  2  It 
Sg  H 20  cc  uv  M  10  1  NL 
Sg  Sv  C-Si  uv  Eg  20  0.5  NL 
Sg  no  cc  uv  Mk  15  0.5  NL 
Cy  Sv  cc  Di .A  M  10  10  s 
Cy  Sv  C-Si  Di .A  M  50  10  NL 
GC  Cy  Sv  C18  ECD  M,Mk,Eg  3,Mk(5)  0.5  G 
Sv  lAC  ECD  K,U  3(K0,1(U)  2(K),0.5(U)  G 
Cy  Sv  CC-Si  ECD  M  5  2  Ir 
Sg  Sv  CC-I on  ECD  L  5  10  Ir 
Sg,Cy  Sv  Sv  ECD  M,K  5  1  Ir 
EIA  Sg  H 20  no  EIA  M  20  5  NL 
Sg  no  no  EIA  u  0.1  50  NL 
Sg  Sv  no  EIA  M,K,Mk  10  7  B 
Sg  Sv  no  EIA  u  0.05  5  p 
Sg  Sv  no  EIA  M  10  20  p 
Sg  Sv  no  EIA  M,K  10  20  UK-NI 
Sg  Sv  no  EIA  M  3  1  D 
Sg  Sv  no  EIA  M  0.5  0.1  Gr 
Sg  no  no  EIA  K  1  1.0  UK 
Sg  Sv  C18  RIA  Fe  1  2  UK 
Sg  no  no  EIA  u  1  5  NL* 
RIA  Sg  Sv  no  RIA  Mk  1  0.2  G 
Sg  Sv  Sv  RIA  M,Eg  3  0.2  G 
Sg,Cv  Sv  C18  RIA  M  1  0.2  Gr 
Sv  no  RIA  M  3  10  p 
Cy  Sv  HPLC  RIA  u  1  0.5  NL* 
Sg  Sv  no  RIA  M  3  0.5  Ir 
GC-MS  Cy  H 20  cc  MS  M  10  0.5  NL 
Cy  no  cc  MS  Mk  10  0.5  NL 
Cy  Sv  Sv  M  10  2  B 
Cy  cc  HPLC  MS  U,M,Eg  10  0.1  NL* 
Cy  Sv  CC-I on  MS  L  5  10  Ir 
Cy  Sv  C18  MS  M,Mk  M(3),Mk(5)  0.1,0.2  G 
LC-MS  Cy  Sv  C18  MS  L  10  1  UK-NI 
Abbreviations  are  at the  end  of  this section. 
4/10 TRANQUILLIZERS 
-----=Procedures------
Substance.  Method  Type  Ext.  Purif.  Det. 
Sg,Cy 
Various  (6)  TLC  Sg,Cy  Sv  Sv  Vis 
Various(3)  HPLC  Sg,Cy  Sv  C18  Di .A 
Various  (5)  Sg,Cy  Sv  C18  uv 
Various  (4)  Sg  Sv  no  uv 
Various(6)  Sv  C-DIOL  UV 
Various  Sg  Sv  C18  uv 
Various  (6)  Sg  Sv  C18  uv 
Various  (6)  Cy  Sv  C-DIOL  UV 
NL* 
Various  (5)  Sg,Cy  Sv  HPLC  uv 
Various  (5)  Sg  Sv  C18  uv 
Various  (5)  GC-MS  Cy  Sv  C18  MS 
Various  (3)  Cy  Sv  C18  MS 
Various  (5)  Sg,Cy  Sv  cc  MS 
BETA-BLOCKERS 
Procedures 
Substance.  Method  Type  Ext.  Purif.  Det. 
Sg,Cy 
Carazolol  TLC  Sg,Cy  Sv  no  Vis 
Carazolol  HPLC  Sg,Cy  Sv  C18  Fl 
Carazolol  Sv  C-DIOL  UV 
Carazolol  Cy  Sv  C-DIOL  UV 
Carazolol  Sg  Sv  Sv  Fl 
Carazolol  Sg  Sv  C18  Fl 
Carazolol  Cy  Sv  C18  Di .A 
Carazolol  Sg  Sv  no  uv 
Carazolol  Sg,Cy  Sv  C18  uv 
Carazolol  Sg,Cy  Sv  C18  uv 
Carazolol  Sg  Sv  no  uv 
--Sample--- LLD 
Type  size  ~g/kg 
ml  or  g  J.LQ/L 
K  20  1.2-3 
M  5  50 
M  5  1-10 
K  2  50 
K  20  1-10 
K  5  1-5 
M,K  5  1-6 
K  20  1-10 
Pl ,Se  2  6 
K  5  0.1 
K  10  50 
M  5  25 
K,M,U  10  10-30 
---Sample--- LLD 
Type  size  ).Lg/kg 
g or  ml  or  J.LQ/L 
K  20  1.5 
M  5  50 
K  20  1 
K  20  20 
K  10  2 
M,K  5  0.3 
K  5  50 
K  2  25 
M  5  1 
K  5  0.3 
Pl,Se  10  10 
Unspec.  is unspecified.  Other  abbreviations  are  at the  end  of  this 
section. 
4/11 
Member 
State 
p 
B 
Gr 
D 
F 
Ir 
NL 
UK-NI 
UK 
NL 
B 
G 
Member 
State 
p 
B 
F 
NL* 
G 
NL 
NL 
D 
Gr 
UK 
UK-NI SULPHONAMIDES 
-----Procedures-------
Substance.  Method  Type  Ext.  Purif.  Det.  --Sample--- LLD  Member 
Sg,Cy  Type  size  J,Lg/kg  State 
ml  or  g  or  J.LQ/L 
Unspec.  TLC  Sg  Sv  no  Fl  M  1  25  F 
Unspec.  Sv  C-Si  Fl  K  10  20  NL* 
Various{4)  HPTLC  Sg  Sv  C-S03H Fl  M,K  10  5  B 
Unspec  Sg  Sv  C-Si  uv  M,K,Mk  5(Mk), 10  5-10  NL 
Various(11)  Sg  Sv  NH2 ,CSX  Fl  K  2.5  20  UK 
Various  Sg  Sv  Fl  K  2.5  50  UK-NI 
SMZ  Cy  Sv  no  Fl  M  2.5  <50  D 
Various  Sg  Sv  C-Si  Fl  M  10  50  s 
Various(11)  HPLC  Cy  Sv  C-S03H Di.A  M,K  10  5  B 
Unspec.  Sv  Sv  uv  Eg,Mk  5  2-5  F 
Unspec.  Sg,Cy  Sv  Sv  Di .A  M,L,K,Eg,Mk  10  2  G 
Unspec.  Cy  Sv  C18  Di .A  M  10  20  NL* 
Unspec.  Sg  H 20  dial.  Vis  M,Mk,Eg  10  25  NL 
Various  (3)  Sg  Sv  no  uv  Se  4  100  D 
Various  Cy  Sv  csx  Di .A  M  10  50  s 
Various  (3)  Sv  CC,C18  UV  M,K  10  25  It 
Various  (5)  Cy  Sv  C-Si  uv  M  5  10  F 
Unspec.  Cy  Sv  C18  uv  M  10  20  Ir 
Unspec.  Cy  Sv  C-Si  Di .A  M  10  25  NL 
Various(4)  Cy  Sv  NH2CSx  UV  K  2.5  20  UK 
SMZ  Cy  Sv  no  UV/Vis  K,M,L  5  50  UK-NI 
SMZ  EIA  Sg  no  no  EIA  Se  0.01  13  D 
SMZ  Sg  no  card  EIA  u  5  0.5  p 
SMZ  Sg  no  no  EIA  u  0.02  100  UK-NI 
SMZ  Sg  no  no  EIA  K,M  2.5  20  UK-NI 
SMZ  Sg  no  no  EIA  u  0.01  100  Gr 
Unspec.  Sg  Sv  no  EIA  K  2.5  3  UK 
Unspec.  Sg  Sv  no  EIA  u  0.01  100  Ir 
SMZ  Sg  Sv  no  EIA  K  2.5  80  Gr 
Various  HPLC/MS  Cy  Sv  C-Si  MS  M  5  30-80  G 
Various(11)  Cy  Sv  HPLC  MS  K  5  100  UK 
SMZ  GC-MS  Cy  Sv  sex  MS  K,M,L  5  20  UK-NI 
Abbreviations  are  at the  end  of  this section. 
4/12 NITROFURANS 
-------Procedures--------
Substance.  Method  Type  Ext.  Purif.  Det.  _Sample  _  LLD  Member 
Sg,Cy  Type  size  J..LQ/kg  State 
ml  or  g  or  J..LQ/L 
Various  (4)  TLC  Sg,Cy  Sv  C-Si  Fl  M  5  1  F 
Furazolidone  HPLC  Sg,Cy  Sv  Sv  Di .A  M,Fish,Eg  10  5  B 
&  Furaltadone 
Unspec.  Sg  Sv  C18  uv  u  22.5  2  Ir 
Various  (3)  Sv  C18  uv  M,L,Eg  5  2  It 
Unspec.  Sg  Sv  Sv  uv  M,L,K,Eg  50  5  G 
Mk,Fish 
Furazolidone  Sg  Sv  Sv  uv  Eg  50  5  NL 
Furazolidone  Sg  Sv  Sv  uv  L  1  1  UK 
Furazolidone  Sg  Sv  Sv  Vis  Meal  1  10  UK-NI 
Various  (4)  Sg  H 20  Dial.  uv  M,Mk,Eg  10  1-10  NL 
Various  (4)  Sg,Cy  Sv  no  uv  M  10  5  D 
Furazolidone  Cy  Sv  Sv  Di .A  M  20  5  NL 
Furazolidone  Cy  Sv  Sv  Di .A  Eg  50  15  NL 
Furazolidone  Cy  Sv  Sv  Di .A  Eg  50  15  NL 
Furazolidone  LC-MS  Cy  Sv  C-NH2  MS  M,L,K  2  1  UK-NI 
Unspec.  is unspecified.  Other  abbreviations  are  at the  end  of  this section. 
4/13 CARBADOX 
-----Procedures------- ---Sample----
Method  Type  Ext.  Purif.  Det.  Type  Size  LLD  Member 
Sg,Cy  ml  or  g  J.LQ/kg  or/L  State 
HPLC  Sg  Sv  CC(Al)  Vis  M,L,K,Eg  10  2,  (Eg,1)  NL 
Cy  Sv  CC (A 1)  Di .A  K  10  10  NL 
GC  Sv  cc  ECD  L  5  30  Ir 
GC-MS  Cy  Sv  HPLC  GC-MS  K  20  <1  NL* 
Cy  Sv  CC(I-Ex)  MS  Meal  5  2  UK-NI 
Residues  of  carbadox  are  normally  monitored  by  measuring  a metabolite. 
ANTHELMINTICS 
------Procedures--------
Substance.  Method  Type  Ext.  Purif.  Det.  _Sample  _  LLD  Member 
Sg/Cy  Type  size  J.LQ/kg  State 
ml  or  g  or  J.LQ/L 
Levamisole  HPLC  Sg,Cy  Sv  Sv  uv  M  10  50  B 
Levamisole  HPLC  Sg  Sv  Sv  uv  L  10  20  NL 
Levamisole  Sg  uv  L  10  5  UK 
Fenbendazole  Sg  Sv  Sv  uv  Pl  1  20  UK-NI 
Thiabendazole  Sg  Sv  Sv  Fl/UV  M,L  10  10  B,NL 
Benzimidazoles  (5)  Sg  no  Dial.  uv  Mk  10  10-50  NL 
Benzimidazoles  (5)  Sg,Cy  Sv  C2  uv  L  5  250  UK 
Ivermectin  Sg  Sv  C18,C-Si  Fl  L  2.5  2.5  D 
Ivermectin  Sg  Sv  CB  Fl  M  10  10  NL 
Ivermectin  Sg,Cy  Sv  C-Si  Fl  M  5  50  B 
Ivermectin  Sg,Cy  Sv  C8,C-Si  Fl  M, 1  ,Mk  5  0.4  G 
Ivermectin  Cy  Sv  CB  Fl  M  5  1  UK-NI 
Oxfendazole  HPLC-MS  Cy  Sv  HPLC  MS  M  3  100  UK-NI 
Fenbendazole  Cy  Sv  Sv  uv  M  3  50  UK-NI 
Rafoxanide  Cy  Sv  no  MS  L,M  3  20  UK-NI 
Nitroxynil  Cy  Sv  no  MS  L,M  2  20  UK-NI 
Levamisole  GC/MS  Cy  Sv  Sv  MS  L  10  5  UK 
Abbreviations  are  at the  end  of  this section 
4/14 ABBREVIATIONS  for  Section  4. 
TECHNICAL  /  METHODS 
Procedures, 
Ext.,  extraction;  Purif.,  purification/clean-up;  Det,  detection  system 
Immunoassay, 
lA,  immunoassay;  RIA,  radioimmunoassay;  EIA,  enzymeimmunoassay; 
Chromatography  (C); 
CC,  column  chromatography; 
GC,  gas  chromatography; 
HPLC,  high  performance  liquid chromatography; 
lAC,  immunoaffinity  chromatography; 
TLC,  thin-layer chromatography; 
SPE;  solid phase  extraction;  CB,  SPE  on  CB  cartridges;  Cl8,  SPE  on  Cl8 
cartridges; 
C-Si,  SPE  on  silica cartridges;  C-S03H,  SPE  on  sulphated  cartridges 
C-DIOL,  SPE  on  hydroxylated  silica cartridges,  CSX  is  ion-exchange  column, 
C-NH2  is aminated  cartridge. 
Spectrometry; 
MS,  mass  spectrometry;  UV,  ultra-violet spectrometry; 
IR,  infra-red spectrometry, 
Dens,  densimetric; 
Dial,  dialysis; 
Di.A,  diode  array; 
ECD,  electro-chemical  detector; 
Fl,  fluorescence; 
FPT,  four-plate test; 
GIB,  growth  inhibition of  bacteria;  Grav,  gravimetric; 
H 20,  aqueous  extraction 
Sv,  solvent  extraction; 
Vis,  visible 
b)  SAMPLES;- M,  muscle;  L,  liver;  K,  kidney;  F,  fat;  U,  urine;  Fe, 
faeces;  Mk,  milk;  Eg,  eggs;  Bi,  bile;  Th,  Thyroid;  Pl,  plasma;  Se,  Serum; 
I.S.,  injection site- normally  muscle;  Imp,  implant;  Meal,  animal  meal. 
c)  Hyphenated  techniques  are  on-line,  I  are  off-line.• 
d)  LLD  is  lower  limit of  detection  (sometimes  limit of  determination). 
e)  Member  States.  P,  Portugal;  S,  Spain;  F,  France;  G,  Germany  (several 
Federal  labs);  It,  Italy;  Ir,  Ireland;  UK,  United  Kingdom;  UK-NI,  UK-
Northern  Ireland;  D,  Denmark;  B,  Belgium;  L,  Luxembourg;  Gr,  Greece;  NL, 
Netherlands  (Holland) 
f)  NL*  are  methods  from  RIVM  submitted  direct to manual  and  are  not 
officially used  in  the  initial  screening  part of  the  National  Programme  on 
hormones  and  other  substances  by  the  National  Inspection  Service  (RVV). 
The  methods  are  used  to confirm  positives where  confirmation  is required 
from  a second  laboratory. 
g)  Type  of  method;- Cy  is confirmatory,  Sg  is screening 
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5.1.  CRITERIA  FOR  ROUTINE  METHODS 
These  criteria were  formulated  by  a  group  of  experts  forming  an  Ad  Hoc 
Committee  brought  together  by  DGVI.  The  members  of  the  committee  were; 
A.  Sanabria,  DGVI,  C.  Gaudot  (Chairmen); 
C.  Ring,  (Rappor!eur  to  Sc.  Vet.  Committee,  EEC) 
F.  Andre,  LDH,  Ecole  Nat.  Vet.,  Nantes 
D.  Arnold,  BGA,  Berlin, 
N.F.  Cunningham,  CVL,  Weybridge; 
N.  De  Ruig,  RIKILT,  Wageningen; 
H.  Durbeck,  Kernforschungsanlage  Institut,  Julich; 
R.J.Heitzman,  Private consultant. 
H.  Meyer,  Institute for  Physiology,  Weihenstephan-Freising; 
G.  Moretti,  Instituto Superiore  di  Sanita,  Rome; 
R.W.  Stephany,  RIVM,  Bilthoven. 
The  full  text  is published  in  Commission  Decision  93/256  laying  down  the 
methods  to  be  used  for  detecting residues  of  substances  having  a  hormonal 
or  thyrostatic action.  [Editors  comment;  Note  that  the  title of the 
Decision  relates  to  hormonal  and  thyrostatic substances.  In  practice the 
criteria can  and  should be  applied to  residues of all veterinary drugs]. 
Article 1 states that the  routine  analytical  procedures  for  detecting 
residues of  substances  having  a  hormonal  action  and  of  substances  having  a 
thyrostatic action  shall  be  ;- immunoassay;  thin-layer chromatography; 
liquid chromatography;  gas  chromatography;  mass  spectrometry;  spectrometry 
:  or  any  other method  which  fulfils comparable  criteria to  those  laid  down 
for  related methods  in  the  Annex  of  this Decision. 
The  Annex  is a revision of  the  guidelines  published  in  the first edition of 
this manual.  The  criteria now  cover  methods  for  both  screening  and 
confirmatory  purposes. 
ANNEX  OF  93/256/EEC 
1. 
1.1. 
1.1.1. 
DEFINITIONS  AND  GENERAL  REQUIREMENTS 
DEFINITIONS 
Routine  Methods  of analysis 
These  are  methods  of  analysis  used  by  Member  States to 
implement  National  Plans  for  the  control  of  residues  in  food-
producing  animals  and  their products  in  compliance  with 
Directive 86/469/EEC.  Routine  methods  must  have  been  validated 
by  operational  laboratories,  and  must  fulfil  the  relevant 
criteria set out  in  this Annex.  They  may  be  used  for screening 
and/or  confirmatory  purposes: 
- Methods  used  for  screening  purposes  (screening methods)  are 
methods  which  are  used  to  detect the  presence  of  an  analyte or 
class of  analytes  at the  level  of  interest.  These  methods 
have  a  high  sample  throughput  capacity and  are  used  to  sift 
large  numbers  of  samples  for  potential  positives.  They  are 
aimed  at avoiding  false  negative  results. 
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- Methods  used  for  confirmatory  purposes  (confirmatory methods) 
are methods  which  provide  full  or  complementary  information 
enabling  the  analyte  to  be  identified unequivocally at the 
level  of  interest.  These  methods  are  aimed  at preventing 
false  positive results as  well  as  having  an  acceptable  low 
probability of  false  negative results. 
Analyte 
This  is a  component  of  a  test sample  which  has  to  be  detected, 
identified and/or  quantified.  The  term 
11analyte
11  includes, 
where  appropriate,  derivatives formed  from  the  analyte  during 
the  analysis. 
A quantitative measure  of  an  analyte  has  to  be  reported  as: 
- an  amount,  expressed  as  a mass  quantity  (e.g.  ~g,  ng) 
- a content,  expressed  as  a mass  fraction  (e.g.  ~g/kg, 
ng/kg),  a mass  concentration  (e.g.  ~g/L) or  a  concentration 
(e.g.  mol/L). 
Samples 
Laboratory  sample 
This  is a  sample  as  prepared  for  sending  to the  laboratory and 
intended  for  inspection or testing. 
Test  sample 
This  is a  sample  prepared  from  the  laboratory sample  and  from 
which  test portions will  be  taken. 
Test  portion 
This  is the  quantity of  material  drawn  from  the test sample 
(or,  if both  are  the  same,  from  the  laboratory sample)  and  on 
which  the  test or observation  is actually carried out. 
Standard  analyte 
This  is a well-defined  substance  in  its highest  available 
purity to  be  used  as  a  reference  in  the  analysis. 
Reference  material 
This  is a material  of which  one,  or  several,  properties  have 
been  confirmed  by  a  validated method,  so  that it can  be  used  to 
calibrate an  apparatus  or  to  verify a method  of measurement. 
Blank  determinations 
Sample  blank  determination 
This  is the  complete  analytical  procedure  applied  to a  test 
portion  taken  from  a  sample  from  which  the  analyte  is absent. 
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Reagent  blank  determination 
This  is the  complete  analytical  procedure  applied with  omission 
of  the  test portion  or  using  an  equivalent  amount  of  suitable 
solvent  in  place  of  the  test portion. 
Specificity 
Specificity is the  ability of  a method  to  distinguish between 
the  analyte  being  measured  and  other substances.  This 
characteristic  is predominantly  a function  of  the measuring 
principle used,  but  can  vary  according  to class of  compound  or 
matrix. 
Details concerning  specificity must  relate at  least to  any 
substances  which  might  be  expected  to  give  rise to a  signal 
when  the measuring  principle described  is used,  e.g. 
homologues,  analogues,  metabolic  products  of  the  residue  of 
interest.  From  the  details concerning  specificity it must  be 
possible  to derive  quantitatively the  extent to which  the 
method  can  distinguish  between  the  analyte  and  the  other 
substances  under  the  experimental 'conditions. 
Accuracy 
In  this Decision  this refers to accuracy  of  the mean.  The 
definition which  shall  be  used  is  laid  down  in  ISO  3534-1977 
under  2.83  (Accuracy  of  the  mean:  the  closeness  of  agreement 
between  the  true value  and  the  mean  result which  would  be 
obtained  by  applying  the  experimental  procedure  a  very  large 
number  of  times). 
The  principal  limitations on  accuracy  are: 
(a)  random  errors; 
{b)  systematic errors. 
For  a very  large  number  of  experiments,  the accuracy  of  the 
mean  approaches  the  systematic error.  For  desk  review  of  a 
method,  the  number  of  experiments  must  be  specified. 
The  measure  of  accuracy  is the  difference  between  the  mean 
value  measured  for  a reference material  and  its true value, 
expressed  as  a  percentage  of  the  true  value.  If no  reference 
material  is available,  relevant  parameters  may  be  evaluated  by 
analyzing  fortified sample  material. 
In  cases  where  neither absolute  defining  methods  nor  certified 
reference materials  are  available,  the  analyte content  of  a 
sample  may  be  defined  by  the  results obtained with  the  aid  of  a 
method  which  exhibits the  highest  degree  of  specificity, 
accuracy  and  precision for  the  analyte. 
Precision 
This  is the  closeness  of  agreement  between  the  results obtained 
by  applying  the  experimental  procedure  several  times  under 
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prescribed  conditions  (ISO  3534-1977,  2.84),  and  covers 
repeatability and  reproducibility. 
Repeatability:  The  closeness  of  agreement  between  mutually 
independent  test results obtained  under  repeatability 
conditions,  i.e. with  the  same  method  on  identical  test 
material  in  the  same  laboratory  by  the  same  operator  using  the 
same  equipment  within  short  intervals of  time. 
Reproducibility:  The  closeness  of  agreement  between  mutually 
independent  test results obtained  under  reproducibility 
conditions,  i.e. with  the  same  method  on  identical  test 
material  in  different  laboratories with  different operators 
using  different equipment. 
According  to  the  Annex  to Directive 85/591/EEC  the  precision 
values  for methods  of  analysis which  are  to  be  considered  for 
adoption  under  the  provisions  of  that Directive  shall  be 
obtained  from  a  collaborative trial which  has  preferably been 
conducted  in  accordance  with  ISO  5725-1986.  For  this purpose, 
the  terms  repeatability and  reproducibility are defined  in  ISO 
5725-1986.  For  conducting  such  trials sample  materials of 
known  analyte  content  ranging  around  the  maximum  residue  limit 
to  be  enforced  shall  be  used. 
Until  such  time  as  the  reproducibility of  a method  has  been 
established  by  a  collaborative trial,  then  for  the  purpose  of 
preselection of  candidate  methods  by  desk  review,  it is 
sufficient that data  on  repeatability are  available. 
The  measure  of  repeatability and  reproducibility to  be  used  is 
the  coefficient of  variation  as  defined  in  ISO  3534-1977,  2.35 
(Coefficient of  variation:  the  ratio of  the  standard  deviation 
to the  absolute  value  of  the  arithmetic mean). 
Limit  of detection 
The  smallest measured  content  from  which  it is possible to 
deduce  the  presence  of  the  analyte with  reasonable  statistical 
certainty (at  least  95%  for  unauthorized  substances  - see 
1.2.6.1). 
The  limit of  detection  can  be  calculated using  different 
approaches: 
(a)  One  way  is to  carry out  sample  blank  determinations  on  at 
least 20  representative blank  samples.  The  limit of 
detection  is calculated as  the  apparent  content 
corresponding  to  the  value  of  the  mean  plus  three times 
the  standard  deviation  for  the  blank  determinations. 
Note  1:  The  amount  of  test portion  typically used  in  the 
analysis  should  be  specified. 
Note  2:  If it is  to  be  expected  that factors  such  as 
species,  sex,  age,  feeding  or  other environmental  factors 
may  influence  the  characteristics of  a method,  then  a  set 
of  at  least 20  blank  samples  is required  for  each 
individual  homogeneous  population  to which  the  method  is 
to  be  applied. 
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(b)  Alternatively,  in  the  case  of  spectrometric 
determinations  in  which  blank  determinations  give  white 
noise  only,  the  limit of  detection  is calculated as  the 
apparent  content  corresponding  to  three times  the  peak-
to-peak  noise. 
Limit  of determination 
This  is the  smallest analyte  content  for  which  the  method  has 
been  validated with  specified accuracy  and  precision. 
Sensitivity 
This  is a measure  of  the  ability of  a method  to  discriminate 
between  differences  in  analyte  content.  In  this Decision, 
sensitivity is calculated as  the  slope  of  the  calibration curve 
at the  level  of  interest. 
Practicability 
This  is a characteristic of  an  analytical  procedure  which  is 
dependent  on  the  scope  of  the  method  and  is determined  by 
requirements  such  as  sample  throughput  and  costs. 
Applicability 
This  is a  list of  the  sample  materials  and/or  analytes  to which 
the  method  can  be  applied  as  presented  or  with  specified minor 
modifications. 
1.1.15.  Interpretation  of results 
1.1.15.1.  Positive result 
The  presence  of  the  analyte  in  the  sample  is proved,  according 
to  the  analytical  procedure,  when  the  general  criteria,  and  the 
criteria specified for  the  individual  detection method,  are 
fulfilled. 
(a)  For  substances with  a zero  tolerance,  the  result of  the 
analysis  is 
11positive
11  if the  identity of  the  analyte  in 
the  sample  is proved  unambiguously. 
(b)  For  substances with  an  established maximum  residue  limit, 
the  result of  the  analysis  is 
11positive
11  if the 
experimentally determined  content  of  the  analyte  in  the 
sample  (after applying  any  correction factor)  is greater 
than  that established maximum  residue  limit,  which  takes 
into  account  the  acceptable  probability of  obtaining 
false positive or  false negative  results. 
1.1.15.2.  Negative  result 
The  result of  the  analysis  is regarded  as 
11negative
11  according 
to  the  analytical  procedure,  when  the  general  criteria and  the 
criteria specified for  the  individual  detection  method  are 
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fulfilled  in  the  case  of  appropriate  reference materials  and 
blank  determination  and: 
(a)  in  the  case  of  substances  for which  there  is a  zero 
tolerance,  the  identity of  the  analyte  has  not  been 
proved  unambiguously,  or 
(b)  in  the  case  of  substances  with  an  established maximum 
residue  limit,  the  measured  content  of  the  analyte  in  the 
sample  is below  the  level  specified  in  1.1.15.1  (b) 
above. 
Note:  A negative  result does  not  prove  in  case  (a)  that the 
analyte  is absent  from  the  sample,  or  in  case  (b)  that the  true 
content of  the  analyte  is  below  the  maximum  residue  limit. 
Co-chromatography 
This  is a  procedure  in  which  the  purified test solution  prior 
to  the  chromatographic  step(s)  is divided  into  two  parts and: 
(a)  one  part  is chromatographed  as  such; 
(b)  the  standard  analyte  that  is to  be  identified  is added  to 
the other part,  and  this mixed  solution of  test solution 
and  standard  analyte  is chromatographed.  The  amount  of 
added  standard  analyte  has  to  be  similar to  the  estimated 
amount  of  the  analyte  in  the  test solution. 
Immunogram 
In  this Decision  an  immunogram  is defined  as  a  graphical  plot 
of  immunochemical  response  versus  retention time  or  elution 
volume  as  obtained  from  chromatographic  separation with  (in 
general  off-line)  immunochemical  detection  of  the  components  of 
the  sample  extract. 
GENERAL  REQUIREMENTS 
Criteria 
In  accordance  with  the  Annex  to  Council  Directive 85/591/EEC, 
the  criteria set out  below  shall  apply  to  the  examination  of 
methods  of  analysis. 
Screening  methods 
Fixed  requirements  cannot  be  set for  screening methods.  The 
most  important  aspect  of  performance  is that the  incidence  of 
false  negatives  at the  level  of  interest must  be  minimal. 
Specificity must  be  defined. 
Accuracy  and  precision:  Quantification  may  not  be  necessary. 
Depending  on  whether  the  use  of  a  substance  is prohibited or 
authorised,  a  screening  method  may  be  qualitative or 
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quantitative.  False  positives are  acceptable  but  false 
negatives  at the  level  of  interest should  be  minimal. 
Limit  of  detection:  This  should  be  appropriate for  the  purpose. 
For  substances with  an  established maximum  residue  limit,  it 
must  be  sufficiently low  to  detect residues  at this  level.  For 
substances  which  are  not  authorised for  use  in  food-producing 
animals,  the  limit of  detection  should  be  as  low  as  possible. 
Practicability:  A high  sample  throughput  capability is required 
and  costs  should  be  low. 
Conf;rmatory  methods 
Specificity:  As  far as  possible,  confirmatory methods  must 
provide  unambiguous  information  on  the  chemical  structure of 
the  analyte.  When  more  than  one  compound  gives  the  same 
response,  then  the  method  cannot  discriminate  between  these 
compounds. 
Methods  based  only  on  chromatographic  analysis without  the  use 
of  molecular  spectroscopic  detection  are  not  suitable for  use 
as  confirmatory methods. 
If a  single technique  lacks  sufficient specificity,  the  desired 
specificity may  be  achieved  by  analytical  procedures  consisting 
of  suitable combinations  of  clean-up,  chromatographic 
separation(s)  and  spectrometric or  immunochemical  detection, 
e.g.  GC-MS,  LC-MS,  IAC/GC-MS,  GC-IR  LC-IR,  LC-Img. 
Accuracy:  In  the  case  of  repeated  analysis of  a reference 
material,  the  guideline  ranges  for  the  deviation  of  the  mean 
experimentally determined  content  (after applying  any 
correction for recovery)  from  the  true value  are  as  follows: 
True  content  (mass  fraction) 
s  1 J.Lg/kg 
>  1 J.Lg/kg  to  10  J.Lg/kg 
>  10  J.Lg/kg 
Range 
-50%  to  +20% 
-30%  to  +10% 
-20%  to  +10%. 
Precision:  In  the  case  of  repeated  analysis of  a reference 
material  under  reproducibility conditions,  typical  values  for 
the  inter-laboratory coefficient of  variatio? 1 (~V~  £al8~lated 
according  to  the  Horwitz  equation  [CV(%)  =  2  - ·  og  ,  where 
C is the  content  as  a  power  of  10]  are  as  follows: 
Content  (mass  fraction)  cv  (%) 
1 J.Lg/kg  45 
10  J.Lg/kg  32 
100  J.Lg/kg  23 
1 mg/kga  16 
[Editors  Note;  a  this  is a correction of  J.Lg/kg  in  official  text] 
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For  analyses  carried out  under  repeatability conditions,  the 
intra-laboratory CV  would  typically be  one-half  to  two-thirds 
of  the  above  values. 
Limit  of  detection:  Adequate  for  the  purpose  (see  1.2.6.1). 
Limit  of  determination:  Adequate  for  the  purpose  (see  1.2.6.2). 
Sensitivity:  Adequate  for  the  purpose. 
Practicability:  Speed  and  cost are  of  lesser  importance 
compared  with  screening  methods. 
For  confirmatory methods,  most  aspects  of  practicability are  of 
minor  significance compared  with  the  other criteria defined  in 
this Decision.  It is usually sufficient that the  required 
reagents  and  equipment  are available. 
Calibration  curves 
If the  method  depends  on  a calibration curve  then  the following 
information  must  be  given: 
- the  mathematical  formula  which  describes  the  calibration 
curve 
- acceptable  ranges  within  which  the  parameters  of  the 
calibration curve  may  vary  from  day  to  day 
- the working  range  of  the  calibration curve 
Whenever  possible,  suitable  internal  standards  and  reference 
materials  should  be  used  for  the  quality control  of  calibration 
curves  of  confirmatory methods,  and  details of  the  variance  of 
the  variables which  is valid at  least for  the working  range  of 
the  calibration curve  should  be  given. 
Susceptibility to  interference 
For  all  experimental  conditions which  could  in  practice be 
subject  to  fluctuation  (e.g.  stability of  reagents,  composition 
of  the  sample,  pH,  temperature)  any  variations which  could 
affect the  analytical  result should  be  indicated.  The  method 
description  shall  include  means  of  overcoming  any  foreseeable 
interference.  If necessary,  alternative detection  principles 
suited for  confirmation  shall  be  described. 
If co-chromatography  is carried out,  then  only  one  peak  should 
be  obtained,  the  enhanced  peak  height  (or  area)  being 
equivalent  to  the  amount  of  added  analyte.  With  GC  or  LC,  the 
peak  width  at half  maximum  height  should  be  within  the  range 
90-110%  of  the  original  width,  and  the  retention times  should 
be  identical  within  a margin  of  5%.  For  TLC  methods,  the  spot 
presumed  to  be  due  to  the  analyte  should  be  intensified only;  a 
new  spot  should  not  appear,  and  the  visual  appearance  should 
not  change. 
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It is of  prime  importance  that  interference which  might  arise 
from  matrix  components  should  be  investigated. 
Relationship  between  permitted  residue  levels and  analytical 
limits 
For  substances  which  are  not  authorised  for  use  in 
food-producing  animals,  the  limit of  detection  of  the 
analytical  method  must  be  sufficiently  low  that residue  levels 
which  would  be  expected  after illegal  use  will  be  detected with 
at  least  95%  probability. 
For  substances  with  an  established maximum  residue  limit,  the 
limit of  determination  of  the  method  plus  three times  the 
standard  deviation  which  the  method  produces  for  a  sample  at 
the  maximum  residue  limit shall  not  exceed  the  established 
maximum  residue  limit. 
For  substances  with  an  established maximum  residue  limit,  the 
method  should  be  validated at that  limit and  at one-half  and 
twice  the  limit. 
CRITERIA  FOR  THE  IDENTIFICATION  AND  QUANTIFICATION  OF  RESIDUES. 
GENERAL  REQUIREMENT 
Laboratories  carrying  out  analyses  for  the  final  confirmation 
of  the  presence  of  residues  of  low  molecular  weight  organic 
substances  shall  ensure  that the  criteria for  the 
interpretation of  results are fulfilled  in  accordance  with  the 
requirements  of  this section.  The  criteria are  designed  for 
the  identification of  the  analyte  and  aim  to  prevent false 
positive results.  For  a positive conclusion,  the  analytical 
results  have  to fulfil  the  criteria  laid  down  for  the 
particular analytical  method. 
GENERAL  CONSIDERATIONS  FOR  THE  WHOLE  ANALYTICAL  METHOD 
Preparation  of the  sample 
The  sample  should  be  obtained,  handled  and  processed  in  such  a 
way  that there  is a  maximum  chance  of  detecting  the  analyte,  if 
present. 
Susceptibility to  interference 
Information  as  detailed under  1.2.5  (Susceptibility to 
interference)  should  be  submitted. 
General  criteria for  the  whole  procedure 
The  specificity (1.1.7)  and  the  limit of  detection  (1.1.10)  of 
the  method  for  the  analyte  in  the  matrix  under  investigation 
have  to  be  known. 
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Note:  this  information  can  be  obtained  from  experimental  data 
and/or  theoretical  considerations. 
For  a  positive result,  the  physical  and  chemical  behaviour  of 
the  analyte during  the  analysis  should  be  indistinguishable 
from  those  of  the  corresponding  standard  analyte  in  the 
appropriate  sample  material. 
The  positive or  negative  result of  the  analysis will  hold  only 
within  the  borders  of  specificity and  limit of detection of  the 
procedure  for  the  analyte  and  sample  material  under 
investigation. 
Reference  material  containing  known  amounts  of  analyte  should 
preferably be  carried through  the entire procedure 
simultaneously with  each  batch  of  test samples  analyzed. 
Alternatively,  an  internal  standard  may  be  added  to test 
samples. 
Criteria for  off-line physical  and/or  chemical 
preconcentration,  purification,  and  separation 
The  analyte  should  be  in  the  fraction which  is typical  for  the 
corresponding  standard  analyte  in  the  appropriate sample 
material  under  the  same  experimental  conditions. 
Retention  data  for  standards,  control  samples  and  test portions 
should  be  submitted  together with  the  final  result:  positive or 
negative. 
Criteria for  quantitative measurements 
The  recovery must  be  controlled  and  specified for all 
quantitative measurements. 
Intra-laboratory variability in  recovery  should  be  as  low  as 
possible. 
It must  be  clearly stated whether  or  not  final  results  have 
been  corrected for recovery  using  a  correction factor.  If they 
have  then  the  method  used  for correction must  be  described. 
CRITERIA  FOR  METHODS  OF  ANALYSIS  WHICH  MAY  BE  USED  FOR 
CONFIRMATORY  PURPOSES  ONLY  IN  COMBINATION  WITH  OTHER  METHODS. 
The  methods  considered  in  this Section  may  only  be  used  for 
confirmatory  purposes  in  combination  with  other methods. 
Quality  requirements  for  the  determination  of an  analyte  by  IA 
The  working  range  of  the  calibration curve  has  to  be  specified 
and  has  in  general  to cover  a  concentration  range  of at  least 
one  decade. 
A minimum  of  six calibration points  is required,  adequately 
distributed along  the  calibration curve. 
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Adequate  quality control  parameters  have  to  be  in  line with 
those  of  preceding  assays,  e.g.  NSB  and  parameters  of  the 
calibration curve. 
Control  samples  have  to  be  included  in  each  assay. 
Concentration  levels:  zero  and  at lower,  middle  and  upper 
parts of  the working  range.  Results  for  these  have  to  be  in 
line with  those  of  previous  assays. 
All  raw  data  for  the  control  samples  and  for  the  test portion 
should  be  submitted  together with  the  final  result:  positive or 
negative. 
Criteria for the determination  of an  analyte by  GC  or  LC  using 
non-specific detection. 
The  analyte  should  elute at the  retention time  which  is typical 
for  the  corresponding  standard  analyte  under  the  same 
experimental  conditions. 
The  nearest  peak  maximum  in  the  chromatogram  should  be 
separated  from  the  designated  analyte  peak  by  at  least one  full 
width  at  10%  of  the  maximum  height. 
For  additional  information,  co-chromatography  may  be  used  and 
chromatography  using  at  least two  columns  of  different 
polarity. 
Criteria for the determination  of  an  analyte  by  TLC. 
The  Rf  value(s)  of  the  analyte  should  agree  with  the  Rf 
value(s)  typical  for  the  standard  analyte.  This  requirement  is 
fulfilled when  the  Rf  value(s)  of  the  analyte  is  (are)  within  ± 
3%  of  the  Rf  value(s)  of  the  standard  analyte  under  the  same 
experimental  conditions. 
The  visual  appearance  of  the  analyte  should  be 
indistinguishable from  that of  the  standard  analyte. 
The  centre of  the  spot  nearest to that due  to  the  analyte 
should  be  separated  from  it by  at  least half  the  sum  of  the 
spot  diameters. 
For  additional  information,  co-chromatography  and/or 
two-dimensional  TLC  may  be  used. 
CRITERIA  FOR  METHODS  OF  ANALYSIS  WHICH  MAY  BE  USED  FOR 
CONFIRMATORY  PURPOSES 
Criteria for the determination  of  an  analyte by  LC/IA  or LC/Img 
For  LC/Img,  the  analyte  peak  in  the  Img  should  be 
constructed from  at  least 5  LC  fractions. 
Criteria 2.2.4.1  and  2.2.4.2 must  be  fulfilled. 
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Reagents 
The  source  and  characteristics of  the  antibody  and  other 
reagents  should  be  specified. 
Calibration  curve 
As  the  method  depends  on  calibration curves,  the  information 
itemised  under  1.2.4  (Calibration curves)  must  be  given. 
The  quality requirements  specified for  IA  (2.3.1.1  to 2.3.1.4) 
must  be  fulfilled. 
For  confirmatory  purposes,  if the  method  is not  used  in 
combination  with  other methods,  then  two  different  LC  or  two 
immunograms  using  antibodies with  different specificities must 
be  carried out. 
Criteria for  the  determination  of an  analyte  by  LC-SP. 
The  absorption  maxima  in  the  spectrum  of  the  analyte 
should  be  at the  same  wavelengths  as  those  of  the  standard 
analyte within  a margin  determined  by  the  resolution of  the 
detection  system.  For  diode  array detection this  is typically 
within  ±  2  nm. 
The  spectrum  of  the  analyte  above  220  nm  should  not  be  visually 
different from  the  spectrum  of  the  standard  analyte for  those 
parts of  the  two  spectra with  a  relative absorbance  ~10%.  This 
criterion  is met  when  the  same  maxima  are  present  and  at  no 
observed  point  is the  difference between  the  two  spectra more 
than  10%  of  the  absorbance  of  the  standard  analyte. 
For  confirmatory  purposes,  if the  method  is not  used  in 
combination  with  other methods,  then  co-chromatography  in  the 
LC  step  is mandatory.  See  1.2.5.2 for  the  requirements  to be 
fulfilled  by  co-chromatography. 
Criteria for  the  determination  of an  analyte  by  TLC-SP 
The  method  must  fulfil  the  criteria specified for  TLC  (2.3.3.1 
to 2.3.3.3). 
The  absorption  maxima  in  the  spectrum  of  the  analyte  should  be 
at the  same  wavelengths  as  those  of  the  standard  analyte, 
within  a margin  determined  by  the  resolution of  the  detection 
system. 
The  spectrum  of  the  analyte  should  not  be  visually different 
from  the  spectrum  of  the  standard  analyte. 
For  confirmatory  purposes,  if the  method  is not  used  in 
combination  with  other methods,  then  co-chromatography  in  the 
TLC  step  is mandatory.  See  1.2.5.2 for  the  requirements  to  be 
fulfilled  by  co-chromatography. 
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2.4.4.1.  GC  criteria 
2.4.4.1.1.  Criteria 2.3.2.1  and  2.3.2.2 must  be  fulfilled 
2.4.4.1.2.  An  internal  standard  should  be  used  if a material  suitable for 
this purpose  is available.  It should  preferably be  a  stable 
isotope  labelled form  of  the  analyte  or,  if this  is not 
available,  a related standard with  a retention  time  close  to 
that of  the  analyte. 
2.4.4.1.3.  The  ratio of  the  retention time  of  the  analyte  on  GC  to that of 
the  internal  standard,  i.e.  the  relative retention time  of  the 
analyte,  should  be  the  same  as  that of  the  standard  analyte  in 
the  appropriate matrix,  within  a margin  of  ±  0.5%. 
2.4.4.1.4.  For  use  as  a  confirmatory method:  if no  internal 
standard  is used,  then  identification of  the  analyte must  be 
supported  by  using  co-chromatography. 
2.4.4.2.  Criteria for  LRMS 
2.4.4.2.1.  For  use  as  a  screening  method,  at  least the  intensity of  the 
most  abundant  diagnostic  ion  must  be  measured. 
2.4.4.2.2.  For  use  as  a confirmatory method,  the  intensities of  at  least 
four  diagnostic  ions  should  be  measured.  If the  compound  does 
not  yield four  diagnostic  ions  with  the method  used,  then 
identification of  the  analyte  should  be  based  on  the  results of 
at  least two  independent  GC-LRMS  methods  with  different 
derivatives  and/or  ionization techniques,  each  producing  two  or 
three diagnostic  ions. 
The  molecular  ion  should  preferably  be  one  of  the  four 
diagnostic  ions  selected. 
2.4.4.2.3.  The  relative abundances  of  all  diagnostic  ions  monitored  from 
the  analyte  should  match  those  of  the  standard  analyte, 
preferably within  a margin  of  ~ 10%  (EI  mode)  or  ~ 20%  (CI 
mode). 
2.4.5.  Criteria for  the  identification of  an  analyte  by  IR. 
2.4.5.1.  Definition of  adequate  peaks 
Adequate  peaks  are  absorption  maxima  in  the  IR  spectrum  of  a 
standard  analyte,  fulfilling the  following  requirements: 
2.4.5.1.1.  The  absorption  maximum  is  in  the  wavenumber  range  1800-500cm-1 . 
2.4.5.1.2.  The  intensity of  the  absorption  is not  less than: 
(a)  A specific molar  absorbance  of  40  with  respect to zero 
absorbance  and  20  with  respect  to  peak  base  line,  or 
(b)  A relative absorbance  of  12.5%  of  the  abiorbance  of  the 
most  intense  peak  in  the  region  1800-500  em- when  both  are 
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measured  with  respect  to  zero  absorbance,  and  5%  of  the 
absorbance  of  the  most  intense  peak  in  the  region  1800-500  cm-1 
when  both  are measured  with  respect  to  their peak  base  line. 
Note:  Although  adequate  peaks  according  to  (a)  may  be 
preferred  from  a  theoretical  point of  view,  those  according  to 
(b)  are easier to  determine  in  practice. 
The  number  of  peaks  in  the  IR  spectrum  of  the  analyte whose 
frequencies  correspond  with  an  adequate  peak  in  the
1IR  spectrum 
of  the  standard  analyte,  within  a margin  of~ 1 em- is 
determined. 
2.4.5.3.  IR  criteria 
2.4.5.4.1  Absorption  must  be  present  in  all  regions  of  the  analyte 
spectrum  which  correspond  with  an  adequate  peak  in  the 
reference  spectrum  of  the  standard  analyte. 
2.4.5.3.2.  A minimum  of  6 adequate  peaks  is required  in  the  IR  spectrum  of 
the  standard  analyte.  If there  are  less  than  6 adequate  peaks, 
then  the  IR  spectrum  at  issue  cannot  be  used  as  a reference 
spectrum. 
2.4.5.4.3.  The  "score",  i.e.  the  percentage  of  the  adequate  peaks  found  in 
the  IR  spectrum  of  the  analyte,  shall  be  at  least 50. 
2.4.5.4.4.  Where  there  is  no  exact  match  for  an  adequate  peak,  the 
relevant region  of  the  analyte  spectrum  must  be  consistent with 
the  presence  of  a matching  peak. 
2.4.5.4.5.  The  procedure  is only  applicable  to  absorption  peaks  in  the 
sample  spectrum  with  an  intensity of  at  least 3 times  the  peak-
to-peak  noise. 
2.5.  OTHER  METHODS  OF  ANALYSIS 
Analytical  methods  or  combinations  of  methods  other than  those 
considered  in  Sections  2.3  and  2.4  (e.g.  LC-MS,  MS-MS,  GC-IR) 
may  be  used  for  screening  or  confirmatory  purposes  provided 
they fulfil  comparable  criteria which  permit  unambiguous 
identification of  the  analyte at the  level  of  interest. 
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EI 
GC 
lA 
lAC 
IMG 
IR 
LC 
LRMS 
MS 
NSB 
Rf 
SP 
TLC 
I 
e.g. 
APPENDIX 
LIST  OF  ABBREVIATIONS  AND  SYMBOLS 
=  chemical  ionization 
=  electron  impact  ionization 
=  gas  chromatography 
=  immunoassay 
=  immunoaffinity  chromatography 
=  immunogram 
=  infrared  spectroscopy 
=  liquid chromatography 
=  low  resolution mass  spectrometry 
=  mass  spectrometry 
=  non-specific  binding 
=  distance  moved  relative to  the  solvent front 
=  spectrometry,  e.g.  diode  array 
=  thin-layer chromatography 
=  off-line hyphenated  techniques 
=  on-line hyphenated  techniques 
LC/GC-MS  =  LC  off-line followed  by  GC  with  on-line  MS 
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5.2.1.  Introduction. 
Clients of  laboratories need  to  know  that measurements,  tests or  analyses 
carried out  for  them  are  accurate  and  reliable.  Laboratories  often  provide 
this  level  of  quality assurance  (QA)  by  working  to  internationally or 
nationally accepted  standards.  The  main  standards  are  set out  in  the 
documents,  EN  29000,  ISO  9000,  ISO  Guide  25  and  EN  45001. 
There  is  an  International  Laboratory  Accreditation  Conference  (ILAC)  which 
aims  to  harmonise  criteria and  procedures  for  laboratory accreditation as  a 
means  of  dismantling  technical  barriers to  trade,  as  required  by  the 
General  Agreement  of  Tariffs and  Trade  (GATT),  and  to facilitate 
international  acceptance  of  calibration measurements,  test data  and 
certificates from  accredited  laboratories.  The  results of  this technical 
work  are  published  as  ISO/ICE  Guides. 
Several  countries  have  mutual  recognition  agreements  recognising  the 
equivalence  of  services  and  mutual  recognition  of  calibration and  test 
results of  accredited  laboratories. 
In  Western  Europe  laboratory accreditation  in  EC  and  EFTA  is coordinated  by 
two  organisations whose  members  are  national  accreditation  bodies.  These 
organisations  are; 
- Western  European  Calibration Cooperation  (WECC)  for 
calibaration  laboratories  and 
- Western  European  Laboratory Accreditation Cooperation  (WELAC)  for 
testing  laboratories. 
The  criteria used  by  these  bodies  for Accreditation  are  based  on  the  EN 
45000  series and  ISO/IEC  Guide  25. 
Two  Multilateral  Agreements,  one  for  WECC  and  one  for  WELAC  have  been 
signed.  The  signatories are; 
WECC;  Denmark,  Finland,  France,  Germany,  Italy,  the  Netherlands, 
Norway,  Sweden,  Switzterland  and  the  United  Kingdom. 
WELAC;  Denmark,  France  the  Neterlands,  Spain,  Sweden  and  the  United 
Kingdom. 
It is expected  that the  number  of  signatories will  very  soon  be  increased. 
Many  laboratories  and  especially those  carrying out  contract work  find  that 
they  are only  able  to obtain  and  undertake  work  if they  can  show  that they 
are working  to accepted  standards.  In  the field of  veterinary drugs  and 
their residues,  the  standards  required  are either working  under 
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Laboratory  Practice  ..  (GLP)  or  through  a recognised  analytical  accreditation 
scheme.  GLP  is found  more  useful  for  drug  development  and  assessment, 
particulary toxicology,  where  animal  studies are  required.  On  the other 
hand,  analytical  measurement  accreditation  is probably  more  appropriate for 
the  measurement  of  residues. 
This  section  summarises  the  general  requirements  of  QA  and  makes 
suggestions  as  to  how  QA  can  be  achieved  and  improved  for  the  measurement 
of  residues. 
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Quality  is fitness for  purpose. 
The  USDA,  FSIS,  "Chemistry  Quality Assurance  Handbook,  (1982)  states that 
quality assurance  (QA)  and  quality control  (QC)  have  been  defined  in 
several  different ways.  QC  may  be  understood  as  "internal  quality 
control",  namely,  routine  checks  included  in  normal  internal  procedures, 
periodic calibrations,  duplicate checks,  split samples  and  spiked  samples. 
QA  may  also  be  viewed  as  "external  quality control",  those  activities that 
are  performed  on  a more  occasional  basis,  usually  by  a  person  outside of 
the  normal  routine operations,  e.g.  laboratory  inspections,  independent 
performance  audits,  interlaboratory comparisons,  and  periodic evaluation of 
internal  QC  data. 
As  in  the  FSIS  handbook  the  term  Quality Assurance  is used  in  this  section 
to  include  the  above  meanings  of  QA  and  QC. 
Analytical  Quality Assurance  covers  "All  activities and  functions 
concerned  with  the  attainment  of  accurate  and  precise  information  of  the 
required  quality". 
Accreditation  of  a  Laboratory  is achieved  through  a  third party  (competent 
authority)  providing  an  independent  assurance  of  the  competence  of  a 
laboratory and  the  validity of  the  test data  or  calibration it produces. 
Accreditation  should  not  be  carried out  in-house  or  by  the  customer. 
Interlaboratory Comparison  Tests.  These  tests are  carried out  by  a 
recognised  authority  (e.g.  CRL)  using  reference  samples  and  formalised 
protocols.  The  results are  appraised  by  the  competent  authority using 
approved  statistical methods.  ISO/IUPAC/AOAC  have  recently published 
11The 
international  harmonised  protocol  for  the  proficiency testing of  (chemical) 
analytical  laboratories"  and  is  recommended  for  further  information  on  this 
type  of  QA  testing  (ISO/REMCO  N280  report paper  by  Thompson  &  Wood,  1993). 
5.2.3.  Role  of  Community  Reference  Laboratories  {CRLs). 
The  Council  Decision,  89/187/EEC,  lists  in  Article 1 the  functions  of  the 
CRL.  Many  of  these  refer to  providing  a  QA  programme  for  the measurement 
of  residues  by  the  National  Reference  Laboratories  (NRLs).  In  particular 
the  following  summarised  clauses  are  relevant;-
The  CRLs  will;-
a)  coordinate  the  application,  within  the  various  NRL,  of  GLP,  in 
accordance  with  Directives 87/18/EEC  and  88/320/EEC. 
b)  distribute blank  samples  and  control  samples  containing  known 
amounts  of  analyte  to  be  analyzed  blind  in  comparative  tests to  be 
carried out  by  NRLs. 
c)  organize  comparative  tests between  NRLs ... 
d)  conduct  training courses  for  the  analysts  in  the  NRLs. 
5.2.4.  Role  of  Management 
The  management  of  an  organisation/laboratory are  responsible for  setting up 
and  managing  a  QA  system.  The  QA  system  will  address  the  resources, 
processes  and  procedures  by  which  measurements  of  the  required  standard  are 
achieved. 
5/17 The  management  should  have  a written quality policy. 
The  management  should  identify responsibility and  authority for  managing 
the  QA  system.  This  may  entail  the  appointment  of  a  "Quality Manager",  the 
choice  of  inspectors,  auditors  and  testers. 
The  management  are  responsible for  achieving,  allocating and  maintaining 
the  necessary  resources  for  the  QA  system.  The  key  resources  are 
accommodation,  staff and  equipment.  A laboratory will  not  get  accreditation 
if any  of  these  do  not  meet  the  required  standards  set by  the  accreditation 
bodies. 
The  management  should  review  the  QA  system  periodically and  consider  all 
audits  and  complaints. 
Equipment  should  be  adequate  for  the  required measurements  and  should  be 
calibrated and  maintained  on  a  systematic  basis  (see  below). 
5.2.5.  The  QA  System 
The  system  which  should  be  set out  in  the  QA  manual,  will  have  to  take  into 
account  most  of  the  components  listed below. 
1.  Management  and  Organisation. 
2.  Sampling  and  Sample  Handling. 
3.  Staff standards. 
4.  Equipment  Maintenance  and  Calibration. 
5.  Methods  and  Procedures. 
6.  Records 
7.  Certificates and  Reports. 
8.  Audit  and  Review. 
9.  Calibrants,  reagents  and  supplies. 
10.  Handling  of  complaints  and  anomalies. 
5.2.5.1.  Management  and  Organisation. 
A QA  manager  should  be  appointed  who  will  have  the  responsibility of 
managing  and  organising  the  QA  system  preferably on  an  independent  basis  as 
described  in  the  EN  45000  series. 
He  (or  she)  would  report directly to  senior management  and  work  very 
closely with  the  head/manager  of  the  laboratory. 
He  is responsible for checking  and  assuring  that all  the activities  in  the 
laboratory are  set up  and  performed  to  the  required  standard. 
He  will  have  a major  input  into  the  assessment  and  training of  staff. 
He  must  ensure  that the  documentation  for methods,  procedures,  records  and 
reports meet  the  accreditation requirement  (e.g  EN  45000 
series) 
He  will  be  responsible for  internal  auditing,  checking  and  calibration of 
the  performance  of  procedures  and  equipment. 
He  will  liaise with  any  external  auditors  and  have  a major  role  in  inter-
laboratory comparison  studies. 
5/18 5.2.5.2.  QA  System  Procedures 
These  procedures  cover  the  whole  of  the  QA  system.  All  procedures  must  be 
documented,  controlled  and  made  available to the  staff concerned.  There 
should  be  a  .. Quality Manual ..  giving  a general  guide  to the  QA  system.  This 
should  be  produced  by  the  laboratory staff and  will  describe  the  quality 
policy objective and  the  system  to  achieve  it.  It will  include,  detail  of 
the  scope  of  the  laboratory's  accreditation,  an  organization  chart of  the 
laboratory  and  the  staff together with  their  job  descriptions  and 
authorities.  There  should  be  a  list of  approved  signatories. 
There  should  be  easily accessible written  procedures  to cover, 
administration,  documentation,  sampling,  calibration and  standardisation, 
analytical  methods,  testing protocols,  QC  and  QA  analytical  procedures, 
verdicts,  certificates,  reports  and  records.  Some  of  these  procedures  are 
expanded  below. 
5.2.5.3.  Document  Control 
The  control  of  documents  covers  approval  and  issue  and  also  any  changes  and 
alterations.  There  should  be  a  set of  master  documents  which  are  properly 
identified.  Copies  are  issued  to  those  that need  them  and  a record  of 
their distribution kept.  Alterations  and  changes  of  documents  should  be 
done  at the  master  copy  level  and  then  new  copies  and  identities  issued  and 
recorded.  Previous  master  copies  should  be  kept  and  marked 
11SUPERSEDED
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All  obsolete  copies  should  be  collected and  destroyed. 
5.2.5.4.  Staff 
Staff should  have  the  required  skills,  always  where  complex  techniques  and 
equipment  are  used.  Training  and  continuous  education  is essential  and 
within  the  Community  attendance  at  EC  workshops  should  be  encouraged. 
5.2.5.5.  Equipment. 
All  measuring  equipment  that can  influence  quality must  be  controlled, 
calibrated and  maintained. 
The  choice  of  equipment  is  important.  The  equipment  must  be  capable  of 
measuring  to the  required  sensitivity and  tolerance.  An  established design 
from  a reputable  company  is preferred.  Consideration  should  be  given  to 
the  availability of  good  and  reliable service,  maintenance,  spares  and 
repairs.  In  third world  countries this  is of  vital  importance. 
The  replacement  of  equipment  should  be  planned  in  collaboration with  the 
management. 
The  equipment  should  be  uniquely  identified. 
The  documentation  for  the equipment  should  be  properly filed.  It will 
consist of  the  manufacturers  instructions/manuals  and  an  in-house  file. 
This  file should  contain; 
List of  equipment 
Equipment  requiring  calibration and  maintenance. 
Dates  or  intervals for  calibration and  maintenance. 
Calibration procedures  to  be  performed  by  authorised  staff. 
Records  of  calibration and  maintenance. 
5/19 Maintenance  and  Calibration of  Equipment;-
The  regular maintenance  and  calibration of  important  measuring  equipment  is 
essential  for  achieving  accuracy  an  precision of  results.  For  residue 
analysis at  least the  following  items  should  be  checked  and  /or calibrated. 
Balances, 
pipettes  (especially the  automatic  type,  check  the  automatic  pipette 
stations  including  those  for  HPLC  or  GC), 
pH  meters, 
spectrophotometers,  Mass  spectrometers 
HPLC  and  GC; 
Radioisotope  counters 
Temperature  of  fridges,  freezers  and  cold  rooms, 
Thermometers 
5.2.5.6.  Sampling  and  Sample  Handling. 
The  sample  should  be  representative and  its history documented  and 
transferred to  the  analyst.  It must  arrive at the  laboratory  in  a 
condition  which  does  not  alter the  content  of  the  analyte  from  that at the 
immediate  time  of  sampling.  The  procedures  for  proper  sampling  of  animals 
and  food  products  are  described  in  section  6  (6.3.1).  Even  with  the  best 
analytical  methods  and  QA,  inaccurate results are  guaranteed  if the 
original  sample  is wrongly  taken  or  has  deteriorated  and  the  content  of  the 
analyte  been  affected  • 
There  should  be  detailed written  procedures  of  how  to  handle,  store and 
record  samples  on  arrival  at the  laboratory.  The  procedure  should  preserve 
best approximation  of  the  true content  of  the  analyte  in  the  sample  to  be 
analyzed  and  in  replicate samples  and  contra-samples.  Special  attention 
has  to  be  paid  to those  analytes,  e.g.  the  nitrofurans,  which  degrade  very 
quickly  in  biological  tissues. 
5.2.5.7.  Analytical  Methods 
Analytical  methods  may  be  from  different sources;-
Official  Standard  Methods  (e.g.  ISO  methods) 
Standard  Operating  Procedures  which  have  been  accredited  by  a 
recognised  authority or  scheme. 
In-house  methods  which  are  validated  but  not  accredited. 
Several  of  the  methods  in  section 6 are  Standard  Operating  Procedures  (SOP) 
which  have  received  accreditation. 
Methods  should  include  the  following, 
Sampling,  sample  handling  and  storage. 
Safety precautions. 
Scope,  field of  application,  references,  definitions,  principle of 
method. 
Details of  Materials;  reagents,  standards  and  calibrants. 
Details of  equipment. 
Details of  calibration 
Test  sample  preparation. 
Testing  procedure. 
Data  handling;  Calculation  of  results,  checking  results,  data 
transfer,  estimation  of  uncertainty. 
Quality control  procedure  which  include  using  CRMs  and/or  in-house 
reference materials. 
Flow  diagrams. 
5/20 The  methods  require  planned  quality control  and  there  should  be  records  of 
all  QA  measurement.  It is vital  that what  is written  in  the  procedure  is 
carried out,  any  variation  should  be  recorded. 
5.2.5.8.  QC  Procedures  for  analytical  methods  for  residues. 
The  criteria for  the  methods  are  set out  in  the 
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93/256,  given  in  this section.  How  these  are  controlled varies  between 
laboratories.  This  is evident  from  the  different  QC  procedures  detailed  in 
section  6.  However  some  of  the  most  important  and  common  features  for  QC 
are  listed below. 
1.  Method  is accredited or  fully validated  (some  of  the  texts  in  section 
6 are  similar to  the  official  SOP). 
2.  The  analysis,  testing,  calibrating,  calculations and  recording  of 
results are  done  by  authorised  staff and  exactly as  in  the written 
procedures. 
3.  QC  samples  are  used.  These  ideally should  be  in-house  reference 
materials  preferably standardised  against  EC  certified reference 
materials  (CRM)  or  other  internationally approved  standards  if 
available.  The  QC  samples  recommended  are;-
i).  a  blank  with  no  analyte  present, 
ii).  an  incurred  sample  either with  the  analyte  concentration  equal 
to the  MRL  for  the  analyte  or  in  the  case  of  prohibited  substances  at 
a concentration  at or  just above  the  limit of  detection  and/or 
determination  of  the  method. 
iii).  an  incurred  sample  above  the  MRL  or  limit of  detection  but 
approximating  to  a concentration which  might  be  found  in  practice. 
4.  QC  samples  are  measured  in  every  assay.  The  use  of  blind  check 
samples  might  be  used  for  both  internal  and  external  performance 
assessment. 
5.  Spiked  samples  (with  analyte  and/or  internal  standard)  are  used  to 
check  recoveries,  linearity of  response  and  to  produce  calibration 
curves. 
6.  Major  equipment,  which  must  be  suitable for  the measurements,  is 
calibrated and  maintained. 
7.  The  method  for  the  calculation of  results  is detailed and  the  quality 
of  the  results  is tested using  approved  statistical  procedures  such 
as  laid  down  in  ISO  REMCO  N263  (1992)  (Thompson  &  Wood,  1993)  and  see 
also  Heydorn  (1991). 
5.2.5.9.  Tools  for  checking  data. 
The  statistical control  of  data  is recommended  and  reviewed  by  Heydorn 
(1991).  Some  good  examples  of  the  use  of  charts  is given  in  volume  I  of 
the  USDA,  FSIS,  Chemistry  Quality Assurance  Handbook,  1987  and  also 
Griepink  (1990a,  1990b). 
Charts  are  a  useful  approach  to  reviewing  measurement.  Their  construction 
is used  to  detect trends,  biases  and  performance  of  an  analytical  method. 
Eaasy  to  use  and  construct are either Cusum  or  Shewhart  charts. 
5/21 Cusum  Charts.  A Cusum  (Cumulative  sum)  control  chart  is useful  in  a 
laboratory carrying out  the  same  analyses  many  times  over  a  long  period  of 
time.  It is a  graphic  plot of  the  running  summation  of  process  deviation 
from  a  control  value.  Its underlying  mathematical  concepts  are  highly 
involved,  but  its construction  is simple.  An  example  which  might  be 
appropriate  to  residue analysis  is  shown  below.  In  this example  the 
recovery of  an  internal  standard  is measured;  the  normal  expected  recovery 
is  60%  and  values  between  50%  and  65%  are acceptable.  During  the first six 
months  the  analysis  is functioning  properly but  by  September  there  is a 
clear warning  that the analysis  may  be  out  of  control.  By  November  the 
analysis  is out  of  control.  Remedial  action  had  clearly cured  the  problem 
by  December  and  into  the  new  year. 
Date  of Analyses. 
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5/22 Shewhart  Control  Charts.  These  charts are  a graphical  representation of 
control  limits for  the  average  mean  and  range  of  results for  a  set of 
analyses.  The  determination  of  the  appropriate  control  limits  (upper  and 
lower  confidence  limits  and  the  upper  and  lower  warning  limits)  can  be 
based  on  the  capability of  the  procedure  itself as  known  from  past 
experience  or  on  the  specified requirements  of  the  measurement  procedure 
(e.g.  a function  of  the  standard  deviation  as  set out  in  the  Criteria 
Decision,  93/256/EEC,  see  above). 
An  example  (hypothetical)  of  a Shewhart  graph  is  shown  below.  A reference 
sample  was  measured  in  duplicate  as  a  QC  control  in  each  of  a series of 
analyses.  The  results of  the  mean  values  and  the  range  for  the  QC  samples 
are  plotted.  The  mean  values  are  all within  the  confidence  limits although 
one  value  (analysis 9)  is suspiciously high  especially since  the  range  was 
low  probably  caused  by  a  systematic error.  One  of  the  values  (analysis 6) 
for  the  range  is unacceptable.  Checking  the  raw  data  for  this analysis  may 
well  indicate that one  or  both  of  the  results  is a 
11rogue
11  or 
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This  may  be  caused  by  a  random  error. 
Figure  2.  Shewhart  Control  Graphs  for  means  and  ranges. 
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The  upper  and  lower  confidence  limits are  shown  as  solid  lines;  the  dotted 
lines are  the  upper  and  lower  warning  limits which  are  sometimes  set at 
twice  the  SD.  Further  information  can  be  found  in  volume  I  of  the  USDA, 
FSIS,  Chemistry  Quality Assurance  Handbook,  1987. 
5.2.5.10.  Audit  and  Review. 
Audit;  The  laboratory should  always  carry out  regular  internal  audits of 
the  QA  system  and  pay  particular attention to  the  procedures  and  methods 
for  analysis.  With  both  GLP  and  accreditation of  methods,  audits  are 
compulsory.  Under  GLP  all  procedures  are  audited  on  a regular  basis  by 
personnel  who  are  independent  of  the  laboratory staff carrying  out  a 
particular study.  Under  most  accreditation  schemes,  there  is third party 
examination  of  the  analytical  methods.  Failure to  meet  the  required 
standards  after being  allowed  a short period  for  corrective action  can  lead 
to  loss  of  accreditation.  Under  the  NAMAS  scheme  in  the  UK  the 
laboratories may  be  required  to  measure  audit samples.  Similarly under  EC 
Directive 86/469  the  CRLs  could  make  use  of  RMs  to check  the  performance  of 
the  NRLs  in  their measurement  of  residues. 
5/23 Review;  Reviews  of  the  QA  system  should  be  done  on  a  regular  basis  by 
senior·  management  in  consultation with  the  QA  management.  The  results of 
the  review  should  be  communicated  to  the  relevant staff. 
5.2.5.11.  Reports  and  Records. 
The  laboratory will  keep  all  raw  data  and  copies  of  results,  reports  and 
records.  The  QA  manager  will  be  responsible for  checking  and  auditing  that 
the  data  is calculated,  recorded  and  reported  according  to  the  agreed 
procedures.  Good  quality reports  and  records  are  of  great benefit  in  the 
event  of  problems  with  the  analyses,  queries  by  customers  and  for external 
audit.  The  retention time  of  the  reports  and  records  is decided  and 
written  into the  procedures.  For  GLP  they  must  be  kept  for  10  years,  for 
an  accreditation  scheme  e.g.  NAMAS,  UK,  for  6 years. 
5.2.5.12.  Corrective  Actions. 
The  QA  system  should  have  a  documented  procedure  to  investigate anomalies, 
complaints  and  serious  non-compliancies.  All  corrective actions  and  their 
effectiveness  is recorded.  All  non-compliancies  reported  through  the 
audits  must  be  subject to  corrective action.  If doubt  arises about  the 
data  reported  by  the  laboratory,  the  clients must  be  notified  in  writing. 
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5/24 6.  ROUTINE  METHODS  FOR  DETECTING  RESIDUES. 
THE  METHODS  CHOSEN  FOR  INCLUSION  IN  THIS  MANUAL  ARE  A SELECTION  OF  METHODS 
USED  IN  VARIOUS  MEMBER  STATES.  THEY  DO  NOT  HAVE  OFFICIAL  STATUS  FROM  THE 
EUROPEAN  COMMISSION  AND  AT  THIS  STAGE  CANNOT  BE  TREATED  AS  OFFICIAL 
COMMUNITY  REFERENCE  METHODS. 
The  definitions of  routine methods  for  screening  and  confirmatory  purposes 
is given  in  section  5.1.1.  All  of  the  methods  covered  in  this section 
should  meet  the  criteria laid  down  in  section  5 and  published  as  EC 
Decision  93/256/EEC.  The  routine  screening  and  some  of  the  confirmatory 
tests used  by  Member  States as  of  August  1993  are  tabled  in  section 4. 
The  Council  Decision  91/664  designating  the  Community  reference 
laboratories  (CRL)  for testing certain substances  for residues  and  the 
Council  Decision  89/187  determining  the  powers  and  conditions  of  operation 
of  CRL  provided  for  by  directive 86/469  EEC  concerning  the  examination  of 
animals  and  fresh  meat  for  the  presence  of  residues  have  established a 
major  role for  the  four  CRL  in  the  development,  testing,  quality assurance, 
advice  and  training for  analytical  methodology.  This  manual  serves  as  an 
adjunct  to  their role. 
6.1.  ROUTINE  SCREENING  METHODS. 
Routine  screening  methods  should  be  rapid with  high  throughputs,  rugged, 
inexpensive  and  be  sensitive enough  to  monitor  the  levels of  interest  (e.g. 
MRLs)  with  the  minimum  of  false negatives. 
The  wide  variety of  drugs  and  their residues  requires  that several 
different procedures  are  needed  to  monitor  all  the  possibilities.  The 
ideal  would  be  to  analyze  a  sample  for  all  possible residues  using  one 
procedure.  The  complete  separation  of  residues  by  chromatography  coupled 
with  a  sensitive end-point  detection  system  has  been  attempted  with  limited 
success  (e.g.  Verbeke,  1979,  Malisch,  1986).  In  general  the  most  promising 
results are where  procedures  have  been  limited  to residues  of  substances 
within  classes of  drugs.  Multiresidue  screening  methods  are  available for; 
1.  Antibiotic  substances  using  the  Four  Plate Test 
2.  Sulphonamides  by  TLC  or  IA. 
3.  Anabolics  by  IA  or  GC-MS 
4.  Benzimidazoles  by  HPLC 
5.  B-agonists  by  GC-MS  or  IA. 
6.  Sedatives  and  tranquillisers  by  HPLC. 
6.1.1  Assay  Kits  for  screening  for  Residues. 
Screening  procedures  are well  suited for  the  application of  commercially 
available assay  kits.  The  kits must  be  rugged  and  transportable  on  an 
international  basis.  A list of  commercial  suppliers  and  their assay kits 
is given  in  section 8.4  and  a  summary  is  shown  in  table 1 below.  Some 
important  antibodies  and  other  reagents  for  assays  are  also  listed  in 
Section  8. 
6/1 Table  1.  Assay  Kits  for  Veterinary  Drug  Residues. 
Group  Drug  Residue  Assay  Supplier 
19-Nortestosterone  EIA  Euro-diagnost 
19-Norandrostenedione  ica,  NL 
AI  Stilbenes,  Zeranol,  RIA  Genego,  Italy 
Anabolics  Trenbolone. 
Zeranol,  DES,  ELISA  Genego,  Italy 
19-Nortestosterone, 
19-Nortestosterone,  ELISA  Randox,  UK-NI 
Trenbolone, 
19-Nortestosterone,  ELISA  R-BIOPHARM  GmbH 
Ethinyloestradiol,  Germany 
Trenbolone,  DES,  Zeranol. 
DES,  19-Nortestosterone  ELISA  RIEDEL-DE-HAEN 
Zeranol,  Taleranol,  Germany 
Trenbolone,  Oestradiol, 
Ethinyloestradiol, 
Testosterone, 
Acetylgestagenes 
All  Progesterone  ELISA  Genego,  Italy 
Natural  Testosterone  ELISA  Randox,  UK-NI 
Steroids  Oestradiol-17B  ELISA  R-BIOPHARM  GmbH 
Testosterone  Germany 
Progesterone  ELISA  RIEDEL-DE-HAEN 
Germany 
Chloramphenicol  EIA  Euro-diagnost-
ica,  NL 
All  Chloramphenicol,  ELISA  Genego,  Italy 
Sulphadimidine,  Penicillin-G 
Antibiotics  Sulphonamides  ELISA  Randox,  UK-NI 
Chloramphenicol,  EIA  Rhone-Poulenc, 
Sulphadimidine,  Card  France 
Sulphamethoxine,  Gentamicin 
Chloramphenicol,  ELISA  R-BIOPHARM  GmbH 
Sulphadimidine,  Germany 
Streptomycin,  Tetracycline. 
6/2 Table  1 continued. 
Group  Drug  Residue  Assay  Supplier 
B-agonists  Clenbuterol,  salbutamol,  EIA  Euro-diagnost-
mabuterol  &  mapenterol  ica,  NL 
Clenbuterol,  salbutamol,  ELISA  Genego,  Italy 
mabuterol,  mapenterol  and 
terbutaline 
Clenbuterol,  salbutamol  ELISA  R-BIOPHARM 
mabuterol,  terbutaline,  GmbH,  Germany 
Clenbuterol,  mabuterol,  ELISA  RIEDEL-DE-HAEN 
salbutamol,  mapenterol  Germany 
and  terbutaline 
Clenbuterol,  mabuterol,  ELISA  MARLOIE, 
salbutamol,  terbutaline,  Belgium 
cimaterol 
6.1.2  Residues  in  Milk. 
This  manual  does  not  give  detailed methods  for  residues  in  milk  as  the 
methods  are  suitably described  in  the  Bulletin of  the  International  Dairy 
Federation  ~258/1991.  The  methods  are  divided  into  two  sections;-
1.  Methods  for  the  detection of  inhibitors. 
- Microbial  inhibition tests,  screening  and  confirmatory 
- Other  tests not  based  on  microbial  inhibition. 
2.  Special  Methods  for  the  detection  of  the  antibiotics,  B-lactams, 
chloramphenicol,  tetracyclines,  macrolides,  aminoglycosides  and 
sulphonamides  in  milk  and  milk  products. 
- Many  of  these methods  are  similar to  those  used  for  testing 
animals  and  other animal  products  but  are  specially adapted  for 
use  with  milk  and  milk  products.  They  include  lA,  HPLC,  TLC, 
electrophoresis  and  GC. 
6.1.3  Screening  for  residues  of  antimicrobial  substances. 
6.1.3.1.  Introduction. 
Antimicrobial  substances  are widely  used  in  farm  animals.  There  is both 
therapeutic  and  prophylactic  use.  The  drugs  are  administered  either 
parentally or  added  to the  drinking  water  or  feed.  The  unique  property of 
antimicrobial  substances  is that they  can  be  assayed  for  their 
antimicrobial  activity.  Vast  numbers  of  meat  (and  milk)  samples  are  assayed 
for  the  determination  of  the  antimicrobial  activity of  any  residues 
present.  Because  there  is such  a  large  variety of  antimicrobial  compounds 
with  very  different chemical  structures and  molecular  weights  it is not 
easy  to  identify the  nature  of  the  chemical  substance  causing  the 
antimicrobial  activity in  the  tests.  Also  the microbiological  methods  are 
less  sensitive for  some  drugs  than  others  and  many  antibiotics  (e.g. 
chloramphenicol,  sulphonamides,  nitrofurans)  are  not  successfully detected 
in  the  standard  tests such  as  the 
11Frontier Post  Test
11
•  Many 
antimicrobials  and  especially those  insensitive to the 
11Frontier Post  Test  .. 
are  regulated  as  individual  substances  using  chemical  methods.  These 
methods  are  sensitive enough  to regulate  MRLs  (see  section  2). 
6/3 6.1.3.2.  General  scheme  for  testing for antibiotics. 
Routine  Screening  tests;  These  are  carried out  using  one  of  the  following 
procedures  for  testing meat;-
1.  The  official  EC  "Frontier Post  Test"  (Bogaerts  and  Wolf,  1980)  which 
is  sometimes  called the  Four  Plate Test,  or  a modified  version  of 
this test.  In  1993  the  CRL  at Fougeres  recommends  a modified  version 
(see  method  Sg  3.1)  for  general  use  by  Member  States. 
2.  An  enzyme  immunoassay  test.  (e.g.  for  sulphonamides,  chloramphenicol 
gentamicin) 
3.  Chromatographic  methods  using  TLC,  HPLC  or  occasionally GC. 
Numerous  sensitive and  well  developed  methods  for  testing for  antibiotics 
in  milk  are  available  (see  6.1.2). 
Routine  Confirmatory  Tests;  Methods  based  on  GC-MS,  LC-MS  or  HPLC,  are 
well  developed  for  confirming  the  presence  of  individual  substances  which 
have  been  tentatively identified  in  the  screening  tests.  Examples  of 
methods  are  given  in  section  6 for  the  confirmation  of  residues  of  the 
sulphonamides,  chloramphenicol,  tetracyclines and  nitrofurans.  It is 
difficult to  identify the  nature  of  residues which  are  positive with 
respect  to  their antimicrobial  activity.  A method  combining  the  separation 
of  antibiotics  into groups  by  using  High  Voltage  Electrophoresis  and 
identifying the  separated  groups  with  a microbial  inhibition test has  had 
some  success  (Smither  and  Vaughan,  1978). 
Tests  based  on  Antimicrobial  Activity. 
Frontier Post  Test. 
This  test  is carried out  as  an  agar  diffusion test,  and  the meat  samples 
are  applied  to  four  plates of  agar  medium  inoculated with  Bacillus  subtilis 
spores  (at  pH  6.0,  7.2  and  8.0)  and  Micrococcus  luteus  (at  pH  8.0). 
Trimethoprim  is  incorporated  into  the  pH  7.2  medium  to  enhance  the  test's 
sensitivity toward  sulphonamide  residues.  Diffusion  of  an  antibacterial 
substance  is  shown  by  the  formation  of  zones  of  inhibition of  one  or  both 
microorganisms.  The  test  is  an  official  EC  method  based  on  the  method  of 
Bogaerts  and  Wolf,  (1980). 
The  detection of  an  antimicrobial  agent  by  this test depends  on  the  lower 
limit of  sensitivity for  that agent  using  the  most  sensitive combination  of 
test organism  and  growth  conditions  applied  to  the  target tissue.  The 
data  shows  that the  test  is sensitive for  B-lactam  antibiotics,  all  tested 
aminoglycosides,  macrolides  and  tetracyclines,  novobiocin,  and  the  one 
tested polypeptide  antibiotic,  bacitracin.  The  test is relatively 
insensitive for  chloramphenicol,  furazolidone  and  trimethoprim.  Many  other 
groups  of  antibiotics  have  only  been  partially tested.  The  CRL  at 
Fougeres,  have  modified  the  method  by  reducing  the  volume  of  agar  in  the 
Petri  dishes.  This  modified  method  which  is replacing  the  official  method 
in  France  is given  in  full  detail  in  Method  number  Sg  3.1. 
It is suggested  that for  all  agents  which  cannot  be  measured  by  this test 
at a sensitivity of  1 mg  per  kg  muscle,  alternative assay  procedures  are 
developed  in  order  to reach  this  level  of  sensitivity.  Agents  of  special 
interest  in  this class are  chloramphenicol,  sulphonamides  and  nitrofurans. 
6/4 
I High  Voltage  Electrophoresis  (HVE)  Method. 
Since 
11false  positive  ..  results must  be  eliminated  from  the  Frontier Post 
Test  results  by  further  analysis,  it makes  sense  to determine  at the  same 
time  which  antimicrobial  agent  is present  in  the 
11true positive  ..  results. 
This  may  be  achieved  in  a method  combining  HVE  with  microbial  inhibition 
(Smither  and  Vaughan,  1978).  The  antimicrobial  substances  are  separated  on 
an  agar  coated  plate  into  groups  which  are  then  positionally  identified 
with  a microbial  inhibition test. 
The  test  is  both  difficult to  perform  and  sometimes  lacks  precision. 
Nevertheless  fifty antimicrobial  substances  have  been  identified by  this 
test including  chloramphenicol  and  furazolidone. 
[Editor;  There  is probably  scope  for  improvement  in  this type  of  test 
because  of  the  rapid  development  in  techniques  for  separation  by 
electrophoresis.]. 
Chemical  Methods. 
The  methods  used  for  the  measurement  and  detection  of  antimicrobials with  a 
molecular  weight  less  than  1000  daltons  (e.g.  tetracyclines,  sulphonamides, 
B-lactams  and  chloramphenicol)  are  no  different from  those  for other 
veterinary drugs  of  similar molecular  weights. 
Some  antimicrobials  are  very  big  molecules  with  high  molecular  weights  and 
these  drugs  are  among  the  most  difficult to  measure  and  identify.  These 
substances  are  not  ideal  for  GC-MS  or  immunoassay  methods.  Immunoassay  is 
sometimes  a  problem  because  of  the  difficulty of  making  a suitable 
immunogen  without  disturbing  the  quaternary  structure of  the  large  parent 
molecule.  These  drugs  can  often  be  best measured  using  HPLC,  where  mild 
solvents  and  low  temperatures  are  less  damaging.  A good  example  is the 
measurement  of  Ciprofloxacin  and  Enrofloxacin  (see  Method  number  Sg  3.5. 
The  combination  of  HPLC  with  MS  (LC-MS)  is  new  technology which  is being 
successfully applied  to  the  analysis  of  high  molecular  weight  veterinary 
drugs  and  proteins. 
6.2  ROUTINE  CONFIRMATORY  METHODS. 
The  purpose  of  the  confirmatory methods  is to  determine  the  presence  or 
absence  of  a residue  in  a  sample  found  positive  in  a routine  screening 
analysis.  In  the  future  some  of  the  confirmatory methods  may  be  approved 
by  the  Community  and  be  designated  Community  Reference  methods. 
The  selection of  a method  depends  on  a combination  of  resources  and  the 
selectivity of  the  method.  The  selectivity index  (see  Van  Ginkel  and 
Stephany,  1989;  Stephany  and  Van  Ginkel,  1990)  is based  on  the  summation  of 
the  partial  indices  for  each  stage  of  the method.  Not  surprisingly methods 
with  several  stages  have  a  high  selectivity index  and  those  methods  which 
combine  chromatographic  clean  up  (particulary  IAC,  HPLC  and  GC)  with  end-
point  spectrometry  score  best. 
Confirmatory  methods  should  preferably be  based  on  molecular  spectrometry 
to  provide  direct  information  about  the  molecular  structure of  the  residue 
(see  Criteria,  section  5).  The  application of  spectrometry  to  residue 
determination  is progressing  rapidly but  the  measurement  of  residues  at 
concentrations  <1  ~g per  kg  is difficult,  especially  in  the  transfer of 
6/5 methods  to  other  laboratories.  In  the  interim period  until  spectroscopic 
methods  are  further  developed,  validated methods,  or  a  battery of  methods, 
providing  indirect  information  on  the  molecular  structure may  be  used. 
An  earlier problem  with  detection  and  determination  of  anabolics  at 
concentrations  in  the  sub  ppb  level  was  the  sensitivity of  the  end-point 
detection  system.  Until  recently routine confirmatory methods  were  limited 
to  the  use  of  immunoassay  at this  level  whereas  spectroscopic methods  were 
applied  at higher  levels.  The  sensitivity and  availability of  MS  and  IR 
has  improved  and  although  the  HPLC/RIA  methods  have  been  shown  to  give  the 
same  results as  MS  methods  (Jansen  et al,  1986)  the  spectroscopic methods 
are  the  recommended  methods  of  choice  (see  Criteria,  Section  5). 
The  approximate  applicability limits for  various  molecular 
11full  spectrum  .. 
detectors  as  such  or  on-line with  chromatographic  separation  techniques  can 
be  estimated  by  considering  the  sensitivity of  the  detectors as  shown 
below. 
Spectrum  Detector  Minimum  mass  for 
full  spectrum 
IR 
GC-IR 
HPLC-UV 
TLC-UV 
*GC-FTIR 
GC-MSD 
eLC-MS 
GC-MS 
MS-MS 
(ng) 
100 
100 
100 
100 
(cryotrapping)  1 
0.1 
0.02 
0.01 
0.001 
Lowest  content  Mass  of  sample  toR 
for  1 g sampleR  find  1  ~g per  kg 
(ug  per  kg)  (g) 
100 
100 
100 
100 
1 
0.1 
0.02 
0.01 
0.001 
100 
100 
100 
100 
1 
0.1 
0.02 
0.01 
0.001 
Data  pr~sented by  R.  Schothorst  at  EEC  Workshop,  RIVM  - RIKILT,  28th  Nov. 
1988;  at  EEC  Workshop,  RIVM,  22-26  April,  1991;  eat Euroresidues  II, 
~eldhoven,  The  Netherlands,  May,1993. 
assuming  100%  recovery  of  analyte. 
The  rapid  emergence  of  spectroscopic methods  has  a  drawback  for  this manual 
in  that the  technology  is continually developing  and  methods  are  either not 
published  or  are  published  as  single methods  used  in  only  one  or  two 
laboratories.  Many  of  these methods  and  the  other types  of  confirmatory 
methods  have  not  been  validated  by  ring  tests between  the  Member  States nor 
have  they  been  approved  as  Community  Reference  Methods. 
6.2.1  EEC  WORKSHOPS. 
There  is a  programme  organised  through  DGVI  to  hold  EEC  workshops  where 
scientists from  the  Member  States receive  training  in  residue method 
technology.  To  date  the  following  workshops  have  been  held; 
DATE 
1981 
1985 
PLACE 
BGA,  Berlin 
Brussels 
TITLE 
RIA  methods  for  the  stilbenes. 
TLC  methods  for  thyreostats 
6/6 1986  BGA,  Berlin  RIA  method  for  chloramphenicol 
1987  Weihenstephan  IA  methods  for  anabolic  agents 
1988  RIVM,  Bilthoven  HPLC  and  IAC/GC-MS  for  anabolic  agents 
1990  Brussels  TLC  methods  for  B-agonists 
1991  RIVM,  Bilthoven  MS  methods  for  B-agonists 
1994  RIVM,  Bilthoven  GLP  for  NRLs 
also 
1993  Univ.  Liege  - EC-Flair  Workshop  ,  MS  for  residue  analysis 
6.2.2.  Multiresidue  and  Modular  Methods. 
Traditional  analytical  strategies are  gradually being  replaced  by 
multiresidue  techniques  of  a modular  nature.  Van  Ginkel  and  Stephany 
(1990)  conclude  that these  alternative strategies are more  flexible with 
respect  to  changes  in  matrix  and  analyte. 
More  than  thirty of  the  most  probable  residues which  could  occur  in  animal 
products  can  be  determined  using  just three multi-residue  GC-MS  methods. 
Special  attention  is also  given  to  making  these multi-residue methods  into 
modular  methods.  The  purpose  of  these  methods  is to reduce  the  number  of 
methods  which  a  laboratory needs  to establish.  The  methods  contain  options 
which  could  fulfil  the  Criteria  in  Section  5.  The  methods  contain  three 
key  elements,  an  initial extraction,  a clean-up  and  purification  by 
chromatography  and  an  end  point  determination  using  either  GC  or  HPLC 
coupled  to  MS.  Future  development  will  almost  certainly include  GC-FTIR 
using  a  cryotrapping  technique  (Visser et 1993).  For  some  large molecules 
the  application of  capillary gel  electrophoresis  coupled  toMS  is an 
exciting prospect. 
6.2.3  Availability of  reagents  and  standards. 
The  choice  of  method  is also governed  by  the availability of  reagents  and 
standards.  In  some  cases  there  is difficulty obtaining  immunoaffinity 
chromatography  (lAC)  columns  or  the  antibodies  for  lAC,  also  the 
availability of  pure  standards  and  especially deuterated  standards  is a 
problem.  The  Measurement  and  Testing  Programme  (BCR)  is funding  programmes 
and  encouraging  the  production  of  many  of  these  reference  compounds  and  RMs 
so  that they  are  available throughout  the  Community  (see  section 8).  For 
the  validation of  these methods  certified reference materials  are of  great 
importance.  Many  reagents  and  reference  compounds  are  available 
commercially  but  in  an  industry where  the market  is small  the  supply  of  the 
materials  may  change  very  quickly.  A list of  suppliers of  immunochemicals 
and  reagents  is given  in  section 8.4. 
6.3.  GENERAL  PROCEDURE  FOR  ROUTINE  METHODS  TO  DETERMINE  RESIDUES  OF 
ORGANIC  ANALYTES. 
All  the  methods  follow  a  similar sequence  of  procedures  shown  in  the  flow 
chart.  In  some  of  the  methods  the  extraction  and  chromatographic 
purifications steps  may  overlap  or  be  merged  and  for  some  screening  methods 
a  simple  extraction procedure  followed  by  a rapid end-point  determination 
is often  sufficient. 
6/7 FLOW  CHART  OF  PROCEDURES. 
(i) Representative  sample  or  RM. 
(ii)  Add  internal  standard 
(iii) Homogenise  tissues I  dilute fluids 
(iv)  Hydrolyse 
(v)  Initial extraction 
(vi)  Clean  up  extraction  by  solvent/solvent partition 
(vii) Clean  up  and/or  resolution  by  chromatography 
(viii)  End  point  determination 
(ix)  Quality assurance  procedures. 
(x)  Calculation of  results. 
(xi)  Reporting  of  results 
GENERAL  COMMENTS  ON  PROCEDURES. 
6.3.1  (i)  Representative  sample; 
6.3.1.1  Legal  Basis  (EC  legislation). 
The  sampling  for  the  National  Surveillance  Schemes  is regulated  under 
- The  Council  Directive 86/469  concerning  the  examination  of  animals 
and  fresh  meat  for  the  presence  of  residues.  This  Directive  is 
undergoing  modification. 
- Commission  Decision  83/153  concerning  the  correlation of  samples 
taken  for  residue examination  with  animals  and  their farm  of origin. 
6.3.2.  Technical  and  Administrative  Procedures. 
6.3.2.1.  Which  Samples? 
The  choice  of  matrix  shall  depend  on  : 
- the  analyte  and  its route of  excretion. 
- the  analytical  method  of  detection 
The  biological  fluid  sample  is either urine,  bile,  blood  (as  plasma  or 
serum)  or  milk. 
The  tissue samples  are either muscle,  liver,  kidney,  fat or  eggs.  In  rare 
cases  other organs  may  have  to  be  examined  (e.g.  residues  of  B-agonists  may 
investigated using  the  eyes  of  cattle). 
Also  the  difficulty/ease of  collecting the  sample  should  be  considered:  It 
is easier to collect blood  or  faeces  than  urine from  live bovine  animals  at 
the  farm.  In  this case  the  laboratory has  to develop  specific clearing 
procedures  if faecal  materials  are  the  only  matrix  at its disposal. 
6.3.2.2.  Quantity  (How  much?) 
This  must  be  divided  into  several  parts  (see  6.3.2.4.)  and  each  part 
sufficient for  the  analysis.  Large  volumes  of  fluids  are  recommended 
although  the  use  of  a diuretic to  increase  the  volume  of  urine  is not 
recommended  as  this may  have  a dilution effect on  the  concentration  of  the 
residue. 
6.3.2.4.  Division  of  the  Samples. 
According  to  the  different national  laws  it can  be  compulsory  to  divide  the 
sample  into  two  or  three  parts as  aliquots  into  suitable containers  (e.g 
bottles,  tubes  or  bags).  These  samples  are  used 
1.  for  the  routine  analyses. 
6/8 2.  as  contra-samples  for  use  by  the  owner  of  the  animal  or  meat. 
3.  put  at the  disposal  of  a Court  of  Justice. 
The  sample  may  be  divided  at the  point  of  collection  i.e.  farm  or 
slaughterhouse.  More  usual  and  to  be  recommended  is the  division of  the 
sample  on  reception  at the  laboratory.  This  latter procedure  is preferred 
especially where  some  pretreatment  of  the  sample  is essential  before 
storage. 
6.3.2.5.  Identification. 
The  identification on  the  container  should  be; 
indelible 
marked  on  the  main  part of  the  container  (not  just the  removable  top) 
linked  with  the  complete  information  written  on  the official  sampling 
form. 
The  following  information  must  be  recorded;-
the  name  and  address  of  the  owner  or  person  in  charge  of  the  animal; 
the  name  and  address  of  the  premises  where  the  sample  was  taken; 
the  species,  sex  and  age  of  the  animal; 
the  type,  amount  and  method  of  collection; 
the  identification of  the  animal  or  a reference  permitting the  farm 
of  origin of  the  animal  to  be  identified; 
the  name,  position  and  signature of  the  official  agent  collecting the 
sample 
the  date  of  sampling  and  the  date  of  expedition  to  the  laboratory. 
6.3.2.6.  Sealing. 
The  package  shall  be  sealed  (e.g.  wax  or  lead  seal)  in  order  to prevent  any 
change  in  the matrix  during  storage or  transport. 
6.3.2.7.  Storage. 
If the  sample  cannot  go  immediately  to  the  laboratory,  it must  be  stored as 
soon  as  possible,  in  a chilling room  or  freezing  room,  on  the  condition 
that the freezing  procedure  does  not  destroy the  molecules  of  the  residue. 
6.3.2.8.  Transport. 
Transport  to  the  laboratory must  be  carried out  under  such  conditions  that 
the  sample  is kept  at its temperature  of  conservation. 
Expedition  before  a week-end  or  a  holiday  period  shall  be  avoided.  Too 
often  the  laboratories receive  samples  impossible  to  use  because  of  bad 
conditions of  transport,  e.g.  broken  package,  matrix  at the  ambient 
temperature  or  the  sampling  form  lost. 
6.3.2.9  Summary. 
These  general  recommendations  have  to  be  adapted  to  each  situation,  but  it 
is clear that the reliability of  the  result  is very  dependant  on  the 
quality of  the  sampling  procedure. 
The  samples  are  usually stored  deep  frozen  and  only  thawed  immediately 
before  analysis. 
6.3.3  (ii) Addition  of  internal  standard  (ISTD). 
Internal  standards  are  used  a)  to monitor  and  measure  recovery 
b)  as  calibrants for retention times  or  reference  values  in  chromatography 
systems. 
6/9 For  RIA  end  point measurements  the  ISTD  is a  radiolabelled form  of  the 
analyte  in  question. 
For  methods  with  chromatographic  end  points  a  substance with  similar 
chemical  and  physical  properties  to  the  analyte  is  used  but  it must  be 
clearly separated  from  the  analyte  and  other major  residues  in  the  final 
chromatographic  analysis. 
ForMS  methods  an  isotope  labelled form  of  the  analyte  is used  which  must 
be  distinguishable from  the  analyte  in  the  MS  and  have  a  similar  ionisation 
mechanism  compared  to  the  analyte.  If the  isotope  is deuterium  then  the 
possibility of  hydrogen  - deuterium  exchange  between  the  ISTD  and  the 
analyte  should  be  checked. 
6.3.4  (iii) Homogenisation; 
Fluids  do  not  normally  require  homogenisation  and  bile,  urine,  plasma  or 
serum  are  thawed  and  an  aliquot diluted  in  buffer.  Milk  which  has  separate 
fat  and  aqueous  phases  will  require  special  treatment  depending  whether 
whole  milk  or  one  of  the  phases  is to  be  tested. 
Tissues  except  fat are  thawed  and  a  representative sample  is added  to a 
buffer  and  the  sample  homogenised  at ooc  using  a  blade  homogeniser  or  in 
some  cases  a  stomacher.  Losses  can  occur  due  to  inadequate  transfer of 
materials  during  this procedure. 
Fat  is often  cut  into  small  pieces  and  either melted  or  dissolved  into  an 
organic  lipophilic solvent  from  whence  it is treated as  a fluid. 
6.3.5  (iv)  Hydrolysis; 
Many  analytes  form  conjugates  e.g.  as  sulphates or glucuronides.  The 
conjugates  are  normally  soluble  in  buffer solutions  and  may  be  hydrolysed 
to  liberate the  free analyte. 
Hydrolysis  is best achieved  using  suitable enzyme  preparations  and  mild 
conditions.  Hydrolysis  using  acids  or  alkalis should  only  be  used  when  it 
is certain  no  degradation  of  the  analyte occurs. 
6.3.6  (v)  Initial  Extraction; 
Solvent/solvent  partition  has  formed  the  basis of  extraction and  clean  up 
procedures  for most  of  this century.  It still plays  an  important  role and 
is the  primary  extraction step  in  most  assays  measuring  organic  molecules. 
The  purpose  of  the  extraction  is to  remove  as  much  of  the  interfering 
cellular material  and  organic  compounds  as  possible while  retaining the 
majority of  the  analyte. 
The  solvents  used  depend  on  the  properties of  the  analyte  as  determined  by 
polarity,  pH  and  solubility in  different solvents. 
The  commonly  used  systems  include;-
Homogenate  or  solution  in  aqueous  buffer I  immiscible  organic  solvent 
Organic  solvent  I  aqueous  phase  various  pH 
Polar  phase  (e.g.  methanol/water)  I  Non-polar  solvent 
(e.g.  petroleum  ether) 
Matrix  Solid-phase  Dispersion  (MSPD). 
The  method  involves  the mechanical  blending  of  the  sample  with  bulk 
sorbent.  The  initial  studies were  performed  using  a  C-18  sorbent,  a 
silicate based  bonded  phase  that can  solubilize samples  rich  in  lipid 
6/10 material.  The  silicate particles act as  a  strong  abrasive  and  also  provide 
a structurally stable support  for  the C-18  molecule.  As  the  sample  becomes 
disrupted  it is dispersed  over  the  surface of  the  support  by 
hydrophobic/hydrophillic  interactions.  The  mixture  is semidry  and  is 
readily packed  into  columns.  The  analyte  can  be  eluted using  selected 
solvents.  This  technique  coupled  with  SPE  (see  below)  has  provided  a 
successful  method  for  measuring  residues of  Ivermectin  at the  1-2  ~g per  kg 
levels  (Schenk,  Barker  and  Long,  1989) 
6.3.7  (vi)  Chromatographic  clean  up; 
Chromatography  is perhaps  the  most  important  technique  in  the  methods,  not 
only  is  it used  to give  highly  purified fractions  containing  the  analyte 
prior to  the  end  point  determination  but  it is also a  key  step  in 
hyphenated  end  point  determinations. 
Simple  clean  up  procedures;- Two  types  of  chromatography  are widely  used; 
solid phase  column  chromatography  (SPE)  and  immunoaffinity  chromatography 
(lAC). 
SPE  is used  to extract groups  or  classes of residues  from  the  initial 
extract.  The  columns  are characterised  by  low  affinity,  high  capacity and 
low  specificity.  Either  very  small  columns  e.g.  Sep-Pak  C18  cartridges, 
are  used  with  small  volumes  of  eluting fluids or  larger columns  are  used 
with  much  larger  solvent  volumes,  e.g.  XAD-2  columns  for  cleaning  up 
anabolic  agents.  The  small  columns  are  disposable  and  cost  little. 
lAC  is a relatively new  procedure  and  the  system  uses  a  small  column  packed 
with  one  or  more  specific antibodies  immobilised  onto  a  solid matrix.  The 
antibodies  are  specific for  one  or  more  analytes.  The  columns  are 
characterised  by  high  affinity,  low  capacity and  high  specificity.  However 
attention should  be  paid  to  the  possibility of  interference from  unknown 
metabolites which  may  cross-react with  the  antibodies.  The  use  of  lAC  in 
the  determination  of  steroids  and  B-agonists  is  increasing  and  examples  are 
given  in  methods  M  1.1.  and  M 1.3. 
Chromatography  as  part of  end  point  determination;- HPLC  and  GC  are 
powerful  techniques  used  for  obtaining  highly  purified extracts containing 
specific analytes.  Methods  using  the  resolving  power  of  HPLC  and  GC  in 
combination  with  specific  lA  or  MS  can  meet  all  the  Criteria of  EC  Decision 
93/256/EEC  (see  section  5)  necessary for  the  unambiguous  identification of 
a residue. 
HPLC  and  GC  procedures  must  be  carried out  using  equipment  that  is suitable 
to achieve  the  minimum  Criteria as  detailed  in  section 5  (2.6  and  2.7). 
Many  of  the  machines  now  on  the  market  allow  the  fulfilment of  these 
criteria and  examples  are  to found  in  the  specific methods.  The  ability 
of  the  system  to resolve  the  analyte(s)  in  question  from  similar molecules 
and  separate  the  analyte from  a major  proportion  of  the  interfering 
substances  is very  important. 
6.3.8  (viii)  End  point  Determination;- The  techniques  include;-
- Spectrometry:  IR,  MS,  UV,  AA 
Immunoassay:  RIA,  EIA 
Chromatography:  TLC 
Hyphenated  techniques:  i.e.  a combination  of  two  or  more 
procedures:  TLC  &  lA;  HPLC  &  lA;  HPLC  &  MS;  GC  &  MS;  MS  &  MS; 
GC  &  MS  &  MS;  GC  &  FTIR  (see  6.3.1.). 
6/11 A technical  description of  the  equipment,  materials  and  reagents  is 
included  with  each  assay  method.  The  quality of  the  equipment  must  be 
good  enough  to  allow  the  method  to fulfil  the  Criteria for  the 
identification and  quantification of  an  analyte  as  laid  down  in  section  5. 
6.3.9  (ix)  Quality assurance  is  covered  in  section  5. 
6.3.10  (x)  Calculation of  results;- Each  method  contains  instructions  on 
the  calculation of  results.  The  calculation takes  into  account  the 
recovery  of  an  internal  standard  and  the  quality control  of  the  method 
using  RMs  or  other  suitable standards. 
6.3.11  (xi)  Results  should  be  reported  in  the  agreed  format.  All  data 
should  be  properly recorded  which  together with  all  raw  data  must  be  filed 
for future  reference.  See  also  section  on  Quality Assurance  in  section  5. 
6.3.12.  Note  on  GC-FTIR. 
IR  is  an  alternative spectroscopic  method  to  MS  for  the  identification of 
known  analytes.  For  unknown  analytes  MS  and  FTIR  are  complimentary 
techniques,  MS  yielding  information  on  the  molecular  masses  of  the  analyte 
and  of  the  different fragment  ions,  FTIR  on  the  functional  groups  and  their 
chemical  surroundings.  The  development  of  very  sensitive cryotrapping  GC-
FTIR  spectrometry with  limits of  detection  in  the  sub  ng  range  makes  this 
technique  suitable for  residue  analysis. 
The  technique  of  cryotrapping GC-eluates  at  77°K  on  an  IR  transparent 
window  has  recently bee  incorporated  into  a commercially  available  GC-FTIR 
instrument.  The  eluates are  crystallised onto  a window  of  zinc  selenide at 
77°K  immediately  after  leaving  a  small  deposition  tip at the  end  of  the  GC. 
The  window  is  slow  moving  in  such  a way  that each  component  passes  an  IR 
light  beam  a  few  seconds  after deposition  and  can  be  scanned  immediately. 
An  advantage  of  the  technique  is that as  a result of  movement  of  the  window 
the  complete  chromatogram  is 
11frozen
11  onto  the  widow  as  a  trace.  It 
remains  stored for  as  long  as  cryogenic  conditions  are  maintained.  This 
offers the  opportunity to  perform  post-run  scanning  of  the  cryotrapped 
components  and  to  improve  the  signal-to-noise ratio of  the  spectra. 
The  data  processing  is carried out  on  a  computer  which  must  have  the 
capability of  handling  and  storing  large  numbers  of  IR  spectra. 
The  technique  is successfully used  at RIVM,  Bilthoven,  for  the  confirmation 
of  B-agonists  in  urine  at the  2.5  ~g per  kg  or  L level  (Visser et al 
1993). 
6.4.  TYPE  OF  METHODS 
The  methods  are  allocated  into  sections  covering  either screening  or 
confirmatory methods.  They  are  sub-divided  into modular  multi-residue 
methods,  multi-residue methods,  and  methods  for  specific veterinary drug 
residues.  At  this stage  the  well  tried and  tested multiresidue methods  for 
pesticide analysis  and  the  EC  documented  methods  for  heavy  metals  are  not 
included.  A full  list of  the  methods  is given  in  the  contents. 
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6/13 Sg.  1.1  ANABOLICS  - A ROUTINE  METHOD  FOR  THE  DETERMINATION  OF  RESIDUES  OF 
ANABOLICS  IN  PERIRENAL  FAT  USING  HPLC-HPTLC. 
WARNING  AND  SAFETY  PRECAUTIONS 
0.  INTRODUCTION 
Throughout  the  EEC  the  use  of  xenobiotic  anabolic  agents  is prohibited  in 
food-producing  animals  and  no  residues of  these  anabolics  should  be  present 
in  animal  products  imported  into or  produced  within  the Community. 
Preparations of  natural  steroids or  their esters may  be  used  in  farm 
animals  under  strictly controlled conditions  (see  EEC  Directive 88/146/EEC) 
and  the  maximum  concentrations of  natural  steroids allowed  in  plasma  are 
set  (see  section  2)  but  the  levels  permitted  in  edible tissues  have  not  yet 
been  defined  (August  1993). 
1.  SCOPE 
This  method  of  analysis  describes  the  determination  of  the  presence  of 
individual  analytes for  a  large  number  of  Anabolic  Agents  in  samples  of 
perirenal  fat.  This  work  is carried out  in  compliance  with  the  Residues 
Directive  (86/469/EEC)  and  the  method  is used  in  several  Member  States. 
2.  FIELD  OF  APPLICATION. 
The  method  is used  to  perform  routine screening  and  confirmatory analyses 
in  bovine  perirenal  fat samples. 
The  method  can  be  adapted*for  muscle  a~d urine.  Thjs  modular  method  is 
suitable for  testosterone  ,  trenbolone  ,  oestradiol  ,  oestrone,  zeranol, 
diethylstilboestrol,  hexoestrol,  dienoestrol,  19-nortestosterone*, 
methyltestosterone,  ethinyloestradiol,  medroxyprogesterone  acetate, 
chlormadinone  acetate,  melengestrol  acetate and  megestrol  acetate, 
*  either the  17a- or  the  17B- hydroxy  compounds. 
The  .limit of  detection  is about  1  ~g per  kg  for  most  of  the  compounds. 
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Commission  Decision,  93/256/EEC,  laying  down  the methods  for detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
ISO  Standard  78/2-1982  Layout  for  standards  - Part  2:  Standard  for  Chemical 
Analysis 
Verbeke,  R (1979).  Sensitive multi-residue method  for  detection of 
anabolics  in  urine  and  in  tissues of  slaughtered  animals.  J.Chromatog.  177, 
69-84 
Smets,  F.,  (1988),  Methode  Analytique  pour  le  determination  des  residus 
d'anabolisants  dans  l'urine a l'aide de  la  HPLC-HPTLC.  Union  economique 
Benelux,  SP/LAB/h  (88),  33 
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4.  DEFINITIONS. 
Anabolic  substance  content  is taken  to  mean  the  amount  of  anabolic 
substance  in  perirenal  fat determined  according  to the  described method  and 
expressed  as  ~g anabolic  substance  per  kg  of  test sample. 
5.  PRINCIPLE 
The  methods  comprises  5 stages;-
- Homogenisation  of  fat samples  in  acetate buffer. 
- Extraction  using  methanol.(Remove  fat with  n-hexane) 
- Extraction  using  ether and  washing  with  carbonate  buffer 
- Purification of  concentrated extract by  HPLC  fractionation. 
- Detection  and  identification by  fluorescence  and  visible  light on  TLC 
6.  MATERIALS 
Note:  The  reagents  for which  examples  of  their source  are quoted  are 
known  to  be  satisfactory,  nevertheless  reagents  of  comparable  purity from 
other sources  may  be  equally suitable. 
6.1.  Reference  Compounds  and  Standard  Solutions. 
Testosterone*,  trenbolone*,  oestradiol*,  oestrone,  zeranol, 
diethylstilboestrol,  hexoestrol,  dienoestrol,  19-nortestosterone*, 
methyltestosterone,  ethinyloestradiol,  medroxyprogesterone  acetate, 
chlormadinone  acetate,  melengestrol  acetate and  megestrol  acetate, 
*  either the  17a- or  the  17B- hydroxy  compounds. 
17a-Trenbolone  and  epi-19-nortestosterone were  obtained  from  the  ANAREF 
collection  (Benelux),  all  the  other  compounds  were  from  Steraloids  Inc. 
6.2 
6.2.1 
6.2.2 
6.2.3 
6.2.4 
6.2.5 
6.2.6 
6.2.7 
6.2.8 
6.2.9 
6.2.10 
6.2.11 
6.2.12 
6.3 
6.3.1 
6.3.2 
Chemicals 
Methanol 
Water  (HPLC  grade) 
n-hexane 
diethylether 
dichloromethane 
chloroform 
acetone 
cyclohexane 
ethyl  acetate 
ethanol 
tetrahydrofuran 
sulphuric  acid 
Solvents  and  Solutions 
HPLC  conditioning  solvent;  Methanol:Water,  (75:25  (v/v)) 
HPLC  eluent - mixtures  of  methanol  and  water  (see  procedure  9.16.1) 
Sg  1.1/2 6.3.3 
6.3.3.1 
6.3.3.2 
6.3.3.3 
6.3.3.4 
6.3.3.5 
6.3.4 
6.3.5 
6.3.6 
7 
7.1 
7.2 
7.3 
7.4 
7.4.1 
7.5 
7.6 
7.7 
7.8 
7.9 
7.10 
7.11 
7.12 
7.13 
7.14 
7.14.1 
7.14.2 
7.14.3 
7.14.4 
7.14.5 
7.14.6 
7.14.7 
7.14.8 
8. 
HPTLC  eluents 
Eluent  1;  n-hexane  - diethylether - dichloromethane  (25/45/30) 
Eluent  2;  chloroform  - acetone  (90/10) 
Eluent  3;  cyclohexane  - ethyl  acetate - ethanol  (60/40/2.5) 
Eluent  4;  chloroform  - n-hexane  - acetone  (50/40/10) 
Eluent  5;  tetrahydrofuran  - n-hexane  (35/65) 
HPTLC  detecting  reagent;  5%  solution of  sulphuric  acid  in 
ethanol. 
0.04M Sodium  acetate buffer,  pH  5.2 
10%  Sodium  Carbonate  buffer,  pH  s10.25 
EQUIPMENT 
Ultra Turrax  homogeniser 
Rotary  evaporator 
Vortex  mixer(s) 
HPTLC  equipment  for  running  HPTLC  plates. 
HPTLC  silica gel  plates,  (Merck  ~ 5631) 
UV  lamp  at  366  nm 
Drying  cabinet 
Cabinet  at 95°C  for  heating  HPTLC  plates 
Centrifuge  tubes,  300  ml  capacity 
Water  bath  at 80°C 
Centrifuge 
Erlenmeyer  flasks,  300  ml  capacity 
Cotton  wool 
Vortex  evaporator  (Buchler) 
HPLC 
Basic  instrument with  pump,  (Perkin  Elmer,  Series  4) 
Automatic  injector  (Perkin  Elmer,  ISS-100) 
Automatic  switching  valve  (VICI)  (Valco) 
UV  detector  (model  440  - Waters) 
Fraction  Collector  (model  202  - Gilson) 
Column  - C-18  semi-preparative:  ODS  (5  ~m)  25  em  x 10  mm  i.d. 
(Altex  part  ~ 235328) 
Guard  column:  pellicular ODS  (C18);  37  - 53  ~m;  3 em  x 4.6  mm 
i.d.  (Whatman  ~ 4102-010) 
Precolumn:  Cartridge  MCH-10  C18  10~;  3 em  x 4.6  mm  i.d.  (Varian 
~ 00-996750-00) 
SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is  drawn  to  section  6.3.1  and  to  ISO  document  78/2-1982  and 
also the following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to  enable  the 
detection  of  residues  in  fat as  defined  in  Directive 64/433/EEC. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to 
allow  the  method  to  be  carried out  and  to allow  repeat  analysis 
where  required.  Each  analysis  needs  a  50  g sample. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to allow 
proper  identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain 
the  integrity of  the  sample  and  not  prejudice  the result of  the 
examination. 
Samples  for  the  analysis  of  anabolics  must  be  stored at 
temperatures  below  -18°C. 
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9.1 
9.2 
9.3 
9.4 
9.5 
9.6 
9.7 
9.8 
9.9 
9.10 
9.11 
9.12 
9.13 
9.14 
9.15 
9.16 
PROCEDURE 
Cut  50  g perirenal  fat  into  small  pieces  and  weigh  into  a  300  ml 
centrifuge tube  (7.8). 
Add  70  ml  sodium  acetate buffer  (6.3.5)  and  warm  up  the mixture 
in  a water  bath  at 80°C  for  10  min. 
Homogenise  with  an  Ultra Turrax 
Extract with  180  ml  methanol  utilising the  Ultra  turrax for 
mixing. 
Centrifuge  at 5000  g for  20  min. 
Filter the  supernatant  through  a  cotton  wool  plug  into a  300  ml 
Erlenmeyer  flask  (7.11). 
Transfer  two  fifths of  the  supernatant  (equivalent  to  20  g fat) 
into  a  250  ml  separating funnel. 
Extract with  2 x 20  ml  n-hexane  and  discard  the  n-hexane  phase. 
Add  40  ml  water  and  extract with  2 x 100  ml  of  diethylether. 
Wash  the  combined  ether phases  with  10  ml  of  carbonate  buffer 
(9.3.6)  and  2 x  15  ml  water.  Discard  the  aqueous  phases. 
Evaporate  the  ether phase  to  dryness  on  a  rotary evaporator  at 
40°C. 
Transfer  the  contents  into  a  vial  with  3 x 1 ml  methanol 
Evaporate  the  mixture  to  dryness  using  a  Vortex  evaporator. 
Dissolve  the  residue with  vortex  mixing  into  100  ~L methanol. 
Inject  100  ~L  into  the  HPLC. 
HPLC 
9 16  1  .  .  El  t.  P  u  1on  rogramme 
Step  Time  Flow  Water  MeOH  Curve 
(min)  ml/min  ~  0  ~  0 
a.  Injection  0  3  25  75 
b.  Front  cut  1.2  3  25  75 
c.  Backflush  1.3  3  0  100  0 
guard  and  precolumn  5  3  25  75  0 
d.  Elution  Fn.  1-3  10  3  25  75 
Fn.  4&5  5  3  0  100  1 
5  3  0  100 
e.  Reconditioning  15  3  25  25  0 
9.16.2 
9.17 
Collection  of  fractions. 
Five  fractions  are  collected over  the  time  period  14  to  22  min. 
Fractions  1 to  3 are  collected during  the  elution with  25%  water 
and  75%  methanol.  Fractions  4 and  5 are  collected during  the 
gradient  period,  17.5  to  22.5  min.  The  exact  time  windows  should 
be  determined  using  pure  standards. 
The  five fractions  are  collected with  windows  which  will  allow 
the  collection of  the  following  anabolics. 
Fraction  1:  DES/HEX/DEN;  zeranol;  a/B-trenbolone 
Fraction  2:  B-19-nortestosterone;  alB-oestradiol;  oestrone 
Fraction  3:  a-19-nortestosterone;  B-testosterone 
Fraction  4:  a-testosterone;  methyltestosterone 
Fraction  5:  medroxyprogesterone  acetate;  chlormadinone  acetate; 
melengestrol  acetate;  megestrol  acetate. 
HPTLC 
Sg  1.1/4 9.17.1 
9.17.2 
9.17.3 
9.17.4 
9.17.5 
10 
10.1 
11. 
12. 
13. 
Evaporate  to dryness  the  fractions  1 to 5 obtained  from  the  HPLC. 
Dissolve  the fractions  in  either 20  ~L acetone  or  ethanol.  Use 
1/4  of  the  volume  (equivalent  to 5 g fat)  to  apply  to  the  HPTLC 
plate  (7.4.1).  Apply  10  ng  of  the  appropriate  standards  at a 
separate  spot. 
Run  the  plates using  eluents 1  (6.3.3.1)  and  then  2  (6.3.3.2)  for 
fractions  1 to  4 from  the  HPLC. 
Run  the  plates using  eluents 3  (6.3.3.3)  and  then  4  (6.3.3.4)  or 
using  eluents 4  (6.3.3.4)  and  then  5  (6.3.3.5)  for fraction  5 
containing  the  gestagens  from  the  HPLC. 
Detection  of  spots;  Induction  of fluorescence  is obtained  by 
plunging  the  plates  in  a  solution of  5%  sulphuric  acid  in  ethanol 
(6.3.4)  and  drying  the  plates at 95°C  for  10  min. 
The  spots  can  be  detected  under  UV  light at 366  nm  and  in  visible 
light.  The  spots  for  the  gestagens  for  instance,  have 
characteristic colours  in  visible  light being;-
Blue  - megestrol  acetate and  chlormadinone  acetate 
Pale  brown  - melengestrol  acetate 
Greenish  - medroxyprogesterone  acetate. 
INTERPRETATION  OF  RESULTS 
Identification of  the  analytes  on  the  TLC  is obtained  when  the 
spots  have  the  same  Rf  and  colours  as  the  standards.  The 
analytes must  elute  in  the  correct fraction  from  the  HPLC. 
SPECIAL  CASES 
NOTES  ON  PROCEDURE. 
QUALITY  CONTROLS 
See  section 8 of  manual  detailing the  RMs  for  the  anabolics. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS 
A full  list of  abbreviations  is given  in  Annex  I,  Section  12 
16.  FLOW  DIAGRAM 
homogenise  de-fat with  wash 
FAT  ------------->  METHANOL  ---------------->  ETHER  --------->  HPLC 
extract  n-hexane  I 
collect  I 
fractions I 
l 
IDENTIFY  with  UV  <---------- HPTLC 
Sg  1.1/5 Sg.  1.2  ANABOLICS  - A ROUTINE  METHOD  FOR  THE  DETECTION  OF  RESIDUES  OF 
ANABOLICS  IN  BOVINE  URINE  USING  GC-MS  IN  THE  ELECTRON  IMPACT  MODE. 
[Note;  Method  can  be  extended  to a confirming  method]. 
WARNING  AND  SAFETY  PRECAUTIONS 
Wear  gloves  for  handling  acids,  bases  and  organic  solvents.  Handle 
solvents  in  a  fume  cupboard. 
0.  INTRODUCTION 
Throughout  the  EEC  the  use  of  xenobiotic  anabolic  agents  is prohibited  in 
food-producing  animals  and  no  residues  of  these  anabolics  should  be  present 
in  animal  products  imported  into or  produced  within  the  Community. 
Preparations  of  natural  steroids or  their esters may  be  used  in  farm 
animals  under  strictly controlled conditions  (see  EEC  Directive 86/469/EEC) 
and  the  maximum  concentrations  of  natural  steroids permitted  in  edible 
tissues  have  not  yet  been  defined  (August  1993). 
1.  SCOPE 
This  method  of  analysis  describes  the  detection  of  the  presence  of 
individual  analytes  for  a  large  number  of  Anabolic  Agents  in  samples  of 
bovine  urine.  This  work  is carried out  in  compliance  with  the  Residues 
Directive  (86/469/EEC)  and  the  method  is used  in  France. 
2.  FIELD  OF  APPLICATION. 
The  method  is used  to  perform  routine  screening  jn  urine  sampJes. 
This  modular  method  is  suitable for  testosterone  ,  trenbolone  , 
oestradiol*,  oestrone,  zeranol,  cis- and  trans- diethylstilboestrol, 
hexoestrol,  dienoestrol,  19-nortestosterone*,  methyltestosterone, 
ethinyltestosterone,  boldenone,  stanolone,  norethandrone,  dianabol, 
bolasterone,  a-chlorotestosterone,  chloromethandienone,  vinyloestradiol, 
ethinyloestradiol,  medroxyprogesterone,  chlormadinone  and  megestrol, 
*  either the  17a- or  the  17B- hydroxy  compounds. 
The  limit of  detection  is about  1  ~g per  L for most  of  the  compounds. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  N 1 
L.118,  14.4.93.  pp  64-74] 
ISO  Standard  78/2-1982  Layout  for  standards  - Part  2:  Standard  for  Chemical 
Analysis 
LeBizec,  B.,  Montrade,  M.-P.,  Manteau,  F.  and  Andre,  F.  (1993),  Detection 
and  identification of  anabolic  steroids  in  bovine  urine  by  gas 
chromatography-mass  spectrometry.  Anal.  Chim.  Acta.,  275,  123-133 
LeBizec,  B.,  Montrade,  M.P.  and  Andre,  F.  (1993),  Method  of  detection  and 
identification of  anabolic  steroid agents  in  urine  by  gas  chromatography-
mass  spectrometry  in  the  electron  impact  mode.  Document.  LDH/93/02.  Lab. 
Dosages  Hormonaux,  Nantes,  France. 
Sg  1.2/1 4.  DEFINITIONS. 
Anabolic  substance  content  is taken  to mean  the  amount  of  anabolic 
substance  in  bovine  urine  determined  according  to  the  described  method  and 
expressed  as  ~g anabolic  substance  per  L of  test sample. 
5.  PRINCIPLE 
The  methods  comprises  6 stages;-
- Hydrolysis  of  urine  samples  in  acetate buffer. 
- Extraction  on  a  C-18  cartridge 
- Wash  with  carbonate  buffer 
- Fractionation of  anabolic  groups  on  a  Si-gel  60  column. 
- Derivatization 
- Detection  on  GC-MS  in  EI  mode. 
6.  MATERIALS 
Note:  The  reagents  for  which  examples  of  their source  are  quoted  are 
known  to  be  satisfactory,  nevertheless  reagents  from  other  sources  may  be 
equally suitable. 
6.1.  Reference  Compounds  and  Standard  Solutions. 
6.1.1.  The  steroids;- testosterone*,  trenbolone*,  oestradiol*,  oestrone, 
zeranol,  cjs- a~d  trans- diethylstilboestrol,  hexoestrol,  dienoestrol,  19-
nortestosterone  ,  methyltestosterone,  boldenone,  stanolone,  norethandrone, 
dianabol,  bolasterone,  chlorotestosterone,  ethinyltestosterone, 
chloromethandienone,  ethinyloestradiol,  vinyloestradiol,  norethandrolone, 
medroxyprogesterone,  chlormadinone  and  megestrol, 
were  obtained  from  Steraloids  (Wilton,  USA),  Sigma  (St.  Louis,  USA)  and 
Re~earch Plus  (Bayonne,  USA), 
either the  17a- or  the  17B- hydroxy  compounds. 
6.1.2 
6.1.3 
6.2 
6.2.1 
6.2.2 
6.2.3 
6.2.4 
6.2.5 
6.2.6 
6.2.7 
6.2.8 
6.2.9 
6.2.10 
6.2.11 
6.2.12 
Internal  standards 
Deuterated  (d3)  methyl-testosterone  (Sigma) 
Deuterated  (d2)  17B-oestradiol  (Sigma) 
External  standard 
Dichlorophene  (Aldrich) 
Norgestrel  (Sigma) 
Chemicals 
Methanol  (Merck-6009) 
Ultra-pure water  (>18  Mn.cm) 
n-hexane  (Merck-4367) 
HeJjx  pomatja  juice  (B-glucuronidase-arylsulfatase,  Merck-4114) 
Sodium  carbonate  (Merck-6392) 
Sodium  hydroxide  (Merck-9137) 
Sodium  acetate  (Merck-6268) 
Glacial  acetic acid  (Merck-55) 
Ethyl  acetate  (Merck-9623) 
Absolute  ethanol  (Merck-693) 
Silica gel  60  (Merck-7734) 
Nitrogen  (dry  over  Silica gel) 
Sg  1.2/2 6.2.13 
6.2.14 
6.2.15 
6.2.16 
6.2.17 
6.2.18 
6.3 
6.3.1 
6.3.2 
6.3.3 
6.3.3.1 
6.3.3.2 
6.3.3.3 
6.3.4 
7 
7.1 
7.2 
7.3 
7.4 
7.5 
7.6 
7.7 
7.8 
7.9 
7.11 
7.12 
7.13 
7.14 
7.15 
7.16 
7.17 
7.18 
7.19 
1,1,1-Trichloroethane  (Merck-8749) 
N-methyl-N-trimethylsilyl-trifluoroacetamide  MSTFA  (Fluka-
69482) 
Trimethyliodosilane  :  TMIS  (Fluka-58118) 
Dithiothreitol  :  DTE  (Aldrich-15046-0) 
N-methyl-N-(tertbutylmethylsilyl)trifluoracetamide  MTBSTFA 
(Pierce-48920) 
T.H.P  Helium  (Carboxyque) 
Solutions 
2M Acetate  buffer,  pH  5.2  ±  0.2,  for  hydrolysis  of  conjugates. 
Dissolve  164  g sodium  acetate  (6.2.7)  in  900  ml  water  (6.2.3)  and 
adjust the  pH  to  5.2  ±  0.2 with  glacial  acetic acid  (6.2.8).  Make 
up  to  1 L with  water  and  store at +4°C.  Use  for  up  to 1 month. 
10%  Sodium  carbonate  solution;  Dissolve  100  g sodium  carbonate  in 
1 L water. 
Eluents 
Eluent  1;  methanol/ethyl  acetate 30/70 
Eluent  2;  1,1,1-trichloroethane/ethyl  acetate 80/20 
Eluent  3;  1,1,1-trichloroethane/ethyl  acetate 20/80 
Derivatization  solution.  Prepare  under  anhydrous  conditions  IN  A 
FUME  CUPBOARD  a  solution of  MSTFA  (6.2.14)  /  TMIS  (6.2.15)  /  DTE 
(6.2.16),  100/5/5  (v/v/w).  Keep  in  the  freezer excluding  light 
and  moisture. 
EQUIPMENT 
Hamilton  syringes,  5  ~L,  50  ~L,  1000  ~L 
Automatic  pipettes,  20  ~L,  200  ~L,  1000  ~L,  5000  ~L 
Vortex  mixer(s) 
Ultrasonic  bath 
Heating  block  with  nitrogen  evaporation  system, 
Heating  block  for  derivatization  (Pierce-18780) 
Heating  block  for 6 ml  and  12  ml  haemolysis  tubes  with  nitrogen 
evaporation  system. 
Plastic bottles with  screw  tops,  30  ml  capacity. 
Centrifuge 
Oven  for  hydrolysis 
Derivatization  vials suited for  either manual  or  automatic 
injection  into  the  GC. 
Vacuum  suction  system  for  SPE  columns  (Vac  Elut,  Prolabo  -
07485001) 
Glass  haemolysis  tubes,  6 ml  and  12  ml,  with  stoppers  use  only 
once. 
pH  paper 
Pasteur  pipettes. 
Parafi lm 
Mega  Bondelut  C-18  columns  (Varian-A!  122560-15). 
Contain  2 g grafted  resin  in  a  10  ml  container. 
Conditioning;  Wash  with  10  ml  methanol  and  then  10  ml  of 
ultrapure water.  Do  not  allow  the  column  to  dry. 
G60  silica column;  Use  a glass  column  (15  em  x 10  mm  i.d.) 
equipped  with  a  10  ml  reservoir and  a manual  flow  regulator 
(L.N.R.). 
Preparation;  Put  the  gel  into  a  beaker  containing  Eluent  2; 
1,1,1-trichloroethane/ethyl  acetate 80/20  (6.3.3.2)  and  stir. 
Pour  the  resin  into  the  column  up  to 8  em.  Rinse  with  6.3.3.2 
Sg  1.2/3 7.20 
7.20.1 
and  tamp  the  gel.  Rinse  with  a further  10  ml  6.3.3.2.  Do  not  run 
to dryness.  The  column  is  now  ready. 
GC-MS; 
GC.  (Hewlett  Packard  HP-5890) 
Injection;  Splitless,  open  valve  at 1 min. 
Volume  injected;  2  ~L 
Column;  Fused  silica capillary type,  30m  x 0.25  mm  i.d.  with 
25  ~m film of  SE-30 
Temperatures;  Injector,  280°C,  Transfer  line,  280°C; 
15°C  I  min  soc  I  min 
Oven  120°C  for  1 min.  -------------> 250°C  --------------> 300°C  for 4 min 
then  to  120°C 
7.20.2 
8. 
Carrier gas;  T.H.P  Helium 
Flow  rate;  1 ml  per  min. 
Pressure  at head  of  column;  5 psi. 
MS.  (Hewlett  Packard  HP-5971A) 
EI  mode  at 70  eV. 
Dwell  time  (msec)  is selected  so  that the  number  of  cycles  per 
sec  is close  to  2. 
Source  temp.;  190°C 
The  electromultiplier,  ion  focus  and  entrance  lens  values  will  be 
calculated  by  the  autotune. 
SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is  drawn  to  section  6.3.1  and  to  ISO  document  78/2-1982  and 
also the  following  notes  derived  from  Annex  II  of  2052IVI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to  enable  the 
detection  of  residues  in  meat  as  defined  in  Directive 64I433IEEC.  Failing 
this biological  fluids  (here  urine)  or  faeces  may  constitute the  samples 
for  the  detection  of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to allow 
the  method  to be  carried out  and  to  allow  repeat  analysis where  required. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to  allow  proper 
identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice the  result of  the  examination. 
Samples  for  the  analysis of  anabolics  must  be  stored  and  transported at 
temperatures  below  -18°C. 
9  PROCEDURE 
9.1  Thaw  the  urine  sample. 
9.2.  Centrifuge  >20  ml  at 3000  rpm  and  transfer  20  ml  of  the 
supernatant  to  a  plastic container  (7.8). 
9.3  Add  2 ml  acetate buffer  (6.3.1)  and  adjust the  pH  to  5.2  ±  0.2 
with  glacial  acetic acid  (6.2.8).  Add  200  ng  of  d3-
methyltestosterone. 
9.4  Repeat  9.1  to  9.3  for  two  blank  urines.  To  one  of  the  blanks  add 
anabolic  standards. 
9.5  Add  100  ~L Helix  Pomatia  (6.2.4)  to  all  the  urines.  Incubate  for 
Sg  1.214 15  h at 52°C  in  an  oven. 
9.6  SPE  Clean  up; 
9.6.1  Transfer  the  hydrolysed  urines  to a conditioned  Mega  Bond  Elut 
column  (7.18).  Allow  the  column  to  dry  for  30  sec.  Wash  with  10 
ml  ultrapure water  under  vacuum  suction  until  drained.  Wash  with 
10  ml  n-hexane. 
9.6.2  Elute  all  the  steroids with  5 ml  eluent  1 (6.3.3.1)  into  a  12  ml 
tube  (7.14). 
9.7  Add  2 mL  carbonate  solution  (6.3.2)  to  the  eluate and  vortex  for 
10  sec.  Centrifuge  at 10,000  rpm  for  1 min.  Transfer  the  upper 
organic  phase  to  a clean  tube. 
9.8  Add  2 ml  carbonate  solution  (6.3.2)  to  the  organic  phase  and 
vortex  for  10  sec.  Centrifuge  at 10,000  rpm  for  1 min.  Transfer 
the  upper  organic  phase  to  a clean  tube. 
9.9  Evaporate  the  organic  phase  to  near  dryness  using  nitrogen  on  a 
50°C  heating  block.  Avoid  thermolysis  of  the  residue. 
9.10  Purification on  Silica gel  60  column. 
9.10.1  Add  1 ml  eluting solution  2  (6.3.3.2)  to  the  residue.  Vortex  and 
place  in  an  ultrasonic bath  for  a few  seconds. 
9.10.2  Transfer  the  solution  to  the  bed  of  a  prepared  Si  gel  60  column 
(7.19)  with  a  Pasteur  pipette.  Allow  to  drain  into the  column. 
Repeat  once  9.10.1  with  0.5  ml  of  eluent 2 (6.3.3.2). 
9.10.3  Wash  with  4 ml  eluent 2 (6.3.3.2). 
9.10.4  Elute  oestrogenic  substances  with  13  ml  eluent 2  (6.3.3.2). 
Collect as  fraction  I.  Add  100  ng  dichlorophene  as  external 
standard. 
9.10.5  Elute  the  androgens  and  gestagens  with  12  ml  eluent 3  (6.3.3.3) 
and  collect as  fraction  II.  Add  100  ng  norgestrel  as  external 
standard. 
9.11  Reduce  the  volumes  of  both  fractions  I  and  II  to ca.  500  ~L under 
a  nitrogen  stream  at 50°C. 
9.12  Vortex  the  tubes  to wet  the walls  and  then  centrifuge at 1000  rpm 
for  1 min  to  bring  the  liquid to  the  bottom  of  the  tubes. 
9.13  Transfer  the  contents  of  the  tubes  to  reactivials  (7.12)  and 
evaporate  just to  dryness  using  nitrogen  on  a  50°C  heating  block. 
Avoid  thermolysis  of  the  residue. 
9.14  Derivatization; 
[Must  be  done  under  anhydrous  conditions] 
9.14.1  Add  20  ~L of  derivatising solution 6.3.4 and  close  vial 
immediately.  Vortex  and  ultrasonicate.  Heat  at 60°C  for  30  min. 
9.14.2  The  derivatives  are  ready  for  injection but  may  be  stored  in 
sealed  vials for  up  to  48  h at 4°C. 
[Note;  It is possible  to  derivatize the  stilbenes  in  Fraction  I with  N-
methyl-N-(tertbutylmethylsilyl)trifluoracetamide  :  MTBSTFA  (6.2.17)  to 
increase  the  retention times  and  the  mass  of  the  ions,  therefore their 
specificity.] 
9.15  Inject 2  ~L into  the  GC-MS  equipment  using  the  conditions 
described  in  7.20. 
10  INTERPRETATION  OF  RESULTS 
10.1  The  approximate  retention  times  of  the  anabolics  are  shown  in 
table 1.  They  will  vary  and  should  be  studied  systematically  in 
relationship to  the  retention time  of  the  internal  standard. 
10.2  The  ions  selected for monitoring  should  be  determined  beforehand. 
As  a rule they will  be;  high  mass,  high  intensity;  free of 
interference with  ions  from  the  column  and  background. 
10.3  If 2 or  3  ions  have  a  signal  to  noise  ratio >  3 then  the  sample 
Sg  1.2/5 is suspected 
11positive  ... 
10.4  The  criteria in  EEC  93/256  (see  section  5)  must  be  met  for  the  GC 
parameters. 
10.5  The  blank  urine  must  be  clear of  all  evidence  of  ions 
attributable to  xenobiotic  anabolics. 
10.6  The  ions  for  the  external  and  internal  standards  must  be  present. 
11.  SPECIAL  CASES 
12.  NOTES  ON  PROCEDURE. 
13.  QUALITY  CONTROLS 
See  section 8 of  manual  detailing the  RMs  for  the  anabolics. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS 
A full  list of  abbreviations  is given  in  Annex  I,  Section  12 
16.  FLOW  DIAGRAM 
hydrolyse 
URINE  -------------> SPE  C-18--------------> WASH  WITH  CARBONATE 
I 
I 
I 
I 
!------- FRACTION  I  l 
TMS-DERIVATIVES  <-------- FRACTION  II <----------- Si  GEL  60  COLUMN 
I 
I 
I 
I 
l 
GC-MS  ------------>  INTERPRET  RESULTS 
Sg  1.2/6 Table  1.  List of  steroids and  their respective  ions  and  retention times. 
Substances  in  Fraction  I 
Analyte  Retention  Diagnostic  Other  ions 
time  (min)  ions  m/z  m/z 
cis-DES  11.63  412,  383  397,  368 
Dichlorophene  (E.S.)  12.07  414,  412,  377 
Hexoestrol  12.33  399,  207,  414 
Dienoestrol  12.38  410,  395  381,  217,  193 
trans-DES  12.46  412,  383  397,  368 
Ethinyloestradiol  16.67  440,  425  300,  285 
Vinyl  oestradiol  17.00  442,  352  427,  300,  285 
Steroids  in  Fraction  II 
17a-Nortestosterone  14.75  418,  194  403,  287,  182 
17B-Nortestosterone  15.20  418,  194  403,  287,  182 
17a-Trenbolone  15.37  414,  283  399,  324 
Stano lone  15.39  434,  405  419,  202 
Boldenone  15.49  430,  206  415,  325,  299 
17B-oestradiol-d2  (I.S.)  15.50  418,  287 
17B-oestradiol  15.52  416,  285  401,  326 
17B-Testosterone  15.63  432,  209  417,301 
17B-Trenbolone  15.82  414,  283  399,  324 
Norethandrone  16.21  432,  287  417,  342 
Dianabol  16.50  444,  206  339,  299,  283 
Methyltestosterone-d3  (I.S)  16.63  449,  301 
Methyltestosterone  16.66  446,  301  431,  356 
Bolasterone  16.72  460,  445  355,  315 
Ethinyltestosterone  16.82  456,  301  441,  316 
Zeranol  16.97  538,  433  523,  379,  307 
Norgestrel  (E.S.)  17.43  456,  316 
a-chlorotestosterone  17.50  466,  431  468,  451 
Norethandrolone  17.57  446,  287  431,  356 
B-chlorotestosterone  18.25  466,  431  468,  451 
Fluoxymesterone  18.43  552,  462  407,  319 
Bromoestradiol  18.90  496,  365  494,  481,  406 
Chloromethandienone*  19.20  480,  335  482,  465,  390,  375 
Medroxyprogesterone  19.41  560,  330  545,  455,  315 
*  19.14  558,  453  543,  353,  231  Megestrol 
Chlormadinone*  20.76  578,  488  563,  473,  231 
*measured  as  di-TMS. 
The 
110ther  ions
11  may  be  used  as  supplementary  ions  for  confirmation 
purposes. 
Data  from  Lab.  des  Dosages  Hormonaux,  Nantes,  France. 
Sg  1.2/7 Sg  1.3.  DIETHYLSTILBOESTROL  - METHOD  FOR  THE  DETECTION  OF  RESIDUES  OF 
DIETHYLSTILBOESTROL  IN  BOVINE  URINE  USING  RADIOIMMUNOASSAY  (RIA). 
WARNING  AND  SAFETY  PRECAUTIONS. 
1.  INTRODUCTION. 
Throughout  the  EEC  the  use  of  stilbenes  is prohibited  in  food  producing 
animals. 
2.  SCOPE  AND  FIELD  OF  APPLICATION 
This  method  of  analysis  describes  the  detection  of  diethylstilboestrol 
(DES)  in  bovine  urine.  The  detection  limit,  defined  as  three  times  the 
standard  deviation  of  the  blank  determination,  is 0.23  ~g per  litre of 
urine for  the  stilbene.  The  limit of  determination  defined  as  six times 
the  standard  deviation  of  the  blank  determination  for  20  samples,  is 0.38 
~g per  litre. 
3.  REFERENCES. 
ISO  Standard  78/2-1982  Layout  for  standards  - Part  2:  Standard  for Chemical 
Analysis 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
Standard  Operating  Procedure  for  the  estimation  of  diethylstilboestrol  in 
urine  from  the  Central  Meat  Control  Laboratory,  Dublin,  Ireland. 
Other  references. 
Bates,  M.L.,  Warwick,  M.J.  and  Shearer,  G.  (1985),  Determination  of 
synthetic growth  promoters  in  bile.  Food  Additives  &  Contaminants.  z,  37-
46 
Gaspar,  P.  and  Maghuin-Rogister,  G.,  (1985),  Rapid  extraction and 
purification of  diethylstilboestrol  in  bovine  urine  hydrolysates  using 
reversed  phase  C 18  columns  before  determination  by  radioimmunoassay.  J. 
Chromat.  328,  413-416 
Harwood,  D.J.,  Heitzman,  R.J.  and  Jouquey,  A.,  (1980),  A radioimmunoassay 
method  for  the  measurement  of  residues  of  the  anabolic  agent  hexoestrol  in 
tissues of  cattle and  sheep.  J.Vet.  Pharmacal.  &  Therapeutics,  1,  245-254 
Heitzman,  R.J.  and  Harwood,  D.J.  (1983),  Radioimmunoassay  of  hexoestrol 
residues  in  faeces,  tissues and  body  fluids  of  bulls  and  steers.  Vet.  Rec. 
112,  120-123 
Jansen,  E.H.J.M.,  (1985),  A highly  specific detection  method  for 
diethylstilboestrol  in  bovine  urine  by  radioimmunoassay  following  high 
performance  liquid chromatography.  Food  Additives  &  Contaminants.  z,  271-
281 
Vogt,  von  K.,  (1985),  Vereinfachte  Absicherung  des  radioimmunologischen 
Nachweises  von  Diethylstilbestrol  in  Fleischhaltigen Konserven  und 
tierischen Ausscheidungen.  Arch.  fur  Lebensm.hygiene.  36,  1-24 
Sg  1.3/1 4.  DEFINITIONS. 
DES  content  is taken  to mean  the  amount  of  DES  in  the  substance  in 
question,  regardless of  the  chemical  form,  determined  according  to  the 
described  method  and  expressed  as  ~g DES  per  litre of  test sample. 
5.  PRINCIPLE 
The  method  comprises  5 stages;-
Diluting  urine  in  buffer 
Hydrolysis  of  conjugates  in  buffer/homogenate  with  enzyme 
Extraction  of  DES  with  diethylether 
End  point  determination  with  RIA 
The  amount  of  DES  is calculated  by  interpolation from  a standard 
curve  and  taking  into  account  the  recovery. 
6.  REAGENTS  FOR  EXTRACTION  OF  TISSUES. 
Note:  The  reagents  for  which  examples  of  their source  are  quoted  are 
known  to  be  satisfactory,  nevertheless  reagents  from  other sources  may  be 
equally suitable. 
6.1. 
6.1.1. 
6.1.2. 
6.1.3. 
6.1.4 
6.1.5 
6.1.6 
6.1.7 
6.1.8 
6.1.9 
6.1.10 
6.1.11 
6.1.12 
6.1.13 
6.1.14 
6.1.15 
6.1.16 
6.2 
6.2.1 
6.3 
6.3.1 
6.3.2 
Chemicals 
Acetone 
Dry  ice 
Diethyl-ether  (peroxide  free  and  very  high  purity) 
Sodium  dihydrogen  phosphate,  anhydrous 
Disodium  hydrogen  phosphate,  anhydrous 
Sodium  chloride 
Thiomersal 
Gelatin 
Methanol 
Purified water  - by  reverse  osmosis  followed  by  deionisation, 
absorption  and  filtration. 
Tritiated  DES  (Amersham,  UK.  Monoethyl-3H-DES.  S.A.  91  Ci/mmol. 
1 mCi  per  ml).  Store  at -20°C. 
Charcoal  (Sigma  C-5260) 
Dextran  (Pharmacia  T70) 
Scintillation fluid  (Optiphase  Hisafe  11  - LKB) 
Antiserum  against  stilbenes stored  at -20°C.  (Marloie,  Belgium) 
Cross-reactivities.  Trans-DES,  100%;  trans-DES  dipropionate, 
9.7%;  Hexoestrol,  3.3%;  Dienoestrol,  1%;  Other  stilbenes <0.4%; 
Other  anabolics  and  steroids <0.1%. 
Nitrogen 
Standards 
DES  (Sigma  D-4628) 
Solutions 
Stock  Solution;  (100  ng  per  ml)  Dissolve  100  mg  DES  in  methanol 
and  make  up  to  100  ml.  Dilute with  methanol  to  give  a 
concentration of  100  ng  per  ml.  Store  at -20°C. 
Working  solutions;  Prepare  working  standards  from  the  stock 
solution  to  give  concentrations  of  DES  in  methanol  of  5,  10,  20, 
50,  100,  200  and  500  pg  per  ml.  Store  at +4°C. 
Sg  1.3/2 6.3.3  Phosphate-gelatin  buffer  - 4.68  g sodium  dihydrogen  phosphate 
anhyd.  (e.g.  Analar  BDH).  8.66  g disodium  hydrogen  phosphate 
anhyd.  (e.g.  Analar  BDH).  9.0  g sodium  chloride  (e.g.  Analar 
BDH).  0.1  g thiomersal  (e.g.  BDH).  1.0  g gelatin  (e.g.  BDH). 
Made  up  to  1 litre  (pH  7.0)  with  purified water,  stored at +4°C. 
6.3.4  B-glucuronidase  (e.g.  Sigma  G-0876)  diluted with  ten  volumes 
double  distilled water. 
6.3.5  Charcoal  suspension  - 5 g charcoal  (6.1.12).  0.5  g dextran 
(6.1.13).  Made  up  in  1 litre with  phosphate  buffer  (6.3.3) 
6.3.6  Tritiated stilbenes;  Dilute  50  ~L stock  solution  6.1.11  with  10 
ml  methanol  to  give  a radioactive concentration  of  ca.  2~Ci  per 
ml.  Store  at -20°C. 
6.3.7  Tritiated stilbene assay  solution,  prepared  from  stock  solution 
6.3.6.  by  evaporation  and  redissolving  in  buffer  (6.5.4.)  to give 
10,000  cpm/0.1  ml.  Prepared  on  day  of  use. 
[Note;  The  non-specific  binding  (NSB)  of  the  3H-stilbene must  be  determined 
and  if it exceeds  10%  of  the  total  count  (SA)  of  3H-stilbene  should  be 
repurified or  replaced.] 
6.3.8  Prepare  solution of  antibody  in  buffer  (6.3.3).  It will  be 
necessary  to  follow  the  instructions pertaining to  the  individual 
antibody  preparations.  The  concentration of  antibody  in  buffer 
should  be  8x  greater than  the  concentration  needed  in  the final 
RIA  incubation  mixture. 
7.  EQUIPMENT. 
Reference  to a  company  and/or  product  is for  purposes  of  information  and 
identification only.  Equivalent  types  or  products  also  may  be  suitable. 
7.1 
7.2 
7.3 
7.4 
7.5 
7.6 
7.7 
7.8 
7.9 
7.10 
7.11 
7.12 
7.13 
7.14 
7.15 
7.16 
7.17 
7.18 
7.19 
7.20 
7.21 
7.22 
7.23 
7.24 
Liquid  scintillation Counter,  with  automatic  sample  changer. 
Scintillation vials. 
Cold  storage  space. 
Cold  room/refrigerator space. 
Deep  freeze  -20°C. 
Fume  cupboards. 
Centrifuges. 
Refrigerated  centrifuge with  large  capacity for  small  tubes. 
Bench  centrifuge. 
Heating  units. 
37°C  water  bath/incubator. 
40/45°C  water  bath. 
Magnetic  stirrer. 
Glassware. 
Glass  tubes  75  mm  x 12  mm. 
Glass  stoppered  tubes  125  mm  x 16  mm. 
Glass  universal  bottles,  approx  25  ml  with  plastic screw  tops. 
Vortex  mixer. 
Pipettes and  dispensers. 
Semi-automatic  pipettes with  disposable  tips. 
Pasteur  pipettes. 
Tilt measures  (5  ml  for diethyl  ether). 
Dispenser  for scintillator. 
Apparatus  suitable for  evaporation  of  solvents.  e.g.  Compressed 
nitrogen  supply  and  evaporation  manifold  or  rotary film 
evaporator. 
[Note;  Solvent  should  be  evaporated  at temperatures  not  exceeding  50°C 
using  e.g.  either a  stream  of  nitrogen  or  a rotary film evaporator.] 
Sg  1.3/3 8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section  6.3.1  and  ISO  document  78/2-1982  and 
the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to  enable  the 
detection of  residues  in  meat  as  defined  in  Directive 64/433/EEC. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to  allow 
the  reference method  to  be  carried out  and  to  allow  repeat  analysis where 
required. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to  allow  proper 
identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice  the  result of  the  examination. 
Samples  for  the  analysis of  stilbenes must  be  stored  and  transported at 
temperatures  below  -18°C. 
9. 
9.1.1 
9.1.2 
9.1.3. 
9.1.4 
9.2 
9.3 
9.4 
9.5 
9.6 
PROCEDURE. 
Into  four  test tubes  (7.16)  or  universal  bottles  (7.17)  add  0.5 
mL  blank  urine. 
Into  four  test tubes  (7.16)  or  universal  bottles  (7.17)  add  0.5 
mL  blank  urine  and  100  pg  DES  for  recovery. 
Into four  test tubes  (7.16)  or  universal  bottles  (7.17)  add  0.5 
mL  blank  urine  and  90  pg  DES  for  QC  check. 
Add  0.2  mL  urine  sample  in  duplicate  to  test tubes  or  universals. 
Normal  equipment  would  allow  30  samples  to  be  used. 
Add  to  universals/tubes 9.1.1  - 9.1.4.  50  ~L enzyme  (6.3.4)  and 
incubate  for  2 h at 37°C. 
Allow  to  cool  and  add  5 mL  diethyl-ether  (6.1.3.),  vortex  mix  for 
15  seconds. 
Centrifuge  at 2000  rpm  for  5 min. 
Freeze  samples  in  dry  ice/acetone  bath  and  decant  ether phase 
into  glass  tubes  (7.15). 
Evaporate  to  dryness  under  nitrogen.  (7.24). 
9.7  Radioimmunoassay. 
The  method  chosen  for  separation  of  antibody-bound  and  free  ligand  uses 
charcoal. 
9.7.1.  Into  7 RIA  tubes  (7.15)  pipette 0.1  mL  methanol  (3  tubes  for  Non-
specific binding  {NSB}  and  4 tubes  as  zero  standard  tubes).  Into 
RIA  tubes,  pipette  in  triplicate 0.1  mL  of  stilbene standard 
solutions  (6.3.2)  to  give  range  5 - 500  pg  per  tube.  Evaporate 
9.7.2.1 
9.7.2.2 
9.7.2.3 
9.7.3 
9.7.4 
methanol  to dryness  e.g.under  nitrogen  (7.24). 
Add  60  ~L methanol  to  all  tubes  (9.7.1  and  9.6).  Add  640  ~L 
gelatin-phosphate  buffer  (6.3.4)  to the  3 tubes  for  NSBs.  and  540 
~L buffer  to all  the  other  tubes. 
Add  0.1  mL  tritiated stilbene solution  (6.3.7)  to all  tubes  and 
to  two  scintillation vials  (for total  counts). 
Add  0.1  mL  antibody  (6.3.8)  to all  tubes  except  the  3 zero 
standard  tubes  designated  for  NSB,  to  these  3 tubes  add  0.1  mL 
buffer  (6.3.4). 
Vortex  mix  for  a  few  seconds. 
Place  all  tubes  in  a water  bath  at 37°C  for  15  minutes  and  then 
Sg  1.3/4 9.7.5 
9.7.6 
9.7.7 
9.7.8 
9.7.9 
incubate  overnight  at +4°C. 
Add  0.5  mL  charcoal  suspension  (6.3.5)  at 4°C. 
Shake  all  tubes  gently  by  hand  for  1 minute  and  stand  at 4°C  for 
10  min. 
Centrifuge  at 2000-3000  rpm  at 4°C  for  20  minutes. 
Decant  supernatant  into  scintillation vials  (7.2). 
Add  10  mL  scintillator (6.5.2.)  to  all  vials  including  2 vials 
containing 0.1  mL  tritiated stilbene solution  (9.7.2.2)  and  also 
two  vials containing 0.1  mL  gelatin-phosphate  buffer  (Background 
counts) 
9.7.10.  Place  samples  in  liquid scintillation counter  (7.1)  and  count 
(preset time  or  counts)  e.g.  10000  counts  or  10  minutes. 
10. 
10.1 
10.2 
10.4. 
CALCULATION  OF  RESULTS. 
Prepare  calibration curve  by  plotting cpm  3H-DES  bound  (cpm 
bound)  to  antibody  for  vials containing  standards  0 - 500  pg 
against  pg  standard. 
Read  off calibration curve  pg  DES  against  cpm  for  test samples 
and  solvent  blanks. 
Calculate the  concentration  of  DES  in  sample  -
pg  stilbene  =  (curve  pg  - blank  pg)  x 5 x recovery  factor. 
curve  pg  =  pg  obtained  in  step  10.2. 
blank  pg  =  pg  for  solvent  blanks  obtained  in  step  10.2. 
recovery  factor  is determined  by  the  recovery  of  the  100  pg  in  tubes 
(9.1.2) 
10.5.  Alternative calculations. 
B =  cpm  bound  to antibody- cpm  for  NSB  (NSB  tubes  9.7.2.3.). 
Bo  =  cpm  bound  to  antibody  in  zero  standard  tubes  - cpm  for  NSB. 
Bo  should  be  between  40-60%  of  total  cpm  (cpm  3H-DES(SA)) 
Prepare  calibration curve  by  plotting 8/Bo  against  pg  standard. 
If a microcomputer  programme  is possible  then  a  best  line plot of  log  pg 
standard  against  Ln  Z/(1-Z)  where 
Z =  B/Bo  (LOGIT  plot)  can  be  used  to  interpolate results. 
Calculate  8/Bo  for test sample  and  for  the  solvent  blank  using  cpm  - NSB 
and  estimate  pg  DES  from  calibration curve.  Proceed  as  10.3. 
The  original  counting  data  should  be  included  with  the  final  results. 
10.6  Recovery  and  Precision  Data  for fortified  blank  urines. 
Cone  (ng  per  mL) 
0.5 
5 
10 
Recovery  (%) 
85 
90 
92 
Data  from  Meat  Control  Lab.  Dublin,  Ireland. 
Sg  1.3/5 
Within  lab.  CV  (%) 
15 
12 
8 11.  SPECIAL  CASES 
12.  NOTES  ON  PROCEDURE 
- Better results were  observed  if the  RIA  tubes  were  not  siliconised. 
- The  addition  of  methanol  into  the  RIA  tubes  (9.7.2.1)  aids  the 
reconstitution of  the  DES  into  solution. 
13.  ANTIBODIES 
Antibodies  to  DES  are  commercially  available  but  recommend  up  to  date 
information  is obtained  from  the  Community  Reference  Laboratories. 
14.  QUALITY  CONTROLS 
See  section 8 of  manual  detailing the  RMs  available for  the  stilbenes. 
15.  LIST  OF  ABBREVIATIONS 
NSB,  non-specific  binding;  SA,  standard  addition. 
A full  list of  abbreviations  is given  in  Annex  I,  Section  12 
16.  FLOW  DIAGRAM 
URINE  ------------>  Hydrolyse 
I 
I 
! 
Calculate <----- RIA  <----- ether extraction 
results 
Sg  1.3/6 Sg.  1.4.  THYREOSTATS  - METHOD  FOR  THE  MEASUREMENT  OF  RESIDUES  OF 
THYREOSTATIC  SUBSTANCES  IN  ANIMALS  AND  ANIMAL  TISSUES  ON  THE  BASIS  OF  HIGH 
PERFORMANCE  THIN  LAYER  CHROMATOGRAPHY  (HPTLC). 
WARNING  AND  SAFETY  PRECAUTIONS. 
1.  INTRODUCTION. 
Throughout  the  EEC  the  use  of  thyreostatic  (anti-thyroid)  substances  is 
prohibited  in  food  producing  animals.  Also  the  MRL  for  residues  of 
thyreostatics  in  animal  products  imported  into or  produced  within  the 
Community  is zero. 
2.  SCOPE  AND  FIELD  OF  APPLICATION 
This  method  of  analysis  describes  the  determination  of  the  presence  of 
thyreostatic substances  in  foodstuffs  and  samples  of  animal  origin.  The 
method  can  be  used  for  meat  and  also for  biological  material  such  as  animal 
organs,  biological  fluids  and  excreta.  The  limit of  detection  for  2-
thiouracil  (TU);  4(6)-Methyl-2-thiouracil  (MTU)  and  4(6)-n-propyl-2-
thiouracil  (PTU)  is about  25  ~9 per  kg  or  L.  Because  the  recovery  of 
4(6)-phenyl-2-thiouracil  (PhTU)  and  1-methyl-2-mercaptoimidazole  (tapazole, 
TAP)  from  the mercurated  column  is  less efficient the  limit of  detection 
for  these  two  compounds  is about  100  ~g per  kg  or  L. 
For  confirmation  of  the  thyreostats the  spots  can  be  scraped  from  the  HPTLC 
plate,  derivatised and  identified by  GC-MS  in  the  CI  mode  (De  Brabander  et 
al,  1992).  See  Method  Cy  1.9. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
ISO  Standard  78/2-1982  Layout  for  standards  - Part  2:  Standard  for  Chemical 
Analysis 
EEC  Working  paper  VI/3186/84-EN,  File 6.21  II-4.  Method  of  analysis for 
detecting  anti-thyroid substances  in  fresh  muscle  tissue using  a  selective 
mercurated  column. 
De  Brabander,  H.F.  and  Verbeke,  R.  (1984),  Determination  of 
methylthiouracil  and  analogous  thyreostatic drugs.  Proc.  30th  Eur.  Meat 
Res.  Workers,  Bristol,  387-388. 
De  Brabander,  H.F.,  Batjoens,  P.  and  Van  Hoof,  J.  (1992),  Determination  of 
thyreostatic drugs  by  HPTLC  with  confirmation  by  GC-MS.  J.  Planar  Chrom.  ~. 
124-130 
4.  DEFINITIONS. 
Thyreostatic  substances  detected  in  this assay  are; 
2-thiouracil  (TU);  4(6)-Methyl-2-thiouracil  (MTU); 
4(6)-n-propyl-2-thiouracil  (PTU);  4(6)-phenyl-2-thiouracil  (PhTU); 
1-methyl-2-mercaptoimidazole  (tapazole,  TAP); 
Sg  1.4/1 5.  PRINCIPLE 
The  method  comprises  4 stages; 
- Homogenisation  of  tissue samples  or  diluting fluids  in  methanol 
- Percolation  of  supernatant  through  mercurated  ion-exchange  resin 
chromatographic  column 
- Derivatization 
- Separation  and  identification by  two  dimensional  HPTLC 
Note;  See  confirmatory method  Cy  1.9. 
6.  CHEMICALS 
Note:  The  reagents  for which  examples  of  their source  are  quoted  are 
known  to  be  satisfactory,  nevertheless  reagents  from  other  sources  may  be 
equally  suitable.  All  the  reagents  must  be  of  analytical  grade. 
6.1. 
6.2. 
6.3. 
6.4. 
6.5. 
6.6. 
6.7. 
6.8. 
6.9. 
6.10. 
6.11. 
6.11.1. 
6.11.2. 
6.11.3. 
6.12. 
6.12.1. 
6.12.2. 
6.12.3. 
6.12.4. 
7. 
Methanol 
Absolute  ethanol 
Hydrochloric  acid,  use  HCl  fumans  (min  37%  HCl)  and  dilute with 
water  accordingly. 
KOH 
Diethyl-ether  (peroxide  free  and  very  high  purity) 
Anhydrous  sodium  sulphate 
Eluting  Solution  for  resin.  0.5M  NaCl,  0.1M  HCl,  pH=  1. 
NBD-Cl  solution.  Dissolve  5 mg  NBD-Cl  (7-chloro-4-nitrobenzo-2-
oxa-1,3-diazole)  in  1 mL  methanol.  Prepare  this solution fresh 
daily and  keep  in  a cool  dark  place. 
NaOH 
NaCl 
Spray  solutions; 
Solution  I  -mix 50  mL  denatured  alcohol  with  50  mL  propan-2-ol. 
Add  2 mL  25%  ammonia. 
Solution  II  - dissolve 0.6  g cysteine  hydrochloride  (or  2-
mercaptoethylamine)  in  20  mL  water.  Keep  in  refrigerator at 
about  +4°C.  Make  fresh  daily. 
Spray  reagent  - Immediately  before  use,  mix  2 mL  solution  II  with 
100  mL  solution  I. 
Standards 
The  thyreostats,  TU,  MTU,  PTU,  PhTU  and  TAP  are  prepared  as  stock 
solutions of  20  mg  thyreostat  in  100  mL  methanol.  For  MTU, 
distilled water  and  a  trace of  HCl  must  be  added  to dissolve  the 
substance.  PhTU  is dissolved  in  a mixture  of  benzene  and 
methanol  (8:92  v/v).  The  working  solutions  are  made  by  diluting 
aliquots of  the  stock  solution  100  times  with  buffer  (6.12.4) 
The  internal  standard  is 4  (5,6)-dimethyl-2-thiouracil  (DMTU). 
20  mg  DMTU  is dissolved  in  100  mL  methanol  (stock  solution)  and  a 
working  solution  is made  immediately  before  use  by  diluting 0.5 
mL  stock  solution  to  100  mL  with  methanol. 
Spiked  tissues.  2.0  g minced  meat  (or  other tissue)  is spiked  by 
the  addition of  100  ~L methanol  solutions containing 0.05  ~g TU, 
MTU,  PTU,  0.2  ~g TAP  and  0.05  ~g DMTU  as  the  internal  standard. 
Phosphate  buffer;  94.5  mL  of  0.2M  Na2HP04  is mixed  with  5.5  ml 
of  0.2m  KH2P04 •  The  pH  is adjusted  to  pH  8.8. 
EQUIPMENT. 
Sg  1.4/2 7.1.  Air- and  water-tight reaction  tubes,  10  ml  and  20  ml. 
7.2.  Homogeniser  (Ultra-Turrax  type). 
7.3.  Extraction  tubes  with  ground  glass  neck,  50  ml 
7.4.  Refrigerator  +4°C 
7.5.  Deep  freeze  -20°C. 
7.6.  Centrifuge. 
7.7.  TLC  ancillary equipment,  e.g.  solvent  tanks 
7.8.  UV  lamp,  366  nm,  with  contrast filter or  protective 
chromatography  spectacles. 
7.9.  Glass  columns  about  300  mm  long,  4  mm  i.d.and 6 mm  o.d., 
7.10.  200  ml  glass flasks with  B 14  glass  joint. 
7.11.  Micro-litre syringes  with  end  of  needle  cut at 90°.  Capacity  1 
~L,  10  ~L and  100  ~L. 
7.12.  Preparation  of  the  Mercurated  resin. 
20  ml  Oowex  1 x 2  (50-100  mesh,  Analytical  grade)  is washed 
successively with  10  bed  volumes  of  distilled water,  0.5M  NaOH, 
distilled water,  0.5M  acetic acid  and  distilled water.  The  wet 
resin  (20  ml)  is then  shaken  with  200  ml  aqueous  solution of  2,7-
dibromo-4-hydroxymercrifluorescein  (500  mg  dissolved  in  200  ml 
water)  for  24  hours.  The  mercurated  resin  is then  washed  with 
water  until  the  eluate  is colourless.  The  resin  is treated with 
100  ml  0.1M  HCl  and  0.5M  NaCl,  washed  with  500  ml  distilled 
water,  treated with  100  ml  0.1M  NaOH  and  washed  with  500  ml 
distilled water.  The  resin  is stored  in  the  dark. 
7.13.  Preparation  of  Micro-Column  for  clean-up  stage. 
2 
7 
3 
1 
26cm 
5cm 
5 
6 
I  4 
4 
1.  glass  column  4  mm  i.d.,  6 mm  o.d. 
2.  glass  rod  3 mm  i.d. 
3.  connected  with  silicone tubing 
4.  silicone tubing  0.3  mm  i.d.  0.7  mm  o.d. 
5.  silicone tubing  0.5  mm  i.d.  1 mm  o.d. 
6.  silicone tubing  0.5  mm  i.d.  4  mm  o.d. 
7.  glass funnel 
R is resin 
The  column  is filled with  water  and  the 
glass rod  removed.  Approximately  0.6 
ml  mercurated  resin  is suspended  in 
water  and  added  via  the  funnel.  When 
the  resin  sediments  to a  height of  5 
em,  the  excess  resin  is removed  and  the 
glass rod  replaced  to rest on  top  of 
the  resin bed.  The  column  is ready  for 
use. 
Sg  1.4/3 7.14.  HPTLC 
7.14.1.  Plates;  Silicagel  60  aluminium  sheets without  fluorescent 
indicator  (e.g.  Merck  No.  5613  or  5547).  The  plates are 
activated at 110°C  overnight  before  use. 
7.14.2  Solvents.  Use  either system  a or  system  b. 
System  a 
7.14.2.1a First direction solvent;,  chloroform 
7.14.2.2a  Second  direction solvent;  chloroform 
ethanol  95:5  v/v 
propionic  acid  95:5  v/v. 
System  b 
7.14.2.1b  First direction  solvent;  methylene  chloride 
7.14.2.2b  Second  direction  solvent;  methylene  chloride 
98:2  v/v. 
7.14.3.  Spray  solutions,  see  6.11. 
methanol  98:2  v/v 
propionic  acid 
Reference  to a  company  and/or  product  is for  purposes  of  information  and 
identification only.  Equivalent  types  or  products  also may  be  suitable. 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section 6.3.1  and  to  ISO  document  78/2-1982  and 
also  the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to  enable  the 
detection of  residues  in  meat  as  defined  in  Directive 64/433/EEC.  Failing 
this biological  fluids or faeces  may  constitute the  samples  for  the 
detection of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large enough  to  allow 
the  method  to  be  carried out  and  to allow  repeat  analysis where  required. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to allow  proper 
identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice  the  result of  the  examination. 
Samples  for  the  analysis of  thyreostatic substances  must  be  stored  and 
transported at temperatures  below  -18°C. 
9.  PROCEDURE. 
9.1  2 g tissue,  2 mL  urine,  plasma  or  skim  milk,  are  homogenised  in 
10  mL  methanol  using  an  Ultra-Turrax  homogeniser  (7.2). 
9.2.  100  ~L internal  standard  solution,  containing 0.2  ~g DMTU, 
(6.12.2)  is added  and  the  homogenate  centrifuged at 10,000  rpm 
(12,000  g)  for  10  minutes. 
9.3.  The  supernatant  is decanted  and  then  percolated  through  the 
mercury  column  (7.13).  Air  is removed  by  moving  the  glass rod 
carefully up  and  down. 
9.4.  The  column  is washed  with  10  mL  water  and  the  thyreostats are 
eluted with  5 mL  elution solution  (6.7). 
9.5.  The  eluate  is neutralised with  100  ~L 4M  NaOH  and  1 mL  buffer 
(6.12.4)  and  adjusted  to  pH  =  8. 
9.6.  0.1  mL  NBD-Cl  solution  (6.8)  is added  and  the  reaction  allowed  to 
proceed  in  the  dark  at 40°C  for one  hour.  The  optimum  reaction 
time  may  vary  between  1 - 2 hours  depending  on  the  quality of  the 
Sg  1.4/4 NBD-Cl.  The  time  should  be  checked  in  advance. 
9.7.  The  pH  of  the  reaction mixture  is adjusted  to  pH  3-4  by  adding 
0.2  mL  6M  HCl. 
9.8.  The  NBD  derivatives  are extracted with  3 mL,  2  mL  and  2  ml 
diethyl-ether and  the  combined  ether extracts are  dried  over 
anhydrous  sodium  sulphate  (0.5  -1  g).  No  water  must  be  present. 
9.9.  The  ether  is evaporated  under  a  stream  of  nitrogen  to yield, 
according  to  the  concentration  range  of  interest,  a  volume 
between  0.2  mL  and  1 mL. 
9.10.  Standards  are  prepared  for  derivatisation by  mixing  0.1  mL  stock 
solution  in  5 mL  buffer  (6.12.4).  The  mixture  is derivatised  by 
carrying out  steps  9.6  to  9.9  and  evaporating  the  ether to  a 
volume  of  2  mL. 
9.11.  50-100  ~L of  the  extracts  (9.9)  are  analyzed  by  bi-dimensional 
HPTLC. 
9.12.  The  plate  is run  first with  solvent  7.14.2.1.(a or  b),  dried 
carefully in  a  stream  of  air and  then  run  in  the  other direction 
using  solvent  7.14.2.2.(a or  b). 
9.13.  Standards  which  are  derivatised at the  same  time  may  be  run 
parallel with  the extracts during  the  second  solvent  step for 
accurate  identification of  the  individual  thyreostats. 
9.14.  The  plates are  sprayed  with  the  cysteine based  spray  (6.11)  and 
the  spots  identified.  The  spots,  which  are  not  visible before 
spraying,  should  appear  as  yellow  fluorescent  spots  on  a  blue 
background.  The  relative  intensities of  the  fluorescence  at 366 
nm  of  the  suspected  thyreostats  are  compared  with  the  intensity 
of  the  spot  due  to  the  internal  standard. 
Note;  Interferences  on  the  plate may  be  reduced  by  allowing  the  plate to 
stand  overnight. 
10.  CALCULATION  OF  RESULTS. 
10.1.  IDENTIFICATION. 
The  spots  are yellow  fluorescent  spots  and  must  have  the  same  Rf  values  as 
the  standards.  In  the  system  using  the  solvents  7.14.2.1a  and  7.14.2.2a 
the  Rf  values  relative to  the  internal  standard  DMTU  should  be  similar to 
those  in  table 1. 
Table  1.  RRf  of  thyreostats relative to  DMTU  on  HPTLC  plates. 
Thyreostat  RRf  in  1st solvent  RRf  in  2nd  solvent 
DMTU  1.0  1.0 
TU  0.34  0.22 
MTU  0.59  0.43 
PTU  0.73  0.77 
PhTU  0.94  0.89 
TAP  1.09  0.53 
Data  from  EEC  Working  paper  VI/3186/84-EN,  File 6.21  II-4. 
10.1.  RECOVERIES. 
The  recoveries of  the  thyreostats from  the mercurated  column  is  >78%  for 
TU,  MTU,  PTU  and  DMTU  but  only  about  17%  for  PhTU  and  60%  for  TAP. 
The  recoveries  of  the  internal  standard,  DMTU,  from  meat,  plasma  and  milk 
are  shown  in  table 2; 
Sg  1.4/5 Table  2;  Recoveries  of  100  ~g per  kg  spike  of  DMTU. 
Sample. 
Meat 
Plasma 
Milk 
Concentration  found  +  SO 
(~g per  kg)  -
PTU  MTU 
106  ±  5.5 
84  ±  6.2 
88  ±  6.9 
102  ±  13.7 
98  ±  5.0 
105  ±  3.6 
10.2.  PRECISION 
TU 
97  ±  21.8 
76  ±  5.7 
85  ±  8.0 
10.2.1.  Reproducibility;  The  reproducibility of  the  analysis of  meat 
spiked  at the  100  ~g per  kg  level  was  recorded  for  each  step of  the  assay. 
The  results obtained  by  De  Brabander  and  Verbeke  (1984),  Ghent,  are  shown 
in  table 3; 
Table  3; 
Step  n  recovery 
mean  ±  SO  (~g/kg) 
Column  elution  26  81  ±  3.9 
Derivatisation  26  76  ±  5.0 
HPTLC  22  88  ±  4.7 
Total  procedure  22  55  ±  6.9 
11.  SPECIAL  CASES 
12.  NOTES  ON  PROCEDURE 
13.  QUALITY  CONTROLS 
cv 
~  0 
4.8 
6.6 
5.4 
12.6 
See  section  8  of  manual  detailing the  RMs  available for  the  thyreostatics. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS 
A full  list of  abbreviations  is given  in  Annex  I,  Section  12 
16.  FLOW  DIAGRAM 
Tissue  --> add  methanol  and  internal  standard  ---> Homogenise 
I 
I 
I 
I 
! 
HPTLC  <------- Derivatise <------- percolate  through  Hg  column 
I 
I 
! 
Measure  fluorescence  at 366  nm  -------> Calculate  results. 
Sg  1.4/6 Sg  2.1.  B-AGONISTS  - A SCREENING  METHOD  FOR  THE  DETECTION  OF  B-AGONISTS 
IN  BOVINE  URINE  BY  GC-MS  IN  THE  ELECTRON  IMPACT  MODE  FOR  THE  TRIMETHYLSILYL 
DERIVATIVES. 
1.  SCOPE 
This  method  of  analysis  describes  the  detection  of  the  presence  of 
individual  ~-agonists in  samples  of  urine of  veal  calves  and  adult cattle. 
The  method  is used  officially in  France  and  is carried out  in  compliance 
with  the  Residues  Directive  (86/469/EEC). 
2.  FIELD  OF  APPLICATION 
The  method  is used  to  perform  routine  screening  in  urine  from  veal  calves 
and  adult cattle.  The  method  is used  to test for  the  presence  of  residues 
of  clenbuterol,  clenpenterol,  hydroxymethyl-clenbuterol,  salbutamol, 
terbutaline,  cimaterol,  cimbuterol,  mabuterol,  mapenterol,  tulobuterol, 
fenoterol  and  ractopamine. 
The  detection  limit,  defined  as  a  signal  noise  ratio >3  is  below  1  ~g per  L 
3.  REFERENCES 
Montrade,  M-P.,  Le  Bizec,  B.,  Manteau,  F.,  Siliart,  B.  and  Andre,  F. 
(1993),  Multi-residue  analysis forB-agonistic drugs  in  urine  of  meat-
producing  animals  by  gas  chromatography- mass  spectrometry.  Anal.  Chim. 
Acta.  275,  253-268 
Montrade,  M-P.,  Le  Bizec,  B.  and  Andre,  F.  (1992),  Methode  de  recherche 
urinaire  (screening)  d'agonistes B-adrenergiques  par  chromatographie 
gazeuse  couplee  a la spectrometie  de  masse  (GC-MS)  en  mode  impact 
electronique.  Document  LDH/92/01  Lab.  Dosage  Hormonaux,  Nantes. 
DGAL/SDHA/H92.8066 
[Note;  This  method  is available  in  French,  Spanish  or  Portuguese] 
4.  DEFINITIONS 
B-agonists  content  is taken  to  be  the  amount  of  ~-agonists in  the  substance 
in  question  determined  according  to  the  described  method  and  expressed  as 
~g ~-agonists per  L of  test sample. 
5.  PRINCIPLE 
The  method  comprises  6 stages; 
1.  hydrolysis  of  conjugates 
2.  methanol  precipitation  (optional),  particulary for 
11dirty
11  urine of 
adult cattle 
3.  extract purification and  concentration  using  mixed  solid-phase 
extraction  (SPE)  chromatography 
4.  derivatisation 
5.  detection  by  GC-MS  in  electron  impact  mode 
6.  calculation  and  evaluation of  results 
6.  MATERIALS 
Note:  The  reagents  (and  equipment)  for which  examples  of  their source  are 
quoted  are  known  to  be  satisfactory,  nevertheless  reagents  and  equipment 
from  other sources  may  be  equally suitable.  All  the  reagents  should  be  of 
Sg  2.1/1 analytical  grade  or  better. 
6.1  Reference  compounds  and  Standards. 
Clenbuterol  hydrochloride  (lnterchim,  Montlucon,  France) 
Salbutamol  hemisulphate,  Terbutaline  hemisulphate  and  metoprolol  tartrate 
(Sigma). 
Cimaterol,  clenpenterol  (NAB  760),  mabuterol,  fenoterol  hydrobromide  and 
hydroxymethyl  clenbuterol  (NA1141)  (Boehringer  Ingleheim) 
Tulobuterol  hydrochloride  (Abbott) 
Ractopamine  hydrochloride  (Eli  Lilly) 
Cimbuterol  and  marpenterol  were  synthesised  by  Chern  Dept,  University of 
Rennes,  France 
6.2 
6.2.1 
6.2.2 
6.2.3 
6.2.4 
6.2.5 
6.2.6 
6.2.7 
6.2.8 
6.2.9 
6.2.10 
6.2.11 
6.2.12 
6.2.13 
6.2.14 
6.3 
6.3.1 
6.3.2 
6.3.3 
6.3.4 
6.3.5 
7.0 
7.1. 
7.2 
7.3 
7.4 
7.5 
7.6 
Chemicals 
Helix pomatia  juice  (B-glucuronidase-arylsulfatase,  Merck-4114) 
Glacial  acetic acid  (Panreac  - 131008  or Merck.62) 
Ultra-pure water  (>14  M  n.cm) 
Methanol  (Carlo-Erba  RS  CLHP-412002  or  Merck.6009) 
Ethyl  acetate  (Merck  ZA-9623) 
32%  Ammonium  hydroxide  (Merck  5426) 
1M Potassium  hydroxide  (Merck  ZA-9018920) 
1M Acetic  acid 
N-0-bis(trimethylsilyl)trifluoracetamide  (BSTFA)  (Regisil-270111 
or  FLUKA  -15244) 
Toluene  (FLUKA  - 89677)  by  molecular  sieving. 
Sodium  acetate  (Merck  ZA-6268) 
Potassium  dihydrogen  phosphate  (Merck  ZA-4873) 
Nitrogen  (dried  over  silica gel) 
Helium  (very  high  purity,  N55,  Carboxyque) 
Solutions 
B-agonists.  Prepare  stock  solutions of  the  standards  (6.1.1)  in 
methanol  (1  g per  L and  100  mg  per  L)  and  store at -18°C. 
B-agonists.  Prepare  working  solutions  by  dilution of  stock 
solutions  (6.3.1)  with  methanol  to  final  concentrations of  10  ~g 
and  1~g per  ml.  Store  at -18°C  in  the  dark. 
2M Acetate  buffer,  pH  5.2,  for  hydrolysis  of  conjugates. 
Dissolve  164  g sodium  acetate  (6.2.11)  in  900  ml  water  (6.2.3) 
and  adjust the  pH  to  5.2  ±  0.1  with  glacial  acetic acid  (6.2.2). 
Make  up  to  1 L with  water  and  store at +4°C.  Use  for  up  to  1 
month. 
0.1M Phosphate  buffer,  pH  6.0.  Dissolve  13.6  ~ 0.1  g potassium 
dihydrogen  phosphate  (6.2.12)  in  900  ml  water  (6.2.3)  and  adjust 
the  pH  to  6.0  ±  0.1  with  1M  potassium  hydroxide  (6.2.7).  Make  up 
to  1 L with  water  and  store at +4°C.  Use  for  up  to  1 month. 
Mix  ethyl  acetate and  32%  ammonium  hydroxide  97:3  (v/v).  100  ml 
does  16  samples.  Stir/agitate the mixture  prior to  use  and  then 
place  into  an  ultra-sonic bath  during  step 9.13.3. 
EQUIPMENT 
Centrifuge 
Rotary  evaporator 
Vortex  mixer 
pH  meter 
Pipettes 
Balance 
Sg  2.1/2 7.7 
7.8 
7.9 
7.10 
7.11 
7.12 
7.13 
7.14 
7.14.1 
7.14.2 
8. 
Vacuum  filtration system  (Vac-Elut  from  Analytichem 
International) 
Ultra-sonic  bath 
Magnetic  stirrer/agitator 
Conical  reaction  vials for  derivatisation 
Heating  block  for  reaction  vials 7.10 
Heating  block  with  evaporation  system 
SPE-Columns;  CLEAN  SCREEN  DAU  (Worldwide  monitoring  - Horsham, 
PA,  USA  and  sold  by  Technical,  Stockport,  Cheshire,  UK).  These 
columns  of  6 mL  volume  contain  500  mg  of  a mixed  phase  support 
which  has  hydrophobic  and  ion-exchange  properties. 
GC-MS 
GC;  GC  Hewlett  Packard  5890. 
Capillary column,  30m X 0.25  mm  i.d. with  SE-30  stationary phase 
of  0.25  ~m thickness. 
Injection mode;  splitless over  1 minute 
Injection  volume;  2  ~L 
Injector temp.  250°C;  Transfer  temp.  280°C 
Temp.  programme; 
lSOC/min  SOC/min 
70°C  (2  min)  ----------->  200°C  (0  min)  --------->  245°C  (0  min) 
2SOC/min 
----------->  300°C  (12  min) 
Gas;  Helium  at 1 mL  per  min  and  5 psi. 
MS;  Hewlett  Packard  5971  with  UNIX  station. 
Electron  Impact  ionisation mode  (70  eV) 
Source  temp.  190°C  ~ soc 
Pressure,  30-40  mm  Torr 
SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section  6.3.1  and  to  ISO  document  78/2-1982  and 
also  the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection  of  residues  in  urine  as  defined  in  Directive 
64/433/EEC. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large enough  to 
allow  the  method  to  be  carried out  and  to  allow  repeat analysis 
where  required.  Each  analysis  needs  a  10  mL  sample. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to  allow 
proper  identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain 
the  integrity of  the  sample  and  not  prejudice  the  result of  the 
examination. 
Samples  for  the  analysis  of  B-agonists  must  be  stored at 
temperatures  below  -18°C. 
Sg  2.1/3 9.0. 
9.1 
9.2 
9.3 
9.4 
9.5 
PROCEDURE 
Thaw  the  primary  samples  and  transfer more  than  10  ml  to  a 
centrifuge tube.  Centrifuge  at 3000  rpm  for  15  min.  Pipette  10 
ml  to  a  screw-topped  tube  (e.g.  scintillation counting  vial). 
Add  60  ng  metoprolol  as  internal  standard  to all  urines  including 
two  blank  urines. 
To  one  of  the  blank  urines  (9.2)  add  40  ng  (equiv.  4 ppb) 
tulobuterol,  fenoterol  and  ractopamine  and  20  ng  (equiv.  2 ppb) 
of  the  other  B-agonist  standards  (6.3.2). 
Add  1 ml  acetate buffer  (6.3.3)  and  check  the  pH  is about  5.2 ± 
0.3.  Adjust  the  pH  to  about  5.2 with  acetic acid  if necessary. 
Add  50  ~L Helix  pomatia  juice (6.2.1)  and  incubate  overnight  at 
sooc  in  a water  bath  or  oven. 
Steps  9.6  to 9.11  are  optional  and  can  be  used  for  urines  from  adult 
cattle. 
9.6 
9.7 
9.8 
9.9 
9.10 
9.11 
9.12 
9.13 
9.13.1 
9.13.2 
9.13.3 
9.13.4 
9.13.5 
9.14 
9.15 
9.16 
9.17 
9.18 
9.19 
9.19.1 
9.19.2 
9.19.3 
Transfer  the  hydrolysed  urines  to  rotary evaporation  flasks. 
Add  25  ml  methanol.  Evaporate  the methanol  using  a  rotary 
evaporator  and  a water  bath  at about  45°C. 
Concentrate  the  aqueous  phase  to about  3 ml. 
Transfer  the  aqueous  phase  to  a test tube  with  a  pasteur  pipette 
and  rinse out  the  flask  twice  with  5 ml  phosphate  buffer  (6.3.4). 
Centrifuge  at 3500  rpm  for  about  10  min.  A precipitate should 
form  on  the  tube. 
Check  and  adjust  the  pH  to  6.0  ±  0.3  if necessary.  Use  all  the 
clear aqueous  phase  for  step  9.13. 
If steps  9.6  to  9.11  were  not  carried out  add  4 ml  phosphate 
buffer  (6.3.4)  to  the  hydrolysate,  adjust the  pH  to  6.0  (final 
volume  to  15  ml). 
Column  extraction; 
Place  the  columns  on  the  Vac-Elut  system  and  successively rinse 
with;  2 ml  methanol;  2 ml  water  (6.2.3);  2 ml  phosphate  buffer 
(6.3.4). 
Transfer  the  clear extracts  (9.11  or  9.12)  with  a  pasteur  pipette 
to the  top  of  the  column  and  allow  to  drain  slowly  using  slight 
negative  (  ca.12  em  Hg)  pressure. 
Rinse  the  columns  using  negative  pressure of  about  40  em  Hg  with 
1 ml  1M  acetic acid  (6.2.8)  and  allow  to  dry  before  rinsing with 
6 ml  methanol  by  applying  a  strong  vacuum. 
Place  the  ethyl  acetate I  ammonium  hydroxide  solution  (6.3.5)  in 
an  ultra-sonic bath  to agitate the mixture  during  step 9.13.3. 
Elute  the  analytes with  6 ml  the  ethyl  acetate I  ammonium 
hydroxide  solution  (6.3.5) 
Evaporate  the eluate with  nitrogen  using  an  evaporation  system 
and  a  heating  block  at 40  ±  5°C. 
Dissolve  the  residue  in  200  ~L methanol  with  vigorous  vortexing. 
Transfer  the  solution  to  a reaction  vial. 
Dissolve  and  transfer to the  reaction  vial  any  remaining  residue 
with  a further  100  ~L methanol  and  vortexing. 
Evaporate  the methanol  to dryness  on  a  heating  block  at 40°±  soc. 
Derivatisation 
Add  50  ~L BSTFA  (6.2.9)  and  vortex. 
Place  vials  in  heating  block  at 75°C  ± soc  for  90  min. 
Transfer  the  vials to a  heating  block  at 40°  ±  5°C.  Allow  the 
vials  and  block  to  cool  to  room  temperature  (25°C)  evaporate  to 
dryness  with  nitrogen. 
Sg  2.114 9.19.4 
9.19.5 
9.20 
Add  25  ~L toluene  (6.2.10)  and  vortex  vigorously. 
The  vials may  be  stored  in  a refrigerator at +4°C. 
Inject 2  ~L of  9.19.5  into  the  GC-MS. 
9.21  The  GC-MS  is run  in  the  selected  ion  monitoring  mode.  The  ions 
and  the  retention times  of  the  derivatives of  the  B-agonists  are 
shown  in  table 1. 
Table  1. 
B-agonist  N  RT  (min)  Selected  ions  Mo 1. 
Ion 
Tulobuterol  1  9.34  86,  194,  284  299 
Mabuterol  1  10.36  86,  277,  296  382 
Mapenterol  1  11.04  100,  277,  296  396 
Terbutaline  3  11.67  86,  356  441 
Clenbuterol  1  12.02  86,  243,  262  (264)  348 
Cimaterol  1  12.14  72,  219  291 
Salbutamol  3  12.27  86,  369  455 
Cimbuterol  1  12.36  86,  219  305 
Cimaterol  2  12.62  72,  291  363 
Metoprolol  (I.S)  1  12.7  72,  223  339 
Cimbuterol  2  12.8  86,  291  377 
Clenpenterol  1  12.86  100,  243,  262  (264)  362 
Hydroxymethyl- 2  14.05  174,  243,  262  436 
clenbuterol  (NA 
1141) 
Fenoterol  4  18.39  322,  356,  412  591 
Ractopamine  3  18.63  250,  267  517 
N is the  number  of  TMS  groups.  RT  are  the  retention times  recorded  in  an 
analysis  at  LDH,  Nantes. 
10.0  INTERPRETATION  OF  RESULTS 
10.1  Validity of  Analysis;  The  criteria set out  in  EC  Decision  256 
must  be  fulfilled especially the following;-
10.1.1  The  relative retention times  for  the  TMS  derivatives of  the 
standard  analytes  in  the  appropriate matrix  and  the  suspected  B-
agonist must  be  the  same. 
10.1.2  The  relative  intensities of  the  selected  ions  to  the  base  peak 
must  be  same  as  in  the  assay of  spiked  blank  urines  and  of 
standards. 
10.1.3  The  ions  for  the  internal  standard  (metoprolol-monoTMS)  must  be 
present at the  correct retention time. 
Sg  2.1/5 10.1.4  The  analysis  of  the  blank  urine  containing  the  internal  standard 
must  show  NO  evidence  of  carry-over of  B-agonists  from  the  GC-MS 
system.  This  is a  check  for  contamination  of  the  system. 
11.  SPECIAL  CASES 
12.  NOTES  ON  PROCEDURE. 
13.  QUALITY  CONTROLS 
See  section 8 of  manual  detailing the  RMs  for  the  B-agonists. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS 
A full  list of  abbreviations  is given  in  Annex  I,  Section  12 
16.  FLOW  DIAGRAM 
hydrolysis 
URINE  ------------> METHANOL  PRECIPITATION-------->  EXTRACT  by  SPE 
(Optional)  :  Chrom. 
I 
I 
I 
I 
I 
I 
INTERPRET  RESULTS  <----- GC-MS  <------------ TMS  DERIVATIVES 
(EI-mode) 
Sg  2.1/6 Sg  2.2.  B-AGONISTS  - AN  ELISA  SCREENING  METHOD  USING  A COMMERCIALLY 
AVAILABLE  KIT  FOR  THE  DETECTION  OF  B-AGONISTS  IN  BOVINE  URINE. 
WARNING;  The  stop  solution  (6.1.1.9)  contains  sodium  fluoride,  handle  with 
care  and  in  case  of  contact wash  thoroughly with  tap water. 
1.  SCOPE 
This  method  of  analysis  describes  the  detection  of  the  presence  of  ~­
agonists  in  urine  samples  of  cattle using  a commercially  available kit. 
The  method  has  been  mainly  tested for  residues  of  clenbuterol,  salbutamol, 
mabuterol,  mapenterol  and  terbutaline.  The  kit manufacturer  claim  that the 
kit may  be  used  for  bovine  liver and  milk  and  also milk  replacer powder. 
This  work  is carried out  in  compliance  with  the  Residues  Directive 
(86/469/EEC). 
2.  FIELD  OF  APPLICATION 
This  ELISA  method  is  used  to  perform  routine  screening  in  bovine  urine for 
the  presence  of  residues  of  clenbuterol,  salbutamol,  terbutaline, 
mapenterol  and  mabuterol. 
The  lower  limits of  detection  for  urine  (and  liver,  milk  and  milk  powder) 
in  ~g per  L or  kg  calculated  (see  EEC  93/256)  as  mean  of  blanks  ±  3 S.D. 
are;- Clenbuterol  and  mabuterol,  1;  salbutamol  and  mapenterol,  3.5; 
terbutaline 4.5. 
EIA  kits for  measuring  B-agonists  in  urine  and  serum  and  using  different 
antibodies  are marketed  by  several  manufacturers  (see  Section 8.4.2).  The 
lower  limits of  detection  and  the  specificities are  different from  those  in 
the  method  reported  here. 
3.  REFERENCES 
Commission  Decision,  93/256/EEC,  laying  down  the methods  for detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
Angeletti,  R.,  Paleologo  Oriundi,  M.,  Piro,  R.  and  Bagnati,  R.  (1993), 
Application  of  an  enzyme-linked  immunosorbent  assay  kit forB-agonist 
screening  of  bovine  tissues  in  north-eastern  Italy.  Anal.  Chim.  Acta.275, 
215-219. 
Quantitative B-agonists  ELISA  kit.  Enzyme  immunoassay  for  in  vitro 
diagnostic  use.  Cat.~ AG310.  Genego  S.P.A.,  34170  Gorizia,  Italy. 
4.  DEFINITIONS 
B-agonists  content  is taken  to  be  the  amount  of  ~-agonists in  the  substance 
in  question  determined  according  to  the  described  method  and  expressed  as 
~g ~-agonists per  litre of  urine. 
5.  PRINCIPLE 
The  method  comprises  3 stages. 
1.  Dilution  of  primary  urine  sample 
2.  ELISA  using  kit 
5.  Calculation  and  evaluation of  results 
Sg  2.2/1 6.  MATERIALS 
Note:  The  reagents  (and  equipment)  for which  examples  of  their source  are 
quoted  are  known  to  be  satisfactory,  nevertheless  reagents  and  equipment 
from  other  sources  may  be  equally suitable. 
6.1 
6.1.1 
6.1.1.1 
6.1.1.2 
6.1.1.3 
6.1.1.4 
6.1.1.5 
6.1.1.6 
6.1.1.7 
6.1.1.8 
6.1.1.9 
6.2 
7. 
Chemicals 
ELISA  kit  (Cat.~ AG310.  Genego  S.P.A.,  34170  Gorizia,  Italy.) 
containing;-
Clenbuterol  standard  solutions,  0.3,  0.6,  1.25,  2.5,  5.0,  10  ng 
per  mL  - ready  to  use 
Enzyme  conjugate;  salbutamol  peroxidase  - ready  to use 
Anti  B-agonists  antibody 
Wash  buffer;  Dilute  lOx  with  distilled water. 
Diluent  solution;  Dilute  20x  with  distilled water. 
Chromogen 
Citrate buffer 
Developing  solution;  Dilute  the  chromogen  (6.1.1.6)  25x  with 
citrate buffer  (6.1.1.7). 
Stop  solution  - ready  to  use 
Distilled water 
EQUIPMENT 
7.1  Micropipettes,  50,  100  and  200  ~L. 
7.2  Multichannel  micropipette,  50-200  ~L 
7.3  Plate washing  equipment,  manual  or  automatic 
7.4  Microplate  reader with  414  or  405  nm  filter with  optional  EIA/RIA 
data  processing. 
7.5  Normal  laboratory glassware. 
7.6  Centrifuge  (optional) 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is  drawn  to section  6.3.1  and  to  ISO  document  78/2-1982  and 
also  the following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to  enable  the 
detection  of  residues  in  meat  as  defined  in  Directive  64/433/EEC.  Failing 
this biological  fluids  (here  urine)  or  liver may  constitute the  samples  for 
the  detection  of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to  allow 
the method  to  be  carried out  and  to allow  repeat  analysis where  required. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to  allow  proper 
identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice  the  result of  the  examination. 
Samples  for  the  analysis of  B-agonists  must  be  stored at temperatures  below 
-18°C. 
9.  PROCEDURE 
9.1  Clarify the  urine  sample  (0.5-2  mL)  by  centrifugation at 1000  g 
for  5 min  or filtration. 
Sg  2.2/2 9.2  Dilute  0.5  mL  urine with  0.5  mL  dilution buffer  (6.1.1.5) 
9.3  ELISA  - follow  the  kit  instructions using  50  ~L of  sample  (9.2) 
or  standards  (6.1.1.1)  in  duplicate.  The  incubation  time  is  35 
min.  at room  temperature  and  development  time  for  the  chromogen 
is  30  min.  at room  temperature. 
9.4  Measure  the  absorbance  at 405  or  414  nm  of  the  test samples,  the 
standards  and  the  assay blanks  after the  addition  of  the  stop 
solution  (6.1.1.9). 
10.  INTERPRETATION  OF  RESULTS 
10.1  Precision;  The  intra-assay and  inter assay  variation was 
measured  using  the  1.25,  2.5  and  5.0  ng  per  mL  standards.  The 
values  were 
Intra-assay  CV  (%)  was  < 6%  n=6 
Inter-assay  CV  (%)  was<  9%  n=5  (Angeletti  et al.,  1993) 
Accuracy  was  measured  by  spiking  blank  urines with  1 ng 
clenbuterol  per  mL  or 2 ng  salbutamol  per  mL  gave  a  small 
overestimation  of  the  analyte  concentration  (10-15%  in  the  low  ng 
per  mL  range). 
10.2  The  action  limit was  estimated  for field  samples  by  comparing  the 
number  of  positives detected  above  either 0.6  or 1.0  ng  per  mL 
with  the  number  of  confirmed  positives for clenbuterol  and 
salbutamol  only.  Samples  were  examined  from  815  cattle and  the 
results are  shown  in  the  table of  the  data  reported  by  Angeletti 
et al.,  (1993) .• 
Animals  or  ~ +ve  >0.6  ng/mL  W  +ve  >1  ng/mL  ~ Confirmed  +ve 
Herds 
815  cattle  141  89  59 
180  herds  35  25  18 
11.  SPECIAL  CASES 
12.  NOTES  ON  PROCEDURE. 
The  kit can  be  used  for  testing residues  in  bovine  liver,  milk  and  milk 
replacer  powders  (see  Genego  instructions for  the  kit). 
13.  QUALITY  CONTROLS 
See  section 8 of  manual  detailing the  RMs  for  the  B-agonists. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS 
A full  list of  abbreviations  is given  in  Annex  I,  Section  12 
16.  FLOW  DIAGRAM 
dilute 
URINE  -----------> ELISA  ------------> RESULTS 
Sg  2.2/3 Sg.2.3.  B-AGONISTS  - AN  EIA  SCREENING  METHOD  FOR  THE  DETECTION  OF 
B-AGONISTS  IN  BOVINE  URINE. 
1.  SCOPE 
This  method  of  analysis  describes  the  detection  of  the  presence  of  ~­
agonists  in  urine  samples  of  cattle.  The  method  has  been  mainly  tested for 
residues  of  clenbuterol  and  salbutamol.  This  work  is carried out  in 
compliance  with  the  Residues  Directive  (86/469/EEC). 
2.  FIELD  OF  APPLICATION 
This  EIA  method  is used  to perform  routine  screening  in  bovine  urine for 
the  presence  of  residues  of  clenbuterol,  salbutamol,  terbutaline,  cimaterol 
and  mabuterol.  In  principle it is also  suitable for  the  detection  and 
confirmation  of  other t-butyl  or  isopropyl-~-agonists. 
The  lower  limit of  detection  is 0.14  ~g per  L urine  and  the  limit of 
determination  is 0.18  ~g per  L.  The  method  was  developed  at the  University 
of  Liege  and  Laboratoire  d'Hormonologie,  Marloie,  Belgium  (Degand  et al, 
1993) 
Note;  There  is also  an  RIA  kit for  the  same  B-agonists  and  using  the  same 
antiserum  also available from  Laboratoire  d'Hormonologie,  Rue  de  Carmel  1, 
6900-Marloie,  Belgium. 
An  EIA  kit for measuring  B-agonists  in  urine  and  serum  and  using  a 
different antibody  is marketed  by  Riedel-de  Haen  (see  Section  8.4.2).  The 
lower  limits of  detection  are  higher  than  those  in  the  method  reported 
here. 
3.  REFERENCES 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  N 1 
L.118,  14.4.93.  pp  64-74] 
Degand,  G.,  Bernes-Duyckaerts,  A.  and  Maghuin-Rogister,  G.  (1992), 
Determination  of  clenbuterol  in  bovine  tissues and  urine  by  enzyme 
immunoassay.  J.  Agric.  Food  Chern.  40,  70-75 
Degand,  G.,  Bernes-Duyckaerts,  A.,  Delahaut,  Ph.  and  Maghuin-Rogister,  G. 
(1993),  Determination  of  B-agonists  in  urine  by  an  enzyme  immunoassay  based 
on  the  use  of  an  anti-salbutamol  antiserum.  Anal.  Chim.  Acta.  275,  241-248 
Yamamoto  I  and  Iwalak,  1982  Enzyme  immunoassay  for  clenbuterol,  a  ~-2-
adrenergic  stimulant.  Journal  of  Immunoassay,  3:15 
4.  DEFINITIONS 
B-agonists  content  is taken  to  be  the  amount  of  ~-agonists in  the  substance 
in  question  determined  according  to  the  described  method  and  expressed  as 
~g ~-agonists per  litre of  urine. 
5.  PRINCIPLE 
The  method  comprises  5 stages;  the first two  are  optional. 
1.  Preparation  of  enzyme  conjugate. 
Sg  2.3/1 2.  Coating  EIA  plates 
3.  Dilution  of  primary  urine  sample 
4.  EIA 
5.  Calculation  and  evaluation  of  results 
6.  MATERIALS 
Note:  The  reagents  (and  equipment)  for which  examples  of  their source  are 
quoted  are  known  to  be  satisfactory,  nevertheless  reagents  and  equipment 
from  other  sources  may  be  equally suitable.  All  the  reagents  must  be  of 
analytical  grade. 
6.1.  Chemicals  and  reagents.  All  chemicals  were  analytical  grade  or 
better. 
6.1.1.  Reference  compounds. 
The  following  standard  compounds  are  used. 
Compound  CAS-No  mol  formula  Mol.  Wt. 
277.18  clenbuterol  37148-27-9  C 12H 18C 12N 20  (Boehringer 
cimaterol  54239-37-1  C 12H 17N 30  219.29 
239.31 
235.29 
310.75 
Ingleheim) 
Sigma  salbutamol  18559-94-9  C13H21N03 
terbutaline 23031-25-6  C 12H 19N03  Sigma 
mabuterol  56341-08-3  C13H18ClF3NzO  Sigma 
isoproterenol  Sigma 
pirbuterol  Sigma 
and  additional  ~-agonists if desired. 
6.1.2. 
6.1.3. 
6.1.4. 
6.1.5. 
6.1.6. 
6.1.7. 
6.1.8 
6.1.9 
6.1.10 
6.1.11 
6.1.12. 
6.2. 
6.2.1. 
6.2.1. 
6.2.3. 
Tween-20  (Merck) 
Thiomersal  (Merck) 
Bovine  Serum  albumin  (BSA)  (Sigma) 
Antiserum  from  Marloie.  Cat.  as  anti-salbutamol  serum. 
Cross  reactivities; 
Salbutamol,  100%;  clenbuterol,  115%; 
Mabuterol,  65%;  terbutaline,  31%;  Cimaterol,  13% 
Pirbuterol,  0.02%;  isoproterenol,  0.02%; 
Adrenaline  0.01%,  noradrenaline,  <0.01% 
Deionised  water  (Milli  Q,  Millipore) 
Sodium  carbonate 
Sodium  bicarbonate 
6M  sulphuric  acid 
Sodium  dihydrogen  phosphate  (Merck). 
Sodium  chloride 
Disodium  hydrogen  phosphate  (Merck). 
Solutions 
Stock  solutions of  standards  containing  1 g/L  in  ethanol,  stored 
at -20°C  in  the  dark. 
Working  solutions of  standards  containing  0.01  g/L  in  ethanol, 
stored at +4°C  for  a  maximum  period  of  2 weeks. 
Smallest  volume  pipetted out  of  the  stock  solution  is 0.1  ml. 
Phosphate-saline-BSA  buffer,  0.01  mol/L,  pH=  7.4 
Dissolve  in  800  ml  water  1.6  g disodium  hydrogen  phosphate 
(6.1.12.),  0.14  g sodium  dihydrogen  phosphate  (6.1.10),  8.6 g 
sodium  chloride  (6.1.11),  1 g BSA  (6.1.4)  and  0.1  g thiomersal 
(6.1.3).  Adjust  the  pH  at 7.4  ±  0,1  and  add  water  to  a final 
Sg  2.3/2 6.2.4. 
6.2.4.1 
6.2.4.2 
6.2.5 
6.2.6. 
6.2.7 
6.2.8 
6.2.9 
6.3 
6.3.1 
6.3.2 
6.3.3 
6.3.4 
6.3.5 
6.3.6 
6.3.7 
7. 
7.1 
7.2 
7.3. 
7.4. 
7.5. 
7.6. 
7.7. 
7.7.1 
7.7.2 
7.7.3 
7.7.4 
7.7.5 
7.7.5 
volume  of  1000  mL. 
Coating  Solution. 
Coating  Buffer,  50  mmol  per  L,  pH  9.6 
Dissolve  1.59  g sodium  carbonate  and  2.93  g sodium  bicarbonate  in 
1 L distilled water. 
1 volume  of  Antiserum  (6.1.5)  from  Marloie  is diluted with  9 
volumes  PBS  buffer  (6.2.3)  and  10  volumes  glycerol.  7  ~L of 
diluted antiserum  are  added  to  7 mL  coating  buffer  (6.2.4.1)  to 
give  a  1 in  20,000  dilution.  100  ~L are  added  to  a well. 
Washing  solution. 
Dissolve 8.76  g sodium  chloride  and  0.5  mL  Tween-20  in  1 L water 
(6.1.6). 
TMB  Microwell  peroxidase  substrate system.  KPL  Cat.  N 1  50.76.00 
Mix  equal  volumes  of  TMB  chromogen  with  hydrogen  peroxide 
solution.  Add  150  ~L to  a well. 
Stopping  Solution  - use  6M  sulphuric  acid 
Phosphate  buffer,  0.01M,  pH  7.5.  Dissolve  1.49  g  Na2P04 •  2H20 
and  0.22  g  NaH2P04.H20  in  1 L water  (6.1.6). 
Reagents  for  Preparation  of  Enzyme  Conjugate. 
Horse  radish  peroxidase  (Boehringer  [Mannheim]) 
Methanol 
Succinic  anhydride 
Dimethylformamide 
N-methylmorpholine 
Isobutyl  chloroformate 
Sephadex  G-25 
EQUIPMENT 
Dispensing  pipettes 
ELISA  plates  (NUNC-Immuno  plate Maxisorb  F96-,  Roskilde, 
Denmark. 
Microplate  reader,  (Multiscan  MCC/340,  Flow  Labs) 
Oven  at 37°C 
ELISA  plate sealer,  {plastic film  from  TechGen,  Zellik, 
Belgium) 
Optional  microcomputer  with  EXCEL  (Microsoft)  for  data 
calculations. 
For  preparation  of  Enzyme  conjugate. 
TLC  system 
Column  chromatographic  system  for  purifying  conjugate. 
Cryostatic  bath  at -15°C 
Dialysis  tubing  and  3 L vessel. 
Ultrasonic  bath  (Branson  1200  VEL  Belgium) 
Stirrer (magnetic) 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section  6.3.1  and  to  ISO  document  78/2-1982  and 
also  the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to  enable  the 
detection  of  residues  in  meat  as  defined  in  Directive 64/433/EEC.  Failing 
this biological  fluids  (here  urine)  or  faeces  may  constitute the  samples 
for  the  detection  of  residues. 
Sg  2.3/3 8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to allow 
the  method  to  be  carried out  and  to allow  repeat  analysis where  required. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to  allow  proper 
identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice  the  result of  the  examination. 
Samples  for  the  analysis of  B-agonists  must  be  stored  and  transported at 
temperatures  below  -18°C. 
9.  PROCEDURE. 
Note;  This  method  is given  with  two  options. 
1.  The  96-well  plates coated  with  either anti-clenbuterol  or  anti-
salbutamol  antiserum  and  both  the  salbutamol-HRP  conjugate  and  the 
clenbuterol-HRP  conjugate  may  be  purchased  from  Marloie  (see  Section 
8.4.2). 
2.  In  the  form  of  a 
11do  it yourself  ..  EIA,  in  which  all  the  reagents  except 
the  salbutamol-enzyme  conjugate  can  be  purchased  and  the  96-well  plates 
have  to  be  coated  and  all  the  solutions  prepared. 
9.1 
9.1.1 
9.1.2 
9.2 
9.3 
9.3.1 
9.3.2 
9.3.3 
9.3.4 
Optional  Coating  of  the  EIA  plates and  preparation  of  enzyme 
conjugate. 
Coating  the  plates.  Add  100  ~L of  the  diluted antiserum 
(6.2.4.2)  to each  of  the  inner  60  wells  of  a  96-well  plate  (the 
values  for well  to well  variation are  greatly reduced  in  certain 
plates  if only  the  inner wells  are  used).  Cover  the  plate with 
the  plastic film  and  store at 4°C  for  16  h or at 37°C  for  2 h. 
Wash  the  plate with  four  rinses of  6.2.5.  before  use. 
Preparation  of  enzyme  conjugate.  Suspend  12.5  mg  salbutamol 
succinate  (37.5  ~mol)  in  2 ml  dimethylformamide  and  30  ~L 
triethylamine.  Place  the  flask  in  an  ultrasonic bath  for  15  min 
and  then  add  2 x 200  ~L distilled water.  Cool  the  solution at -
15°C  and  add  4  ~L N-Methylmorpholine.  followed  by  37.5  ~mol 
isobutylchloroformate.  Stir the mixture  for  5 min.  Add  the  cold 
mixture  to  horse  radish  peroxidase  (6.3.1)  solution  in  500  ~L 
0.1M phosphate  buffer,  pH  7.5,  to yield a molar  ratio of  25:1 
salbutamol  to  HRP.  Stir for one  h at -15°C  and  2 h at 0°C.  Add 
10  mg  sodium  bicarbonate  and  dialyse  against 3 L of 0.01M 
phosphate  buffer,  pH  7.4  Unreacted  material  can  be  easily 
separated  by  gel  filtration on  Sephadex  G-25. 
Pretreatment of  urine  samples.  It is recommended  that the  urine 
is centrifuged gently to  remove  any  solid material.  Dilute  the 
clear urine  sample  10  times  with  in  the  PBS-BSA  buffer  (6.2.3). 
EIA. 
Add  50  ~L of  diluted  urine  (9.1.4)  in  duplicate  to the  inner 
wells. 
Add  50  ~L standards  (6.2.1)  in  duplicate  to  give  six values  over 
the  range  0.04-10  ~g per  L. 
Add  100  ~L enzyme-conjugate  solution which  contains  a final 
concentration  of  70  ng  per  ml  of  HRP.  This  will  require 
approximately  an  8000  fold  dilution  in  PBS-BSA  buffer  (6.2.3)  or 
follow  manufacturers  instructions. 
Cover  the  plate with  plastic film,  shake  and  incubate  overnight 
Sg  2.3/4 at 4°C. 
9.3.5  Wash  the wells  four  times  with  solution  6.2.5. 
9.3.6  Add  the  substrate solution  (6.2.7)  and  incubate  for  30  min  at 18-
200C  in  the  dark. 
9.3.7  Stop  the  reaction  by  adding  the  stopping  solution of  sulphuric 
acid  (6.2.8)  to each  well.  Do  this  in  the  same  order  and  at the 
same  rate as  the  substrate was  added  to  keep  the  reaction  time 
near  constant.  Shake  the  plate gently  and  measure  the  absorbance 
at 450  nm  on  a  plate reader. 
10.0  CALCULATION  OF  RESULTS. 
10.1  The  results can  be  calculated using  a  logit transformation.  The 
interpolation from  the  calibration curve  using  the  standards  where  the 
bound  enzyme  activity,  expressed  as  the  logit of  the  ratio  (in percent) 
between  absorbance  increase  per  30  min,  at each  concentration  of  salbutamol 
(B)  and  the  bound  activity in  the  absence  of  unlabelled  salbutamol  (80 )  was 
plotted versus  the  log  of  the  salbutamol  concentration.  A suitable EIA 
data  handling  package  can  be  adapted  to  perform  this calculation. 
10.2.  Validation.  (Degand  et al,  1993).  The  inter-assay variation was 
determined  using  data  from  10  separate days.  The  mean  slope  ±  SD  of  the 
curve  was  -(0.82  ±  0.01),  CV  =  1%.  The  mean  mid-point  of  the  curve  for 
salbutamol  was  16.8  ±  2.2  pg,  CV  =  6.7%. 
The  reproducibility of  measuring  incurred  urines  containing  approximately  2 
and  5  ~g Salbutamol  per  L were; 
Cone.  Salbutamol 
~g per  L 
2 
5 
intra-assay CV(%) 
(n  =  8) 
5.9 
7.2 
inter-assay CV(%) 
(n  =  8) 
8.8 
9.7 
The  blank  value  was  determined  as  the  mean  +  3  SD  using  20  blank  urines 
from  untreated  veal  calves  was  0.14  ~g.  The  limit of  determination  was 
0.18  ~g as  required  by  EC  Decision  89/610. 
Recoveries  were  measured  by  spiking  blank  urines  and  were 
11. 
Added  spike 
(~g per  L) 
1 
2 
5 
SPECIAL  CASES 
12.  NOTES  ON  PROCEDURE. 
Measured 
(~g per  L) 
1.1  ±  0.2 
2.2  ±  0.3 
4.8  ±  0.4 
Recovery 
{%) 
112 
113 
97 
The  preparation of  the  enzyme  conjugate  and  coating  the  plates can  be 
performed  as  a  batch  process  and  stored for  use  in  subsequent  assays. 
13.  QUALITY  CONTROLS 
See  section 8 of manual  detailing the  RMs  for  the  B-agonists. 
14.  TEST  REPORT 
Sg  2.3/5 15.  LIST  OF  ABBREVIATIONS 
A full  list of  abbreviations  is given  in  Annex  I,  Section  12 
16.  FLOW  DIAGRAM 
COAT  EIA  PLATES---->-<--------- PREPARE  ENZYME  CONJUGATE 
(optional)  (optional) 
dilute 10  x 
URINE  ---------------->  EIA  -------------> CALCULATE  RESULTS 
Sg  2.3/6 Sg  2.4.  B-AGONISTS  - A SCREENING  METHOD  FOR  THE  DETECTION  OF  B-AGONISTS 
IN  BOVINE  LIVER,  KIDNEY  AND  MEAT  BY  GC-MS  IN  THE  ELECTRON  IMPACT  MODE  FOR 
THE  TRIMETHYLSILYL  DERIVATIVES. 
1.  SCOPE 
This  multi-residue method  of  analysis  describes  the  detection  of  the 
presence  of  twelve  individual  ~-agonists in  samples  of  liver,  kidney  and 
meat  of  veal  calves  and  adult cattle.  The  method  is used  officially in 
France  and  is carried out  in  compliance  with  the  Residues  Directive 
(86/469/EEC). 
2.  FIELD  OF  APPLICATION 
The  method  is used  to  perform  routine screening  in  liver,  kidney  and  meat 
from  veal  calves  and  adult cattle.  The  method  is used  to  test for  the 
presence  of  residues  of  clenbuterol,  clenpenterol,  hydroxymethyl-
clenbuterol,  salbutamol,  terbutaline,  cimaterol,  cimbuterol,  mabuterol, 
mapenterol,  tulobuterol,  fenoterol  and  ractopamine. 
The  detection  limit,  defined  as  a  signal  noise  ratio >3  is below  2  ~g per 
kg  for most  compounds. 
3.  REFERENCES 
Montrade,  M-P.,  Le  Bizec,  B.,  Manteau,  F.,  Siliart,  B.  and  Andre,  F. 
(1993),  Multi-residue  analysis forB-agonistic drugs  in  urine  of  meat-
producing  animals  by  gas  chromatography- mass  spectrometry.  Anal.  Chim. 
Acta.  275,  253-268 
Montrade,  M-P.,  Le  Bizec,  B.  and  Andre,  F.  (1992),  Methode  de  recherche 
urinaire  (screening)  d'agonistes  B-adrenergiques  par  chromatographie 
gazeuse  couplee  a la  spectrometie  de  masse  (GC-MS)  en  mode  impact 
electronique.  Document  LDH/92/01  Lab.  Dosage  Hormonaux,  Nantes. 
DGAL/SDHA/H92.8066 
[Note;  This  method  is available  in  French] 
Montrade,  M-P.,  Le  Bizec,  B.  and  Andre,  F.  (1993),  Methode  de  depistage 
(screening)  d'agonistes  B-adrenergiques  par  chromatographie  gazeuse  couplee 
a la spectrometie  de  masse  (GC-MS)  en  mode  impact  electronique.  2.  Analyse 
de  prevevements  de  foie,  rein,  viande.  Document  LDH/93/07  Lab.  Dosage 
Hormonaux,  Nantes. 
4.  DEFINITIONS 
B-agonists  content  is taken  to  be  the  amount  of  ~-agonists in  the  substance 
in  question  determined  according  to the  described  method  and  expressed  as 
~g ~-agonists per  litre of  test sample  (liver,  kidney  and  meat). 
5.  PRINCIPLE 
The  method  comprises  8 stages; 
1.  Homogenisation  of  sample  with  Stomacher  and  ultrasonication. 
2.  hydrolysis  of  conjugates 
3.  acid  precipitation 
4.  solvent/solvent partition. 
5.  extract purification and  concentration  using  mixed  solid-phase 
extraction  (SPE)  chromatography 
6.  derivatisation 
Sg  2.4/1 7.  detection  by  GC-MS  in  electron  impact  mode 
8.  calculation  and  evaluation  of  results 
6.  MATERIALS 
Note:  The  reagents  (and  equipment)  for which  examples  of  their source  are 
quoted  are  known  to  be  satisfactory,  nevertheless  reagents  and  equipment 
from  other  sources  may  be  equally suitable.  All  the  reagents  should  be  of 
analytical  grade  or  better. 
6.1  Reference  compounds  and  Standards. 
Clenbuterol  hydrochloride  (Interchim,  Montlucon,  France) 
Salbutamol  hemisulphate,  Terbutaline  hemisulphate  and  metoprolol  tartrate 
(Sigma). 
Cimaterol,  clenpenterol  (NAB  760),  mabuterol,  fenoterol  hydrobromide  and 
hydroxymethyl  clenbuterol  (NA1141)  (Boehringer  Ingleheim) 
Tulobuterol  hydrochloride  (Abbott) 
Ractopamine  hydrochloride  (Eli  Lilly) 
Cimbuterol  and  mapenterol  were  synthesised  by  Chern  Dept,  University of 
Rennes,  France 
6.2 
6.2.1 
6.2.2 
6.2.3 
6.2.4 
6.2.5 
6.2.6 
6.2.7 
6.2.8 
6.2.9 
6.2.10 
6.2.11 
6.2.12 
6.2.13 
6.2.14 
6.2.15 
6.2.16 
6.2.17 
6.2.19 
6.3 
6.3.1 
6.3.2 
6.3.3 
6.3.4 
Chemicals 
Helix pomatia  juice  (B-glucuronidase-arylsulfatase,  Merck-4114) 
Glacial  acetic acid  (Panreac  - 131008  or Merck.62) 
Ultra-pure water  (>14  M  n.cm) 
Methanol  (Carlo-Erba  RS  CLHP-412002  or  Merck.6009) 
Ethyl  acetate  (Merck  ZA-9623) 
32%  Ammonium  hydroxide  (Merck  5426) 
1M Potassium  hydroxide  (Merck  ZA-9018920) 
1M Acetic  acid 
N-0-bis(trimethylsilyl)trifluoracetamide  (BSTFA)  (Regisil-270111 
or  FLUKA  -15244) 
Toluene  (FLUKA  - 89677)  by  molecular  sieving. 
Sodium  acetate  (Merck  ZA-6268) 
Potassium  dihydrogen  phosphate  (Merck  ZA-4873) 
Nitrogen  (dried over  silica gel) 
Helium  (very  high  purity,  NSS,  Carboxyque) 
70%  Perchloric acid  ((Prolabo-20589293) 
Sodium  chloride  (Merck-6404) 
Isopropanol  (Carlo-Erba-412421) 
Nitrogen 
Solutions 
B-agonists.  Prepare  stock  solutions of  the  standards  (6.1.1)  in 
methanol  (1  g per  L and  100  mg  per  L)  and  store at -18°C. 
B-agonists.  Prepare  working  solutions  by  dilution of  stock 
solutions  (6.3.1)  with  methanol  to final  concentrations  of  10  ~g 
and  1~g per  mL.  Store  at -18°C  in  the  dark. 
0.2M Acetate  buffer,  pH  5.2,  for  hydrolysis  of  conjugates. 
Dissolve  16.4  g sodium  acetate  (6.2.11)  in  900  mL  water  (6.2.3) 
and  adjust the  pH  to  5.2  ±  0.1  with  glacial  acetic acid  (6.2.2). 
Make  up  to  1 L with  water  and  store at +4°C.  Use  for  up  to  1 
month. 
0.1M Phosphate  buffer,  pH  6.0.  Dissolve  13.6  ~ 0.1  g potassium 
dihydrogen  phosphate  (6.2.12)  in  900  mL  water  (6.2.3)  and  adjust 
the  pH  to 6.0  ±  0.1  with  1M  potassium  hydroxide  (6.2.7).  Make  up 
Sg  2.4/2 to  1 L with  water  and  store at +4°C.  Use  for  up  to  1 month. 
6.3.5  Mix  ethyl  acetate and  32%  ammonium  hydroxide  97:3  (v/v).  100  ml 
does  16  samples.  Stir/agitate the  mixture  prior to  use  and  then 
place  into  an  ultra-sonic bath  during  step 9.13.3. 
6.3.6  O.lM Perchloric acid  (PCA)  precipitating agent.  Dilute 8.6  mL 
70%  perchloric acid  to  1 L with  water. 
6.3.7  1M acetic acid;  Dilute  5.6  ml  glacial  acetic acid  (6.2.2)  to  100 
ml  with  water. 
6.3.8  Isopropanol/ethyl  acetate 40:60  v/v.  Mix  400  ml  of  isopropanol 
and  600  ml  ethyl  acetate. 
7.0  EQUIPMENT 
7.1.  Centrifuge 
7.2  Rotary  evaporator 
7.3  Horizontal  shaker 
7.4  Stomacher  (Cofralab-07555526)  and  plastic bags  (Cofralab-
07556952) 
7.5  Ultrasonic  bath 
7.6  Blender  or  mincer. 
7.7  Vacuum  filtration system  (Vac-Elut  from  Analytichem 
International) 
7.8  Ultra-sonic  probe  (Cofralab-07580740) 
7.9  Magnetic  stirrer/agitator 
7.10  Conical  reaction  vials for  derivatisation 
7.11  Heating  block  for  reaction  vials 7.10 
7.12  Heating  block  with  evaporation  system  using  nitrogen 
7.13  SPE-Columns;  CLEAN  SCREEN  DAU  1M6  (Worldwide  monitoring-
Horsham,  PA,  USA  and  sold  by  Technical,  Stockport,  Cheshire,  UK). 
These  columns  contain  1000  mg  of  a mixed  phase  support which  has 
hydrophobic  and  ion-exchange  properties. 
7.14 
7.14.1 
7.14.2 
GC-MS 
GC;  GC  Hewlett  Packard  5890. 
Capillary column,  30m  X 0.25  mm  i.d. with  SE-30  stationary phase 
of  0.25  ~m thickness. 
Injection mode;  splitless over  1 minute 
Injection  volume;  2  ~L 
Injector temp.  250°C;  Transfer  temp.  280°C 
Temp.  programme; 
lSO C/ min  5° C/ min 
70°C  (2  min)  ----------->  200°C  (0  min)  --------->  245°C  (0  min) 
2SOC/min 
----------->  300°C  (12  min) 
Gas;  Helium  at 1 ml  per  min  and  5 psi. 
MS;  Hewlett  Packard  5971  with  UNIX  station. 
Electron  Impact  ionisation  mode  (70  eV) 
Source  temp.  190°C  ~ 5°C 
Pressure,  30-40  mm  Torr 
Sg  2.4/3 Table  1. 
B-agonist  N  RT  (min)  Selected  ions  Mo 1. 
Ion 
Tulobuterol  1  9.34  86,  194,  284  299 
Mabuterol  1  10.36  86,  277,  296  382 
Mapenterol  1  11.04  100,  277,  296  396 
Terbutaline  3  11.67  86,  356  441 
Clenbuterol  1  12.02  86,  243,  262  (264)  348 
Cimaterol  1  12.14  72,  219  291 
Salbutamol  3  12.27  86,  369  455 
Cimbuterol  1  12.36  86,  219  305 
Cimaterol  2  12.62  72,  291  363 
Metoprolol  (I.S)  1  12.7  72,  223  339 
Cimbuterol  2  12.8  86,  291  377 
Clenpenterol  1  12.86  100,  243,  262  (264)  362 
Hydroxymethyl-
clenbuterol  (NA 
2  14.05  174,  243,  262  436 
1141) 
Fenoterol  4  18.39  322,  356,  412  591 
Ractopamine  3  18.63  250,  267  517 
N is the  number  of  TMS  groups.  RT  are  the  retention  times  recorded  in  an 
analysis at  LDH,  Nantes. 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section  6.3.1  and  to  ISO  document  78/2-1982  and 
also the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection  of  residues  in  liver,  kidney  and  meat  as  defined  in 
Directive 64/433/EEC. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to 
allow  the  method  to  be  carried out  and  to allow  repeat  analysis 
where  required.  Each  analysis  needs  a  10  g sample. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to allow 
proper  identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain 
the  integrity of  the  sample  and  not  prejudice the  result of  the 
examination. 
Samples  for  analysis within  48  h should  be  stored  in  the 
refrigerator otherwise  they  must  be  stored at temperatures 
below  -18°C. 
Sg  2.4/4 9.0. 
9.1 
9.2 
9.3 
9.4 
9.6 
9.7 
9.8 
9.9 
9.10 
9.11 
9.12 
9.13 
9.14 
9.15 
9.16 
9.17 
9.18 
9.19 
PROCEDURE 
Partially thaw  the  primary  samples  and  transfer >15  g to  a 
blender  or  mincer.  Disrupt  the  tissues.  This  step  is not 
necessary for  liver samples. 
Weigh  10  ±  1 g  into  a  Stomacher  bag.  Add  15  ml  acetate buffer, 
pH  5.2  (6.3.3)  and  disrupt for  5 min. 
Transfer  the  contents  to  a  25  ml  flask. 
Sonicate  the  contents  using  the  probe  (7.8)  for 0.5  sec.  Wait  5 
sec  and  then  sonicate again  for 0.5  sec.  Repeat  this  procedure 
for  10  times  for  liver and  kidney  samples  (total  time  50  sec)  and 
20  times  for  meat  (total  time  100  sec). 
Add  120  ng  metoprolol  as  internal  standard  to all  liver,  kidney 
and  meat  samples  including  blank  liver,  kidney  and  meat  samples. 
Concentration  equivalent  to  12  ~g per  kg. 
To  one  blank  liver,  kidney  and  meat  sample  add  120  ng  (equiv.  12 
ppb)  of  metoprolol  and  add  80  ng  (equiv.  8  ppb)  tulobuterol, 
fenoterol  and  ractopamine  and  40  ng  (equiv.  4 ppb)  of  the  other 
B-agonist  standards  (6.3.2). 
Add  50  ~L Helix  pomatia  juice  (6.2.1)  and  incubate  overnight  at 
50°C  (42-52°C)  in  a water  bath  or  oven. 
Transfer  the  hydrolysed  liver,  kidney  and  meats  to  a 
polypropylene  centrifuge tube. 
Add  10  ml  O.lM perchloric acid  (6.3.6).  Mix  and  and  adjust the 
pH  to 1  ±  0.3 with  70%  PCA  (6.2.15). 
Centrifuge for  25  min  at  ~7000 rpm  and  transfer the  supernatant 
to  a  glass  centrifuge tube. 
Adjust  the  pH  to  9.5  ±  0.3 with  ammonium  hydroxide  (6.2.6). 
Saturate the  aqueous  phase  with  sodium  chloride. 
Add  25  ml  of  a mixture  of  isopropanol/ethyl  acetate  (6.3.8)  and 
shake  for  15  min  on  a  horizontal  shaker. 
Centrifuge  at 3000  - 4000  rpm  for  15  min  to  separate the  phases. 
Transfer  the organic  phase  to a  250  ml  rotary evaporation  flask. 
Repeat  the  extraction of  the  aqueous  phase  with  the  addition  of 
15  ml  of  isopropanol/ethyl  acetate  (6.3.8).  Combine  the  organic 
phases. 
Evaporate  the  organic  phase  to dryness  on  a  rotary evaporator  at 
45  ±  5°C. 
Resuspend  the  residue  in  8 ml  phosphate  buffer  (6.3.4)  and 
transfer to  a  haemolysis  tube.  Rinse  the  flask with  a further 4 
ml  of  phosphate  buffer  and  pour  into the  haemolysis  tube. 
9.20  Centrifuge  at 2000  - 3000  rpm  for  15  min. 
[Note  This  step  is  important  when  any  solid material  is present after the 
evaporation  step.] 
9.21  Decant  the  liquid phase  into  a  tube  and  add  3 ml  phosphate  buffer 
9.22 
9.22.1 
9.22.2 
9.22.3 
9.22.4 
(6.3.4). 
SPE  Column  extraction; 
Place  the  columns  on  the  Vac-Elut  system  and  successively rinse 
with;  4 mL  methanol;  4 ml  water  (6.2.3);  4 ml  phosphate  buffer 
(6.3.4). 
Transfer  the  clear extracts with  a pasteur  pipette to the  top  of 
the  column  and  allow  to  drain  slowly  using  slight negative  (  ca.5 
em  Hg)  pressure  - it should  take  at  least 10  min. 
Rinse  the  columns  using  negative  pressure  of  about  40  em  Hg  with 
2 ml  1M acetic acid  (6.2.8)  and  let the  column  dry  for at  least 
15  min  then  rinse with  12  ml  methanol  and  dry  the  column  under  a 
strong  vacuum  for at  least 10  min. 
Place  the  ethyl  acetate I  ammonium  hydroxide  solution  (6.3.5)  in 
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9.23 
9.24 
9.25 
9.26 
9.27 
9.28 
9.28.1 
9.28.2 
9.28.3 
9.28.4 
9.28.5 
9.29 
9.30 
10.0 
10.1 
10.1.1 
10.1.2 
10.1.3 
10.1.4 
an  ultra-sonic bath  to agitate the  mixture  during  step 9.22.3. 
Elute  the  analytes with  12  mL  the  ethyl  acetate I  ammonium 
hydroxide  solution  (6.3.5) 
Evaporate  the eluate with  nitrogen  using  an  evaporation  system 
and  a  heating  block  at 40  ±  5°C. 
Dissolve  the  residue  in  200  ~L methanol  with  vigorous  vortexing. 
Transfer  the  solution  to  a  reaction  vial. 
Dissolve  and  transfer to  the  reaction  vial  any  remaining  residue 
with  a further  100  ~L methanol  and  vortexing. 
Evaporate  the  methanol  to  dryness  using  a  heating  block  at 40°  ± 
5°C. 
Derivatisation 
Add  50  ~L BSTFA  (6.2.9)  and  vortex. 
Place  vials  in  heating  block  at 75°C  ~ soc  for  90  ±  15  min. 
Transfer  the  vials to a  heating  block  at 40°  ±  5°C.  When  the 
vials  have  cooled  to  room  temperature  (25°C)  evaporate  to dryness 
with  nitrogen. 
Add  25  ~L toluene  (6.2.10)  and  vortex  vigorously. 
The  vials may  be  stored  in  a refrigerator at +4°C. 
Inject 2  ~L of  9.28.5  into  the  GC-MS. 
GC-MS.  The  GC-MS  is run  in  the  selected  ion  monitoring  mode. 
The  ions  and  the  retention times  of  the  derivatives of  the  B-
agonists  are  shown  in  table 1. 
INTERPRETATION  OF  RESULTS 
Validity of  Analysis;  The  criteria set out  in  EC  Decision  256 
must  be  fulfilled especially the  following;-
The  relative retention times  for  the  TMS  derivatives of  the 
standard  analytes  in  the  appropriate matrix  and  the  suspected  B-
agonist must  be  the  same. 
The  relative intensities of  the  selected  ions  to  the  base  peak 
must  be  same  as  in  the  assay  of  spiked  blank  liver,  kidney  and 
meats  and  of  standards. 
The  ions  for  the  internal  standard  (metoprolol-monoTMS)  must  be 
present at the  correct retention  time. 
The  analysis of  the  blank  liver,  kidney  and  meat  containing  the 
internal  standard must  show  NO  evidence  of  carry-over of  B-
agonists  from  the  GC-MS  system.  This  is a  check  for 
contamination  of  the  system. 
11.  SPECIAL  CASES 
12.  NOTES  ON  PROCEDURE. 
13.  QUALITY  CONTROLS 
See  section 8 of  manual  detailing the  RMs  for  the  B-agonists. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS 
A full  list of  abbreviations  is given  in  Annex  I,  Section  12 
16.  FLOW  DIAGRAM 
Homogenise 
Liver,  kidney  and  meat------------> PCA  PRECIPITATION-------->  EXTRACT 
1.  Solvent/solvent partition 
2.  SPE  column  Chrom. 
I 
I 
I 
I 
I 
I 
I 
I 
! 
INTERPRET  RESULTS  <----- GC-MS  <------------ TMS  DERIVATIVES 
(EI-mode) 
Sg  2.4/6 Sg.  3.1.  ANTIBACTERIAL  SUBSTANCES.  A SCREENING  METHOD  FOR  THE  DETECTION 
OF  ANTIBACTERIAL  SUBSTANCES  IN  FRESH  MEAT  USING  A MODIFIED  FOUR  PLATE  TEST. 
WARNING  AND  SAFETY  PRECAUTIONS 
0.  INTRODUCTION 
Purpose 
The  detection  of  the  presence  of  antibacterial  substances  in  samples  of 
meat  in  compliance  with  the  Residues  Directive 86/469/EEC. 
Background 
The  primary  control  of  antibacterial  substances  has  been  carried out  in  the 
European  Community  using  the  four  plate test method  developed  by  Bogaerts 
and  Wolf  in  1980.  There  are  several  modifications  to this test,  this one 
is the official  test to  be  used  in  France  and  developed  by  the  Community 
Reference  Laboratory  at Fougeres  in  France. 
1.  SCOPE 
This  method  of  analysis  describes  the  detection  but  not  the  identification 
of  antibacterial  substances  in  fresh  meat. 
2.  FIELD  OF  APPLICATION. 
The  method  is used  for meat.  The  detection  limit varies with  the 
antibacterial  substance  under  investigation.  The  sensitivity in  ~g per  kg 
of  the test for  different antibiotics measured  as  the  optimum  sensity for 
detecting  a  30  ~L solution of  standard  on  a 9 mm  paper  filter disc  and 
giving  a  zone  of  inhibition of  12  mm  is as  follows; 
Penicillins:  Benzylpenicillin,  15;  ampicillin,  50;  cloxacillin,  400; 
amoxicillin,  80;  oxacillin,  250;  dicloxacillin,  200; 
Tetracyclins;  Oxytetracycline,  250;  tetracyclin,  200;  chlortetracycline, 
30. 
Macrolides;  Spiramycin,  130;  erythromycin,  30;  tylosin,  250. 
Aminosides;  Dihydrostreptomycin,  400;  gentamicin,  100. 
Sulphonamides;  All  too  insensitive  in  test. 
Quinolones;  Flumequin,  350. 
Chloramphenicol;  8000 
From  Document  UCM  90/01Rev.1 
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4.  DEFINITIONS. 
The  detection of  an  antibacterial  substance  in  meat  is determined  positive 
when  at  least one  of  the  four  agar  diffusion  plates are  considered  to 
contain  residues  of  antibacterial  substances  determined  according  to  the 
described  method. 
5.  PRINCIPLE 
An  agar  diffusion  test  is used  in  which: 
an  organism  sensitive to  antibacterial  substances  is  inoculated 
in  an  agar  medium  in  a Petri  dish. 
a disc  of  frozen  meat  is placed  on  the  surface of  the  inoculated 
medium,  which  is  incubated  at the  optimal  temperature  for  growth 
of  the  test-organism. 
Diffusion  of  any  antibacterial  substances  present results  in  the  formation 
of  a  zone  around  the  sample  in  which  growth  of  the  test-organism  is 
inhibited. 
The  following  are  the  test-organisms; 
Bacillus subtilis at  pH  6.0,  pH  7.2  and  pH  8.0 and  Micrococcus 
luteus  at  pH  8.0. 
In  the  agar  diffusion method  using  Bacillus subtilis at  pH  7.2,  addition  of 
trimethoprim  allows  the  detection of  sulphonamides  in  meat  due  to 
trimethoprim-sulphonamide  synergy. 
6.  MATERIALS 
Note:  The  reagents  (and  equipment)  for which  examples  of  their source  are 
quoted  are  known  to  be  satisfactory,  nevertheless  reagents  and  equipment 
from  other  sources  may  be  equally suitable.  All  the  reagents  must  be  of 
analytical  grade  or  better.  Distilled water  or water  of  comparable  quality 
should  be  used. 
6.1. 
6.1.1 
6.1.2 
6.1.3 
6.1.4 
6.1.5 
6.1.6 
6.1.7 
6.1.8 
6.1.9 
6.1.10 
6.1.11 
6.1.12 
6.1.13 
CHEMICALS 
Agar  (Difco  0140.01) 
Sodium  chloride  (Merck  6404) 
Pancreatic  digest of  casein  (Difco  0123.01.1) 
Tryptic  digest of  casein  (Biomerieux  5.346.1) 
Papaic  digest of  soya  bean  (Difco  0.436.01.3) 
Beef  extract  (Pasteur  64355) 
Nutrient  agar  (Pasteur  64487) 
Glucose  (Prolabo  24.370) 
Manganese  sulphate monohydrate  (Prolabo  25.301) 
Trimethoprim  (Sigma,  T7883) 
Acetic  acid  Prolabo  (20.104) 
Penicillin G sodium  (Sigma  PEN-NA) 
Sulphadimidine  (Sigma  S 6256) 
Sg  3.1/2 6.1.14 
6.1.15 
6.1.16 
6.1.17 
6.1.18 
6.1.19 
6.1.20 
0.1M Sodium  hydroxide  solution  (Merck  6498) 
Dihydrostreptomycin  sulphate  (Sigma  S 6501) 
Erythromycin  (Sigma  E 6376) 
Methanol  (Prolabo  20.847) 
Test  agar  pH  6.0.  (Merck  dehydrated  medium  ref.  10663) 
Test  agar  pH  7.2.  (Merck  dehydrated  medium  ref.  15787) 
Test  agar  pH  8.0.  (Merck  dehydrated  medium  ref.  10664) 
6.2  Solutions. 
All  solutions  unless  stated otherwise  can  be  stored  in  the  dark  at +4°  to 
+6°C  for  up  to  six months. 
6.2.1 
6.2.2 
6.2.3 
6.2.4 
6.2.5 
6.3 
6.3.1 
6.3.2 
6.3.3 
Peptone-salt  solution 
1 g Pancreatic  digest of  casein  and  8.5 g sodium  chloride are 
dissolved  in  water  and  made  up  to  1 L with  a  pH  of  7.2  ±  0.1  at 
25°C.  The  solution  is autoclaved  at 121°C  for  15  min. 
Tryptic  soy  agar  (T.S.A.)  (Difco  - 0369) 
Dissolve  15  g pancreatic digest of  casein  (6.1.3),  5 g papaic 
digest of  soya  bean  (6.1.5),  5 g sodium  chloride  and  15  g agar  in 
water  and  make  up  to  1 L at  pH  7.3  ±  0.2  at 25°C. 
The  solution  is autoclaved  at 121°C  for  15  min. 
Culture  broth  for freezing  of  strains. 
Dissolve  5 g tryptic digest of  casein  (6.1.4)  and  3 g beef 
extract  (6.1.6)  in  water  and  make  up  to  1 L at  pH  6.8  ±  0.2 at 
20°C. 
The  solution  is autoclaved  at 121°C  for  20  min. 
Finley  and  Fields Medium. 
Dissolve  15  g nutrient agar  (6.1.7),  5 g glucose  (6.1.8)  and  30 
mg  manganese  sulphate monohydrate  (6.1.9)  in  water  and  make  up  to 
1 L at  pH  7.0  ±  0.2  at 25°C. 
The  solution  is autoclaved  at 121°C  for  15  min. 
Trimethoprim  solution 
In  a  500  ml  volumetric  flask  dissolve  50  mg  trimethoprim  (6.1.10) 
in  5 ml  5%  acetic acid  (6.1.11)  and  dilute to  500  ml  with  water. 
Immediately  before  use,  dilute this stock  solution  to  1/20  to 
give  a final  concentration  of  0.005  mg  per  mL.  The  stock 
solution can  be  stored for  up  to  2 weeks  at +4°C  to  +6°C. 
Standard  Solutions. 
Penicillin Solution 
Use  a  100  ml  volumetric  flask.  Dissolve  a quantity of  penicillin 
G sodium  (6.1.12)  equivalent  to 100,000  I.U.  (about  61  mg)  in 
water  and  dilute to  100  ml  with  water.  Immediately  before  use, 
dilute this stock  solution to  1/100  and  then  again  to 1/50  to 
give  a final  concentration of  0.02  I.U.  per  ml.  The  stock 
solution can  be  stored for  up  to  4 days  at +4°C  to  +6°C. 
Sulphadimidine  solution. 
Use  a  50  ml  volumetric  flask.  Dissolve  a quantity of 
sulphadimidine  (6.1.13)  equivalent  to  50  mg  active  substance  in  5 
ml  0.1M sodium  hydroxide  (6.1.14)  and  dilute to  50  ml  with  water. 
Immediately  before  use,  dilute this stock  solution  to  1/50  to 
give  a final  concentration of  0.02  mg  per  ml.  The  stock  solution 
can  be  stored for  up  to  2 weeks  at +4°C  to  +6°C. 
Dihydrostreptomycin  solution. 
Use  a  50  ml  volumetric  flask.  Dissolve  a quantity of 
dihydrostreptomycin  sulphate  (6.1.15)  equivalent  to  50  mg  active 
substance  (about  64  mg)  in  water  and  dilute to  50  ml  with  water. 
Immediately  before  use,  dilute this stock  solution  to  1/200  to 
Sg  3.1/3 6.3.4 
6.4 
6.4.1 
6.4.2 
7.0 
7.1 
7.2 
7.3 
7.4 
7.5 
7.6 
7.7 
7.8 
7.9 
7.10 
7.11 
7.12 
7.13 
7.14 
7.15 
7.16 
7.17 
7.18 
7.19 
7.20 
7.21 
7.22 
7.23 
7.24 
7.25 
7.26 
7.27 
7.28 
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give  a final  concentration of  5  ~g per  ml.  The  stock  solution 
can  be  stored for  up  to  one  month  at +4°C  to  +6°C. 
Erythromycin  solution. 
Use  a  50  ml  volumetric  flask.  Dissolve  a quantity of 
erythromycin  (6.1.16)  equivalent to  50  mg  active substance  (about 
54  mg)  in  3 ml  methanol  (6.1.17)  and  dilute to  50  ml  with  water. 
Immediately  before  use,  dilute this stock  solution  to 1/200  and 
then  again  to 1/20  to  give  a final  concentration of  0.25  ~g per 
ml.  The  stock  solution  can  be  stored for  up  to  2 weeks  at +4°C 
to  +6°C. 
Sensitive organisms 
Bacillus subtilis test organism  obtained  as  Bacillus subtilis 
6  B.G.A  from  Merck  as  ampoules  containing  a  suspension  of 8 x  10 
to 5 x 10
7  spores  per  ml.  (Ref  ~ 10649) 
Micrococcus  luteus  as  test organism  Micrococcus  luteus,  ATCC  9341 
strain,  available from  the  Institut Pasteur  in  freeze-dried  form. 
EQUIPMENT 
Incubators  capable  of  maintaining  temperatures  of  30°  ±  1°C  and 
37°  ±  1°C. 
Freezer  -18°C 
Refrigerator at +4  to  +6°C 
Centrifuge  (JOUAN  JR4.11  or  equivalent) 
Water  bath  capable  of  operating from  room  temperature  to  100°C 
Vortex  mixer 
Balance  sensitive to 0.1  mg 
pH  meter  of  calibration accuracy  0.1  pH  unit at 20°C 
Automatic  micropipette,  10  to  100  ~L 
Disposable  tips for  pipette 7.9 
Cork  borer,  8  mm  diameter 
Sharpener  for  cork  borer  (7.11) 
Scalpel  and  blades 
Wire  loop  of  nickel-chrome  or  Pasteur  pipettes 
Fine  pointed  forceps 
Stainless steel  trays 
Discs  of  absorbent  paper,  diameter  6  mm  (Durieux) 
Flat-bottomed  plastic Petri  dishes,  diameter  90  mm 
Borosilicate glass  bottles with  screw  tops,  125  ml,  250  ml  and 
500  ml 
Raux  flask,  1 L 
Graduated  borosilicate glass  beakers,  1 L 
Volumetric  borosilicate glass flasks,  20  ml,  25  ml,  50  ml,  100  ml 
and  500  ml 
Graduated  borosilicate glass  cylinders,  10  ml,  25  ml,  50  ml 
Borosilicate glass  culture tubes  of  16  x 160  mm  with  and  without 
screw  tops 
Sterile centrifuge tubes  of  at  least 60  ml  capacity,  with  caps 
Sterile 10  ml  pipettes graduated  in  0.1  ml 
Sterile and  non-sterile 5 ml  pipettes graduated  in  0.1  ml 
Sterile and  non-sterile 2 ml  pipettes graduated  in  0.02  ml  or 
0.05  ml 
Sterile and  non-sterile 1 ml  pipettes graduated  in  0.01  ml 
Glass  beads  diameter  3 mm 
Plastic 1.5 ml  tubes  with  caps  (Eppendorf) 
Sg  3.1/4 7.32  Phase-contrast microscope. 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section 6.3.1  and  to  ISO  document  78/2-1982  and 
also  the following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1. 
8.2. 
8.3. 
8.4. 
9. 
(Note; 
9.1 
9.1.1 
9.1.1.1 
9.1.1.2 
Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection  of  residues  in  meat  as  defined  in  Directive  64/433/EEC. 
Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to 
allow  the  method  to  be  carried out  and  to allow  repeat analysis 
where  required. 
The  samples  must  be  taken  and  packed  in  such  a way  as  to  allow 
proper  identification  in  the  laboratory. 
The  method  of  packing,  preservation  and  transport must  maintain 
the  integrity of  the  sample  and  not  prejudice the  result of  the 
examination.  When  practicable the  meat  should  be  collected under 
sterile conditions. 
Samples  for  the  analysis  of  antibacterial  substasces  should  be 
stored  and  transported at temperatures  below  -18  C. 
PROCEDURE 
This  four  plate test is applicable  to meat.) 
Preparation  of  Sensitive Organisms. 
Bacillus subtilis 
Bacillus subtilis stock  inoculum.  Prepare  enough  to  last for  2 
years. 
Use  the  suspension  from  the  commercial  source  (6.4.1)  to 
inoculate  in  streaks  two  T.S.A.  (6.2.2)  plates for  isolation and 
confirmation  of  identification. 
Incubate  for  16  to  18  h at 30°C 
From  a  few  colonies  removed  from  one  of  the  plates,  inoculate one 
or  more  tubes  of  culture broth  for freezing  of  strains.  Incubate 
at 30°C  for  3 to 6 h. 
Divide  the  culture  (which  is  in  the  exponential  growth  phase) 
into fractions of  0.5  to  1 ml  in  capped  microtubes  (7.31).  Store 
at -18°C  for  up  to  two  years. 
Preparation  of  spore  suspension.  From  the  stock  inoculum 
(9.1.1.1)  perform  three successive  subcultures  in  slant T.S.A  to 
reactivate the  strain.  In  parallel  inoculate  in  streaks  two 
T.S.A.  (6.2.2)  plates for  isolation and  confirmation  of 
identification. 
Incubate  for  16  to  18  h at 30°C 
Harvest  a culture of  less  than  24  h in  the  form  of  a  suspension 
using  about  10  glass  beads  and  2 mL  of  peptone  salt solution 
(6.2.1). 
Transfer  the  suspension  to the  surface of  200  mL  of  Finley and 
Fields  sporulation  medium  (6.2.4)  prepoured  into  a  Roux  flask. 
Incubate  at 30°C  for at  least five days,  monitoring  the  advance 
of  sporulation  by  observation  of  samples  of  the  culture under  a 
phase-contrast microscope  (7.32).  If necessary extend  the 
incubation. 
After  incubation,  harvest  the  spores  with  glass  beads  and  50  mL 
Sg  3.1/5 peptone-salt  solution  (6.2.1). 
Centrifuge  the  spore  suspension  for  15  min  at 4,400  g. 
Discard  the  supernatant  and  resuspend  the  pellet  in  50  ml 
peptone-salt solution. 
Centrifuge,  discard  the  supernatant  and  resuspend  the  pellet  in 
50  ml  peptone-salt  solution. 
Centrifuge  and  discard  the  supernatant  and  resuspend  the  pellet 
in  30  ml  peptone-salt  solution  and  heat  to  70°C  for  exactly 35 
min. 
Store  the  spore  suspension  at +4°C. 
9.1.1.3  Enumeration  of  spore  suspension.  This  is required  in  order  to 
detibmine  the  spore  concentration.  After  suitable dilution to 
10- in  diluent  (6.2.1)  incubate  at 30°C  for  24  h before 
enumeration. 
9.1.1.4  Preparation  of  test plates. 
9.1.1.4.1  pH  6.0  Agar 
Inoculate  the molten  agar  medium  (6.1.18)  cooled  to  45°C  with 
pre-diluted spore  suspension  (9.1.1.2)  to  give  a  spore 
concentration  of  5 x 10q  per  mL.  Transfer  5 ml  of  inoculated 
medium  to a  Petri  dish  and  allow  the  agar  to cool  on  a  cold 
horizontal  surface. 
If not  used  on  the  day  of  preparation,  these  test plates may  be 
stored  in  a  refrigerator  {7.3)  for  up  to one  week. 
9.1.1.4.2  pH  7.2  Agar 
Inoculate  the  molten  agar  medium  (6.1.19)  cooled  to  45°C  with 
pre-diluted spore  suspension  (9.1.1.2)  to give  a  spore 
concentration of  5 x 10q  per  ml.  Add  trimethoprim  solution 
(6.2.5)  to  the  agar  to a concentration  of  1%  {v/v).  Transfer  5 
ml  of  inoculated  medium  to  a  Petri  dish  and  allow  the  agar  to 
cool  on  a cold  horizontal  surface. 
If not  used  on  the  day  of  preparation,  these  test plates may  be 
stored  in  a refrigerator  (7.3)  for  up  to  two  days. 
9.1.1.4.3  pH  8.0 Agar 
Inoculate  the molten  agar  medium  (6.1.20)  cooled  to 45°C  with 
pre-diluted spore  suspension  (9.1.1.2)  to  give  a  spore 
concentration  of  5 x 10q  per  mL.  Transfer  5 ml  of  inoculated 
medium  to a  Petri  dish  and  allow  the  agar  to  cool  on  a cold 
horizontal  surface. 
If not  used  on  the  day  of  preparation,  these  test plates may  be 
stored  in  a refrigerator {7.3)  for  up  to  one  week. 
9.1.2  Micrococcus  luteus 
9.1.2.1  Micrococcus  luteus  stock  inoculum.  Prepare  enough  to  last for  2 
years. 
Rehydrate  the  freeze  dried  strain  (6.4.2)  in  2 ml  of  peptone-salt 
solution(6.2.1).  Use  the  suspension  to  inoculate  in  streaks  two 
T.S.A.  (6.2.2)  plates for  isolation and  confirmation  of 
identification. 
Incubate  for  at  least 24  h at 37°C 
From  a  few  colonies  removed  from  one  of  the  plates,  inoculate  one 
or  more  tubes  of  culture broth  for  freezing  of  strains.  Incubate 
at 37°C  for  3 to  6 h. 
Divide  the  culture  (which  is  in  the  exponential  growth  phase) 
into fractions of  0.5  to  1 ml  in  capped  microtubes  (7.31). 
9.1.2.2  Preparation  of  test  inoculum.  From  the  stock  inoculum  (9.1.2.1) 
perform  three successive  subcultures  in  slant T.S.A  to reactivate 
the  strain.  In  parallel  inoculate  in  streaks  two  T.S.A. 
Sg  3.1/6 (6.2.2)  plates for  isolation and  confirmation  of  identification. 
Incubate  at 37°C  for  at  least 24  h. 
Harvest  a culture of  less  than  24  h in  the  form  of  a  suspension 
using  about  10  glass  beads  and  2 ml  of  peptone  salt solution 
(6.2.1). 
Transfer  the  suspension  to  the  surface of  200  ml  of  T.S.A. 
(6.2.2)  prepoured  into  a  Raux  flask. 
Incubate  at 37°C  for  at  least  24  h. 
After  incubation,  harvest  the  culture with  about  20  glass  beads 
and  10  ml  peptone-salt  solution  (6.2.1).  Dilute  to  50  ml  in  the 
bottle. 
Store  the  suspension  at +4°  to  6°C  for  up  to  one  month. 
9.1.2.3  Enumeration  of  bacterial  suspension.  This  is required  in  order 
to  ~5termine the  germ  concentration.  After  suitable dilution to 
10- in  diluent  (6.2.1)  incubate  at 37°C  for  24  to  48  h before 
enumeration. 
9.1.2.4  Preparation  of  test plates. 
Inoculate  the  molten  agar  medium  (6.1.20)  cooled  to  45°C  with 
pre-diluted bacterial  s~spension (9.1.2.2)  to give  a  bacteria 
concentration  of  5 x 10  per  ml.  Transfer  5 ml  of  inoculated 
medium  to  a Petri  dish  and  allow  the  agar  to  cool  on  a  cold 
horizontal  surface. 
If not  used  on  the  day  of  preparation,  these  test plates may  be 
stored  in  a refrigerator  (7.3)  for  up  to one  week. 
9.2  Preparation  of  samples. 
Remove  the  samples  from  the  deep-freeze  a  few  minutes  before  use 
and  place  them  on  a stainless steel  tray. 
Remove  from  each  sample  a cylindrical  plug  8  mm  in  diameter  and 
two  em  long  using  a cork  borer. 
Push  the  meat  from  the  borer  and  cut  into eight discs  of  2 mm 
thickness  using  a  scalpel. 
Use  forceps  to  place  two  discs  opposite  each  other  in  each  of  the 
four  test plates  (9.1.1.4.1,  9.1.1.4.2,  9.1.1.4.3 and  9.1.2.4). 
In  this way  it is possible  to  place  in  each  plate up  to six 
discs,  corresponding  to  three test samples.  The  discs  should 
form  a circle about  1  em  from  the  rim  of  the  plate. 
9.3  Diffusion  technique. 
9.3.1  Bacillus subtilis at  pH  6.0. 
Use  forceps  to  place  a  disc of  filter paper  (7.17)  in  the  centre 
of  the  dish.  Transfer  10  ~L penicillin solution  (6.3.1)  to the 
disc. 
Incubate  the  plates for  at  least 18  h.  at 30°C. 
After  incubation,  the  disc  impregnated  with  standard  solution 
should  present  a  zone  of  inhibition of  minimum  width  6  mm  (the 
width  is the  distance  between  the  edge  of  the  disc  and  the  outer 
limit of  the  zone  of  inhibition). 
9.3.2  Bacillus subtilis at  pH  7.2. 
Use  forceps  to  place  a disc of  filter paper  (7.17)  in  the  centre 
of  the  dish.  Transfer  10  ~L sulphadimidine  solution  (6.3.2)  to 
the  disc. 
Incubate  the  plates for  at  least 18  h.  at 30°C. 
After  incubation,  the  disc  impregnated  with  standard  solution 
should  present  a  zone  of  inhibition of  minimum  width  6  mm. 
9.3.3  Bacillus subtilis at  pH  8.0. 
Use  forceps  to place  a disc  of  filter paper  (7.17)  in  the  centre 
of  the  dish.  Transfer  10  ~L dihydrostreptomycin  solution  (6.3.3) 
Sg  3.1/7 9.3.4 
10.0 
to  the  disc. 
Incubate  the  plates for  at  least 18  h.  at 30°C. 
After  incubation,  the  disc  impregnated  with  standard  solution 
should  present  a  zone  of  inhibition of  minimum  width  6 mm. 
Micrococcus  luteus  at  pH  8.0. 
Use  forceps  to  place  a disc of  filter paper  (7.17)  in  the  centre 
of  the  dish.  Transfer  10  ~L erythromycin  solution  (6.3.4)  to  the 
disc. 
Incubate  the  plates for  at  least 24  h.  at 37°C. 
After  incubation,  the  disc  impregnated  with  standard  solution 
should  present  a  zone  of  inhibition of  minimum  width  6 mm. 
CALCULATION  OF  RESULTS 
The  detection of  an  antibacterial  substance  in  meat  is determined  positive 
when  at  least one  of  the  four  agar  diffusion  plates  is considered  to 
contain  residues  of  antibacterial  substances  as  shown  by  suitable duplicate 
zones  of  inhibition of  at  least 2 mm  in  width. 
11.  SPECIAL  CASES 
12.  NOTES  ON  PROCEDURE 
12.1.  The  action  level  at which  reanalysis of  a  suspected  positive must  be 
decided  (e.g only  one  positive zone  of  inhibition on  a  single plate).  Also 
similar decisions  need  to  be  taken  when  to  proceed  to a confirming  method. 
13.  QUALITY  CONTROLS 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS 
A full  list of  abbreviations  is given  in  Annex  I,  Section  12 
16.  FLOW  DIAGRAM 
FROZEN  MEAT  ---->  CORE  ---->  8  DISCS  ----->  2 DISCS/PLATE  (4  PLATES) 
I 
I 
I 
I 
! 
+ve  or  -ve  RESULT  <----- VIEW  <---------- INCUBATE 
Sg  3.1/8 Sg.  3.2.  SULPHONAMIDES  - SCREENING  METHOD  USING  HPTLC  FOR  THE  DETECTION 
OF  SULPHONAMIDES  IN  THE  MEAT  OF  FARM  ANIMALS. 
WARNING  AND  SAFETY  PRECAUTIONS 
SAFETY 
Organic  solvents  - all  organic  solvents  must  be  treated as 
potentially  hazardous  and  all  procedures  using  them  must  be 
performed  in  a fume  cupboard. 
FIRST  AID 
1.  Solvents,  acids  and  alkalis  in  contact with  skin  - wash  with 
copious  amounts  of  cold  water.  Splashes  in  the  eye  - irrigate 
with  water  and  seek  medical  attention  immediately. 
2.  Cuts  - seek  assistance of first aider  immediately. 
3.  Burns  and  frostbite - run  affected  part under  cold  water  (burns) 
or  tepid water  (frostbite) for  10  minutes  and  seek  medical 
attention. 
0.  INTRODUCTION 
Sulphonamides  are antibiotics widely  used  prophylactically and  as  growth 
enhancers. 
To  minimise  risks from  residues  in  the  human  diet, withdrawal  periods  are 
set.  High  residue  levels exceeding  the  MRLs  may  occur  if these  periods  are 
not  adhered  to.  The  MRL  for  sulphonamides  is  100  ~g per  kg  and  for  dapsone 
25  ~g per  kg. 
1.  SCOPE 
This  method  of  analysis  describes  the  detection of  sulphonamides  and 
dapsone  in  meat. 
2.  FIELD  OF  APPLICATION. 
The  method  is described  to  be  used  for  meat  from  adult cattle,  calves,  pigs 
and  poultry.  This  method  is used  in  The  Netherlands  to monitor  residue 
levels  in  tissues taken  at slaughter  and  is carried out  in  compliance  with 
the  Residues  Directive  (86/469/EEC).  The  minimum  limit of  determination  for 
sulphonamides  is 2  ~g per  kg  of  meat. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
ISO  Standard  78/2-1982  Layout  for  standards  - Part 2:  Standard  for Chemical 
Analysis 
Beek,  W.M.J.,  Binnendijk,  G.M.,  Smidt,  R.A.,  Keukens,  H.J.  and  de  Vries, 
P.H.U.  (1992),  Vlees  - Screening  von  sulfonamiden  en  dapson  - HPTLC. 
RIKILT-DLO.  SOP  ~ A0644,  DAM  code;  0800302,  Edition  2.  Sept.  1992. 
The  USDA,  USA,  has  developed  a  pig-side  TLC  test called the  "Swine  urine 
screen  Sulfa-on-site"  (SOS-test). 
Sg  3.2/1 4.  DEFINITIONS. 
Sulphonamides  or  dapsone  content  is taken  to  mean  the  amount  of 
sulphonamides  or  dapsone  in  meat  determined  according  to  the  described 
method  and  expressed  as  ~g analyte  per  kg  test sample. 
5.  PRINCIPLE. 
The  method  consists of  four  stages;-
- Homogenisation  and  extraction with  dichloromethane 
- Clean  up  with  Sep-Pak  silica cartridge using  phosphate  buffer 
- Back  extraction to ethyl  acetate 
- HPTLC  chromatography  on  silica gel  plates with  flourescence  detection. 
6  MATERIALS 
Note:  The  reagents  (and  equipment)  for which  examples  of  their source  are 
quoted  are  known  to  be  satisfactory,  nevertheless  reagents  and  equipment 
from  other  sources  may  be  equally suitable.  All  the  reagents  must  be  of 
analytical  grade  or  better. 
6.1 
6.1.1 
6.1.2 
6.1.3 
6.1.4 
6.1.5 
6.1.6 
6.1.7 
6.1.8 
6.1.9 
6.1.10 
6.1.11 
6.1.12 
6.1.13 
6.2 
6.2.1 
6.2.2 
6.2.3 
6.2.4 
6.2.5 
6.3 
6.3.1 
6.3.2 
Chemicals 
Acetone  (Merck  - 14) 
n-butanol  (Merck  - 1990) 
Chloroform  (Merck  - 2445) 
Dichloromethane  (Merck  - 6050) 
Di-potassium  hydrogen  phosphate  (Merck  - 5104) 
Ethyl  acetate,  Uvasol  grade,  (Merck  863) 
Fluorescamine  (Sigma  - F-9878) 
Methanol  (Merck  - 6009) 
Sodium  hydroxide  (Merck  - 6495) 
Sodium  sulphate  (Merck  - 6649) 
Light  Petroleum  (Merck- 909) 
Distilled water 
Orthophosphoric  acid  (Merck  - 573) 
Solutions 
Sodium  hydroxide  0.1M,  Dissolve  4 g sodium  hydroxide  in  1 L 
water. 
Phosphate  buffer,  0.05M;  pH  =  10:  Dissolve  4.36  g di-potassium 
hydrogen  phosphate  (6.1.5)  in  ca.  400  mL  water.  Adjust  the  pH  to 
10  using  sodium  hydroxide  solution  (6.2.1)  and  make  up  to  1 L 
with  water. 
HPTLC  solvent.  Mix  4 volumes  of  chloroform with  1 volume  of  n-
butanol.  Prepare  on  day  of  analysis. 
Fluorescamine  solution;  Dissolve  5 mg  fluorescamine  (6.1.7)  in 
50  mL  acetone.  Solution  is stable  in  the  dark  for  up  to  two 
weeks. 
Orthophophoric  acid,  0.5M;  Add  about  50  mL  water  to  a measuring 
cylinder  and  add  carefully 3.4  mL  orthophosphoric  acid  (6.1.13). 
Make  up  to  100  mL  with  water. 
Standards. 
Standards  for  Sulphonamides  from  Serva. 
Stock  solutions,  ca.  100  ~g per  mL.  Weigh  accurately ca.  10  mg 
standard  into a  100  mL  graduated  flask  and  make  up  to  100  mL  with 
methanol  (6.1.8).  Store  in  the  dark  at 4 - 8°C  •  Stable  not 
Sg  3.2/2 6.3.3 
6.3.4 
7 
7.1 
7.2 
7.3 
7.4 
7.5 
7.6 
7.7 
7.8 
7.9 
7.10 
7.11 
7.12 
7.13 
7.14 
7.15 
7.16 
7.17 
7.18 
7.19 
7.20 
7.21 
7.22 
8. 
longer  than  one  month. 
Working  standards,  1  ~g per  mL.  Pipette 1 mL  stock  standard 
(6.3.2)  into  a  100  mL  graduated  flask  and  make  up  to  100  mL  with 
methanol  (6.1.8).  Store  in  the  dark  at 4 - 8°C  •  Stable  not 
longer  than  one  month. 
Spiking  solution,  1  ~g per  mL.  Pipette 1 mL  stock  standard 
(6.3.2)  into  a  100  mL  graduated  flask  and  make  up  to  100  mL  with 
water.  Make  fresh  on  day  of  analysis. 
EQUIPMENT 
Analytical  balance 
Balance 
Vibromixer 
Stomacher  400  (Labblender) 
Ultrasonic  bath  (Bransonic  32) 
Centrifuge 
GlasswoRl  or  paper  filters  (S&S  595~ ~ 15  em) 
Sep-Pak  silica cartridges  (Waters  - 51900) 
Evacuator  system  for  Sep-Pak  cartridges 
Heating  block  with  nitrogen  evaporation  system. 
HPTLC  plates  10  x 10  em,  Kieselgel  60  without  fluorescence 
indicator  (Merck  - 5631) 
Micropipette,  5  ~L 
TLC  tank  system  for  10  x 10  em  plates. 
Kitchen  blender  (Moulinette  or  Waring) 
Syringes,  50mL,  2 mL 
Other  standard  laboratory glassware 
Transilluminator  (UV)  at 366  nm 
pH  papers  pH  5-9. 
pH  meter 
Stomacher  bags  1 L 
Camag  Unispray  kit  (Camag) 
System  for  photographing  the  yellow-green  fluorescent  spots. 
Recommended  filters for  photography  are  Wratten  ~ 2E,  Kodak  CC10M 
and  Wratten  1A.  Exposure  22.5  sec  at f  8 on  Polaroid  600  plus) 
SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section  6.3.1  and  to  ISO  document  78/2-1982  and 
also  the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to  enable  the 
detection  of  residues  in  meat  as  defined  in  Directive  64/433/EEC. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to allow 
the  method  to  be  carried out  and  to allow  repeat  analysis where  required. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to allow  proper 
identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice  the  result of  the  examination. 
Samples  for  the  analysis  of  Sulphonamides  must  be  stored at temperatures 
below  -18°C. 
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9.1 
9.2 
9.3 
9.3.1 
9.3.2 
9.4 
9.5 
9.5.1 
9.5.2 
9.5.3 
9.5.4 
9.6 
9.7 
9.7.1 
9.7.1.1 
9.7.2 
9.7.3 
PROCEDURE 
Quality controls;  Meat  from  animals  known  not  to  have  been 
treated or  contaminated  with  sulphonamides  or  dapsone  is blended 
to prepare  a  blank  sample  and  a  positive control  sample  and 
stored at -20°C  until  day  of  analysis.  For  the  positive control 
add  the equivalent of  10  ~g per  kg  of  sulphonamides  and/or 
dapsone  to  the  blank  meat  and  wait  15  min  before  blending. 
Meat  samples  for  testing are  blended  and  stored at -20°C  until 
day  of  analysis. 
Primary  extraction 
Poultry meat  (chicken); 
Weigh  10  g blended  meat  for  samples  9.1  and  9.2  and  mix  with  25 
ml  dichloromethane  in  a Stomacher.  Extract for  2 min  with  the 
Stomacher.  Filter through  glass wool  into a  100  ml  flask. 
Repeat  this extraction step  twice  more.  Proceed  to 9.4. 
Cattle and  Pig  meat; 
Weigh  10  g blended  meat  for  samples  9.1  and  9.2  and  mix  with  25 
ml  dichloromethane  in  a beaker.  Place  in  an  ultrasonic bath  for 
10  min.  Do  not  allow  the  temperature  to  exceed  40°C.  Filter 
through  glass wool  into a  100  ml  flask.  Repeat  this extraction 
step twice  more. 
Add  25  ml  light petroleum  to  the  combined  dichloromethane 
extracts. 
Sep-Pak  clean  up; 
Connect  a  50  ml  reservoir to  a Sep-Pak  cartridge  (7.8). 
Put  the  whole  contents  of  the  primary  extract  (9.4)  onto  the 
column.  Rinse  the  flask  with  5 ml  dichloromethane  and  transfer 
the  solution  to the  column.  [Note  - the  50  ml  volumne  should 
pass  through  the  column  in  about  15  min  with  slight suction. 
Elute  the  sulphonamides  with  5 ml  phophate  buffer,  pH  10  (6.2.2). 
Collect  the first three  ml  in  a calibrated tube. 
Control  the  pH  with  the  aid  of  pH  papers  (7.18).  Bring  the  pH  of 
the  collected eluate to 6.5  to  7 with  phosphoric  acid  (6.2.5)  or 
with  sodium  hydroxide  (6.2.1). 
Extract  the  eluate  (9.5.4)  with  1 ml  ethyl  acetate  by  mixing  on  a 
Vibromixer  for  30  sec  and  then  separating  the  phases  using  a 
bench  centrifuge.  Transfer  0.5  ml  of  the  ethyl  acetate phase  to 
a 4 ml  vial.  Evaporate  to  dryness  under  a  stream  of  nitrogen  and 
take  up  the  residue  by  vortexing  in  50  ~L ethyl  acetate. 
HPTLC 
Using  the  plan  in  9.7.1.1,  pipette 10  ~L of  sample  extract onto 
the  plate,  1.5  em  from  the  bottom  of  the  plate and  with  a 
distance of  about  0.75  - 1 em  between  the  spotting places.  Use  a 
stream  of  nitrogen  to control  the evaporation  on  the  plate. 
Place  the extracts for  quality controls,  standards  and  a 
reference  sample  as  in  9.7.1.1. 
Order  of  spots  on  plate from  left to right,  1.5  em  from  bottom 
edge. 
1.  Standard;  2.  Blank;  3.  Spiked  blank;  4.  test sample  1; 
5.  test 2;  6.  test 3;  7.  standard;  8.  test 4;  9.  test 5; 
10.  test 6;  11.  reference  standard;  12.  standard 
Place  the  solvent  (6.2.3)  in  the  tank  to  a depth  of  0.5  em  and 
allow  30  min  for  equilibration. 
Place  the  plate  in  the  solvent  and  allow  the  system  to run  until 
the  solvent front  has  moved  4 em. 
Sg  3.2/4 9.7.4  Remove  the  plate and  mark  the  position of  the  solvent front with 
a pencil. 
9.7.5  Dry  the  plate for  20  min  in  a  fume  cupboard.  Spray  the  plate 
with  the  fluorescamine  solution  (6.2.4).  After  5 min  view  the 
plates under  UV  light at 366  nm. 
9.7.6  The  sulphonamide  spots  can  be  seen  to  have  a  characteristic 
yellow-green  colour. 
9.7.7  Record  the  spots  if positives are  identified either by  marking 
with  a  pencil  or  photographically  (see  7.22). 
10  INTERPRETATION  OF  RESULTS 
10.1  The  Rf  values  for  the  sulphonamides  of  interest and  Dapsone  are;-
(data  from  RIKILT-DLO,  NL) 
Component  Rf 
Sulphanilamide  0.33 
Sulphathiazole  0.39 
Mono-acetyl  dapsone  0.43 
Sulphadiazine  0.57 
Dapsone  0.60 
Sulphadimidine  0.64 
Sulphachlorpyrazine  0.69 
Sulphaquinoxaline  0.70 
Sulphadimethoxine  0.78 
Sulphadoxine  0.80 
10.2  The  sulphonamide  spots  can  be  seen  to  have  a  characteristic 
yellow-green  colour. 
10.3  The  analytes  in  the  spiked  blanks  must  be  detected. 
10.4  Stability;  The  spots  disappear  very  quickly  if exposed  to 
daylight  and  within  2 hours  if kept  in  the  dark.  The  plates 
should  be  viewed  within  30  min  of  spraying with  fluorescamine. 
10.5  Identification of  dapsone.  The  presence  of  dapsone  is valid  if 
its metabolite  mono-acetyl  dapsone  is also  detected  on  the  plate. 
11.  SPECIAL  CASES. 
12.  NOTES  ON  PROCEDURE. 
The  fluorescent  spots  are  unstable  in  light. 
13.  SAMPLE  CONTROLS 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS. 
See  abbreviations  in  Annex  I,  Section  12  of  Manual. 
16.  FLOW  DIAGRAM 
Homogenise  meat  ----->  extract with  dichloromethane  ----->  C18  Sep-Pak 
I 
I 
I 
I 
l 
Identify under  UV  light<-- Spray  with  fluorescamine  <------- HPTLC 
Sg  3.2/5 Sg  3.3.  CHLORAMPHENICOL  - RIA  SCREENING  METHOD  FOR  THE  DETECTION  OF 
CHLORAMPHENICOL  IN  MEAT,  MILK  AND  EGGS. 
WARNING  AND  SAFETY  PRECAUTIONS 
SAFETY 
Organic  solvents  - all organic  solvents  must  be  treated as  potentially 
hazardous  and  all  procedures  using  them  must  be  performed  in  a  fume 
cupboard. 
0.  INTRODUCTION 
Chloramphenicol  (CAP)  is a bacteriostatic with  a broad  spectrum  of 
activity,  frequently  used  for  therapeutic  and  prophylolactic purposes  in 
veterinary medicine.  The  EEC,  through  the  CVMP,  specifically does  not 
recommend  the  use  of  CAP  in  laying  hens  and  lactating cattle. 
1.  SCOPE 
The  use  of  CAP  is restricted throughout  the  EEC.  To  ensure  that farmers 
are  not  continuing  to  use  chloramphenicol  in  laying  hens  or  lactating 
cattle,  and  to control  the  use  in  meat  producing  animals  samples  are 
collected on  farms  and  at slaughterhouses  and  screened  for  the  presence  of 
this compound.  Whenever  there  is a  positive screening  result,  this must  be 
confirmed. 
2.  FIELD  OF  APPLICATION. 
This  method  is used  for  confirmation  of  the  presence  of  chloramphenicol  in 
meat,  milk  and  eggs.  The  detection  limit for milk  and  eggs  is 1  ~g per  L 
or  kg  of  matrix  and  for meat  10  ~g per  kg,  for Chloramphenicol. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
ISO  Standard  78/2-1982  Layout  for  standards  - Part 2:  Standard  for  Chemical 
Analysis 
ISO  Standard  5725  (1986) 
Radioimmunoassay  for  the  measurement  of  chloramphenicol  residues  in  eggs, 
milk  and  meat.  (1993)  Bundesgesundheitsampt,  Berlin. 
Arnold,  D.,  1st Draft  of  the  summary  report of  EEC  Collaborative  study 
11Chloramphenicol  Methods .. ,  July  1987- February  1988. 
Arnold,  D.,  vom  Berg,  D.,  Boertz,  A.k.,  Mallik,  U.  and  Somogyi,  A.  (1984), 
Radioimmunologische  Bestimmung  von  Chloramphenicol-Ruckstanden  in 
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Sg  3.3/1 4.  DEFINITIONS. 
Chloramphenicol  content  is taken  to  mean  the  amount  of  chloramphenicol  in 
meat,  eggs  and  milk  determined  according  to  the  described  method  and 
expressed  as  ~g chloramphenicol  per  L or  kg  test sample. 
5.  PRINCIPLE. 
The  method  comprises  three  stages 
- Samples  are  extracted using  ethyl  acetate. 
- purification of  extract with  solvent-solvent partition  (SPE  for  milk) 
- detection  and  quantification  by  RIA 
6.  MATERIALS 
6.1.  Chemicals 
Note:  The  chemicals  were  all  of  analytical  grade.  Reagents  of  similar 
quality may  be  used  from  other  sources. 
6.1.1 
6.1.2 
6.1.3 
6.1.4 
6.1.5 
6.1.6 
6.1.7 
6.1.8 
6.1.9 
6.1.10 
6.1.11 
6.1.12 
6.1.13 
6.1.14 
6.1.15 
6.1.16 
Ethyl  acetate,  (Merck  9623). 
Methanol,  (Merck  6009) 
Chloroform,  (Merck  2445) 
n-Hexane,  (Merck  4371) 
Acetonitrile,  (Merck  17) 
Isooctane  (Merck  4727) 
Sodium  Chloride  (Merck  6404) 
Ethanol  (absolute)  (Merck  983.25) 
Sheep  albumin  (Sigma,  A-3264) 
Potassium  dihydrogen  phosphate  (Merck  4871) 
Disodium  hydrogen  phosphate  (Merck  6586) 
Sodium  azide  (Merck  6688) 
Charcoal,  Norit  A pract.  (Serva  30890) 
Dextran,  M.Wt  ca  70,000  Daltons  (Pharmacia  1702800) 
Scintillation fluid compatible  with  aqueous  phases  (Beckmann 
270453721A) 
Chloramphenicol  (Sigma  C-0378) 
[Note;  The  radiolabelled  CAP  (6.1.17)  and  the  specific antiserum  (6.1.18) 
are  not  available commercially  but  may  be  purchased  by  negotiation with  the 
BGA,  Berlin] 
6.1.17  Rad!olabelled  Propionyl-CAP.  3-hydroxy-3-(4'-nitrophenyl)-2-
(H/  H/propionyl)-aminopropane-1-ol;  specific activity,  61  Ci  per 
6.1.18 
6.1.19 
6.1.20 
mmol  (2.26  TBq  per  mmol),  TRQ  5394.  (Custom  synthesised for  BGA). 
Supplied  in  ethanol  at 14.47  ~Ci per  mL.  Store  at -20°C. 
Sheep  antiserum  against  CAP  (BGA) 
Distilled water 
Supply  of  ice. 
6.2  CAP  Standards. 
6.2.1  Standard  solution;  10  ~g per  mL  chloramphenicol  in  ethanol. 
Store  at 4°C.  Stable for  at  least six months. 
6.2.2  Working  Standards  Within  one  week  of  use,  dilute  intermediate 
solutions with  phosphate  buffer  (6.3.1)  to  give  a set of  9 
Sg  3.3/2 standards with  concentrations  in  ng  per  mL  equal  to  10,  25,  50, 
100,  125,  250,  500,  1250,  2500. 
[Note;  The  performance  characteristics of  the  assay were  determined  using 
20  calibration points.] 
6.3  Solutions. 
6.3.1  Phosphate  buffer,  pH  7.45.  Dissolve  3.4  g  KH2P04,  3.55  g Na2HP04 
and  0.5  g sodium  azide  in  950  mL  water.  Adjust  the  pH  to  7.45 
and  make  up  to  1 L with  water. 
6.3.2  Antiserum  predilution  1/200  (w/w);  Contains  2.5  mg  sheep 
antiserum  (6.1.18)  per  mL  phosphate  buffer.  Store  at -20°C. 
If the  material  is  in  a  lyophilised  form  supplied  by  BGA  then; 
- centrifuge tube  to  prevent  losses 
- add  1 mL  water 
- shake  overnight  at 4°C  to  reconstitute the  antiserum 
6.3.3  Antiserum  working  solution,  1/75,000  (w/w);  Dilute  an  aliquot of 
the  antiserum  predilution solution  (6.3.2)  375  fold.  Store at 
+4°C. 
6.3.4  Radioligand  working  solution.  An  aliquot of  the  radiolabelled 
analogue  (6.1.17)  is diluted  in  phosphate  buffer  to  give  a  1.08 
nanomolar  solution.  Prepare  weekly  and  store at 4°C. 
6.3.5  Charcoal  suspension;  Mix  3 g charcoal,  0.5  g dextran  and  0.25  g 
sheep  albumin  in  1 L phosphate  buffer,  pH  7.45  (6.3.1). 
6.3.6  Acetonitrile I  4%  sodium  chloride  (1/1,  v/v);  Add  an  equal 
volume  of  acetonitrile to a  4%  solution of  sodium  chloride  in 
water. 
7.  EQUIPMENT 
7.1  Dispensing  pipettes;  0-20  ~L,  0-1000  ~L,  0-5000  ~L 
7.2  Centrifuge  tubes  with  stoppers,  10-12  mL,  15-20  mL  (Schmidt, 
Germany) 
7.3  Micro  test tubes  (Eppendorf  3812) 
7.4  Universal  vials,  10-20  mL  with  screw  tops.  (Beckmann) 
7.5  Volumetric  stoppered  flasks,  10  mL  and  100  mL 
7.6  Automatic  dispenser  (
11Dispensette
11
,  Brand,  Germany) 
7.7  Scintillation vials  (beckmann) 
7.8  Speed  Vac  (Savant,  USA) 
7.9  Stirrer for  tubes,  type  HEIDOLPH 
11Top-mix
11 
7.10  Rotary  stirrer with  rotating plates,  type  HEIDOLPH 
11Reax  2
11 
7.11  Vortex  mixer 
7.12  Fume  cupboards 
7.13  Vacuum  centrifuge  (UniEquip,  Germany) 
7.14  Liquid  scintillation counter  (Beckmann) 
7.15  Cold  storage  space,  ca  -18°  to  -20°C 
7.16  Working  cold  room/refrigerator  space 
7.17  Pasteur  pipettes 
7.18  Tubes  75  mm  x 12  mm 
7.19  Analytical  balance 
7.20  Refrigerated  centrifuge,  (Sorvall,  USA) 
7.21  Bench  centrifuge 
7.22  C-18  cartridges  (Sep-Pak,  C-18,  Waters-Millipore  Cat.~ 519) 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section  6.3.1  and  ISO  document  78/2-1982  and 
Sg  3.3/3 the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  of  milk,  meat  and  eggs  shall  be  such 
as  to enable  the  detection  of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to allow 
the  reference method  to  be  carried out  and  to  allow  repeat analysis where 
required. 
8.3.  The  sample  must  be  cooled  after collection and  stored  at~ -20°C 
pending  analysis. 
9. 
9.1. 
9.1.1 
9.1.2 
9.1.3 
9.2 
9.2.1 
9.2.2 
9.2.3 
9.2.4 
9.2.5 
9.2.6 
9.2.7 
9.2.8 
9.2.9 
9.2.10 
9.2.11 
9.2.12 
9.2.13 
9.3 
9.3.1 
9.3.2 
9.3.3 
9.3.4 
9.3.5 
9.3.6 
PROCEDURE 
Preparation  of  test sample; 
Meat;  Take  a coherent  part of  muscle  tissue and  mince  at 0-4°C. 
In  the  case  of  frozen  meat  add  the  excess  liquid,  produced  when 
the  meat  is thawed,  quantitatively to  the  minced  meat  and  mix 
well.  The  sample  can  now  be  stored at 0-4°C  fro  analysis within 
the  next  48  h.  For  prolonged  storage,  freeze  aliquots at -20°C 
or  preferably at -80°C  to  ensure  stability. 
Eggs.  Should  be  homogenised. 
Milk;  Samples  taken  from  raw  milk  or  any  type  of  homogeneous 
undenatured  heated  milk. 
Primary  extraction of  Meat  and  Eggs; 
Place  3 g of  comminuted  meat  or  homogenised  eggs  into a 
centrifuge tube. 
To  the  egg  samples  add  dropwise  5 ml  acetonitrile while  mixing. 
To  the  meat  samples  add  8 ml  acetonitrile/4% sodium  chloride 
solution  (6.3.6). 
Mix  well  or  homogenise. 
Centrifuge  10  min  at 4000  g. 
Weigh  the  supernatant  into  a universal  vial. 
Pipette ca.  1/6th  (w/w)  of  the  supernatant  into  a glass  stoppered 
centrifuge tube. 
Add  5 ml  n-hexane  and  2 ml  water  and  mix  well. 
Centrifuge  for  5 min  at 1700  g 
Discard  the  upper  layer 
Repeat  steps  9.2.7  to  9.2.9. 
Add  3.5  ml  of  water  saturated ethyl  acetate to  the  aqueous  phase 
and  mix  well. 
Centrifuge  for  5 min  at 1700  g 
Separate  the  organic  phase  and  evaporate  it to  dryness. 
Extraction  of  Milk. 
Mix  1 ml  milk  with  0.75  ml  chloroform-isooctane  (3/2,  v/v)  in  a 
glass  tube. 
Centrifuge  15  min  at 4000  g 
Load  0.7  ml  of  the  supernatant onto  a C-18  cartridge conditioned 
as  follows; 
Wash  the  cartridge  in  the  following  order with;-
- 5 ml  methanol;  5 ml  chloroform;  5 ml  methanol;  10  ml  distilled 
water. 
Wash  test sample  with  10  ml  distilled water  (6.1.19) 
Elute  the  CAP  with  5 ml  acetonitrile/water  (1/1,  v/v). 
Extract  CAP  from  the  column  eluent with  5 ml  of  water  saturated 
ethyl  acetate.  Centrifuge  at 1700  g. 
Sg  3.3/4 9.3.7 
9.3.8 
9.5 
[Note; 
9.5.1 
9.5.2 
[Note; 
9.5.3 
9.5.4 
9.5.5 
9.5.6 
9.5.7 
9.5.8 
Transfer  the  upper  layer  and  evaporate  it to  dryness  using  a 
Speed  Vac. 
Dissolve  the  residue  in  0.7  mL  phosphate  buffer  (6.3.1)  and 
proceed  directly to  9.5.2. 
Radioimmunoassay. 
All  steps must  be  performed  at 0°C  using  an  ice  bath.] 
Dissolve  the  meat/eggs  extract  (9.2.13)  with  450  ~L phosphate 
buffer  (6.3.1).  For  the  meat  extract it may  be  necessary  to 
adjust  the  concentration  of  CAP  to  ca.  150  pg  per  200  ~L buffer 
by  diluting  up  to  10  fold  with  buffer. 
Combine  in  a  glass  tube; 
- 200  ~L extract  (9.5.1  or  9.3.8)  or  standard  solutions  (6.2.2) 
- 200  ~L radioligand  solution  (6.3.4) 
- 400  ~L antiserum working  solution  (6.3.3) 
Start the  incubation  by  adding  the  antiserum  last. 
Two  replicates are  used  for  each  test sample.] 
Incubate  overnight  at +4°C 
Pipette 1  mL  of  well  stirred charcoal  suspension  into each  tube. 
The  additions must  be  completed  within  5 min. 
Incubate  30  min  at ooc 
Centrifuge  10  min  at 1700  g 
Decant  the  supernatant  to a  sufficient amount  of  scintillation 
fluid. 
Count  the  .. radioactivity  ..  for  10  min.  or  to  a  2%  statistical 
error. 
10.0  CALCULATION  OF  RESULTS 
10.1  It is strongly recommended  to  use  non-linear  curve  fitting 
procedures  for  the  calculation of  the  calibration curves. 
[Note;  For  this  RIA  the  CAP  concentrations  of  the  calibration standards  and  11Bound 11/ 11Total .. ,  (B/T),  the  fraction  bound  of  the  radioligand  are  the  best 
suited  independent  and  dependant  variables for  the  non-linear  11least-
squares11  curve  fitting.  Frequently only  the  central  part of  the 
calibration curve  can  be  linearized  using  the  logit-log-transformation.] 
For  the  calculation of  the  CAP  contents  of  the  test samples  the following 
data  are  required; 
A  The  amount  of  CAP  found  per  tube  (mean  of  replicates).  These 
values  are  determined  from  the  calibration curve. 
F  The  correction factor  due  to  the  fraction of  the  total  residue 
transferred to  the  RIA  tube. 
EA  The  weight  of  the  aliquot of  the  crude  extract taken  for extract 
clean  up. 
EW  The  weight  of  the  crude  extract. 
SW  The  sample  weight 
For  eggs 
F =  2.25  for  analyses  at 1 ppb 
EA  =  ca.  1/6th of  EW,  use  exact  value 
EW  = typically 5 to  6.5  g,  use  exact  value 
SW  =  ca.  3 g,  use  exact  value 
For  meat 
F =  22.5  for  analyses  at 10  ppb 
EA  =  ca.  1/6th of  EW,  use  exact  value 
EW  = typically 7.5  to  9 g,  use  exact  value 
SW  =  ca.  3 g,  use  exact  value 
Sg  3.3/5 For  milk 
F =  5 for  analyses  at 1 ppb 
EA  =  ca.  1 for  analyses  at 1 ppb 
EW  = ca.  1 for  analyses  at 1 ppb 
SW  = ca.  1 for  analyses  at 1 ppb 
The  results are  calculated as;  F = A x F x  EW 
1000  X EA  X SW 
10.2  Precision. 
This  was  determined  in  an  EEC  collaborative trial  using  meat  and  milk.  The 
results were;-
Meat  Milk 
True  Content  (~g per  kg)  11.6  1.0 
Mean  level  found1  (~g per  kg)  6.9  1.1 
Repeatability  (ng  per  g)  3.2  0.72 
Repeatability  CV%  16  23 
Reproducibility  (ng  per  g)  7.0  1.1 
Reproducibility  CV%  36  36 
Between  laboratory  CV%  32  28 
Superscript  1 is the  value  calculated without  account  of  recovery. 
The  results were  analyzed  according  to  ISO  standard  5725/1986. 
10.3  Quality controls 
Each  assay  must  include  duplicate assays  for;  reagent  blanks,  blank 
tissues,  fortified  (spiked)  tissues and  Reference  Materials where 
available. 
The  total  radioactivity pipetted  into each  assay  tube  should  be  determined. 
The  non-specific  binding  of  the  radioligand  should  be  determined  and  should 
not  exceed  8% 
11.  SPECIAL  CASES. 
12.  NOTES  ON  PROCEDURE. 
13.  SAMPLE  CONTROLS. 
Reference  Materials  for muscle,  milk  and  eggs  were  prepared  by  the  BGA  and 
are  undergoing  the  final  intercomparison  and  certification procedures  under 
the  Measurement  and  Testing  Programme  of  DG12. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS. 
See  abbreviations  in  Annex  I,  Section  12  of  Manual. 
16.  FLOW  DIAGRAM 
MEAT/EGGS  ---> SOLVENT  EXTRACT  ------------------------
! 
MILK  ----->  SOLVENT  EXTRACT  ------>  C-18  SPE  ---->  RIA  -->  RESULTS 
Sg  3.3/6 Sg.  3.4.  NITROIMIDAZOLES  AND  NITROFURANS  - ANALYSIS  WITH  DIALYSIS  AND  ON-
LINE  HPLC  FOR  DETERMINING  RESIDUES  OF  NITROIMIDAZOLES  AND  NITROFURANS  IN 
POULTRY  (CHICKENS,  DUCKS  AND  TURKEYS)  MEAT. 
WARNING  AND  SAFETY  PRECAUTIONS 
SAFETY 
Organic  solvents  - all  organic  solvents  must  be  treated as  potentially 
hazardous  and  all  procedures  using  them  must  be  performed  in  a  fume 
cupboard. 
0.  INTRODUCTION 
Nitroimidazoles  (here  dimetridazole  and  ronidazole)  are  coccidiostats used 
in  poultry.  The  MRL  for  dimetridazole  is  10  ~g per  kg  and  for  ronidazole 
is 2  ~g per  kg.  Both  nitroimidazoles  have  a  common  metabolite,  1-methyl-2-
hydroxymethyl-5-nitroimidazole.  Nitrofurans  (here  furazolidone,  and 
furaltadone)  are  antibacterial  agents  used  in  pigs  and  poultry. 
1.  SCOPE 
This  work  is carried out  in  compliance  with  the  Residues  Directive 
(86/469/EEC). 
2.  FIELD  OF  APPLICATION. 
This  method  is used  for  determining  the  presence  of  ronidazole  and 
dimetridazole  and  their common  metabolite  1-methyl-2-hydroxymethyl-5-
nitroimidazole  in  poultry meat.  The  method  also  includes  the monitoring  of 
furazolidone  and  furadaltone  in  poultry meat.  The  method  is operated  at 
RIKILT-DLO  in  the  Netherlands,  as  a routine monitoring  method.  The  limit 
of  detection  is 2  ~g per  kg  of  matrix  for  nitroimidazoles  and  1-methyl-2-
hydroxymethyl-5-nitroimidazole  and  furazolidone.  For  furadaltone  the  limit 
of  detection  is 4 ug  per  kg. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
ISO  Standard  78/2-1982  Layout  for  standards  - Part 2:  Standard  for Chemical 
Analysis 
ISO  Standard  5725  (1986) 
Aerts,  M.M.L.,  Beek,W.M.J.  and  Brinkman,  U.A.Th.,  (1990),  On-line 
combination  of  dialysis and  column-switching  liquid chromatography  as  a 
fully automated  sample  preparation  technique  for  biological  samples. 
Determination  of  nitrofuran residues  in  edible  products.  J.Chromatogr. 
500,  453-468 
Elema,  M.C.,  Beek,  W.M.J.  and  Keukens,  H.J.  (1992),  Kip-,  kalkoen- en 
eendevlees- Bepaling  van  ronidazol,  dimetridazol,  furazolidon  en 
furaltadon  - CF-LC.  RIKILT-DLO,  SOP  ~ A0656,  RIKILT,  Wageningen,  NL. 
Sg  3.4  /1 Keukens,  H.J.,  Elema,  M.C.,  Beek,  W.M.J.  and  Boekestein,  A.  (1993),  Sample 
pretreatment  based  on  dialysis;  Determination  of  residues  of 
nitroimidazoles  in  poultry meat.  Proc.  Euroresidues  II,  May  1993,  pp  410-
414. 
4.  DEFINITIONS. 
Nitroimidazoles/nitrofurans  content  is taken  to  mean  the  amount  of 
nitroimidazoles  in  meat  determined  according  to  the  described  method  and 
expressed  as  ug  nitroimidazoles/nitrofurans  per  kg  test sample. 
5.  PRINCIPLE. 
The  method  comprises  four  stages  all  carried out  in  the  absence  of  daylight 
or white  light. 
- Meat  is homogenised  in  water. 
- Centrifugation 
- purification of  the  supernatant extract  by  dialysis 
- quantification  by  HPLC  with  UV  detection  at 320  nm. 
6.  MATERIALS 
6.1.  Chemicals 
6.1.1  Methanol,  Analytical  grade  (Merck  - 6009) 
6.1.2  Acetonitrile,  HPLC  grade  (Merck  - 3) 
6.1.3  Anhydrous  sodium  acetate  (Merck  - 6268) 
6.1.4  Glacial  acetic acid  (Merck  - 63) 
6.1.5  Demineralised  water,  filtered on  Milli-Q  purification system 
(Millipore,  Milford,  USA) 
6.2. 
6.2.1 
6.2.2 
6.3 
6.3.1 
6.3.2 
6.3.3 
6.3.4 
Solutions 
0.01M sodium  acetate - acetic acid  buffer;  pH  4.3.  Dissolve  0.82 
g anhydrous  sodium  acetate  (6.1.3)  in  about  800  ml  water.  Adjust 
the  pH  to 4.3 with  glacial  acetic acid  (6.1.4).  Make  up  the 
volume  to  1 l  with  water. 
HPLC  eluent;  Mix  850  ml  of  acetate buffer  (6.2.1)  with  150  ml 
acetonitrile  (6.1.2).  Filter the  solution  through  a 0.22  ~m 
Millipore filter and  degas  in  an  ultrasonic bath.  The  solution 
is stable for  one  month. 
Standards 
Ronidazole  and  dimetridazole  (Sigma),  1-methyl-2-hydroxymethyl-
5-nitroimidazole was  a gift from  Merck,  Sharpe  and  Dohme. 
Furazolidone  and  furaltadone  were  obtained  from  Sigma,  USA. 
Stock  standards;  Make  up  stock  solutions of  nitroimidazoles, 
nitrofurans  and  1-methyl-2-hydroxymethyl-5-nitroimidazole  in 
methanol  to  give  concentrations  of  ca.  100  ~g per  ml.  The 
solution  is stable for  one  month  at 4°  to 8°C  in  the  dark. 
Dilute Standards;  Make  up  in  a  volumetric  flask  1 ml  of  stock 
standard  (6.3.2)  to  100  ml  with  water. 
Working  Standards;  A (5  ng  per  ml);  Dilute 0.5  ml  6.3.3 to  100 
ml  with  water.  B (20  ng  per  ml);  Dilute  2 ml  6.3.3 to  100  ml 
with  water. 
Sg  3.4  /2 7  EQUIPMENT 
7.1.  Glassware 
7.1.1  Graduated  pipettes, 
7.1.2  Glass  centrifuge tubes 
7.1.3  Glass  test tubes  to  take  6 ml  samples. 
7.1.4  Graduated  volumetric  flasks,  100  ml  capacity 
7.1.5  Normal  laboratory glassware 
7.2.  Apparatus 
7.2.1  Automatic  pipettes, 
7.2.2  Analytical  balance 
7.2.3  Refrigerated  centrifuge 
7.2.4  Refrigerator at <-18°C 
7.2.5  Vibromixer 
7.2.6  Homogeniser,  Model  400  Stomacher  laboratory blender,  (Lameris, 
NL) 
7.2.7  Filter paper  (Schleicher &  Schuell  595~;  ~ 15  em) 
7.2.8  pH  meter 
7.2.9  Filter system  for  eluents;  0.22  ~m (Millipore 83813) 
7.3  Dialysis  Equipment  (see  schematic  representation) 
An  autosampler-dialysis  module  system  consisted of  a Model  232-401  Gilson 
autosampling  injector,  two  automatic  six-port valves  (Rheodyne  model  7010), 
a second  Model  401  diluter  ,  a Kel-F  flat-plate dialyser block  fitted with 
a Cuprophan  membrane  (10,000-15,000  Daltons  cut-off)  having  a donor  volume 
of  370  ul  and  an  acceptor  volume  of  650  ~L.  a  liquid chromatographic  pump 
capable  of  maintaining  a constant  pulseless flow  of  0.1-2  ml  per  min  (model 
305,  Gilson).  The  diluters were  equipped  with  two  5 ml  syringes. 
The  sample  tray of  the  injector device  must  be  cooled  to  4°C  to keep  the 
test samples  at 4°C. 
Schematic  representation of  dialysis and  HPLC  system. 
Auto 
Samp. 
Dial. 
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Basic  System  :  Gilson  305  and  805 
Guard  Column  :  Bondapack/Corasil  37-SO~m,  10  mm  x 2.1  mm  i.d.  (Millipore 
27248) 
Analytical  Column  :  Lichrosorb  C-18  5  ~m,  200  mm  x 3.0  mm  i.d.  Chrompack) 
Recorder  :  10  mV,  0.5  em  per  min  (Kipp  BD-41) 
Detector  :  UV  at 320  nm.  0.002  Aufs,  Rise  time  2 sec.  (ABI  Type  785A) 
Flow  rate  :  0.4  mL  per  min 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section  6.3.1  and  ISO  document  78/2-1982  and 
the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  of  meat,  milk  and  eggs  shall  be  such 
as  to  enable  the  detection of  residues.  Only  samples  which  are  not  spoiled 
by  bacteria may  be  examined. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large enough  to allow 
the  reference method  to  be  carried out  and  to allow  repeat  analysis where 
required. 
8.3.  The  samples  must  be  cooled  after collection  and  stored  at~ -20°C 
pending  analysis. 
9. 
Note; 
light. 
9.1 
9.2 
9.2 
9.3 
9.4 
9.5 
9.5.1 
PROCEDURE 
All  steps must  be  carried out  in  the  absence  of  daylight or white 
Samples  of  meat  are  blended  in  a Waring  blender  or  Moulinette. 
Control  and  blank  samples;  Pipette  into  10  g portions  of  blended 
meat  0,  100,  200  and  500  ~L of  each  of  the  diluted standards 
6.3.3. 
The  control  and  blank  samples  and  separate  samples  of  10  g of 
blended  meat  (test samples)  are  further  blended  for  3 min  in  a 
Stomacher  (7.2.6)  with  20  mL  water. 
Transfer  the  material  to  a centrifuge tube.  Centrifuge at 4000  g 
for  5 min  at 10  °C. 
Filter through  filter paper  (7.2.7).  The  filtrate  is ready  for 
introduction  into the  dialysis system. 
Dialysis-HPLC 
The  working  standards  are  injected  into  the  dialysis according  to 
the  following  procedure  until  a  stable base  line and  consistent 
peak  height  response(s)  are  observed. 
The  samples  are  placed  in  the  automatic  sample  injector and 
maintained  at 4°C.  Two  sample  doses  (2  x 370  ~L) are  introduced 
into  the  dialysis block.  Two  mL  of  acceptor  solvent  (water)  are 
sucked  through  the  concentration  column  (CC)  by  the  second 
diluter  (Di1).  After  completion  of  the  dialysis,  the 
concentration  column  is flushed  with  water  by  switching  the 
second  six-port valve  (Va.2).  The  enriched  sample  is backflushed 
with  HPLC  eluent  (6.2.2)  to  the  guard  column  and  analytical 
column  with  the  pump  by  switching  the  six-port valve  (Va.1).  The 
analytes  are  detected  at  320  nm  by  UV  detection. 
[Note;  This  procedure  (9.5)  may  be  automated  with  home-made  software 
installed on  the  232  mainframe.] 
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10.1  The  content  of  the  meat  sample  is given  by  the  formula;-
Conc.  in  meat  (mg  per  kg)  =  Hm  x Cst  x f 
Hst 
Hm  =  peak  height  of  analyte  in  sample 
Hst  =  peak  height  of  standard  added  to  blank  sample 
Cst  =  concentration  of  standard  in  blank  sample  in  mg  per  kg 
f  =  Dilution  factor 
10.2  Recoveries; 
Recoveries  for  meat  were  measured  on  the  basis  of  the  standards  dissolved 
in  water.  The  values  were;-
Cone.  recovery  % 
~g per  kg  2-0H-Metab  Ronidazole  Dimetridazole  Furazolidone  Furaltadone 
5  82  91  90  109  84 
10  89  90  92  99  85 
20  94  93  93  96  76 
10.3  The  suspect  peaks  must  have  the  same  retention  time  as  the 
standards  as  defined  in  the  EC  decision  93/256  (see  section  5). 
11.  SPECIAL  CASES. 
12.  NOTES  ON  PROCEDURE. 
NITROFURANS  DECOMPOSE  IN  WHITE/DAY  LIGHT.  IT  IS  ESSENTIAL  THAT  All 
PROCEDURES  ARE  CARRIED  OUT  IN  THE  ABSENCE  OF  DAYLIGHT  AND  WHITE  LIGHT. 
13.  SAMPLE  CONTROLS 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS. 
See  abbreviations  in  Annex  I,  Section  12  of  Manual. 
16.  FLOW  DIAGRAM 
MEAT  ---------->  WATER  EXTRACT  ------>  DIALYSIS 
I 
I 
I 
I 
! 
CALCULATE  RESULTS  <--------- HPLC 
Sg  3.4  /5 Sg  3.5.  CIPROFLOXACIN  AND  ENROFLOXACIN  - ROUTINE  SCREENING  METHOD  FOR  THE 
DETERMINATION  BY  HPLC  AFTER  CATION-EXCHANGE  COLUMN  CHROMATOGRAPHY  IN  PIG 
MUSCLE,  BACON  AND  BOVINE  MUSCLE. 
WARNING  AND  SAFETY  PRECAUTIONS 
SAFETY 
Organic  solvents  - all  organic  solvents  must  be  treated as 
potentially hazardous  and  all  procedures  using  them  must  be 
performed  in  a fume  cupboard. 
FIRST  AID 
1.  Solvents,  acids  and  alkalis  in  contact with  skin  -wash with 
copious  amounts  of  cold  water.  Splashes  in  the  eye  - irrigate 
with  water  and  seek  medical  attention  immediately. 
2.  Cuts  - seek  assistance of  first aider  immediately. 
3.  Burns  and  frostbite - run  affected  part under  cold  water  (burns) 
or  tepid water  (frostbite) for  10  minutes  and  seek  medical 
attention. 
1.  INTRODUCTION 
Purpose 
The  detection of  the  presence  of  Ciprofloxacin  and  Enrofloxacin  in  samples 
taken  from  cattle and  pigs  in  compliance  with  the  Residues  Directive 
86/469/EEC. 
Background 
Ciprofloxacin  and  Enrofloxacin  are  animal  drugs  with  broad  spectrum 
antibacterial  activity. 
1.  SCOPE 
This  method  of  analysis  in  use  at MAFF,  FSD,  Norwich,  UK,  describes  the 
determination  of  the  total  content  of  Ciprofloxacin  and  Enrofloxacin  in  pig 
muscle,  bacon  and  bovine  muscle. 
2.  FIELD  OF  APPLICATION. 
The  method  is described  to  be  used  for  samples  from  pigs  and  cattle.  It 
may  be  suitable for  other species  but  would  require  validation.  The  limit 
of  determination  is not  accurately defined  but  is taken  to  be  0.01  mg 
Ciprofloxacin  or  Enrofloxacin  per  kg  although  this may  vary  between  samples 
because  of  variable  background  noise.  Validation  data  are  provided  for 
0.001  - 0.002  mg  per  kg. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
ISO  Standard  78/2-1982  Layout  for  standards  - Part 2:  Standard  for  Chemical 
Analysis 
Sg  3.5/1 Determination  of  Ciprofloxacin  and  Enrofloxacin  at residue  levels  in  cattle 
muscle,  pig  muscle  and  bacon.  (1993),  MAFF,  Food  Safety Directorate,  Food 
Science  Lab.  Norwich  UK.  SOP10(1) 
4.  DEFINITIONS. 
Ciprofloxacin  or  Enrofloxacin  content  is taken  to  mean  the  amount  of 
Ciprofloxacin  or  Enrofloxacin  in  muscle  or  bacon  determined  according  to 
the  described  method  and  expressed  as  ~g Ciprofloxacin  or  Enrofloxacin  per 
kg  test sample. 
5.0  PRINCIPLE 
Ciprofloxacin  and  Enrofloxacin  are  extracted with  solvents  from  homogenised 
samples  into  1%  acetic acid  in  ethanol.  The  extract  is cleaned  up  using 
ion-exchange  resin  column  chromatography  and  eluting with  25%  methanolic  -
ammonia.  End-point  analysis  is performed  with  reversed-phase  HPLC  and 
fluorescence  detection. 
6.  MATERIALS 
Note:  The  reagents  (and  equipment)  for which  examples  of  their source  are 
quoted  are  known  to  be  satisfactory,  nevertheless  reagents  and  equipment 
from  other  sources  may  be  equally suitable.  All  the  reagents  must  be  of 
analytical  grade  or  better. 
6.1. 
6.1.1. 
6.1.2. 
6.1.3. 
6.1.4. 
6.1.5. 
6.1.6. 
6.1.7. 
6.1.8 
6.1.9. 
6.1.10 
Chemicals 
Acetonitrile  (Rathburn  Chern  Ltd) 
Ammonia  solution  sp.gr.  0.88  (BDH  Ltd.) 
Absolute  alcohol  (ethanol)  (Hayman  Ltd) 
Glacial  acetic acid  (FSA) 
Orthophosphoric  acid  (BDH  Ltd) 
Methanol  (FSA) 
Triethylamine  (BDH) 
Ciprofloxacin  hydrochloride  (Sigma) 
Enrofloxacin  (Bayer) 
Deionised  water  further processed  by  Elgastat  UHP  unit  is used 
throughout. 
Standards 
all  solutions of  standards  in  the  refridgerator. 
6.2. 
Store 
6.2.1 
6.2.1.1 
6.2.1.2 
6.2.2 
6.2.3 
6.2.4 
6.2.5 
Stock  standards. 
Dissolve  5 mg  Ciprofloxacin  in  10  mL  water.  Prepare  monthly. 
Dissolve  5 mg  Enrofloxacin  in  10  mL  water.  Prepare  monthly. 
First  intermediate  standard  (10  ~g per  mL).  Take  200  ~L of  each 
stock  (6.2.1.1 &  6.2.1.2),  combine  and  dilute to  10  mL  with 
methanol.  Prepare  daily. 
Second  intermediate  standard  (0.2  ~g per  mL).  Take  200  ~L of 
intermediate  standard  (6.2.2)  and  dilute to  10  mL  with  mobile 
phase  (6.3.4).  Prepare  daily. 
Working  standards  of  concentrations  4  ~g per  mL  and  20  ~g per  mL. 
Take  0.2  mL  or  1.0  mL  of  the  second  intermediate  standard 
solution  and  dilute to  10  mL  with  the  HPLC  mobile  phase  (6.3.4). 
Tissue  working  standard  (4  or  20  ~g per  mL).  Redissolve  the 
residue  from  the  blank  extract  (blank  extraction  through  to  9.13) 
in  1 mL  working  standard  (6.2.4). 
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6.2.7 
6.3 
6.3.1 
6.3.2 
6.3.3 
6.3.4 
7. 
7.1 
7.2 
7.3 
7.4 
7.5 
7.6 
7.7 
7.8 
7.9 
7.10 
7.11 
7.12 
7.13 
7.14 
7.15 
7.16 
7.17 
7.17.1 
7.17.2 
7.17.3 
7.17.4 
7.17.5 
7.25 
Intermediate  spiking  solution.  Take  200  ~L of  10  ~g per  mL 
solution  (6.2.2)  and  dilute to  10  mL  with  1%  acetic acid  in 
ethanol  (6.3.1). 
Spiking  solution.  Take  0.2  mL  or  1 mL  of  0.2  ~g per  mL  solution 
(6.2.3)  and  dilute to  10  mL  with  1%  acetic acid  in  ethanol 
(6.3.1). 
Solutions 
1%  acetic acid  in  ethanol;  10  mL  acetic acid  (6.1.4)  made  up  to 
1 L with  ethanol  (6.1.3) 
25%  ammonia  in  methanol;  125  mL  ammonia  solution  (6.1.2)  made  up 
to  500  mL  with  methanol  (6.1.6). 
0.01M phosphate/TEA  buffer,  pH  3;  0.68  mL  phosphoric  acid 
(6.1.5)  diluted to  1 L with  water.  Adjust  the  pH  to  3.0 with 
triethylamine  (6.1.7). 
HPLC  mobile  phase.  Mix  0.01M phosphate/TEA  buffer  and 
acetonitrile, 80:20  (v/v).  Filter (7.14)  and  degas  by 
ultrasonication  (7.3)  under  reduced  pressure. 
EQUIPMENT 
Centrifuge,  Jouan  CR422 
Plastic centrifuge tubes,  50  mL  and  100  mL  capacity 
Ultrasonic  bath,  L&R  140S 
Glass  vials and  caps,  2 mL  capacity 
HPLC  vials  and  caps,  0.3  mL  capacity 
All  glass filter holder  47  mm.  (Millipore  UK  Ltd) 
Homogeniser  (Ultra-Turrax  or  equivalent) 
Test  tubes  125  mm  x 16  mm  (to fit Speed  mate  30  vacuum  manifold) 
Disposable  syringes  1 mL  capacity 
Heater  block  assembly  for  evaporation  using  nitrogen 
Vortex  mixer(s) 
Magnetic  stirrer 
Disposable  syringe filters,  Cameo  3N,  0.45  micron,  3 mm  - (Jones 
Chromatography) 
Membrane  filter 0.45  1-1m 
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,  47  mm.  (Millipore  UK  Ltd) 
Refridgerator  +4°C 
Safety pipettes,  0.2  mL,  1.0  mL  and  5.0  mL.  (e.g.  Gilson 
Pipetman) 
Solid  Phase  extraction 
Bond-Elut  adapters 
Bond-Elut  SCX  cartridges  500  mg  in  2.8  mL  (Jones  Chromatography) 
Bond-Elut  reservoirs,  75  ml  capacity 
Speed  Mate  30  vacuum  manifold  (Applied  Separations) 
Preparation  SCX  column;  Wash  the  Bond-Elut  SCX  columns  (7.17.2) 
with  5 ml  1%  acetic acid  in  ethanol  (6.3.1)  prior to  use. 
HPLC 
Pump  :  Gilson  307 
Injector:  Gilson  model  231,  20  J.LL  injection 
Detector:  Philips Scientific PU4027  fluorescence  detector, 
excitation  278  nm,  emission  445  nm. 
Column:  250  mm  x 4.6  mm  i.d.  Zorbax  RX-C8  column  maintained  at a 
constant  35°C  in  an  oven.  Mobile  phase  pumped  at 0.5  mL  per  min. 
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N.B.  Attention  is drawn  to  section  6.3.1  and  to  ISO  document  78/2-1982  and 
also the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection  of  residues  in  meat  as  defined  in  Directive 64/433/EEC. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large enough  to 
allow  the  method  to  be  carried out  and  to allow  repeat  analysis 
where  required. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to allow 
proper  identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain 
the  integrity of  the  sample  and  not  prejudice  the  result of  the 
examination. 
Samples  for  the  analysis  of  Ciprofloxacin  and  Enrof6oxacin  must 
be  stored  and  transported at temperatures  below  -18  C. 
9.0.  PROCEDURE 
9.1.  Sample  preparation 
Samples  may  be  processed  in  batches  of  up  to eight.  A control  sample 
and/or  one  of  the eight samples  should  be  spiked  at the  limit of 
determination. 
9.1.1 
9.1.2 
9.1.3 
9.1.4 
9.1.5 
9.1.6 
9.2 
9.2.1 
2 g thawed  sample  is sliced and  placed  into  a  50  mL  centrifuge 
tube. 
20  mL  of  1%  acetic acid  in  ethanol  (6.2.1)  is added  and  the 
mixture  homogenised  for  about  1 min  and  then  placed  in  an 
ultrasonic bath  for  3 min. 
The  tubes  are  centrifuged at 4500  rpm  for  about  5 min. 
The  supernatant  is poured  carefully into  a  100  mL  plastic 
centrifuge tube. 
The  residue  is re-extracted with  a further  20  mL  of  1%  acetic 
acid  in  ethanol  (6.2.1) 
The  combined  supernatants  are  centrifuged  for 5 min  at 4500  rpm. 
Column  Clean  up; 
The  clear supernatant  is  passed  through  a  prepared  (7.17.5)  Bond-
Elut  sex  column  at a flow  rate not  exceeding  5  mL  per  min. 
NOTE;  The  column  should  not  be  allowed  to  run  dry  at any  stage  during  the 
washing  loading  and  elution  steps. 
9.2.2  The  column  is washed  with  5 mL  methanol  (6.1.6)  follwed  by  10  mL 
9.2.3 
9.2.4 
9.2.5 
9.2.6 
water  and  a further 5 mL  methanol. 
The  Ciprofloxacin  and  Enrofloxacin  are  eluted with  5 mL  25% 
ammonia  in  methanol  (6.3.2)  into  a test tube  (7.8). 
The  test tube  is stood  a  heated  block  for  5 min  to equilibrate 
and  the  liquid phase  evaporated  to  dryness  under  a  stream of 
nitrogen.  Acetonitrile may  be  added  to  assist evaporation  of  the 
last 1 to 2 mL  extract. 
The  residue  is redissolved  in  1 ml  HPLC  mobile  phase  (6.3.4)  by 
vortex  mixing  and  ultrasonication for  3 min. 
The  extract  is transferred to  glass  vial  (7.4)  and  centrifuged 
for for  5 min  at 4500  rpm. 
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9.3 
9.3.1 
9.3.2 
9.3.3 
9.3.4 
10.0 
10.1 
10.2 
The  supernatant  is transferred to a  1 mL  disposable  syringe  and 
filtered through  a  Cameo  3N  0.45  ~m syringe filter  (7.13)  into a 
HPLC  vial  (7.5). 
HPLC 
Using  the  conditions  set out  in  7.25  20  ~L are  injected onto  the 
column  using  the  automated  injector. 
Standards  corresponding  to 4 ng  per  mL  (equiv.  2  ~g per  kg  tissue 
cone.)  or  20  ng  per  mL  (equiv.  10  ~g per  kg  tissue cone.)  are 
injected  in  triplicate to  determine  the  average  peak  height  for 
both  Ciprofloxacin  and  Enrofloxacin. 
The  peaks  corresponding  to Ciprofloxacin  and  Enrofloxacin  and 
should  be  devoid  of  interfering peaks  from  the matrix. 
The  linearity of  the  detector  response  to  Ciprofloxacin  and 
Enrofloxacin  can  be  checked  by  running  a full  calibration curve. 
CALCULATION  OF  RESULTS 
The  concentration of  Ciprofloxacin  or  Enrofloxacin  in  a  sample  is 
determined  by  interpolation from  the  spiked  samples  using  the 
area  of  the  peak  corresponding  to Ciprofloxacin  or  Enrofloxacin. 
If  in  doubt,  suspect  positive samples  may  be  overspiked with 
standard Ciprofloxacin  or  Enrofloxacin  solution.  A resultant 
single peak  indicates  a positive  (in  screening)  sample. 
Screening  procedure.  A minimum  of  three  injections of  20  ~L of 
standard  Ciprofloxacin  or  Enrofloxacin  solution are carried out 
to determine  the  average  peak  height  (see  9.3.2}. 
Uncorrected  cone.  of  sample  in  ~g per  kg  is given  by 
peak  height  for  sample  X  2.0  X  standard  cone.  (as  ~g per 
peak  height  of  standard  kg  tissue cone.) 
10.3  [Editors  note.  Positive  samples  will  be  rare and  therefore a 
vigorous  procedure  to  confirm  the  positive finding  is 
recommended].  Quantitation of  positive samples  is carried out  by 
performing  a repeat  duplicate analysis  and  interpolation from  a 
full  standard  curve  constructed over  the  suspect  range.  The 
curve  should  have  at  least 5 points  (each  point  done  in 
triplicate)  and  cover  the  range  from  0 to  10%  greater than  the 
estimated  concentration  in  the  sample.  Two  blank  samples 
fortified with  Ciprofloxacin  or  Enrofloxacin  to  the  same  level  as 
the  suspected  positive should  also  be  analysed  in  the  same  batch. 
10.4  Validation  of  method  prior to  use.  Before  adopting  this method 
for  use  it it should  be  validated for  in-house  repeatability and 
reproducibility.  Batches  of  up  to 8 samples  are  spiked  at the 
0.002  and  0.01  mg  per  kg  level  using  1 mL  of  spiking  solutions 
6.2.7  (batches  should  include  one  blank  sample  and  one  blank 
sample  for  tissue working  standard).  Batches  should  be  analysed 
on  each  of  three  separate  days  at each  level.  Recovery  of 
analyte  should  fall  within  the  range  45-110%.  CV  values  should 
be  less  than  15%  for  inter and  intra batch  precision. 
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CPX  is Ciprofloxacin;  EFX  is Enrofloxacin 
Bovine  muscle  for  intra-assay, 
Bovine  muscle  fortified at 0.001  mg  per  kg;  80.9%  ±  12.4%  (CPX),  82.4  ± 
7.5%  (EFX);  at 0.01  mg  per  kg;  73.1%  ±  2.1%  (CPX),  88.0  ±  4.0%  (EFX),  and 
at 0.05  mg  per  kg  77.7  ±  2.5%  (CPX),  90.2  ±  6.6%  (EFX). 
For  inter-assay with  3 assays  on  separate days, 
Bovine  muscle  fortified at 0.01  mg  per  kg;  74.9%  ±  6.9%  (CPX),  90.4  ± 
5.6%  (EFX) 
Pig  muscle  for  intra-assay, 
Pig  muscle  fortified at 0.002  mg  per  kg;  52.8%  ±  1.3%  (CPX),  67.3  ±  4.9% 
(EFX);  at 0.01  mg  per  kg;  51.3%  ±  3.5%  (CPX),  75.6  ±  5.5%  (EFX) 
For  inter-assay with  3 assays  on  separate  days, 
Pig  muscle  fortified at 0.01  mg  per  kg;  53.9%  ±  4.4%  (CPX),  74.8  ± 
4.4%  (EFX) 
Pig  bacon  for  intra-assay, 
Pig  bacon  fortified at 0.002  mg  per  kg;  65.0%  ±  3.9%  (CPX),  85.0  ±  4.1% 
(EFX);  at 0.01  mg  per  kg;  63.2%  ±  1.6%  (CPX),  79.0  ±  1.1%  (EFX} 
For  inter-assay with  3 assays  on  separate  days, 
Pig  bacon  fortified at 0.01  mg  per  kg;  63.2%  ±  44.7  (CPX),  81.2  ± 
5.9%  (EFX) 
11.  SPECIAL  CASES 
12.  NOTES  ON  PROCEDURE 
12.1.  The  action  level  at which  reanalysis of  a  suspected  positive must  be 
decided.  Also  similar decisions  need  to  taken  when  to  proceed  to  a 
confirming  method. 
13.  QUALITY  CONTROLS 
Batches  must  include  at  least two  blank  samples,  one  sample  for  use  as 
tissue standard,  the  other as  the  corresponding  blank  tissue.  These  will 
act as  the  quality control  reference  samples  for  that batch  and  determine 
whether  the  data  obtained  is acceptable.  They  will  also  be  used  to 
estimate  the  overall  recovery  of  analyte  in  any  positive sample  found  in 
the  batch. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS 
A full  list of  abbreviations  is given  in  Annex  I,  Section  12 
16.  FLOW  DIAGRAM 
Tissue  --> Extract  into  1%  acetic acid  in  ethanol  ----> Ion  exchange 
chromatography 
I 
I 
l 
Calculate  results <---------------- HPLC 
Sg  3.5/6 Sg  3.6.  GENTAMICIN  AND  NEOMYCIN  - ROUTINE  SCREENING  METHOD  FOR  THE 
DETERMINATION  BY  HPLC  IN  MUSCLE  OF  CATTLE,  SHEEP  AND  PIGS  AND  IN  MUSCLE, 
LIVER,  KIDNEY  AND  FAT  OF  VEAL  CALVES. 
WARNING  AND  SAFETY  PRECAUTIONS 
SAFETY  Organic  solvents  - all  organic  solvents  must  be  treated as 
potentially hazardous  and  all  procedures  using  them  must  be 
performed  in  a  fume  cupboard. 
FIRST  AID 
1.  Solvents,  acids  and  alkalis  in  contact with  skin  - wash  with 
copious  amounts  of  cold  water.  Splashes  in  the  eye  - irrigate 
with  water  and  seek  medical  attention  immediately. 
2.  Cuts  - seek  assistance of  first aider  immediately. 
3.  Burns  and  frostbite - run  affected part under  cold water  (burns) 
or  tepid water  (frostbite) for  10  minutes  and  seek  medical 
attention. 
1.  INTRODUCTION 
Purpose 
The  detection  of  the  presence  of  Gentamicin  and  Neomycin  in  samples  taken 
from  cattle,  sheep  and  pigs  in  compliance  with  the  Residues  Directive 
86/469/EEC. 
Background 
Gentamicin  and  Neomycin  are animal  drugs  with  broad  spectrum  antibacterial 
activity.  Gentamicin  is composed  of  three major  components,  C 1 ,  C 2  and  C 1a 
which  have  similar antibacterial  properties. 
1.  SCOPE 
This  method  of  analysis  in  use  at the  Analytical  Chemistry  Laboratory, 
Faculty of  Pharmacy,  B.P.403,  54001  Nancy,  Cedex-France,  describes  the 
determination  of  the  total  content  of  Gentamicin  (all  three components)  and 
Neomycin  in  edible tissues. 
2.  FIELD  OF  APPLICATION. 
The  method  is described  to  be  used  for  samples  from  pigs,  sheep  and  cattle. 
It may  be  suitable for other species  but  would  require validation.  The 
limit of  quantitation for gentamicin  is  50  ng  per  g for  muscle  and  fat  and 
100  ng  per  g for  liver and  kidney.  The  limit of  quantitation for  neomycin 
is  50  ng  per  g for  muscle. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
ISO  Standard  78/2-1982  Layout  for  standards  - Part 2:  Standard  for Chemical 
Analysis 
Sar,  F.,  Nicolas,  A.  and  Archimbault,  P.,  (1993),  Development  and 
Optimization  of  a  liquid chromatographic  method  for  the  determination  of 
gentamicin  in  calf tissues.  Anal.  Chim.  Acta.  275,  285-293. 
Sg  3.6/1 4.  DEFINITIONS. 
Gentamicin  or  Neomycin  content  is taken  to  mean  the  amount  of  Gentamicin  or 
Neomycin  in  tissue determined  according  to  the  described  method  and 
expressed  as  ~g Gentamicin  or  Neomycin  per  kg  test sample. 
5.0  PRINCIPLE 
The  method  consists of  5 stages;-
Homogenisation 
Precipitation of  protein with  5%  trichloroacetic acid 
Clean  up  on  Ion  exchange  column  using  CM-Sephadex. 
HPLC  with  post-column  derivatisation. 
Interpolation of  results 
6.  MATERIALS 
Note:  The  reagents  (and  equipment)  for which  examples  of  their source  are 
quoted  are  known  to be  satisfactory,  nevertheless  reagents  and  equipment 
from  other sources  may  be  equally suitable.  All  the  reagents  must  be  of 
analytical  grade  or  better. 
6.1. 
6.1.1. 
6.1.2. 
6.1.3. 
6.1.4. 
6.1.5. 
6.1.6. 
6.1.7. 
6.1.8 
6.1.9. 
6.1.10 
6.1.11 
6.1.12 
6.1.13 
6.1.14 
6.1.15 
6.1.16 
6.1.17 
6.1.18 
6.1.19 
6.1.20 
Chemicals 
Disodium  EDTA  dihydrate  (Merck) 
Acetonitrile 
Sodium-dl-camphor-10-sulphonate  (Aldrich) 
o-phthalaldehyde  (Fluka) 
Boric  acid  (Merck) 
Sodium  hydroxide 
Ethanol 
Gentamicin  sulphate,  potency  equiv.  620  ~g per  mg,  (Virbac  SA, 
Carros,  France) 
Neomycin  (Bayer) 
Double  distilled water  further  processed  for  HPLC  by  degassing 
with  ultrasonication for  5 min  before  use  and  discarded  if not 
used  within  24  h. 
2-mercaptoethanol  (Aldrich) 
Brij-35  (Sigma) 
Trichloroacetic acid  [TCA] 
CM-Sephadex  C-25  (Pharmacia) 
Sodium  azide 
Sodium  sulphate 
Hydrophillic  cotton  (Pharmacopoeia  grade) 
1M  hydrochloric  acid 
Dipotassium  hydrogen  phosphate 
Methanol 
6.2.  Standards 
Store  all  solutions of  standards  in  the  refrigerator. 
6.2.1  Stock  standards. 
6.2.1.1  Dissolve  162.1  mg  Gentamicin  in  100  ml  water.  Store  in  a 
polypropylene  container.  Prepare  monthly. 
6.2.1.2  Dissolve  ca.320  mg  Neomycin  in  100  ml  water.  Prepare  monthly. 
6.2.3  Working  standards  and  spiking  solutions for muscle,  liver and 
kidney;  Prepare  concentrations  of  free  base  of  0.5,  1.0,  1.5, 
2.0,  4.0,  8.0,  16.0  and  32.0  ~g per  mL  by  dilution with  1mM  EDTA. 
Sg  3.6/2 6.2.4  Spiking  solution for fat.  Prepare  in  acetonitrile  1 mM  EDTA 
(6.3.20)  at the  same  concentrations  as  in  6.2.3. 
6.3 
6.3.1 
6.3.2 
6.3.3 
6.3.4 
6.3.5 
6.3.6 
6.3.7 
6.3.8 
6.3.9 
6.3.10 
7. 
7.1 
7.2 
7.3 
7.4 
7.5 
7.6 
7.7 
7.8 
7.9 
7.10 
7.11 
7.12 
7.13 
7.14 
7.15 
7.16 
7.18 
7.19 
7.20 
7.21 
Solutions 
1mM  EDTA.  Dissolve  372  mg  disodium  EDTA  (6.1.1)  in  700  ml  water 
and  make  up  to  1 L with  water. 
1mM  EDTA-Acetonitrile  {1:1,  v/v).  Mix  equal  volumes  of  1mM  EDTA 
and  acetonitrile {6.1.2). 
5%  trichloroacetic acid.  Dissolve  50  g TCA  (6.1.13)  in  600  ml 
water  and  make  up  to  1 L with  water. 
EDTA/TCA.  Dissolve  372  mg  disodium  EDTA  in  1 L 5%  TCA  (6.3.3). 
EDTA/0.2M Sodium  sulphate/sodium  azide.  Dissolve  28.4  g sodium 
sulphate  (6.1.16)  and  200  mg  sodium  azide  in  1 L EDTA  solution 
(6.3.1) 
0.1M buffer,  pH  7.0.  Dissolve  14.2  g sodium  sulphate  and  17.4  g 
dipotassium  hydrogen  phosphate  in  ca.  700  ml  water.  Adjust  the  pH 
to 7.0  if necessary  and  make  up  to  1 L with  water. 
0.5M  camphor  sulphonate.  Dissolve  12.7  g camphor  sulphonate 
(6.1.3)  in  water  and  make  up  to  100  ml  with  water. 
Mobile  phase  for  HPLC;  Dissolve  12.7  g camphor  sulphonate 
(6.1.3)  in  100  ml  1mM  EDTA  ((6.3.1)  and  add  ca.  500  ml  degassed 
water.  Adjust  the  pH  to 2.2 with  hydrochloric  acid  and  make  up 
to  1 L with  degassed  water.  Mix  with  methanol  in  the ratio 55:45 
(v/v).  Filter through  a 0.2  ~m filter before  use. 
OPA  solution.  Place  5.3  g boric  acid  (6.1.5)  and  7.5  ml  30% 
sodium  hydroxide  in  a  250  ml  volumetric  flask.  Add  ca.  200  ml 
water  (6.1.10).  Dissolve  0.2  g of  o-phthalaldehyde  in  10  ml  of 
95%  ethanol  and  add  to flask.  Add  0.5  ml  mercaptoethanol  and  1 
ml  30%  Brij-35  solution  (6.1.12).  Adjust  the  volume  to  250  ml 
with  the  degassed  water.  Use  within  24  h. 
HPLC  flushing  solution.  Mix  300  ml  methanol  with  200  ml  degassed 
water  (6.1.10). 
EQUIPMENT 
Refrigerated  centrifuge,  Jouan  CR422 
Teflon  centrifuge tubes,  40  ml  capacity 
Ultrasonic  bath,  L&R  140S 
Glass  vials and  caps,  2 ml  capacity 
HPLC  vials  and  caps,  0.3  mL  capacity 
All  glass filter holder  47  mm.  (Millipore  UK  Ltd) 
Virtis blender  (Virtis Model  45) 
Virtis glass tubes,  50  ml  capacity 
Analytical  balance. 
Balance  accurate  to 0.1  g 
Vortex  mixer(s) 
Magnetic  stirrer 
Mincer 
Volumetric  flasks,  50  ml,  250  ml,  100  ml  and  1 L capacity. 
Refrigerator  +4°C 
Safety pipettes,  0.2  mL,  0.5 ml,  1.0  mL.  (e.g.  Gilson  Pipetman) 
pH  meter 
Pasteur  pipettes 
Rubber  bulbs  for  Pasteur  pipettes 
0.2  ~m nylon  filter 
Sg  3.6/3 7.22  HPLC 
Pump  :  Spectroflow  400  fitted with  membrane  pulse  damper  (Applied 
Biosystems,  Foster City,  USA) 
Injector:  Autosampler  (Model  507  Beckmann)  with  100  ~L column 
loop. 
Detector:  Shimadzu  Model  RF-551  fluorescence  detector equipped 
with  a150-W  xenon  short  arc  lamp,  excitation  340  nm,  emission  440 
nm.  Set  sensitivity to 
11high
11  and  gain  to  1  (these values  may  be 
adjusted  according  to  the  concentration  range  tested for 
linearity). 
Column:  125  mm  x 4  mm  i.d.  LiChrospher  100  RP-18  (5  ~m) end-
capped  column  maintained  at a  constant  45°C  in  an  oven.  The 
column  is regenerated  on  a weekly  basis  by  initial  flushing with 
methanol-water  (6.3.10)  and  then  running  a  gradient  up  to  100% 
methanol  in  15  min  and  flushing with  100%  methanol  for  15  min  at 
1.2  mL  per  min.  Replace  the  column  after 300  injections. 
Post  column  derivatisation was  done  using  a  second  similar  pump 
and  a  low-dead-volume  tee  (Model  5-8283;  Supelco,  St.  Germain-en-
Laye,  France)  for  the  addition  of  the  OPA  solution  (6.3.9). 
Derivatisation  took  place  in  a Teflon  knitted open  tubular  (KNOT) 
reactor  (3m x 0.5  mm  i.d.)  (Model  5-9206,  Supelco)  maintained 
at 45°C.  The  OPA  is  pumped  at 0.5  mL  per  min. 
Mobile  phase  is  pumped  at 1.2  mL  per  min. 
Guard  column,  4  mm  x 4  mm  i.d.  (replace every  100  injections) 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is  drawn  to  section  6.3.1  and  to  ISO  document  78/2-1982  and 
also  the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to  enable  the 
detection  of  residues  in  meat  as  defined  in  Directive 64/433/EEC. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to 
allow  the  method  to  be  carried out  and  to  allow  repeat  analysis 
where  required. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to allow 
proper  identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain 
the  integrity of  the  sample  and  not  prejudice  the result of  the 
examination. 
Samples  for  the  analysis of  Gentamicin  and  Neomy0in  must  be 
stored  and  transported at temperatures  below  -18  C. 
9.0.  PROCEDURE 
9.1.  Sample  preparation 
Samples  may  be  processed  in  batches.  A control  sample  should  be  spiked  at 
the  limit of  determination. 
9.1.1  Allow  the  sample  to  thaw  and  then  mince  the  tissue. 
9.1.2.1  Weigh  5  ±  0.1  g minced  test sample  into  a  50  mL  Virtis tube. 
9.1.2.2  Weigh  5 ±  0.1  g minced  blank  sample  into eight 50  mL  Virtis tube. 
9.1.3  Add  500  ~L of  spiking  solutions  (6.2.3 or  6.2.4  (fat))  to the 
blank  samples  (9.1.2.2).  Allow  the  mixture  to equilibrate for  30 
min. 
9.1.4  Add  20  mL  TCA/EDTA  solution  (6.3.4)  and  homogenise  for  10  min  in 
a  Virtis blender with  U-shaped  blades. 
Sg  3.6/4 9.1.5  Transfer  the  homogenate  to  a teflon centrifuge tube  (7.2)  and 
centrifuge at 8000  rpm  (7000  g)  for  15  min  at 5°C. 
9.1.6  The  supernatant  is poured  carefully into  a  50  mL  volumetric 
flask. 
9.1.7  Adjust  the  pH  to  7.0  ±  0.1  with  30%  sodium  hydroxide  and  make  up 
the  volume  to  50  mL  with  pH  7.0  buffer  (6.3.6). 
9.2  Column  Clean  up; 
9.2.1  Preparation  of  columns. 
Allow  5 g CM-Sephadex  C-25  (6.1.14)  to  swell  overnight  in  the 
sodium  sulphate/EDTA/azide  solution  (6.3.5).  Plug  a Pasteur 
pipette with  cotton  (6.1.17)  and  fill the  pipette with  1 mL  of 
the  swollen  gel.  Wash  the  gel  with  2 x 1 mL  of  sodium 
sulphate/EDTA/azide  solution  (6.3.5). 
9.2.2  Pipette  10  mL  of  extract 9.1.7  in  1 mL  fractions  onto  the  column. 
Wash  with  2 x 1 mL  of  sodium  sulphate/EDTA/azide  solution 
(6.3.5),  1 mL  water  (6.1.10)  and  250  ~L O.OSM  sodium  hydroxide. 
9.2.3  Elute  the  gentamicin  and  neomycin  with  1 mL  O.OSM  sodium 
hydroxide  applying  pressure  until  the  bed  runs  dry. 
9.2.4  Add  100  ~L  1M  HCl  and  100  ~L camphor  sulphonate  solution  (6.3.7). 
9.3  Standards  containing  no  biological  material  are  processed  in  the 
same  way  but  omitting  the  blending  and  centrifugation  steps. 
9.4  HPLC 
9.4.1  Using  the  conditions  set out  in  7.22  100  ~L are  injected onto  the 
column  using  the  automated  injector. 
9.4.2  The  peaks  corresponding  to Gentamicin  and  Neomycin  and  should  be 
devoid  of  interfering peaks  from  the matrix. 
9.4.3  The  linearity of  the  detector  response  to Gentamicin  and  Neomycin 
is checked  by  running  the full  calibration curve. 
9.4.4  The  retention time  for  the  combined  peak  of  three  components  of 
gentamicin  was  4.0  - 4.1  min  and  that for  the  peak  for  neomycin 
was  5.3  - 5.4 min. 
10.0  CALCULATION  OF  RESULTS 
10.1  The  concentration  of  Gentamicin  or  Neomycin  in  a  sample  is 
determined  by  interpolation from  the  spiked  samples  using  the 
area  of  the  peak  corresponding  to Gentamicin  or  Neomycin.  If  in 
doubt,  suspect  positive samples  may  be  overspiked with  standard 
Gentamicin  or  Neomycin  solution.  A resultant single peak 
indicates a positive  (in  screening)  sample. 
10.2  [Editors  note.  Positive  samples  will  be  rare and  therefore  a 
vigorous  procedure  to  confirm  the  positive finding  is 
recommended].  Quantitation of  positive samples  is carried out  by 
performing  a repeat  duplicate  analysis  and  interpolation from  a 
full  standard  curve  constructed  over  the  suspect  range.  The 
curve  should  have  at  least 5 points  (each  point  done  in 
triplicate)  and  cover  the  range  from  0 to  10%  greater than  the 
estimated  concentration  in  the  sample.  Two  blank  samples 
fortified wi·th  Gentamicin  or  Neomycin  to  the  same  level  as  the 
suspected  positive should  also  be  analyzed  in  the  same  batch. 
10.3  Validation  of  method  prior to  use.  Before  adopting  this method 
for  use  it should  be  validated for  in-house  repeatability and 
reproducibility.  Batches  of  spiked  samples  should  be  analyzed 
Sg  3.6/5 on  each  of  three separate days  at each  level.  Recovery  of 
analyte  should  fall  within  the  range  45-110%.  CV  values  should 
be  less  than  15%  for  inter and  intra batch  precision. 
Typical  results reported  by  the  Analytical  Lab.  Nancy  for  CALF  tissues 
fortified with  gentamicin  were; 
Tissue  Corr.  Coef  Recovery  Recovery  SO  at 0.1  so  at 0.8 
(r)  of  at 0.1  at 0.8  J.Lg/g  J.Lg/g 
curve  n=7  J.Lg/g  (%)  J.LQ/g  (%)  (%)  (%) 
Standard  0.9999  100  100  3.2  2.2 
Liver  0.9986  98  70  11.8  5.6 
Kidney  0.9974  68  83  12.7  8.2 
Fat  0.9991  79  77  6.1  4.3 
Muscle  0.9989  88  74  9.9  8.2 
10.4  The  HPLC  parameters  for  the  gentamicin  and  neomycin  peaks  were 
calculated for  standards  at aconcentration  of  0.5  J.L9  per  mL. 
Retention  time  (min) 
Capacity factor  (k') 
~ theoretical  plates/m 
Tailing factor 
Selectivity factor  (a) 
Resolution  (R 8 ) 
11.  SPECIAL  CASES 
12.  NOTES  ON  PROCEDURE 
Gentamicin 
4.0  - 4.1 
2.2 
16225 
1.2 
1.5 
2.1 
Neomycin 
5.3  - 5.4 
3.3 
9784 
1.4 
1.5 
2.1 
12.1.  The  action  level  at which  reanalysis of  a  suspected  positive must  be 
decided.  Also  similar decisions  need  to  taken  when  to proceed  to a 
confirming  method. 
13.  QUALITY  CONTROLS 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS 
A full  list of  abbreviations  is given  in  Annex  I,  Section  12 
16.  FLOW  DIAGRAM 
Tissue  --> Extract  into  trichloroacetic acid  ----> Ion  exchange 
chromatography 
I 
I 
! 
Calculate results <---------------- HPLC 
Sg  3.6/6 Sg.  4.1.  TRANQUILLIZERS  - AN  HPLC  METHOD  WITH  ON-·LINE  UV  SPECTRUM 
IDENTIFICATION  BY  DIODE-ARRAY  FOR  RESIDUES  IN  PIG  KIDNEYS. 
WARNING  AND  SAFETY  PRECAUTIONS 
SAFETY 
Organic  solvents  - all  organic  solvents  must  be  treated as  potentially 
hazardous  and  all  procedures  using  them  must  be  performed  in  a fume 
cupboard. 
Dilute  the  concentrated  sulphuric with  care. 
0.  INTRODUCTION 
Tranquillizers  and  the  B-blocker  carazolol  are  used  to  aid  the  management 
of  stress  in  many  veterinary practices.  Of  particular interest for 
residues  is the  treatment  of  pigs  to  prevent  mortality and  loss  of  meat 
quality during  transport to  the  slaughterhouse.  The  time  between  drug 
administration  and  slaughter  is usually not  more  than  a few  hours  and  this 
can  result  in  high  residues  in  the  edible tissues. 
1.  SCOPE 
The  use  of  many  of  the  tranquillizers and  carazolol  varies  throughout  the 
EEC.  To  ensure  that farmers  are  not  using  these  drugs  in  non-approved 
situations and  to  control  the  use  in  meat  producing  animals  samples  of 
kidneys  are  taken  at slaughterhouses  and  screened  for  the  presence  of  these 
compounds.  Whenever  there  is a positive screening  result,  this must  be 
confirmed  (see methods  Cy  4.5  and  Cy  4.6.  This  work  is carried out  in 
compliance  with  the Residues  Directive  (86/469/EEC)  and  is operated  at 
RIKILT-DLO  in  The  Netherlands. 
2.  FIELD  OF  APPLICATION. 
This  method  is used  for  quantification  and  confirmation  of  the  presence  of 
six tranquillizers and  carazolol  in  pig  kidney.  The  limits of 
identification are  50  ug  per  kg  kidney  for  the  tranquillizers.  Azaperone 
forms  a major  metabolite,  azaperol,  and  the  two  compounds  appear  together 
as  residues. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
2052/VI/84  File 6.11  II-4,  Scientific Veterinary Committee,  Working 
Group-
11Reference  Methods  for  Residues .. ,  General  Criteria for  the 
establishment  of  Reference  Methods  for  the  Detection  of  Residues. 
ISO  Standard  78/2-1982  Layout  for  standards  - Part  2:  Standard  for  Chemical 
Analysis 
ISO  Standard  5725  (1986) 
Arneth,  W.  (1990),  Multiresidue  method  for  the  residue-analysis of  some 
rtanquillizers and  carazolol  in  animal  tissue and  urine.  Proc. 
Euroresidues  I,  Noorijkerhout,  NL.  May  1990,  pp  101-104 
Sg  4.1/1 Hoogland,  H.,  Beek,  W.M.J.,  Keukens,  H.J.  and  Aerts,  M.M.L.  (1991), 
Confirmation  of  tranquillizers  in  porcine  kidney  by  GC-MS.  Archiv.  fUr 
Lebensm.  42,  79-83 
Keukens,  H.J.  and  Aerts,  M.M.L.,  (1989),  Determination  of  residues  of 
carazolol  and  a  number  of  tranquillizers  in  swine  kidney  by  high-
performance  liquid chromatography  with  ultraviolet and  fluorescence 
detection.  J.Chromatog.  464,  149-161 
Van  Ginkel,  L.A .. Schwillens,  P.L.W.J.  and  Olling,  M.,  (1989),  Liquid 
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4.  DEFINITIONS. 
Tranquillizers or  carazolol  content  is taken  to  mean  the  amount  of 
tranquillizers or  carazolol  in  kidney  determined  according  to  the  described 
method  and  expressed  as  ug  tranquillizers or  carazolol  per  kg  test sample. 
5.  PRINCIPLE. 
The  method  comprises  four  stages 
- Samples  of  kidney  are  extracted with  acetonitrile 
- clean-up  with  Sep-Pak  C18  cartridges 
- analysis  and  fractionation of  eluate with  HPLC  using  a  UV  or 
fluorescence  detector 
- identification of  tranquillizers  by  diode-array of  selected  HPLC 
fractions. 
6.  MATERIALS 
6.1.  Chemicals 
Note:  The  chemicals  were  all  of  analytical  grade  and  obtained  from  Merck 
unless  stated otherwise.  Reagents  of  similar quality may  be  used  from 
other  sources. 
6.1.1  Acetone  (Merck-14) 
6.1.2  Methanol  (Merck-6009) 
6.1.3  25%  ammonia  solution  (Merck-5432) 
6.1.4  n-Hexane  (Merck-714) 
6.1.5  Acetonitrile,  HPLC  grade  (Merck-3) 
6.1.6  Sodium  chloride  (Merck-6404) 
6.1.7  Acetic  acid  (Merck-63) 
6.1.8  Anhydrous  sodium  acetate  (Merck-6268) 
6.1.9  Cone.  sulphuric  acid  (Merck-714) 
6.2  Solutions 
6.2.1  Sodium  chloride  solution;  Dissolve  100  g sodium  chloride  in 
water  and  make  up  to  1 L. 
6.2.2  Sulphuric  acid  solution,  0.01  - 0.05M;  Mix  28  mL  of  sulphuric 
acid  (6.1.9)  in  a  beaker  with  500  ml  water.  Allow  the  solution 
to  reach  room  temperature  and  add  water  with  mixing  to  1 L. 
Transfer  20  to  100  mL  of  this solution  to  250  ml  water  in  a  1 L 
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beaker.  Fill  the  beaker  with  more  water. 
Acidic  Acetonitrile  :  Add  1 ml  of  0.01M sulphuric  acid  solution 
(6.2.2)  to  100  ml  acetonitrile. 
HPLC-eluent;  Weigh  2.46  g sodium  acetate  (6.1.8)  into a 2 L 
beaker  and  add  450  ml  water  and  550  ml  acetonitrile solution 
(6.2.3).  Use  measuring  cylinders  for  these  additions.  Bring  the 
pH  to 6.4 with  acetic acid.  Filter the  solution with  the  aid  of 
a  suction  pump  through  a  0.22~m filter and  place  the  filtrate in 
an  ultrasonic bath  for  10  min.  to degas  the  solution.  This 
solution  is stable for  1 month. 
Standards;  Acepromazine,  Azaperol  and  Haloperidol  (RIVM) 
Chlorpromazine  hydrochloride,  Propionylpromazine  and  xylazine 
(Sigma).  Azaperone;  (Janssen  Pharm- Beerse,  Belgium),  Carazolol 
(AUU  Cugijk) 
Stock  Standards.  Weigh  accurately  10  ±  1 mg  of  an  individual 
standard  (6.3)  into  a  100  ml  graduated  flask.  Make  up  to  100  ml 
with  methanol.  The  solution  is stored  in  the  dark  at 4-8°C  and 
is stable for  up  to  one  year. 
Working  Standards.  Pipette 1 ml  of  stock  standard  for 
acepromazine  and  haloperidol,  chlorpromazine  hydrochloride, 
propionylpromazine  and  azaperone  and  2 ml  of  the  xylazine  and  0.5 
ml  for  the  carazolol  into  a  100  ml  graduated  flask  and  make  up  to 
100  ml  with  sulphuric  acid  solution,  0.01M,  (6.2.2). 
Working  Standard  for  azaperone  and  azaperol;  Pipette 1 ml  of 
stock  standard  for  azaperol  and  azaperone  into a  100  ml  graduated 
flask  and  make  up  to  100  ml  with  sulphuric  acid  solution,  0.01M, 
(6.2.2).  Transfer  20  ml  of  this solution  into another  100  ml 
graduated  flask  and  make  up  to  100  ml  with  sulphuric  acid 
solution,  0.01  - 0.05M,  (6.2.2).  The  concentration  of  each 
standard  is 0.2  mg  per  L. 
Control  Samples;  Certified blank  samples  of  pig  kidneys  should 
be  spiked  with  the  standards  at concentrations  of  20  and  50  ~g 
per  kg.  Do  this  by  pipetting  100  or  250  ~L of  the working 
standard  6.3.2 and/or  6.3.3  into  an  80  ml  centrifuge tube 
containing  5 g homogenised  sample  and  allow  to  stand  for  10  min. 
before  extraction. 
EQUIPMENT 
Analytical  balances 
Normal  laboratory glassware  including  graduated  volumetric 
flasks,  100  ml  capacity 
Centrifuge  (MSE-Coolspin) 
Polypropylene  centrifuge tubes,  capacity 80  ml 
Ultrasonic  bath 
Sep-Pak  C18  cartridges  (Waters  art.  51910) 
Heating  block  with  thermostat  and  evaporation  system  with 
nitrogen  (Pierce Reacti  Therm  Module  ~ 18790  and  Pierce Reacti 
Vap  ~ 18780) 
Vibromixer 
Food  Processor  (Moulinette) 
Syringe,  50  ml  (Terumo) 
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8. 
pH  meter 
HPLC 
Basic  system  with  pump  (Waters  6000  A) 
Automatic  injection system  with  50  ~L  injection  volume  (Waters 
WISP  710  B). 
UV  detector  (Kratos  783  or  diode-array Hewlett  Packard  HP  1040  A) 
Fluorescence  detector  (Hewlett  Packard  HP  1046  A) 
Recorder  (Kipp  BD  41) 
Precolumn;  Bondapak  C18,  37-50  ~m,  10  mm  x 2.1  mm  i.d.  (Waters) 
Analytical  column;  ~ Bondapak  C18,  10  ~m,  300  mm  x 3.9  mm  i.d. 
(Waters) 
Filtering unit for  the  eluent  (Waters  ~ 85124) 
Eluent  filter,  0.22  ~m (Millipore  ~ 83813) 
SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section  6.3.1  and  to  ISO  document  78/2-1982  and 
also  the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
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Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection  of  residues  in  meat  as  defined  in  Directive 64/433/EEC. 
Size  of  Sample;  The  size of  the  sample  must  be  large enough  to 
allow  the  method  to  be  carried out  and  to  allow  repeat  analysis 
where  required. 
The  samples  must  be  taken  and  packed  in  such  a way  as  to allow 
proper  identification  in  the  laboratory. 
The  method  of  packing,  preservation  and  transport must  maintain 
the  integrity of  the  sample  and  not  prejudice  the  result of  the 
examination. 
Samples  for  the  analysis of  tranqui113zers  must  be  stored  and 
transported at temperatures  below  -18  C. 
PROCEDURE 
Homogenise  the  kidney  sample  in  a food  processor  (7.8) 
Weigh  5 g of  the  homogenised  sample  into  an  80  mL  centrifuge tube 
(7.3.1). 
Place  the  samples  and  controls  (6.4)  in  a Vibromixer  (7.7)  and 
spin  at 750  rpm.  Pipette 20  mL  acetonitrile solution  (6.2.3) 
into the  tube  and  increase  the  speed  to  1500  rpm  for  45  sec. 
Transfer  the  tubes  to  an  ultrasonic bath  for  2 min.  Centrifuge 
for  5 min  at 4000  g. 
Clean  up  with  Sep-Pak  cartridges; 
Activate  the  cartridges  (7.5)  with  5 mL  methanol  and  5  mL  water. 
Drain  the cartridges using  a  syringe  (7.9). 
Add  50  mL  10%  sodium  chloride  solution  (6.2.1)  and  7.5  mL 
supernatant  from  the  sample  extract  (9.3)  together,  mix  and  flush 
through  the  column. 
Pass  through  the  column  1 ml  0.01M sulphuric  acid  (6.2.2)  and 
then  2 mL  of  air. 
Prepare  calibrated  10  ml  test tubes  by  washing  with  ammonia 
solution  (6.1.3),  water,  methanol  and  acetone. 
Elute  the  analytes with  2 mL  acidic acetonitrile solution  (6.2.3) 
into the  prepared  test tubes  (9.4.5). 
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Reduce  the  volume  of  the  eluate to  300  ~L by  evaporation  with 
nitrogen  on  a  heating  block  at 70°C.  Do  not  dry. 
Add  1 ml  n-hexane.  Mix  for  30  sec  on  a Vibromixer  at 700  rpm  and 
centrifuge at 2000  g for  5 min. 
Transfer  the  aqueous  phase  with  a Pasteur  pipette to  an  injection 
vial  for  the  HPLC. 
HPLC 
Conditions;  Equipment  as  in  7.11 
Flow  rate;  1.2  ml  per  min 
Injection  volume;  50  ~L 
UV  detector at 240  nm,  0.002  Aufs,  Recorder  10  mV;  10  mm  per  min 
Fluorescence  detector;  Excitation,  246  nm;  Emission  351  nm,  PMT 
gain,  12;  Recorder,  10  mV,  10  mm  per  min. 
Allow  the  system  to equilibrate for  1 hour. 
Inject the  working  standards  (6.3.2 and  6.3.3)  to achieve 
reproducible  peak  heights. 
Inject 50  ~L of  the  samples  (9.4.9). 
Use  of  Diode-array for  suspected  positive peaks. 
Conditions  ; 
Detector  ;  HP1040A 
Wave  length;  240  nm 
Bandwidth  ;  4  nm 
Reference  wave  length  ;  450  nm 
Band  width  for  reference  ;  100  nm 
Threshold  ;  1mAu 
Spectrum  aquisition  ;  top,  slope,  base 
Spectrum  range  ;  225  - 400  nm 
Spectrum  step  ;  2 nm 
Suspect  peaks  observed  during  the  HPLC  separation are  analyzed  by 
diode-array to  establish the  identity of  the  analyte.  The 
spectrum  is compared  with  that of  the  standard. 
INTERPRETATION  OF  RESULTS 
The  identity of  an  analyte  is confirmed  when;-
The  retention time  of  the  suspect  compound  is within  5%  of  that 
of  the  standard. 
The  diode-array  spectra of  the  suspect  peak  and  that of  the 
standard  on  the  top  corrected for  background  must  be  similar 
within  15%. 
The  maximum  absorbance  of  the  suspect  analyte  and  that of  the 
standard must  be  within  2 nm  of each  other. 
QUANTIFICATION 
The  concentration of  the  tranquillizer or  carazolol  can  be 
determined  by  using  the  equation;-
Conc.  in  mg  per  kg  =  Hm  x Cst  x Ve  x 100  x 
Hst  x m x R 
Hm  =  peak  height  of  analyte 
Hst  =  peak  height  of  standard 
Cst  =  cone.  standard  in  working  solution expressed  as  mg  per  L. 
Ve  =  total  volume  of  extract +  water  volume  (23.5  ml) 
m  =  initial weight  of  sample 
f  =  dilution factor for  sample 
R  =  Recovery  correction  calculated from  spiked  samples 
Sg  4.1/5 The  percentage  recoveries  must  be  in  the  following  ranges; 
Carazolol,  84-113;  xylazine,  24-80;  azaperone,  74-124;  haloperidol,  75-115; 
acepromazine,  78-124;  propionylpromazine,  77-113;  chlorpromazine,  58-128. 
11.  SPECIAL  CASES. 
12.  NOTES  ON  PROCEDURE. 
The  analytes  are  unstable  in  light.  Keep  all  samples  in  the  dark  and  work 
only  under  an  amber  light. 
13.  SAMPLE  CONTROLS 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS. 
See  abbreviations  in  Annex  I,  Section  12  of  Manual. 
16.  FLOW  DIAGRAM 
Homogenise  kidney  ----->  extract with  acetonitrile ----->  C18  Sep-Pak 
I 
I 
I 
I 
l 
Identify <---- Diode-array <------ Suspect  peaks  <----------- HPLC 
Sg  4.1/6 Sg  4.2.  CARBADOX  AS  QCA  - ROUTINE  SCREENING  METHOD  FOR  THE  DETERMINATION 
BY  HPLC  OF  QUINOXALINE  CARBOXYLIC  ACID  (QCA)  IN  PIG  KIDNEY  TISSUE. 
WARNING  AND  SAFETY  PRECAUTIONS 
SAFETY 
Organic  solvents  - all  organic  solvents  must  be  treated as 
potentially hazardous  and  all  procedures  using  them  must  be 
performed  in  a fume  cupboard. 
FIRST  AID 
1.  Solvents,  acids  and  alkalis  in  contact with  skin  -wash with 
copious  amounts  of  cold  water.  Splashes  in  the  eye  - irrigate 
with  water  and  seek  medical  attention  immediately. 
2.  Cuts  - seek  assistance of  first aider  immediately. 
3.  Burns  and  frostbite - run  affected  part under  cold  water  (burns) 
or  tepid water  (frostbite) for  10  minutes  and  seek  medical 
attention. 
1.  INTRODUCTION 
Purpose 
The  detection  of  the  presence  of  QCA  in  samples  taken  from  farm  animals  in 
compliance  with  the  Residues  Directive 86/469/EEC. 
Background 
Carbadox  is an  animal  drug  used  to  increase  the  rate of  weight  gain, 
improve  feed  efficiency and  control  swine  dysentery  and  bacterial 
enteritis.  Carbadox  is a  suspected  carcinogen  but  is  itself not  normally 
found  as  a residue  in  edible tissues.  The  major  metabolite  quinoxaline-2-
carboxylic  acid  (QCA)  is found  as  a residue  and  may  also  be  produced  as  an 
artefact during  the  assay  for  QCA.  QCA  is not  a carcinogen. 
1.  SCOPE 
This  method  of  analysis  in  use  at MAFF,  FSD,  Norwich,  UK,  describes  the 
determination  of  the  total  content  of  QCA  in  pig  kidney. 
2.  FIELD  OF  APPLICATION. 
The  method  is described  to  be  used  for  porcine  kidney.  The  limit of 
determination  is not  accurately defined  but  is taken  to be  0.01  mg  QCA  per 
kg  although  this may  vary  between  samples  because  of  variable  background 
noise. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
ISO  Standard  78/2-1982  Layout  for  standards  - Part 2:  Standard  for  Chemical 
Analysis 
Bygrave,  J., Tarbin,  J.A.  and  Rose,  M.D.  (1993),  A method  for  the 
Sg  4.2/1 development  of  quinoxaline  carboxylic  aacid  (metabolite of  carbadox)  in  pig 
kidney  by  HPLC.  MAFF,  Food  Safety Directorate,  Food  Science  Lab,  Norwich, 
UK.  Report.  93/6. 
Farrington,  W.H.H.  The  determination  of  QCA  at residue  levels  in  pig 
kidney.  (1993),  MAFF,  Food  Safety Directorate,  Food  Science  Lab,  Norwich, 
UK.  SOP  (1). 
Standard  operating  procedure  - CVL.  Confirmation  of  a metabolite  of 
Carbadox  in  tissues  by  GC-MS.  (1988) 
Farrington,  W.H.H.,  Bygrave,  J.,  Croucher,  J  and  Shearer,  G.  (1988), 
Analysis  of  UK  and  imported  porcine  kidney  for  quinoxaline  carboxylic acid, 
a metabolic  product  of  the  drug  carbadox.  Food  Science  Lab.  Report,  26th 
April,  1988 
4.  DEFINITIONS. 
QCA  content  is taken  to  mean  the  amount  of  QCA  in  kidney  determined 
according  to  the  described  method  and  expressed  as  ~g QCA  per  kg  test 
sample. 
5.0  PRINCIPLE 
QCA  is extracted with  solvents  from  homogenised  kidney  samples  following 
alkaline hydrolysis.  The  extract  is cleaned  up  using  ion-exchange  resin 
column  chromatography  and  end-point  analysis  performed  with  reversed-phase 
HPLC  and  UV  detection. 
6.  MATERIALS 
Note:  The  reagents  (and  equipment)  for which  examples  of  their source  are 
quoted  are  known  to  be  satisfactory,  nevertheless  reagents  and  equipment 
from  other sources  may  be  equally suitable.  All  the  reagents  must  be  of 
analytical  grade  or  better. 
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Chemicals 
2-Quinoxaline  carboxylic  acid  (QCA)  (Aldrich  Chern.  Co.) 
Cone.  hydrochloric  acid  (BDH  Ltd.) 
1M  hydrochloric  acid  (see  6.3.5) 
Tetrabutylammonium  phosphate  (Sigma) 
Sodium  hydroxide  (BDH  Ltd.) 
Methanol  (Rathburn  Chern.  Ltd) 
Nitrogen 
Ethyl  acetate  (Rathburn  Chern.  Ltd) 
Chloroform  (Rathburn  Chern.  Ltd) 
Deionised  water  further processed  by  Elgastat  UHP  unit  is used 
throughout. 
Potassium  dihydrogen  phosphate  (BDH  Ltd) 
Dowex  50X8-200  cation exchange  resin  (Sigma) 
Disodium  hydrogen  phosphate  (BDH  Ltd) 
6.2.  Standards 
Solid  QCA  may  be  obtained  from  Pfizer or Aldrich  Chemical  Co.(>97%  pure). 
6.2.1  A standard  of  concentration  =  0.1  mg/L  of  QCA  in  methanol  should 
be  prepared  using  available  QCA. 
Sg  4.2/2 6.2.2  Working  standards  of  concentrations  =  0.025  ~g/mL, 0.05  ~g/mL, 
0.1  ~g/mL, 0.2  ~g/mL, 0.5  ~g/mL should  be  prepared  by  dilution 
from  the  stock  using  the  HPLC  mobile  phase  (7.13.). 
6.2.3  Spiking  Solution;  Dilute 0.25  mL  of  stock  standard  (6.2.1)  to  50 
mL  with  water. 
6.3  Solutions 
6.3.1  1M  Sodium  hydroxide.  40  g sodium  hydroxide  (6.1.5)  made  up  to  1 
L with  water. 
6.3.2  O.lM sodium  hydroxide.  100  mL  1M  Sodium  hydroxide  (6.3.1)  made 
up  to  1 L with  water. 
6.3.3  0.01M sodium  hydroxide.  100  mL  O.lM Sodium  hydroxide  (6.3.2) 
made  up  to  1 L with  water. 
6.3.4  0.1M disodium  hydrogen  phophate  buffer,  pH  11.0. 
14.2  g disodium  hydrogen  phophate  (6.1.13)  is dissolved  in  900  mL 
water,  adjusted  to  pH  11.0 with  1M  sodium  hydroxide  and  made  up 
to  1 L with  water. 
6.3.5  1M  hyrdochloric  acid.  Add  86  mL  of  concentrated  HCl  to  900  mL 
water  and  make  up  to  1 L with  water. 
7.  EQUIPMENT 
7.1  Centrifuge  (low  speed) 
7.2  Separating funnels  with  teflon stopcock  100  mL,  250  mL 
7.3  Screw  topped  plastic centrifuge tubes,  50  mL 
7.4  Vortex  mixer(s) 
7.5  Magnetic  stirrer 
7.6  Glass  chromatography  column,  200  mm  x 20  mm  i.d. with  sintered 
glass frit and  stopcock. 
7.7  Water  bath 
7.8  Round  bottomed  flask,  250  mL 
7.9  Heater  block  assembly  for evaporation  using  nitrogen 
7.10  Refridgerator  +4°C 
7.11  Beakers  100  mL  and  1 L capacity. 
7.12  Pear-shaped  flasks  50  mL 
7.13  Bulb  pipettes  10  mL  fixed  and  graduated 
7.14  All  glass filter holder  47  mm.  (Millipore  UK  Ltd) 
7.15  Measuring  cylinders  50  mL  and  100  mL  capacity 
7.16  Glass  syringe with  disposable  needles 
7.17  Volumetric  flasks  50  mL  and  100  mL  capacity 
7.18  Homogeniser  (Ultra-Turrax or  equivalent) 
7.19  Ultrasonic  bath 
7.20  Rotary  evaporator  plus  water  bath 
7.21  Disposable  syringe filters 0.2  ~m (Whatman) 
7.22  Safety pipettes  (e.g.  Gilson  Pipetman) 
7.23  Membrane  filter 0.45  ~m 
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,  47  mm.  (Millipore  UK  Ltd) 
7.24  Preparation  of  Resin  and  Ion-exchange  column; 
Prepare  a slurry of  50  g resin  (6.1.12)  and  200  mL  methanol  in  a 
1 L beaker.  Stir using  a glass  rod  or  magnetic  stirrer (7.5) 
Pour  off the  methanol  and  repeast the wash,  then  wash  the  resin 
twice  with  200  mL  water  and  twice  with  200  mL  1M  HCl. 
Transfer  the  resin to the  chromatography  columns.  Pack  the  resin 
to  a  height  of  50  mm  and  maintain  the  level  of  HCl  just above  the 
resin bed. 
Sg  4.2/3 7.25  HPLC 
Pump  :  LKB  2150 
Injector:  Waters  WISP  7108,  50  ~L injected 
Detector:  Severn  Analytical  6510  UV  monitor,  320nm  at 0.005  AUFS 
Integrator:  Spectraphysics  4290 
Column:  200  mm  x 3 mm  i.d.  cartridge columns  (Chromsep, 
Chrompack)  packed  with  Chromsher  C18  with  integral  guard 
column  packed  with  pellicular  (30-40  ~m) reverse  phase. 
Mobile  Phase:  Dissolve  10.2  g tetrabutylammonium  phosphate 
(6.1.4) 
and  1.4  g potassium  dihydrogen  phosphate  (6.1.11)  in  900  mL 
water.  Adjust  the  pH  to  7.5  with  1.0M sodium  hydroxide  solution 
(6.3.1).  Make  up  to  1 L with  water.  Mix  650  mL  of  this buffer 
with  350  mL  methanol  and  pass  through  a 0.45  ~m filter  (7.23) 
assisted by  pressure. 
The  mobile  phase  is  pumped  at 0.45  mL  per  min. 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section  6.3.1  and  to  ISO  document  78/2-1982  and 
also  the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the Sample;  Samples  shall  be  such  as  to enable  the 
detection  of  residues  in  meat  as  defined  in  Directive 64/433/EEC. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large enough  to 
allow  the  method  to  be  carried out  and  to allow  repeat  analysis 
where  required. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to  allow 
proper  identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain 
the  integrity of  the  sample  and  not  prejudice the  result of  the 
examination. 
Samples  for  the  analysis of  QCA  must  be  stored  and  transported at 
temperatures  below  -18°C. 
9.0.  PROCEDURE 
9.1.  Sample  preparation 
Samples  may  be  processed  in  batches  of  up  to eight.  A control  sample 
and/or  one  of  the  eight samples  should  be  spiked  with  QCA  at the  0.02  mg 
per  kg  level. 
9.1.1. 
9.1~2. 
9.1.3. 
9.1.4 
9.1.5 
5 g thawed  sample  is minced  and  placed  into  a  50  mL  centrifuge 
tube. 
10  mL  of  0.1M sodium  hydroxide  is added  and  homogenised  for  about 
1 min.  Add  4 mL  cone.  HCl. 
After  capping  the  tubes  15  mL  ethyl  acetate  is added  and  the 
mixture  shaken  for  1 min.  before  centrifuging at 3000  rpm  for 
about  5 min  to  clarify the  organic  phase. 
The  ethyl  acetate phase  is transferred with  a  Pasteur  pipette to 
a  second  50  mL  plastic centrifuge tube. 
The  aqueous  phase  is re-extracted with  2 additional  15  mL  of 
ethyl  acetate as  in  9.1.3 and  the  ethyl  acetate phases  combined. 
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9.1.7 
9.1.8 
9.2 
9.2.1 
9.2.2 
9.3 
9.3.1 
9.3.2 
9.3.3 
9.3.4 
10.0 
10.1 
7 ml  water  )s  added  and  the mixture  shaken  for  1 minute. 
Centrifuge for  3 min  at 3000  r.c.f.  The  upper  ethyl  acetate 
layer  is transferred using  a  pasteur  pipette to  a  100  ml 
separating funnel. 
Extract  three  times  with  10  ml  dihydrogen  sodium  phosphate,  pH 
11.0,  buffer  (6.3.4)  by  shaking  vigorously for  approx.  1 min.  , 
running  the  lower  aqueous  phase  off each  time  into a  50  ml 
plastic tube.  Centrifuge for  3 min.  at 3000  r.c.f.  Remove  any 
residual  ethyl  acetate  by  pasteur  pipette,  then  bubble  nitrogen 
through  the  extract for  30  min ..  The  extract may  be  refrigerated 
and  stored overnight  at this stage. 
The  aqueous  phase  is acidified with  6 ml  cone.  HCl. 
Ion  exchange  Chromatography 
The  acidified extract  is transferred to  the  ion-exchange  column 
(7.24)  and  the  column  drained  to  the  top  of  the  bed.  The  resin 
is washed  with  30  ml  1M  HCl  followed  by  40  ml  water  and  the 
eluent discarded.  A 100  ml  beaker  is placed  beneath  the  column 
and  the  column  eluted with  75  ml  O.OlM  sodium  hydroxide  until  the 
eluent reaches  the  top  of  the  column  bed. 
1 ml  cone  HCl  is added  to  the  eluate and  transferred to  a  250  ml 
separating funnel.  The  eluate  is extracted with  3 x 50  ml 
chloroform  into a  250  ml  round  bottomed  flask.  The  chloroform 
extract  is evaporated  to  dryness  using  a rotary evaporator  at 35-
450C.  The  residue  is transferred to  a  50  ml  pear-shaped  flask 
with  3 x 2 ml  methanol.  The  volume  is reduced  to  dryness  under 
rotary evaporation  at 35-45°C  and  taken  up  in  0.5  ml  HPLC  mobile 
phase  (7.13.v).  Use  vortexing  and  ultrasonication  to  take  up  all 
the  residue. 
HPLC 
Using  the  conditions  set out  in  7.25  50  ~L are  injected onto  the 
column  using  the  automated  injector. 
Standard  QCA  corresponding  to 0.02  mg  per  kg  is  injected  in 
duplicate. 
The  peak  at ca.  7.1  min  corresponds  to  QCA  and  should  be  devoid 
of  interfering peaks  from  the  matrix.  A near  full  scale  height 
peak  should  be  found  with  20  ng  QCA  and  in  the  spiked  samples. 
The  linearity of  the  detector response  to  QCA  ca  be  checked  by 
running  50  ~L of  each  of  the  working  standards. 
CALCUALATION  OF  RESULTS 
The  concentration of  QCA  in  a  sample  is determined  by 
interpolation from  the  spiked  samples  using  the  area  of  the  peak 
corresponding  to  QCA.  If  in  doubt,  suspect  positive samples  may 
be  overspiked  with  standard  QCA  solution,.  A resultant single 
peak  indicates  a  positive  (in  screening)  sample. 
10.2  Screening  procedure.  A minimum  of  three  injections of  50  ~L of 
standard  QCA  solution  (0.5  ~g per  ml)  are  carried out  to 
determine  the  average  peak  height. 
[Note;  A 50  ~L  injection contains  25  ng  and  is equivalent  to  50  ~g per  kg 
or  50  ppb  tissue concentration.] 
Uncorrected  cone.  of  sample  in  ~g per  kg  is given  by 
peak  height  for  sample 
peak  height  of  standard 
X  50 
Sg  4.2/5 10.3  [Editors  note.  Positive samples  will  be  rare and  therefore a 
vigorous  procedure  to  confirm  the  positive finding  is 
recommended].  Quantitation of  positive samples  is carried out  by 
performing  a repeat  duplicate analysis  and  interpolation from  a 
full  standard  curve  constructed over  the  suspect  range.  The 
curve  should  have  at  least 5 points  (each  point  done  in 
triplicate)  and  cover  the  range  from  0 to  10%  greater than  the 
estimated  concentration  in  the  sample.  Two  blank  samples 
fortified with  QCA  to the  same  level  as  the  suspected  positive 
should  also  be  analysed  in  the  same  batch. 
10.4  Recovery  and  intra-assay variation.  Recovery  is measured  for 
each  batch  of  analyses  by  calculating the  recovery  from  spiked 
samples.  For  example  this was  measured  four  times  using  6  single 
replicate spikes  in  kidney  samples. 
The  results were;  Fortified at 0.05  mg  per  kg;  79%  ±  5.6%,  74  ±  5.6%,  72% 
±  7.8%  and  at 0.01  mg  per  kg;  100%  ±  9.8%.  (MAFF,  Food  Safety Directorate, 
Norwich,  UK). 
11.  SPECIAL  CASES 
11.1  Where  the  method  is to  be  used  for  analysing  tissues other than 
kidney,  e.g.  the  method  may  be  used  for  liver,  then  the  method 
should  be  fully validated for  this tissue. 
12.  NOTES  ON  PROCEDURE 
12.1.  The  action  level  at which  reanalysis of  a  suspected  positive must 
be  decided.  Also  similar decisions  need  to  taken  when  to  proceed 
to a confirming  method. 
13.  QUALITY  CONTROLS 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS 
A full  list of  abbreviations  is given  in  Annex  I,  Section  12 
16.  FLOW  DIAGRAM 
Tissue  --> add  sodium  hydroxide  and  homogenise  ---> Extract  EtAc 
I 
I 
! 
Ion  exclusion  chrom.  <-------- Extract  to  Na2HP04,  pH  11  buffer 
I 
I 
! 
HPLC  -------> Calculate results 
Sg  4.2/6 Sg  4.3.  CARBADOX  AS  DESOXYCARBADOX  - ROUTINE  SCREENING  METHOD  FOR  THE 
DETERMINATION  BY  HPLC  OF  CARBADOX  AND  DESOXYCARBADOX  IN  PIG  MEAT,  LIVER  AND 
KIDNEY  TISSUE. 
WARNING  AND  SAFETY  PRECAUTIONS 
SAFETY 
Organic  solvents  - all  organic  solvents  must  be  treated as 
potentially hazardous  and  all  procedures  using  them  must  be 
performed  in  a fume  cupboard. 
FIRST  AID 
1.  Solvents,  acids  and  alkalis  in  contact with  skin  - wash  with 
copious  amounts  of  cold  water.  Splashes  in  the  eye  - irrigate 
with  water  and  seek  medical  attention  immediately. 
2.  Cuts  - seek  assistance of  first aider  immediately. 
3.  Burns  and  frostbite - run  affected  part under  cold  water  (burns) 
or  tepid water  (frostbite) for  10  minutes  and  seek  medical 
attention. 
1.  INTRODUCTION 
Purpose 
The  detection of  the  presence  of  Carbadox  and  Desoxycarbadox  in  samples 
taken  from  pigs  in  compliance  with  the  Residues  Directive 86/469/EEC. 
Background 
Carbadox  is an  animal  drug  used  to  increase  the  rate of  weight  gain, 
improve  feed  efficiency and  control  swine  dysentery  and  bacterial 
enteritis.  Carbadox  is a suspected  carcinogen  but  is  itself not  normally 
found  as  a residue  in  edible tissues.  Desoxycarbadox  is a metabolite  of 
carbadox  which  persists for  up  to  15  days  in  treated animals.  The 
toxicology  of  this metabolite  is not  fully evaluated  but  there  is a 
possibility that it may  be  mutagenic/carcinogenic.  The  major  metabolite 
quinoxaline-2-carboxylic  acid  (QCA)  is found  as  a residue  and  may  also  be 
produced  as  an  artefact during  the  assay  for  QCA.  QCA  is not  a carcinogen. 
The  assays  for  QCA  are  detailed  in  Sg  4.2  and  Cy  4.3. 
1.  SCOPE 
This  method  of  analysis  in  use  at RIKILT-OLO,  Wageningen,  NL  describes  the 
determination  of  the  total  content  of  carbadox  and  desoxycarbadox  in  pig 
meat,  liver and  kidney.  The  suspect  positives can  be  identified by 
rerunning  the  HPLC  and  using  Diode-array  detection. 
2.  FIELD  OF  APPLICATION. 
The  method  is described  to  be  used  for  porcine  meat,  liver and  kidney.  The 
limit of  determination  is 1  ~g per  kg  for  carbadox  and  2  ~g per  kg  for 
desoxycarbadox. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
ISO  Standard  78/2-1982  Layout  for  standards  - Part  2:  Standard  for  Chemical 
Analysis 
Sg  4.3/1 Aerts,  M.M.L.,  Beek,  W.M.J.,  Keukens,  H.J.  and  Brinkman,  U.A.Th.,  (1988), 
Determination  of  residues  of  carbadox  and  some  of  its metabolites  in  swine 
tissues  by  high  performance  liquid  chromatography  using  on-line pre-column 
enrichment  and  post-column  derivatization with  UV-Vis  detection.  J. 
Chromatog.  456,  105-119 
Binnendijk,  G.M.,  Aerts,  M.M.L.,  Keukens,  H.J.  and  Brinkman,  U.A.Th., 
(1991),  Determination  of  residues  of  carbadox  and  metabolites  in  products 
of  animal  origin;  Stability studies  in  animal  tissues.  J.  Chromatog.  541, 
401-410 
4.  DEFINITIONS. 
Carbadox  or  desoxycarbadox  content  is taken  to  mean  the  amount  of  carbadox 
or  desoxycarbadox  in  meat,  liver or  kidney  determined  according  to  the 
described  method  and  expressed  as  ~g carbadox  or  desoxycarbadox  per  kg  test 
sample. 
5.0  PRINCIPLE 
Carbadox  and  desoxycarbadox  are  extracted with  solvents  from  homogenised 
tissue samples.  The  extract  is  cleaned  up  using  aluminium  oxide  - Florisil 
column  chromatography  and  end-point  analysis  performed  with  reversed-phase 
HPLC  and  UV/Vis  detection after post-column  derivatization.  The  suspect 
positives can  be  identified  by  rerunning  the  HPLC  and  using  Diode-array 
detection. 
6.  MATERIALS 
Note:  The  reagents  (and  equipment)  for which  examples  of  their source  are 
quoted  are  known  to  be  satisfactory,  nevertheless  reagents  and  equipment 
from  other sources  may  be  equally  suitable.  All  the  reagents  must  be  of 
analytical  grade  or  better. 
6.1. 
6.1.1 
6.1.2 
6.1.3 
6.1.4 
6.1.5 
6.1.6 
6.1.7 
6.1.8 
6.1.9 
6.1.10 
Chemicals 
Acetonitrile  (Merck-3) 
Aluminium  oxide  - Neutral  activity 1  (Woelm-21190) 
Acetic  acid  (Merck-63) 
Florisil  0.150-0.250  mm  (Merck-12518) 
Sodium  hydroxide  (Merck-6498) 
Methanol  (Merck-6009) 
Sodium  acetate  (Merck-6268) 
Iso-octane  (Merck-4727) 
Helium 
Nitrogen 
6.2.  Standards 
Solid  Carbadox  may  be  obtained  from  Pfizer. 
Desoxycarbadox  was  a gift from  Centr.  Diergeneeskundig  Instituut. 
[Note;  Use  brown  glassware  for  the  standard  solutions.] 
6.2.1  Stock  standard  solutions  (100  ~g per  mL).  A concentration  =  0.1 
mg/mL  in  acetonitrile/methanol  (6.3.1)  should  be  prepared 
separately 100  mL  volumetric  flasks  using  available carbadox  and 
desoxycarbadox.  Store  the  solution  in  the  dark  at 6-8°C. 
6.2.2  Diluted  standard  (1  ~g per  mL).  Dilute  1 mL  of  the  stock 
solution 6.2.1  with  water  to  100  mL.  The  solution  stored  in  the 
dark  at 6-8°C  is stable for  1 month. 
Sg  4.3/2 6.2.3 
6.2.4 
6.3 
6.3.1 
6.3.2 
6.3.3 
6.3.4 
6.3.5 
7. 
7.1. 
7.1.1 
7.1.2 
7.1.3 
7.1.4 
7.1.5 
7.1.6 
7.1.7 
7.2. 
7.2.1 
7.2.2 
7.2.3 
7.2.4 
7.2.5 
7.2.6 
7.2.7 
7.2.8 
7.2.9 
7.2.10 
7.2.11 
7.2.12 
7.2.13 
7.2.14 
7.2.15 
7.2.16 
7.2.17 
7.2.18 
7.3 
Working  standards  (0.1  ~g per  ml).  Dilute  2 ml  of  the  stock 
solution 6.2.1  with  water  to  20  mL. 
Standar  curves.  Concentrations  =  1 ng  per  ml,  2.5  ng  per  ml  and 
5 ng  per  ml  should  be  prepared  by  dilution of  6.2.3 using  water. 
Solutions 
Acetonitrile/methanol.  Mix  500  mL  acetonitrile with  500  ml 
water. 
0.5M Sodium  hydroxide.  20  g sodium  hydroxide  (6.1.5)  made  up  to 
1 L with  water.  Degas  the  solution  by  passing  helium  through  it 
for  15  min. 
Sodium  acetate buffer,  0.01M,  pH  =  6.0.  Dissolve  0.82  g sodium 
acetate  in  ca  700  ml  water.  Adjust  the  pH  to 6.0 with  acetic 
acid  and  make  up  to  1 L with  water. 
HPLC  Eluent  1.  Mix  860  ml  of  acetate buffer  (6.3.3)  with  140  ml 
acetonitrile.  Filter the  solution  through  a 0.22  ~m filter and 
degas  the  filtrate with  helium.  Use  for  not  more  than  2 weeks. 
HPLC  eluent 2 for  diode-array detection.  Mix  825  ml  of  acetate 
buffer  (6.3.3)  with  175  ml  acetonitrile.  Filter the  solution 
through  a 0.22  ~m filter and  degas  the  filtrate with  helium.  Use 
for  not  more  than  2 weeks. 
EQUIPMENT 
Glassware 
Graduated  pipettes, 
Glass  centrifuge tubes 
Glass  test tubes  to  take  6 ml  samples. 
Brown  graduated  volumetric  flasks,  100  ml  capacity 
Pear-shaped  flasks  50  ml 
Glass  chromatography  column,  300  mm  x 10  mm  i.d. 
Normal  laboratory glassware 
Apparatus 
Automatic  pipettes, 
Analytical  balance 
Centrifuge  (MSE  2000) 
Refrigerator 
Vibromixer 
Homogeniser,  Model  400  Stomacher  laboratory  blender,  (Lameris, 
NL) 
Blender  (Moulinette) 
pH  meter 
Filter system  for eluents;  0.22  ~m (Millipore 83813) 
Acrodisc  filters 0.45  ~m  (Gelman  4184) 
Deep  freeze. 
Screw  topped  plastic centrifuge tubes,  80  ml 
Vortex  mixer(s) 
Magnetic  stirrer 
Water  bath 
Rotary  evaporator  plus  water  bath  at 40-50°C 
Cotton  wool 
Stomacher  bags,  1 L volume. 
Preparation  of  Aluminium  oxide-Florisil  column; 
Plug  a glass  column  (7.1.6)  with  cotton  wool.  Add  to  the  column 
8 g aluminium  oxide  (6.1.2)  and  afterwards  2 g Florisil  (6.1.4). 
Sg  4.3/3 7.4  HPLC 
Pumps:  (Waters  M-6000) 
Peristaltic pump  (Skalar-2002) 
Injector:  For  1 mL  (Gilson  231/401) 
Detector:  390  nm  at 0.001  AUFS  (ABI  783) 
Recorder:  (Kipp  BD-41) 
Diode  Array  Detector:  (HP-1040A) 
Teflon  reaction  spiral  2m x 0.5  mm  i.d.,  spiral  diam.  1.5  em 
RVS  T-piece  1/16  x 0.75  mm  (Valco) 
Guard  Column  :  Bondapack/Corasil  37-50~m,  10  mm  x 2.1  mm  i.d. 
(Millipore  27248) 
Analytical  Column  :  Chromspher  C-18  5  ~m,  100  mm  x 3.0  mm  i.d. 
Chrompack-028268) 
Concentration  column  :  Sep-Pak  C-18  (Waters-51910)  10  mm  x 2.1 
mm,  screens  20  ~m (Chrompack-28240) 
The  mobile  phase,  eluent  1  (6.3.4)  is  pumped  at 0.5  mL  per  min. 
Water  is  pumped  at 0.3  mL  per  min 
Peristaltic pump  at 0.23  mL  per  min. 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to section 6.3.1  and  to  ISO  document  78/2-1982  and 
also the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection of  residues  in  meat  as  defined  in  Directive 64/433/EEC. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to 
allow  the method  to  be  carried out  and  to  allow  repeat  analysis 
where  required. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to  allow 
proper  identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain 
the  integrity of  the  sample  and  not  prejudice  the  result of  the 
examination. 
Samples  for  the  analysis of  carbadox  and  desoxycarbadox  must  be 
stored  and  transported at temperatures  below  -18°C. 
9.0.  PROCEDURE 
9.1.  Sample  preparation 
Samples  are  processed  in  duplicate.  Also  assay  a control  sample  in 
duplicate  and  two  control  (blank)  samples  should  be  spiked  with  carbadox 
and  desoxycarbadox  at the  10  ~g per  kg  level. 
9.1.1 
9.1.2 
9.1.3 
9.1.4 
9.1.5 
9.1.6 
Control  (blank)  sample  is thawed  and  blended. 
Weigh  10  g of  9.1.1  into  a  Stomacher  bag,  (7.2.18)  and  add  100  ~L 
of  the  diluted carbadox  standard  (6.2.2).  Proceed  to  step 9.1.5. 
Weigh  10  g of  9.1.1  into  a Stomacher  bag,  (7.2.18)  and  add  100  ~L 
of  the  diluted desoxycarbadox  standard  (6.2.2).  Mix  the  contents 
and  allow  to  stand  for  15  min.  Proceed  to  step 9.1.5. 
The  test samples  are  thawed  and  blended  and  10  g are weighed  into 
a  Stomacher  bag. 
Add  40  mL  extraction solution  (6.3.1)  and  extract  in  the 
Stomacher  for 3 min. 
Transfer  the  contents  of  the  bag  into  a 80  mL  plastic centrifuge 
tube  and  centrifuge for  5 min  at 2000  g. 
Sg  4.3/4 9.2 
9.3 
9.4 
9.5 
9.6 
9.6.1 
9.6.2 
9.6.3 
9.6.4 
Column  Chromatography. 
Transfer  the  clear supernatant onto  the  prepared  column  (7.3)  and 
collect the  eluate  into a  50  mL  flask. 
Pipette  10  mL  into a calibrated test tube.  Evaporate  under  a 
stream  of  nitrogen  at 40-50°C  down  to  a  volume  of  0.9-1.1  mL. 
Make  the  volume  up  to 4 mL  with  water.  Extract with  2 mL  iso-
octane  using  shaking  for  30  sec  on  a Vibro-mixer  and  centrifuging 
at 2000  g for  5 min.  Separate  the  aqueous  phase  and  pass  it 
through  an  Acrodisc  filter (7.2.10). 
Inject 1 mL  of  the  aqueous  filtrate  into  the  HPLC  system. 
HPLC 
The  HPLC  is equilibrated by  injecting 1 mL  of  the  5 ng  per  mL 
standard  solution  (6.2.4)  until  both  components  give  reproducible 
peaks  and  a  stable base  line. 
The  linearity of  the  detector response  to carbadox  and 
desoxycarbadox  can  be  checked  by  running  the  standards  6.2.4. 
This  should  be  done  routinely after every  10  test samples. 
Using  the  conditions  set out  in  7.4,  1.0  mL  of  the  blank  sample 
is  injected onto  the  concentration  column  using  the  injector. 
Inject 1 mL  of  the  spiked  blank  samples.  After  flushing  for  20 
min  with  water  the  concentration  column  is switched  to the  HPLC 
system. 
[Note;  The  peaks  for  the  spikes  must  be  symmetrical  (fAs<2)  before 
proceeding  to  step 9.6.5] 
9.6.4  Inject 1 mL  of  the  samples  (9.5). 
9.7 
9.7.1 
9.7.2 
9.7.3 
9.7.4 
10.0 
10.1 
HPLC  of  suspect  positive peaks  using  diode-array detection. 
If the  suspect  peak  is  indicative of  a concentration  of  either 
carbadox  or  desoxycarbadox  >5  ~g per  kg  then  a  spectrum  using 
diode-array  is determined. 
Conditions  for  Detection. 
Eluent  2  (6.3.5)  at 0.6  mL  per  min. 
Measuring  wavelength  :  350  nm,  Bandwidth  4  nm. 
Reference  wavelength  :  450  nm,  bandwidth  100  nm 
Stoptime  15  min  after switching  the  concentration  column  in  the 
HPLC  system. 
Threshold  :  0.5  mAu 
Spectrum  :  top,  slope  and  base 
Spectrum  range  :  225  - 400  nm,  step  2nm 
Repeat  steps 9.3  and  9.4  on  10  mL  of  eluate from  the  column. 
Inject as  much  as  possible aqueous  phase  onto  the  concentration 
column  in  accordance  with  9.6.3. 
Examine  the  diode-array spectrum  at the  suspect  peak. 
CALCULATION  OF  RESULTS 
The  concentration  of  carbadox  and  desoxycarbadox  in  a  sample  is 
determined  by  interpolation from  the  spiked  samples  using  the 
area  of  the  peaks  corresponding  to carbadox  and  desoxycarbadox. 
If  in  doubt,  suspect  positive samples  may  be  overspiked  with 
standard  Desoxycarbadox  solution,.  A resultant single peak 
indicates a  positive  (in  screening)  sample.  Suspects  are 
examined  also  by  diode-array detection. 
[Editors  note.  Positive samples  will  be  rare and  therefore a  vigorous 
procedure  to confirm  the  positive finding  is recommended]. 
Sg  4.3/5 The  concentration  of  carbadox  and  desoxycarbadox  in  a  sample  is 
calculated using  the  formula;-
Can  =  Om  x Cst  x Ve  x Va  x 100 
Ost  a  Vk  R 
Can  =  concentration  of  carbadox  or  desoxycarbadox  in  ~g per  kg 
Om  =  peak  area  for  test sample 
Ost  =  peak  area  for  standard 
Cst  =  cone.  of  standard  in  ~g per  L 
Ve  =  volume  of  extract + water  content  of  sample  in  mL 
(normally  47  mL).  The  water  content  of  the  samples  is 
usually  70  -75%). 
Vm  =  volume  of  analysis  solution  (normally  4  mL) 
Vk  =  Volume  of  aliquot  from  alumina  column  (normally  10  mL) 
a  =  weight  in  g of  tissue 
R  =  recovery  in  % 
Calculate  the  mean  for  the  duplicate  determinations. 
10.2  Recovery  is measured  for  each  batch  of  analyses  by  calculating 
the  recovery  from  spiked  samples.  Data  reported  by  RIKILT-OLO  for 
recovery for  spikes  of  10  ~g per  kg  in  20  samples  are  >90%  for 
carbadox  and  95%  for  desoxycarbadox  with  a  CV  = 10.7%. 
10.3  The  limit of  detection  in  meat,  liver and  kidney  was  0.5  ~g per 
kg  for  carbadox  and  1.0  ~g per  kg  for  desoxycarbadox. 
10.4  The  sample  was  positive when  according  to  the  EEC  criteria in  EEC 
93/256  (see  section  5). 
1.  The  concentration  of  carbadox  or  desoxycarbadox  ~ 5  ~g per  kg 
2.  The  spectrum  of  carbadox  or  desoxycarbadox  was  confirmed  by 
diode-array. 
11.  SPECIAL  CASES 
12.  NOTES  ON  PROCEDURE 
12.1.  The  action  level  at which  reanalysis of  a suspected  positive must 
be  decided.  In  this method  ~ 5  ~g per  kg  is the  action  level 
used  in  The  Netherlands. 
13.  QUALITY  CONTROLS 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS 
A full  list of  abbreviations  is given  in  Annex  I,  Section  12 
16.  FLOW  DIAGRAM 
Tissue  --->  Extract  in  acetonitrile/methanol  ------>  Alumina-Florisil 
column 
I 
I 
l 
Calculate  cone.  <----- UV  det.<------ Post  column  <------ HPLC 
I  derivatization 
l 
If  ~ 5  ~g/kg rerun  HPLC  with  Diode  Array  to  identify analyte. 
Sg  4.3/6 Sg.  4.4  IONOPHORES  - A ROUTINE  METHOD  FOR  THE  DETERMINATION  OF  RESIDUES  OF 
IONOPHORES  IN  CHICKEN  MEAT,  LIVER  AND  KIDNEY,  USING  HPTLC. 
WARNING  AND  SAFETY  PRECAUTIONS 
0.  INTRODUCTION 
Ionophores  are  administered  as  in-feed  additives  to  poultry and  cattle. 
They  are  used  to  prevent  coccidiosis  in  poultry. 
Ionophores  are  weak  antibiotic substances  which  have  growth  enhancing 
properties when  used  in  poultry and  ruminating  cattle. 
1.  SCOPE 
This  method  of  analysis  describes  the  determination  of  the  presence  of 
individual  analytes  for  THREE  ionophores,  monensin,  narasin  and  salinomycin 
in  samples  of  tissues of  chickens.  This  work  is carried out  in  compliance 
with  the  Residues  Directive  (86/469/EEC)  and  the  method  is used  routinely 
in  The  Netherlands  at RIKILT-DLO. 
2.  FIELD  OF  APPLICATION. 
The  method  is used  to  perform  routine  screening  and  confirmatory  analyses 
in  chicken  samples. 
The  limit of  detection  using  UV  detection  is 0.02  mg  per  kg  for meat,  liver 
and  kidney.  The  limit of  detection  using  autobiographical  detection  is 
0.005  mg  per  kg  for all  samples. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
ISO  Standard  78/2-1982  Layout  for  standards  - Part 2:  Standard  for  Chemical 
Analysis 
RIKILT  (1988),  Diervoeders,  kipmatrices- Bepaling  van  monensin,  narasin  and 
salinomycin.  Intern Analyseschrift  A493  2e  oplage  1988-03-07. 
4.  DEFINITIONS. 
Ionophore  substance  content  is taken  to  mean  the  amount  of  ionophore 
substance  in  the  sample  determined  according  to  the  described  method  and 
expressed  as  mg  ionophore  substance  per  kg  of  test sample. 
5.  PRINCIPLE 
The  methods  comprises  7 stages;-
Homogenisation 
Extraction  using  methanol. 
Clean  up  of  ionophore  substance  by  aluminium  oxide  column 
chromatography 
End  point determination  with  TLC  by  derivatisation  and  UV  light 
or  - End  point  determination  with  TLC  and  Autobiography 
Sg  4.4/1 The  detection  of  ionophore  substance  is made  by  comparison  with 
standards  run  on  TLC. 
6.  MATERIALS 
Note:  The  reagents  for which  examples  of  their source  are quoted  are 
known  to  be  satisfactory,  nevertheless  reagents  from  other sources  may  be 
equally suitable. 
6.1. 
6.1.1 
6.1.2 
6.1.3 
6.2 
6.2.1 
6.2.2 
6.2.3 
6.2.4 
6.2.5 
6.2.6 
6.2.7 
6.2.8 
6.2.9 
6.2.10 
6.2.11 
6.2.12 
6.2.13 
6.2.14 
6.3 
6.3.1 
6.3.2 
6.3.3 
6.3.4 
6.3.5 
6.3.6 
6.3.6.1 
6.3.6.2 
6.3.7 
Standards 
Sodium  monensin  (Elanco) 
Sodium  narasin  (Elanco) 
Salinomycin  (Hoechst) 
Chemicals 
Methanol  (Merck  6009) 
Water  (HPLC  grade) 
Ethyl  acetate  (Merck  9623) 
Aluminium  oxide  (Alumina  Woelm  N,  Art.  I) 
Sodium  Chloride  (Merck  6404) 
p-anisaldehyde  (Merck  822134) 
Dextrose  (Difco  0155-17-4) 
Potassium  dihydrogen  phosphate  (Merck  4873) 
Disodium  hydrogen  phosphate.  2H20.  (Merck  6580) 
Sulphuric  acid  (Merck  732) 
Acetic  acid  (Merck  63) 
Triphenyltetrazoliumchloride  (Merck  8380) 
Stand  II  Nutrient  agar  (Merck  7883) 
Micro-organism  Bacillus Subtilis  (BGA  Berlin) 
Solutions 
90%  Methanol;  Mix  900  ml  methanol  with  100  ml  water. 
Ethyl  acetate/1% water;  Add  1 ml  water  to  100  ml  ethyl  acetate 
(6.2.3) 
10%  sodium  chloride;  Dissolve  100  g of  sodium  chloride  in  about 
700  ml  water  and  make  up  the  solution  to 1 L. 
Reaction  mixture  for dipping  HPTLC  plates.  Mix  4 ml  p-
anisaldehyde  (6.2.6)  in  68  ml  methanol  (6.2.1).  Add  carefully 4 
ml  sulphuric acid  (6.2.10)  and  2 ml  acetic acid  (6.2.11). 
Triphenyltetrazoliumchloride.  . 
Mix  0.2  g triphenyltetrazoliumchloride  (6.2.12)  and  5 g dextrose 
(6.2.7)  in  100  ml  water. 
Standards. 
Stock  solutions.  Weigh  accurately about  25  mg  ionophore  (6.1) 
and  transfer with  methanol  to  100  ml  volumetric  flask.  Make  up 
to  100  ml  with  methanol. 
Working  solutions.  Pipette  into three  100  ml  volumetric  flasks, 
1 ml,  5 ml  and  10  ml  of  stock  solution  (6.3.6.1)  respectively. 
Make  up  to  100  ml  with  methanol.  The  concentrations  in  the 
flasks  are;- 2.5;  12.5  and  25  ~g per  ml. 
Solution  for  the Autobiography  detection for 2  HPTLC  plates. 
Into  a round  bottomed  flask weigh  2.5  g nutrient agar  (6.2.13), 
0.5 g sodium  chloride  (6.2.5),  1 g dextrose  (6.2.7),  0.42  g 
potassium  dihydrogen  phosphate  (6.2.8),  0.045  g disodium  hydrogen 
phosphate  (6.2.9).  Add  100  ml  water  and  dissolve the  reagents  in 
Sg  4.4/2 a Magnetron  for  15  sec.  Sterilise the  mixture  for  15  min  at 121 
±  1°C.  Stand  the  mixture  in  a water  bath  at 60°C  and  adjust the 
pH  to  6.0  ±  0.1  if necessary.  Add  1 mL  bacterial  suspension 
(6.2.14)  and  1 mL  diphenyltetrazoliumchloride  solution  (6.3.5). 
7  EQUIPMENT 
7.1  Ultra Turrax  homogeniser  or  a Stomacher 
7.2  Rotary  evaporator 
7.3  Vortex  mixer(s) 
7.4  HPTLC  equipment  for  running  HPTLC  plates. 
7.4.1  HPTLC  silica gel  plates,  (Merck~ 5631).  The  plates must  be 
dried  for  2 h at 110°C  immediately  before  use. 
7.5  UV  lamp  at 366  nm 
7.6  Drying  cabinet 
7.7  Cabinet  at 110°C  for  HPTLC  plates 
7.8  Centrifuge  tubes,  300  mL  capacity 
7.9  Water  bath  at 60°C 
7.10  Centrifuge 
7.11  Erlenmeyer  flasks,  100  mL  capacity 
7.12  Glass  chromatography  columns,  40  em  long  x 10  mm  i.d. with  2 mm 
outlet. 
7.13  Petri  dishes,  ca  14  em  diam. 
7.14  Shaking  apparatus 
7.15  pH  meter 
7.16  Incubator  at 37  ±  1°C 
7.17  Volumetric  flasks,  100  mL 
7.18  Evaporating  system  using  nitrogen  and  heating.  (Pierce) 
7.19  Vacuum  system  for  cartridges 
7.20  Sterilisation apparatus 
7.21  Paper  filters. 
7.22  Cotton  wool 
7.23  Baker  C-18  SPE  cartridges.  Activate  the  columns  by  washing  with 
5 mL  methanol  and  2 x 5 mL  water. 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section 6.3.1  and  to  ISO  document  78/2-1982  and 
also  the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN.  and  EEC 
93/256. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection  of  residues  in  tissues as  defined  in  Directive 
64/433/EEC. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to 
allow  the  method  to  be  carried out  and  to  allow  repeat analysis 
where  required.  Each  analysis  needs  a  10  g sample. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to  allow 
proper  identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain 
the  integrity of  the  sample  and  not  prejudice  the  result of  the 
examination. 
Samples  for  the  analysis  of  ionophores  must  be  stored at 
temperatures  below  -18°C. 
Sg  4.4/3 9  PROCEDURE 
9.1  Cut  the  sample  into  small  pieces  and  weigh  10  g  into  a  100  ml 
Erlenmeyer  flask. 
9.2  Add  50  ml  90%  methanol  solution  (6.3.1). 
9.3  Primary  extraction  - For  meat,  liver and  kidney  homogenise  with 
an  Ultra  Turrax  for  3 min. 
9.4  Centrifuge  at 4000  rpm  for  5 min. 
9.5  Filter the  supernatant  through  a cotton  wool  plug  into  a  100  ml 
Erlenmeyer  flask  . 
9.6  Mix  the  sediment  with  10  ml  90%  methanol  (6.3.1)  using  a 
vibromixer,  centrifuge at 1000  rpm  and  decant  the  supernatant 
through  a  cotton  wool  filter  into  the  Erlenmeyer  flask. 
9.7  Clean-up  with  Chromatography 
9.7.1  Aluminium  oxide  columns.  Use  a  cotton  wool  plug  to act as  filter 
for  the  columns.  Add  7 g aluminium  oxide  (6.2.4)  into  a  column 
(7.12).  Pour  the  extract  (9.5  &  9.6)  onto  the  column.  Use  a  200 
ml  flask  to collect the  eluate. 
9.7.2  Rinse  the  flask  containing  any  residual  extract with  10  ml  90% 
methanol  and  transfer the  solution onto  the  column. 
9.7.3  Add  to the  collected eluate 60  ml  10%  sodium  chloride solution 
(6.3.3).  Filter the  mixture  through  a filter paper.  Rinse. 
9.7.4  Attach  an  activated Baker  C-18  column  (7.23)  to a  solvent 
reservoir.  Pass  the  eluate  (9.7.3)  through  the  column  with  the 
aid  of  suction.  Do  not  allow  the  column  to run  dry.  Rinse  the 
contents  of  the  Erlenmeyer  flask  onto  the  column  with  10  ml  water 
and  then  5 ml  water.  Allow  the  column  to  run  dry  and  if 
necessary  remove  any  residual  water  by  centrifuging the 
cartridges. 
9.7.5  Elute  the  columns  with  6 ml  methanol  into  a  10  ml  tube. 
9.8  Evaporate  the  methanol  to  dryness  and  redissolve  the  residue  in 
400  ~L methanol. 
9.9  HPTLC 
9.9.1  Transfer  20  ~L of  extract  (9.8)  onto  a  plate at 1.5  em  above  the 
base  of  the  plate using  a  stream  of  nitrogen  to minimise  the  size 
of  the  spots.  Use  10  mm  distances  between  the  spots for  UV 
detection  and  20  mm  for Autobiography. 
9.9.2  Add  20  ~L of  the working  standards  (6.3.6.2)  onto  the  plate. 
9.9.3  Pour  the  mobile  phase,  ethyl  acetate/!% water  (6.3.2),  into the 
tank  and  allow  30  min  for  equilibration at room  temperature. 
9.9.4  Run  the  plates for  5  em  above  the  spotting places.  After  the  run 
allow  the  plates to  dry  for  30  min  at room  temperature. 
9.9.5  UV  Detection. 
9.9.5.1  Dip  the  dried  HPTLC  plate  in  the  p-anisaldehyde  solution  (6.3.4) 
and  stand  to  dry  at room  temperature  for  1~ h.  in  a  stream  of 
air. 
9.9.5.2  Detect  the  spots  for  the  ionophores  under  UV  light at 366  nm. 
Either mark  the  spots  on  the  plate or  photograph  them. 
9.9.6  Autobiography  detection 
9.9.6.1  Lie  the  plate  in  the  bottom  of  a  level  petri  dish.  Pour  46  ml  of 
the  agar  solution  (6.3.7)  over  the  plate.  Allow  the  agar  to 
solidify and  cover  the  plate. 
9.9.6.2  Incubate  the  plate at 37°C  overnight  and  examine  the  plate for 
zones  of  inhibition. 
Sg  4.4/4 10  INTERPRETATION  OF  RESULTS 
10.1  Identification of  the  analytes  on  the  HPTLC  is obtained  when  the 
spots  or  zones  of  inhibition  have  the  same  Rf  (and  colours  under 
UV)  as  the  standards.  The  diameter  of  the  measured  zones  are 
correlated with  the  logarithm  of  the  concentration  of  the 
analyte. 
11.  SPECIAL  CASES 
12.  NOTES  ON  PROCEDURE. 
13.  QUALITY  CONTROLS 
Blank  samples  should  be  spiked  with  ionophore  standards. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS 
A full  list of  abbreviations  is given  in  Annex  I,  Section  12 
16.  FLOW  DIAGRAM 
homogenise 
SAMPLE  ------------->  METHANOL  -------->  ALUMINA  COLUMN 
extract  I 
collect  I 
fraction  I 
! 
IDENTIFY  with  UV  <--------- HPTLC  <------------ C-18  SPE 
or  AUTOBIOGRAPHY 
Sg  4.4/5 Sg  4.5.  LEVAMISOLE  - A ROUTINE  METHOD  FOR  THE  DETERMINATION  OF  RESIDUES 
OF  LEVAMISOLE  IN  ANIMAL  LIVERS  BY  GC-MS. 
[Note;  Method  can  be  extended  to  a confirming  method] 
WARNING  AND  SAFETY  PRECAUTIONS 
Wear  disposable  gloves  when  handling  tissues.  All  operations  involving 
solvents  must  be  conducted  in  a  fume  cupboard. 
0.  INTRODUCTION 
Levamisole  is a  broad  spectrum  anthelmintic  drug  used  for  the  control  of 
gastrointestinal  and  lungworm  nematodes  in  ruminants,  horses  and  pigs. 
The  MRL  set  in  the  EEC  is  10  ~g per  kg  for edible tissues. 
1.  SCOPE 
This  method  of  analysis  describes  the  determination  of  the  content  of 
Levamisole  in  liver samples.  The  method  is set out  as  a  routine  screening 
method  but  can  easily be  extended  for  use  as  a  confirming  method. 
2.  FIELD  OF  APPLICATION. 
The  method  was  developed  for monitoring  liver tissue.  The  limit of 
determination  following  validation of  the  method  is 5  ~g per  kg  of  liver. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
ISO  Standard  78/2-1982  Layout  for  standards  - Part  2:  Standard  for Chemical 
Analysis 
Neate,  S.  (1993),  The  determination  of  levamisole  in  liver by  gas 
chromatography  - mass  spectrometry.  Standard  Operating  Proc.  ACU  0267A, 
CVL.,  UK. 
Porter,  S.,  Patel,  R.,  Neate,  S.  and  Osso,  P.  (1993).  Determination  of 
levamisole  in  liver by  gas  chromatography  - mass  spectrometry.  Euroresidues 
II,  Proc.  Residues  of  veterinary drugs  in  food.  Ed.  Haagsma,  N.,  Ruiter,  A. 
&  Czediik-Eysenberg,  P.B.,  Veldhoven,  NL.  pp  548-552. 
4.  DEFINITIONS. 
Levamisole  content  is taken  to mean  the  amount  of  Levamisole  in  the 
substance  in  question,  regardless of  the  chemical  form,  determined 
according  to  the  described  method  and  expressed  as  ~g Levamisole  per  kg  of 
test sample. 
Sg  4.5/1 5.  PRINCIPLE 
The  methods  comprises  4 stages;-
6. 
6.1.1 
6.1.2 
6.1.3 
6.1.4 
6.1.5 
6.1.6 
6.1.7 
6.1.8 
6.2. 
6.2.1 
6.2.2 
6.3. 
6.3.1. 
6.3.2. 
6.3.3 
6.3.3.1 
6.3.3.2 
6.5. 
Homogenisation  of  tissue samples  in  alkali  and  ethyl  acetate. 
Clean  up  with  liquid/liquid partition. 
GC-MS  in  EI-PI  mode. 
The  amount  of  Levamisole  is calculated  by  interpolation from  a 
standard  curve  and  taking  into  account  the  recovery  of 
Levamisole. 
CHEMICALS 
Chloroform  (BDH) 
Ethyl  acetate  (BDH) 
Potassium  hydroxide  (BDH) 
Methanol,  HPLC  grade  (BDH) 
Concentrated  Hydrochloric  acid  (BDH) 
Sodium  sulphate  anhydrous  granular  (BDH) 
Ethyl  acetate  (BDH) 
Water  Deionised  and  filtered 0.2  ~m. 
Solutions 
50%  Potassium  hydroxide.  Carefully dissolve  250  g of  KOH  in  400 
mL  water.  Make  up  to  500  mL  when  cool. 
0.5M Hydrochloric  acid.  Carefully add  22  mL  cone.  HCl  to  400  mL 
water  and  make  up  to  500  Ml  when  cool. 
Standards 
Levamisole  hydrochloride  (Sigma  - L9756) 
Stock  standards;  Dissolve  50  mg  Levamisole  in  methanol  and 
dilute to  50  mL.  Make  fresh  monthly. 
Working  standards; 
Dilute  1 mL  stock  to  100  mL  with  chloroform.  Final  concentration 
is  10  ~g per  mL.  Make  fresh  daily. 
Dilute  1,2  and  5 mL  6.3.3.1  to  10  mL  with  chloroform.  Final 
concentrations  are  1,  2 and  5  ~g per  mL  respectively.  Make  fresh 
daily.  These  are  equivalent  to  1,  2 and  5 times  the  MRL. 
Spiking  Procedure 
Using  separately the working  standards  (6.3.6.1 &  6.3.6.2)  spike 
5 g sample  with  1 mL  of  solution.  Allow  to  stand  for  15  minutes. 
7.  EQUIPMENT 
7.1  Centrifuge  tubes  50  mL  capacity,  Sarsted  polypropylene  with  screw 
cap. 
7.2  Conical  centrifuge tubes,  Polypropylene,  12  mL,  with  push  cap. 
7.3  Conical  centrifuge tubes,  glass,  10  mL,  with  plastic stopper 
7.4  Measuring  cylinders,  25  mL,  500  mL  and  1 L 
7.5  Volumetric  flasks,  10  mL,  25  mL,  50  mL  100  mL  and  500  mL. 
7.6  Glass  pipettes,  1 mL,  2 mL  and  5 mL. 
7.7  Glass  beakers,  100  mL,  250  mL,  500  mL  and  1 L. 
7.8  Sartorius cellulose acetate,  0.2  ~m 
7.9  Short  tipped  Pasteur  pipettes. 
Sg  4.5/2 7.10  Glass  microsyringes,  100  ~L  (SGE  UK) 
7.11  Mixer  (Vortex) 
7.12.  Centrifuge- MSE  Mistral  2L  or  equivalent 
7.13  Homogeniser  (Silverson  heavy  duty  sealed  unit) 
7.14  Shaker,  mechanical  flat bed  (Denley) 
7.15  Glass  microvials,  1.5  mL  with  crimp-on  metal  caps  and  inserts. 
7.16  Falcon  710S  bottle top  (Becton  Dickinson) 
7.17  200  ~L microvial  (Chromacol,  Type  02-CVTG) 
7.18  Balances 
7.19  Heating  blocks  and  accompanying  nitrogen  evaporation  system. 
7.20  Adjustable  pipettes 200  ~L,  1000  ~Land 5000  ~L 
7.21  GC-MS 
Mass  selective detector  (Hewlett  Packard  - HP5970)  coupled  to  HP-
5890  gas  chromatograph  and  linked  to  HP  Vectra  486/33U  PC  or 
equivalent.  The  GC-MS  was  equipped  with  an  autosampler  (Hewlett 
Packard  7673A). 
GC  column;  15m  x 0.25  mm  i.d. with  a  phase  of  DB5  film,  0.25  ~m 
thickness  (J&W  Scientific) 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
Note;  Attention  is drawn  to  section 6.3.1  and  ISO  document  78/2-
1982  and  the  following  notes  derived  from  Annex  II  of  2052/VI/84-
EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection  of  residues  in  meat,  as  defined  in  Directive 
64/433/EEC. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large enough  to 
allow  the  reference method  to  be  carried out  and  to  allow  repeat 
analysis where  required. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to allow 
proper  identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain 
the  integrity of  the  sample  and  not  prejudice  the  result of  the 
examination. 
Samples  for  the  analysis of  Levamisole  must  be  stored  and 
transported at temperatures  below  -18°C. 
9.  PROCEDURE 
9.1  Samples  are  prepared  in  batches  of  up  to  13  test samples,  plus  2 
control  spikes  at the  MRL  and  1 control  blank. 
9.2  Weigh  out  10  ±  0.09  g of  liver tissue  into  a  Sarsted  tube  (7.1) 
9.3  To  each  of  two  control  livers add  100  ~L of  1  ~g per  mL  standard 
(6.3.3.2)  using  a  100  ~L syringe. 
9.4  To  each  tube  add  5 g of  anhydrous  sodium  sulphate,  spreading  it 
evenly over  the  tissue surface. 
9.5  Add  1 ml  of  50%  KOH  to  each  tube  and  15  ml  ethyl  acetate. 
9.6  Homogenise  at maximum  speed  for  2 min. 
9.7  Attach  samples  to  the  horizontal  shaker  (7.14)  and  shake  for  15 
min. 
9.8  Centrifuge  for  15  min  at 2500-3500  rpm. 
Sg  4.5/3 9.9 
9.10 
9.11 
9.12 
9.13 
9.14 
9.15 
[Note; 
9.16 
9.17 
9.18 
9.19 
9.20 
[Note; 
9.21 
9.22 
9.23 
9.23.1. 
Remove  the  ethyl  acetate  into  clean  Sarsted  tubes. 
Add  15  ml  ethyl  acetate to  the  precipitate and  break  up  the 
tissue residue with  a metal  spatula  and  repeat  stages  9.8  and 
9.9. 
Pool  and  mix  the  second  ethyl  acetate fraction with  the first. 
Transfer  a  20  ml  aliquot to a clean  labelled Sarsted  tube  (7.1) 
Add  5 ml  0.5M  HCl  shake  by  hand  vigorously for 2 min  and  then 
centrifuge at 3000  rpm  for  5 min. 
Draw  off the  upper  ethyl  acetate  layer with  a  Pasteur  pipette 
connected  via  a  vacuum  line.  Discard  the  ethyl  acetate fraction. 
Transfer  the  acid  layer  to a clean  glass  centrifuge tube.  Add  1 
ml  50%  KOH  to  each  of  the  tubes  and  vortex  mix. 
If necessary  these  extracts can  be  stored  overnight  at 4°C] 
Add  100  ~L chloroform,  shake  vigorously  by  hand  for  one  min. 
Allow  to  stand  for  10  min. 
Centrifuge  at 3000  rpm  for  5 min. 
Remove  and  discard most  of  the  upper  aqueous  phase  with  a  Pasteur 
pipette. 
Using  a  100  ~L syringe  transfer all  of  the  organic  phase  to 200 
~L microvial.  Rinse  the  syringe with  100  ~L chloroform  and 
transfer the  rinsing to  the  microvial. 
Evaporate  to  dryness  using  a  stream  of  nitrogen. 
The  sample  can  be  stored for  up  to  five  days  at -18°C] 
Add  100  ~L chloroform  and  redissolve with  vortexing. 
Inject 1  ~L into  the  GC. 
GC-MS  Analysis 
The  GC  parameters  are  set up  as  follows; 
COLUMN:  see  7.21 
INJECTIONS:  1  ~1  manual  injections. 
TEMPERATURES:  Interface:  240°C 
Injector:  240°C 
OVEN  TEMPERATURES: 
from  temp  to  temp 
(oc)  (oc) 
60 
60 
240 
60 
240 
240 
CARRIER  GAS:  Helium 
rate 
(°C/min) 
25.5 
time  total  time 
(min)  (min) 
2.0  2.0 
7.06  9.06 
7.0  16.06 
flow  rate  column  head  pressure  =  70  Kpa. 
The  retention time  for  Levamisole  in  this system  is 8.47  min 
9.23.2  The  mass  spectrometry  parameters  are 
IONISER:  Electron-Impact 
Calibration of  the  mass  axis  plus  tuning  of  the  ion  source  is carried out 
using  the 
11autotune  programme .. ,  using  the  calibration  compound 
perfluorotributylamine  (PFTBA). 
Sg  4.5/4 10.  CALCULATION  OF  RESULTS 
10.1  The  presence  of  Levamisole  is suspected  if 
The  retention of  the  analyte  in  the  GC  is within  5 sec  of  the 
retention time  of  the  Levamisole  standard. 
The  presence  of  the  ion  at m/z  204  is observed. 
10.2  Confirmation  procedure. 
Examine  the  spectra for  the  ions  at m/z  121,  148,  203  and  204. 
Calculate their ratios  in  relationship to  the  base  peak,  m/z  148. 
The  ratios must  be  within  10%  of  those  of  the  reference  standard 
Levamisole.  This  was  shown  to  hold  true for  ions  two  ions,  203 
and  204  (Porter et al.,  1993)  and  acceptable  for  ion  121;-
ION  m/z  Relative Abundance  %  CV% 
Standard  Spike  Standard  Spike 
121  29.9  30.0  9.1  13 
203  40.6  44.8  6.1  4.1 
204  90.2  100.7  13.2  7.3 
10.3.  Quantitation. 
A calibration curve  is constructed of  peak  height  against 
concentration  for  a range  of  standards.  A linear curve  was 
obtained  over  the  range  5- 100  ~g per  kg  liver  (Porter et al., 
1993).  The  quantity of  Levamisole  in  each  sample  injection  is 
then  calculated from  the  measured  peak  height 
% recovery  =  amount  of  Levamisole  found  x 100 
amount  of  Spike  added 
Concentration  of  Levamisole  in  sample  (~g/kg)  = 
~g Levamisole  (from  calibration curve)  x ----~1~0--~~ 
mass  of  sample 
For  samples  containing  Levamisole  at concentrations  beyond  the 
range  of  the  standard  curve,  a dilution of  the extract  is 
prepared  and  chromatographed,  and  the  appropriate  volumetric 
correction  is applied. 
10.4.  SENSITIVITY 
The  minimum  limit of  determination  of  Levamisole  by  this method 
is 5  ~g/kg. 
10.5.  QUALITY  ASSURANCE  PROCEDURES. 
Recovery  of  the  analyte  should  fall  within  50-80%. 
11.  SPECIAL  CASES. 
12.  NOTES  ON  PROCEDURE. 
The  method  should  be  validated  in-house  especially if its use  is 
extended  to confirming  procedures. 
Sg  4.5/5 13.  SAMPLE  CONTROLS 
The  blank  samples  were  obtained  from  a  sample  previously analyzed 
and  found  to contain  no  Levamisole. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS. 
See  abbreviations  in  Annex  I,  section  12  of  Manual. 
16.  FLOW  DIAGRAM 
Tissue  --~ add  ethyl  acetate  -----~ Homogenise  ------> Solvent/solvent 
I 
I 
! 
Calculate results <---- Confirm  <------- GC-MS 
Sg  4.5/6 Cy  1.1.  ANABOLIC  AGENTS  - A MODULAR  METHOD  FOR  THE  ANALYSIS  OF  BIOLOGICAL 
MATERIALS  FOR  RESIDUES  OF  ANABOLIC  AGENTS  (STEROID-LIKE  GROWTH  PROMOTERS). 
WARNING  AND  SAFETY  PRECAUTIONS 
Pentafluorobenzyl  bromide  is a  strong  lachrymator  agent. 
0.  INTRODUCTION 
Throughout  the  EEC  the  use  of  xenobiotic  anabolic  agents  is prohibited  in 
food-producing  animals.  Also  the  MRL  for residues of  these  anabolics  in 
animal  products  imported  into or  produced  within  the  Community  is zero. 
Preparations  of  natural  steroids or  their esters may  be  used  in  farm 
animals  under  strictly controlled conditions  (see  EEC  Directive 86/469/EEC) 
and  the  maximum  concentrations  of  natural  steroids allowed  in  plasma  are 
set  (see  section  2)  but  the  levels  permitted  in  edible tissues  have  not  yet 
been  defined  (August  1991). 
1.  SCOPE 
This  modular  method  of  analysis  describes  the  detection  and  confirmation  of 
the  presence  of  individual  analytes  for  a  large  number  of  Anabolic  Agent(s) 
(AnAg)  in  samples  of  animal  origin - the  method  has  been  mainly  tested for 
residues  in  urine  and  muscle  including  minced  meat  for  the  gestagens.  This 
work  is carried out  in  compliance  with  the  Residues  Directive  (86/469/EEC). 
2.  FIELD  OF  APPLICATION. 
The  method  is used  to  perform  routine  screening  and  confirmatory analyses 
in  bovine  urine  and  muscle  samples. 
The  method  can  be  adapted  for  fish  and  also for  biological  material  such  as 
animal  organs,  biological*fluids and  f~eces.  This  modular  method  is 
suitable for  testosterone  ,  trenbolone  ,  oestradiol,  zeranol,  taleranol, 
diethylstilboestrol,  hexoestrol,  dienoestrol,  19-nortestosterone*, 
methyltestosterone,  boldenone,  ethinyloestradiol*,  medroxyprogesterone 
acetate,  chlormadinone  acetate and  megestrol  acetate, 
*  either the  17a- or  the  17B- hydroxy  compounds. 
The  limit of  detection  is  below  1 ug  per  L or  ug  per  kg  for all  compounds. 
The  limit of  detection  is based  on  the  detection  of  the  most  abundant  ion 
with  a  response  at the  correct retention  time  exceeding  the  average  noise  ~ 
3 SD.  The  limit of  identification ranges  from  0.5  - 2.0  ug  per  kg  or L 
depending  on  the  analyte  and  the  matrix.  The  limit of  identification 
equals  the  limit of  detection  as  based  on  the  fourth  diagnostic  ion. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the methods  for  detecting 
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Bagnati,  R.,  Castelli,  M.G.,  Airoldi,  L.,  Oriundi,  M.P.,  Ubaldi,  A.  and 
Fanelli,  R.  (1990),  Analysis  of  diethylstilboestrol,  dienoestrol  and 
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chromatography  - negative  ion  chemical  ionization  mass  spectrometry 
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immunoaffinity  extraction  and  gas  chromatography  - mass  spectrometry  after 
repeated  administrations  of  zeranol.  J.Chromatogr.  564,  493-502 
Cunningham,  N.,  Communication  to  EEC,  DGVI,  of  GC-MS  methods  for  detection 
of  Stilbenes,  Zeranol,  and  17a-Trenbolone  in  bile,  CVL,  Weybridge,  UK,  17th 
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Daeseleire,  E.,  De  Guesquiere,  A.  and  Van  Peteghem,  C.,  (1991), 
Derivatization  and  gas  chromatographic-mass  spectrometric  detection  of 
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Van  Ginkel,  L.A.,  Stephany,  R.W.,  Van  Rosum,  H.J.,  Steinbuch,  H.M.,  Zomer, 
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4.  DEFINITIONS. 
AnAg  content  is taken  to  mean  the  amount  of  AnAg  in  the  substance  in 
question,  regardless  of  the  chemical  form,  determined  according  to  the 
described  method  and  expressed  as  ug  AnAg  per  kg  or  litre of  test sample. 
5.  PRINCIPLE 
5.1.  The  methods  comprises  4 stages;-
1.  preparation  of  a primary  extract 
2.  extract purification  and  concentration  using  lAC  and/or  HPLC. 
[Note;  GC-MS  methods  from  CVL,  UK,  for  measuring  residues  of  stilbenes, 
trenbolone  and  zeranol  in  bile are  described  elsewhere  in  this section  (Cy 
1.3,  Cy  1.4,  Cy  1.5). 
3.  detection  and  identification by  GC-MS 
4.  calculation of  results. 
The  method  allows  choice  of  biological  material,  equipment,  reagents  and 
the  procedures. 
Cy  1.1/2 TABLE.  5.1. 
A  nAg  Sample  lAC  HPLC  Derivative  for  GCMS 
RIVM  GENE GO  TMS  HFB  PFB  PFB/TMS 
DES  U,M  +  +  +  ++  +c  + 
HEX  U,M  +  +  +  ++  +c  + 
DE  U,M  +  +  +  ++  +c  + 
B-E2  M  +  +  +  +  ++  + 
EE  U,M  +  +  ++ 
z  U,M  +  +  +  ++  +c  + 
Taleranol  u  +  + 
17B-TB  U,M  +  +  +  +c 
17a-TB  u  +  +  +c 
B-NT  U,M  +  +  +  +  ++ 
a-NT  u  +  +  +  ++ 
MT  U,M  +  +  +  + 
17a-T  u  +  +  +  ++ 
17B-T  u  +  +  +  +  ++ 
Boldenone  u  +  +  ++ 
MPA  Fat  +  + 
MGA  Fat  +  + 
CMA  Fat  +  + 
++  indicates  that it is the  most  suitable derivative when  RIVM  compared  the 
TMS  and  HFB  derivatives.  c refers to  the  derivatives  made  for  extracts of 
bile used  in  the  CVL  method  (M  1.2). 
THE  MODULAR  STEPS  AND  THE  OPTIONS.  5.2. 
5.2.1.  Choice  of  modules  for  different analytes  for  clean-up  and  GCMS. 
5.2.2. 
STEP 
THE  OPTIONS  FOR  PROCEDURES. 
OPTIONS 
1.  Select tissue  a.  U,Bi, 
b.  Fe 
c.  M 
d.  L,  K 
e.  F 
f.  Mi, 
g,  Eg 
Required  steps 
between  2 and  5 
Use  incurred  and  blank  RMs  if available. 
2.  Dilute  Select  buffer 
NOTES. 
2,3,4a 
2,3,4a,5a 
2, 3, (  4b) , Sa/ b 
2,3,4a,5a 
3,5c 
2,3 
2,3, 
as  per  matrix 
3.  Internal  Standard.  Select  and  add  internal  standard  (IS). 
Cy  1.1/3 4.  Hydrolyse 
5.  Homogenise 
a.  enzyme  for  conjugates, 
b.  alkali  for  esters 
Select  time,  temp,  pH. 
Glucuronides,  S04 
Especially  injection sites 
a.  Mechanical  (e.g.  Ultra-Turrax) 
b.  Enzymatic;  Select  time,  temp,  pH 
c.  Dissolve  in  lipophilic solvent  Fat  only 
6.  Solvent  Extract.  Select solvents  and  quantities.  Omit  if possible. 
Note;  In  the  method  for muscle  (Daeseleire et al.  1991)  further clean-up  is 
achieved  by  passing  an  ether extract through  disposable  C-18  cartridges. 
Recoveries  were  >97%  forT,  EE,  MPA,  MT  and  NT  and  85%  for  E 2B. 
7.  Go  to  step 8  or  9 
8.  lAC. 
9.  HPLC 
(omit  8) 
10.  Derivatives 
11.  GC-MS 
12.  Results 
14.  Decisions. 
6.  MATERIALS 
Select  column  (see  Table  1) 
Follow  instructions of  suppliers. 
Collect analyte fractions. 
Omit  step 9 
Select  column,  solvent  and  conditions 
Determine  RT  with  Ref.  Compounds. 
Collect analyte fractions. 
Select  derivatives  (TMS/HFB/PFB) 
Make  derivatives of  analyte  in  fraction 
Make  derivatives of  Ref.  Compounds 
Use  off-line derivatisation. 
Select  instruments  and  operating  conditions 
Run  Reference  compounds  as  derivatives. 
Run  derivatised analyte  fraction. 
Check  analytes  for  correct  RT  on  GC  as  derivatives 
Check  at  least four  ions  for  correct abundance  in  MS 
Determine  recovery  from  IS  data. 
Determine  accuracy  and  precision  using  RM. 
Decide  if analyte  present. 
Determine  amount  of  analyte  in  sample. 
Present results as  required. 
a.  Did  method  meet  criteria  section  5 
b.  Was  the  analyte  present 
c.  How  much  analyte  in  sample.  mass  per  kg  or  L 
d.  Should  the  analysis  be  repeated? 
[Note:  The  reagents  for which  examples  of  their source  are  quoted  are 
known  to  be  satisfactory,  nevertheless  reagents  from  other  sources  may  be 
equally suitable.] 
Cy  1.1/4 6.1.  Reference  Compounds  and  Standard  Solutions. 
6.1.1  As  used  at  IRFMN 
Stock  solution containing;  0.4  mg  cis-DESD8 ,  0.75  mg  @-DESD8  and  1 mg 
trans-DESD8 • 
Stock  solution containing  1.16  mg  zeranol-D2  and  0.78  mg  B-zearalanol-02 
per  ml  ethyl  acetate. 
Stock  solution  containing  1 mg  zeranol-D2  per  ml  ethyl  acetate. 
Stock  solution  containing  1 mg  B-oestradiol-D2  per  ml  ethyl  acetate 
6.1.2.  As  used  at RIVM. 
Pure  standards  of  steroids and  anabolics  are  those  listed  in  Section  8. 
d-medroxyprogesterone  and  d-178-testosterone  are  recommended  as  the 
internal  standards  for  the  HPLC  module. 
6.2.  Chemicals 
6.2.1.  As  used  at  RIVM. 
All  listed chemicals  are  of  Pro  Analyze  quality or  better,  unless  otherwise 
stated. 
6.2.1.1 
6.2.1.2 
6.2.1.3 
6.2.1.4 
6.2.1.5 
6.2.1.6 
6.2.1.7 
6.2.1.8 
6.2.1.9 
6.2.1.10 
6.2.1.11 
6.2.1.12 
6.2.1.13 
6.2.1.14 
6.2.1.15 
6.2.1.16 
6.2.1.17 
6.2.1.18 
6.2.1.19 
Acetone  (Merck,  art.  no.  14) 
Ethanol  (Merck,  art.  no.  983) 
Hexane  (Baker,  art.  no.  8044) 
Methanol  (Merck,  art.  no.  6007) 
Toluene  (Merck,  art.  no.  8325) 
Acetonitrile  (Merck,  art.  no.  30) 
tert-Butylmethylether  (Merck,  art.  no.  1845) 
Sodium  hydroxide  (Merck,  art.  no.  6498) 
Hydrochloric  acid,  37%  solution  (Merck,  art.  no.  317) 
Ethyl  acetate  (Merck,  art.  no.  9623) 
Acetic  acid  (Merck,  art.  no.  63) 
Sodium  acetate  (merck,  art.  no.  6268) 
Sodium  chloride  (Analar  BDH  art.  no.  10241) 
Potassium  hydroxide  (Merck,  art.  no  9033) 
Disodium  hydrogenphosphate  (Merck,  art.  no.  6568) 
Potassium  dihydrogenphosphate  (Merck,  art.  no.  4873) 
Beta-glucuronidase/sulphatase  (suc'Helix  Pomatia  containing 
100,000  units beta-glucuronidase  and  1 million  units  sulphatase 
per  ml,  Industrie Biologique,  France,  code  IBF  213473) 
Subtilisin A (Sigma,  P-5380) 
Derivatization  reagents:  - N,O-
bis(trimethylsilyl)trifluoracetamide  (BSTFA)  with  10%  TMCS 
(Pierce art.  no.8253). 
Heptafluorobutyric  acid  anhydride  (HFBA),  (Pierce art.  no. 
63163). 
6.2.1.20  Buffer-solutions 
6.2.1.20.1  Phosphate  buffered  saline  (PBS),  0.02  mol/L,  pH  7.4 
Dissolve  in  800  ml  water  2.278  g disodium  hydrogenphosphate, 
0.416  g potassium  dihydrogenphosphate  and  9.0  g sodium  chloride. 
Cy  1.1/5 Adjust  the  pH  at 7.0  ~ 0.1  and  add  water  to  a final  volume  of 
1000  ml. 
6.2.1.20.2  Acetate  buffer,  2 mol/L  ,  pH  5.2 
Dissolve  25.2  g acetic acid  and  129.5  g anhydrous  sodium  acetate 
in  1000  ml  water. 
6.2.1.20.3  Tris  buffer,  0.1  mol  per  L,  pH  9.5,  Dissolve  12.1  g 
Tris(hydroxymethyl)aminomethane  in  800  ml  water.  Adjust  the  pH 
to  9.5  ~ 0.1  and  add  water  to  final  volume  of  1 L. 
6.2.1.21  Other  solutions 
6.2.1.21.1  lAC-eluting  solution;  Add  to  50  ml  of  ethanol  water  to  a final 
volume  of  100  ml. 
6.2.1.21.2  lAC-washing  solution;  Add  to  80  ml  of  ethanol  water  to  a final 
volume  of  100  ml. 
6.2.1.21.3  Alkaline  hydrolysis  solution;  Dissolve  5.6  g  KOH  in  50  ml 
ethanol. 
6.2.1.21.4  Acidic  buffer;  Mix  1.70  ml  hydrochloric  acid  with  5 ml  2 mol/L 
acetate buffer  (pH  =  5.2)  and  add  water  to  a final  volume  of  100 
ml. 
6.2.1.22 Solutions  of  Standards. 
6.2.1.22.1  Stock  solutions of  standards  containing 0.01  g/L  in  ethanol, 
stored at -20°C  in  the  dark. 
6.2.1.22.2  Working  solutions of  standards  containing  0.01  g/L  in  ethanol, 
stored at +4°C  for  a maximum  period  of  2 weeks.  N.b.  smallest 
volume  pipetted out  of  the  stock  solution  is 0.1  mL. 
6.2.2.  As  used  at  IRFMN,  Milan. 
6.2.2.0  Chemicals 
6.2.2.1  Acetone  (Merck,  art.  no.  14) 
6.2.2.2  Acetonitrile  (Merck,  art.  no.  30) 
6.2.2.3  B-glucuronidase/arylsulphatase  (Boehringer,  art no.  127060) 
6.2.2.4  Ethanol  absolute  (Merck,  art.  no.  983) 
6.2.2.5  KOH  (Farmitalia Carlo  Erbna,  art no.  472057) 
6.2.2.6  N,O-bis(trimethylsilyl)trifluoroacetamide  (BSTFA),  Pierce,  art 
no.  38830) 
6.2.2.7  Pentafluorobenzyl  bromide  (PFBBr)  (Aldrich  art no.  10,105-2) 
6.2.2.8  Disodium  hydrogen  phosphate  dihydrate  (Na2HP04)  (Farmitalia Carlo 
Erbna,  art no.  480226) 
6.2.2.9  Potassium  dihydrogen  phosphate  (KH2P04)  (Farmitalia Carlo  Erbna, 
art no.  471686) 
6.2.2.10  Sodium  acetate trihydrate  (Farmitalia Carlo  Erbna,  art no. 
478137) 
6.2.2.11  Thiomersal  (Sigma,  art no.  T 5125) 
6.2.2.12  Buffer  Solutions. 
6.2.2.12.1  Phosphate  buffer,  0.05M,  pH  7.4 
Dissolve  in  about  900  ml  water  1.51  g  KH2P04  and  6.92  g 
Na2HP04.2H20.  Adjust  the  pH  to  7.4  and  dilute to  a final  volume 
of  1 L. 
6.2.2.12.2  Acetate  buffer,  0.05M,  pH  4.5 
Dissolve  in  about  900  ml  water  3.5  g sodium  acetate trihydrate 
and  1.5  ml  glacial  acetic acid.  Adjust  the  pH  to  7.4  and  dilute 
to  a final  volume  of  1 L. 
6.2.2.12.3  Phosphate  buffer,  0.05M,  pH  7.4,  0.02%  thiomersal 
Dissolve  0.2  g thiomersal  in  1 L phosphate  buffer,  0.05M,  pH  7.4, 
Cy  1.1/6 6.2.2.13  Other  Solutions. 
6.2.2.13.1  lAC  eluting and  washing  solution;  add  SmL  water  to  95  ml 
acetone. 
6.2.2.13.2  Derivatization  solutions;  PFBBr  is diluted 1 to 40  with 
acetonitrile and  stored at 4°C. 
6.2.2.13.3  KOH/ethanol;  40  mg  KOH  is dissolved  in  10  ml  anhydrous  ethanol 
and  stored at 4°C.  Make  fresh  every month. 
6.2.2.14  Solutions  of  Standards. 
6.2.2.14.1  Standard  solutions;  Stock  solutions of  standards  containing 
1 mg  per  ml  in  acetonitrile or  ethanol  are  stored  in  the  dark  at 
-18°C; 
6.2.2.14.2  Working  solutions of  standards  containing  100  ng  per  ml  or  10 
ng  per  ml  in  ethanol  are  stored  in  the  dark  at4°C. 
7.  EQUIPMENT 
Reference  to  a  company  and/or  product  is for  purposes  of  information  and 
identification only.  Equivalent  types  or  products  also  may  be  suitable. 
7.1.1. 
7.1.2. 
7.1.3. 
7.1.4. 
7.1.5. 
7.1.6. 
7.1.7. 
7.1.8. 
7.1.9. 
7.1.10. 
7.1.11. 
7.1.12. 
7.1.13. 
7.1.14. 
7.1.15. 
7.1.15.1 
7.1.15.2 
7.1.15.3 
7.1.15.4 
7.1.15.5 
7.1.15.6 
7.1.16 
7.1.17. 
Glass  round  bottomed  flasks,  150  ml  (Corex,  art.  no.  8422-A). 
Glass  Pasteur capillary pipettes. 
Automatic  pipettes  (Gilson  P20,  P200,  P1000  and  P5000) 
Refrigerated  centrifuge  (RC-3,  Sorvall). 
Bench-top  centrifuge  (GLC-4,  Sorvall). 
Centrifuge  tubes,  glass  (55  mm  x 11,5  mm)  (Renes,  RB55) 
Electric water  bath  with  thermostat  adjustable to  50  ±  2°C  (GFL, 
Salm  &  Kipp)  with  nitrogen  facility. 
Vortex  (Vortex-genic,  Wilton  &  Co). 
Ultrasonic water  bath  (Bransonic  32). 
Glass  derivatization vials  (chromacol  250  (A))  with  screw  caps 
(chromacol  85c)  and  septa  (chromacol  8-ST15). 
Incubator  60°  C (Seelvis). 
Heating  module  for  derivatization vials  (Pierce  no.  18790)  with 
nitrogen  facility. 
Glass  injection vials  (Chrompack,  art.  no.  10201)  with  glass 
inserts  (Chrompack,  art.  no.  10381). 
Aluminium  caps  (Chrompack,  art.  no.  10210). 
GC-MS  equipment. 
Gas  chromatograph  (Hewlett  Packard,  type  5890). 
Automatic  injector  (Hewlett  Packard,  type  7637A). 
Mass  selective detector  (Hewlett  Packard,  type  5970). 
Workstation  (Hewlett  Packard,  type  59970). 
Printer  (Hewlett  Packard,  ink  jet). 
GC-column,  fused  silica permaband  SE-52,  25  m x 0,25  mm  ID,  film 
thickness  0,25  ~m (Machery-Nagel,  art.  no.  723054). 
Rotavapor  with  water  bath  at 40  ±  2°  C (Rotavapor). 
IRFMN,  Milan 
7.1.17.1  Conical  tubes 
7.1.17.2 Water  bath 
7.1.17.3 Drying  apparatus  using  nitrogen  or  dry  air 
7.1.17.4  Hamilton  syringes  10ul,  100uL 
7.1.17.5 Heating  module  for  derivatization  in  vials  and  conical  tubes. 
(Pierce) 
Cy  1.1/7 7.2.  lAC-COLUMNS 
RIVM- The  columns  are  glass  (100  mm  x 9 mm  i.d.)  and  contain  1 ml  gel.  A 
multi-analyte  column  was  successfully tested and  is moving  towards 
commercial  development.  The  column  has  a capacity of  at  least 20  ng  per 
analyte.  The  analytes  tested are  DES,  Z,  17a-TB,  17B-TB,  NT,  MT,  T,  E 2 • 
The  internal  standards  were  the  deuterated  anabolic  agents.(see Section  8 
of  manual  for  availability) 
GENEGO,  34170  Gorizia,  Italy - This  company  market  three multi-analyte 
columns  claiming  a capacity of  at  least 20  ng  or  100  ng  (high  capacity 
column)  per  analyte.  The  products  are  -
Multi-Prep  I  for  DES,  HEX,  DE,  Z,  Taleranol  B-E2 ,  NT,  T,  MT,  and 
TB 
Multi-Prep  II  for  DES,  HEX,  DE,  Z,  NT,  MT,T,  TB  and  Taleranol 
Multi-Prep  III  for Clenbuterol,  salbutamol,  terbutaline, 
carbuterol  and  marbuterol  all  B-agonists. 
These  columns  are  marketed  as  a complete  kit,  comprising  the  enzyme  and  the 
buffer for  the  digestion  of  samples,  extraction  and  washing  buffers  and 
detailed  instructions. 
IFRMN  give  a method  for  use  with  Genego  columns  (9.2.1.3) 
LABORATORY  OF  HORMONOLOGY  - MARLOIE,  Rue  de  Point  de  Jour,  8,  B-6900, 
Marloie,  Belgium. 
Antibodies  are  available against;  for  testosterone*,  oestradiol*, 
oestrone,  androstenedione,  dehydroepiandrosterone,  cortisol, 
desoxycortjcosterone,  17a-hydroxyprogesterone  and  progesteron~, 
trenbolone  ,  zeranol,  diethylstilboestrol,  19-nortestosterone  , 
methyltestosterone,  ethinyloestradiol*,  medroxyprogesterone  acetate, 
dexamethasone 
*  either the  17a- or  the  17B- hydroxy  compounds. 
Gels  for  immunoaffinity  chromatography  are  available  (minimum  quantity 1 
ml)  prepared  from  high  affinity antisera and  with  a minimum  capacity of  50 
ng  per  ml  for;  Nortestosterone,  methyltestosterone,  trenbolone, 
ethinyloestradiol,  diethylstilboestrol 
7.3  GCMS 
There  are  several  suitable  GCMS  machines  available.  The  equipment  used 
must  be  capable  of  fulfilling the  criteria for  GCMS  detailed  in  the 
criteria document  (see  section  5 of  this manual).  The  machines  used 
are;-
RIVM 
GC 
column 
injection 
programme 
temperature  transfer  line 
MS 
HP  5890 
Macherey-Nagel  Permabondr  SE  52 
1-5  ml  splitless 225°C 
100°C  - 280°C  at 20°C/min. 
280°C 
HP  5970 
Cy  1.1/8 IRFMN,  Milan 
GC-MS 
or  GC-MS 
HP  5890  coupled  to  a  VG  TS-250 
DANI  6500  GC  coupled  to 
Finnigan  4000  MS 
Negative  ion  CI  mode  with 
Column 
ammonia  or  methane  as  reacting gas. 
CP  Sil  5 CB  25  m X 0.32  mm 
film  thickness  0.12  ~m 
(Chrompack) 
Injection 
programme 
temperature 
Acquisition 
1 - 2  ~L splitless 240°C 
160°C  (1  min)  - 20°C  /min  - 220°C  - 12°C/min  - 300°C 
transfer  line  280°C 
see  9.2.4.2 
Note: 
CVL 
The  mass  spectrometer  is a Finnigan  MAT,  coupled  to  a  gas 
chromatograph  using  a  J&W  fused  Silica capillary column  (SE-54,  15m 
X 0.25  mm)  and  linked  to  an  INCOS  data  system. 
University of  Ghent, 
The  mass  spectrometer  is a Hewlett  Packard  HP  5970  mass-selective 
detector coupled  to  a  HP  5890  gas  chromatograph  using  an  HP  Ultra-2 
(5%  phenylmethyl  silicone) fused  silica capillary column  (25m X 0.20 
mm)  and  an  all-glass moving  needle  injection  system.  Carrier gas  was 
helium  at a flow  rate of  0.47  mL  per  min.  The  injection  and 
interface temperatures  were  maintained  at 290°C.  The  oven 
temperature  was  programmed  from  200-280°C  at soc  per  min,  the final 
temperature  was  held  for  10  min.  The  ionization  voltage  was  70  eV. 
7.4.  HPLC 
A variety of  HPLC  machines  for  the  analysis  of  anabolic  agents  are  suitable 
but  the  one  chosen  must  fulfil  the  criteria for  HPLC  laid  down  in  the 
criteria document,  (see  Section  5).  The  following  reversed  phase  system 
used  at  RIVM  has  proven  to  be  adequate  for extract purification prior to 
GC-MS: 
pre-column 
analytical  column 
eluent 
flow-rate 
chromguard-reversed  phase  cartridge 
ODS-hypersil  C18  (150  x 7.5  (mm  x mm)) 
acetonitrile:water::45:55  V/V  (see  also  9.2.2.1) 
1.5  mL/min 
At  the  University of  Ghent  the  HPLC  conditions were 
pre-column  - 75  mm  chromguard-pellicular  reversed  phase  cartridge,30-50  ~m 
analytical  column- Li-Chrospher  RP-18  (Merck)  (125  mm  x 4  mm  i.d.,  5  ~m) 
eluent  - methanol:water,  65:35  V/V 
flow-rate  - 1.0 mL/min 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section  6.3.1  and  ISO  document  78/2-1982  (E) 
and  the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection  of  residues  in  meat  as  defined  in  Directive 64/433/EEC.  Failing 
this biological  fluids or  faeces  may  constitute the  samples  for  the 
detection of  residues. 
Cy  1.1/9 8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to allow 
the  reference  method  to  be  carried out  and  to  allow  repeat  analysis where 
required. 
In  this method  for Anabolics  the  sizes shall  not  be  less  than 
5 g muscle,  liver,  kidney  or  fat 
0.5  - 2 ml  urine  (IRFMN),  5 ml  urine  (RIVM) 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to  allow  proper 
identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice  the  result of  the  examination. 
Samples  for  the  analysis  of  AnAg  must  be  stored  and  transported  at 
temperatures  below  -18°C. 
9.  PROCEDURE. 
9.1  Preparation  of  a primary  extract 
9.1.1  Liquid  samples 
For  extraction of  liquid  samples  liquid-liquid partition  is most  frequently 
used.  Alternatives  like direct application  to  immunoaffinity  (lAC) 
materials  and  HPLC  column  switching,  however,  can  be  suitable or  preferable 
in  particular cases. 
9.1.1.1  Urine  samples 
From  the  laboratory  sample  a test portion  of  5.0  ml  is taken  to which  the 
internal  standards  are  added,  preferably the  isotopically substituted 
analyte  (e.g.  in  the  case  of  nortestosterone  (NT)  5 ng  of  trideutero-NT 
(NT-d3)).  The  pH  is adjusted  to  5.2 with  acetic acid  (HAc)  and  1.0  ml  2.0 
mol/L  HAc/NaAc  is added.  To  deconjugate  glucuronide- and  sulphate 
conjugates  of  the  analytes  0.1  ml  B-glucuronidase/sulphatase  (e.g. 
suc'Helix Pomatia  containing  100,000  units  B-glucuronidase  and  1 million 
units  sulphatase  per  ml)  is added  and  the  sample  is  incubated  for  2 hours 
at 37°C. 
After  incubation  the  test portions  are  cooled  to  room  temperature  and 
extracted twice  with  5 ml  t-butylmethylether  (TBME).  The  combined  extracts 
are  evaporated  to  dryness  under  a stream  of  nitrogen  in  a water  bath  at 
50°C. 
9.1.1.2 Bile  samples 
The  procedure  for  bile  is the  same  as  for  urine with  the  exception  that the 
test portion  for  analysis  is a mixture  of  1 ml  of  the  laboratory sample  and 
4 ml  of  water.  Note;  CVL  method  uses  5 ml  bile. 
9.1.2  Tissue  samples 
Two  different procedures  are  considered,  the first  is an  enzymatic 
procedure  which  uses  a protease,  the  second  a mechanical  procedure.  The 
advantage  of  the  enzymatic  procedure  is the  protein digestion frees 
analytes  from  cells and  from  conjugates with  proteins  (non  covalently 
protein  bound  residues).  However,  some  analytes  are  not  stable under  the 
conditions  used  (pH  9.5,  60°C)  and  therefore  sometimes  a mechanical 
procedure  has  to  be  used.  As  far as  data  are  available  (based  on  incurred 
Cy  1.1/10 tissues)  enzymatic  digestion  results  in  slightly higher  values  of  analyte 
contents. 
Remark:  It should  be  noted  that  internal  standards  do  not  give  adequate 
information  about  the  extractability of  incurred  residues. 
9.1.2.1  Enzymatic  digestion 
From  the  laboratory sample  a test sample  of  50-100  g  is homogenized 
thoroughly  and  a test portion  of  5.0  g  is weighted  into  a  50  ml  glass 
centrifuge tube.  Internal  standards  are  added  and  mixed  with  the  test 
portions  at  least 30  minutes  prior to  the  addition  of  20  ml  0.1  mol/L  Tris 
buffer,  pH  9.5,  containing  5 mg  Subtilisin A (e.g.  Sigma  P-5380).  The 
mixture  is shaken  a few  times  and  incubated  for  2 hours  at 55°C,  shaking  at 
least every  30  minutes.  After  the  samples  are  cooled  to  room  temperature 
the  mixture  is washed  with  20  ml  hexane  (shaking  one  minute  and 
centrifuging for  5 minutes  at 1600  g)  and  extracted twice  with  TBME.  The 
combined  extracts are evaporated  to dryness  under  a  stream  of  nitrogen  in  a 
water  bath  at 50°C.  The  dry  residue  is dissolved  in  10  ml  methanol/water 
(4:1,  V/V)  and  washed  twice  with  10  ml  petroleum  ether.  Subsequently  the 
methanol/water  phase  is evaporated  to dryness. 
9.1.2.2 Mechanical  extraction 
From  the  laboratory sample  a test sample  of  50-100  g  is  homogenized 
thoroughly  and  a test portion  of  5.0  g  is weighted  into  a  20  ml  glass  vial. 
Internal  standards  are  added  and  mixed  with  the  test portions  at  least 30 
minutes  prior to the  addition of  10  ml  methanol.  The  samples  are  shaken 
thoroughly  during  15  minutes  and  subsequently  placed  in  an  ultrasonic water 
bath  for  15  minutes.  The  supernatant  is removed  (centrifuging 5 minutes  at 
1600  g)  and  the  extraction procedure  is repeated.  The  combined  extracts are 
evaporated  to dryness  under  a  stream  of  nitrogen  in  a water  bath  at 50°C. 
The  dry  residue  is dissolved  in  10  ml  methanol-water  (4:1,V/V)  and  washed 
twice  with  10  ml  petroleum  ether.  Subsequently  the  methanol/water  phase  is 
evaporated  to dryness. 
9.1.3 Alkaline  hydrolyses 
In  the  case  of  analysis for  compounds  which  might  be  present  in  the  form  of 
small  esters  (e.g.  the  gestagens  and  trenbolone  acetate)  an  additional 
basic  hydrolysis  is applied.  The  residue obtained  is dissolved  in  0.2 ml 
methanol  and  0.2  ml  of  a  solution of  5.6  g potassium  hydroxide  in  50  ml 
ethanol  is added.  This  mixture  is  incubated  at  37°C  for  30  minutes.  The 
hydrolyses  is ended  by  the  addition of  1.0  ml  acidic buffer  (6.2.1.3). 
This  mixture  is extracted twice  with  t-butylmethylether.  The  combined 
extract  is evaporated  to  dryness  under  a  stream  of  nitrogen.  In  some  cases 
it is necessary  to  repeat  the  above  described  procedure  for defatting. 
9.2.  Extract  clean-up 
To  allow  detection  and  identification of  low  concentrations  of  analytes  in 
extracts of  biological  samples  adequate  extract clean-up  is necessary.  One 
of  the  most  powerful  techniques  is  immunoaffinity  chromatography  (lAC), 
however,  other alternatives  like high  performance  liquid chromatography 
(HPLC)  are  also  suitable. 
9.2.1  Immunoaffinity  chromatography.  (  DES,  HEX,  DE,  Z,  Taleranol,  17«-TB, 
17B-TB,  NT,  MT,  T,  E2) 
9.2.1.1.  RIVM  method. 
The  procedure  for  sample  preparation  by  lAC  depends  on  the  characteristics 
Cy  1.1/11 of  the  lAC-material  used.  The  following  procedure  is used  at RIVM  and  is 
suitable for  the  polyclonal  rabbit antibodies  tested. 
The  lAC  materials  usually  have  a capacity of  20  ng  or  more  per  ml  of  gel. 
For  multi-residue analysis  combinations  of  gels  can  be  made. 
The  primary  extract  is dissolved  in  0.05  ml  ethanol.  Subsequently  5 to  10 
ml  water  is added  and  the  total mixture  is applied  to  the  lAC  column.  After 
sample  application the  column  is washed  with  5 ml  water  and  eluted with  5 
mL  ethanol-water  (1:1,V/V)  mixture.  The  eluate  is evaporated  to  dryness 
under  a cold  stream  of  nitrogen  in  a water  bath  at  50°C  or  alternatively 
extracted twice  with  5 mL  TBME. 
The  dry  residue  is suitable for  analysis with  gas  chromatography-mass 
spectrometry 
9.2.1.2.  GENEGO  method. 
Full  details of  the  use  of  the  Multi-Prep  columns  are  supplied with  the 
columns  by  the  company. 
The  columns  are washed  with  a buffer  solution  and  the  fraction  containing 
the  analytes  is eluted with  1 ml  acetone/water,  95:5,  v/v.  The  dry 
residue  is suitable for  derivatization and  analysis with  gas 
chromatography-mass  spectrometry 
9.2.1.3.  IRFMN  method. 
The  centrifuged  samples  (0.5  - 2 ml  urine)  are  diluted with  2 ml  acetate 
buffer  (0.05M,  pH  4.5)  into  polystyrene  tubes  and  digested  by  the  addition 
of  25  -100  ~L glucuronidase/arylsulphatase  and  incubated  for  2 hour  at 37°C 
or  overnight  at room  temperature.  The  digested  urines  are  diluted 8 ml 
with  phosphate  buffer  (0.05M,  pH  7.4)  and  directly applied  to  the  lAC 
columns.  After  allowing  4 minutes  for  binding  and  with  gentle mixing  of 
the  gel,  the  urines  are  left to elute and  the  gel  is washed  with  2 X 10  ml 
phosphate  buffer  and  2 mL  distilled water.  The  analytes  are eluted  into 
conical  glass  tubes  with  2 X 1.5  ml  acetone:water  95:5  v/v,  and  the  eluate 
is evaporated  to dryness  under  a stream  of  air at 60°C.  The  dry  residue  is 
suitable for  derivatization. 
The  lAC  columns  are  washed  with  10  ml  acetone  water,  2 ml  distilled water 
and  finally 5 ml  phosphate  buff  containing  0.02%  thiomersal.  The  columns 
are  stored  in  this buffer  in  the  dark  at 4°C. 
9.2.2  High  performance  liquid chromatography 
A variety of  HPLC  systems  for  the  analysis  of  anabolic  agents  has  been 
described.  The  following  reversed  phase  system  used  at RIVM  has  proven  to 
be  adequate  for  extract purification prior to  GC-MS: 
pre-column 
analytical  column 
eluent 
flow-rate 
detector 
chromguard-reversed  phase  cartridge 
ODS-hypersil  C18  (150  x 7.5  (mm  x mm)) 
acetonitrile:water  (45:55,V/V) 
1.5 ml/min 
UV  at 254  nm  and  330  nm •. 
The  residue  is dissolved  in  0.10  ml  of  the  HPLC  eluent of  which 
subsequently 0.09  ml  is  injected  into  the  system.  The  fractions of  interest 
are  collected,  usually starting 0.5 minutes  before  the  retention time  of 
the  analyte  and  ending  1 minute  later.  Sometimes  it is possible or 
advantageous  to  combine  different analytes  in  a  single fraction.  The  eluent 
Cy  1.1/12 is removed  under  a cold  stream  of  nitrogen  in  a water  bath  at 50°C 
Where  the deuterated-compound  of  the  analyte of  interest  is not  available 
other deuterated  anabolics  may  be  used  (RIVM  recommend  d-B-T  and  d-
medroxyprogesterone).  The  fraction  containing  these  compounds  is collected 
and  is needed  for  the estimation  of  recoveries  (see  Calculation of  Results. 
10). 
9.2.2.1  Retention  times  on  HPLC  systems. 
Data  provided  by  RIVM  for  RT  of  anabolics  in  three  separate solvent 
systems. 
This  data  should  only  be  used  as  a  guideline for  the  development  of  one's 
own  system  using  standards. 
Anabolic  Agent.  Retention  Time. 
(min) 
UV  wavelength 
nm. 
UV  Max. 
nm 
System  A:  Acetonitrile:water::45:55 V/V 
Ethinyloestradiol  4.99 
Boldenone  3.22 
Medroxyprogesterone  8.99 
Chlormadinone  8.28 
Megestrol  7.39 
System  B: 
DES 
Methanol:water::65:35  V/V 
5.27 
HEX 
DEN 
a-oestradiol 
B-NT 
a-NT 
B-T 
a-T 
MT 
6.16 
5.66 
4.45 
4.34 
7.0 
5.34 
7.62 
6.69 
280 
254 
254 
280 
280 
254 
280 
254 
280 
254 
254 
254 
254 
254 
System  C:  Methanol:acetonitrile:water:::4:38:58 
B-trenbolone  3.49  350 
a-trenbolone  4.13  350 
zeranol  4.80  265 
197 
245 
195 
195 
195 
197 
243 
243 
245 
245 
254 
350 
350 
215 
At  University of  Ghent  the  following  retention windows  were  used  to collect 
fractions containing  anabolic  agents. 
A  nAg  Retention  window 
(min) 
A  nAg  Retention  window 
(min) 
TbOH,  3.5  - 3.5  MT  8.5 - 10.0 
EE  5.17  - 6.17  MGA  10.0  - 12.0 
E 2B,  NT  5.5  - 6.5  CMA  11.0  - 13.0 
T  6.5  - 8.0  MPA  11.5  - 13.5 
Cy  1.1/13 9.2.3  Gas  chromatography-mass  spectrometry 
For  GC-MS  analysis  on  the  system  described  below  both  the  TMS- and  HFB-
derivatives  are  suitable. 
9.2.3.1  Preparation  of  TMS-derivatives 
The  residue  obtained  after extract clean-up  is transferred to  a 
derivatization  vial  with  0.5  ml  absolute  ethanol.  The  ethanol  is evaporated 
and  0.05  ml  10%  TMS  in  BSTFA  (e.g Pierce  no  8253)  is added.  The  vial  is 
vortexed  and  the  reaction mixture  incubated  during  1 hour  at 80°C.  After 
incubation  the  reaction mixture  is evaporated  to  dryness  under  a  stream  of 
nitrogen  at 50°C  and  the  derivatized residue  is dissolved  in  0.025  ml 
isooctane. 
9.2.3.2 Preparation  of  HFB-derivatives 
The  residue  obtained  after extract clean-up  is transferred to  a 
derivatization  vial  with  0.5  ml  absolute  ethanol.  The  ethanol  is evaporated 
and  0.1  ml  HFBA  (e.g.  Pierce  no  63163)  in  acetone  (1:4,V/V)  is added.  The 
vial  is vortexed  and  incubated  during  1 hour  at 80°C.  After  incubation  the 
reaction mixture  is evaporated  to  dryness  under  a stream  of  nitrogen  at 
50°C  and  the  derivatized residue  is dissolved  in  0.025  ml  isooctane. 
9.2.3.3 Preparation  of  PFB-TMS  derivatives 
The  dried  samples  (equiv.  to  0.5-2  ml  urine)  from  the  lAC-columns  were 
reacted with  50  ~L of  a  solution of  PFBBr  in  acetonitrile(1:20,  v/v)  and  50 
~L of  a  solution of  KOH  in  anhydrous  EtOH  (8  mg/ml)  in  a conical  tube  at 
60°C  for  30  min.  After  evaporation  of  the  solvents  the  samples  were 
redissolved  in  50  ~L of  BSTFA,  heated  for  30  min.  and  then  injected  into 
the  gas  chromatograph. 
Under  these  conditions  PFBBr  reacts with  phenolic  groups  and  BSTFA  with  the 
remaining  aliphatic hydroxyl  groups.  BSTFA  also  is also  used  as  the 
solvent for  the  GC  injection. 
9.2.4  GC-MS  analysis 
The  following  conditions  are  used  during  GC-MS  analysis at RIVM. 
GC  HP  5890 
column  Macherey-Nagel  Permabondr  SE  52 
injection  1-5  ml  splitless 225°C 
programme  100°C  - 280°C  at 20°C/min. 
temperature  transfer  line  280°C 
MS  HP  5970 
acquisition:  see  table 
IRFMN,  Milan 
GC-MS 
or  GC-MS 
Mode 
Column 
HP  5890  coupled  to  a  VG  TS-250 
DANI  6500  GC  coupled  to  Finnigan  4000  MS 
Negative  ion  CI  mode  with  ammonia  or  methane  as  reacting 
gas. 
CP  Sil  5 CB  25m  X 0.32  mm  film  thickness  0.12  ~m 
(Chrompack) 
Injection  1 - 2  ~L splitless 240°C 
Cy  1.1/14 Programme  160°C  (1  min)  - 20°C  /min  - 220°C  - 12°C/min  - 300°C 
Temperature  transfer  line;  280°C 
Acquisition  see  9.2.4.2 
9.2.4.1.  Retention  times  on  GC  systems. 
The  following  times  in  minutes  are observed  at  IRFMN,  they will  vary 
slightly with  day  to day  operation. 
cis-DES,  7.67~ @-DES,  7.97;  trans-DES,  8.38;  DE,  8.22;  Hex,  8.25; 
B-E2 ,  7.93;  E ,  8.85;  Z,  10.18;  Taleranol,  10.29 
9.2.4.2.  Selected  Ions. 
Ions  monitored  during  GC-MS  analysis.  Most  suitable derivative  is  indicated 
(++).  The  ion  used  during  initial  screening  is underlined 
17B-NT 
17a-NT 
17B-T 
17a-T 
MT 
Bol 
17B-TB 
17a-TB 
EE2 
MPA 
CMA 
MGA 
ZER 
TAL 
DES 
DE 
HEX 
17B-E2 
17a-E2 
E3 
derivative  IONS  of  ++  derivative  IONS 
TMS  HFB  derivative  (RIVM)  IRFMN  NI-CI  EI 
+ 
+ 
+ 
+ 
(+) 
+ 
++ 
++ 
+ 
+ 
+ 
++ 
++ 
++ 
+ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
+ 
+ 
+ 
++ 
666  453  306  133 
.  666  453  306  133 
680  467  355  320 
680  467  355  320 
480  465  369  355 
678  464  369  169 
342  252  237  211 
342  252  237  211 
474  459  446  353 
479  331  317  147 
540  497  462  440 
520  477  421  381 
538  433  335  307 
538  433  335  307 
412  397  383 
410  395  381 
207  191  179 
664  451  409  356 
664  451  409  356 
PFB2/TMS 
PFB2/TMS 
PFB2 
PFB2 
PFB2 
PFB/TMS 
PFB/TMS2 
573  393 
573  393 
447  427 
445  425 
449  429 
343 
431 
754  664  566  523 
754  664  566  523 
628  447  238  181 
626  445  249  181 
315  287  181 
524  393  253  181 
612  494  453  419 
10.  CALCULATION  OF  RESULTS. 
10.1.  PRECISION.  To  take  into account  the  Criteria document  (89/610  EEC) 
and  will  explain  how  the  precision of  the  method  is determined  using  the 
standards  available. 
11.  SPECIAL  CASES.  e.g.  if a  particular species  presents  unique  problems. 
12.  NOTES  ON  PROCEDURE.  The  procedure  chosen  will  depend  on  the 
availability of  reagents,reference  compounds  and  equipment. 
13.  QUALITY  CONTROL.  STANDARDS,  REFERENCE  MATERIALS  AND  ANTIBODIES. 
A description of  the  source  and  quality of  the  key  reagents  and  standards 
is given  in  Section 8. 
Cy  1.1/15 13.1  lAC.  Follow  the  instructions relating to  the  storage  and  procedures 
as  recommended  by  the  supplier. 
13.2.  Source  of  lAC  columns  and  gel  packings. 
GENEGO  S.p.A.,  Via  Ressel  S.  Andrea  zona  ind.,  34170  Gorizia,  Italy 
LABORATORY  OF  HORMONOLOGY  - MARLOIE,  Rue  de  Point  de  Jour,  8,  B-6900, 
Marloie. 
Gels  for  immunoaffinity  chromatography  are  available  (minimum  quantity 1 
mL)  prepared  from  high  affinity antisera and  with  a minimum  capacity of  50 
ng  per  mL  for;  nortestosterone,  methyltestosterone,  trenbolone, 
ethinyloestradiol,  diethylstilboestrol 
13.3.  Deuterated  standards. 
Deuterated  standards  are  held  at RIVM  (see  section 8).  The  supply  is 
limited  and  available to  approved  laboratories against  payment. 
14.  TEST  REPORT. 
To  give  the  indications  necessary for  the  identification of  the  sample,  the 
reference  to the  method  employed,  the  results and  the  form  in  which  these 
are  expressed,  any  particular points  observed  in  the  course  of  the  test and 
any  operations  not  specified  in  the  method  or  regarded  as  optional  which 
might  affect the  results. 
15.  LIST  OF  ABBREVIATIONS 
A list of  the  most  important  abbreviations  is given  in  Annex  I  section  12. 
16.  FLOW  DIAGRAM. 
Tissue  --~ add  buffer  and  recovery  standard  --~ Homogenise 
I 
I 
I 
I 
Fluid  (urine,  bile,  plasma,  serum)  I 
I  I 
I  I 
l  l 
add  buffer  and  recovery  standard  ------------~ Hydrolyse 
I 
I 
I 
I 
l 
Calculate  ~---- GCMS  ~----- lAC  or  SPE  ~---- organic  solvent 
results  and/or  HPLC  extraction 
Cy  1.1/16 Cy  1.2  ANABOLIC  AGENTS  - A MULTI-RESIDUE  METHOD  USING  GC-MS  FOR 
DETERMINING  RESIDUES  OF  ANABOLIC  AGENTS  (ANDROGENS,  OESTROGENS  AND 
GESTAGENS)  IN  ANIMAL  TISSUES  . 
WARNING  AND  SAFETY  PRECAUTIONS 
0.  INTRODUCTION 
Throughout  the  EEC  the  use  of  xenobiotic  anabolic  agents  is prohibited  in 
food  producing  animals.  Also  the  MRL  for residues  of  these  anabolics  in 
animal  products  imported  into or  produced  within  the  Community  is zero. 
Preparations  of  natural  steroids or  their esters may  be  used  in  farm 
animals  under  strictly controlled conditions  (see  EEC  Directive 86/469/EEC) 
and  the  maximum  concentrations  of  natural  steroids allowed  in  edible 
tissues  is defined  (see  section  2,  2.3). 
1.  SCOPE 
This  multiresidue  method  of  analysis  describes  the  detection  and 
confirmation  of  the  presence  of  individual  analytes  for  a  large  number  of 
Anabolic  Agents  in  samples  of  animal  origin - the  method  has  been  mainly 
tested for  residues  in  edible tissues.  This  work  is carried out officially 
in  Germany  in  compliance  with  the  Residues  Directive  (86/469/EEC). 
2.  FIELD  OF  APPLICATION. 
The  method  is used  to  perform  routine  screening  and  confirmatory  analyses 
in  edible tissue samples.  *  * 
This  method  is  suitable for  testosterone  ,  oestradiol  ,  oestriol,  oestrone, 
diethylstilboestrol,  hexoestrol,  dienoestrol,  ethinyloestradiol*,  19-
*  nortestosterone  ,  methyltestosterone,  androsterone,  boldenone, 
chlorotestosterone,  medroxy-progesterone  acetate,  progesterone, 
hydroxyprogesterone. 
*  either the  17a- or  the  17B- hydroxy  compounds. 
The  data  obtained  in  interlaboratory comparison  in  7 German  laboratories 
have  shown  that  in  veal,  DES  and  DE  may  be  determined  in  concentrations 
>0.5  ~g per  kg  and  EE  and  NT  in  concentrations  > 1  ~g per  kg. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
2052/VI/84  File 6.11  II-4,  Scientific Veterinary Committee,  Working 
Group-
11Reference  Methods  for  Residues .. ,  General  Criteria for the 
establishment  of  Reference  Methods  for  the  Detection  of  Residues. 
ISO  Standard  78/2-1982  Layout  for  standards  - Part  2:  Standard  for Chemical 
Analysis 
Official  Collection  of  Methods  of  Analysis  according  to  §  35  of  the  Foods 
Act  (LM8G)  Examination  of  Foodstuffs.  Germany.  (1989)  Bundesgesundhbl.  ~ 
76-80. 
Cy  1.2/1 Bergner-Lang,  B.  and  Kachele,  M.  (1981).  Anabolica  in  Kalbfleisch  -
Nachweis  und  Bestimmung,  Befunde  und  Beobachtungen.  Dtsch.  Lebensm.  -
Rundschau,  ll, 305-313 
Bergner-Lang,  B.  and  Kachele,  M.  (1987).  Anabolica  in  Kalbfleisch  -
Nachweis  und  Bestimmung,  Befunde  und  Beobachtungen.  Dtsch.  Lebensm.  -
Rundschau,  83,  349-351 
Bergner-Lang,  B.  and  Kachele,  M.  (1989).  Anabolica  in  Kalbfleisch  -
Nachweis  und  Bestimmung,  Befunde  und  Beobachtungen.  Dtsch.  Lebensm.  -
Rundschau,  85,  78-79 
4.  DEFINITIONS. 
Anabolic  agent  content  is taken  to  mean  the  amount  of  anabolic  agent  in  the 
substance  in  question,  regardless of  the  chemical  form,  determined 
according  to  the  described  method  and  expressed  as  ~g anabolic  agent  per  kg 
of  test sample. 
5.  PRINCIPLE 
5.1.  The  methods  comprises  8 stages;-
1.  preparation  of  a  primary  extract 
2.  hydrolysis  of  conjugates  with  enzyme. 
3.  extraction with  organic  solvent  partition. 
4.  clean  up  using  XAD-2  column 
5.  separation  into  androgens,  oestrogens  and  gestagens  using  Extrelut 
celite and  Al 203  columns 
6.  derivatisation to  TMSi  ethers 
7.  detection  and  identification  by  GCMS 
8.  calculation of  results. 
6.  MATERIALS 
Note:  The  reagents  for  which  examples  of  their source  are  quoted  are 
known  to  be  satisfactory,  nevertheless  reagents  from  other  sources  may  be 
equally suitable.  Unless  specified otherwise  chemicals  are  of  AR  grade. 
6.1.  Reference  Compounds  and  Standard  Solutions. 
6.1.1  Solutions  of  2  ~g per  ml  methanol,  stored  in  brown  glass  bottles 
in  the  dark  at  +4°C 
6.1.2  Internal  standard  for oestrogen  fraction  is 1  ~g Dichlorophene 
per  ml  methanol. 
6.1.3  Internal  standard  for  androgen-gestagen  fraction  is 2  ~g 3,4-
13-C2-testosterone per  mL  methanol. 
Pure  standards  of  steroids  and  anabolics  are  those  listed  in  Section  8. 
6.2. 
6.2.1. 
6.2.2. 
6.2.3. 
6.2.4. 
6.2.5. 
6.2.6. 
6.2.7. 
6.2.8. 
Chemicals 
Acetone  (Merck,  art.  no.  14) 
Ethanol  (Merck,  art.  no.  983) 
Hexane  (Baker,  art.  no.  8024) 
Methanol  (Merck,  art.  no.  9623) 
Toluene  (Merck,  art.  no.  8325) 
Chloroform 
Dichloromethane 
Diethyl-ether  (peroxide  free) 
Cy  1.2/2 6.2.9. 
6.2.10 
6.2.11 
6.2.12 
6.2.13 
6.2.14 
6.3 
6.3.1 
6.3.2 
6.3.3 
6.4 
6.4.1 
6.5. 
6.5.1 
6.5.2 
6.5.3 
7. 
Isooctane;  2,2,4-trimethylpentane 
Acetonitrile  (Merck,  art.  no.  30) 
Acetic  acid  (Merck,  art.  no.  63) 
Sodium  acetate  (Merck,  art.  no.  6268) 
Potassium  hydroxide  0.25  mol  per  L (Merck,  art.  no  9033) 
Beta-glucuronidase/sulphatase  (suc•Helix  Pomatia  containing 
100.000  units beta-glucuronidase  and  1000.000  units  sulphatase 
per  ml,  Industrie Biologique,  France,  code  IBF  213473)  or 
Boehringer  Mannheim,  Germany,  art No.  127060  or  127698 
Derivatization  reagents: 
60  parts  (v/v)  of  acetonitrile are mixed  with  40  parts N-methyl-
N-trimethylsilyl-trifluoracetamide  (MSTFA)  containing  5%  by  mass 
trimethylchlorosilane  (TMCS)  as  a catalyst.  The  mixture  must  be 
freshly prepared. 
200  mg  dithioerythritole  (Sigma  - 08255)  and  100  mg  ammonium 
iodide  (Merck  - 1173)  are  dissolved  in  5 ml  N-methyl-N-trimethyl-
silyltrifluor-(0)-acetamide  (MSTFA)  (Macherys  Nagel  - 70127)  in  a 
headspace  vial  in  an  oven  at 60°C.  1 part  (v/v)  of  this solution 
is mixed  with  9 parts of  MSTFA  •  (Stable for  up  to 1 month  stored 
in  the  dark).  Before  use  for  silylation mix  one  part of  this 
solution with  1 part acetonitrile (v/v). 
Heptafluorobutyric  acid  anhydride  (HFBA),  (Pierce art.  no. 
63163). 
Buffer-solutions 
Acetate  buffer,  0.04  mol/L  ,  pH  5.2 
Dissolve  25.2  g acetic acid  and  43.0  g sodium  acetate.3H20  in 
1000  ml  water. 
Packings  for  Chromatography  Columns 
Amberlite  XAD-2  (300-1000  urn)  (Serva  Ltd) 
Pretreatment  - low  molecular  weight  and  turbid  substances  are 
eliminated  by  allowing  the  resin to  sediment  in  methanol.  50  g 
resin  is added  to  250  ml  methanol  and  stirred for  3 minutes. 
After  sedimentation  for  2 minutes  in  a  500  ml  measuring  cylinder 
the  supernatant  is removed  by  suction.  The  resin  is resuspended 
in  250  ml  water  and  decanted  after standing for  5 minutes.  The 
resin  is stored  in  a  humid  state. 
Celite Granulate;  (Extrelut Merck  art No.  11738).  Store  in 
desiccator over  drying  agent  (e.g.  calcium  chloride) 
Aluminium  oxide  (neutral;  Brockmann  stage activity 1). 
Pretreatment;  20  g Al 203  are  treated with  1.2 ml  distilled water 
in  a wide-necked  bottle provided  with  a  glass  stopper.  After 
violent  shaking  the mixture  is allowed  to  stand  overnight  at room 
temperature. 
EQUIPMENT 
Reference  to  a  company  and/or  product  is for  purposes  of  information  and 
identification only.  Equivalent  types  or  products  also  may  be  suitable. 
7.1.1. 
7.1.2. 
7.1.3. 
7.1.4. 
Beakers,  250  ml 
Glass  Pasteur capillary pipettes. 
Automatic  pipettes  (e.g.Gilson  P20,  P200,  P1000  and  P5000) 
Centrifuge  (e.g.  RC-3,  Sorvall). 
Cy  1.2/3 7.1.5. 
7.1.6 
7.1.7. 
7.1.8. 
7.1.9 
7.1.10 
7.1.11. 
7.1.12. 
7.1.13. 
7.1.14. 
7.1.15 
7.1.16 
7.1.17 
7.1.18 
7.1.19 
7.1.20. 
7.1.20.1 
7.1.20.2 
7.1.20.3 
7.1.20.4 
7.1.20.5 
7.1.20.6 
7.1.20.7 
7.2. 
7.2.1 
7.2.2 
7.2.3. 
7.2.4 
7.2.5 
Centrifuge  tubes,  minimum  volume  250  ml  if stainless steel 
pH  meter  with  glass  electrode. 
Electric water  bath  with  adjustable  thermostat. 
Vortex  (Vortex-genic,  Wilton  & Co). 
Small  filter funnels 
Separating funnels,  500  ml 
Glass  derivatization vials  (chromacol  250  (A))  with  screw  caps 
(chromacol  85c)  and  septa  (chromacol  8-ST15)  or  alternatively 
pointed  flasks  or  conical  tubes  with  glass  stoppers. 
Heating  module  for  derivatization vials  (Pierce  no.  18790)  with 
nitrogen facility. 
Glass  injection  vials  (Chrompack,  art.  no.  10201)  with  glass 
inserts  (Chrompack,  art.  no.  10381). 
Aluminium  caps  (Chrompack,  art.  no.  10210). 
Pointed  flasks,  100  mL 
Rotavapor  with  water  bath  at 40  ±  2°C  (Rotavapor). 
Ultra-Turrax  (or  similar)  homogeniser. 
Desiccator  or  vacuum  oven  at 40°C. 
Round  bottomed  flasks,  500  ml 
GC-MS  equipment. 
Capillary gas  chromatograph  with  all  glass  injector at up  to 
250°C  and  splitless operation. 
Automatic  injection for  GC  - not  compulsory 
A mass  spectrometer with  a  low  resolution  and  a mass  range  of  at 
least 600  amu.  It must  be  possible  to  apply  the  MID  (multiple 
ion  detection)  mode,  also  a mass  specific detector and  an  ion 
trap detector. 
Workstation  (e.g.  Hewlett  Packard,  type  59970). 
Printer 
GC-column,  fused  silica OV-1,  SE-30  or  SE  54,  25  m x 0.32  mm  ID, 
film  thickness  0.30  - 0.50  urn 
The  coupling  of  GC-MS  may  be  by  means  of  a fused  silica capillary 
heated  to  280°C  using  the  direct or  open  principle. 
COLUMNS 
The  columns  require  glass frits,  a  stopcock  and  ground  glass 
joints and  stoppers.  The  sizes are 
Extrelut and  XAD-2  250  mm  x 8-10  mm  i.d.,  Al 203  150  mm  x 8-10 
mm.  i.d. 
Amberlite-XAD2  column;  8 g resin  (6.5.3)  was  suspended  in  30  ml 
water  and  the  suspension  used  to form  a  column  about  8  em  long. 
The  resin was  washed  with  50  ml  water. 
Extrelut celite 9ranulate;  Treat  1.5  g pretreated celite 
granulate  (6.5.2)  with  0.75  ml  KOH  (6.2.13.)  in  a  stoppered  flask 
and  shake  vigorously.  After  standing  for  15  minutes  fill  one 
half of  a  column  with  a  toluene:hexane::1:9  (v/v)  and  add  through 
a funnel  the  prepared  celite.  The  column  is washed  with  a 
further  20  ml  toluene:isooctane.  The  column  must  not  run  dry. 
Aluminium  oxide  column;  4 g prepared  aluminium  oxide  (6.5.3)  was 
mixed  with  10  ml  toluene  and  the  suspension  poured  into  a  column. 
After  draining  the  bed  was  washed  with  15  ml 
toluene:isooctane::1:9  (v/v).  The  tap  was  closed  when  the  level 
of  liquid  is 3 to 4  em  above  the  top  of  the  bed. 
The  Extrelut  column  was  fixed  onto  the  top  of  the  aluminium  oxide 
column  so  that the  eluate from  the  Extrelut dropped  directly onto 
the  oxide  column. 
Cy  1.2/4 8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section  6.3.1  and  ISO  document  78/2-1982  (E) 
and  the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection  of  residues  in  meat  as  defined  in  Directive 64/433/EEC. 
Failing this biological  fluids or  faeces  may  constitute the 
samples  for  the  detection of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to 
allow  the  reference method  to  be  carried out  using  50  g and  to 
allow  repeat  analysis where  required. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to allow 
proper  identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain 
the  integrity of  the  sample  and  not  prejudice  the  result of  the 
examination.  Samples  for  the  analysis of  anabolic  agent  must  be 
stored  and  transported at temperatures  below  -18°C.  If samples 
are  analyzed  within  48  hours  of  collection then  they  may  be 
stored  and  transported at 0 to  +4°C. 
9.  PROCEDURE. 
9.1.  Preparation of  a  primary  extract 
9.1.1  Homogenisation  and  Enzymatic  digestion 
From  the  laboratory sample  a test sample  of  50  g  is mixed  with  50 
ml  acetate buffer  (6.4.1)  in  a  250  mL  beaker.  100  ~L  internal 
standards  are  added  and  the  mixture  homogenised  using  an  Ultra-
Turrax  machine.  Fat  tissues are melted  at 80°C  and  then 
homogenised  with  80  mL  acetate buffer.  The  pH  is readjusted  to 
5.2  using  a  glass electrode and  0.25  mL  enzyme  solution  (6.2.14) 
and  a  few  drops  of  chloroform  added.  The  mixture  is  incubated 
overnight  at 37°C.  The  hydrolysis  may  be  omitted  for fat tissues 
9.1.2.  Extract  clean-up 
9.1.2.1  The  mixture  is transferred to a  centrifuge tube,  mixed  with  180 
mL  methanol  and  rehomogenised.  The  homogenate  is centrifuged for 
10  minutes  at ca.  2000g. 
The  supernatant  is decanted  into a  separating funnel  and 
extracted  (defatted) with  2 x 50  mL  hexane.  The  hexane  fraction 
is discarded. 
[Note;  The  methanol  phase  may  remain  turbid  but  this does  not  have  a 
detrimental  effect.] 
9.1.2.2  The  methanol  phase  is extracted with,  150,  90  and  90  mL 
dichloromethane.  The  dichloromethane  phases  are  combined  in  a 
round  bottomed  flask  and  evaporated  to  dryness  using  a rotary 
evaporator  at 45°C.  The  residue  is taken  up  in  20  mL  water. 
[Notes;  Water  (5-10  mL)  may  be  added  to  assist the  separation of  the 
phases.  Foaming  in  the evaporator  can  be  reduced  by  the  addition  of  a  few 
drops  of  methanol.] 
9.2  Column  Chromatography. 
9.2.1  The  aqueous  extract  is added  to  the  top  of  the Amberlite  XAD-2 
column  with  a  drop  rate of  ca.  2 mL  per  minute.  The  flask  is 
rinsed  twice  with  20  mL  water  and  the  rinsings  passed  through  the 
column  at ca.  5 mL  per  minute.  The  water  eluates are  discarded. 
The  anabolic  agents  are eluted from  the  column  with  40  mL 
methanol.  The  methanol  is evaporated  to dryness  at 45°C.  The 
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residue  is dissolved  in  1 ml  chloroform. 
5 ml  toluene  and  9 ml  isooctane  are  added  to  the  chloroform 
extract  (9.2.1)  and  the  solution  transferred quantitatively to 
the  assembled  Extrelut and  Al 203  columns  (7.2.4).  The  residues 
are  rinsed  twice  with  5 ml  toluene/isooctane  and  the  rinsings 
passed  through  the  column.  The  flow  should  be  about  0.5 ml  per 
minute.  The  columns  are  separated. 
The  Extrelut column  is washed  with  20  ml  toluene/isooctane 
mixture  and  the  oestrogens  eluted at 1 ml  per  minute  with  70  ml 
of  water-washed  ether  into  a flask  containing  1 ml  ethanol.  The 
ether  is evaporated  to  dryness  in  a rotary evaporator  at 45°C. 
The  Al 203  column  is washed  with  25  ml  toluene  and  the  androgens 
and  gestagens  eluted with  30  ml  toluene:ethanol::99:1  (v/v) 
mixture.  After  addition  of  1 ml  ethanol  the  mixture  is 
evaporated  to  dryness  in  a rotary evaporator  at 45°C. 
The  dry  extracts from  the  columns  are  transferred with  3 x 1 ml 
acetone  to  the  derivatization vessels  (7.1.11).  The  solvent  is 
evaporated  under  nitrogen. 
Derivatisation. 
The  extracts  (9.2.5)  are  dried  carefully in  a  vacuum  oven  or  a 
heated  desiccator at 40°C.  100  ~L silylation mixture  (6.3)  are 
added  and  heated  in  a metal  block  at 60°C  for  10  minutes.  The 
resulting mixture  is  used  for  injection onto  the  GC  column. 
The  extracts 9.2.5 are  dried  carefully in  a  vacuum  oven  or  a 
heated  desiccator at 40°C.  100  ~L silylation mixture  (6.3.2)  are 
added  shaken  very  carefully.  The  sample  is transferred  in  a 
conical  derivatization vial  and  heated  in  an  oven  at 60°C  for  15 
min. 
[Note;  The  silylation should  be  tested for  uniformity  by  means  of  standard 
solutions.  With  hexoestrol  and  perhaps  other  compounds  further 
confirmation  may  be  necessary  and  the  hexafluorabutyrate  (HFB)  derivative 
can  be  prepared  and  evaluated  (see  also M 1.1.)] 
9.3.3  Preparation of  HFB-derivatives 
9.4. 
9.4.1. 
The  residue  obtained  after extract clean-up  is transferred to a 
derivatization vial  with  0.5  ml  absolute  ethanol.  The  ethanol  is 
evaporated  and  0.1  ml  HFBA  (e.g.  Pierce  no  63163)  in  acetone 
(1:4,V/V)  is added.  The  vial  is vortexed  and  incubated  during  1 
hour  at 80°C.  After  incubation  the  reaction mixture  is evaporated 
to dryness  under  a stream  of  nitrogen  at 50°C  and  the 
derivatized residue  is dissolved  in  0.025  ml  isooctane.  The 
resulting solution  is used  for  injection onto  the  GC  column. 
Gas  chromatography-mass  spectrometry 
For  GC-MS  analysis  on  the  system  described  below  both  the  TMS-
and  HFB-derivatives  are  suitable. 
The  following  conditions  are  used  during  GC-MS  analysis. 
GC  Capillary  GC  (HP  5840) 
column  SE  54,  25  m x 0.32  mm,  film 0.5  urn 
injection  2  ~L splitless 250°C 
carrier gas  Helium  at 2.5  ml  per  minute 
Initial  column  pressure  0.68  bar 
programme  160°C  for  1 min.,  160°C- 300°C  at 20°C/min. 
temperature  transfer  line  280°C 
Under  thi~e conditions  retention times  are;  Dichlorophene  8.6  min 
and  3,4- C-testosterone ca.  13.3  min. 
Cy  1.2/6 9.4.2.1  Selected  Ions. 
Ions  monitored  during  GC-MS  analysis. 
TMS-derivatives  after silylation with  6.3.1. 
Oestrogens; 
Dichlorophene  (ISTD)  412,  414,  377,  413 
DES  412,  413,  397,  383 
HEX  207  as  HFB  303,  331 
DE  41 0 ,  3  9  5  ,  381 ,  411 
Ethinyloestradiol  425,  440,  300,  285 
Oestradiol  {a  or  B)  285,  416,  231,  232,  326 
Oestriol  504,  345,  324,  386 
Oestrone  342,  257,  218,  244 
Andr£~ens; 
3,4- C-testosterone  (I.S.)  362,  272,  228,  347 
Testosterone  360,  270,  226,  345 
Androsterone  362,  347,  272,  246 
Androstenedione  286,  201,  148,  124 
Boldenone  358,  268,  237,  194,  147,  122 
Methyltestosterone  143,  284,  240,  269,  304 
19-nortestosterone  346,  331,  256,  215 
Trenbolone  (a  or  B)  342,  252,  237,  211 
Gestagens; 
Progesterone 
Medroxyprogesterone 
Hydroxyprogesterone 
314,  272 
373,  283,  265,  145 
359,  269,  227,  145 
9.4.2.2  Ions  monitored  during  GC-MS  analysis after silylation with  6.3.2. 
Oestrogens  as  TMS-derivatives 
Dichlorophene  (I.S.)  412,  413,  414,  377 
cis-DES  412,  413,  397,  383 
trans-DES  412,  413 
Hexoestrol  207 
Dienoestrol  410,  395,  381,  411 
Oestradiol  416,  285,  231,  326 
Oestriol  504,  345,  324,  386 
Oestrone  414,  399,  309,  270 
Andr£~ens and  Gestagens  as  TMS-enol-TMS  derivatives 
3,4- C-testosterone  (I.S)  434,  419,  303,  211 
Testosterone  432,  417,  301,  209 
Androstenedione  430,  234,  209 
4-chlorotestosterone  466,  468 
Boldenone  430,  431,  206,  299 
Methyltestosterone  446,  301,  314,  356 
19-nortestosterone  418,  403,  287 
Progesterone 
Medroxyprogesterone 
458,  353,  443 
315,  330,  455 
[Notes;  1)  values  for  TMS  and  HFB  derivatives are also given  in  method  Cy 
1.1.  2)  Trenbolone  TMSi-ethers  are  not  stable and  must  be  injected 
immediately  after silylation.  3)  Trenbolone  TMS-enol-TMS-derivative  is not 
produced,  possibly trenbolone  is destroyed  during  this silylation.] 
Cy  1.2/7 10.  CALCULATION  OF  RESULTS. 
10.1.  Expression  of  Results. 
Correction  factors  have  to  be  determined  and  applied  to  the  TMS 
derivatives,  because  the  responses  of  the  peak  areas  are  not  identical  when 
compared  with  the  internal  standards  (ISTD).  It is essential  that the 
determination  of  the  correction factors  is performed  within  the 
concentration  range  expected  for  the  anabolics.  1 to  10  ng  of  the 
derivatives of  the  internal  standards  has  to  be  injected.  The  correction 
factors  are  based  on  the  common  peak  area method. 
The  following  formula  is applied 
gx  =  f  X 
Fst  X E 
where  gx  = anabolic  content  (ug  per  kg) 
gst  =  quantity of  ISTD  (ng)  added 
Fx  =  area of  anabolic  derivative 
Fst = area  of  ISTD 
f  =  correction factor 
E  =  quantity sample  (g)  used 
10.2.  Quality Assurance  Procedure 
10.2.1  Validation;  Batches  of  two  blanks  and  five  blank  samples  spiked 
at the  2  ~g per  kg  level  for  the  analytes  of  interest are  required. 
Recovery  of  the  analyte  should  be  within  50-120%  with  a  CV  value  <30%. 
10.2.2  Examples  of  quality assurance  data  obtained  by  Bergner-Lang,  B. 
and  Kachele,  M.  (Dt.  Lebensm.  Rundschau,  1989,  85,  78-79)  for  the  recovery 
of  10  anabolic  agents  added  to  homogenised  kidney  tissue are  shown  below; 
Agent  n  spike  mean  Recovery  cv 
(ug  per  kg)  (%)  (%) 
DES  5  2  1.3  65  12.2 
DEN  5  2  1.34  67  18.0 
HEX  5  2  1.34  67  14.5 
EE  5  2  1.26  63  15.5 
E 2a  5  2  1.20  60  33.3 
E2B  5  2  1.16  58  16.8 
El  5  2  1.38  69  15.7 
E3  5  2  1.16  56  20.8 
NT  6  3  1.53  52  40.3 
MT  6  3  2.12  70  7.0 
10.3.  Reliability 
The  method  has  been  verified with  good  success  in  seven  laboratories  in 
Germany  having  experience with  the  analysis of  anabolic  agents.  The 
results met  the criteria of  the  EEC  set out  in  section  5. 
Cy  1.2/8 The  data  obtained  in  the  interlaboratory comparison  have  shown  that  in 
veal,  DES  and  DE  may  be  determined  in  concentrations  >0.5  ~g per  kg  and  EE 
and  NT  in  concentrations  > 1  ~g per  kg.  Similar results and  statistical 
data  were  obtained  in  one  of  the  laboratories for  the  substances,  HEX,  a-
and  B- oestradiol,  oestrone,  oestriol  and  methyltestosterone. 
11.  SPECIAL  CASES.  e.g.  if a  particular analyte  presents  problems 
with  the  TMS  derivatives then  the  HFB  derivatives  should  also  be  prepared 
and  analyzed. 
If a 
11Baby
11  food  is analyzed  the  starting material  will  contain  less meat 
and  100  g should  be  used. 
The  silylation  (9.3.2)  produces  TMS-enol-TMS-derivatives.  This  procedure 
allows  good  results also  in  problematical  samples  with  dirty extracts and 
small  traces of  hormones,  especially for  oestrone,  gestagens  and  androgens. 
The  TMSi-ethers  of  trenbolone  are  unstable.  The  method  is only  applicable 
for  trenbolone  if the  TMSi-ethers  are  injected onto  the  GC  after their 
preparation.  The  TMS-enol-TMS-derivatives  of  trenbolone  are  not  produced. 
The  method  is not  suitable for  zeranol  because  the  Extrelut column  is not 
useful  for  separating zeranol. 
12.  NOTES  ON  PROCEDURE.  The  procedure  chosen  will  depend  on  the 
availability of  reagents,reference  compounds  and  equipment. 
13.  QUALITY  CONTROL.  STANDARDS,  REFERENCE  MATERIALS  AND  ANTIBODIES. 
A description of  the  source  and  quality of  key  reagents  and  standards  is 
given  in  Section  8. 
14.  TEST  REPORT. 
To  give  the  indications  necessary  for  the  identification of  the  sample,  the 
reference  to  the  method  employed,  the  results and  the  form  in  which  these 
are  expressed,  any  particular points  observed  in  the  course  of  the  test and 
any  operations  not  specified  in  the  method  or  regarded  as  optional  which 
might  affect the  results. 
15.  LIST  OF  ABBREVIATIONS 
A list of  the  most  important  abbreviations  is given  in  Annex  I  section  12. 
16.  FLOW  DIAGRAM. 
Tissue  --~ add  buffer and  recovery  standard  --~ Homogenise 
I 
I 
I 
I 
! 
XAD-2  column  <------- solvent  extraction <---- Hydrolyse 
I 
I 
I 
I 
! 
Extrelut column  and  Al 203  columns 
I  I 
I  I 
I  I 
I  I 
!  ! 
Oestrogens  Androgens  and  Gestagens 
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I  I 
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Derivatize --------> GC-MS  --------> Calculate results 
Cy  1.2/9 Cy  1.3.  STILBENES  - CONFIRMATION  OF  STILBENES  IN  BILE  BY  GAS 
CHROMATOGRAPHY-MASS  SPECTROMETRY. 
SAFETY  - When  using  ammonia  CI,  ensure  that there  are  no  leaks  in  the 
system  and  that there  is adequate  ventilation.  If you  feel  unwell  leave 
the  room  and  get  some  fresh  air. 
0.  INTRODUCTION 
Purpose 
To  confirm  the  presence  and  identity of  stilbene compounds  in  bile sampled 
from  farm  animals.  This  work  is carried out  in  compliance  with  the 
Residues  Directive  (86/469/EEC). 
Background 
Stilbenes  are  administered  to  animals  because  of  their growth  promoting 
properties.  Three  stilbene compounds  commonly  in  use  are:  diethylstilboes-
trol  (DES),  dienoestrol  (DE)  and  hexoestrol  (HEX). 
In  1981  the  administration  of  stilbene growth  promoters  to animals  was 
prohibited  throughout  the  EEC.  The  presence  of  these  compounds  in 
slaughtered  animals  is monitored  under  the  National  Surveillance  Scheme 
which  is now  carried out  in  compliance  with  the  Residues  Directive 
(86/469/EEC). 
1.  SCOPE 
With  effect from  1 January  1988,  the  use  of  hormonal  growth  promoters  was 
prohibited throughout  the  EEC.  To  ensure  that farmers  are  not  continuing 
to  use  stilbenes,  bile  is sampled  at slaughterhouses  and  screened  for  the 
presence  of  these  compounds  using  a radioimmunoassay  technique.  Whenever 
there  is a positive screening  result,  this must  be  confirmed.  In  the  UK 
this  is done  using  this gas  chromatography-mass  spectrometry  (GC-MS) 
method. 
2.  FIELD  OF  APPLICATION. 
This  method  is used  for  confirmation  of  the  presence  of  stilbenes  in  bile 
samples  found  positive  in  the  UK.  The  detection  limit  in  bile  is 5  ~g/L 
for  DES  and  1  ~g/L for  Hexoestrol. 
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Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
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4.  DEFINITIONS. 
Stilbenes  content  is taken  to mean  the  amount  of  stilbenes  in  the  substance 
in  question,  regardless of  the  chemical  form,  determined  according  to  the 
described  method  and  expressed  as  ~g stilbenes per  litre of  test sample. 
5.  PRINCIPLE. 
The  method  of  analysis  comprises  six stages: 
(1)  Overnight  hydrolysis  of  the  bile. 
(2)  Extrelut  column  clean-up. 
(3)  Double  Bond-Elut  column  purification. 
(4)  Derivatisation. 
(5)  Post-derivatisation clean-up. 
(6)  Analysis  by  gas  chromatography-mass  spectrometry  (GC-MS). 
6.0.  MATERIALS 
6.1.  Glucuronidase  Boehringer  BCL  (Cat  No.  127051) 
6.2.  Dichloromethane  Fisons  Distal  grade  (stabilised 
with  aniline) 
6.3.  Diethyl  ether  Fisons  Distal  grade 
6.4.  Petroleum  ether  Fisons  Distal  grade  (40-60°C 
fraction) 
6.5.  Methanol  Fisons  Distal  grade 
6.6.  Heptafluorobutyrate  (HFBA)  Phase  Sep  Ltd  (Cat  No.  940851) 
6.7.  Extrelut columns  Merck  BDH 
6.8.  Bond-Elut  columns  500  mg  CN,  Jones  Scientific 
(Cat  No.  613303) 
6.9.  Bond-Elut  columns  500  mg  NH2 ,  Jones  Scientific 
(Cat  No.  611303) 
6.10  Phosphate  buffer  pH  7  (0.06M)  [3.3  g  Na2HP04  + 
5.75  g  NaH2P04 made  up  to  1 litre] 
6.11  Phosphate  buffer  pH  6  (1.0M)  [35  g  NaH2P04 +  3g 
NaH2P04 made  up  to 1 litre] 
6.12  Hexane  Distal  grade 
6.13  Heptane  Distal  grade 
6.14  Perfluorotributylamine  Finnigan  MAT. 
Cy  1.3/2 6.15.  Standards 
DES 
Hexoestrol 
Dienoestrol 
Sigma 
Sigma 
Sigma 
These  should  be  made  up  in  methanol  to a concentration  of  1 mg/mL  and 
diluted to working  standards  of  concentrations  of  10  ~g/mL,  1  ~g/mL,  100 
ng/mL,  10  ng/mL  and  1 ng/mL. 
7.  EQUIPMENT 
7.1. 
7.2. 
7.3. 
7.4. 
7.5. 
7.6. 
7.7. 
7.8. 
7.9. 
Universal  bottles 
Techni  Dri-block 
Quick-fit tubes 
Quick-fit expansion 
Screw  cap  tubes 
Water  bath 
Manifold 
GC  vials and  caps 
Mass  spectrometer 
20  mL 
50  mL  (MF-24) 
adaptor  (34/35-24/29) 
J  Bibby  (Cat  No.  5142-10) 
Supplying  oxygen-free  nitrogen 
Finnigan  MAT,  coupled  to  a gas 
chromatograph  and  linked  to  an 
INCOS  data  system. 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to section  6.3.1  and  ISO  document  78/2-1982(E)  and 
the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection of  residues  in  meat  as  defined  in  Directive 64/433/EEC.  Failing 
this biological  fluids  (in  this method  bile)  or faeces  may  constitute the 
samples  for  the  detection  of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to allow 
the  reference method  to  be  carried out  and  to  allow  repeat  analysis where 
required. 
This  method  for  Stilbenes  uses  5 mL  bile therefore the  size shall  not  be 
less  than  20  mL  bile 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to  allow  proper 
identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice  the  result of  the  examination. 
Samples  for  the  analysis  of  stilbenes must  be  stored  and  transported at 
temperatures  below  -18°C. 
9.0.  PROCEDURE 
9.1.  Hydrolysis 
Place  5 mL  bile,  15  mL  of  phosphate  buffer  pH  7 and  50  ~L of  glucuronidase 
in  a  20  mL  universal  bottle and  incubate  overnight  at 37°C. 
Cy  1.3/3 9.2.  Extrelut Clean-up 
Prepare  an  Extrelut column  according  to  the maker's  instructions.  Onto  a  50 
ml  (MF-24)  Quick-fit tube  place  a  34/35-24/29  Quick-fit expansion  adaptor 
and  place  the  column  in  the  adaptor. 
Add  the  bile/buffer mix  and  leave  for  30  minutes  before  eluting the  column 
with  2 x 35  ml  of  diethyl  ether. 
Reduce  the  ether under  nitrogen  to  approximately  5 ml  before washing  into  a 
10  ml  conical  centrifuge tube  and  drying  under  nitrogen.  A small  residue 
is normally  left after drying.  Resuspend  the  extract  in  2 ml  of  40%  (v/v) 
dichloromethane/hexane. 
9.3.  Bond-Elut  Purification 
The  CN  Bond-Elut  columns  should  be  prepared  by  washing  twice  with  2 ml  of 
methanol  and  twice  with  2 ml  of  petroleum  ether.  Before  the  columns  are 
dry  add  the  extract and  wash  with  2 ml  of  dichloromethane/hexane  (70:30 
v/v). 
Prepare  the  NH2  columns  by  washing  twice  with  methanol  then  twice  with  2 ml 
of  petroleum  ether.  Fill  the  NH2  column  with  diethyl  ether and  attach  the 
CN  column  to the  top  of  it.  Elute  the  CN  column  into  the  NH2  column  using 
3 ml  of  diethyl  ether.  Discard  the  CN  column.  Wash  the  NH2  column  with  2 
ml  of  2%  (v/v)  methanol  in  dichloromethane. 
Elute  the  NH2  column  into  a  screw  cap  centrifuge tube  with  3 ml  of  33% 
(v/v)  methanol  in  dichloromethane. 
9.4.  Derivatisation 
Dry  the  methanol/dichloromethane  extract and  resuspend  in  1 ml  heptane  and 
100  ~L of  HFBA  (from  a fresh  ampoule).  Cap  the  tube  and  incubate  the 
extract at 80°C  for  20  minutes  in  the  Techni  Dri-block.  Shake  after 3 
minutes  to ensure  adequate  mixing  of  the  two  layers.  After  20  minutes 
remove  the  tubes  and  allow  to  cool. 
Concurrently  run  stilbenes standards  through  the  derivatisation  steps. 
Standard  concentrations  =  1 ng,  10  ng,  50  ng,  100  ng,  500  ng,  1  ~g,  10 
~g/ml. 
9.5  Post-Derivatisation Column  Clean-up 
To  improve  chromatography,  clean  up  the  derivatised extracts  by  adding  5 ml 
of  phosphate  buffer  pH  6.  Shake  vigorously for exactly 30  seconds,  then 
allow  layers  to  settle.  (If necessary,  spin  at 2000  rpm  for  5 minutes). 
Carefully pipette off the  upper  heptane  layer,  using  a Multipette set to 
0.7  ml  and  vial  up  ready  for  GC-MS.  The  vials should  be  capped 
immediately. 
Cy  1.3/4 9.6 
9.6.1. 
GC-MS  Analysis 
The  GC  parameters  are  set up  as  follows; 
COLUMN:  J&W  fused  silica capillary column, 
INJECTIONS:  0.5  ~1  manual  injections. 
TEMPERATURES:  Interface:  230°C 
SE-54,  15  m x 0.25  mm. 
Injector:  220°C 
OVEN  TEMPERATURES: 
from  temp  to  temp 
(oC)  (oc) 
time 
(min) 
total  time 
(min) 
55 
55 
240 
55 
240 
240 
20 
Capillary  close  =  0.00 
Divert  close = 0.00 
CARRIER  GAS:  Helium 
1.0 
9.2 
10.0 
open  =  0.7 
open  = 20.7 
1.0 
10.2 
20.2 
flow  rate  =  1  cm3/min  injector pressure= 10  psi~ 
9.6.2  The  mass  spectrometry  parameters  are 
IONISER: 
Mode:  Chemical  ionisation  (CI) 
Temperature:  130°C 
Pressure;  50  Torr 
MANIFOLD  TEMPERATURE:  90  (±  5)  oc 
ELECTRON  MULTIPLIER:  1.2  kV 
ELECTRON  ENERGY:  70  electron  volts. 
MAKE-UP  GASES;  DES  use  methane,  DE  and  HEX  use  ammonia 
Other  parameters  should  be  set up  by  adjusting  the  instrument  controls  to 
give  the  optimum  peak  height  and  shape  for  a  suitable calibration compound. 
The  CVL  uses  perfluorotributylamine  (PFTBA). 
9.6.3  In  CI  mode,  using  ammonia  as  the  make-up  gas,  and  scanning 
between  m/z  = 50  and  700,  run  (a)  a  blank  hexane  (b)  10  ~g in  100  ~L 
stilbenes standard.  Collect  1000  scans. 
9.6.4.  Focus  in  on  the  GC  peak  of  the  stilbene standard.  Find  the  exact 
masses  in  the  spectrum  for  the  three selected  ions: 
DES  464,  465,  661  (using  CH4  CI) 
Dienoestrol  462,  480,  676  (using  CH4  CI) 
Hexoestrol  466,  484,  680  (using  CH4  CI) 
9.6.5.  Use  these masses  to  set up  or  modify  a multiple  ion  detection 
(MID)  scan  list.  Create  the  scan  list. 
9.6.6.  Rerun  hexane  to  ensure  there  is  no  carry over  of  the  stilbene. 
9.6.7.  Using  the  scan  list just created,  analyse  the  sample  and  the 
standards  on  the  GC-MS.  It is advisable  to: 
(a)  Analyse  the  100  ~g standard first to ensure  that the  MID  is set 
up  correctly.  Follow  this with  hexane. 
(b)  Analyse  standards  in  order  of  increasing  concentration. 
(c)  Switch  the  filament  on  100  scans  before  the  peak  is  due  to  elute 
from  the  column  and  enter the  source  and  turn  it off  100  scans 
afterwards. 
(d)  Run  hexane  between  each  injection. 
Cy  1.3/5 10.0.  RESULTS 
The  presence  of  the  suspected  stilbene  in  a  sample  is confirmed  if the  GC-
MS  data  agree  with  the  following  criteria: 
1.  The  peak  has  the  same  retention  time  on  GC  as  the  standards. 
2.  All  the  selected  ions  are  present  in  the  mass  spectrum  of  that 
peak  after subtraction of  the  background. 
3.  The  selected  ions  are  present  in  the  same  ratio to one  another  as 
seen  in  the  standard. 
If the  stilbene  is present  in  a  sample,  and  satisfies the  above  criteria, 
then  an  estimate of  the  quantity present  may  be  calculated using  one  of  two 
methods: 
1. 
2. 
Use  the  data  system  to calculate peak  areas  and  create a 
quantitation  list.  Use  a relevant  standard  to  set up  a 
quantitation  library,  or  use  a range  of  standards.  Refer  the 
sample  to  this and  obtain  a quantitation report.  This  is the 
preferred method. 
Measure  the  peak  area  of  the  sample  and  a relevant  standard.  The 
concentration of  stilbene  in  the  TOTAL  sample  submitted  is then 
found  using  the  equation: 
peak  height  sample  x  concentration  of  standard 
peak  height  standard 
Limit  of  detection:  DES  5  ~g per  L of  bile 
Hexoestrol  1  ~g per  L of  bile. 
11.  SPECIAL  CASES 
12.  NOTES  ON  PROCEDURE 
13.  QUALITY  CONTROL.  STANDARDS  AND  REFERERENCE  MATERIALS. 
14.  TEST  REPORT. 
To  give  the  indications necessary for  the  identification of  the  sample,  the 
reference  to  the  method  employed,  the  results  and  the  form  in  which  these 
are  expressed,  any  particular points  observed  in  the  course  of  the  test and 
any  operations  not  specified  in  the  method  or  regarded  as  optional  which 
might  affect the  results. 
15.  LIST  OF  ABBREVIATIONS 
A list of  the  most  important  abbreviations  is given  in  Annex  I  section  12. 
16.  FLOW  DIAGRAGM. 
enzyme  hydrolysis  ether eluate 
BILE  ----------------------> EXTRELUT  COLUMN  --------------> DRY  ---> 
elute  elute 
---->CH2Cl 2/MeOH  -----> CN-BOND-ELUT  ----------->  NH2-BOND-ELUT  ------> 
COLUMN  COLUMN 
----> CH2Cl 2/MeOH  -----> DERIVATISE  WITH  HFBA  -------> CLEAN  UP  WITH 
PHOSPHATE  BUFFER  --> 
----> GC-MS  OF  HFB  DERIVATIVES  -----------------> CALCULATE  RESULTS 
Cy  1.3/6 Cy.  1.4 ..  TRENBOLONE- CONFIRMATION  OF  TRENBOLONE  IN  BILE  BY  GAS 
CHROMATOGRAPHY-MASS  SPECTROMETRY 
SAFETY 
Take  care  when  handling  the  BSTFA-TMCS.  It is  irritating to  eyes, 
respiratory system  and  skin.  After  contact with  skin  wash  immediately  with 
water.  There  is also a danger  of  cumulative  effects. 
0.  INTRODUCTION 
Purpose 
The  confirmation  of  the  presence  of  trenbolone  (TB)  in  bile samples  taken 
from  farm  animals  in  compliance  with  the  Residues  Directive  (86/469/EEC). 
Background 
Trenbolone  is a  synthetic steroid with  androgenic  activity used  to  promote 
growth  in  farm  livestock.  With  effect from  1 January  1988,  the  use  of 
hormonal  substances  for fattening  purposes  was  prohibited throughout  the 
EEC. 
Metabolism 
Trenbolone  is administered  to  farm  animals  as  the  ester trenbolone  acetate. 
The  active  ingredient  is 17B-hydroxy-TB  (BTB)  which  is the  major  residue  in 
muscle  and  blood.  BTB  is metabolised  in  the  liver to  17a-hydroxy-TB  (aTB) 
and  this  is the  most  abundant  residue  in  bile,  urine  and  faeces.  This 
method  is capable  of  measuring  the  total  content  of  both  isomers  but  the 
aTB  accounts  for most  of  the  residue  in  bile. 
1.  SCOPE 
To  ensure  that farmers  are  not  continuing  to  use  trenbolone,  bile  is 
sampled  at slaughterhouses  and  screened  for  the  presence  of  this compound 
using  an  ELISA  technique.  Whenever  there  is a positive screening  result, 
this must  be  confirmed  (in  the  UK)  by  gas  chromatography-mass  spectrometry 
(GC-MS).  This  work  is carried out  in  compliance  with  the  Residues 
Directive  (86/469/EEC). 
2.  FIELD  OF  APPLICATION. 
This  method  is used  for  confirmation  of  the  presence  of  trenbolone  in  bile 
samples  found  positive  in  the  UK.  The  detection  limit for  trenbolone  is 1 
ng  of  TOTAL  bile. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
2052/VI/84  File 6.11  II-4,  Scientific Veterinary Committee,  Working 
Group- "Reference  Methods  for  Residues",  General  Criteria for  the 
establishment of  Reference  Methods  for  the  Detection  of  Residues. 
Cy  1.4/1 ISO  Standard  78/2-1982  Layout  for  standards  - Part 2:  Standard  for  Chemical 
Analysis 
CVL  (1990)  Standard  operating  procedure  for  Confirmation  of  trenbolone  in 
bile by  GC-MS.  27th  June  1990 
Other  references; 
Hsu,  S.S.,  Eckerlin,  R.  and  Henion  J.  (1988)  Identification and 
quantification of  trenbolone  in  bovine  tissue by  gas  chromatography-mass 
spectrometry.  J.  Chromatog.  424,  219-225 
Daeseleire,  E.,  De  Guesquiere,  A.  and  Van  Peteghem,  C.,  (1991), 
Derivatisation  and  gas  chromatographic-mass  spectrometric  detection  of 
anabolic  steroid residues  isolated from  edible muscle  tissues.  J. 
Chromatog.  562,  673-679 
4.  DEFINITIONS. 
Trenbolone  content  is taken  to  mean  the  amount  of  trenbolone  in  the 
substance  in  question,  regardless of  the  chemical  form,  determined 
according  to  the  described  method  and  expressed  as  ~g trenbolone  per  kg  or 
litre of  test sample. 
5.  PRINCIPLE. 
The  method  of 
(1) 
(2) 
(3) 
(4) 
(5) 
(6) 
analysis  comprises  six stages: 
Overnight  hydrolysis  of  the  bile. 
Extrelut  column  clean-up. 
Double  Bond-Elut  column  purification. 
Derivatisation. 
Post-derivatisation clean-up. 
Analysis  by  gas  chromatography-mass  spectrometry 
6.0.  CHEMICALS 
(GC-MS). 
Note:  The  reagents  (and  equipment)  for which  examples  of  their source  are 
quoted  are  known  to  be  satisfactory,  nevertheless  reagents  and  equipment 
from  other sources  may  be  equally suitable.  All  the  reagents  should  be  of 
analytical  grade  or  better. 
6.1.  Bis-(trimethylsilyl)  trifluoroacetamide  [BSTFA]  with  1% 
trimethylchlorosilane  [TMCS]  (Pierce Chemical  Company) 
6.2.  Diethyl  ether,  Distal  grade 
6.3  Acetonitrile,  HPLC  grade 
6.4  !so-octane  (trimethylpentane)  Distal  grade 
6.5  Perfluorotributylamine  (Finnigan  MAT) 
6.6.  Standards 
17«-trenbolone  (Roussel  Uclaf) 
17«-trenbolone  in  methanol;  10  ~g/mL,  1  ~g/mL,  100  ng/mL,  10 
ng/mL. 
7.0.  EQUIPMENT 
7.1.  Centrifuge  tubes,  screw  capped  (J  Bibby) 
7.2.  Dri-block  (Techni) 
7.3  Water  bath 
7.4.  Manifold  supplying  oxygen-free  nitrogen 
Cy  1.4/2 7.5.  GC  mini-vials,  (Chromacol,  Cat  No.  03-CV) 
7.6.  Vial  caps,  (Chromacol,  Cat  No.  8-AC3) 
7.7.  GC  column,  SE54  (Jones  Chromatography) 
7.8  Sonic  water  bath  (or  Whirlimixer) 
7.9  Mass  spectrometer,  Finnigan  MAT  Model  4600  coupled  to  GC  and 
linked  to  an  INCOS  data  system. 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section  6.3.1  and  ISO  document  78/2-1982  and 
the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection of  residues  in  meat  as  defined  in  Directive 64/433/EEC.  Failing 
this biological  fluids  (in  this method  bile) or  faeces  may  constitute the 
samples  for  the  detection  of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to  allow 
the  reference  method  to  be  carried out  and  to  allow  repeat  analysis where 
required. 
This  method  for Trenbolone  uses  5 mL  bile therefore the  size shall  not  be 
less  than  20  mL  bile 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to allow  proper 
identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice  the  result of  the  examination. 
Samples  for  the  analysis  of  trenbolone  must  be  stored  and  transported at 
temperatures  below  -18°C. 
9.0  PROCEDURE 
9.1.  Hydrolysis 
Place  5 mL  bile,  15  mL  of  phosphate  buffer  pH  7 and  50  ~L of  glucuronidase 
in  a  20  mL  universal  bottle and  incubate  overnight  at 37°C. 
9.2.  Extrelut Clean-up 
Prepare  an  Extrelut  column  according  to  the  maker•s  instructions.  Onto  a  50 
mL  (MF-24)  Quick-fit tube  place  a 34/35-24/29  Quick-fit expansion  adaptor 
and  place  the  column  in  the  adaptor. 
Add  the  bile/buffer mix  and  leave  for  30  minutes  before  eluting the  column 
with  2 x 35  mL  of  diethyl  ether. 
Reduce  the  ether under  nitrogen  to  approximately  5 mL  before washing  into a 
10  mL  conical  centrifuge tube  and  drying  under  nitrogen.  A small  residue 
is normally  left after drying.  Resuspend  the  extract  in  2 mL  of  40%  (v/v) 
dichloromethane/hexane. 
9.3.  Bond-Elut  Purification 
The  CN  Bond-Elut  columns  should  be  prepared  by  washing  twice  with  2 mL  of 
methanol  and  twice  with  2 mL  of  petroleum  ether.  Before  the  columns  are 
dry  add  the  extract and  wash  with  2 mL  of  dichloromethane/hexane  (70:30 
v/v). 
Cy  1.4/3 Prepare  the  NH2  columns  by  washing  twice  with  methanol  then  twice  with  2 mL 
of  petroleum  ether.  Fill  the  NH2  column  with  diethyl  ether and  attach  the 
CN  column  to  the  top  of  it.  Elute  the  CN  column  into  the  NH2  column  using 
3 mL  of  diethyl  ether.  Discard  the  CN  column.  Wash  the  NH2  column  with  2 
mL  of  2%  (v/v)  methanol  in  dichloromethane. 
Elute  the  NH2  column  into  a  screw  cap  centrifuge tube  with  3 mL  of  33% 
(v/v)  methanol  in  dichloromethane. 
9.4. 
9.4.1. 
9.4.2. 
9.4.3. 
Derivatisation: 
Resuspend  the  dried  sample  in  5 mL  ether.  Sonicate  for  a  few 
seconds  then  transfer to  a  screw  capped  centrifuge tube  using  a 
Pasteur  pipette. 
Evaporate  to dryness  under  nitrogen. 
Add  200  ~L BSTFA-TMCS  and  cap  IMMEDIATELY.  Place  in  Techi  Dri-
block  and  incubate  at 60°C  for  1 hour. 
[NOTE:  The  derivatising reagent  absorbs  water  very  easily.  Do  not  open 
vial  until  you  are ready  to use  it and  seal  it immediately  if there  is any 
left.  The  derivatisation will  not  work  if there  is any  water  present. 
9.4.4. 
9.4.5. 
9.4.6. 
9.4.7. 
9.5. 
9.6. 
9.6.1. 
Allow  to cool,  then  add  200  ~L acetonitrile.  Evaporate  as  an 
azeotropic mixture.  Gently  take  to  dryness  under  nitrogen. 
Resuspend  in  200  ~L  iso-octane.  Sonicate  briefly,  then  transfer 
to a  GC  mini-vial. 
Evaporate  to dryness  under  a  very  gentle  stream  of  nitrogen. 
Resuspend  in  20  ~L iso-octane  and  sonicate briefly. 
Concurrently run  trenbolone  standards.  Concentrations  of  1 ng,  5 
ng,  10  ng,  50  ng,  100  ng  and  10  ~g/mL should  be  taken  to  dryness 
and  the  same  procedure  followed. 
GC-MS  Analysis 
The  GC  parameters  are 
COLUMN:  J&W  fused  silica capillary column,  SE-54,  15  m x 0.25  mm. 
INJECTIONS:  0.5  ~L manual  injections. 
TEMPERATURES:  Interface:  230°C;  Injector:  220°C 
OVEN  TEMPERATURES: 
from  temp  to  temp 
(oc)  (oc) 
55 
55 
240 
GC  Valves: 
55 
240 
240 
rate 
(°C/min) 
20 
time 
(min) 
1.0 
9.2 
10.0 
total  time 
(min) 
1.0 
10.2 
20.2 
Capillary 
Divert 
close  =  0.00 
close  =  0.00 
open  = 0.7 
open  =  20.2 
Carrier Gas: 
Helium;  Flow  rate  =  1  cm3/min 
Injector pressure  =  10  psi 
9.6.2  Set  up  the  MS  parameters  as  shown  below.  The  MS  should  be  tuned 
in  using  a  suitable calibrant  (e.g.  PFTBA). 
Cy  1.4/4 Ionizer:  Mode  =  EI  positive  ion 
Temperature  = 150°C. 
Manifold:  Temperature:  90  (±5°C). 
Electron  Multiplier:  1.2  kV 
Electron  Energy:  70  electron volts. 
Various  settings:  These  parameters  should  be  optimised  by  calibrating the 
instrument  using  PFTBA.  The  actual  values  will  depend  upon  the  instrument 
and  the  condition  of  source  etc but  default values  may  be  found  in  the 
instrument  manual. 
9.6.3.  Operate  the  MS  in  EI  mode  and  scan  between  m/z  =  50  and  400. 
Analyze: 
(a)  Hexane 
(b)  10  ~g in  200  ~L trenbolone  standard. 
Collect  1000  scans.  After  7 minutes  turn  on  the  filament. 
9.6.4.  The  trenbolone  peak  elutes between  10-13  minutes  after  injection. 
Focus  on  the  GC  peak  and  find  the  exact masses  (to  3 decimal  places)  for at 
least the  ions: 
m/z  =  211,  237,  252,  342. 
9.6.5.  Use  these  ions  to set up  or  modify  a multiple  ion  detection  (MID) 
scan  list.  Create  the  scan  list. 
9.6.6.  Re-run  hexane  to ensure  there  is no  carry over  of  trenbolone. 
9.6.7.  Using  the  scan  list just created,  analyze  the  standards  and  the 
sample  on  GC-MS.  It is advisable  to: 
(a) 
(b) 
(c) 
(d) 
analyze  the  1 ~g standard first to ensure  that the  MID  is set up 
correctly.  Follow  this  by  hexane. 
analyze  the  standards  in  order  of  increasing  concentration. 
switch  the filament  on  100  scans  before  the  trenbolone  is due  to 
elute from  the  column  and  turn  it off 100  scans  afterwards. 
run  hexane  between  each  injection. 
10.  RESULTS 
10.1.  Rationale 
Dried  bile extracts,  prepared  by  column  chromatography,  are  derivatised 
with  BSTFA-TMCS  and  the  derivatised extract  is analyzed  by  GC-MS. 
Three  criteria must  be  satisfied for the  positive confirmation  of 
trenbolone: 
1.  The  GC  retention time  of  trenbolone  must  be  the  same  as  that of 
the  standard. 
2.  All  the  characteristic ions  must  be  detected  after subtraction of 
the  background. 
3.  The  characteristic ions  must  be  present  in  the  spectrum  of  the 
sample  in  the  same  ratios as  in  the  spectrum  of  the  standard. 
If trenbolone  is present  in  the  sample,  and  satisfies the  above  criteria, 
then  an  estimate of  the  quantity present may  be  calculated using  one  of  two 
methods: 
1.  Use  the  data  system  to calculate peak  areas  and  create a 
quantisation  list.  Use  a relevant standard  to set up  a 
quantisation  library,  or  use  a range  of  standards.  Refer  the 
Cy  1.4/5 sample  to  this and  obtain  a quantisation  report.  This  is the 
preferred method. 
2.  Measure  the  peak  area  of  the  sample  and  a relevant  standard.  The 
concentration of  trenbolone  in  the  TOTAL  sample  submitted  is then 
found  using  the  equation: 
peak  height  sample  x  concentration  of  standard 
peak  height  standard 
Limit  of  detection:  1  ng  trenbolone  per  L bile. 
11.  SPECIAL  CASES 
12.  NOTES  ON  PROCEDURE 
13.  QUALITY  CONTROL.  STANDARDS  AND  REFERENCE  MATERIALS. 
14.  TEST  REPORT. 
To  give  the  indications  necessary  for  the  identification of  the  sample,  the 
reference  to  the  method  employed,  the  results  and  the  form  in  which  these 
are  expressed,  any  particular points  observed  in  the  course  of  the  test and 
any  operations  not  specified  in  the  method  or regarded  as  optional  which 
might  affect the  results. 
15.  LIST  OF  ABBREVIATIONS 
A list of  the most  important  abbreviations  is given  in  Annex  I  section  12. 
16.  FLOW  DIAGRAM. 
enzyme  hydrolysis  ether eluate 
BILE  ----------------------> EXTRELUT  COLUMN  --------------> DRY  ---> 
elute  elute 
---->CH2Cl 2/MeOH  -----> CN-BOND-ELUT  -----------> NH2-BOND-ELUT  ------> 
COLUMN  COLUMN 
----> CH2Cl 2/MeOH  -----> DERIVATISE  WITH  HFBA  -------> CLEAN  UP  WITH 
PHOSPHATE  BUFFER  --> 
----> GCMS  OF  HFB  DERIVATIVES  -----------------> CALCULATE  RESULTS 
Cy  1.4/6 Cy  1.5.  ZERANOL  - CONFIRMATION  OF  ZERANOL  IN  BILE  BY  GAS  CHROMATOGRAPHY-
MASS  SPECTROMETRY. 
WARNING  AND  SAFETY  PRECAUTIONS 
When  using  ammonia  CI,  ensure  that there are  no  leaks  in  the  system  and 
that there  is adequate  ventilation.  If you  feel  unwell  leave  the  room  and 
get  some  fresh  air. 
0.  INTRODUCTION 
Zeranol  is a  synthetic anabolic  agent  with  weak  oestrogenic activity.  It is 
structurally related to  the  naturally occurring  oestrogenic mycotoxin 
zearalenone  which  was  originally isolated from  mouldy  maize.  Like  other 
anabolic  compounds,  zeranol  is used  to  promote  growth  in  farm  livestock. 
1.  SCOPE 
With  effect from  1 January  1988,  the  use  of  hormonal  growth  promoters  was 
prohibited  throughout  the  EEC.  To  ensure  that farmers  are  not  continuing 
to use  zeranol,  bile  is sampled  at slaughterhouses  and  screened  for  the 
presence  of  this  compound  using  a radioimmunoassay  technique.  Whenever 
there  is a positive screening  result,  this must  be  confirmed  (in  the  UK)  by 
gas  chromatography-mass  spectrometry  (GC-MS).  This  work  is carried out  in 
compliance  with  the  Residues  Directive  (86/469/EEC). 
2.  FIELD  OF  APPLICATION. 
This  method  is used  for  confirmation  of  the  presence  of  zeranol  in  bile 
samples  found  positive  in  the  UK.  The  detection  limit  is 2  ~g/litre of 
bile for  zeranol. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  N 2 
L.118,  14.4.93.  pp  64-74] 
2052/VI/84  File 6.11  II-4,  Scientific Veterinary Committee,  Working 
Group-
11Reference  Methods  for Residues .. ,  General  Criteria for  the 
establishment  of  Reference  Methods  for  the  Detection  of  Residues. 
ISO  Standard  78/2-1982  Layout  for  standards  - Part 2:  Standard  for  Chemical 
Analysis 
CVL  (1990)  Standard  operating  procedure  for Confirmation  of  zeranol  in 
bile by  GC-MS.  27th  June  1990 
4.  DEFINITIONS. 
Zeranol  content  is taken  to  mean  the  amount  of  zeranol  in  the  substance  in 
question,  regardless  of  the  chemical  form,  determined  according  to  the 
described  method  and  expressed  as  ~g zeranol  per  kg  or  litre of  test 
sample. 
5.  PRINCIPLE. 
Cy  1.5/1 The  method  of  analysis  comprises  six stages: 
6.0. 
6.1. 
6.2. 
6.3. 
6.4. 
6.5. 
6.6. 
6.7. 
6.8. 
6.9. 
6.10 
6.11 
6.12 
6.13 
6.14 
(1)  Overnight  hydrolysis  of  the  bile. 
(2)  Extrelut  column  clean-up. 
(3)  Double  Bond-Elut  column  purification. 
(4)  Derivatisation. 
(5)  Post-derivatisation clean-up. 
(6)  Analysis  by  gas  chromatography-mass  spectrometry  (GC-MS). 
CHEMICALS 
Glucuronidase 
Dichloromethane 
Diethyl  ether 
Petroleum  ether 
Methanol 
Heptafluorobutyrate  (HFBA) 
Extrelut columns 
Bond-Elut  columns 
Bond-Elut  columns 
Phosphate  buffer 
Phosphate  buffer 
Hexane 
Heptane 
Perfluorotributylamine 
Boehringer  BCL  (Cat  No.  127051) 
Fisons  Distal  grade  (stabilised 
with  aniline) 
Fisons  Distal  grade 
Fisons  Distal  grade  (40-60°C 
fraction) 
Fisons  Distal  grade 
Phase  Sep  Ltd  (Cat  No.  940851) 
Merck  BDH 
500  mg  CN,  Jones  Scientific 
(Cat  No.  613303) 
500  mg  NH2 ,  Jones  Scientific 
(Cat  No.  611303) 
pH  7 (0.06M)  [3.3 g  Na2HP04  + 
5.75  g  NaH2P04  made  up  to 1 litre] 
pH  6  (1.0M)  [35  g  NaH2P04  +  3g 
NaH2P04  made  up  to 1 litre] 
Distal  grade 
Distal  grade 
Finnigan  MAT. 
6.15.  Standards 
Zeranol  International  Minerals  &  Chemical  Corp. 
The  standard  should  be  made  up  in  methanol  to a concentration of 1 mg/mL 
and  diluted to working  standards  of  concentrations  of  100  ~g/mL,  10  ~g/mL, 
1  ~g/mL,  100  ng/mL,10  ng/mL  and  1 ng/mL. 
7.  EQUIPMENT 
7.1.  Universal  bottles  20  mL 
7.2.  Techni  Dri-block 
7.3.  Quick-fit tubes  50  mL  (MF-24) 
7.4.  Quick-fit expansion  adaptor  (34/35-24/29) 
7.5.  Screw  cap  tubes  J  Bibby  (Cat  No.  5142-10) 
7.6.  Water  bath 
7.7.  Manifold  Supplying  oxygen-free  nitrogen 
7.8.  GC  vials  and  caps 
7.9.  Mass  spectrometer  Finnigan  MAT,  coupled  to a  gas 
chromatograph  and  linked  to  an 
INCOS  data  system. 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is  drawn  to  section 6.3.1  and  ISO  document  78/2-1982  and 
the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
Cy  1.5/2 8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection  of  residues  in  meat  as  defined  in  Directive  64/433/EEC.  Failing 
this biological  fluids  (in  this method  bile) or  faeces  may  constitute the 
samples  for  the  detection  of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to  allow 
the  reference method  to  be  carried out  and  to  allow  repeat  analysis where 
required. 
This  method  for  Zeranol  uses  5 ml  bile therefore the  size shall  not  be  less 
than  20  ml  bile 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to  allow  proper 
identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice  the  result of  the  examination. 
Samples  for  the  analysis  of  zeranol  must  be  stored  and  transported at 
temperatures  below  -l8°C. 
9.  PROCEDURE 
9.1.  Hydrolysis 
Place  5 ml  bile,  15  ml  of  phosphate  buffer  pH  7 and  50  ~L of  glucuronidase 
in  a  20  ml  universal  bottle and  incubate  overnight  at 37°C. 
9.2.  Extrelut Clean-up 
Prepare  an  Extrelut column  according  to  the  maker•s  instructions.  Onto  a  50 
ml  (MF-24)  Quick-f·it  tube  place  a 34/35-24/29  Quick-fit expansion  adaptor 
and  place  the  column  in  the  adaptor. 
Add  the  bile/buffer mix  and  leave  for  30  minutes  before  eluting the  column 
with  2 x 35  ml  of  diethyl  ether. 
Reduce  the  ether  under  nitrogen  to  approximately  5 ml  before  washing  into a 
10  ml  conical  centrifuge tube  and  drying  under  nitrogen.  A small  residue 
is normally  left after drying.  Resuspend  the  extract  in  2 ml  of  40%  (v/v) 
dichloromethane/hexane. 
9.3.  Bond-Elut  Purification 
The  CN  Bond-Elut  columns  should  be  prepared  by  washing  twice  with  2 ml  of 
methanol  and  twice  with  2 ml  of  petroleum  ether.  Before  the  columns  are 
dry  add  the  extract and  wash  with  2 ml  of  dichloromethane/hexane  (70:30 
v/v). 
Prepare  the  NH2  columns  by  washing  twice  with  methanol  then  twice  with  2 ml 
of  petroleum  ether.  Fill  the  NH2  column  with  diethyl  ether and  attach the 
CN  column  to  the  top  of  it.  Elute  the  CN  column  into the  NH2  column  using 
3 ml  of  diethyl  ether.  Discard  the  CN  column.  Wash  the  NH2  column  with  2 
mL  of  2%  (v/v)  methanol  in  dichloromethane. 
Elute  the  NH2  column  into  a screw  cap  centrifuge tube  with  3 mL  of  33% 
(v/v)  methanol  in  dichloromethane. 
Cy  1.5/3 9.4.  Derivatisation 
Dry  the  methanol/dichloromethane  extract and  resuspend  in  1 ml  heptane  and 
100  ~L of  HFBA  (from  a fresh  ampoule).  Cap  the  tube  and  incubate  the 
extract at 80°C  for  20  minutes  in  the  Techni  Dri-block.  Shake  after 3 
minutes  to ensure  adequate  mixing  of  the  two  layers.  After  20  minutes 
remove  the  tubes  and  allow  to cool. 
Concurrently  run  zeranol  standards  through  the  derivatisation  steps. 
Standard  concentrations  =  1 ng,  10  ng,  50  ng,  100  ng,  500  ng,  1  ~g,  10 
~g/mL. 
9.5  Post-Derivatisation  Column  Clean-up 
To  improve  chromatography,  clean-up  the  derivatised extracts  by  adding  5 ml 
of  phosphate  buffer  pH  6.  Shake  vigorously for  exactly 30  seconds,  then 
allow  layers  to settle.  (If necessary,  spin  at 2000  rpm  for  5 minutes). 
Carefully pipette off the  upper  heptane  layer,  using  a Multipette  set to 
0.7  ml  and  vial  up  ready  for  GC-MS.  The  vials should  be  capped 
immediately. 
9.6 
9.6.1. 
GC-MS  Analysis 
The  GC  parameters  are 
COLUMN:  J&W  fused  silica capillary column, 
INJECTIONS:  0.5  ~1  manual  injections. 
TEMPERATURES:  Interface:  230°C 
SE-54,  15  m x 0.25  mm. 
Injector:  220°C 
OVEN  TEMPERATURES: 
from  temp  to temp 
(oc)  (oc) 
55 
55 
240 
55 
240 
240 
20 
CARRIER  GAS:  Helium 
flow  rate  =  1 cm
3/min 
injector pressure  =  10  psi. 
GC  Valves:  Capillary  close:  0.00 
Divert  close:  0.00 
time 
(min) 
1.0 
9.2 
10.0 
total  time 
(min) 
open:  0.7 
open:  20.2 
1.0 
10.2 
20.2 
9.6.2  Set  up  the  MS  parameters  as  shown  below.  The  MS  should  be 
tuned  in  using  a  suitable calibrant  (e.g.  PFTBA). 
Ionizer: 
Mode:  chemical  ionisation  (CI) 
Temperature:  130°C. 
Pressure:  50  Torr 
Manifold:  Temperature:  90  (±  5)°C. 
Electron  Multiplier:  1.2  kV 
Electron  Energy:  70  electron volts. 
Make-up  Gas:  Ammonia 
Other  parameters  should  be  optimised  by  calibrating the  instrument.  Further 
details on  setting up  the  instrument  may  be  found  in  the  instrument  manual. 
9.6.3  In  CI  mode,  using  ammonia  as  the  make-up  gas,  and  scanning 
Cy  1.5/4 between  m/z  = 50  and  700,  run 
(a)  a  blank  hexane 
(b)  10  ~g in  100  ~L zeranol  standard. 
Collect  1000  scans. 
9.6.4  Focus  in  on  the  GC  peak  from  the  zeranol  standard.  Find  the 
exact masses  in  the  spectrum  for  the  selected  ions:  279,  296,  519,  536. 
9.6.5  Use  these masses  to set up  or  modify  a multiple  ion  detection 
(MID)  scan  list. Create  the  scan  list. 
9.6.6  Re-run  hexane  to ensure  there  is  no  carry over  of  the  zeranol. 
9.6.7  Using  the  scan  list just created,  analyze  the  sample  and  the 
standards  on  the  GC-MS.  It is advisable  to: 
(a)  analyze  the  100  ~g standard first to ensure  that the  MID  is set up 
correctly.  Follow  this with  hexane. 
(b)  analyze  standards  in  order  of  increasing  concentration. 
(c)  switch  the filament  on  100  scans  before  the  peak  is due  to elute from 
the  column  and  enter the  source  and  turn  it off  100  scans  afterwards. 
(d)  run  hexane  between  each  injection. 
10.  CALCULATION  OF  RESULTS 
The  presence  of  zeranol  in  a sample  is confirmed  if the  GC-MS  data  agree 
with  the  following  criteria: 
1.  The  peak  has  the  same  retention  time  on  GC  as  the  standards. 
2.  All  the  selected  ions  are  present  in  the  mass  spectrum  of  that 
peak  after subtraction of  the  background. 
3.  The  selected  ions  are  present  in  the  same  ratio to one  another  as 
seen  in  the  standard. 
If zeranol  is present  in  a  sample  and  satisfies the  above  criteria,  then  an 
estimate of  the  quantity present  may  be  calculated using  one  of  two 
methods: 
1. 
2. 
Use  the  data  system  to  calculate peak  areas  and  create a 
quantisation  list.  Use  a relevant standard  to set up  a 
quantisation  library,  or  use  a range  of  standards.  Refer  the 
sample  to this and  obtain  a quantisation  report.  This  is the 
preferred method. 
Measure  the  peak  area  of  the  sample  and  that of  the  relevant 
standard.  The  concentration  of  zeranol  in  the  TOTAL  sample 
analyzed  is given  by  the equation: 
peak  height  sample  x  concentration  of  standard 
peak  height  standard 
Limit  of  detection:  2  ~g per  L of  bile. 
TMS  derivatisation used  for  trenbolone  (refer to  trenbolone  Standard 
Operating  Procedure)  can  also  be  used  for  zeranol.  In  this case  the  MS  is 
operated  in  the  EI  mode  and  the  ions  focused  on  are:  307,  335,  433,  538. 
Cy  1.5/5 11.  SPECIAL  CASES 
12.  NOTES  ON  PROCEDURE 
13.  QUALITY  CONTROL.  STANDARDS  AND  REFERENCE  MATERIALS. 
Reference  materials  for  zeranol  are  being  prepared  under  the  Measurement 
and  Testing  Programme  of  DG12. 
14.  TEST  REPORT. 
To  give  the  indications  necessary  for  the  identification of  the  sample,  the 
reference  to  the  method  employed,  the  results and  the  form  in  which  these 
are  expressed,  any  particular points  observed  in  the  course  of  the  test and 
any  operations  not  specified  in  the  method  or  regarded  as  optional  which 
might  affect the  results. 
15.  LIST  OF  ABBREVIATIONS 
A list of  the  most  important  abbreviations  is given  in  Annex  I  section  12. 
16.  FLOW  DIAGRAM. 
enzyme  hydrolysis  ether eluate 
BILE  ----------------------> EXTRELUT  COLUMN  --------------> DRY  ---> 
elute  elute 
---->CH2Cl 2/MeOH  -----> CN-BOND-ELUT  -----------> NH2-BOND-ELUT  ------> 
COLUMN  COLUMN 
----> CH2Cl 2/MeOH  -----> DERIVATISE  WITH  HFBA  -------> CLEAN  UP  WITH 
PHOSPHATE  BUFFER  --> 
----> GCMS  OF  HFB  DERIVATIVES  -----------------> CALCULATE  RESULTS 
Cy  1.5/6 Cy  1.6.  ZERANOL  - METHOD  FOR  MEASUREMENT  OF  RESIDUES  OF  ZERANOL  IN  ANIMALS 
AND  ANIMAL  TISSUES  USING  RADIOIMMUNOASSAY  (RIA) 
WARNING  AND  SAFETY  PRECAUTIONS 
1.  INTRODUCTION. 
Throughout  the  EEC  the  use  of  zeranol  is prohibited  in  food  producing 
animals.  Also  the  MRL  for  residues  of  zeranol  in  animal  products  imported 
into or  produced  within  the  Community  is zero. 
2.  SCOPE  AND  FIELD  OF  APPLICATION 
This  method  of  analysis  describes  the  determination  of  the  total  content  of 
zeranol  in  foodstuffs  and  samples  of  animal  origin.  The  method  can  be  used 
for meat  and  fish  and  also for  biological  material  such  as  animal  organs, 
biological  fluids  and  faeces.  The  detection  limit,  defined  as  three  times 
the  standard  deviation  of  the  blank  determination,  is 0.1  - 1  ~g per  kg  or 
litre of  sample  for  zeranol. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
2052/VI/84-EN  File 6.21  II-4,  Scientific Veterinary Committee,  Working 
Group- "Reference  Methods  for  Residues",  General  Criteria for  the 
establishment  of  Reference  Methods  for  the  Detection  of  Residues. 
ISO  Standard  78/2-1982  Layout  for  standards  - Part 2:  Standard  for  Chemical 
Analysis 
Method  based  on  modifications  of  methods  described  by;-
Dixon,  S.N.  and  Russel,  K.L.  (1983),  Radioimmunoassay  of  the  anabolic  agent 
zeranol.  II.  Zeranol  concentrations  in  the  urine  of  sheep  and  cattle 
implanted  with  zeranol  (Ralgro).  J.Vet.  Pharmacal.  Therap.  ~  173-179. 
Dixon,  S.N.  and  Mallinson,  C,B.  (1986),  Radioimmunoassay  of  the  anabolic 
agent  Zeranol.  III.  Zeranol  concentrations  in  the  faeces  of  steers 
implanted  with  zeranol  Ralgro).  J.Vet.  Pharmacal.  Therap.  ~  88-93. 
Dixon,  S.N.  and  Russel,  K.L.  (1986),  Radioimmunoassay  of  the  anabolic  agent 
zeranol.IV.  Zeranol  concentrations  in  the  tissues  of  sheep  and  cattle 
implanted  with  zeranol  (Ralgro).  J.Vet.  Pharmacal.  Therap.  ~  94-100. 
Determination  of  zeranol  in  bile by  HPLC/RIA.  (1989).  Central  Veterinary 
Laboratory,  Surrey,  KT15  3NB. 
Other  references; 
Bates,  M.L.,  Warwick,M.J.  and  Shearer,  G.,  (1985)  Determination  of 
synthetic growth  promoters  in  bile.  Food  Add.  Contaminants,  z,  37-46 
Duchatel,  J.P.,  (1985),  Free  and  conjugated  zeranol  residues  determined  by 
radioimmunoassay  in  urine  and  plasma  of  calves  treated with  Forplix.  ANN. 
rech.  Vet.  lQ,  93-97 
Cy  1.6/1 4.  DEFINITIONS. 
Zeranol  content  is taken  to  mean  the  amount  of  zeranol  in  the  substance  in 
question,  regardless  of  the  chemical  form,  determined  according  to  the 
described  method  and  expressed  as  ~g zeranol  per  kg  or  litre of  test 
sample. 
5.  PRINCIPLE 
The  methods  comprises  6/7  stages;-
- Homogenisation  of  tissue samples  in  buffer or  diluting biological  fluid 
in  buffer 
- Hydrolysis  of  conjugates  in  buffer/homogenate  with  enzyme 
- Extraction  of  zeranol  with  organic  solvents 
- Purification  on  Sep-Pak  18  minicolumn  (optional) 
- Purification of  zeranol  by  HPLC 
- End  point  determination  with  RIA 
- The  amount  of  zeranol  is calculated  by  interpolation from  a  standard 
curve  and  taking  into  account  the  recovery  of  zeranol,  especially from 
tissue samples. 
6.  REAGENTS  FOR  EXTRACTION  OF  TISSUES 
N.B.:  The  reagents  for  which  examples  of  their source  are  quoted  are 
known  to  be  satisfactory,  nevertheless  reagents  from  other  sources  may  be 
equally suitable. 
6.1. 
6.1.1. 
6.1.2. 
6.1.3. 
6.1.4. 
6.2. 
6.2.1. 
6.2.2. 
6.2.3.1. 
6.2.3.2. 
6.3. 
6.3.1. 
6.3.2. 
6.3.3. 
6.3.4. 
6.3.4.2 
6.3.5. 
6.4. 
6.4.1. 
6.4.2. 
6.4.2.1 
FOR  ALL  TISSUES 
Acetone 
Dry  ice 
Diethyl-ether  (peroxide  free  and  very  high  purity)  Methyl 
tert-butyl  ether can  be  substituted for  diethyl  ether. 
Double  distilled water 
REAGENTS  SPECIFIC  FOR  LIVER,  KIDNEY,  BILE  AND  URINE. 
Phosphate  buffer  pH  7.0  (as  6.5.4.). 
B-glucuronidase  (e.g.  Sigma  G-0876)  diluted with  ten  volumes 
double  distilled water.  This  enzyme  works  at  pH  7. 
Quality control  urine  or  bile from  cattle treated with  zeranol. 
Quality control  urine  or  bile from  cattle not  treated with 
zeranol. 
REAGENTS  SPECIFIC  FOR  MUSCLE  AND  FAECES 
Chloroform 
1M  sodium  hydroxide 
90%  acetic acid 
Methanol  3.4.1.  Methanol:water  60:40  (v/v) 
Methanol:water  30:70  (v/v) 
Quality control  faeces  from  untreated  cattle 
REAGENTS  SPECIFIC  FOR  MUSCLE,  LIVER,  KIDNEY  AND  FAT. 
Tritiated zeranol  recovery  solution  prepared  from  stock  solution 
(6.5.6.1.)  by  evaporation  and  redissolving  in  buffer  (6.5.4.)  to 
1000  cpm/0.1  mL,  prepared  immediately  before  use. 
Quality Controls 
Quality control  1.  Muscle,  liver,  kidney  and  fat from  cattle not 
Cy  1.6/2 treated with  zeranol. 
Quality control  2.  Muscle,  liver  ,  kidney  and  fat from  cattle 
treated with  zeranol. 
6.5.  REAGENTS  FOR  RIA  PROCEDURE. 
6.5.1.  Zeranol  standard  solutions  in  methanol  (6.3.4.)  stored  at +4°C. 
Number  1  2  3  4  5  6  7  8  9  10  11  12 
pg/0.1mL  0  25  50  75  100  150  200  300  400  600  800  1000 
6.5.2.  Scintillation solution  suitable for  mixing  with  1.5  mL  aqueous 
solution.  e.g.  4.5  g 2,5,diphenyl  oxazone  (PPO)  (e.g. 
Hopkin/Williams  scintillation grade).  500  mL  triton X-114  (e.g. 
Koch  Light  Scintillation grade).  1.5  litres toluene  (6.5.9.). 
6.5.3.  Charcoal  suspension  - 5 g charcoal  (e.g.  Sigma  Norit-A).  0.5  g 
dextran  (e.g.  Pharmacia  T70).  Made  up  in  1 litre double 
distilled water. 
6.5.4.  Phosphate-gelatin  buffer  - 4.68  g sodium  dihydrogen 
orthophosphate  anhyd.  (e.g.  Analar  BDH).  8.66  9 disodium 
hydrogen  orthophosphate  anhyd.  (e.g.  Analar  BDH).  9.0  9 sodium 
chloride  (e.g.  Analar  BDH).  0.1  g thiomersal  (e.g.  BDH)  or  1.0  g 
sodium  azide.  1.0 g gelatin  (e.g.  BDH).  Made  up  to  1 litre  (pH 
7.0)  with  double  dist.  water,  stored at +4°C 
6.5.5.  Pure  zeranol  for  making  standard  solutions. 
6.5.6.  Tritiated zeranol  stored at -20°C.  from  which  stock  solutions 
(6.5.6.1.)  are  prepared.  e.g.  3H-Zeranol  from  Amersham 
International  (custom  synthesis). 
6.5.6.1  Dilute  solutions  (6.5.6)  with  methanol  to yield  stock  solution of 
3H-zeranol  with  approximate  activity of  1 uCi/mL  methanol.  Store 
at -20°C. 
6.5.6.2  Tritiated zeranol  assay  solution,  prepared  from  stock  solution 
6.5.6.1.  by  evaporation  and  redissolving  in  buffer  (6.5.4.)  to 
give  approximately  10,000  cpm/0.1  mL.  Prepared  on  day  of  use. 
6.5.6.3  The  non-specific  binding  (NSB)  of  the  3H-zeranol  must  be 
determined  and  if it exceeds  10%  of  the  total  count  (T)  of 
3H-zeranol  should  be  repurified or  replaced. 
6.5.7.  Antiserum  against  zeranol  stored at -20°C.  (see  section  13) 
6.5.7.1  Prepare  solution of  antibody  in  buffer  (6.5.4.).  It will  be 
necessary  to follow  the  instructions pertaining to  the  individual 
antibody  preparations.  The  concentration  of  antibody  in  buffer 
should  be  7x  greater than  the  concentration  needed  in  the  final 
RIA  incubation  mixture  (see  9.5.2.1.- 9.5.2.3.). 
6.5.8  Siliconising fluid  (e.g.  Serva  35130). 
6.5.9  Toluene. 
7. 
7.1. 
7.2. 
7.3. 
7.3.1. 
7.3.2. 
7.4. 
7.5. 
7.5.1. 
7.5.2. 
7.6. 
7.6.1. 
EQUIPMENT. 
Liquid  scintillation Counter,  with  automatic  sample  changer. 
Homogeniser  (Silverson  type). 
Cold  storage  space. 
Cold  room/refrigerator  space. 
Deep  freeze  -20°C. 
Fume  cupboards. 
Centrifuges. 
Refrigerated  centrifuge with  large  capacity for  small  tubes. 
Bench  centrifuge. 
Heating  units. 
37°C  water  bath/incubator. 
Cy  1.6/3 7.6.2. 
7.6.3. 
7.7. 
7.7.1. 
7.7.2. 
7.7.3. 
7.7.4. 
7.8. 
7.9. 
7.10. 
7.10.1. 
7.10.2. 
7.10.3. 
7.10.4. 
7.11. 
7.11.1. 
7.12. 
7.13. 
7.14. 
7.14.1. 
7.14.2. 
7.14.4. 
8. 
40/45°C  water  bath. 
110°C  oven. 
Glassware. 
Glass  tubes  75  mm  x 16  mm. 
Glass  conical  centrifuge  tubes. 
Glass  universal  bottles,  approx  25  mL  with  plastic screw  tops. 
Glass  tubes  7.7.1.  were  siliconised by  rinsing with  siliconising 
fluid  and  baking  for  1 hour  at 100°C. 
Scintillation vials. 
Vortex  mixer. 
Pipettes  and  dispensers. 
Semi-automatic  pipettes with  disposable  tips. 
Pasteur  pipettes. 
Tilt measures  (10  mL  and  5 mL  for  diethyl  ether). 
Dispenser  for scintillator. 
Apparatus  suitable for evaporation  of  solvents.  e.g. 
Compressed  nitrogen  supply  and  evaporation  manifold. 
Facilities for evaporating  at temperatures  not  exceeding  50°C. 
Magnetic  stirrer. 
Measuring  cylinder,  25  mL. 
HPLC  apparatus.  Reference  to  a  company  and/or  product  is for 
purposes  of  information  and  identification only.  Equivalent 
types  or  products  also  may  be  suitable. 
Injector  (Reodyne,  model  7125)  equipped  with  a 0.25  mL  sample 
loop. 
HPLC-pump  (Waters  Ass.,  model  510  or  LKB,  model  2150).  7.14.3. 
UV-detector,  variable or  fixed  wave-length  at 254  or  240  nm 
(Waters  Ass.,  model  440) 
Fraction  collector  (LKB,  model  Redirac),  see  note  2.  7.14.5. 
HPLC-column  (150mm  x 4.6mm  I.D.)  with  Valco  fittings  (Chrompack) 
packed  with  Hypersil  ODS,  5  ~m or  a  column  (100mm  x 4.6mm)  packed 
with  CP  microsphere  C18,  3  ~m (Chrompack).  7.14.6. 
Recorder-printer. 
SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section  6.3.1  and  ISO  document  78/2-1982  and 
the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to  enable  the 
detection  of  residues  in  meat  as  defined  in  Directive 64/433/EEC.  Failing 
this biological  fluids or  faeces  may  constitute the  samples  for  the 
detection  of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to allow 
the  reference method  to  be  carried out  and  to  allow  repeat  analysis where 
required. 
In  this method  for  zeranol  the  sizes shall  not  be  less  than 
20  g muscle,  liver,  kidney  or fat;  10  g faeces;  20  mL  blood 
5 mL  urine;  1 mL  bile 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to  allow  proper 
identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
Cy  1.6/4 integrity of  the  sample  and  not  prejudice  the  result of  the  examination. 
Samples  for  the  analysis of  zeranol  must  be  stored  and  transported at 
temperatures  below  -18°C. 
9.0.  PROCEDURE 
9.1.  EXTRACTION  PROCEDURE 
[Note;  For  all  samples  recovery  of  zeranol  is measured  by  addition  of 
tritiated zeranol  before  the  extraction procedure  and  determining  the 
recovery of  tritiated zeranol  in  an  aliquot of  extract before  the  RIA 
stage.] 
9.1.1.  URINE  AND  BILE 
The  method  measures  the  total  concentration  of  zeranol.  The  conjugated 
form  of  the  zeranol  in  the  samples  is  hydrolysed  to  the free  form  and  the 
total  residue  of  zeranol  is extracted  into ether.  The  extract can  be 
further  purified  by  HPLC  step  before  proceeding  to the  RIA  step. 
9.1.2. 
9.1.2.1 
9.1.3. 
9.1.4. 
9.1.5. 
9.1.6. 
9.1.7 
9.1.8. 
9.1.9. 
9.1.10. 
9.1.10.1 
9.1.10.2 
9.1.10.3 
9.1.10.4 
Into  universal  bottles  (7.7.3.)  place  2.0  ml  double  distilled 
water  (6.1.4.)  and  0.1  ml  tritiated recovery  solution  (6.4.1.) 
Add  0.1  ml  recovery  solution  {6.4.1.)  to  2 scintillation vials 
(7.8.). 
Into  universal  bottles from  9.1.2.  add  0.05  ml  bile or  urine  {if 
the  concentration of  zeranol  is extremely  high  a  smaller  aliquot 
of  bile or  urine  may  be  used).  All  samples  are  assayed  in 
duplicate. 
Into  2 other universal  bottles from  9.1.2.  add  0.05  ml  quality 
control  urine  or  bile  (6.2.3.1.  or  6.2.3.2.). 
Two  universal  bottles from  9.1.2.  are  used  as  solvent  blanks. 
Add  to universals 9.1.3.-9.1.5.  100  ~L enzyme  (6.2.2.)  and 
incubate  for  2 h at 37°C. 
Allow  to  cool  and  add  5 ml  diethyl-ether {6.1.3.),  vortex  mix  for 
15  seconds. 
Freeze  samples  in  dry  ice/acetone  bath  (6.1.1.,  6.1.2.)  and 
decant  ether phase  into  glass  tubes. 
Evaporate  to dryness.(7.11.1). 
HPLC  step. 
Dissolve  the  dry  residue  in  0.25  ml  methanol/water  (30:70  v/v) 
Apply  the  redissolved extract  (9.1.10.1)  to  the  HPLC-system. 
Operate  the  HPLC-system  isocratically using  methanol/water  {60:40 
v/v)  as  mobile  phase  with  a flow  of  1-2  ml  per  min. 
Collect one  fraction of  5 min  around  the  retention time  of 
zeranol  as  determined  for  standards  of  zeranol  and  related 
compounds  shortly before  the  run  with  the  extract {9.1.10.1). 
Separation  of  zeranol  from  related compounds  should  be  complete. 
Notes  on  HPLC.  1.  For  tissue extracts an  additional  Sep-Pak  C18  clean-up 
is recommended  prior to  HPLC  purification to  save  the  HPLC  column.  2. 
Fraction  collector can  be  operated  manually  or  by  an  electric pulse  from 
the  injection to the  fraction  collector. 
9.1.10.5  Evaporate  the  solvent from  the  single fraction. 
9.1.11.  Add  1.0 ml  buffer  (6.5.4.)  and  vortex  mixed. 
9.1.12.  Proceed  as  9.3.17  - 9.3.21. 
Cy  1.6/5 9.2.  FAECES 
The  principal  of  the  method  is to  extract free  zeranol  from  faeces  using 
ether.  The  ether extract  is further  purified  by  solvent/solvent 
partition systems  before  RIA. 
9.2.1. 
9.2.2. 
9.2.3. 
9.2.4. 
9.2.5. 
9.2.6. 
9.2.7. 
9.2.8. 
9.2.9. 
9.2.10. 
9.2.11 
9.2.12. 
9.2.13. 
9.2.14. 
9.2.15. 
9.2.16. 
9.2.16.1 
9.2.17. 
9.2.17.1 
Into  universal  bottles  (7.7.3.)  are weighed  1 g faeces  in 
duplicate. 
Into  2 universal  bottles are weighed  1 g of  quality control 
faeces  (6.3.5.). 
Into  2 universal  bottles and  universal  bottles 9.2.1.  and  9.2.2. 
are  added  5 mL  water. 
Add  0.1  mL  zeranol  recovery  solution  (4.1.)  to  universals 
9.2.1.,9.2.2.,9.2.3.  and  vortex  mix  for  15  seconds.  9.2.4.1.  Add 
0.1  mL  of  zeranol  recovery  solution  to  2 scintillation vials 
(7.8.). 
Add  10  mL  diethyl-ether,  vortex  mix  for  15  seconds,  centrifuge at 
2000-3000  rpm  for  10  minutes. 
Freeze  the  universal  bottles  in  dry  ice/acetone  (6.1.1.,  6.1.2.) 
and  decant  the  ether phase  into  glass  conical  centrifuge tubes 
(7.7.2.). 
Thaw  the  aqueous  phase  and  repeat  procedures  9.2.5.  and  9.2.6. 
Evaporate  the  combined  ether phases  to  dryness.(7.11.1). 
Dissolve  the  residue  in  1 mL  chloroform  (6.3.1.). 
Extract  zeranol  from  the  chloroform  using  1 x 3  mL  (1M)  sodium 
hydroxide  (6.3.2.).  Vortex  mix  for  15  seconds  and  centrifuge at 
lOOOg  for  10  minutes.  Pipette the  upper  sodium  hydroxide  phase 
into  universal  bottles  (7.7.3.). 
Repeat  9.2.10. 
The  combined  alkaline extracts are  acidified with  0.6  mL  of  90% 
acetic acid  (6.3.3). 
Extract  zeranol  from  the  aqueous  phase  with  1 x 10  mL 
diethyl-ether  separate  the  ether phase  by  freezing  in  dry 
ice/acetone  (9.2.6).  Each  step  was  facilitated  by  vortex  mixing 
and  gentle centrifugation  prior to  freezing  if required. 
Evaporate  the  combined  ether extracts to  dryness. 
HPLC  step  (see  9.1.10.  to  9.1.10.5.) 
Dissolve  the  residue  in  1 mL  MeOH  (6.3.4.). 
Transfer  0.2  mL  to  a scintillation vial  (7.8.)  and  proceed 
9.3.16.  - 9.3.18.  to measure  recovery. 
Prepare  aliquots of  1/50  to  1/10  sample  for  RIA  as  in  9.2.16.1. 
Transfer 0.1  mL  MeOH  extract  (9.2.15.)  to  siliconised glass  tubes 
(7.7.4.)  and  evaporate  to  dryness  under  nitrogen.  Add  0.5  mL 
buffer  (6.5.4.)  for  RIA  stage  (9.5.1.to 9.5.10.) 
9.3.  MUSCLE,  LIVER,  KIDNEY. 
The  method  is based  on  further  purification by  ether extraction of  muscle 
followed  by  solvent/solvent partition and  HPLC.  Liver  and  kidney  require  an 
additional  hydrolysis  step  prior to  the  extraction. 
9.3.1. 
9.3.2. 
9.3.3. 
9.3.4. 
9.3.5. 
1 g tissue  is  cut  into  small  pieces  and  weighed  in  universal 
bottles  (7.7.3.). 
Add  2 mL  water  and  homogenise  (7.2). 
Repeat  9.3.1.-9.3.4.  using  quality control  tissue  (6.4.2.1-2). 
Add  2  mL  water  to  two  universal  bottles which  serve  as  solvent 
blanks. 
Add  0.1  mL  radiolabelled zeranol  recovery  solution  (6.4.1.)  to 
universals  9.3.2.,  9.3.3.,  and  into 2 scintillation vials  (7.8.) 
Cy  1.6/6 9.3.6. 
9.3.7. 
9.3.7.1 
9.3.8. 
9.3.9. 
9.3.10. 
9.3.11. 
9.3.12. 
9.3.13. 
9.3.14. 
9.3.15. 
9.3.16. 
9.3.17. 
9.3.18. 
9.3.19. 
9.3.20. 
9.3.21. 
9.4. 
9.4.1. 
9.4.2. 
9.4.3. 
9.4.4. 
9.4.5. 
9.4.6. 
9.4.7. 
9.4.8. 
9.4.9. 
9.4.11. 
and  homogenise  the  contents  of  the  universals. 
For  liver and  kidney  add  0.1  ml  of  enzyme  (6.2.2.)  to  each 
universal  and  incubate  for  2 hours  at 37°C. 
Add  10  ml  diethyl  ether,  vortex  mix  for  30  seconds,  centrifuge at 
2000-3000  rpm  at l8°C. 
Freeze  the  universal  bottles  in  dry  ice/acetone  (6.1.1.,  6.1.2.) 
and  decant  the  ether phase  to  glass  conical  centrifuge tubes 
(7.7.2.). 
Thaw  the  aqueous  phase  and  add  5 ml  diethyl  ether to  aqueous 
phase  and  repeat extraction  as  in  9.3.7. 
Pool  ether extracts and  evaporate  to  dryness  (7.11.1). 
Dissolve  residue  in  1 ml  chloroform  (6.3.1.). 
Extract zeranol  with  1 x 3 ml  of  1M  sodium  hydroxide  (6.3.2.)  (30 
seconds  vortex  mixing  and  centrifugation,  1000g  for  10  min  at 
l8°C). 
The  sodium  hydroxide  extract is pipetted  into a universal  bottle 
(7.7.2.)  containing  90%  acetic acid  (250  ~L)  (6.3.3.). 
Extract zeranol  with  5 ml  diethyl-ether  (vortex  mix  and  gentle 
centrifugation).  Freeze  the  universals  in  dry  ice/acetone  and 
decant  the  ether phase  into glass  conical  centrifuge tubes 
(7.7.2.). 
Evaporate  to  dryness  (7.11.1). 
HPLC  step.(9.1.10.  to 9.1.10.5.). 
Add  1 ml  gelatin-phosphate  buffer  (6.5.4.)  and  vortex  mix  for  30 
seconds. 
Transfer  0.25  ml  of  9.3.16.  into  scintillation vial  (7.8.). 
Add  10  mL  scintillation fluid to  9.3.17  and  2 scintillation vials 
containing  recovery  solution  (see  9.3.5.,  9.2.4.1.  and  9.1.2.1.). 
Add  10  ml  scintillator to  2 scintillation vials  (7.8)  containing 
0.2  ml  gelatin-phosphate  buffer  (6.5.4.).  This  is  for  the 
background  count. 
Count  vials 9.3.18.  and  9.3.19.  for  20  minutes  on  B-counter  (7.1.) 
Transfer  0.5 ml  of  9.3.16  into  siliconised tube  (7.7.4.)  for  RIA 
step  (see  9.5.1.  to  9.5.10.). 
FAT 
1 g fat  is cut  into  small  pieces  and  weighed  into  universal 
bottles  (7.7.3). 
Add  2 ml  double  distilled water  (6.1.4) 
Repeat  9.4.1  and  9.4.2 using  quality control  fat  (6.4.2.1-2) 
Add  0.1  ml  radiolabelled recovery  solution  (6.4.1)  to  universals 
9.4.2,  9.4.3. 
Add  to all  universals  (9.4.2,  9.4.3)  10  ml  of  diethyl  ether and 
vortex for  1 minute. 
Centrifuge  all  universals  at 1000g  for  10  minutes  and  separate 
the  two  phases  by  freezing  at -20°C  in  a deep  freeze  (7.3.2). 
Decant  the  ether phase  into  glass  tubes  (7.7.2). 
Add  5 ml  diethyl  ether to  all  universals  and  repeat  the 
extraction  (9.4.5,  9.4.6). 
Pool  ether extracts and  evaporate  to  dryness  (7.11.1).  9.4.10. 
Dissolve  residue  in  2 ml  chloroform  (6.3.1). 
Proceed  as  from  9.3.10. 
9.5.  RADIOIMMUNOASSAY  PROCEDURE. 
The  method  chosen  for  separation of  antibody-bound  and  free  ligand  uses 
charcoal.  The  RIA  procedure  is the  same  for all extracts obtained  from 
bile,  urine,  faeces,  muscle,  liver,  kidney  or  fat. 
Cy  1.6/7 9.5.1. 
9.5.2.1 
9.5.2.2 
9.5.2.3 
9.5.3. 
9.5.4. 
9.5.5. 
9.5.6. 
9.5.8. 
9.5.9. 
9.5.10. 
10. 
Into  4 siliconised tubes  (7.7.4.)  pipette 0.1  mL  methanol  (zero 
standard  tubes).  Into  siliconised tubes  (7.7.4.)  pipette  in 
duplicate 0.1  mL  of  zeranol  standard  solutions  (6.5.1.)  to  give 
range  0-1000  pg  per  tube.  Evaporate  methanol  to dryness 
e.g.under  nitrogen  (7.11.1.). 
Add  0.5  mL  gelatin-phosphate  buffer  (6.5.4.). 
Add  to  9.5.2.1.  and  to test samples  (see  9.1.11,  9.2.16. 
9.2.16.2.,9.3.20.)  0.1  mL  tritiated zeranol  solution  (6.5.6.2.). 
Add  0.1  mL  antibody  (6.5.7.1.)  to  all  tubes  except  2 of  the  zero 
standard  tubes  to which  is added  0.1  mL  buffer  (6.5.4.)  (NSB 
tubes). 
Vortex  mix  for  a  few  seconds.  Incubate  overnight  at 41°C. 
Add  0.5  mL  charcoal  suspension  (6.5.3)  at 4°C. 
Shake  all  tubes  gently  by  hand  for  1 minute  and  stand  at 4°C  for 
10  minutes. 
Centrifuge  at 2000-3000  rpm  at 4°C  for  10  minutes.  9.5.7. 
Decant  supernatant  into scintillation vial  (7.8.),  at 4°C. 
Add  10  mL  scintillator (6.5.2.)  to  all  vials  including  2 vials 
containing  0.1  ml  tritiated zeranol  solution  (6.5.6.2.)  and  0.1 
mL  gelatin-phosphate  buffer  (6.5.4.). 
Stand  vials  in  dark  for at  least 20  minutes  before  counting. 
Place  samples  in  liquid scintillation counter  (7.1)  and  count 
(preset time  or  counts)  e.g.  10000  counts  or  4 minutes. 
CALCULATION  OF  RESULTS. 
10.1.  METHOD  OF  CALCULATION. 
Prepare  calibration curve  by  plotting cpm  3H-zeranol  bound  (cpm  bound  to 
antibody  for  vials containing  standards  0-1000  pg  (see  6.5.1)  against  pg 
standard. 
[Note.:  Two  corrections are  needed,  one  for  the  radioactivity carried  into 
the  RIA  from  the  recovery  solution  and  another  for  the  recovery  of 
zeranol.] 
10.2.  Correction  equation  for  cpm 
corrected  cpm  =  cpm  bound  x cpm  3H-zeranol  (T) 
cpm  3H-zeranol  (T)  +  N(cpm  recovery  - cpm  Bg) 
Volume  of  sample  to  RIA 
N = 
Volume  of  sample  to recovery  determination 
cpm  bound  =  cpm  bound  for  test sample 
cpm  3H-zeranol  (T)  =  cpm  for  0.1  ml  3H-Zeranol  solution  (6.5.6.2)  used  in 
RIA  incubations  (see  9.5.10). 
cpm  recovery  =  cpm  for  0.25  ml  extract of  test sample  (9.3.17). 
cpm  Bg  is  cpm  for  background  (see  9.3.19). 
10.3.  Read  off calibration curve  pg  zeranol  against corrected  cpm  for 
test samples  and  solvent  blanks. 
10.4.  Calculation  for  concentration  of  zeranol  in  sample 
Cy  1.6/8 pg  zeranol  in  sample  i.e.  1 g muscle,  50  ~L bile and  50  ~L urine. 
(curve  pg  - blank  pg)(recovery  stnd.  - cpm  Bg) 
pg  = 
N(cpm  recovery  - cpm  Bg) 
curve  pg  = pg  obtained  in  step  10.3. 
blank  pg  = pg  for  solvent  blanks  obtained  in  step  10.3. 
recovery  standard= cpm  for 0.1  mL  3H-zeranol  recovery  solution  (6.4.1.). 
cpm  recovery  = cpm  for  volume  of  extract of  test sample  used  for recovery 
estimation  (9.2.16.1.,  9.3.17) 
cpm  Bg  = cpm  for  background  (9.3.19). 
10.5.  Alternative calculations. 
B = cpm  bound  to antibody- cpm  for  NSB  (NSB  tubes  9.5.2.3.). 
Bo  = cpm  bound  to  antibody  in  zero  standard  tubes  - cpm  for  NSB.  Bo  should 
be  between  40-60%  of  total  cpm  (cpm  3H-zeranol(T))  (see  10.2.). 
10.5.1.  Prepare  calibration curve  by  plotting B/Bo  against  pg  standard. 
10.5.1.1  If a microcomputer  programme  is possible  then  a  best  line plot of 
log  pg  standard  against  Ln  Z/(1-Z)  where 
Z = B/Bo  (LOGIT  plot)  can  be  used  to  interpolate results. 
10.5.2.  Calculate  B/Bo  for  test sample  and  for  the  solvent  blank  using 
corrected cpm- NSB  (see  10.2.)  and  estimate  pg  zeranol  from 
calibration curve. 
10.5.3.  Proceed  as  10.4. 
10.5.4.  The  original  counting  data  should  be  included with  the  final 
results. 
10.6.  PRECISION.  To  take  into  account  the Criteria document  (89/610 
EEC)  and  will  explain  how  the  precision of  the  method  is determined  using 
the  standards  available. 
11.  SPECIAL  CASES 
This  method  is  an  alternative method  to  spectroscopic methods.  However  it 
is strongly emphasised  that the  spectroscopic methods  (e.g.  GC-MS)  are 
preferred  (see  EEC  93/256  1.2.3.1 {section  5}). 
12.  NOTES  ON  PROCEDURE 
In  order  to  have  even  greater certainty when  positives are found  it is 
recommended  to repeat  the  HPLC  separation  using  an  alternative column  with 
different properties  (e.g.  different polarity). 
11.  SPECIAL  CASES.  e.g.  if a particular species  presents  unique 
problems. 
12.  NOTES  ON  PROCEDURE. 
13.  QUALITY  CONTROL.  STANDARDS,  REFERENCE  MATERIALS  AND  ANTIBODIES. 
A description of  the  source  and  quality of  the  key  reagents  and  standards. 
Cy  1.6/9 13.1  ANTIBODIES.  Follow  the  instructions relating to  the  storage  and 
dilution of  the  antibody  as  recommended  by  the  supplier. 
13.2.  Source  of  antibodies. 
Commercial  suppliers;-
Laboratoire  d
1Hormonologie,  C.E.R,  Rue  de  Carmel  1,  B-5406,  Marloie, 
Belgium 
Genego,  Via  Ressel  S Andrea  zona  ind.,  34170,  Gorizia,· Italy 
14.  TEST  REPORT.  To  give  the  indications  necessary for  the 
identification of  the  sample,  the  reference  to  the  method  employed,  the 
results and  the  form  in  which  these  are expressed,  any  particular points 
observed  in  the  course  of  the  test and  any  operations  not  specified  in  the 
method  or  regarded  as  optional  which  might  affect the  results. 
15.  LIST  OF  ABBREVIATIONS 
A list of  the  most  important  abbreviations  is given  in  Annex  I  section  12 
and  also  in  section  5 (criteria).  NSB  is non-specific  binding. 
16.  FLOW  DIAGRAM. 
Tissue  --~ add  buffer  and  recovery  standard  --~ Homogenise 
I 
Fluid  (urine,  bile,  plasma,  serum) 
I 
I 
! 
add  buffer and  recovery  standard  ------------~ 
I 
I 
I 
I 
I 
I 
I 
! 
Hydrolyse 
I 
I 
I 
I 
! 
Calculate  ~----- RIA  ~----- HPLC  ~----- organic  solvent 
results  extraction 
Cy  1.6/10 Cy  1.7.  STILBENES  - METHOD  FOR  THE  MEASUREMENT  OF  RESIDUES  OF 
DIETHYLSTILBOESTROL,  HEXOESTROL  AND  DIENOESTROL  IN  ANIMALS  AND  ANIMAL 
TISSUES  ON  THE  BASIS  OF  HPLC/RIA. 
WARNING  AND  SAFETY  PRECAUTIONS. 
1.  INTRODUCTION. 
Throughout  the  EEC  the  use  of  stilbenes  is prohibited  in  food  producing 
animals.  Also  the  MRL  for  residues  of  stilbenes  in  animal  products 
imported  into or  produced  within  the  Community  is zero. 
2.  SCOPE  AND  FIELD  OF  APPLICATION 
This  method  of  analysis  describes  the  determination  of  the  total  content of 
diethylstilboestrol  (DES),  hexoestrol  (HEX)  or  dienoestrol  (DEN)  in 
foodstuffs  and  samples  of  animal  origin.  The  method  can  be  used  for meat 
and  fish  and  also for  biological  material  such  as  animal  organs,  biological 
fluids  and  faeces.  The  detection  limit,  defined  as  three times  the  standard 
deviation  of  the  blank  determination,  is 0.1-1  ~g/kg or  litre of  sample  for 
the  stilbene. 
3.  REFERENCES. 
ISO  Standard  78/2-1982  Layout  for  standards  - Part 2:  Standard  for  Chemical 
Analysis 
EEC  Interim Report  of  Scientific Veterinary Committee,  Working  Group  on 
Reference  Methods  for Residues.  Draft  reference method  for  the  measurement 
of  stilbenes  in  animals  and  animal  tissues 2526/VI/84-EN  File 6.21  11-4 
Bates,  M.L.,  Warwick,  M.J.  and  Shearer,  G.  (1985),  Determination  of 
synthetic growth  promoters  in  bile.  Food  Additives  &  Contaminants.  z,  37-
46 
Gaspar,  P.  and  Maghuin-Rogister,  G.,  (1985),  Rapid  extraction  and 
purification of  diethylstilboestrol  in  bovine  urine  hydrolysates  using 
reversed  phase  C 18  columns  before  determination  by  radioimmunoassay.  J. 
Chromat.  328,  413-416 
Harwood,  D.J.,  Heitzman,  R.J.  and  Jouquey,  A.,  (1980),  A radioimmunoassay 
method  for  the  measurement  of  residues  of  the  anabolic  agent  hexoestrol  in 
tissues of  cattle and  sheep.  J.Vet.  Pharmacal.  &  Therapeutics,  J,  245-254 
Heitzman,  R.J.  and  Harwood,  D.J.  (1983),  Radioimmunoassay  of  hexoestrol 
residues  in  faeces,  tissues and  body  fluids  of  bulls and  steers.  Vet.  Rec. 
112,  120-123 
Jansen,  E.H.J.M.,  (1985),  A highly  specific detection  method  for 
diethylstilboestrol  in  bovine  urine  by  radioimmunoassay  following  high 
performance  liquid chromatography.  Food  Additives  &  Contaminants.  z,  271-
281 
Richou-Bac,  L.,  (1977),  Recherche  et dosage  par  radioimmunologie 
d'estradiol-17a,  d'estrone et de  DES  sur  les  jeunes  bovines  traites uax 
anabolisants.  Bull  Acad.  Vet.  de  France.  50,  359-363 
Cy  1.7/1 Vogt,  von  K.,  (1985),  Vereinfachte  Absicherung  des  radioimmunologischen 
Nachweises  von  Diethylstilbestrol  in  Fleischhaltigen Konserven  und 
tierischen Ausscheidungen.  Arch.  fur  Lebensm.hygiene.  36,  1-24 
4.  DEFINITIONS. 
DES,  HEX  or  DEN  content  is taken  to  mean  the  amount  of  DES,  HEX  or  DEN  in 
the  substance  in  question,  regardless  of  the  chemical  form,  determined 
according  to  the  described  method  and  expressed  as  ~g DES,  HEX  or  DEN  per 
kg  or  litre of  test sample. 
5.  PRINCIPLE 
The  method  comprises  6 stages;-
Homogenisation  of tissue samples  in  buffer or  diluting 
biological  fluid  in  buffer 
Hydrolysis  of  conjugates  in  buffer/homogenate  with  enzyme 
Extraction  of  DES,  HEX  or  DEN  with  organic  solvents 
Purification of  DES,  HEX  or  DEN  by  HPLC 
End  point  determination with  RIA 
The  amount  of  DES,  HEX  or  DEN  is calculated  by  interpolation from 
a  standard  curve  and  taking  into account  the  recovery  of  DES,  HEX 
or  DEN,  especially from  tissue samples. 
6.  REAGENTS  FOR  EXTRACTION  OF  TISSUES. 
Note:  The  reagents  for which  examples  of  their source  are  quoted  are 
known  to be  satisfactory,  nevertheless  reagents  from  other sources  may  be 
equally suitable. 
6.1. 
6.1.1. 
6.1.2. 
6.1.3. 
6.2. 
6.2.1. 
6.2.2. 
6.2.3.1 
6.3. 
6.3.1. 
6.3.2. 
6.3.3. 
6.3.4. 
6.3.4.1 
6.3.5.1 
6.3.5.2 
6.4. 
6.4.1. 
FOR  ALL  TISSUES 
Acetone 
Dry  ice 
Diethyl-ether  (peroxide  free  and  very  high  purity) 
Reagents  specific for  bile and  urine 
Phosphate  buffer  pH  7.0  (as  6.5.4.  but  omit  gelatin). 
B-glucuronidase  (e.g.  Sigma  G-0876)  diluted with  two  volumes 
double  distilled water.  This  enzyme  works  at  pH  7.  If an 
Arylsulphatase  - glucuronidase  preparation  from  Helix  Pomatia  is 
used  then  the  hydrolysis  stage  (9.1.6.)  is performed  in  buffer 
adjusted  to  pH  4.7. 
Quality control  urines  or  biles from  cattle treated with 
stilbenes. 
Reagents  specific for muscle  and  faeces 
Chloroform 
1M  sodium  hydroxide 
6M  hydrochloric  acid 
Methanol 
Methanol:water  75:25  (v/v) 
Quality control  faeces  from  untreated  calf 
Quality control  faeces  from  untreated  steer 
Reagents  specific for muscle 
Tritiated stilbene recovery  solution  prepared  from  stock  solution 
Cy  1.7/2 6.4.2. 
6.4.3. 
6.4.4. 
6.4.5. 
6.4.5.1 
6.4.5.2 
6.5. 
6.5.1. 
(6.5.6.1.)  by  evaporation  and  redissolving  in  buffer  (5.4.)  to 
1000  cpm/0.1  mL  stored at 4°C. 
Petroleum  ether  bp  40°-60°C  (or  50-70°C)  for method  1. 
Diethyl-ether:n-butanol  9:1  (v/v)  method  2. 
1M  hydrochloric  acid  for  method  2. 
Quality control  muscle  tissue. 
Quality control  1.  Muscle  from  untreated cattle. 
Quality control  2.  Muscle  from  cattle treated with  stilbene. 
Reagents  for  RIA  procedure 
Stilbene  standard  solutions  in  methanol  (6.3.4.)  stored at +4°C. 
Number  1 
pg/0.1  mL  0 
2  3  4  5  6  7 
20  50  100  200  400  600 
8  9 
800  1000 
6.5.2.  Scintillation solution  suitable for mixing  with  1.5  mL  aqueous 
solution.  e.g.  4.5  g 2,5,diphenyl  oxazone  (PPO)  (e.g. 
Hopkin/Williams  scintillation grade).  500  mL  triton X-114  (e.g. 
Koch  Light  Scintillation grade).  1.5  litres toluene  (6.5.9.). 
6.5.3.  Charcoal  suspension  - 5 g charcoal  (e.g.  Sigma  Norit-A).  0.5  g 
dextran  (e.g.  Pharmacia  T70).  Made  up  in  1 litre double 
distilled water. 
6.5.4.  Phosphate-gelatin  buffer  - 4.68  g sodium  dihydrogen  phosphate 
anhyd.  (e.g.  Analar  BDH).  8.66  g disodium  hydrogen  phosphate 
anhyd.  (e.g.  Analar  BDH).  9.0  g sodium  chloride  (e.g.  Analar 
BDH).  0.1  g thiomersal  (e.g.  BDH)  or  1.0 sodium  azide.  1.0 g 
gelatin  (e.g.  BDH).  Made  up  to  1 litre  (pH  7.0)  with  double 
distilled water,  stored at +4°C. 
6.5.5.  Pure  DES,  HEX  and  DEN  (e.g.  Sigma)  for  making  standard  solutions. 
6.5.6.  Tritiated stilbenes stored at -20°C  from  which  stock  solutions 
(6.5.6.1.)  are  prepared.  e.g.  3H-DES  from  Amersham  International. 
6.5.6.1  Dilute solutions  (6.5.6)  with  methanol  to yield stock  solution of 
3H-stilbene with  approximate  activity of  1 uCi/mL  methanol. 
Store  at +4°C. 
6.5.6.2  Tritiated stilbene assay  solution,  prepared  from  stock  solution 
6.5.6.1.  by  evaporation  and  redissolving  in  buffer  (6.5.4.)  to 
give  10,000  cpm/0.1  mL.  Prepared  on  day  of  use. 
6.5.6.3  The  non-specific  binding  (NSB)  of  the  3H-stilbene must  be 
determined  and  if it exceeds  10%  of  the  total  count  (SA)  of 
3H-stilbene  should  be  repurified or  replaced. 
6.5.7.  Antiserum  against stilbenes stored at -20°C. 
6.5.7.1  Prepare  solution of  antibody  in  buffer  (6.5.4.).  It will  be 
necessary  to follow  the  instructions pertaining  to  the  individual 
antibody  preparations.  The  concentration of  antibody  in  buffer 
should  be  8x  greater than  the  concentration  needed  in  the  final 
RIA  incubation  mixture  (see  9.5.2.1.-9.5.2.3.) 
6.5.8.  Siliconising fluid  (e.g.  Serva  35130). 
7.  EQUIPMENT. 
7.1. 
7.2. 
7.3. 
7.3.1. 
7.3.2. 
7.4. 
7.5. 
7.5.1. 
Liquid  scintillation Counter,  with  automatic  sample  changer. 
Homogeniser  (Silverson  type). 
Cold  storage  space. 
Cold  room/refrigerator  space. 
Deep  freeze  -20°C. 
Fume  cupboards. 
Centrifuges. 
Refrigerated  centrifuge with  large  capacity for  small  tubes. 
Cy  1.7/3 7.5.2. 
7.6. 
7.6.1. 
7.6.2. 
7.6.3. 
7.7. 
7.7.1. 
7.7.2. 
7.7.3. 
7.7.4. 
7.8. 
7.9. 
7.10. 
7.10.1. 
7.10.2. 
7.10.3. 
7.10.4. 
7.11. 
7.11.1. 
7.12. 
7.13. 
7.14. 
Bench  centrifuge. 
Heating  units. 
37°C  water  bath/incubator. 
40/45°C  water  bath. 
110°C  oven. 
Glassware. 
Glass  tubes  75  mm  x 12.5  mm. 
Glass  stoppered  tubes  100  mm  x  16  mm. 
Glass  universal  bottles,  approx  25  mL  with  plastic screw  tops. 
Glass  tubes  7.7.1.  were  siliconised  by  rinsing with  siliconising 
fluid  and  baking  for  1 hour  at 105°C. 
Scintillation vials. 
Vortex  mixer. 
Pipettes and  dispensers. 
Semi-automatic  pipettes with  disposable  tips. 
Pasteur  pipettes. 
Tilt measures  (10  mL  for  diethyl  ether). 
Dispenser  for  scintillator. 
Apparatus  suitable for evaporation  of  solvents.  e.g.  Compressed 
nitrogen  supply  and  evaporation  manifold  or  rotary film 
evaporator. 
Solvent  should  be  evaporated  at temperatures  not  exceeding  50°C 
using  e.g.  either a  stream  of  nitrogen  or  a rotary film 
evaporator. 
Magnetic  stirrer. 
Measuring  cylinder,  25  mL. 
HPLC  apparatus. 
Reference  to  a  company  and/or  product  is for  purposes  of  information  and 
identification only.  Equivalent  types  or  products  also  may  be  suitable. 
7.14.1.  Injector  (Reodyne,  model  7125)  equipped  with  a 0.25  mL  sample 
loop. 
7.14.2.  HPLC-pump  (Waters  Ass.,  model  510  or  LKB,  model  2150). 
7.14.3.  UV-detector,  variable or  fixed  wave-length  at 254  or  240  nm 
(Waters  Ass.,  model  440) 
7.14.4.  Fraction  collector  (LKB,  model  Redirac),  see  note  2. 
7.14.5.  HPLC-column  (150mm  x 4.6mm  I.D.)  with  Valco  fittings  (Chrompack) 
packed  with  Hypersil  ODS,  Sum  or  a  column  (100mm  x 4.6mm)  packed 
with  CP  microsphere  C18,  3um  (Chrompack). 
7.14.6.  Recorder-printer. 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section  6.3.1  and  ISO  document  78/2-1982  and 
the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection  of  residues  in  meat  as  defined  in  Directive 64/433/EEC.  Failing 
this biological  fluids or  faeces  may  constitute the  samples  for  the 
detection  of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to allow 
the  reference method  to  be  carried out  and  to  allow  repeat  analysis where 
required. 
In  this method  for  stilbenes the  sizes  shall  not  be  less  than 
Cy  1.7/4 20  g muscle,  liver,  kidney  or  fat 
10  g faeces 
20  mL  blood 
5 ml  urine 
1 ml  bile 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to allow  proper 
identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice  the  result of  the  examination. 
Samples  for  the  analysis  of  stilbenes must  be  stored  and  transported at 
temperatures  below  -18°C. 
9.  PROCEDURE. 
9.1.- 9.4.  EXTRACTION  PROCEDURE. 
Note:  For  all  samples  recovery  of  stilbene  is measured  by  addition  of 
tritiated stilbene before  the  extraction  procedure  and  determining  the 
recovery  of  tritiated stilbene  in  an  aliquot of  extract before  the  RIA 
stage. 
9.1. 
9.1.1. 
9.1.2. 
9.1.2.1 
9.1.3. 
9.1.4. 
9.1.5. 
9.1.6. 
9.1.7. 
9.1.8. 
9.1.9. 
9.1.10. 
9.1.10.1 
9.1.10.2 
9.1.10.3 
9.1.10.4 
9.1.10.5 
9.1.10.6 
URINE  AND  BILE. 
The  method  measures  the  total  concentration of  stilbenes.  The 
conjugated  form  of  the  stilbenes  in  the  samples  is hydrolysed  to 
the  free form  and  the  total  residue  of  stilbene  is extracted  into 
ether.  The  extract  is further  purified  by  a chromatography  step 
before  proceeding  to  the  RIA  step. 
Into  universal  bottles  (7.7.3.)  place  1.0 ml  buffer  (6.5.4.)  and 
0.1  ml  tritiated recovery  solution  (6.4.1.). 
Add  0.1  ml  recovery  solution  (6.4.1.)  to 2 scintillation vials 
(7.8.). 
Into  universal  bottles from  9.1.2.  add  0.05  ml  bile or  urine  (if 
the  concentration of  stilbene  is extremely  high  a smaller  aliquot 
of  bile or  urine  may  be  used).  All  samples  are  assayed  in 
duplicate. 
Into  2 other  universal  bottles from  9.1.2.  add  0.05  ml  quality 
control  urine  (6.2.3.1.  or  6.2.3.2.). 
Two  universal  bottles from  9.1.2.  are  used  as  solvent  blanks. 
Add  to  universals  9.1.3.- 9.1.5.  10  ~L enzyme  (2.2.)  and  incubate 
for  2 h at 37°C. 
Allow  to  cool  and  add  5 ml  diethyl-ether  (6.1.3.),  vortex  mix  for 
15  seconds. 
Freeze  samples  in  dry  ice/acetone  bath  (6.1.1.,  6.1.2.)  and 
decant  ether phase  into  glass  tubes. 
Evaporate  to dryness.(7.11.1). 
HPLC  step.(see also  9.2.14;  9.3.21;  9.4.12) 
Dissolve  the  dry  residue  in  0.25  ml  methanol/water  (60:40  v/v) 
Apply  the  redissolved extract (9.1.10.1)  to  the  HPLC-system 
Operate  the  HPLC-system  isocratically using  methanol/water  (60:40 
v/v)  as  mobile  phase  with  a flow  of  1-2  ml  per  min. 
Collect  three fractions of  1 min  around  the  retention times  as 
determined  for  standards  of  DES,DEN  and  HEX  shortly before  the 
run  with  the  extract  (9.1.10.1).  Separation  of  DES,  DEN  and  HEX 
should  be  complete  (see  note  3). 
Evaporate  the  solvent of  the  three fractions  under  nitrogen. 
For  each  fraction  continue  with  9.1.11. 
Cy  1.7/5 Notes  on  HPLC. 
1.  For  tissue extracts  an  additional  LH-20  column  clean-up  is  recommended 
prior to  HPLC  purification to  save  the  HPLC  column. 
2.  Fraction  collector can  be  operated manually  or  by  an  electric pulse  from 
the  injection to  the  fraction  collector. 
3.  For  typical  examples  see:  E.H.J.M.Jansen,  R Both-Miedema,  H.  van 
Blitterswijk  and  R.W.Stephany;  J  Chromatography,  1984,  299,  450-455 
9.1.11.  1.0  ml  buffer  (6.5.4.)  are  added  and  vortex  mixed. 
9.1.12.  Proceed  as  9.3.23  - 9.3.27. 
9.2.  FAECES. 
The  principal  of  the  method  is to extract free  stilbene from  faeces  using 
ether.  The  ether extract  is further  purified by  solvent/solvent partition 
systems  before  RIA. 
9.2.1. 
9.2.2. 
9.2.3. 
9.2.4. 
Into  universal  bottles  (7.7.3.)  are weighed  1 g faeces  in 
duplicate. 
Into  2 universal  bottles are weighed  1 g of  quality control 
faeces  (6.3.5.1.  or  6.3.5.2.). 
Into  2 universal  bottles and  universal  bottles 9.2.1.  and 
9.3.2.2.  are  added  5 ml  water. 
Add  0.1  ml  stilbene recovery  solution  (6.4.1.)  and  vortex  mix  for 
1 minute. 
9.2.4.1  Add  0.1  ml  recovery  solution  to  2 scintillation vials  (7.8.). 
9.2.5.  Add  10  ml  diethyl-ether,  vortex  mix  for  30  seconds,  centrifuge at 
9.2.6. 
9.2.7. 
9.2.8. 
9.2.9. 
9.2.10. 
2000-3000  rpm  for  5 minutes. 
Separate ether phase  into  glass  tubes  (7.7.2.). 
Repeat  procedures  9.2.5.  and  9.2.6.  using  5 ml  diethyl-ether. 
Evaporate  the  combined  ether phases  to  dryness  (7.11.1). 
Dissolve  the  residue  in  1 ml  chloroform  (6.3.1.). 
Extract  stilbene from  the  chloroform  using  1 x 2 ml  M  sodium 
hydroxide  and  1 x 1 ml  M  sodium  hydroxide.  In  each  case  the 
samples  are  vortex  mixed  and  then  separated  by  gentle 
centrifugation. 
9.2.11.  Adjust  pH  of  the  combined  alkaline extracts to about  pH  8 with  6M 
HCl  and  to  pH  7-8  with  1M  HCl. 
9.2.12.  Extract  stilbene from  the  aqueous  phase  with  3 x 2 ml 
diethyl-ether.  Each  step was  facilitated  by  vortex  mixing  and 
gentle  centrifugation. 
9.2.13.  Evaporate  the  combined  ether extracts to dryness. 
9.2.14.  HPLC  step  (see  9.1.10.) 
9.2.15.  Dissolve  the  residue  in  1 ml  MeOH  (6.3.4.). 
9.2.15.1.  Transfer  0.2  ml  to a scintillation vial  (7.8.)  and  proceed 
9.3.23.  - 9.3.26.  to measure  recovery. 
9.2.16.  Prepare  aliquots of  1/50  to  1/10  sample  for  RIA  as  in  9.2.16.1. 
or  9.2. 16.2. 
9.2.16.1  Method  for  veal  calves:  dissolve 0.1  ml  MeOH  extract  (9.2.15.)  in 
6 ml  buffer  (6.5.4.)  and  transfer 0.6  ml  to  siliconised tubes 
(7.7.4.)  for  RIA  stage. 
9.2.16.2  Method  for  other farm  animals:  transfer 0.1  ml  MeOH  extract 
(9.2.15.)  to  siliconised glass  tubes  (7.7.4.)  and  evaporate  to 
dryness  under  nitrogen  (9.1.9.).  Add  0.6  ml  buffer  (6.5.4.)  for 
RIA  stage. 
Cy  1.7/6 9.3.  MUSCLE  - method  1 
Two  methods  are  described  and  appear  equally reliable.  The  method  is based 
on  further  purification  by  ether extraction of  muscle  followed  by 
solvent/solvent partition and  HPLC. 
9.3.1. 
9.3.2. 
9.3.3. 
9.3.4. 
9.3.5. 
9.3.6. 
9.3.7. 
9.3.8. 
9.3.9. 
9.3.10. 
9.3.11. 
9.3.12. 
9.3.13. 
9.3.14. 
9.3.15. 
9.3.16. 
9.3.17. 
9.3.18. 
9.3.19. 
9.3.20. 
9.3.21. 
9.3.22. 
9.3.23. 
9.3.24. 
9.3.25. 
9.3.26. 
9.3.27. 
9.4. 
9.4.1. 
9.4.2. 
5 g muscle  is cut  into  small  pieces  and  weighed  in  universal 
bottles  (7.7.3.). 
Add  15  mL  water  and  homogenise. 
Transfer  to measuring  cylinder  and  adjust  volume  to  20  mL  with 
water. 
Transfer  in  duplicate  (or  more  if capacity allows)  4  mL  of 
homogenate  9.3.3.  to  universal  bottles  (7.7.3.). 
Repeat  9.3.1.- 9.3.4.  using  quality control  muscle  (6.4.5.1,  2,  3 
or 4). 
Add  4 ml  water  to  two  universal  bottles which  serve  as  solvent 
blanks. 
Add  0.1  mL  radiolabelled  stilbene recovery  solution  (6.4.1.)  to 
universals  9.3.4.  to  9.3.6.  and  into  2 scintillation vials 
(7.8.). 
Add  10  ml  diethyl  ether,  vortex  mix  for  30  seconds,  centrifuge at 
2000-3000  rpm  at 4°C  and  transfer ether phase  to  glass  tube 
(7.7.2.). 
Add  5 ml  diethyl  ether to aqueous  phase  and  repeat  extraction as 
in  9.3.8. 
Pool  ether extracts and  evaporate  to  dryness  (7.11.1). 
Dissolve  residue  in  1 ml  chloroform  (6.3.1.). 
Extract  stilbene with  1 x 2 ml  and  2 x 1 ml  volumes  of  1M  sodium 
hydroxide  (30  seconds  vortex  mixing  and  gentle centrifugation). 
Pool  sodium  hydroxide  extracts and  reduce  pH  to about  pH  8 with 
6M  hydrochloric  acid  and  to  pH  7-8  with  1M  HCl. 
Extract  stilbene with  3 x 2 mL  diethyl-ether  (vortex  mix  and 
gentle centrifugation). 
Pool  ether extracts and  evaporate  to  dryness  (7.11.1). 
Add  1 ml  methanol:water:  3:1  (v/v,  6.3.4.1.). 
Wash  aqueous  methanol  with  2 x 2 ml  petroleum  ether 
(6.4.2.)(vortex mix  and  gentle centrifugation). 
Evaporate  aqueous  methanol  phase  to dryness. 
Add  1 ml  water  and  extract stilbene with  3 x 2 ml  diethyl-ether. 
Pool  ether extracts and  evaporate  to  dryness  (7.11.1.). 
HPLC  step.(see 9.1.10.). 
Add  1 ml  gelatin-phosphate  buffer  (6.5.4.)  and  vortex  mix  for  30 
seconds. 
Transfer 0.2  ml  of  9.3.22.  into  scintillation vial. 
Add  10  ml  scintillation fluid  to 9.3.23  and  2 scintillation vials 
containing  recovery  solution  (see  9.3.7.,  9.2.4.1.  and  9.1.2.1.). 
Add  10  ml  scintillator to  2 scintillation vials containing 0.2  ml 
gelatin-phosphate  buffer  (6.5.4.).  This  is for  the  background 
count. 
Count  vials 9.24.  and  9.25.  for  20  minutes  on  B-counter  (7.1.). 
Transfer  0.6  ml  of  9.3.22  into  siliconised tube  (7.7.4.)  for  RIA 
step. 
MUSCLE  - method  2 
Proceed  as  from  9.3.1.  to  9.3.10. 
Add  1 mL  1M  NaOH  and  dissolve  residue  by  vortex  mixing.  9.4.3. 
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9.4.5. 
9.4.6. 
9.4.7. 
9.4.8. 
9.4.9. 
9.4.10. 
9.4.11. 
9.4.12. 
9.4.13. 
9.5. 
Add  to all  tubes  4.0  mL  diethyl-ether:n-butanol:  9:1  (v/v}  and 
vortex  for  5 seconds. 
Centrifuge for  5 minutes  at 3000  rpm. 
Freeze  the  aqueous  phase  in  dry  ice-acetone  bath  and  discard  the 
organic  phase. 
Add  4.0  ml  diethyl-ether and  vortex  for  2 seconds.  Repeat  9.4.5. 
once. 
Repeat  9.4.6.  once. 
Acidify all  tubes  with  1.2  mL  1M  hydrochloric  acid. 
Add  8.0  mL  diethyl-ether and  extract on  a  shaking  machine,  15 
min. 
Freeze  the  aqueous  phase  in  dry  ice-acetone  bath. 
Decant  ether phase  and  evaporate  to dryness. 
HPLC  step.(see 9.1.10.). 
Proceed  as  9.3.23.  to 9.3.27. 
RADIOIMMUNOASSAY. 
The  method  chosen  for  separation  of  antibody-bound  and  free  ligand  uses 
charcoal.  The  RIA  procedure  is the  same  for  all  extracts obtained  from 
bile,  urine,  faeces  or muscle. 
9.5.1. 
9.5.2.1 
9.5.2.2 
9.5.2.3 
9.5.3. 
9.5.4. 
9.5.5. 
9.5.6. 
9.5.7. 
9.5.8. 
9.5.9. 
9.5.10. 
10. 
Into  4 siliconised tubes  (7.7.4.)  pipette 0.1  mL  methanol  (zero 
standard  tubes).  Into  siliconised tubes  (7.7.4.)  pipette  in 
duplicate 0.1  mL  of  stilbene standard  solutions  (6.5.1.)  to give 
range  20-1000  pg  per  tube.  Evaporate  methanol  to  dryness 
e.g.under nitrogen  (9.1.9.). 
Add  0.6  mL  gelatin-phosphate  buffer  (6.5.4.). 
Add  to 9.5.2.1.  and  to test samples  (see  9.1.11,  9.2.16.,  9.3.27. 
and  9.4.13)  and  0.1  mL  tritiated stilbene solution  (6.5.6.2.). 
Add  0.1  mL  antibody  (6.5.7.1.)  to  all  tubes  except  2 of  the  zero 
standard  tubes  to which  is added  0.1  mL  buffer  (6.5.4.)  (NSB 
tubes). 
Vortex  mix  for  a few  seconds. 
Either  - place  in  water  bath  at 37°C  for  15  minutes  and  then 
incubate  overnight  at +4°C.  Or  place  in  water  bath  at 37°C  for  1 
hour  and  then  cool  in  ice  bath  to 0-4°C. 
Add  0.5  mL  charcoal  suspension  (5.3)  at 4°C. 
Shake  all  tubes  gently  by  hand  for  1 minute  and  stand  at 4°C  for 
5 minutes. 
Centrifuge  at 2000-3000  rpm  at 4°C  for  10  minutes. 
Decant  supernatant  into  scintillation vial  (7.8.). 
Add  10  mL  scintillator (6.5.2.)  to all  vials  including  2 vials 
containing 0.1  mL  tritiated stilbene solution  (6.5.6.2.)  and  0.1 
mL  gelatin-phosphate  buffer  (6.5.4.). 
Place  samples  in  liquid scintillation counter  (7.1)  and  count 
(preset time  or  counts)  e.g.  10000  counts  or  4 minutes. 
CALCULATION  OF  RESULTS. 
Note:  The  example  given  is for the  calculation using  DES.  The  calculation 
for  hexoestrol  is the  same. 
10.1.  Prepare  calibration curve  by  plotting cpm  H3-DES  bound  (cpm  bound 
to antibody  for  vials containing  standards  0-1000  pg  (see  6.5.1) 
against  pg  standard. 
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the  RIA  from  the  recovery  solution  and  another  for  the  recovery  of 
stilbene. 
10.2.  Correction  equation  for  cpm  -
corrected  cpm  =  cpm  bound  x cpm  3H-DES 
cpm  3H-DES  (SA)  +  3(cpm  recovery  - cpm  Bg) 
cpm  bound  = cpm  bound  for  test sample 
cpm  3H-DES  (SA)  = cpm  for 0.1  mL  3H-DES  solution  (6.S.6.2)  used  in  RIA 
incubations  (see  9.S.10). 
cpm  recovery=  cpm  for  0.2  mL  extract of  test sample  (see  9.3.23). 
cpm  Bg  is  cpm  for  background  (see  9.3.2S). 
10.3.  Read  off calibration curve  pg  DES  against  corrected  cpm  for  test 
samples  and  solvent  blanks. 
10.4.  Calculation  for  concentration  of  stilbene  (as  DES)  in  sample  -
pg  stilbene  in  sample  i.e.  1g  muscle,  SOuL  bile,  SOuL  urine  and 
either 20mg  (from  9.2.16.1.)  or  100mg  (from  9.2.16.2.)  faeces. 
= (curve  pg  - blank  pg)(recovery  stnd.  - cpm  Bg) 
3(cpm  recovery  - cpm  Bg) 
curve  pg  = pg  obtained  in  step  10.3. 
blank  pg  = pg  for  solvent  blanks  obtained  in  step 10.3. 
recovery  standard= cpm  for  0.1  mL  3H-DES  recovery  solution  (6.4.1.). 
cpm  recovery  = cpm  for  extract of  test sample  (9.S.11). 
cpm  Bg  = cpm  for  background  (9.3.2S). 
10.S.  Alternative calculations. 
B = cpm  bound  to  antibody- cpm  for  NSB  (NSB  tubes  9.S.2.3.). 
Bo  = cpm  bound  to  antibody  in  zero  standard  tubes  - cpm  for  NSB. 
Bo  should  be  between  40-60%  of  total  cpm  (cpm  3H-DES(SA))  (see  10.2.). 
10.S.1.  Prepare  calibration curve  by  plotting B/Bo  against  pg  standard. 
10.S.1.1  If a microcomputer  programme  is possible  then  a  best  line plot of 
log  pg  standard  against  Ln  Z/(1-Z)  where 
Z = B/Bo  (LOGIT  plot)  can  be  used  to  interpolate results. 
10.S.2.  Calculate  B/Bo  for  test sample  and  for  the  solvent  blank  using 
corrected cpm- NSB  (see  10.2.)  and  estimate  pg  DES  from 
calibration curve. 
10.S.3.  Proceed  as  10.4. 
10.S.4.  The  original  counting  data  should  be  included  with  the  final 
results. 
11.  SPECIAL  CASES 
This  method  is  an  alternative method  to  spectroscopic methods.  However  it 
is strongly emphasised  that the  spectroscopic methods  (e.g.  GC-MS)  are 
preferred  (see  EEC  93/2S6  1.2.3.1 {sectionS}). 
Cy  1.7/9 12.  NOTES  ON  PROCEDURE 
This  method  in  which  the  separation of  the  stilbenes by  HPLC  and  the 
measurement  by  RIA  has  been  compared  with  a  GC-MS  procedure  at RIVM, 
Bilthoven.  No  discrepancies  between  positives  and  negatives  for  both 
methods  were  observed.  However  for  even  greater certainty when  positives 
are  found  it is  recommended  to  repeat  the  HPLC  separation  using  an 
alternative column  with  different properties  (e.g.  different polarity). 
13.  ANTIBODIES 
Some  antibodies  are  commercially  available but  recommend  up  to date 
information  is obtained  from  the  Community  Reference  Laboratories. 
14.  QUALITY  CONTROLS 
See  section 8  of  manual  detailing the  RMs  available for  the  stilbenes. 
15.  LIST  OF  ABBREVIATIONS 
NSB,  non-specific  binding;  SA,  standard  addition;  Bg,  background 
counts/min 
A full  list of  abbreviations  is given  in  Annex  I,  Section  12 
16.  FLOW  DIAGRAM 
Tissue  --> add  buffer  and  recovery  standard  ---> Homogenise 
I 
Fluid  (urine,  bile,  plasma,  serum) 
I 
I 
! 
add  buffer  and  recovery  standard ------------> 
I 
I 
I 
I 
I 
I 
I 
! 
Hydrolyse 
I 
I 
! 
Calculate <----- RIA  <----- HPLC  <----- organic  solvent 
results  extraction 
Cy  1.7/10 Cy  1.8.  ETHINYLOESTRADIOL  - METHOD  FOR  THE  MEASUREMENT  OF  RESIDUES  OF 
ETHINYLOESTRADIOL  IN  CATTLE  URINE  BY  GC-MS. 
WARNING  AND  SAFETY  PRECAUTIONS 
0.  INTRODUCTION 
Throughout  the  EEC  the  use  of  xenobiotic  anabolic  agents  is prohibited  in 
food  producing  animals. 
1.  SCOPE 
This  method  of  analysis  describes  the  detection  and  confirmation  of  the 
presence  of  ethinyloestradiol  in  urine  of  cattle 
2.  FIELD  OF  APPLICATION. 
The  method  is used  to  perform  routine  screening  and  confirmatory analyses 
in  bovine  urine  samples.  The  detection  limit of  ethinyloestradiol  was  0.7 
~g per  L. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
ISO  Standard  78/2-1982  Layout  for  standards  - Part  2:  Standard  for  Chemical 
Analysis 
Daeseleire,  E.,  De  Guesquiere,  A.  and  Van  Peteghem,  C,  (1991),  Detection 
of  the  illegal  use  of  ethinyloestradiol  in  cattle urine  by  gas 
chromatography-mass  spectrometry.  J.  Chromatog.  564,  469-475 
4.  DEFINITIONS. 
Ethinyloestradiol  content  is taken  to  mean  the  amount  of  ethinyloestradiol 
in  bovine  urine,  regardless of  the  chemical  form,  determined  according  to 
the  described  method  and  expressed  as  ~g ethinyloestradiol  per  L urine. 
5.  PRINCIPLE 
5.1.  The  methods  comprises  7 stages;-
1.  Concentration  using  C18  column 
2.  Hydrolysis  of  conjugates  with  enzyme. 
3.  Clean  up  using  linked  C18  and  amino  SPE  columns 
4.  Purification on  HPLC 
5.  Derivatisation to  diTMSi  ethers 
6.  Detection  and  identification  by  GCMS 
7.  Calculation  of  results. 
Cy  1.8/1 6.  MATERIALS 
Note:  The  reagents  for  which  examples  of  their source  are  quoted  are 
known  to  be  satisfactory,  nevertheless  reagents  from  other  sources  may  be 
equally suitable.  Unless  specified otherwise  chemicals  are of  AR  grade. 
6.1.  Reference  Compounds  and  Standard  Solutions. 
Ethinyloestradiol  was  from  Sigma,  USA 
Solutions  of  1 mg  per  mL  methanol,  stored  in  brown  glass  bottles 
in  the  dark  at +4°C 
6.2.  Sodium  acetate 
6.3  Glacial  acetic acid 
6.4.  Methanol,  HPLC  grade  (Alltech  Assoc,  USA) 
6.5.  Water,  HPLC  grade  (Alltech  Assoc,  USA) 
6.6.  Helix  Pomatia  extract  (B-glucuronidase  plus  aryl  sulphatase from 
Boehringer,  Mannheim,  Germany). 
6.7.  Nitrogen 
6.8.  Ethyl  acetate  (Janssen,  Belgium) 
6.9.  Pyridine  (Pierce,  USA) 
6.10.  N-methyl-N-trimethylsilyltrifluoroacetamide  (MSTFA)  (Aldrich, 
USA) 
6.11.  Trimethylchlorosilane  (TMCS)  (Fluka,  Buchs,  Switzerland) 
6.12.  Helium  (L
1Aire  Liqiude,  Liege,  Belgium) 
6.13.  n-hexane 
6.14.  Dimethyldichlorosilane  (Merck) 
6.15.  Toluene  (Merck) 
6.16.  Acetate  buffer  solution  3 mol/L  ,  pH  4.6 
Dissolve  18.015  g acetic acid  and  40.83  g sodium  acetate.3H20  in 
100  mL  water. 
6.17.  Acetate  buffer  solution  0.2 mol/L  ,  pH  4.6,  The  acetate buffer 
(6.16)  is diluted  15  times  with  water. 
6.18.  Derivatization  reagents:  10  parts  (v/v)  of  pyridine  are mixed 
with  3 parts N-methyl-N-trimethylsilyl-trifluoracetamide  (MSTFA) 
and  1 part trimethylchlorosilane  (TMCS)  as  a catalyst.  The 
mixture  must  be  freshly prepared. 
7.  EQUIPMENT. 
Reference  to  a  company  and/or  product  is for  purposes  of  information  and 
identification only.  Equivalent  types  or  products  also  may  be  suitable. 
7.1. 
7.2. 
7.3 
7.4. 
7.5. 
7.6 
7.7 
7.8. 
7.9. 
7.9.1. 
Glass  Pasteur capillary pipettes. 
Automatic  pipettes 
pH  meter  with  glass electrode. 
Electric water  bath  with  adjustable thermostat. 
Vortex  Mixer 
Small  filter funnels 
Glass  derivatization vials  (Chromacol  250  (A))  with  screw  caps 
(Chromacol  85c)  and  septa  (Chromacol  8-ST15)  or  alternatively 
pointed  flasks  or  conical  tubes  with  glass  stoppers.  The  vials 
were  silanised with  dimethyldichlorosilane  (6.14)  before  use. 
Heating  module  set at 60°C  for  derivatization vials  (Pierce  no. 
18790)  with  nitrogen  facility. 
SPE  Columns. 
C18  column;  (6  mL  disposable,  Baker,  USA).  The  column  was 
conditioned  by  washing  with  2 x 5 mL  methanol  and  2 x 5 mL  water. 
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7.10. 
7.10.1. 
7.10.2. 
7.10.3. 
7.10.4. 
7.11. 
7.11.1. 
7.11.2. 
7.11.3. 
7.11.4. 
7.11.5. 
7.11.6. 
7.11.7. 
7.11.8. 
8. 
Amino  column;  (3  mL  disposable,  Baker,  USA).  The  column  was 
conditioned  by  washing  with  2 x 3 mL  ethyl  acetate. 
HPLC  equipment 
The  system  consisted of  a  pump  (Waters  6000A),  automatic  injector 
(Waters  Wisp  7108),  a fraction  collector  (2212  Helirac, 
Pharmacia),  and  a  UV  detector  (Pye  Unicam,  PU  4020)  set at 280 
nm. 
The  column  was  a LiChospher  RP18,  125  mm  x 4  mm  i.d.,  (Merck) 
protected  by  a guard  column  of  pellicular reversed  phase  30-50 
urn,  75  mm  x 2.1  mm  i.d.,  (Chrompack,  Cat  no.28603,  Middelburg, 
NL). 
The  mobile  phase  was  methanol:water  (65:35,  v/v)  pumped  at a flow 
rate of  1 mL  per  min. 
The  time-window  for  collecting ethinyloestradiol  is established 
by  first running  25  ng  of  ethinyloestradiol. 
GC-MS  equipment. 
Capillary gas  chromatograph  with  all  glass  injector maintained  at 
290°C.  (Hewlett  Packard  HP  5890) 
Automatic  injection for  GC  - not  compulsory 
A mass  spectrometer with  a  low  resolution  and  a mass  range  of  at 
least 600  amu.  It must  be  possible to  apply  the  MID  (multiple 
ion  detection)  mode,  also a mass  specific detector  and  an  ion 
trap detector.  (Hewlett  Packard  HP  5970) 
Workstation  (e.g.  Hewlett  Packard,  type  59970). 
Printer 
GC-column, 
The  carrier gas  was  helium 
The  coupling  of  GC-MS  may  be  by  means  of  a fused  silica capillary 
heated  to 290°C. 
SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section  6.3.1  and  ISO  document  78/2-1982  and 
the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  of  urine  shall  be  such  as  to enable 
the  detection  of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to  allow 
the  reference method  to  be  carried out  and  to  allow  repeat  analysis where 
required. 
8.3.  The  urine  must  be  cooled  after collection  and  stored  at~ -20°C 
pending  analysis. 
9.  PROCEDURE 
9.1.  10  mL  of  urine  sample  is adjusted  to  pH  4.6 with  acetate buffer 
(6.16). 
9.2.  The  urine  is put  on  to  the  C18  column  (7.9.1),  washed  with  2 x 5 
mL  water  and  eluted with  2 mL  methanol. 
9.3.  The  methanol  is evaporated  to  dryness  under  a stream  of  nitrogen 
at 40°C 
9.4.  The  residue  is taken  up  in  100  ~L methanol  and  5 mL  0.2M  acetate 
buffer  (6.17)  added  and  50  ~L Helix  Pomatia  juice added. 
Cy  1.8/3 9.5.  The  sample  is  incubated  for  16  hours  at 37°C. 
9.6  After  cooling  to room  temperature,  the  sample  is added  to  the 
previously  used  and  reconditioned  C18  column.  The  amino  column 
(7.9.2)  is connected  beneath  the  C18  column. 
9.7.  Ethinyloestradiol  is eluted from  both  columns  with  2 x 1  mL  of 
ethyl  acetate. 
9.8.  The  ethyl  acetate  is evaporated  to  dryness  under  a  stream  of 
nitrogen  at 40°C 
9.9.  The  residue  is taken  up  in  100  ~L methanol  and  50  ~L  injected 
into  the  HPLC  system.  The  methanol-water  fraction  collected 
between  4 and  7 min  (3  mL)  was  evaporated  to dryness  under  a 
stream  of  nitrogen. 
9.10.  The  residue  is dissolved  in  100  ~L of  derivatizing agent  (6.18) 
and  heated  at 60°C  for  1 hour.  After  evaporation  of  the excess 
reagent,  the  final  residue  is dissolved  in  50  ~L of  n-hexane,  2 
~L of which  is  injected  into  the  GC-MS  system. 
9.11.  The  following  conditions  are  used  during  GC-MS  analysis. 
9.11.1.  GC  System 
9.4.2. 
GC  Capillary  GC  (HP  5890) 
column  fused  silica HP  Ultra-2  (5%  phenylmethyl-
silicone)  25m  x 0.2  mm  10,  film  thickness 
0.33  urn 
injection  2  ~L all-glass moving  needle  at 290°C 
carrier gas  Helium  at 0.47  mL  per  minute 
programme  200°C  - 280°C  at  5°C/min.  280°C  for  10  min. 
transfer  line temp.  290°C 
initial  column  pressure  1.2  bar 
Under  these  conditions  retention times  for ethinyloestradiol-
diTMS  is 28.43  expressed  as  methylene-unit  values. 
MS  Conditions. 
The  MS  was  run  in  the  SIM  mode  using  dwell  times  of  100  msec. 
The  selected  ions  for ethinyloestradiol-diTMS were  440,  425,  300  and  285. 
10.  CALCULATION  OF  RESULTS. 
A sample  is declared  positive when  all  ions  simultaneously appeared  at the 
right retention  times,  and  checked  with  retention  behaviour  of  an 
ethinyloestradiol-diTMS  standard. 
The  detection  limit  (Daeseliere et al,  1991)  is 0.7  ~g per  L based  on  all 
ions  being  present at a  value  greater than  3 times  the  signal  to  noise 
ratio for  ion  m/z  440. 
No  false negative  results were  found  in  a collaborative trial  (see 
Daeseliere et al,  1991). 
11.  SPECIAL  CASES. 
12.  NOTES  ON  PROCEDURE. 
Cy  1.8/4 13.  SAMPLE  CONTROLS. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS. 
See  abbreviations  in  Annex  I,  Section  12  of  Manual. 
16.  FLOW  DIAGRAM 
URINE  ----->  SPE  on  C18  ------>  HYDROLYSE  -------- SPE  on  C18 
CALCULATE  <----- GC-MS  <------ diTMS  DERIVATIVES 
RESULTS 
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<----- HPLC Cy  1.9.  THYREOSTATS  - METHOD  FOR  THE  MEASUREMENT  OF  RESIDUES  OF 
THYREOSTATIC  SUBSTANCES  IN  ANIMALS  AND  ANIMAL  TISSUES  ON  THE  BASIS  OF  HIGH 
PERFORMANCE  THIN  LAYER  CHROMATOGRAPHY  (HPTLC)  AND  GAS  CHROMATOGRAPHY  - MASS 
SPECTROMETRY  (GC-MS). 
WARNING  AND  SAFETY  PRECAUTIONS. 
1.  INTRODUCTION. 
Throughout  the  EEC  the  use  of  thyreostatic  (anti-thyroid)  substances  is 
prohibited  in  food  producing  animals.  Also  the  MRL  for residues  of 
thyreostatics  in  animal  products  imported  into or  produced  within  the 
Community  is zero. 
2.  SCOPE  AND  FIELD  OF  APPLICATION 
Through  the  additional  use  of  GC-MS  this confirmatory method  is  an 
extension  of  the  screening  method  Sg  1.4  and  describes  the  determination  of 
the  presence  of  thyreostatic substances  in  foodstuffs  and  samples  of  animal 
origin.  The  method  can  be  used  for  meat  and  also for  biological  material 
such  as  animal  organs,  biological  fluids  and  excreta.  The  limit of 
detection  for  2-thiouracil  (TU);  4(6)-Methyl-2-thiouracil  (MTU)  and  4(6)-n-
propyl-2-thiouracil  (PTU)  is about  25  ~g per  kg  or  L.  Because  the  recovery 
of  4(6)-phenyl-2-thiouracil  (PhTU)  and  1-methyl-2-mercaptoimidazole 
(tapazole,  TAP)  from  the  mercurated  column  is  less efficient the  limit of 
detection  for  these  two  compounds  is about  100  ~g per  kg  or  L. 
3.  REFERENCES. 
ISO  Standard  78/2-1982  Layout  for  standards  - Part 2:  Standard  for Chemical 
Analysis 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  OJ.  ~ 
L.118,  14.4.93,  pp  64-74. 
EEC  Working  paper  VI/3186/84-EN,  File 6.21  II-4.  Method  of  analysis for 
detecting anti-thyroid substances  in  fresh  muscle  tissue using  a  selective 
mercurated  column. 
De  Brabander,  H.F.  and  Verbeke,  R.  (1984),  Determination  of 
methylthiouracil  and  analogous  thyreostatic drugs.  Proc.  30th  Eur.  Meat 
Res.  Workers,  Bristol,  387-388. 
De  Brabander,  H.F.,  Batjoens,  P.  and  Van  Hoof,  J.  (1992),  Determination  of 
thyreostatic drugs  by  HPTLC  with  confirmation  by  GC-MS.  J.  Planar  Chrom.  ~. 
124-130 
4.  DEFINITIONS. 
Thyreostatic  substances  detected  in  this assay  are; 
2-thiouracil  (TU);  4(6)-Methyl-2-thiouracil  (MTU); 
4(6)-n-propyl-2-thiouracil  (PTU);  4(6)-phenyl-2-thiouracil  (PhTU); 
1-methyl-2-mercaptoimidazole  (tapazole,  TAP); 
Cy  1.9/1 5.  PRINCIPLE 
The  method  comprises  4 stages  from  the  screening  method; 
- Homogenisation  of  tissue samples  or  diluting fluids  in  methanol 
- Percolation of  supernatant  through  mercurated  ion-exchange  resin 
chromatographic  column 
- Derivatization 
- Separation  and  identification by  two  dimensional  HPTLC 
and  then  3 stages  for  confirmation; 
- scrape  spots  from  plate 
- derivatise with  MSTFA 
- GC-MS 
6.  CHEMICALS 
Note:  The  reagents  for which  examples  of  their source  are  quoted  are 
known  to  be  satisfactory,  nevertheless  reagents  from  other  sources  may  be 
equally suitable.  All  the  reagents  must  be  of  analytical  grade. 
6.1.  - 6.12.  The  chemicals  for  the  screening  part of  the  assay, 
i.e.  to  the  point of  identification of  the  thyreostats  on  an 
HPTLC  plate are  described  in  method  Sg  1.4. 
6.13.  Derivatising  agent,  N-methyl-N-trimethylsilyl-trifluoroacetamide, 
(MSTFA).  (Pierce,  art~ 70127  or  Machery-Nagel,  Duren,  Germany) 
6.14.  A standard mixture  of  the  thyreostatic drugs  (20  ng  per  ~L) was 
prepared  and  10  ~L of  this solution was  transferred to  an 
autosampler  vial  (7.16)  evaporated  to dryness  and  heated  with  50 
~L MSTFA  at 60°C  for  15  min. 
7.  EQUIPMENT. 
7.1.  - 7.14.  The  chemicals  for  the  screening  part of  the  assay,  i.e.  to 
the  point of  identification of  the  thyreostats  on  an  HPTLC  plate 
are  described  in  method  Sg  1.4. 
7.15.  GC-MS  equipment  was  performed  with  an  ITS40  ion  trap mass 
spectrometer  (Finnigan  MAT,  San  Jose,  CA,  USA). 
7.15.1.  Gas  chromatograph  column  was  a 30m  x 0.25  mm  with  0.25  ~m film 
of  DB-5  (J&W).  The  oven  temperature  for  splitless  injection was 
100°C;  this was  maintained  for  2 min,  programmed  at soc  per  min 
to  150°C  and  then  20°  per  min  to  250°C,  which  was  held  for  3 min. 
(total  programme  20  min). 
7.15.2.  Positive CI  spectra  (reagent  gas,  butane)  between  m/z  90  and  400 
were  aquired  for  20  min  at 1 scan  per  sec  (filament,  multiplier 
delay  600  sec). 
7.15.3.  The  retention times  and  the  ions  used  for  tracing the  peaks  after 
full-scale aquisition are  shown  in  table 1. 
7.15.4.  Workstation 
7.15.5.  Printer 
7.16.  Autosampler  vials  (100  ~L) 
Reference  to  a  company  and/or  product  is for  purposes  of  information  and 
identification only.  Equivalent  types  or  products  also  may  be  suitable. 
Cy  1.9/2 Drug  Rt  (min)  ion  1  ion  2  ion  3  (MH+) 
TAP  13.2  171  186  259 
TU  13.4  257  273  345 
MTU  14.3  271  287  359 
DMTU  15.2  285  301  373 
PTU  15.6  299  315  387 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is  drawn  to  section  6.3.1  and  to  ISO  document  78/2-1982  and 
also  the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection  of  residues  in  meat  as  defined  in  Directive 64/433/EEC.  Failing 
this biological  fluids or faeces  may  constitute the  samples  for  the 
detection  of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large enough  to allow 
the  method  to  be  carried out  and  to  allow  repeat  analysis where  required. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to allow  proper 
identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice  the result of  the  examination. 
Samples  for  the  analysis of  thyreostatic substances  must  be  stored  and 
transported at temperatures  below  -18°C. 
9.  PROCEDURE. 
9.1  to 9.14.  2 g tissue,  2 mL  urine,  plasma  or  skim  milk,  are  homogenised 
in  10  mL  methanol  and  processed  through  to  the  formation  and 
identification of  the  thyreostats  on  HPTLC  plates as  descibed  in 
the  screening method  (see  Sg  1.4) 
9.15.  The  spot  suspected  of  containing  the  drug  was  removed  from  the 
plate by  careful  scraping  and  transferred to  an  autosampler  vial 
(7.16).  25  ~L MSTFA  was  added,  the  contents mixed,  and  the  vial 
heated  to 100°C  for  15  min.  After  sedimentation  of  the  silica 
gel,  1-2  ~L of  the  clear supernatant was  analysed  by  GC-MS. 
9.16.  1  ~L standard mixture  (6.14)  was  analysed  by  GC-MS. 
10.  CALCULATION  OF  RESULTS. 
10.1.  IDENTIFICATION. 
Identification of  the  unknown  compounds  was  performed  by  matching  the 
retention  times  on  the  GC  and  the  specta  on  the  MS  with  the  standards. 
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'  I 10.1.  RECOVERIES. 
The  recoveries  of  the  thyreostats from  the  mercurated  column  is  >78%  for 
TU,  MTU,  PTU  and  DMTU  but  only  about  17%  for  PhTU  and  60%  for  TAP. 
The  recoveries  of  the  internal  standard,  DMTU,  from  meat,  plasma  and  milk 
are  shown  in  table 2; 
Table  2;  Recoveries  of  100  ~g per  kg  spike  of  DMTU. 
Sample. 
Meat 
Plasma 
Milk 
Concentration  found  +  SO 
(ug  per  kg)  -
PTU  MTU 
106  ~ 5.5 
84  ~ 6.2 
88  ~ 6.9 
102  + 13.7 
98 +  5.0 
105  ~  3.6 
TU 
97  +  21.8 
76  ~  5.7 
85  ~  8.0 
Recoveries  from  the  GC-MS  steps  were  not  determined. 
10.2.  PRECISION 
10.2.1.  Reproducibility;  The  reproducibility of  the  analysis  of  meat 
spiked  at the  100  ~g per  kg  level  was  recorded  for  each  step of  the  assay. 
The  results obtained  by  De  Brabander  and  Verbeke  (1984),  Ghent,  are  shown 
in  table  3  in  method  Sg  1.4. 
11.  SPECIAL  CASES 
12.  NOTES  ON  PROCEDURE 
13.  QUALITY  CONTROLS 
See  section  8  of  manual  detailing the  RMs  available for  the  thyreostatics. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS 
A full  list of  abbreviations  is given  in  Annex  I,  Section  12 
16.  FLOW  DIAGRAM 
Tissue  --> add  methanol  and  internal  standard  ---> Homogenise 
I 
I 
! 
HPTLC  <------- Derivatise <------- percolate  through  Hg  column 
I 
I 
l 
Measure  fluorescence  at 366  nm  -------> Elute  spot  from  plate 
I 
I 
! 
Calculate  results <------ GC-MS  <-------TMS  derivatives 
Cy  1.9/4 Cy  2.1.  B-AGONISTS  - A METHOD  FOR  THE  DETECTION  AND  IDENTIFICATION  OF 
B-AGONISTS  IN  BIOLOGICAL  SAMPLES  AND  ANIMAL  FEED. 
1.  SCOPE 
This  method  of  analysis  describes  the  detection  and  confirmation  of  the 
presence  of  individual  ~-agonists in  samples  of  animal  origin and  animal 
feed.  The  method  has  been  mainly  tested for  residues  of  clenbuterol  and 
salbutamol.  This  work  is carried out  in  compliance  with  the  Residues 
Directive  (86/469/EEC). 
2.  FIELD  OF  APPLICATION 
The  method  is used  to  perform  routine screening  and  confirmatory analyses 
in  urine  and  liver from  veal  calves,  cattle and  pigs  as  well  as  in  animal 
feed.  Routinely  the  method  is used  to  test for  the  presence  of  residues  of 
clenbuterol,  salbutamol,  terbutaline,  cimaterol  and  mabuterol  but  is  in 
principle also  suitable for  the  detection  and  confirmation  of  other  t-butyl 
or  isopropyl-~-agonists like carbuterol,  pirbuterol  and  tulobuterol. 
The  detection  limit,  defined  as  three times  the  standard  deviation  of  the 
blank  determination,  measured  in  ~g per  kg  or  litre of  sample  is well  below 
1 for  compounds  during  initial  screening.  The  limit of  detection  for 
confirmation  according  to  the  EC  criteria for  reference methods  is 0.5  to 
1.5  ~g per  kg  or  L but  depends  on  the  ionisation  technique  and  equipment 
used. 
3.  REFERENCES 
Courtheyn  R,  VerneR,  Schilt R,  Hooijerink  H,  Desaever  C and  Bakeroot  V, 
1988.  Detectie en  identificatie van  clenbuterol  en  cinesterol  op  HPLC. 
Benelux  Working  Group  ''Hormones  and  anti-Hormones••.  Brussels,  document 
SP/LAB/h  (88)  43. 
Foerster,  H.J.,  Rominger,  K.L.,  Ecker,  E.,  Peil,  H.  and  Wittrock,  A. 
(1988),  Quantification of  clenbuterol  in  biological  fluids  using  ammonia  CI 
and  automated  capillary GC-MS.  Biomed.  Environ.  Mass  Spec.  ll, 417-420 
Ginkel  L.A.  van,  Blitterswijk  H.  van,  Zoontjes  P.W.,  Bosch  D.  van  den  and 
Stephany  R.W.,  1988.  Assay  for  trenbolone  and  its reduced  metabolite  17  a-
trenbolone  in  bovine  urine  based  on  immunoaffinity  chromatographic  clean-up 
and  off-line high  performance  liquid chromatography/thin  layer 
chromatography,  Journal  Chrom.,  445:385-392. 
Ginkel  L.A.  van,  Stephany  R.W.,  Rossum  H.J.,  (1992).  Development  and 
validation of  a multi-residue method  for  ~-agonists in  biological  samples 
and  animal  feed.  J.  Ass.  Off.  Anal.  Chern.  Int,  75,  554-560 
Ginkel  C.A.  van,  Stephany  R.W.,  Rossum  H.J.  van  and  Farla J.,  1990  Multi 
residue  test for  beta-agonists  in  slaughter animals.  IMAC  Symposium  on 
11 New 
Trends  in  Veal  Calf  Production .. ,  Wageningen,  the  Netherlands,  1990. 
Proceedings  of  the  Symposium. 
Ginkel  C.A.  van,  Stephany,  R.W.,  Rossum,  H.J.  van,  Steinbuch,  H.M.,  Zomer, 
G.,  Heeft,  Evan  der,  and  DeJong,  A.P.J.M.  1989.  Multiimmunoaffinity 
chromatography:  a  simple  and  highly  selective clean-up  method  for multi-
anabolic  residues  in  meat.  J.  Chrom.  489,  111-120 
Cy  2.1/1 Girault,  J., Gobin,  P.  and  Fourtillan,  J.B.  (1990),  Quantitative 
measurement  of  clenbuterol  at the  femtomole  level  in  plasma  and  urine  by 
combined  gas  chromatography/negative  ion  chemical  ionisation  mass 
spectrometry.  Biomed.  Environ.  Mass  Spectrometry.  ~. 80-88 
Yamamoto  I  and  Iwalak,  1982  Enzyme  immunoassay  for clenbuterol,  a  ~-2-
adrenergic  stimulant.  Journal  of  Immunoassay,  ~  15-? 
4.  DEFINITIONS 
B-agonists  content  is taken  to  be  the  amount  of  ~-agonists in  the  substance 
in  question  determined  according  to  the  described  method  and  expressed  as 
~g ~-agonists per  kg  or  litre of  test sample. 
5.  PRINCIPLE 
The  method  comprises  4 stages; 
1.  preparation  of  a primary  extract 
2.  extract purification and  concentration  using  immunoaffinity 
chromatography 
3.  detection  by  GC-MS 
4.  calculation  and  evaluation  of  results 
6.  MATERIALS 
6.1.  Chemicals  and  reagents 
6.1.1.  Reference  compounds. 
The  following  standard  compounds  are  used. 
Compound  CAS-No  mol  formula 
clenbuterol  37148-27-9  C 12H 18C12N 20 
salbutamol  18559-94-9  C13Hz1N03 
terbutaline  23031-25-6  C 12H 19N03 
cimaterol  54239-37-1  C 12H 17N 30 
mabuterol  56341-08-3  C 13H 18ClF3NzO 
and  additional  ~-agonists if desired. 
Mol.  Wt. 
277.18 
239.31 
235.29 
219.29 
310.75 
It is preferred  to  use  isotope  labelled  intery91  standards,  e.g. 
clenbuterol-d6,  salbutamol-d6  or  clenbuterol- Cl2.  It is foreseen  that 
these  reference  compounds  will  be  made  available through  BCR. 
6.1.2.  lAC-materials 
The  immunogens  used  were  prepared  as  described  earlier by  coupling 
diazonium-clenbuterol  and  diazonium-cimaterol  to  bovine  serum  albumin  (BSA, 
Sigma)  (Yamamoto  et al.,  1982).  The  respective  antisera used  to prepare 
the  lAC-matrices  were  obtained  by  immunizing  rabbits four  times  over  a 
period  of  5 months,  with  2 mg  of  immunogen  each  time.  The  isolation of  the 
antiserum  imrnunoglobulin-G  (lgG)  fraction  and  coupling  of  this fraction  to 
the  activated matrix  were  performed  as  described  previously  (Ginkel  et al., 
1989).  The  final  columns  have  a capacity >100  ng  for  the  compounds 
mentioned  (6.1.1). 
6.1.3. 
6.1.4. 
6.1.5. 
6.1.6. 
Ethanol  (Merck,  art.  no.  983). 
Methanol  (Merck,  art.  no.  9623). 
Toluene  (Merck,  art.  no.  8325). 
Acetonitrile  (Merck,  art.  no.  30). 
Cy  2.1/2 6.1.7. 
6.1.8. 
6.1.9. 
6.1.10. 
6.1.11. 
6.1.12. 
6.1.13. 
6.1.14. 
6.1.15. 
6.1.16. 
6.1.17. 
6.1.18. 
6.1.19. 
6.1.20. 
6.1.21. 
6.1.22. 
7. 
7.1. 
7.2. 
7.3. 
7.4. 
7.5. 
7.6. 
7.7. 
7.8. 
7.9. 
7.10. 
7.11. 
7.12. 
7.13. 
7.14. 
7.15. 
7.15.1. 
7.15.2. 
7.15.3. 
Dichloromethane  (Merck,  art.  no.  6050). 
Hydrochloric  acid  (Merck,  art.  no.  317). 
Ethyl  acetate  (Merck,  art.  no.  9623). 
Acetic  acid  (Merck,  art.  no.  63). 
Sodium  acetate  (Merck,  art.  no.  6268). 
Sodium  cHloride  (Analar  BDH  art.  no.  10241). 
Extrelut  (Merck,  art.  no.  11737;  refills art.  no.  11738) 
Acetate  buffer 0.1  mol/L,  pH  4.0. 
Mix  4.92  g acetic acid  (6.1.10)  with  800  ml  water,  add  2.45  g 
sodium  acetate  (6.1.11.)  and  29.25  g sodium  chloride  (6.1.12.). 
Adjust  the  pH  at 4.0  ±  0.1  and  add  water  to a final  volume  of 
1000  ml. 
lAC-eluting  buffer. 
Mix  400  ml  of  ethanol  (6.1.3.) with  75  ml  water  and  25  ml  acetate 
buffer  (6.1.14). 
Disodium  hydrogen  phosphate  (Merck,  art.  no.  6586). 
Potassium  dihydrogen  phosphate  (Merck,  art.  no.  4873). 
Phosphate  buffer,  0.02  mol/L,  pH  =  7.0. 
Dissolve  in  800  ml  water  2.278  g disodium  hydrogen  phosphate 
(6.1.16.),  0.416  g potassium  dihydrogen  phosphate  (6.1.17.)  and 
9.09  sodium  chloride  (6.1.12.).  Adjust  the  pH  at 7.0  ±  0,1  and 
add  water  to a final  volume  of  1000  ml. 
Stock  solutions of  standards  containing  1 g/L  in  ethanol,  stored 
at -20°C  in  the  dark. 
Working  solutions of  standards  containing  0.01  g/L  in  ethanol, 
stored at +4°C  for  a  maximum  period  of  2 weeks. 
Smallest  volume  pipetted out  of  the  stock  solution  is 0.1  ml. 
Derivatization reagent:  N 20-bis  (trimethylsilyl) 
trifluoracetamine  (BSTFA)  with  1%  TMS  (Pierce,  art.  no.  38832). 
Beta-glucuronidase/sulphatase  (suc'Helix  Pomatia,  containing 
100,000  units  ~-glucuronidase and  1 million  units sulphatase  per 
ml,  Industrie Biologique,  France,  code  IBR  213473) 
EQUIPMENT 
Glass  round  bottomed  flasks,  150  ml  (Corex,  art.  no.  8422-A). 
Glass  Pasteur  capillary pipettes. 
Automatic  pipettes  (Gilson  P20,  P200,  P1000  and  P5000). 
Refrigerated  centrifuge  (RC-3,  Sorvall). 
Bench-top  centrifuge  (GLC-4,  Sorvall). 
Centrifuge  tubes,  glass  (55  mm  x 11.5  mm)  (Renes,  RB55) 
Electric water  bath  with  thermostat  adjustable to  50  ±  2°C  (GFL, 
Salm  &  Kipp)  with  nitrogen  facility. 
Vortex  (Vortex-genic,  Wilton  &  Co). 
Ultrasonic water  bath  (Bransonic  32). 
Glass  derivatization vials  (chromacol  250  (A))  with  screw  caps 
(chromacol  85c)  and  septa  (chromacol  8-ST15). 
Incubator  60°C  (Seelvis). 
Heating  module  for  derivatization vials  (Pierce  no.  18790)  with 
nitrogen  facility. 
Glass  injection vials  (Chrompack,  art.  no.  10201)  with  glass 
inserts  (Chrompack,  art.  no.  10381). 
Aluminium  caps  (Chrompack,  art.  no.  10210). 
GC-MS  equipment. 
Gas  chromatograph  (Hewlett  Packard,  type  5890). 
Automatic  injector  (Hewlett  Packard,  type  7637A). 
Mass  selective detector  (Hewlett  Packard,  type  5970). 
Cy  2.1/3 7.15.4.  Workstation  (Hewlett  Packard,  type  59970). 
7.15.5.  Printer  (Hewlett  Packard,  think  yet). 
7.15.6.  GC-column,  fused  silica permabond  SE-52,  25m  x 0.25  mm  ID,  film 
thickness  0.25  urn  (Machery-Nagel,  art.  no.  723054). 
7.15.7.  Rotavapor  with  water  bath  at 40  ±  0.2°C  (Rotavapor). 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to section  6.3.1  and  ISO  document  78/2-1982(E)  and 
the following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to  enable  the 
detection of  residues  in  meat  as  defined  in  Directive  64/433/EEC.  Failing 
this biological  fluids or  faeces  may  constitute the  samples  for  the 
detection of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to  allow 
the  reference method  to  be  carried out  and  to  allow  repeat  analysis where 
required. 
In  this method  for B-agonists  the  amount  required  for  a  single 
determination  is 
3 g liver;  10  mL  urine;  10  g animal  feed 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to  allow  proper 
identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice  the  result of  the examination. 
Samples  for  the  analysis of  B-agonists  must  be  stored  and  transported at 
temperatures  below  -18°C.  Feed  samples  should  be  stored at +4°C. 
9.  ANALYTICAL  PROCEDURE 
Several  procedures  based  on  either c.q.  sublitizin digestion  or  ultrasonic 
extraction may  be  used  for  the  extraction of  liver samples .. Studies  at 
RIVM  revealed  no  significant difference  between  the methods  when  samples 
obtained  from  treated animals  were  analyzed.  However,  ultrasonic 
extraction  is simpler  and  results  in  less  interfering compounds  and  is the 
preferred technique. 
9.1.  Extraction  procedures. 
9.1.1.  Animal  feed. 
Accurately weigh  10.0  g of  animal  feed  into  a glass  flask  and  add 
50.0  mL  of  water.  Place  the flask  in  an  ultrasonic water  bath  and 
extract for  30  minutes.  Subsequently  shake  or  vortex  the  flask for 
10  seconds.  Centrifuge  the  flask  for  10  minutes  (1800  g)  and 
pipette  19  mL  into a clean  flask.  Adjust  to  pH  9.8  ±  0.2 with  1 
mol/L  NaOH  and  add  water  to adjust the  volume  to  20  mL. 
9.1.2.  Liver 
Accurately weigh  3.0  g of  liver  into  a  20  mL  glass flask  and  add 
15  mL  0.01  mol/L  HCl.  Place  the  flask  in  an  ultrasonic water  bath 
and  extract for  15  minutes.  Subsequently  shake  or  vortex  the flask 
for  10  seconds.  Centrifuge  the  flask  for  10  minutes  (1800  g)  and 
decant  the  supernatant  into a clean  flask.  Adjust  the  pH  to  5.2  ± 
0.2 with  1 mol/L  NaOH  and  add  water  to adjust the  volume  to  20  mL. 
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Accurately  pipette 10.0  ml  of  urine  into a  20  ml  glass  flask. 
Adjust  the  pH  to  a value  of  5.2  ±  0.2 with  1 mol/L  NaOH  and  add 
water  to  adjust  the  volume  to  20  ml. 
9.2.  Enzymatic  Hydrolysis 
Samples  of  urine  and  primary  extracts of  liver are  enzymatically 
hydrolysed.  To  the  aqueous  samples  0.1  ml  Helix  Pomatia  (6.1.22) 
is added.  All  samples  are  incubated  overnight  at 37°C.  After 
incubation  the  samples  are  cooled  to  room  temperature  and  the  pH 
is adjusted  to  9.2  ±  0.2.  The  volume  of  the  urine  samples  is 
adjusted  to  20  ml  with  water. 
9.3.  ExtrelutR extraction 
The  aqueous  extract  (20  ml)  is applied  to  an  ExtrelutR extraction 
centrifuge.  After  equilibration for  15  minutes  the water  is 
extracted with  60  ml  ethyl  acetate and  the  extract  is evaporated 
on  a rotation vaporizer  at 50°C. 
9.4.  Sample  clean-up;  immunoaffinity  chromatography. 
The  lAC-columns  are  washed  with  at least 10  ml  of  water.  The  dry 
residue  is dissolved  in  0.1  ml  ethanol.  Subsequently  50  ml  water 
is added  and  the  residue  is further dissolved  by  placing  the flask 
in  an  ultrasonic water  bath  for  at  least 1 minute.  The  aqueous 
extract is applied  to  the  lAC  column  and  flushed  through  with  a 
flow  of  2 ml/minute.  Subsequently  the  column  is washed  with  5 ml 
of  water  after which  the  ~-agonists are  eluted with  5 ml  lAC-
eluting buffer.  The  eluate  is evaporated  to  dryness  in  a water 
bath  at 50°C  under  a cold  stream of  nitrogen.  The  lAC  column  is 
regenerated  by  washing  it with  5 ml  lAC  eluting buffer,  25  ml  of 
water  and  25  ml  PBS. 
9.5.  Desalting  of  the  lAC  eluate. 
The  dry  residue  is resuspended  in  0.5  ml  of  cold  ethanol  and 
centrifuged for  5 minutes  (1800  g)  at 4°C.  The  supernatant  is 
removed  into a derivatization vial  and  the  ethanol  is evaporated 
using  a  heating  block  at 50°C  under  a cold  stream  of  nitrogen. 
9.6.  Derivatization. 
The  dry  residue  is dissolved  in  0.1  ml  derivatization reagent 
(6.1.21).  The  mixture  is  incubated  for  1 hour  at 60°C  (7.11).  The 
reagent  is evaporated  (7.12)  and  the  dry  derivatized residue  is 
dissolved  in  0.025  ml  toluene  (6.15).  The  toluene  solution  is 
transferred to  a derivatization vial  (7.10)  and  subjected  to  GC-
MSD  analysis  and  confirmed  as  in  10.1. 
GC-MSD  settings: 
injection  volume  2  ~L. 
injection temperature·  260°C 
injection mode  splitless 
starting temperature  70°C 
gradient  25°C/min 
first firal  temperature  200°C/min  (6  minutes) 
gradient  25°C/min 
second  firal  temperature  300°C/min  (2  minutes) 
ions  monitored  (screening)  m/Z  =  86  (t-butyl-~-agonists) 
m/Z  =  72  (isopropyl-~-agonists) 
Cy  2.1/5 10.0.  CALCULATION  OF  RESULTS 
The  procedure  used  for  calculation results  (quantification)  depends  on  the 
internal  or  external  standards  used. 
Where  isotope  labelled standards  are  available a  linear calibration curve 
can  be  fitted with  the  ID-ratio  as  dependent  and  the  concentration of 
standard  (e.g.  ng/injection  vial)  as  dependent  variable. 
This  procedure  yields  linear calibration curves  which  give  an  intercept 
deviating  not  significantly from  0. 
For  other B-agonists  quantification  is  less  straight forward.  In  practice 
however  recovery  for  most  compounds  is equal  to  the  recovery  of 
clenbuterol,  both  for muscle  and  liver.  The  only  compound  with 
significantly different analytical  recovery  is salbutamol.  For  this 
compound  however  an  internal  standard  is available  (see  validation). 
For  confirmation  the  simultaneous  detection of  at  least four  ions  response 
ratios  have  to  be  calculated for  both  standards  and  unknown  compounds. 
10.1.  CONFIRMATION 
For  purposes  of  confirmation  additional  (fragment)-ions  have  to  be 
monitored.  Beta-agonists  fragment  according  to  the  scheme  shown  below: 
The  ions  are  shown  in  order  (A  to  F)  of  intensity. 
N  M.W  M.WD.  [A]  [8]  [C]  [D]  [E] 
terbutaline  3  225  441  86  356  336  426  370 
salbutamol  3  239  455  86  369  350  440  384 
clenbuterol  1  276  348  86  262  243  333  277 
cimaterol  1  219  291  72  219  186  276  234 
2  219  363  72  291  258  348 
mabuterol  1  310  382  86  296  277  367  311 
N  = number  of  TMS-groups;  M.W.=  molecular  weight  of  pure  compound 
M.WD  = molecular  weight  after derivatization 
[F] 
280 
294 
187 
221 
For  identification according  to  the  EC-criteria it is mandatory  that at 
least 4  ions  are monitored.  Each  response  should  fulfil  the  criterium that 
the  maximum  exceeds  the  average  noise  ±  3  SD.  If this criterium  is 
fulfilled for all  ions  monitored  the  3  different ratios are  calculated.  The 
same  ratios are  calculated for  the  standard  analyte,  preferably at the  cor-
responding  concentration.  For  positive  identification the  responses 
obtained  for  the  unknown  samples  should  all  be  within  ±  10%  of  the  average 
value  for  the  standard. 
Note:  Frequently  the  variability of  the  MS-equipment  does  not  allow  this 
criterium to  be  strictly applied.  In  this case  the  criterium is replaced  by 
a criterium based  on  the  experimental  variability.  The  response  ratios for 
the  unknown  sample  should  be  within  the  corresponding  standard  ±  3 SD. 
10.1.1.  Fragmentation  pattern for  B-agonists  (See  figure  1). 
10.2.  Validation. 
A number  of  studies was  undertaken  to  validate the  analytical 
procedure.Most  of  these experiments  were  within  laboratory experiments 
(repeatability and  within  laboratory reproducibility).  In  addition  the 
method  was  validated  in  a cooperative  study  on  animal  feed,  organized  by 
the  EC  and  demonstrated  during  an  EC  workshop,  April  22-26,  1991,  at RIVM. 
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10.2.1.  Analytical  recovery  during  lAC 
Each  newly  prepared  batch  of  lAC  material  has  to  be  tested for  its capacity 
to  retain relevant components.  Typical  results are  given  below  (200  ng 
app 1  ied): 
10.2.3. 
Compound  recovery  during  lAC 
clenbuterol 
mabuterol 
salbutamol 
cimaterol 
.!k  0 
95 
111 
103 
96 
Analytical  recovery  of  the  procedure 
When  the  lAC  materials were  demonstrated  to  be  suitable the  procedure  was 
validated  by  determining  the  analytical  recovery of  components  spiked  to 
blank  urine.  The  internal  standard  was  added  after the  analysis for 
corrections  during  derivatization and  GC-MSD  analysis. 
Compound 
clenbuterol 
salbutamol 
mabuterol 
cimaterol 
analytical  recovery 
% 
(average  ±  SD,  N = 2) 
102  ±  8 
56  ±  5 
115  ±  4 
100  ±  5 
Cy  2.1/7 10.2.4.  Repeatability and  reproducibility 
Repeatability and  within  laboratory reproducibility were  determined  for 
clenbuterol  and  salbutamol  by  analyzing  samples  of  urine  and  liver obtained 
from  treated animals  (urine from  veal  calves  and  liver from  a  pig).The 
samples  were  analyzed  on  three different occasions,  each  time  in  duplicate. 
Salbutamol  in  liver 
individual  values 
J.1Q/kg 
3.6  3.3 
3.4  3.3 
3.7  3.7 
Clenbuterol  in  liver 
individual  values 
J.1Q/kg 
13.8  11.2 
12.9  12.6 
15.1  14.1 
Clenbuterol  in  urine 
individual  values 
J.LQ/kg 
4.4  4.3 
4.2  4.6 
4.7  4.9 
Salbutamol  in  urine 
10.2.5. 
individual  values 
J.1Q/kg 
2.0  2.0 
1.8  2.0 
2.1  2.1 
Sensitivity. 
within  assay 
variability 
s2  = 0.016 
s  = 0.13 
%RSD  =  3.7 
within  assay 
variability 
52  = 1.31 
s  = 1.14 
%RSD  =  8.5 
within  assay 
variability 
s2  = 0.035 
s  = 0.19 
%RSD  = 4.2 
within  assay 
variability 
s  = 0.007 
s  = 0.08 
%RSD  =  4.0 
between  assay 
s2  = 0.065 
s  = 0.25 
%RSD  =  7.1 
between  assay 
variability 
52  = 2.63 
s  = 1.62 
%RSD  =12.1 
between  assay 
variability 
s2  = 0.122 
s  = 0.35 
%RSD  =  7.8 
between  assay 
variability 
s  = 0.020 
s  = 0.14 
%RSD  = 7.0 
The  sensitivity depends  on  whether  the  method  is used  for  screening where 
only  the  most  abundant  ion  (m/Z  =  86  or  72)  is monitored  or  for 
confirmation  when  four  ions  must  be  monitored.  In  the  latter case  the 
sensitivity is reduced  to the  limit of  detection for  the weakest  of  the 
four  ions. 
Cy  2.1/8 11.  SPECIAL  CASES. 
This  procedure  includes  a  special  step for  deconjugation  of B-agonists 
which  might  be  present  in  the  form  of  glucuronide- or  sulphate-esters.  For 
clenbuterol  all  data  available  lead  to  the  conclusion  that  no  conjugates 
are formed.  For  salbutamol  the  presence  of  sulphate-esters  is described. 
Studies  at  RIVM  show  that  in  cattle salbutamol  is more  than  95%  conjugated. 
The  use  of  prolonged  incubations  and  relative  large  amounts  of  enzymes  is 
needed.  Based  on  these results  it was  concluded  that  in  routine  it is 
necessary to  perform  a deconjugation  step during  multi  residue  sample 
preparation.  For  the  specific analysis of  clenbuterol  the  hydrolysis  step 
can  be  omitted.  For  other  ~-agonists no  data  are available at the  moment. 
12.  NOTES  ON  PROCEDURE.  The  procedure  chosen  will  depend  on  the 
availability of  reagents,reference  compounds  and  equipment. 
13.  QUALITY  CONTROL.  STANDARDS,  REFERENCE  MATERIALS  AND  ANTIBODIES. 
A description of  the  source  and  quality of  the  key  reagents  and  standards 
is given  in  Section 8.  In-house  standards were  prepared  at RIVM  by  spiking 
blank  bovine  liver with  clenbuterol  at 1 or  2  ~g per  kg  and  preparing  a 
hompgenious  batch  of  lyophilized  samples.  Using  these  samples  the  inter-
assay  variation for  was  13%  at 1  ~g per  kg  and  8.6%  at 2  ~g per  kg  and  the 
average  value  was  85-100%  of  the  target value. 
13.1  lAC.  Follow  the  instructions relating to the  storage  and 
procedures  as  recommended  by  the  supplier. 
13.2.  Source  of  lAC  columns  and  gel  packings. 
Commercial  suppliers;-
Laboratory  of  Hormonology  - Marloie,  Rue  de  Point  de  Jour,  8,  B-6900, 
Marloie,  Belgium. 
Gels  for  immunoaffinity  chromatography  are  available  (minimum  quantity 1 
mL)  prepared  from  high  affinity antisera and  with  a  minimum  capacity of  50 
ng  per  mL  for; 
B 2-agonists;  Clenbuterol,  Salbutamol  (single or  combined) 
GENEGO  S.p.A.,  Via  Ressel  S.  Andrea  zona  ind.,  34170  Gorizia,  Italy 
This  company  market  three multi-analyte  columns  claiming  a capacity of  at 
least 20  ng  or  100  ng  (high  capacity column)  per  analyte.  The  products 
are  -
Multi-Prep  I  for  DES,  HEX,  DE,  Z,  Taleranol  B-E2 ,  NT,  T,  MT,  and 
TB 
Multi-Prep  II  for  DES,  HEX,  DE,  Z,  NT,  MT,T,  TB  and  Taleranol 
Multi-Prep  III  for  Clenbuterol,  salbutamol,  terbutaline, 
carbuterol  and  marbuterol  all  B-agonists. 
These  columns  are marketed  as  a complete  kit,  comprising  the  enzyme  and  the 
buffer for  the  digestion  of  samples,  extraction and  washing  buffers  and 
detailed  instructions. 
13.3.  Deuterated  standards. 
Deuterated  B-agonists  are  held  at RIKILT. 
Cy  2.1/9 14.  TEST  REPORT. 
To  give  the  indications  necessary  for  the  identification of  the sample,  the 
reference to the method  employed,  the  results and  the form  in  which  these 
are  expressed,  any  particular points observed  in  the  course  of  the  test and 
any  operations  not  specified  in  the method  or  regarded  as  optional  which 
might  affect the results. 
15.  LIST  OF  ABBREVIATIONS 
A list of  the most  important  abbreviations  is given  in  Annex  I  section 12. 
16.  FLOW  DIAGRAM. 
Tissue  --~ add  buffer  and  recovery  standard  --~ Homogenise  with 
Fluid  (urine,  bile,  plasma,  serum) 
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I 
! 
:  ultrasonics 
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! 
add  buffer  and  recovery  standard  ------------~ Enzyme  hydrolysis 
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Calculate results 
extraction 
Cy  2.1/10 Cy  2.2.  CLENBUTEROL  - DETERMINATION  OF  CLENBUTEROL  AT  RESIDUE  LEVELS  IN 
BOVINE  PLASMA  AND  TISSUES  BY  GC-MS. 
1.  SCOPE 
Clenbuterol  is a  potent  B-agonist  used  as  a  bronchodilator  in  humans  and 
also  a repartitioning agent  in  farm  animals.  Clenbuterol  may  be 
administered  orally or  parentally.  The  oral  dose  is  usually administered 
as  a feed  supplement  equivalent  to  approximately  3 mg  per  kg  feed. 
This  method  of  analysis  describes  the  detection  and  confirmation  of  the 
presence  of  clenbuterol  in  bovine  plasma  and  tissue samples. 
2.  FIELD  OF  APPLICATION 
The  method  is used  to  determine  the  residues  of  clenbuterol  in  bovine 
plasma  and  tissues  (liver,  kidney,  heart,  lung,  thymus,  spleen  cord, 
muscle,  brain,  suet {fat}). 
The  limit of  detection,  as  defined  in  the  paper  by  Girault  and  Fourtillan 
(1990)  and  defined  differently from  that  in  the  EC  criteria document  93/256 
(Section  5),  is 5 ng  per  L for  plasma  and  10  ng  per  kg  for  tissues. 
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4.  DEFINITIONS 
Clenbuterol  content  is taken  to  be  the  amount  of  clenbuterol  in  the 
substance  in  question  determined  according  to  the  described  method  and 
expressed  as  ~g clenbuterol  per  kg  or  litre of  test sample. 
Cy  2.2/1 5.  PRINCIPLE 
The  method  comprises  five  stages; 
1.  preparation  of  a primary  extract 
2.  extract purification and  concentration  using  solvent  partition 
3.  derivatisation as  perfluoroacyl  derivatives 
4.  detection  by  GC-MS 
5.  calculation and  evaluation  of  results 
6.  MATERIALS 
6.1.  Chemicals  and  reagents 
6.1.1. 
6.1.2. 
6.1.3. 
6.1.4. 
6.1.5. 
6.1.6. 
6.1.7. 
6.1.8. 
6.1.9. 
6.1.10. 
6.1.11. 
6.1.12. 
6.2. 
6.2.1. 
6.2.2. 
6.2.3. 
6.2.4. 
6.2.5. 
6.3. 
6.2.1. 
6.2.2. 
Ethyl  acetate  (Merck,  art.  no.  9623). 
Acetone  (Merck). 
Double  distilled water 
Methanol  (Merck,  art.  no.  9623) 
2M  sodium  hydroxide 
Sodium  hydrogen  carbonate 
Hexane  (Merck) 
0.2M Sulphuric  acid  (Merck,) 
Anhydrous  sodium  sulphate  (Merck) 
Nitrogen 
Pentafluoropropionic  anhydride  (PFPA)  (Pierce,  Rockford,  Ill, 
USA) 
Human  plasma  free of  clenbuterol 
Reference  compounds. 
Clenbuterol  is from  Chiesi  Farmaceutici  Laboratories, 
Parma,Italy. 
The  internal  standard  is the  isotope  labelled standard,[2H 9] 
clenbuterol  from  Chiesi  Farmaceutici  Laboratories,  Parma,Italy. 
Stock  solution of  clenbuterol  standard  containing  0.1  g/L  in 
methanol,  stored at -20°C  in  the  dark. 
Stock  solution of  [2H 9]  clenbuterol  standard  containing 0.1  g/L 
in  methanol,  stored  at -20°C  in  the  dark. 
Working  solutions of  standards  (6.2.3.,  6.2.4.)  are  made  by 
diluting the  stock  solutions  in  distilled water.  The  solutions 
are  protected  from  light by  wrapping  the  flasks  in  aluminium  foil 
and  are  stored  at +4°C  until  used. 
Solutions. 
2M  sodium  hydroxide  buffered  at  pH  12  with  sodium  hydrogen 
carbonate. 
Sorensen  buffer,  pH  7 
7.  EQUIPMENT 
Note;  All  glassware  is cleaned  with  a mechanical  scaling  brush,  then  left 
overnight  in  a  chromic  acid  bath  (Cr03-H2S04 )  and  finally rinsed with 
double  distilled water. 
7.1.  Mechanical  scaling brush 
7.2.  Polytron  tissue grinder  powered  by  overhead  stirrer. 
7.3.  Automatic  pipettes 
7.4.  Refrigerated  centrifuge 
Cy  2.2/2 7.5. 
7.6. 
7.7. 
7.8. 
7.9. 
7.10. 
7.11. 
7.12. 
7.13. 
7.13.1. 
7.13.2. 
7.13.3. 
7.13.4. 
7.13.5. 
7.13.6. 
8. 
Reciprocating  shaker 
Centrifuge  tubes,  10  mL  with  PTFE  screw-caps 
Water  bath  with  nitrogen  evaporator  facility. 
Vortex 
Rotavapor  with  water  bath. 
Glass  derivatization  tubes,  10  mL,  with  seals/stoppers 
Glass  Pasteur capillary pipettes. 
Quick-fit type  glass  tubes  with  stoppers.  (10  mL  and  20  mL) 
GC-MS  equipment. 
Gas  chromatograph  (Hewlett  Packard,  type  HP  5985  B). 
Moving/Falling  needle  injection  system.  One  end  of  the  capillary 
column  is connected  to  the  glass  solid  injector 1 mm  from  the 
bottom  of  the  moving  needle.  The  other end  is  introduced 
directly near  the  ion  source  of  the  mass  spectrometer  via  a 
1/16th  inch  stainless-steel  transfer  line,  the  temperature  of 
which  is  held  at 280°C. 
Mass  selective detection operating  in  NICI  mode 
Workstation 
Printer 
GC-column,  fused  silica capillary column,  25m  x 0.35  mm  o.d/0.22 
mm  i.d.,  coated  with  OV-1701,  film  thickness  0.11  urn. 
SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is  drawn  to section  6.3.1  and  ISO  document  78/2-1982(E)  and 
the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection  of  residues  in  meat  as  defined  in  Directive 64/433/EEC.  Failing 
this biological  fluids  may  constitute the  samples  for  the  detection  of 
residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to  allow 
the  method  to  be  carried out  and  to allow  repeat  analysis where  required. 
In  this method  for clenbuterol  the  amount  required  for  a  single 
determination  is 1 mL  plasma  or  0.2  g tissue. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to allow  proper 
identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice the  result of  the examination. 
Samples  for  the  analysis of  clenbuterol  must  be  stored at temperatures 
below  -l8°C. 
9.  ANALYTICAL  PROCEDURE 
9.1.  Extraction  procedures. 
9.1.1.  Plasma. 
9.1.1.1  Plasma  samples  (1  mL)  spiked  as  stated  in  9.2.  are  placed  in  20 
mL  screw-capped  tubes  and  mixed  with  1 mL  pH  12  buffer  (6.2.1). 
9.1.1.2  6 mL  ethyl  acetate are  added  and  the  mixture  shaken  for  10  min  on 
a reciprocating  shaker. 
9.1.1.3  Centrifuge  for 5 min  at 1,600  g. 
Cy  2.2/3 9.1.1.4  Transfer  the  organic  layer  into a  10  ml  screw-capped  tube 
containing  1 ml  of  0.2M  sulphuric  acid. 
9.1.1.5  The  mixture  is shaken  for  10  min  on  a  reciprocating  shaker  and 
centrifuged for  5 min  at 1,600  g. 
9.1.1.6  The  organic  phase  is evaporated  under  vacuum  and  to the  residual 
aqueous  phase  4 ml  of  ethyl  acetate-hexane  (2:1,  v/v)  is added. 
9.1.1.7  The  mixture  is  shaken  for  a  short period  and  then  gently 
centrifuged.  The  upper  organic  layer  is discarded. 
9.1.1.8  The  sulphuric  acid  phase  is made  alkaline with  1 ml  2M  sodium 
hydroxide  and  extracted with  5 mL  ethyl  acetate. 
9.1.1.9  The  organic  solvent  is decanted  into  a  10  ml  glass  tube  (7.10) 
and  evaporated  to dryness  at 40°C  under  nitrogen. 
9.1.2.  Tissue  Samples. 
9.1.2.1  Tissue  samples  are  accurately weighed  and  placed  in  a  20m~ glass 
tube  with  3 ml  Sorensen  buffer,  pH  7,  (6.2.2.)  and  500  pg[  H 9] 
clenbuterol.  The  sample  is homogenised  for  1 min  with  a Polytron 
homogeniser  (7.2). 
9.1.2.2  After  centrifuging for  15  min  at 1,800  g the  supernatant  is 
decanted  into  another  20  ml  screw-capped  tube.  The  aqueous  phase 
is made  alkaline  by  adding  1 ml  2M  sodium  hydroxide  and  then 
extracted with  6 ml  ethyl  acetate  by  shaking  for  10  min  on  a 
reciprocating shaker. 
9.1.2.3  The  samples  are  then  processed  as  for  the  extraction of  plasma, 
steps 9.1.1.3.  to  9.1.1.9. 
9.2.  Spiking  of  Quality Controls. 
9.2.1.  Plasma;  Aliquots  of  dr~g-free human  plasma  are fortified with  50 
~L of  a  10  ng  per  ml  [  H 9]  clenbuterol  solution  in  water  (6.2.5) 
and  various  amounts  of  clenbuterol  ranging  fr~m 5 - 250  pg  per 
ml.  Blanks  are  prepared  by  adding  only  the  [  H 9]  clenbuterol  to 
1 ml  plasma. 
9.2.2.  T1ssues;  0.2  g tissue are fortified with  50  ~L of  a  10  ng  per  ml 
[  H 9]  clenbuterol  solution  in  water  (6.2.5)  and  various  amounts 
of  clenbuterol  ranging  from  19  - 500  pg  per  g.  Blanks  are 
prepared  by  adding  only  the  [  H 9]  clenbuterol  to 0.2 g tissue. 
9.3.  Derivatization. 
To  eliminate moisture  in  the  derivatization tubes,  the  insides of 
the  tubes  (7.10)  are  rinsed with  acetone  previously dried  over 
anhydrous  sodium  sulphate.  The  acetone  is evaporated  and  40  ~L 
PFPA  added.  The  tubes  are  tightly capped  and  stood  at room 
temperature  until  analysis. 
9.4.  GC-MS. 
9.4.1.  GC  settings: 
9.4.1.1  injection volume 
injection temperature 
injection mode 
starting temperature 
gradient 
first firal  temperature 
gradient 
second  firal  temperature 
1  ~L of  derivatized  sample  (9.2). 
290°C 
moving/falling  needle 
180°C 
8°C/min 
230°C/min 
20°C/min 
290°C/min 
Cy  2.2/4 9.4.1.2  The  retention  times  of  clenbuterol  is 5.22  min  and  the  [2H 9] 
clenbuterol  5.16  min  (Data  from  Girault and  Fourtillan,  1990) 
9.4.2.  MS  settings 
9.4.3. 
9.4.4. 
10.0. 
Ioniser; 
Mode  negative 
Temperature 
Emission  current 
Electron  energy 
ion  - chemical  ionization 
180°C 
300  ~A 
100  eV 
ions  monitored  m/2  =  368  (clenbuterol) 
m/2  =  377  (internal  standard) 
Reagent  gas  - methane  at source  pressure  ca.  0.8 Torr 
Tuning;  The  instrument  is tuned  using  the  fragments  m/Z  414,  595, 
and  633  from  the  perfluorotributylamine calibrant gas •. 
Determination  of  clenbuterol  content. 
The  NICI  spectra  are  recorded  for  Clenbuterol  and  [2H 9] 
clenbuterol  by  scanning  the  quadrupole  mass  filter every  1.1  sec 
from  m/Z  250  to 450.  Determination  of  clenbuterol  is performed 
by  focusing  the  instrument  in  the  single-ion monitoring  mode  in 
or~er to  measure  the  fragments  of  m/Z  368  (clenbuterol)  and  377 
([  H 9]  clenbuterol).  The  dwell  time  is  100  msec  for  each  mass 
range. 
Confirmation  of  Clenbuterol  (see 10.1). 
CALCULATION  OF  RESULTS 
10.1.  Calibration Curves. 
The  procedure  used  for  the  calculation of  results  (quan~ification) uses  a 
linear calibration curve  which  can  be  fitted with  the  [  H 9]  clenbuterol-
ratio as  dependent  and  the  concentration  of  standard  (e.g.  pg/injection 
vial)  as  the  dependent  variable. 
This  procedure  using  7 points yields  linear calibration curves  (r = 0.9998) 
which  give  an  intercept deviating  not  significantly from  0.  The  slopes  of 
the  plasma  calibration curves  were  reproducible  from  day  to day,  with  a 
relative standard  deviation of  4%.  (Data  from  Girault and  Fourtillan, 
1990) 
10.2.  Recoveries. 
The  yield of  the  extractio2 was  about  80%  and  all  sources  of  variability 
are  reduced  by  including  [  H 9]  clenbuterol  as  internal  standard. 
10.3.  Accuracy  and  Precision. 
The  precision of  the  method  was  measured  by  Girault and  Fourtillan,  (1990), 
in  tissues  and  plasma  and  the  results are  shown  in  table 1. 
Cy  2.2/5 Table  1. 
Sample  Theoretical  n 
concentration 
(pg/mL  or  g) 
Plasma 
200  10 
100  5 
20  5 
5  10 
Tissue  (kidney) 
200  10 
20  10 
10.1.  CONFIRMATION 
Mean  Observed 
concentration 
{pg/mL  or  g) 
196.3 
99.3 
20.0 
4.8 
212.7 
18.9 
so 
5.89 
3.41 
0.74 
0.61 
15.6 
1.7 
cv  Error 
{%)  (%) 
3.0  -1.9 
3.4  -0.7 
3.7  +0.2 
12.8  -4.3 
7.3  +6.4 
9.0  -5.5 
For  confirmation  the  simultaneous  detection  of  at  least four  ions  response 
ratios have  to  be  calculated for  both  standards  and  unknown  compounds. 
The  ions  are  shown  below  for  the monofluoroacyl  derivatives. 
cJenbuterol-PFA 
[  H 9]  clenbuterol-PFA 
M.W 
276 
285 
M.WD. 
404 
413 
----------Ions-----------
368  297  312  350  404 
377  297  313  359  413 
M.W.=  molecular  Wt.  of  pure  compound 
M.WD  = molecular  weight  after derivatization 
For  identification according  to  the  EC-criteria  it is mandatory  that at 
least 4  ions  are  monitored.  Each  response  should  fulfil  the  criterium that 
the  maximum  exceeds  the  average  noise  ~ 3  SD.  If this criterium is 
fulfilled for  all  ions  monitored  the  3  different ratios are  calculated.  The 
same  ratios are  calculated for  the  standard  analyte,  preferably at the  cor-
responding  concentration.  For  positive  identification the  responses 
obtained  for  the  unknown  samples  should  all  be  within~ 10%  of  the  ~verage 
value  for  the  standard. 
Note:  Frequently  the  variability of  the  MS-equipment  does  not  allow  this 
criterium to  be  strictly applied.  In  this case  the  criterium  is replaced  by 
a criterium based  on  the  experimental  variability.  The  response  ratios for 
the  unknown  sample  should  be  within  the  corresponding  standard  ~ 3  SO. 
11.  SPECIAL  CASES. 
12.  NOTES  ON  PROCEDURE. 
13.  QUALITY  CONTROL.  STANDARDS,  REFERENCE  MATERIALS  AND  ANTIBODIES. 
14.  TEST  REPORT. 
15.  LIST  OF  ABBREVIATIONS 
A list of  the  most  important  abbreviations  is given  in  Annex  I  section  12. 
16.  FLOW  DIAGRAM. 
Tissue  --~ add  buffer  and  recovery  standard  --~ Homogenise 
plasma  : 
I  I 
I  I 
!  ! 
add  buffer  and  recovery  standard  --------~ solvent extraction 
! 
Calculate results <---- GC-MS  <---- ~-Derivatize 
Cy  2.2/6 Cy  2.3.  B-AGONISTS  - A METHOD  FOR  CONFIRMING  THE  DETECTION  OF  B-AGONISTS 
IN  BOVINE  URINE  BY  GC-MS  IN  THE  POSITIVE  CHEMICAL  IONISATION  MODE  FOR  THE 
TRIMETHYLSILYL  DERIVATIVES. 
1.  SCOPE 
This  method  of  analysis  describes  the  confirmation  of  the  presence  of 
individual  ~-agonists in  samples  of  urine of  veal  calves  and  adult cattle. 
The  method  is used  officially in  France  and  is carried out  in  compliance 
with  the  Residues  Directive  (86/469/EEC). 
2.  FIELD  OF  APPLICATION 
The  method  is used  to  confirm  positives found  during  the  routine  screening 
of  urine  from  veal  calves  and  adult cattle.  The  method  is used  to  confirm 
the  presence  of  residues  of  clenbuterol,  clenpenterol,  hydroxymethyl-
clenbuterol,  salbutamol,  terbutaline,  cimaterol,  cimbuterol,  mabuterol, 
mapenterol,  tulobuterol,  fenoterol  and  ractopamine. 
The  detection  limit,  defined  as  a  signal  noise  ratio >3  is  below  1  ~g per  L 
It is  important  to  note  that the  method  is applied  specifically to  the 
confirmation  of  an  already  suspected  known  B-agonist.  Thus  the  analysis  is 
targeted at compounds  with  specific retention times  on  the  GC  and  with 
known  spectra. 
3.  REFERENCES 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
Montrade,  M-P.,  Le  Bizec,  B.,  Manteau,  F.,  Siliart,  B.  and  Andre,  F. 
(1993),  Multi-residue  analysis forB-agonistic  drugs  in  urine  of  meat-
producing  animals  by  gas  chromatography- mass  spectrometry.  Anal.  Chim. 
Acta.  275,  253-268 
Montrade,  M-P.,  Le  Bizec,  B.  and  Andre,  F.  (1992),  Methode  de  recherche 
urinaire  (screening)  d•agonistes  B-adrenergiques  par  chromatographie 
gazeuse  couplee  a la  spectrometie  de  masse  (GC-MS)  en  mode  impact 
electronique.  Document  LDH/92/01  Lab.  Dosage  Hormonaux,  Nantes, 
DGAL/SDHA/~.92-8066 
Montrade,  M-P.,  Le  Bizec,  B.  and  Andre,  F.  (1993),  Research  and 
identification of  B-agonistic  drugs  in  biological  samples  by  gas 
chromatography  coupled  with  mass  spectrometry.  Confirmation  method  in 
positive  ion  chemical  ionisation.  Document  LDH/93/05  Lab.  Dosage 
Hormonaux,  Nantes,  DGAL/SDHA/~.93-8065. 
4.  DEFINITIONS 
B-agonists  content  is taken  to  be  the  amount  of  ~-agonists in  the  substance 
in  question  determined  according  to  the  described  method  and  expressed  as 
ug  ~-agonists per  litre of  test sample  (urine). 
Cy  2.3/1 5.  PRINCIPLE 
The  method  comprises  6 stages; 
1.  hydrolysis  of  conjugates 
2.  methanol  precipitation  (optional),  particulary for  "dirty"  urine  of 
adult cattle 
3.  extract purification  and  concentration  using  mixed  solid-phase 
extraction  (SPE)  chromatography 
4.  derivatisation 
5.  detection  by  GC-MS  in  positive chemical  ionisation  mode  using  methane 
as  the  react gas 
6.  calculation  and  evaluation  of  results 
6.  MATERIALS 
Note:  The  reagents  (and  equipment)  for which  examples  of  their source  are 
quoted  are  known  to  be  satisfactory,  nevertheless  reagents  and  equipment 
from  other  sources  may  be  equally suitable.  All  the  reagents  should  be  of 
analytical  grade  or  better. 
6.1  Reference  compounds  and  Standards. 
6.1.1  The  following  standard  compounds  are  used. 
Clenbuterol  hydrochloride  (lnterchim,  Montlucon,  France) 
Salbutamol  hemisulphate,  Terbutaline  hemisulphate,  metoprolol  tartrate and 
meterproterenol  hemisulphate  (Sigma) 
Cimaterol,  Clenpenterol  (NAB  760),  mabuterol,  fenoterol  hydrobromide  and 
hydroxymethyl  clenbuterol  (NA1141)  (Boehringer  Ingleheim) 
Tulobuterol  hydrochloride  (Abbott) 
Ractopamine  hydrochloride  (Eli  Lilly) 
Cimbuterol  and  marpenterol  were  synthesised  by  Chern  Dept,  University of 
Rennes,  France 
Isotope  labelled  internal  standards,  clenbuterol-d6  and  salbutamol-d6  were 
obtained  as  a gift from  RIKILT,  Wageningen,  The  Netherlands.  It is 
foreseen  that these  reference  compounds  will  be  made  available through  the 
Measurement  and  Testing  Programme  of  DGXII. 
6.2 
6.2.1 
6.2.2 
6.2.3 
6.2.4 
6.2.5 
6.2.6 
6.2.7 
6.2.8 
6.2.9 
6.2.10 
6.2.11 
6.2.12 
6.2.13 
6.2.14 
6.2.15 
Chemicals 
Helix pomatia  juice  (B-glucuronidase-arylsulfatase,  Merck-4114) 
Glacial  acetic acid  (Panreac  - 131008  or  Merck-62) 
Ultra-pure water  (>14  M  n.cm) 
Methanol  (Carlo-Erba  RS  CLHP-412002  or  Merck-6009) 
Ethyl  acetate  (Merck  ZA-9623) 
32%  Ammonium  hydroxide  (Merck  5426) 
1M Potassium  hydroxide  (Merck  ZA-9018920) 
1M Acetic  acid 
N-0-bis(trimethylsilyl)trifluoracetamide  (BSTFA)  (Regisil-270111 
or  FLUKA  - 15244) 
Toluene  (Fluka  - 89677)  on  molecular  sieve. 
Sodium  acetate  (Merck  ZA-6268) 
Potassium  dihydrogen  phosphate  (Merck  ZA-4873) 
Nitrogen  (dried over  silica gel) 
Helium  (very  high  purity)  (N55,  Carboxyque) 
Methane  (very  high  purity)  (N45,  Carboxyque) 
Cy  2.3/2 6.3 
6.3.1 
6.3.2 
6.3.3 
6.3.4 
6.3.5 
7.0 
7.1. 
7.2 
7.3 
7.4 
7.5 
7.6 
7.7 
7.8 
7.9 
7.10 
7.11 
7.12 
7.13 
7.14 
7.14.1 
7.14.2 
Solutions 
B-agonists.  Prepare  stock  solutions of  the  standards  (6.1.1)  in 
methanol  (1  g per  L and  100  ~g per  L)  and  store at -l8°C. 
B-agonists.  Prepare working  solutions  by  dilution of  stock 
solutions  (6.3.1)  with  methanol  to final  concentrations  of  10  ~g 
and  l~g per  L.  Store  at -l8°C. 
2M Acetate  buffer,  pH  5.2,  for  hydrolysis  of  conjugates. 
Dissolve  164  g sodium  acetate  (6.2.11)  in  900  ml  water  (6.2.3) 
and  adjust  the  pH  to  5.2  ±  0.1  with  glacial  acetic acid  (6.2.2). 
Make  up  to 1 L with  water  and  store at +4°C.  Use  for  up  to 1 
month. 
O.lM Phosphate  buffer,  pH  6.  Dissolve  13.6  ~  0.1  g potassium 
dihydrogen  phosphate  (6.2.12)  in  900  ml  water  (6.2.3)  and  adjust 
the  pH  to  6.0  ±  0.1  with  1M  potassium  hydroxide  (6.2.7).  Make  up 
to  1 L with  water  and  store at +4°C.  Use  for  up  to  1 month. 
Mix  ethyl  acetate and  32%  ammonium  hydroxide  97:3  (v/v).  100  ml 
does  16  samples.  Stir/agitate the  mixture  prior to  use  and  then 
place  into  an  ultra-sonic bath  during  step 9.13.3. 
EQUIPMENT 
Centrifuge 
Rotary  evaporator 
Vortex  mixer 
pH  meter 
Pipettes 
Balance 
Vacuum  filtration system  (Vac-Elut  from  Analytichem 
International) 
Ultra-sonic  bath 
Magnetic  stirrer/agitator 
Conical  reaction  vials for  derivatisation 
Heating  block  for  reaction  vials  7.10 
Heating  block  with  evaporation  system 
SPE-Columns;  CLEAN  SCREEN  DAU  (Worldwide  monitoring  - Horsham, 
PA,  USA  and  sold  by  Technical,  Stockport,  Cheshire,  UK).  These 
columns  of  6 ml  volume  contain  500  mg  of  a mixed  phase  support 
which  has  hydrophobic  and  ion-exchange  properties. 
GC-MS 
GC;  GC  Hewlett  packard  5890. 
Capillary column,  30m X 0.25  mm  i.d. with  SE-30  (or  OV-1  or  HP-
1)  stationary phase  of  0.25  ~m thickness. 
Injection mode;  splitless over  1 minute 
Injection  volume;  2  ~L 
Injector temp.  250°C;  Transfer  temp.  280°C 
Temp.  programme; 
lSOC/min  SOC/min 
70°C  (2  min)  ----------->  200°C  (0  min)  --------->  245°C  (0  min) 
25°C/min 
--------------->  300°C  (12  min) 
Gas;  Helium  at 1 ml  per  min  and  5 psi. 
MS;  Hewlett  Packard  5971  with  UNIX  station. 
Positive Chemical  ionisation mode  (70  eV) 
Source  temp.  190°  ±  soc 
Cy  2.3/3 The  reactant gas  is methane:- regulate  the  flow  of  reactant gas 
in  such
5a way  as  to  2btain  a pressure  in  the  ion  source  of 
6 x 10- to  1 x 10  - Torr,  according  to  the  functioning 
conditions of  the  apparatus. 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section 6.3.1  and  to  ISO  document  78/2-1982  and 
also  the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN  and  EEC 
93/256. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection  of  residues  in  urine  as  defined  in  Directive 
64/433/EEC. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to 
allow  the  method  to  be  carried out  and  to  allow  repeat analysis 
where  required.  Each  analysis  needs  a  10  mL  sample. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to  allow 
proper  identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain 
the  integrity of  the  sample  and  not  prejudice  the  result of  the 
examination. 
Samples  for  the  analysis of  B-agonists  must  be  stored at 
temperatures  below  -18°C. 
9.0.  PROCEDURE 
Note;  The  steps 9.1  to  9.20  are  identical  to  those  reported  in  the 
screening method,  M.Sg.  v.v. 
9.1 
9.2 
9.3 
9.4 
9.5 
Thaw  the  primary  samples  and  transfer more  than  10  mL  to  a 
centrifuge tube.  Centrifuge  at 3000  rpm  for  15  min.  Pipette  10 
mL  to a  screw-topped  tube  (e.g.  scintillation counting  vial). 
Add  60  ng  metoprolol  as  internal  standard  to  all  urines  including 
two  blank  urines. 
To  one  of  the  blank  urines  (9.2)  add  40  ng  (equiv.  4 ppb) 
tulobuterol,  fenoterol  and  ractopamine  and  20  ng  (equiv.  2 ppb) 
of  the  other  B-agonist  standards  (6.3.2). 
Add  1 mL  acetate buffer  (6.3.3)  and  check  the  pH  is about  5.2  ~ 
0.3.  Adjust  the  pH  to about  5.2 with  acetic acid  if necessary. 
Add  50  ~L Helix pomatia  juice  (6.2.1)  and  incubate  overnight  at 
50°C  in  a water  bath  or  oven. 
Steps  9.6  to 9.11  are  optional  and  can  be  used  for  urines  from  adult 
cattle. 
9.6 
9.7 
9.8 
9.9 
9.10 
9.11 
Transfer  the  hydrolysed  urines  to rotary evaporation  flasks. 
Add  25  mL  methanol.  Evaporate  the  methanol  using  a rotary 
evaporator  and  a water  bath  at about  45°C. 
Concentrate  the  aqueous  phase  to about  3 mL. 
Transfer  the  aqueous  phase  to  a test tube  with  a  pasteur  pipette 
and  rinse out  the  flask  twice  with  5 mL  phosphate  buffer  (6.3.4). 
Centrifuge  at 3500  rpm  for  about  10  min.  A precipitate should 
form  on  the  tube. 
Check  and  adjust the  pH  to  6.0  ±  0.3  if necessary.  Use  all  the 
clear aqueous  phase  for  step 9.13. 
Cy  2.3/4 9.12 
9.13 
9.13.1 
9.13.2 
9.13.3 
9.13.4 
9.13.5 
9.14 
9.15 
9.16 
9.17 
9.18 
9.19 
9.19.1 
9.19.2 
9.19.3 
9.19.4 
9.19.5 
9.20 
If steps  9.6  to  9.11  were  not  carried out  add  4 ml  phosphate 
buffer  (6.3.4)  to  the  hydrolysate,  adjust the  pH  to  6.0  (final 
volume  to  15  ml. 
Column  extraction; 
Place  the  columns  on  the  Vac-Elut  system  and  successively rinse 
with;  2 ml  methanol;  2 mL  water  (6.2.3);  2 ml  phosphate  buffer 
(6.3.4). 
Transfer  the  clear extracts  (9.11  or  9.12)  with  a  pasteur  pipette 
to  the  top  of  the  column  and  allow  to drain  slowly  using  slight 
negative  (  ca.12  em  Hg)  pressure. 
Rinse  the  columns  using  negative  pressure of  about  40  em  Hg  with 
1 ml  1M acetic acid  (6.2.8)  and  allow  to  dry  before  rinsing with 
6 ml  methanol  by  applying  a  strong  vacuum. 
Place  the  ethyl  acetate I  ammonium  hydroxide  solution  (6.3.5)  in 
an  ultra-sonic bath  to agitate the  mixture  during  step 9.13.3. 
Elute  the  analytes with  6 ml  the  ethyl  acetate I  ammonium 
hydroxide  solution  (6.3.5) 
Evaporate  the  eluate with  nitrogen  using  an  evaporation  system 
and  a  heating  block  at 40  ±  5°C. 
Dissolve  the  residue  in  200  ~L methanol  with  vigorous  vortexing. 
Transfer  the  solution  to  a  reaction  vial. 
Dissolve  and  transfer to  the  reaction  vial  any  remaining  residue 
with  a further  100  ~L methanol  and  vortexing. 
Evaporate  the methanol  to  dryness  using  a  heating  block  at 40°  ± 
5°C. 
Derivatisation 
Add  50  ~L BSTFA  (6.2.9)  and  vortex. 
Place  vials  in  heating  block  at 75°C  ~ 5°C  for 90  min. 
Transfer  the  vials to  a  heating  block  at 40°  ±  5°C.  Allow  the 
vials and  block  to  cool  to  room  temperature  (25°C)  then  evaporate 
to dryness  with  nitrogen. 
Add  25  ~L toluene  (6.2.10)  and  vortex  vigorously. 
The  vials may  be  stored  in  a refrigerator at +4°C. 
Inject 2  ~L of  9.19.5  into  the  GC-MS. 
Cy  2.315 9.21  The  GC-MS  is run  in  the  positive chemical  ionisation mode  seeking 
four  major  characteristic  ions  for each  suspected  B-agonist.  The 
major  ions  and  the  retention times  of  the  derivatives of  the  B-
agonists  are  shown  in  table 1. 
Table  1. 
B-agonist  N  RT  (M+H)  (M-15)  (M-89)  Other  Adducts 
(min) 
Tulobuterol  1  9.43  300  284  210  328 
Mabuterol  1  10.61  383  367  293  363  411 
Mapenterol  1  11.42  397  381  307  377  425 
Terbutaline  3  12.29  442  426  352  356  470 
Clenbuterol  1  12.56  349  333  259  377 
Cimaterol  1  12.69  292  276  202  320 
332 
Cimbuterol  1  12.97  306  290  216  334 
346 
Salbutamol  3  13.03  456  440  366  394 
369 
350 
Cimaterol  2  13.41  364  348  274  292  392 
404 
Metoprolol  (I.S)  1  13.49  340  324 
Clenpenterol  1  13.63  363  347  273  391 
Cimbuterol  2  13.66  378  362  288  306  406 
418 
Hydroxymethyl- 2  15.30  437  421  347  313  465 
clenbuterol  387 
Fenoterol  4  20.73  592  576  502  236 
412 
357 
Ractopamine  3  20.88  518  502  428  250 
456 
N is the  number  of  TMS  groups.  RT  are  the  retention times  recorded  in  an 
analysis at LDH,  Nantes. 
Adducts  are  ions  induced  by  the  gas  which  are  useful  to  select. 
Note.  Experience  shows  that it is rarely possible  to obtain  sufficient 
information  on  at  least four  ions  using  this  PCI  mode  of  mass  spectrometry. 
Therefore  it is recommended  that the  spectra obtained  using  EI  mode  are 
also  taken  into account  (for the  method  using  the  same  extraction procedure 
and  gas  chromatographic  conditions  but  with  detection  in  the  EI  mode  see 
method  Sg  2.1). 
Cy  2.3/6 10.0  INTERPRETATION  OF  RESULTS 
10.1  Validity of  Analysis;  The  criteria set out  in  EC  Decision  256 
must  be  fulfilled especially the  following;-
10.1.1  The  relative retention times  for  the  TMS  derivatives of  the 
standard  analytes  in  the  appropriate matrix  and  the  suspected  B-
agonist  must  be  the  same. 
10.1.2  The  relative  intensities of  the  selected  ions  to  the  base  peak 
must  be  same  as  in  the  assay  of  spiked  blank  urines  and  of 
standards. 
10.1.3  The  ions  for  the  internal  standard  (metoprolol-monoTMS)  must  be 
present  at the  correct retention time. 
10.1.4  The  analysis of  the  blank  urine  containing  the  internal  standard 
must  show  NO  evidence  of  carry-over  of  B-agonists  from  the  GC-MS 
system.  This  is a  check  for  contamination  of  the  system. 
11.  SPECIAL  CASES 
12.  NOTES  ON  PROCEDURE. 
The  retention  times  (RT)  of  the  TMS  derivatives differ slightly from  those 
in  the  screening  method. 
13.  QUALITY  CONTROLS 
See  section 8 of  manual  detailing the  RMs  for  the  B-agonists. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS 
A full  list of  abbreviations  is given  in  Annex  I,  Section  12 
16.  FLOW  DIAGRAM 
hydrolysis 
URINE  -----------> METHANOL  PRECIPITATION-------->  EXTRACT  by  SPE  Chrom. 
I 
I 
I 
I 
(PCI  mode)  l 
INTERPRET  RESULTS  <----------- GC-MS  <------------ TMS  DERIVATIVES 
(methane) 
Cy  2.3/7 Cy  3.1.  SULPHONAMIDES  - CONFIRMATION  OF  SULPHONAMIDES  BY  GAS 
CHROMATOGRAPHY-MASS  SPECTROMETRY 
WARNING  AND  SAFETY  PRECAUTIONS 
SAFETY 
1.  Organic  solvents  - all  organic  solvents  must  be  treated as 
potentially hazardous  and  all  procedures  using  them  must  be 
performed  in  a fume  cupboard. 
2.  Ammonia  - use  only  in  a  fume  cupboard  and  wear  safety 
glasses. 
3.  Homogenising  - perform  in  a fume  cupboard  to  avoid  aerosols. 
4.  Dry  ice  - wear  thick  hide  gloves  and  face  shield.  Dry 
ice  can  cause  burns  and  frostbite  if  in  contact with  the  skin. 
5.  Diazomethane 
ALL  REACTIONS  INVOLVING  THE  PREPARATION  AND  USE  OF  DIAZOMETHANE  MUST  BE 
CARRIED  OUT  IN  A FUME  CUPBOARD.  PROTECTIVE  CLOTHING  MUST  BE  WORN. 
DO  NOT  USE  EQUIPMENT  WITH  GROUND  GLASS  JOINTS  - THERE  IS  A POTENTIAL 
EXPLOSION  HAZARD! 
You  should  ensure  that you  and  anyone  else  in  the  room  are  aware  of  the 
potential  explosion  hazards  associated with  diazomethane.  All  diazomethane 
generated  MUST  be  destroyed  immediately  if it is not  being  used  for  direct 
methylation.  This  is achieved  by  bubbling  through  dilute HCl.  All 
glassware  used  should  be  rinsed  in  HCl  before  it leaves  the  fume  cupboard. 
FIRST  AID 
1.  Solvents,  acids  and  alkalis  in  contact with  skin  - wash  with 
copious  amounts  of  cold  water.  Splashes  in  the  eye  - irrigate 
with  water  and  seek  medical  attention  immediately. 
2.  Cuts  - seek  assistance of  first aider  immediately. 
3.  Burns  and  frostbite  - run  affected  part under  cold  water  (burns) 
or  tepid water  (frostbite) for  10  minutes  and  seek  medical 
attention. 
1.  INTRODUCTION 
Purpose 
The  confirmation  of  the  presence  of  sulphonamides  in  samples  taken  from 
farm  animals  in  compliance  with  the  Residues  Directive 86/469/EEC. 
Background 
Sulphonamides  are  antimicrobial  compounds,  which  have  been  developed  to 
combat  disease  caused  by  viruses,  bacteria,  protozoa  or  fungi.  Used  in  sub-
therapeutic doses,  they  may  also exhibit a growth  promoting  action  and  so 
are  added  to feedstuffs  to  increase  productivity. 
Residues  of  these  substances  may  reach  the  consumer,  but  as  some  can  induce 
hypersensitivity reactions  in  consumers  and  one  is a  suspected  carcinogen, 
the  tolerance  level  of  these  substances  in  food  for  human  consumption  has 
been  set at 0.1  ppm  by  the  CVMP.  The  monitoring  of  sulphonamide  residues 
in  meat  is carried out  to ensure  that withdrawal  periods  are  being  observed 
and  that residues  do  not  reach  the  consumer. 
Cy  3.1/1 Residue  levels  are monitored  in  tissues taken  at slaughter  under  the 
National  Surveillance  Scheme  for Residues  in  Meat.  From  1 January  1989 
this monitoring  was  carried out  in  compliance  with  the  Residues  Directive 
(86/469/EEC).  In  the  UK  scheme  kidney  has  been  chosen  as  the  tissue for 
analysis. 
The  samples  are  initially screened  by  TLC  or  ELISA  (refer to  SOP  for  the 
method).  The  CVL,  UK  confirms  positive samples  by  either an  HPLC  method  or 
by  this  GC-MS  method. 
1.  SCOPE 
This  method  of  analysis describes  the  determination  of  the  total  content of 
sulphadimidine  in  pig  kidney. 
2.  FIELD  OF  APPLICATION. 
The  method  is described  to  be  used  for  porcine  kidney.  The  detection 
limit,  for  sulphadimidine  is  100  ug/kg  or  litre of  sample. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
2052/VI/84  File 6.11  11-4,  Scientific Veterinary Committee,  Working 
Group- .. Reference  Methods  for  Residues .. ,  General  Criteria for  the 
establishment  of  Reference  Methods  for  the  Detection  of  Residues. 
ISO  Standard  78/2-1982  Layout  for  standards  - Part  2:  Standard  for  Chemical 
Analysis 
MAFF  (1987)  Working  Party on  Veterinary Residues  in  Animal  Products.  Food 
Surveillance  Paper  No.  22. 
Takatsuki,  E and  Kikuchi,  T.,  (1990),  Gas  chromatographic-mass 
spectrometric determination  of  six  sulfonamide  residues  in  egg  and  animal 
tissues.  J.A.O.A.C.  73,  886-892 
Simpson,  R.M.,  Suhre,  F.B.  and  Shafer,  J.w.  (1985),  Quantitative gas 
chromatographic-mass  spectrometric  assay  of  five sulfonamide  residues  in 
animal  tissue.  J.A.O.A.C.  68,  23-26 
Matusik,  J.E.,  Sternal,  R.S.,  Barnes,  C.J.  Sphon,  J.A.  (1990)  Confirmation 
of  identity by  gas  chromatography/tandem  mass  spectrometry of 
sulfathiazole,  sulfamethazine,  sulfachloropyridazine,  and  sulfademethoxine 
from  bovine  or  swine  liver extracts after quantisation  by  gas 
chromatography/electron  capture  detection. 
4.  DEFINITIONS. 
Sulphadimidine  content  is taken  to  mean  the  amount  of  sulphadimidine  in 
kidney  determined  according  to  the  described  method  and  expressed  as  ug 
sulphadimidine  per  kg  test sample. 
5.0  PRINCIPLE 
Cy  3.1/2 Dried  extracts of  kidney  or  muscle,  cleaned  up  by  a Bond-Elut  method,  are 
methylated  with  diazomethane  and  the  methylated  extracts are  subjected  to 
analysis  by  gas  chromatography-mass  spectrometry  (GC-MS). 
6.  MATERIALS 
6.1.  Chemicals 
6.1.1.  Diazald  Aldrich  Chemical  Co  Ltd 
6.1.2.  Potassium  hydroxide  AR  grade 
6.1.3.  Diethyl  ether  Distal  grade 
6.1.4.  Ethyl  digol  (carbitol)  Technical  grade,  BDH 
6.1.5.  Hydrochloric  acid  AR  grade 
6.1.6.  Methanol  Distal  grade 
6.1.7.  Acetone  Distal  grade 
6.2.  Standards 
Solid  sulphonamides  may  be  obtained  from  Sigma.  A mixed  standard  of 
concentration  = 1 mg/mL  of  each  sulphonamide  in  methanol  should  be  prepared 
using  available sulphonamides.  At  present  CVL  are  using:  sulphamethazine, 
sulphamerazine,  sulphanilamide,  sulphapyridine,  sulphathiazole, 
sulphadiazine,  sulphaguanidine,  sulphachloropyridazine,  sulphadimethoxine 
and  sulphaquinoxaline. 
Working  standards  of  concentrations  =  0.1  ug/mL,  1 ug/mL,  10  ug/mL  and  100 
ug/mL  should  be  prepared  by  dilution from  the  stock. 
7.  EQUIPMENT 
7.1.  Mini  diazald  apparatus  (Aldrich  Chemical  Co  Ltd) 
7.2.  Separating  funnel  with  teflon  stopcock  125  mL 
7.3.  Centrifuge  tubes 
7.4.  Water  bath 
7.5.  Manifold  supplying  oxygen-free  nitrogen 
7.6.  Mass  spectrometer;  Finnigan  MAT,  coupled  to  a gas  chromatograph 
and  linked  to  an  INCOS  data  system 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to section  6.3.1  and  ISO  document  78/2-1982  and 
the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection of  residues  in  meat  as  defined  in  Directive 64/433/EEC.  Failing 
this biological  fluids or  faeces  may  constitute the  samples  for  the 
detection of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to  allow 
the  reference  method  to  be  carried out  and  to  allow  repeat  analysis where 
required.  In  this method  for  sulphadimidine  the  sizes shall  not  be  less 
than  20  g kidney. 
9.0.  PROCEDURE 
Cy  3.1/3 9.1.  Sample  preparation 
Samples  are  extracted via  a Bond-Elut  method  and  the  extracts taken  to 
dryness.  Mixed  standards  of  varying  concentrations  are  also taken  to 
dryness.  Both  standards  and  samples  are  resuspended  in  1 ml  of  methanol. 
9.1.1. 
9.1.2. 
9.1.3. 
9.1.4. 
9.1.5. 
9.1.6. 
9.1.7. 
9.1.8. 
9.1.9.1. 
9.1.10. 
9.1.11. 
9.1.12. 
9.1.13. 
9.2. 
Weigh  2.5  g thawed  and  chopped  sample  into  a  30  ml  tube. 
Add  6 ml  of  0.1M  acetic acid:acetone mixture  (1:1  v/v)  and  add  12 
ml  ethyl  acetate.  Homogenise  for  1 minute  and  centrifuge at 2500 
rpm  for  15  minutes. 
Transfer  supernatant  to  another  30  ml  tube  and  repeat Step  2 on 
the  tissue pellet.  Combine  supernatants  and  place  tubes  in  a 
rack. 
Place  rack  into  cardice  box  until  aqueous  layer  is completely 
frozen  (at  least 15  minutes). 
Decant  ethyl  acetate  into another  30  ml  tube  ready  for  clean-up. 
Using  vacuum  apparatus  prepare  NH2  Bond  Elut  column  by  washing 
with  1 column  volume  of  hexane.  Prepare  SCX  Bond  Elut  column  by 
washing  with  1 column  volume  of  hexane  followed  by  two  column 
volumes  of  5%  acetic acid  in  ethyl  acetate.  (N.B.  Do  NOT  let sex 
column  run  dry.)  Assemble  the  columns  in  tandem. 
Transfer  the  ethyl  acetate extract to  the  reservoir and  draw  it 
through  the  assembly  by  vacuum. 
Wash  the  assembly  with  2 column  volumes  of  methanol  (ca  6 ml). 
Close  the  vacuum  tap  and  discard  the  NH2  column  and  reservoir. 
Wash  the  SCX  column  with  2 column  volumes  of water  followed  by  4 
column  volumes  of  methanol.  (N.B.  Do  NOT  let  SCX  column  run 
dry.) 
Remove  column  from  assembly,  attach  to  Luer  syringe  and  elute 
sulphadimidine  with  3 ml  of  25%  ammonia  in  methanol  into  2 dram 
vial,  using  positive pressure. 
Evaporate  eluate under  N 2  at 45-50°C  in  a water  bath.  Dissolve 
residue  in  0.5  ml  acetone  and  transfer with  a  Pasteur  pipette to 
another  vial.  Wash  with  a further 0.5  ml  acetone  and  combine 
washes.  Eluate  can  then  be  stored overnight at -20°C  if needed. 
Evaporate  eluate under  N 2  at 45-50°C  in  a water  bath.  Dissolve 
residue  in  1 ml  methanol. 
Derivatisation 
DO  NOT  CARRY  OUT  THIS  METHYLATION  UNLESS  YOU  HAVE  BEEN  TRAINED  TO  DO  SO. 
READ  THE  SECTION  ON  SAFETY  AND  FOLLOW  THE  ADVICE  GIVEN  CAREFULLY. 
9.2.1. 
9.2.2. 
9.2.3. 
9.2.4. 
9.2.5. 
9.2.6. 
Prepare  the  following  reagents: 
(a)  2 g diazald  in  20  ml  diethyl  ether. 
(b)  3 g potassium  hydroxide  in  3 ml  distilled water  added  to 
10  ml  ethyl  digol. 
(c)  10%  hydrochloric  acid,  100  mL. 
Set  up  the  Mini-diazald  kit according  to  the maker's 
instructions. 
Until  you  are ready  to methylate  the  samples,  the  diazomethane 
generated  must  be  passed  through  the  10%  HCl,  which  will 
neutralise it.  Ensure  that the  kit  is set up  for  this. 
Place  reagent  (b)  (KOH  in  H 20 +ethyl  digol)  in  the  reaction 
vessel. 
Place  a  separatory funnel  over  the  reaction  vessel.  Reagent  (a) 
(diazald  in  ether)  is placed  in  this funnel. 
Warm  the  reaction  vessel,  by  placing  in  a water  bath  at 50-60°C. 
Cy  3.1/4 Slowly  and  carefully add  the  diazald  solution over  a  period  of 
approximately  20  minutes.  Once  the  reaction  has  started,  the 
diazomethane  is bubbled  through  the  sample  and  standards  until 
the  solution  is coloured  yellow.  Whenever  the  diazomethane  is 
not  bubbling  through  a  sample  or  standard  it is  important  that it 
is passed  through  the  HCl  to  neutralise it. 
9.2.7.  Once  all  of  the  standards  and  samples  have  been  derivatised, 
check  that the  diazomethane  generated  is being  passed  through  the 
HCl  solution,  and  allow  the  reaction  to  continue  until  all  of  the 
reagents  have  been  used  up. 
9.2.8.  Concentrate  the  derivatives  to  dryness  under  nitrogen.  Resuspend 
in  100  ~L acetone. 
9.3.  GC-MS  Analysis 
9.3.1.1.  The  GC  parameters  are 
COLUMN:  J&W  fused  silica capillary column,  SE-54,  15m x 0.25  mm. 
INJECTIONS:  0.5  ~L manual  injections. 
TEMPERATURES:  Interface:  270°C;  Injector:  260°C 
OVEN  TEMPERATURES: 
from  temp  to temp  rate  time  total  time 
(oc)  (oc)  (°C/min)  (min)  (min) 
210  210  2.0  2.0 
210  260  5  12.0 
260  260  4.0  16.0 
CARRIER  GAS:  Helium;  flow  rate  = 1 cm3/min 
injector pressure = 10  psi. 
9.3.1.2. 
Using  an  OV-1  column  and  injecting a mixture  of  methylated  sulphonamides 
(10  ng)  CVL  recorded  the following  retention times  in  minutes. 
Sulphanilamide,  5.3;  Sulphapyridine,  8.8;  Sulphathiazole,  9.0; 
Sulphadiazine,  9.9;  Sulphamerazine,  10.8;  Sulphadimidine,  11.8; 
Sulphaguanidine,  12.1;  Sulphamethizole,  15.2; 
Sulphadimethoxine,  15.7;  Sulphamethoxypyridazine,  19.7 
9.3.2  The  mass  spectrometry  parameters  are 
IONISER: 
Mode:  EI  positive  ion 
Temperature:  150°C 
MANIFOLD  TEMPERATURE:  90  (~ 5)  °C 
ELECTRON  MULTIPLIER:  1.4  kV 
ELECTRON  ENERGY:  70  electron volts. 
Other  parameters  should  be  set up  by  adjusting  the  instrument  controls  to 
give  the  optimum  peak  height  and  shape  for  a  suitable calibration compound. 
The  CVL  uses  perfluorotributylamine  (PFTBA). 
9.3.3. 
9.3.4. 
Operate  the  MS  in  EI  mode  and  scan  between  m/z  =  50  and  500. 
Analyst  the  mixed  standard  (10  ug/100  uL)  and  identify the  peaks 
by  comparison  with  those  previously set up  and  stored  in  a 
library.  The  individual  sulphonamides  are  separated  by  the  GC, 
enabling  identification on  the  basis of  retention time  as  well  as 
Cy  3.1/5 the  mass  spectrum. 
9.3.5.  Analyst  the remaining  samples  and  standards.  It is advisable  to: 
(a)  Analyst  standards  in  order of  increasing concentration. 
(b)  Inject hexane  between  each  injection. 
10.0.  RESULTS 
The  presence  of  a  sulphonamide  in  a  sample  is confirmed  if the  GC-MS  data 
satisfies the  following  criteria: 
1.  The  peak  in  the  sample  has  the  same  GC  retention time  as  that  in 
the  standard. 
2.  The  ions  present  in  the  mass  spectrum  of  the  sample  GC  peak  are 
identical  to  those  in  the  mass  spectrum  of  the  standard. 
3.  The  ratios of  the  ions  to one  another  must  be  the  same  as  those 
in  the  standard. 
The  limit of  detection of  this method  for  sulphadimidine  is  100 
~g per  kg  of  tissue. 
11.  SPECIAL  CASES. 
12.  NOTES  ON  PROCEDURE. 
13.  SAMPLE  CONTROLS 
The  quality control  sample  was  obtained  from  a  sample  previously analyzed 
and  found  to  contain  sulphadimidine  above  the  maximum  residue  limit 
(MRL). 
The  blank  sample  was  obtained  from  a  sample  previously analyzed  and  found 
to contain  no  sulphadimidine.  Fortify (spike)  with  100  ~L of  2.5  ~g mL 
sulphadimidine  standard. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS. 
See  abbreviations  in  Annex  I,  Section  12,  of  Manual. 
16.  FLOW  DIAGRAM 
SAMPLE  --------> Homogenise------>  Bond-Elut  extract  ____ , 
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Calculate results <-------- GC-MS  <--------- Derivatise 
Cy  3.1/6 Cy  3.2.  SULPHADIMIDINE  - CONFIRMATION  AND  DETERMINATION  OF  SULPHADIMIDINE 
IN  PIG  KIDNEY  OR  DIAPHRAGM  MUSCLE  TISSUE  BY  HIGH  PERFORMANCE  LIQUID 
CHROMATOGRAPHY. 
SAFETY 
Personal  safety.  Normal  laboratory protective clothing  and  equipment 
should  be  worn. 
1.0.  INTRODUCTION 
A method  is described  by  which  the  content  of  sulphadimidine  in  pig  kidney 
or  diaphragm  muscle  tissue may  be  confirmed.  This  method  which  is used 
officially in  Northern  Ireland  is different from  the  HPLC  method  (see  Cy 
3.3)  used  at the  Central  Veterinary  Laboratory,  UK 
Sulphadimidine,  otherwise  known  as  sulphamethazine  is one  of  a  group  of 
antimicrobials  called sulphonamides.  Its use  is widespread  in  animal 
production  and  it is most  commonly  fed  to  pigs  in  their ration at 100  g per 
tonne.  Residues  at or  above  the  violative  level  have  been  reported  in  many 
countries. 
2.  SCOPE  AND  FIELD  OF  APPLICATION. 
This  method  of  analysis  describes  the  determination  of  the  total  content of 
Sulphadimidine  in  pig  kidney  or  diaphragm  muscle  tissue. 
The  detection  limit,  defined  as  three times  the  noise  level  of  the  blank 
determination,  is 0.05  mg  per  kg  of  kidney  or  muscle  sample  for 
Sulphadimidine. 
Twelve  kidney  or  muscle  samples  including  two  spiked  samples  can  be 
analysed  in  a working  day. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
ISO  Standard  78/2-1982  Layout  for  standards  - Part  2:  Standard  for  Chemical 
Analysis 
Method  based  on  Standard  Operating  Procedure  SOP  B10  17  V.1,  (1988)  for  the 
confirmatory  determination  of  sulphamethazine  in  porcine  tissue by  HPLC;-
Veterinary Sciences  Division,  Stoney  Road,  Stormont,  BELFAST  BT4  3SD 
Aerts,  M.M.L.,  Beek,  W.M.J.  and  Brinkman,  U.A.Th.  (1988).  Monitoring  of 
Veterinary  Drug  Residues  by  a combination  of  continuous  flow  techniques  and 
column-switching  HPLC.  I.  Sulphonamides  in  egg,  meat  and  milk  using  post-
column  derivatization with  dimethylaminobenzaldehyde.  J.  Chromat.  435,  97-
112. 
4.  DEFINITIONS. 
Sulphadimidine  content  is taken  to  mean  the  amount  of  Sulphadimidine  in  the 
substance  in  question,  regardless  of  the  chemical  form,  determined 
according  to  the  described  method  and  expressed  as  ug  Sulphadimidine  per  kg 
of  test sample. 
Cy  3.2/1 5.  PRINCIPLE 
The  methods  comprises  5 stages;-
- Homogenisation  of  pig  kidney  samples  in  buffer 
- Extraction  of  Sulphadimidine  with  organic  solvents 
- Partition of  Sulphadimidine  between  hexane  and  aqueous  methanol/acetic 
acid. 
- End  point  determination  with  HPLC  with  post  column  derivatisation. 
- The  amount  of  Sulphadimidine  is calculated  by  interpolation from  a 
standard  curve  and  taking  into  account  the  recovery  of  Sulphadimidine, 
especially from  tissue samples. 
6.0  MATERIALS 
N.B.:  The  reagents  for which  examples  of  their source  are quoted  are 
known  to  be  satisfactory,  nevertheless  reagents  from  other sources  may  be 
equally suitable. 
6.1  Reagents 
6.1.1  Chloroform  (Rathburn  Chemicals  Ltd) 
6.1.2  Methanol  (HPLC  Grade,  Rathburn  Chemicals  Ltd) 
6.1.3  Acetone  (Rathburn  Chemicals  Ltd) 
6.1.4  Hexane  (Rathburn  Chemicals  Ltd) 
6.1.5  Deionised  water  prepared  using  equipment  7.16. 
6.1.6  N,  N-Dimethyl-Aminobenzaldehyde  - Ehrlichs  reagent  (Sigma 
Chemical  Co,  Cat  No  08904). 
6.1.7  Glacial  Acetic  acid  (BDH  Lab.  Supplies,  Cat.  No.  27013). 
6.1.8  Sulphamethazine  crystalline sodium  salt  (Sigma  Chemical  Co.,  PO 
Box  14508  St  Louis,  M063178  USA,  Cat  No  S-55637). 
6.2  Solutions 
6.2.1  50%  Methanol  (6.1.2)  v/v  deionised water  (6.1.5) 
6.2.2  50%  methanol  in  2%  acetic acid.  Mix  125  mL  methanol  with  5 mL 
glacial  acetic acid  in  a  250  mL  graduated  flask.  Make  up  to  the 
mark  with  water  and  mix. 
6.2.3  N,  N-Dimethyl-Aminobenzaldehyde  Reagent 
Acetic  Acid  (6.1.7)  125  mL 
Methanol  (6.1.2)  75  mL 
Deionised  water  (6.1.5)  50  mL 
N,  N-Dimethyl-Aminobenzaldehyde  (6.1.6)  3.75  g 
Before  adding  the  N,  N-Dimethylbenzaldehyde  degas  the  solution 
using  the  equipment  described  in  (7.4)  for 2 minutes, 
6.2.4  2%  Acetic  Acid 
Acetic  Acid  (6.1.7)  10  mL 
Deionised  water  (6.1.5)  490  mL 
6.2.5  HPLC  Mobile  Phase 
2%  Acetic  acid  (6.2.4)  325  mL 
Methanol  (6.1.2)  175  mL 
(degas  for  2 minutes  (7.4) 
6.2.6  Wash  solution.  Add  200  mL  of  water  to 800  mL  methanol  in  a  1 L 
measuring  cylinder.  Mix  and  degas  as  in  6.2.3. 
6.2.7  Mix  equal  volumes  of  chloroform  and  acetone  with  stirring. 
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8. 
Standards 
Stock  standard 
Dissolve  an  accurately weighed  (7.2)  quantity of  sulphamethazine 
(6.1.8)  in  Methanol  (6.1.2)  to  give  a solution of  1 mg  to 
sulphamethazine  per  mL  using  a  100  ml  volumetric  flask  (7.12). 
Store  at +4°C.  (7.5). 
Intermediate  standards.  100  ~g per  mL.  Dilute  the  1 mL  stock 
standard  to  10  mL  with  methanol.  Use  a volumetric  flask. 
Intermediate  standards.  10  ~g per  mL.  Dilute  the  1 mL  stock 
standard  to  100  mL  with  methanol.  Use  a volumetric  flask. 
Working  standard.  1  ~g per  mL. 
Take  1 mL  of  intermediate  standard  ((6.3.2.1)  and  make  up  to  100 
mL  with  50%  Methanol  in  2%  acetic acid  (6.2.2).  Prepare  daily and 
store at +4°C. 
EQUIPMENT 
Balance  top-pan  (Sartorius,  Gottingen,  Germany  model  L610D). 
Balance  analytical  (Sartorius,  Gottingen,  Germany  model  R160P). 
Magnetic  Stirrer  (Gallenkamp  model  300). 
Degassing  apparatus. 
Refrigerator  +4°C  (Williams  Refrigeration  Ltd,  Kings  Lynn,  UK). 
Fume  cupboards  (Nordia,  Lab  Design,  Walthamstow,  London,  E17  6AB. 
Test  tubes,  10  mL  round  bottomed  with  ground  glass  stoppers. 
Round  bottomed  flasks,  150  mL 
Polyethylene  bottles,  125  mL,  with  wide  mouth 
Graduated  glass  pipettes,  10  mL  and  25  mL  (FSA  Lab  Supplies,  Cat 
Nos  G519  and  G520). 
Measuring  cylinders,  250  mL  and  1 L (FSA  Lab  Supplies) 
10  mL  and  100  mL  volumetric  flask  (FSA  Lab  Supplies). 
Pasteur  pipettes 
Chromacol  microvials,  200  ~L. 
Water  pump 
Millipore  R060  reverse  osmosis  and  milli Q deionised water 
system.  (Millipore  SA,  67120  Molsheim,  France,  Cat  Nos 
ZFRONC06and  PF00671/U  respectively). 
Silversun  heavy  duty  homogeniser 
Centrifuge,  Sorvall  RT  6000  refrigerated. 
Filtering equipment,  Buchner  funnel,  Hartley  pattern with  PTFE 
perforated  disc. 
Filter paper,  Whatman  glass  GF/C  microfibre filters  (7.0  em) 
Ultrasonic  bath,  Ultrasonics  Ltd/Decon  FS  200 
HPLC  System 
Waters  type  501  pump 
Waters  Model  455LC  Spectrophotometer  set at 450  nm 
Lloyd  Instrument  CR  650  pen  recorder 
Whatman  Particil  SODS- 3 column  (25  em  x 4.6  mm  i.d.) 
Hitachi  AS-2000  autosampler  fitted with  50  ~L loop 
Post  column  equipment.  Reaction  coil  10  ft length  of  Teflon 
Tubing  (0.023  ins  i.d.).  Low  dead  volume  T-piece  mixing  chamber 
SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is  drawn  to  section  6.3.1  and  to  ISO  document  78/2-1982  and 
also  the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN  and  EEC 
93/256. 
Cy  3.2/3 8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection  of  residues  in  meat  as  defined  in  Directive  64/433/EEC.  Failing 
this biological  fluids or faeces  may  constitute the  samples  for  the 
detection  of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large enough  to allow 
the  method  to  be  carried out  and  to  allow  repeat  analysis where  required. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a  way  as  to allow  proper 
identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice  the  result of  the  examination. 
Samples  for  the  analysis  of  thyreosta~ic substances  must  be  stored  and 
transported at temperatures  below  -18  C. 
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PROCEDURE 
All  samples  are  prepared  singly. 
Weigh  into  125  ml  polyethylene  bottle  (7.9)  5 g ~ 0.02  g of  fresh 
tissue. 
Controls  are  prepared  using  3 x 5 g negative  tissue and  adding 
1.  nothing 
2.  100  ~L of  control  solution  (6.3.2.2) 
3.  200  ~L of  control  solution  (6.3.2.2) 
To  all  bottles add  50  ml  of  chloroform/acetone  mixture  (1:1, 
v/v),  (6.2.7) 
Cap  and  homogenise  at full  speed  for  approximately  one  minute 
(7.17). 
Filter through  Whatman  GF/C  glass microfibre filters using  a 
water  pump. 
To  all  bottles add  10  ml  of  chloroform/acetone  mixture.  (6.2.7). 
Wash  and  filter as  in  9.6. 
Combine  the filtrates and  transfer to a  100  ml  pear-shaped  flask. 
Remove  solvent  by  rotary evaporation  at 30°C. 
Add  2 ml  50%  methanol  in  2%  acetic acid  and  6 ml  hexane  to  the 
residue.  Swirl  the  flask  gently to  dissolve,  and  to partition 
the fats  into the  hexane.  Do  not  shake  or  emulsions  will  be 
formed. 
Transfer  into  10  ml  test tubes  (7.7)  and  centrifuge at 2000  rpm 
for  10  min.  Discard  the  top  layer  and  transfer a  200  ~L aliquot 
of  the  bottom  layer  to  the  HPLC  vials  (7.14).  The  samples  are 
now  ready  to  be  analysed  by  HPLC. 
HPLC 
Ensure  wavelength  monitor  is set at 450  nm  (7.22.2). 
The  column  is run  at room  temperature. 
Equilibrate the  system  by  running  the  mobile  phase  (6.2.5) 
through  at 1 ml  per  min  for  30  min.  Introduce  the  post-column 
reagent  at a rate of  0.5  ml  per  min  for  a further  30  min. 
Calibrate the  system  by  injecting 50  ~L of  the  previously 
prepared  working  standard  (6.3.2.3)  until  a constant  height  of 
110  ±  10  mm  is obtained. 
Inject 50  ~L of  each  extract  (9.9).  A 1  ~g per  ml  working 
standard  (6.3.2.3)  is run  after every  fourth  sample.  Each  sample 
takes  10  min  to  run  and  the  retention  time  of  the  sulphadimidine 
is 8 min. 
Cy  3.2/4 9.10.6  If a peak  having  a retention  time  similar to  the  standards  is 
seen  in  the  sample,  mix  equal  volumes  of  an  appropriate  standard 
and  the  sample  and  re-chromatograph  to  check  for  co-elution. 
9.10.7  After  the  last  injection,  allow  80%  (v/v)  methanol/water  to  run 
through  the  system  at 0.5  mL  per  min  overnight.  Store  the  column 
in  80%  methanol/water  when  not  in  use. 
10.0  CALCULATION  OF  RESULTS 
Calculate  the  concentration  of  sulphadimidine  in  the  samples  by  the 
equation 
C(s)  =  S(h)  x  C(Std) 
Std(h) 
where  C(s)  is sample  concentration  in  mg  per  kg 
S(h)  is the  peak  height  of  the  sample 
Std(h)  is the  peak  height  of  the  standard 
C(Std)  is the  cone.  in  mg  per  kg  that the  standard  is equivalent 
to.  In  this extraction the  working  standard  of  1  mg  per  L is 
equivalent  to 0.4  mg  per  kg  (C(Std)). 
10.2  Validation  Data. 
10.2.1  Liver 
Blank  samples  from  untreated  animals  were  spiked  at zero,  0.2  and  0.4  mg 
per  kg  sulphadimidine.  The  assay  was  performed  on  three consecutive  days. 
The  recoveries  were  in  percentages 
Day  Kidney  Kidney  Muscle  Muscle  0.4 
(0.2  mg/kg)  (0.4  mg/kg)  (0.2  mg/kg)  (mg/kg) 
Mean  so  cv  Mean  so  cv  Mean  so  cv  Mean  so  cv 
1  76  ±  6.7  8.8  84  ±  6.0  7.2  86  ±  3.3  3.9  83  ±  4.5  5.4 
2  79  ± 8.7  10.9  84  ±  10.8  12.7  82  ±  7.8  9.5  77  ±  2.9  3.7 
3  84  ±  8.1  9.7  83  ±  6.4  7.7  77  ±  3.9  5.1  76  ±  3.9  5.1 
ALL  80  ±  7.8  9.8  84  ±  7.7  9.2  82  ±  5.0  6.2  79  ±  3.8  4.7 
11.0  SPECIAL  CASES 
Cy  3.2/5 12.0  NOTES  ON  PROCEDURES 
The  retention times  of  other  sulphonamides  were  evaluated  in  the  HPLC 
system  and  were, 
Sulphonamide  Retention  time  (min) 
Sulphadimidine  8.4 
Sulphaguanidine  4.1 
Sulphanilamide  4.2 
Sulphathiazole  5.9 
Sulphadiazine  6.0 
Sulphapyridine  6.2 
Sulphamethoxazole  10.5 
Sulphadoxine  12.0 
Sulphadimethoxine  23.8 
Sulphaquinoxaline  29.3 
13.0  QUALITY  CONTROLS. 
The  RM  for  pig  tissues are  in  the  final  stages  of  preparation  and 
certification.  They  were  prepared  at VRL,  Belfast. 
14.0  TEST  REPORT.  To  give  the  indications  necessary for  the 
identification of  the  sample,  the  reference  to  the  method  employed,  the 
results and  the  form  in  which  these  are  expressed,  any  particular points 
observed  in  the  course  of  the  test and  any  operations  not  specified  in  the 
method  or  regarded  as  optional  which  might  affect the  results. 
15.  LIST  OF  ABBREVIATIONS 
A full  list of  abbreviations  is given  in  Annex  I,  Section  12 
16.  FLOW  DIAGRAM 
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Cy  3.2/6 Cy  3.3. 
KIDNEY 
SULPHADIMIDINE  - HPLC  ANALYSIS  OF  SULPHADIMIDINE  IN  PORCINE 
WARNING  AND  SAFETY  PRECAUTIONS 
SAFETY 
1.  Organic  solvents  - all organic  solvents  must  be  treated as 
potentially  hazardous  and  all  procedures  using  them  must  be 
performed  in  a fume  cupboard. 
2.  Ammonia  - use  only  in  a  fume  cupboard  and  wear  safety glasses. 
3.  Homogenising  - perform  in  a fume  cupboard  to  avoid  aerosols. 
4.  Dry  ice  - wear  thick  hide  gloves  and  face  shield.  Dry  ice 
can  cause  burns  and  frostbite  if  in  contact with  the  skin. 
FIRST  AID 
1.  Solvents,  acids  and  alkalis  in  contact with  skin  - wash  with 
copious  amounts  of  cold  water.  Splashes  in  the  eye  - irrigate 
with  water  and  seek  medical  attention  immediately. 
2.  Cuts  - seek  assistance of  first aider  immediately. 
3.  Burns  and  frostbite - run  affected  part under  cold  water  (burns) 
or  tepid water  (frostbite) for  10  minutes  and  seek  medical 
attention. 
0.  INTRODUCTION 
Sulphadimidine  (sulphamethazine)  is an  antibiotic widely  used 
prophylactically and  as  a  growth  promoter  in  pig  production. 
To  minimise  risks from  residues  in  the  human  diet,  withdrawal  periods  are 
set.  High  residue  levels  may  occur  if these  periods  are not  adhered  to. 
Residue  levels  are monitored  in  tissues taken  at slaughter and  carried out 
in  compliance  with  the  Residues  Directive  (86/469/EEC).  In  the  UK  scheme 
kidney  has  been  chosen  as  the  tissue for  analysis. 
The  samples  are  initially screened  by  TLC  or  ELISA.  The  CVL,  UK  confirms 
positive samples  by  this  HPLC  method  and  by  a  GC-MS  method. 
1.  SCOPE 
This  method  of  analysis  describes  the  determination  of  the  total  content of 
Sulphadimidine  in  pig  kidney. 
2.  FIELD  OF  APPLICATION. 
The  method  is described  to  be  used  for  porcine  kidney.  The  minimum  limit 
of  determination  for  Sulphadimidine  is  10  ~g per  kg  of  kidney. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
2052/VI/84  File 6.11  11-4,  Scientific Veterinary Committee,  Working 
Group- .. Reference  Methods  for  Residues .. ,  General  Criteria for  the 
establishment  of  Reference  Methods  for  the  Detection  of  Residues. 
Cy  3.3/1 ISO  Standard  78/2-1982  Layout  for  standards  - Part  2:  Standard  for  Chemical 
Analysis 
MAFF  (1987)  Working  Party  on  Veterinary Residues  in  Animal  Products.  Food 
Surveillance  Paper  No.  22. 
MAFF,  CVL,  Standard  Operating  Procedure  No  15,  HPLC  Analysis  of 
Sulphadimidine  in  Porcine  Kidney. 
see  also; 
Aerts,  M.M.L.,  Beek,  W.M.J.  and  Brinkman,  U.A.Th.,  (1988),  Monitoring  of 
veterinary drug  residues  by  a combination  of  continuous  flow  techniques  and 
column-switching  HPLC.  I.  Sulphonamides  in  egg,  meat  and  milk  using  post-
column  derivatization with  dimethylaminobenzaldehyde.  J.  Chrom.,  435,  97-
112 
4.  DEFINITIONS. 
Sulphadimidine  content  is taken  to  mean  the  amount  of  sulphadimidine  in 
kidney  determined  according  to  the  described  method  and  expressed  as  ~g 
sulphadimidine  per  kg  test sample. 
5.  PRINCIPLE. 
Samples  are  extracted using  acidified ethyl  acetate.  Co-extractives  are 
removed  using  solid phase  extraction  columns  (Bond-Elut  amino  (NH2 )  and 
cation exchange  (SCX)).  Sulphadimidine  is eluted with  ammoniated  methanol 
and  quantified  by  reverse  phase  high  performance  liquid chromatography 
(HPLC)  with  UV  detection. 
6. 
6.1. 
6.1.1. 
6.1.2 
6.1.3. 
6.1.4. 
6.1.5. 
6.1.6. 
6.1.7. 
MATERIALS 
Chemicals 
Acetone 
Ethyl  acetate 
Hexane 
Methanol 
Ammonia  solution 
Acetonitrile 
Glacial  acetic acid 
HPLC  Grade  (BDH) 
HPLC  Grade  (FSA) 
HPLC  Grade  (FSA) 
HPLC  Grade  (BDH) 
Specific gravity 0.88;  approx  35%  (FSA) 
HPLC  Grade  (BDH) 
AR  Grade  (BDH),  0.1M  (0.57  mL 
made  up  to  100  ml  with  deionised  water) 
6.1.8  Ammonium  acetate solution  AR  Grade  (BDH),  0.0124M  (770  mg 
water) 
6.1.9. 
3.1.10. 
Sulphadimidine 
Solid  carbon  dioxide 
6.1.11.  Solutions 
made  up  to  1  litre deionised with 
Crystalline  (Sigma  Chemicals  Ltd) 
Cardice  (dry  ice)  (Distillers Co) 
6.1.11.1  5%  Acetic  acid  in  ethyl  acetate;- 5 mL  acetic acid  made  up  to 
100  mL  with  ethyl  acetate 
6.1.11.2  25%  Ammonia  in  methanol;- 25  mL  ammonia  made  up  to  100  mL 
with  methanol 
6.1.12.  Mobile  Phase  0.01M ammonium  acetate/methanol/acetonitrile 
85/7.5/7.5;  v/v/v 
6.1.13  Sulphadimidine  Standards 
Cy  3.3/2 6.1.13.1 
6.1.13.2 
6.1.13.3 
7. 
7.1. 
7.1.1 
7.1.2 
7.1.3 
7.1.4 
7.1.5 
7.1.6 
7.1.7 
7.1.8 
7.2 
7.2.1. 
7.2.2. 
7.2.3. 
7.2.4. 
7.2.5. 
7.2.6. 
7.2.7. 
Stock  Standard;  1 mg/ml  sulphadimidine  in  acetone.  Store 
at -20°C.  Stable  for  at least 4 months. 
Intermediate  Standards.  Dilute  stock  standard with  acetone  to 
make  100  ~g/mL standard.  At  monthly  intervals,  dilute 100  ~g/ml 
with  acetone  to  make  10  ~g/mL standard. 
Working  Standards.  On  day  of  use,  take  10  ~g/mL standard.  Take 
aliquots  (12.5,  25,  50,  75  ul)  from  this,  evaporate  and 
redissolve  in  500  ~L mobile  phase  for  HPLC  (i.e.  20  ~L 
injections containing  5,  10,  20,  30  ng  respectively). 
EQUIPMENT 
Glassware 
Centrifuge  tubes,  30  mL,  round  bottomed  with  ground  glass 
stoppers 
Measuring  cylinders,  500,  50  mL 
Volumetric  flasks,  100,  50,  10  mL 
Graduated  pipettes,  10  mL 
Glass  vials with  caps,  2 dram 
Syringes,  100  ul,  25  ~L (Rheodyne) 
Luer-syringe,  5 mL  (disposable) 
Pasteur  pipettes 
Apparatus 
Homogenizer  (Silverson  heavy  duty  laboratory mixer  emulsifier 
(sealed  unit model)) 
Centrifuge  (Mistral  6L  set to  4-5°C) 
Insulated dry  ice  box 
Bond  Elut  reservoirs,  25  mL  capacity 
Bond  Elut  adapters  (Jones  Chromatography) 
Bond  Elut  cartridges,  Amino  (NH2)  and  cation  exchange  (SCX)  (500 
mg/2.8  mL  capacity) 
Filtering equipment  containing  0.45  urn  filter  (Millipore  -
Waters) 
7.2.8.  Water  bath  set at 45-50°C 
7.2.9.  SPE-ED  Mate  30  Vacuum  Apparatus  (Lab  Impex  Ltd) 
7.2.10.  Nitrogen  manifold 
7.2.11.  HPLC  equipment 
Waters  M-45  pump  with  Kratos  Spectroflow  733  absorbance  detector set at 266 
nm  and  Linseis  type  LS4  flat bed  recorder  or  equivalent.  Waters  4 u C 18 
Novapak  column  (15  x 0.46  em)  with  2 em  disposable  LC-18  Pelliguard 
cartridge guard  column  (Supelco)  Rheodyne  injector  (7125)  fitted with  20  ~L 
loop. 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is  drawn  to section  6.3.1  and  ISO  document  78/2-1982  and 
the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection of  residues  in  meat  as  defined  in  Directive 64/433/EEC.  Failing 
this biological  fluids or  faeces  may  constitute the  samples  for  the 
detection of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large enough  to  allow 
the  reference method  to  be  carried out  and  to allow  repeat  analysis where 
Cy  3.3/3 required. 
In  this method  for  sulphadimidine  the  sizes shall  not  be  less than  20  g 
kidney. 
9.  PROCEDURE 
9.1.  Weigh  2.5  g thawed  and  chopped  sample  into  a  30  ml  tube. 
9.2.  Add  6 ml  of  0.1M acetic acid:acetone mixture  (1:1  v/v)  and  add  12 
ml  ethyl  acetate.  Homogenise  for  1 minute  and  centrifuge at 2500 
rpm  for  15  minutes. 
9.3.  Transfer  supernatant  to  another  30  ml  tube  and  repeat  step 9.2  on 
the  tissue pellet.  Combine  supernatants  and  place  tubes  in  a 
rack. 
9.4.  Place  rack  into  cardice  box  until  aqueous  layer  is completely 
frozen  (at  least 15  minutes). 
9.5.  Decant  ethyl  acetate  into  another  30  ml  tube  ready  for  clean-up. 
9.6.  Using  vacuum  apparatus  prepare  NH2  Bond  Elut  column  by  washing 
with  1 column  volume  of  hexane.  Prepare  SCX  Bond  Elut  column  by 
washing  with  1 column  volume  of  hexane  followed  by  two  column 
volumes  of  5%  acetic acid  in  ethyl  acetate.  (N.B.  Do  NOT  let SCX 
column  run  dry.)  Assemble  the  columns  in  tandem. 
9.7.  Transfer  the  ethyl  acetate extract to  the  reservoir and  draw  it 
through  the  assembly  by  vacuum. 
9.8.  Wash  the  assembly  with  2 column  volumes  of  methanol  (ca  6 ml). 
9.9.  Close  the  vacuum  tap  and  discard  the  NH2  column  and  reservoir. 
9.10.  Wash  the  SCX  column  with  2 column  volumes  of water  followed  by  4 
column  volumes  of  methanol.  (N.B.  Do  NOT  let  SCX  column  run 
dry.) 
9.11.  Remove  column  from  assembly,  attach  to  Luer  syringe  and  elute 
sulphadimidine with  3 ml  of  25%  ammonia  in  methanol  into  2 dram 
vial,  using  positive pressure. 
9.12.  Evaporate  eluate under  N 2  at 45-50°C  in  a water  bath.  Dissolve 
residue  in  0.5  ml  acetone  and  transfer with  a  Pasteur  pipette to 
another  vial.  Wash  with  a further 0.5  ml  acetone  and  combine 
washes.  Eluate  can  then  be  stored overnight  at -20°C  if needed. 
9.13.  Evaporate  to  dryness  and  redissolve  in  200  ~L of  acetone.  Take 
an  aliquot of  100  ul,  evaporate  and  redissolve  in  500  ~L of 
mobile  phase  for  HPLC. 
9.14.  HPLC  is performed  at room  temperature.  Equilibrate the  system  by 
running  mobile  phase  through  at 1 ml/min  for about  90  min  before 
commencing  analysis. 
9.15.  Calibrate the  system  by  injecting 20  ~L of  each  of  the  previously 
prepared  HPLC  standards  made  up  in  mobile  phase. 
9.16.  The  extract dissolved  in  mobile  phase  is  injected.  Appropriate 
working  standards  are  run  after every fifth sample.  Each  sample 
takes  about  12  minutes  to run  and  retention time  (TR)  of 
sulphadimidine  is about  7 minutes. 
9.17.  If a  peak  having  a  TR  similar to the  standards  is seen  in  the 
sample,  mix  equal  volumes  of  an  appropriate  standard  and  the 
sample.  Inject the  mixture  to  check  for co-chromatography. 
9.18.  After  the  last  injection,  allow  methanol  to  run  through  the 
system  (0.2 ml/min)  overnight.  Store  column  in  methanol  when  not 
in  use. 
Cy  3.3/4 10.  CALCULATION  OF  RESULTS 
A calibration curve  is constructed of  peak  height  against concentration for 
a range  of  standards  from  5 to  30  ng.  The  quantity of  sulphadimidine  in 
each  sample  injection  is then  calculated from  the  measured  peak  height. 
This  figure  is then  corrected for  injection volume  and  mean  % recovery 
(calculated from  spiked  samples)  to  give  a  concentration  in  mg/kg  (ppm). 
The  standard  injection of  20  ~L is equivalent to 0.05  g of  extracted 
sample. 
% recovery = amount  of  sulphadimidine  found  x  100 
amount  of  sulphadimidine  added 
Concentration  of  sulphadimidine  in  sample  (mg/kg)  = 
ng  sulphadimidine  (from  calibration curve)  x  1  x  100 
1000  0.05  % recovery 
For  samples  containing  sulphadimidine  at concentrations  beyond  the  range  of 
the  standard  curve,  a  dilution of  the extract  is prepared  and 
chromatographed,  and  the  appropriate  volumetric  correction  is applied. 
SENSITIVITY 
The  limit of  determination  of  sulphadimidine  by  this method  is 0.01  mg/kg. 
Recovery  of  added  sulphadimidine  at 0.1  mg/kg  is  in  excess  of  80%. 
11.  SPECIAL  CASES. 
12.  NOTES  ON  PROCEDURE. 
13.  SAMPLE  CONTROLS 
It is convenient  to analyze  11  tissue samples  plus  1  quality control 
sample*  and  2  blank  spike  samples**  in  each  batch. 
* The  quality control  sample  was  obtained  from  a  sample  previously analyzed 
and  found  to contain  sulphadimidine  above  the  maximum  residue  limit  (MRL). 
**The  blank  sample  was  obtained  from  a  sample  previously analyzed  and  found 
to  contain  no  sulphadimidine.  Fortify (spike)  with  100  ~L of  2.5  ~g mL 
sulphadimidine  standard. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS. 
See  abbreviations  in  Annex  I,  Section  12  of Manual. 
16.  FLOW  DIAGRAM 
acidified ethyl  acetate  decant 
KIDNEY  -------------------------->  FREEZE  ------------> ETHYL  ACETATE 
EXTRACT  ----> 
elute  elute 
---->  NH2-BOND-ELUT  -----------> SCX-BOND-ELUT  ------> Ammonia/MeOH  -----> 
COLUMN  COLUMN 
---->DRY  ---->  HPLC  Mobile  -------> HPLC  ---------->CALCULATE  RESULTS 
Cy  3.3/5 Cy  3.4.  SULPHADIMIDINE.  DETERMINATION  OF  SULPHADIMIDINE  IN  REFERENCE 
MATERIAL  AND  FRESH  TISSUES  BY  HIGH  PERFORMANCE  LIQUID  CHROMATOGRAPHY. 
SAFETY 
Personal  safety.  Normal  laboratory protective clothing  and  equipment 
should  be  worn. 
1.0.  INTRODUCTION 
A method  is described  by  which  the  content  of  sulphadimidine  in  reference 
material  and  fresh  tissues may  be  estimated. 
Sulphadimidine,  otherwise  known  as  Sulphamethazine  is one  of  a  group  of 
antimicrobials  called sulphonamides.  Its use  is widespread  in  animal 
production  and  it is most  commonly  fed  to  pigs  in  their ration at 100  g per 
tonne.  Residues  at or  above  the  violative  level  have  been  reported  in  many 
countries. 
2.  SCOPE  AND  FIELD  OF  APPLICATION. 
This  method  of  analysis  describes  the  determination  of  the  total  content  of 
Sulphadimidine  in  foodstuffs  and  samples  of  animal  origin. 
The  method  can  be  used  for  muscle,  liver,  kidney  and  fat.  The  detection 
limit,  defined  as  three times  the  standard  deviation  of  the  blank 
determination,  is  50  ~g per  kg  of  sample  for  Sulphadimidine. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action. 
ISO  Standard  78/2-1982  Layout  for  standards  - Part 2:  Standard  for  Chemical 
Analysis 
Method  based  on  Standard  Operating  Procedure  described  by;- Veterinary 
Sciences  Division,  Stoney  Road,  Stormont,  BELFAST  BT4  3SD 
Aerts,  M.M.L.,  Beek,  W.M.J.  and  Brinkman,  U.A.Th.  (1988).  Monitoring  of 
Veterinary  Drug  Residues  by  a combination  of  continuous  flow  techniques  and 
column-switching  HPLC.  I.  Sulphonamides  in  egg,  meat  and  milk  using  post-
column  derivatization with  dimethylaminobenaldehyde.  J.  Chromat.  435,  97-
112. 
4.  DEFINITIONS. 
Sulphadimidine  content  is taken  to  mean  the  amount  of  Sulphadimidine  in  the 
substance  in  question,  regardless  of  the  chemical  form,  determined 
according  to  the  described  method  and  expressed  as  ~g Sulphadimidine  per  kg 
of  test sample. 
Cy  3.4/1 5.  PRINCIPLE 
The  methods  comprises  5 stages;-
- Homogenisation  of  tissue samples  in  10  mL  dichloromethane  or  dispersing 
lyophilised  tissue  in  buffer 
- Extraction  of  Sulphadimidine  with  organic  solvents 
- Purification of  Sulphadimidine  by  SPE 
- End  point  determination  with  HPLC 
- The  amount  of  Sulphadimidine  is calculated  by  interpolation from  a 
standard  curve  and  taking  into  account  the  recovery  of  Sulphadimidine, 
especially from  tissue samples. 
6.0  MATERIALS 
N.B.:  The  reagents  for which  examples  of  their source  are  quoted  are 
known  to  be  satisfactory,  nevertheless  reagents  from  other  sources  may  be 
equally suitable. 
6.1  Reagents 
6.1.1  Dichloromethane  (HPLC  Grade,  Rathburn  Chemicals  Ltd,  Walkerburn, 
Scotland), 
6.1.2  Methanol  (HPLC  Grade,  Rathburn  Chemicals  Ltd) 
6.1.3  Silica gel  (SiOH)  disposable  extraction columns  - 6 mL  (Bakerbond 
SPE,  7086-06,  J.T.  Baker  Inc.,  Philipsburg,  NJ  08865  USA). 
6.1.4  Sulphamethazine  crystalline  (Sigma  Chemical  Co,  PO  Box  14508  St 
Louis,  M063178  USA,  Cat  No  S-6256). 
6.1.5  Deionised  water  (7.9). 
6.1.6  Sodium  carbonate  anhydrous  •Analar•  (BDH  Lab.  Supplies,  Poole, 
Dorset,  Cat  No  102404H). 
6.1.7  Sodium  hydrogen  carbonate  •Analar•  (BDH  Lab  Supplies,  Cat  No 
102474V). 
6.1.8  N,  N-Dimethyl-Aminobenzaldehyde  - Ehrlichs  reagent  (Sigma 
Chemical  Co,  Cat  No  02004). 
6.1.9  Acetic  acid  GPR  (BDH  Lab.  Supplies,  Cat.  No.  27013). 
6.2  Solutions 
6.2.1  Buffer,  pH  10.0 
0.2  M  sodium  carbonate  (6.1.7)  27.5  mL 
0.2 M  sodium  hydrogen  carbonate  (6.1.8)  22.5  mL 
Deionised  water  (7.9)  150  mL 
6.6.2  50%  Methanol  (6.1.2)  v/v  deionised water  (7.9) 
6.2.3  N,  N-Dimethyl-Aminobenzaldehyde  Reagent 
Acetic  Acid  (6.1.10)  125  mL 
Methanol  (6.1.2)  75  mL 
Deionised  water  (7.9)  50  mL 
N,  N-Dimethyl-Aminobenzaldehyde  (6.1.9)  3.75  g 
Before  adding  the  N,  N-Dimethylbenzaldehyde  degas  the  solution 
using  the  equipment  described  in  (7.12)  for  2 minutes, 
6.2.4  2%  Acetic  Acid 
Acetic  Acid  (6.1.10)  10  mL 
Deionised  water  (7.9)  490  mL 
6.2.5  HPLC  Mobile  Phase 
2%  Acetic  acid  (6.2.4  )  325  mL 
Methanol  (6.1.2)  175  mL 
(degas  for  2 minutes  (7.12)) 
Cy  3.4/2 6.3  Standards 
6.3.1  Intermediate  standard 
Dissolve  an  accurately weighed  (7.2)  quantity of  sulphamethazine 
(6.1.5)  in  methanol  (6.1.2)  to  give  a  solution of  1 mg  to 
sulphamethazine  per  mL  using  a  100  ml  volumetric  flask  (7.27). 
Store  at +4°C.  (7.5). 
6.3.2  Working  standards. 
Diluting  in  50%  Methanol  (6.2.2)  prepare  standard working 
solutions of  20,  40,  80  ng/50  ~L  in  100  ml  volumetric  flasks 
(7.27).  Store  a  +4°C. 
6.3.3  Control  solutions 
Diluting  in  Methanol  (6.1.2)  prepare  control  solutions of  12.5 
~g/mL (6.3.31)  and  25  ~g/mL (6.3.32).  When  50  ~L of  these 
solutions  are  added  to  negative  samples  they  are equivalent to 
250  ng.g  and  500  ng/g  respectively  in  the  final  extract. 
7.0  EQUIPMENT 
7.1  Balance  top-pan  (Sartorius,  Gottingen,  Germany  model  L610D). 
7.2  Balance  analytical  (Sartorius,  Gottingen,  Germany  model  R160P). 
7.3  Magnetic  Stirrer (Gallenkamp  model  300). 
7.4  Vortex  mixer  (SMI  model  2601). 
7.5  Refrigerator  +4°C  (Williams  Refrigeration  Ltd,  Kings  Lynn,  UK) 
7.6  Fume  cupboards  (Nordia,  Lab  Design,  Walthamstow,London,  E17  6AB. 
7.7  Multi  sample  concentrator for  tubes  (Techne,  Jencons  Scientific 
Ltd,  Leighton  Buzzard,  Beds,  England  DB3). 
7.8  Semi-automatic  pipettes with  disposable  tips:  5 - 40  ~L, 
40  - 200  ~L,  200  - 1000  ~L and  1 - 5 ml  volumes  (eg  Finnpipettes, 
Jencons  Scientific Ltd,  Cherrycourt  Way  Ind  Estate,  Leighton 
Buzzard,  Beds,  England). 
7.9  Millipore  R060  reverse osmosis  and  milli  Q deionised water 
system.  (Millipore  SA,  67120  Molsheim,  France,  Cat  Nos  ZFRONC060 
and  PF00671/U  respectively). 
7.10  End  over  end  mixer  (Luckham  Ltd,  Burgess  Hill,  Sussex,  England, 
model  TM/1). 
7.11  Baker  solid phase  extraction  system.  (J.T.  Baker  Inc. 
Philipsburg  NJ  08865  USA). 
7.12  Cylinder  of  helium  gas  filled to  200  bar  max  at 15°C  (BOC  Ltd, 
10  Priestley Road,  Guilford,  Surrey  SI  No  1046). 
7.13  HPLC  Controller  2152  (LKB,  Pharmacia  Ltd,  Pharmacia  LKB 
Biotechnology  Division,  Midsummer  Boulevard,  Central  Milton 
Keynes,  Bucks  MK9  3HP). 
7.14  HPLC  Pump  2150  X2  (LKB). 
7.15  Variable wavelength  monitor  2151  set at 450  nm  wavelength  (LKB). 
7.16  Integrator  (model  HP3396A,  Hewlett-Packard,  Avondale  Division, 
Route  41,  Avondale,  PA,  USA). 
7.17  Column  Oven  (Jones  Chromatography,  Collie  Road,  Llanbrodach,  Mid 
Glamorgan  CF8  3QQ  Wales). 
7.18  Microsorb  C-18  (Octadecylsilane)  80-215-C5  column  (15  em  x 4.6  mm 
ID)  - Rainin  Instrument  Co  Inc,  Mack  Road,  Woburn,  MA  USA). 
7.19  Reaction  coil 10ft length  of  Teflon  Tubing  (0.023  in.  ID). 
7.20  Low  dead  volume  mixing  chamber  (LKB). 
7.21  Rheodyne  injector  (Model  7125),  Rheodyne  Inc,  PO  Box  996,  Cotati, 
California  94931  USA). 
7.22  Glass  tubes  75  mm  by  10  mm  (FSA  Laboratory  Supplies,  Cat  No 
G002/73,  Bishop  Meadow  Road,  Loughborough,  Leics,  LE11  ORG). 
7.23  Glass  tubes  125  mm  by  16  mm  (FSA  Lab  Supplies,  Cat  No  G002/81). 
Cy  3.4/3 7.24  Glass  universal  bottles and  lids,  capacity 29.5  mL  (FSA  Lab 
Supplies,  Cat  No  BM/4). 
7.25  Graduated  glass pipettes,  10  mL  and  25  mL  (FSA  Lab.  Supplies,  Cat 
Nos  G519  and  G520). 
7.26  Measuring  cylinders,  100  mL  and  500  mL  (FSA  Lab.  Supplies,  Cat 
Nos  3200/10  and  3200/14). 
7.27  100  mL  volumetric  flask  (FSA  Lab  Supplies,  Cat  No  BJ138). 
7.28  Piped  Nitrogen  gas  supply. 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to section  6.3.1  and  to  ISO  document  78/2-1982  and 
also the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection  of  residues  in  meat  as  defined  in  Directive 64/433/EEC.  Failing 
this biological  fluids or  faeces  may  constitute the  samples  for  the 
detection  of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to allow 
the  method  to  be  carried out  and  to allow  repeat  analyses  where  required. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to  allow  proper 
identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice  the  result of  the  examination. 
Samples  for  the  analysis of  thyreostaSic  substances  must  be  stored  and 
transported  at temperatures  below  -18  C. 
9.0  PROCEDURE 
9.1  All  samples  are  prepared  singly. 
9.2  Weigh  into  glass  universals  (7.24)  a quantity of  lyophilised 
tissue equivalent  to  2.5  g ~ 0.01  of  fresh  tissue  (approximately 
0.60  g). 
9.3  Controls  are  prepared  from  negative  tissue and  50  ~L of  each 
control  solution  (6.3.31  and  6.3.32). 
9.4  To  all  universals  add  2 mL  of  carbonate/bicarbonate  buffer 
(6.2.1). 
9.5  Cap  and  vortex  each  universal  for  approximately  one  minute  (7.4). 
9.6  To  all  universals  add  15  mL  dichloromethane  (6.1.1). 
9.7  Mix  all  universals  end  over  end  for  20  minutes  at approximately 
60  rpm  (7.10). 
9.8  Pour  dichloromethane  from  universals  into  clean  universals  and 
cap  (7.14). 
9.9  Remove  12  mL  from  each  universal  and  transfer  into test tubes 
(7.23).  If it is not  possible  to  remove  12  mL,  remove  as  much  as 
possible.  The  calculation at the  end  must  be  modified 
accordingly. 
9.10  Using  the  Baker  solid phase  extraction  system  (7.11)  and  the 
silica gel  columns  (6.1.4)  condition  the  columns  with  6  cm3  of 
dichloromethane  (6.1.1)  but  do  not  allow  the  columns  to  dry 
before  the  samples  are  added. 
9.11  To  each  column  add  12  mL  dichloromethane  from  each  sample  (9.9) 
and  pass  through  the  column  at approximately  5 mL/minute. 
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Wash  the  columns  with  a further 6 mL  of  dichloromethane  (6.1.1) 
and  air dry  the  columns  for  10  minutes  at a  vacuum  pressure of  10 
psi. 
Elute  the  sample  from  each  column  with  3 mL  of  methanol  (6.1.2) 
passed  slowly  through  the  column  over  a  20  minute  period. 
Collect  the  eluate  in  test tubes  (7.22). 
Evaporate  the eluate using  the  multi  sample  concentrator  (7.7). 
Resuspend  residue  in  1 mL  50:50  v:v  methanol/deionised 
water(6.2.2).  The  samples  are  now  ready  to  be  analyzed  by  HPLC. 
HPLC 
Ensure  wavelength  monitor  is set at 450  nm  (7.15). 
Turn  the  column  oven  to 40°C  and  allow  to  heat  for  30  minutes 
(7.17). 
Set  one  pump  (pump  A)  at a flow  rate of  1 mL  per  min  and  the 
other  pump  (B)  at a flow  rate of  0.5  mL  per  min. 
Pass  methanol  (6.1.2),  which  has  been  degassed  with  helium  for  2 
min,  through  both  pumps  for  5 min. 
Equilibrate the  system  by  passing  both  the  mobile  phase  (6.2.5) 
via  pump  A and  the  N,N-dimethyl-aminobenzaldehyde  reagent  (6.2.3) 
via  pump  B through  the  column  (7.18),  mixing  chamber  (7.20), 
reaction  coil  (7.19)  and  wavelength  monitor  (7.15)  for  30  min. 
Calibrate the  system  by  injecting 50  ~L of  the  prepared  working 
standards  (6.3.2)  using  the  Rheodyne  injector  (7.21). 
Inject 50  ~L of  each  extract  (9.15).  Each  sample  takes  about  10 
min  to  run  and  the  retention  time  of  sulphadimidine  is 
approximately  4 min. 
After  the  last  injection allow  methanol  to  run  through  the  system 
overnight. 
CALCULATION  OF  RESULTS 
10.1  From  the  height  of  the  peaks  produced  by  the  standards  the  height, 
which  is equivalent  to 1 ng  per  50  ~L,  can  be  calculated  by  dividing  the 
total  height  of  the  peak  by  the  value  of  the  standard. 
e.g.  For  the  40  ng  per  50  ~L standard;  1 ng  per  50  ~L =  height  of  peak 
40 
The  amount  of  sulphadimidine  in  the  samples  (9.15)  can  then  be  calculated 
by  dividing  their peak  height  by  the  height  obtained  from  the  standards 
equivalent  to 1 ng  per  50  ~L.  This  gives  a result  in  ng  per  50  ~L.  This 
can  be  converted  to  ng  per  mL  or  ng  per  g as  required. 
10.2  Validation  Data. 
10.2.1  Liver 
Lyophilised  liver samples  (equiv.  to 2.5  g  liver)  from  untreated  animals 
were  spiked  with  0.625  ~g sulphadimidine.  The  recovery was  91.3%  ±  7.5% 
(CV  =  8.2%),  N =  6 
Six  randomly  selected  lyophilised  liver samples  from  a  batch  of  incurred 
Reference  Material  were  assayed  on  three  different days.  The  results are 
multiplied  by  a fictitious factors  (<4)  to avoid  undue  influence  on  future 
collaborative studies organised  by  MAT. 
~g per  kg 
First day  2018  ±  124 
Second  day  2040  ±  138 
Third  day  1868  ±  50 
Mean  for daily measurement 
cv  (%) 
6.1 
6.8 
2.7 
(interassay)  1976  ±  96  ~g per  kg;  CV  = 4.7% 
Cy  3.4/5 10.2.2  Kidney 
Lyophilised  kidney  samples  (equiv.  to  2.5  g kidney)  from  untreated  animals 
were  spiked  with  0.625  ~g sulphadimidine.  The  recovery was  83.1%  ±  3.6% 
(CV  = 4.3%),  N = 6 
Six  randomly  selected  lyophilised kidney  samples  from  a  batch  of  incurred 
Reference  Material  were  assayed  on  three different days. 
The  results are  multiplied  by  a fictitious factors  (<4)  to  avoid  undue 
influence  on  future  collaborative studies organised  by  MAT. 
~g per  kg  CV  (%) 
First day  1266  ±  45  3.6 
Second  day  1320  ±  24  1.8 
Third  day  1257  ±  54  4.3 
Mean  for  daily measurement  (interassay)  1281  ±  35  ~g per  kg;  CV  =  2.7% 
10.2.3 Muscle 
Lyophilised  muscle  samples  (equiv.  to  2.5  g muscle)  from  untreated  animals 
were  spiked  with  0.625  ~g sulphadimidine.  The  recovery was  80.7%  ±  13.3% 
(CV  = 16.4%),  N = 6 
Six  randomly  selected  lyophilised muscle  samples  from  a  batch  of  incurred 
Reference  Material  were  assayed  on  three  different days.  The  results are 
multiplied  by  a fictitious factors  (<4)  to  avoid  undue  influence  on  future 
collaborative studies organised  by  MAT. 
~g per  kg  CV  (%) 
First day  1400  ±  43  3.0 
Second  day  1414  ±  48  3.4 
Third  day  1193  ±  36  3.0 
Mean  for  daily measurement  (interassay)  1336  ±  124  ~g per  kg;  CV  =  9.3% 
11.0  SPECIAL  CASES 
12.0  NOTES  ON  PROCEDURES 
Sulphadimidine  is not  stable  in  fresh  or  frozen  tissues.  The  rate of  post-
mortem  metabolism  can  be  reduced  by  storage  at  low  temperatures,  however 
the  response  is variable  and  cannot  be  predicted.  In  the  reference 
materials stability has  been  achieved  by  adding  merthiolate  to achieve  a 
final  concentration  of  0.013%  and  removing  available water  by  double  freeze 
drying.  At  this concentration  merthiolate  has  no  effect on  the  HPLC 
analytical  procedure  however  it will  interfere with  immuno- and 
microbiological  assay  procedures.  Freeze  drying  results  in  a fine  powder 
which  must  be  rehydrated  before  extractions are  performed.  For  this 
purpose  the  bicarbonate  buffer  is preferred  and  increases  the  extraction 
efficiency.  There  have  not  been  studies  on  the  stability of  the 
reconstituted tissue powder  or  extract. 
13.0  QUALITY  CONTROLS. 
RMs  for  sulphadimidine  have  been  prepared  for  pig  muscle,  liver and  kidney 
and  are  undergoing  the  intercomparison  and  certification studies  (see 
section 8). 
Cy  3.4/6 14.0  TEST  REPORT. 
To  give  the  indications  necessary  for  the  identification of  the  sample,  the 
reference  to  the  method  employed,  the  results and  the  form  in  which  these 
are  expressed,  any  particular points  observed  in  the  course  of  the  test and 
any  operations  not  specified  in  the  method  or  regarded  as  optional  which 
might  affect the  results. 
15.  LIST  OF  ABBREVIATIONS 
A full  list of  abbreviations  is given  in  Annex  I,  Section  12 
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Cy  3.4/7 Cy  3.5.  CHLORAMPHENICOL  - CONFIRMATION  OF  CHLORAMPHENICOL  IN  MEAT,  MILK, 
EGGS  AND  URINE  BY  GAS  CHROMATOGRAPHY-MASS  SPECTROMETRY. 
WARNING  AND  SAFETY  PRECAUTIONS 
0.  INTRODUCTION 
Chloramphenicol  (CAP)  is a  bacteriostatic with  a  broad  spectrum  of 
activity,  frequently  used  for  therapeutic  and  prophylolactic  purposes  in 
veterinary medicine.  In  several  countries  the  use  of  CAP  is prohibited  in 
laying  hens  and  lactating cattle.  MRLs  in  meat  products  are  set by  many 
countries  between  zero  and  10  ~g per  kg. 
1.  SCOPE 
The  use  of  CAP  is restricted throughout  the  EEC.  To  ensure  that farmers 
are  not  continuing  to  use  chloramphenicol  in  laying  hens  or  lactating 
cattle,  and  to control  the  use  in  meat  producing  animals  samples  are 
collected on  farms  and  at slaughterhouses  and  screened  for  the  presence  of 
this compound  using  a  number  of  techniques  (see  Section  4).  Whenever  there 
is a  positive screening  result,  this must  be  confirmed.  This  work  is 
carried out  in  compliance  with  the  Residues  Directive  (86/469/EEC). 
2.  FIELD  OF  APPLICATION. 
This  method  is used  for  confirmation  of  the  presence  of  chloramphenicol  in 
meat,  eggs  and  urine.  With  appropriate adaption  the  method  is also  suitable 
for milk.  The  detection  limit  is 0.1  ~g/litre or  kg  of  matrix  for 
Chloramphenicol. 
3.  REFERENCES. 
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4.  DEFINITIONS. 
Chloramphenicol  content  is taken  to  mean  the  amount  of  Chloramphenicol  in 
the  substance  in  question,  regardless  of  the  chemical  form,  determined 
according  to  the  described  method  and  expressed  as  ~g Chloramphenicol  per 
kg  or  litre of  test sample. 
5.  PRINCIPLE. 
The  method  of  analysis  comprises  six stages: 
Urine 
Muscle  and  eggs 
(1)  Hydrolysis  of  the  urine. 
(2)  Extrelut  column  extraction 
(3)  Sep-Pak  C18  column  purification. 
(1)  Homogenisation 
(2)  Extract  into ethyl  acetate  (EtAc) 
(3)  Sep-Pak  Si  column  purification 
(4)  HPLC  purification 
(5)  Derivatisation. 
(6)  Analysis  by  gas  chromatography/mass 
spectrometry  (GC/MS). 
Note  (6):  Chloramphenicol  can  be  analyzed  with  mass  spectrometry  using 
either electron  impact  (EI)  or  electron  capture  negative  ion  chemical 
ionisation  (ECNICI).  As  a rule  ECNICI  ionisation result  in  a  5 to  10  times 
more  sensitive detection. 
After  appropriate  defatting,  milk  can  be  extracted as  urine. 
6. 
6.1. 
6.1.1. 
MATERIALS 
Chemicals  and  reagents 
Reference  compounds. 
The  following  standard  compounds  are  used. 
Chloramphenicol,  Cas  No.  56-75-7;  C 11H 12Cl 2N 205 ,  Mol.  Wt.  323.1; 
(Boehringer-Mannheim,  NL,  Art  No.  634433) 
6.1.2. 
6.1.3. 
6.1.4. 
6.1.5. 
6.1.6. 
6.1.7. 
6.1.8. 
6.1.9. 
6.1.10. 
Internal  standard  37Cl 2-chloramphenicol  synthesised  at RIVM. 
Ethanol  (Merck,  art.  no.  983). 
Methanol  (Merck,  art.  no.  9623). 
Isooctane  (Merck,  art.  no.  4727). 
Acetonitrile  (Merck,  art.  no.  30). 
Dichloromethane  (Merck,  art.  no.  6050). 
Hydrochloric  acid  (Merck,  art.  no.  317). 
Ethyl  acetate  (Merck,  art.  no.  9623). 
Acetic  acid  (Merck,  art.  no.  63). 
Cy  3.5/2 6.1.11. 
6.1.12. 
6.1.13. 
6.1.14. 
6.1.15. 
6.1.16. 
6.1.17. 
6.1.18. 
6.1.18.1 
6.1.18.2 
6.1.18.3 
6.1.19. 
6.1.20. 
6.1.21. 
6.1.22. 
6.1.23. 
6.1.24. 
7. 
7.1. 
7.2. 
7.3. 
7.4. 
7.5. 
7.6. 
7.7. 
7.8. 
7.9. 
7.9.1. 
7.9.1.1. 
7.9.1.2. 
7.9.1.3. 
7.9.1.4. 
7.9.1.5. 
7.10. 
7.11. 
Sodium  acetate  (Merck,  art.  no.  6268). 
Sodium  sKlphate  (Merck  art.  no.,  6643). 
Extrelut  (Merck,  art.  no.  11737;  refills art.  no.  11738) 
Acetate  buffer  2.0 mol/L,  pH  5.2. 
Mix  25.2  g acetic acid  (6.1.10)  with  600  ml  water,  add  129.5  g 
sodium  acetate  (6.1.11.).  Adjust  the  pH  at 5.2  ±  0.1  and  add 
water  to a final  volume  of  1000  ml. 
HPLC-eluting  buffer. 
Mixture  of  ethanol/isooctane,  3:97  v/v 
Disodium  hydrogen  phosphate  (Merck,  art.  no.  6586). 
Potassium  dihydrogen  phosphate  (Merck,  art.  no.  4873). 
Solid  phase  extraction solvent mixtures 
Methanol:water,  mixture  10:90  v/v,  mix  10  ml  of  methanol  with  90 
ml  of water 
Methanol:water,  mixture  45:55  v/v,  mix  45  ml  of  methanol  with  55 
ml  of  water 
Acetonitrile:water,  mixture  20:80  v/v,  mix  20  ml  of  acetonitrile 
with  80  ml  of  water 
Stock  solutions of  (internal)  standards  containing  1 g/L  in 
ethanol,  stored  at -20°C  in  the  dark. 
Working  solutions of  (internal)  standards  containing  0.01  g/L  in 
ethanol,  stored at +4°C  for  a  maximum  period  of  2 weeks. 
Smallest  volume  pipetted out  of  the  stock  solution  is 0,1  ml. 
Derivatization reagent:  N,O- 613  (trimethylsilyl) 
trifluoracetamine  (BSTFA)  with  1%  TMS  (Pierce,  art.  no.  38832). 
Beta-glucuronidase/sulfatase,  Sigma  G-0876  (Brunschwig  Chemie, 
Amsterdam,  NL) 
Solid  phase  extraction cartridge  (Sep-Pak,  C18)  (Water-Millipore, 
art.  no.  51910) 
Solid  phase  extraction cartridge  (Sep-Pak,  Silica)  (Waters-
Millipore,  art.  no  51900) 
EQUIPMENT 
Glass  roundbottomed  flasks,  150  ml  (Corex,  art.  no.  8422-A). 
Glass  Pasteur  capillary pipettes. 
Automatic  pipettes  (Gilson  P20,  P200,  P1000  and  P5000) 
Refrigerated  centrifuge  (RC-3,  Sorvall). 
Bench-lop  centrifuge  (GLC-4,  Sorvall). 
Centrifuge  tubes,  glass,  (55  mm  x 11.5  mm)  (Renes,  RB55) 
Electric water  bath  with  thermostat  adjustable to  50  ±  2°C  and  37 
±  2°C  (GFL,  Salm  &  Kipp)  with  nitrogen  facility. 
Vortex  (Vortex-genic,  Wilton  &  Co). 
HPLC-system 
Standard  isocratic  HPLC  equipment  is suitable for extract 
purification. 
HPLC  pump,  model  6000  A (Waters/Millipore). 
Automatic  injection system  Wisp  (Waters/Millipore). 
Fixed  wavelength  UV-detector  (254  nm)  Model  440 
(Waters/Millipore). 
Guard  column,  type  Chromguard  (Chrompack  028185) 
HPLC  column  (150  mm  x 4.6  mm)  packed  with  Lichrosorb  Dial  5  ~m 
(Merck). 
Glass  derivatization vials  (chromacol  250  (A))  with  screw  caps 
(chromacol  85c)  and  septa  (chromacol  8-ST15). 
Incubator  60°C  (Selvis). 
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7.15.4. 
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7.16.1. 
7.16.2. 
7.16.3. 
7.17. 
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8. 
Heating  module  for  derivatization vials  (Pierce  no.  18790)  with 
nitrogen  facility. 
Glass  injection vials  (Chrompack,  art.  no.  10201)  with  glass 
inserts  (Chrompack,  art.  no.  10381). 
Aluminium  caps  (Chrompack,  art.  no.  10210). 
GC-MS  equipment,  system  for EI-ionisation 
Gas  chromatograph  (Hewlett  Packard,  type  5890). 
Automatic  injection  (Hewlett  Packard,  type  7637A). 
Mass  selective detection  (Hewlett  Packard,  type  5970). 
Workstation  (Hewlett  Packard,  type  59970). 
Printer  (Hewlett  Packard,  ink  jet). 
GC-column,  fused  silica permaband  SE-52,  25m  x 0.25  mm  ID,  film 
thickness  0.25  ~m (Machery-Nagel,  art.  no.  723054). 
GC-MS  equipment,  system  for  chemical  ionisation. 
Gas  chromatograph  (Finnigan  type  9610,  San  Jose,  CA). 
Mass  spectrometer  (Finnigan  4500  quadrupole) 
GC-column,  fused  silica CP-Sil-19CB  (25m  x 4.4  mm  i.d., film 
thickness  0.25  urn  (chrompack  Middelburg,  NL). 
Rotavapor  with  water  bath  at 40  ±  2°C  (Rotavapor). 
Moulinette  homogeniser 
Ultra-Turrax  homogeniser 
SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section 6.3.1  and  ISO  document  78/2-1982  and 
the following  notes  derived  from  Annex  II  of  2052/VI/84-EN  and  EEC  93/256 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to  enable  the 
detection  of  residues  in  meat  as  defined  in  Directive 64/433/EEC.  Failing 
this biological  fluids  (in this method  bile) or faeces  may  constitute the 
samples  for  the  detection  of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large enough  to allow 
the  reference method  to  be  carried out  and  to allow  repeat  analysis where 
required. 
This  method  for Chloramphenicol  uses  the  following  amounts  for  a  single 
determination. 
Meat  10  g,  Urine  10  mL,  egg  10  g,  milk  10  mL. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to  allow  proper 
identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice  the  result of  the  examination. 
Samples  for  the  analysis of  CAP  must  be  stored  and  transported  at 
temperatures  below  -18°C. 
9. 
9.1. 
9.1.1. 
PROCEDURE 
URINE 
Hydrolysis 
To  10  mL  urine  add  acetic acid  (6.1.10)  to  adjust  pH  to  5.2.  Add  0.5  mL  of 
Cy  3.5/4 2 mol  per  L acetate buffer  (6.1.14.),  pH  5.2,  and  20  ~L of  glucuronidase 
(6.1.22)  in  a  20  ml  universal  bottle and  incubate  2 hours  at 37°C. 
The  procedure  for addition of  the  internal  standard  is given  in  9.7. 
9.1.2.  Extrelut Clean-up 
Prepare  an  Extrelut column  (6.1.13)  according  to  the maker•s  instructions. 
Add  the  cooled  urine/buffer mix  together with  a further  2 ml  water  and 
allow  to  absorb  onto  the  column  for  15  minutes.  CAP  is extracted from  the 
absorbed  urine with  2 X 25  ml  ethyl  acetate. 
Reduce  the ethyl  acetate to  dryness  under  reduced  pressure at 50°C.  A 
small  residue  is normally  left after drying.  Resuspend  the  extract  in  2 ml 
of  methanol  and  transfer to a  glass  tube  containing  5 mL  of  water.  Two 
additional  volumes  of  methanol  are  used  to complete  the  transfer.  The 
volume  of  the  combined  methanol/water  is reduced  to 4 mL  under  a  stream  of 
nitrogen  in  a water  bath  at 50°C. 
9.1.3.  Sep-Pak  C18  Purification 
The  Sep-Pak  cartridges  (6.1.23)  are  prepared  by  washing  twice  with  2 mL  of 
methanol  (6.1.4)  and  5 mL  of  water.  Add  the  extract and  wash  with  5 mL  of 
water,  and  5 mL  methanol:water::10:90  V/V  (6.1.18.1).  The  CAP  is eluted 
with  5 mL  methanol:water::45:55  V/V  (6.1.18.2).  The  extract  is reduced  to 
dryness  under  a  stream of  nitrogen  in  a water  bath  at 50°C  and  is ready  for 
HPLC  purification. 
9.2.  MILK 
After  proper  defatting an  extract can  be  prepared  a  described  for  urine. 
9.3.  MUSCLE  AND  EGGS. 
9.3.1  Extraction 
If available,  200  g of  muscle  or  eggs  are  homogenised  in  a Moulinette 
homogeniser  (7.18).  10  g of  the  homogenate  is accurately weighed  into  250 
mL  centrifuge tube  (7.6)  and  100  mL  ethyl  acetate  (6.1.9)  and  30  g sodium 
sulphate  (6.1.12)  are  added  and  the mixture  further  homogenised  for  1 
minute  in  an  Ultra-Turrax  homogeniser  (7.19).  The  tubes  are  centrifuged 
for  30  minutes  at 1800  g.  75  mL  of  the  supernatant  is transferred to a 
round  bottomed  150  ml  flask  (7.1)  and  the  solvent  is evaporated  under 
reduced  pressure at 50°C  (7.17). 
The  addition  of  the  internal  standard  is given  in  9.7. 
9.3.2.  Sep-Pak  Clean  Up 
A Sep-pak  silica cartridge  (6.1.24)  is pretreated with  5 mL 
acetonitrile:water:::20:80 V/V  (6.1.18.3)  and  5 mL  dichloromethane  (6.1.7). 
The  cartridge  is flushed  with  nitrogen.  The  residue of  the  extract  is 
dissolved  in  5 mL  dichloromethane  (6.1.7)  and  applied  to  the  cartridge. 
The  transfer  is completed  by  washing  the  flask with  two  further 5 mL 
volumes  of  dichloromethane.  The  cartridge  is flushed  with  nitrogen  until 
all  the  dichloromethane  is removed. 
CAP  is eluted with  5 mL  acetonitrile/water 20:80  V/V.  The  eluate  is 
Cy  3.5/5 extracted three times  with  1 ml  ethyl  acetate.  The  combined  extract  is 
washed  with  1 ml  water  and  evaporated  to  dryness  under  a  stream  of  nitrogen 
in  a water  bath  at 50°C  and  is ready  for  HPLC  purification. 
9.4.  HPLC  Purification. 
The  dry  residue  is dissolved  in  0.3  ml  eluent  (6.1.15).  An  aliquot of  0.25 
ml  is  injected  into  the  HPLC  and  the  CAP  fraction  collected over  a one 
minute  time  period,  starting 0.5  minute  before  the  elution of  CAP.  The 
fraction  is evaporated  to  dryness  under  a  stream  of  nitrogen  in  a water 
bath  at 50°C  and  is ready  for  derivatisation. 
9.5.  Derivatisation 
The  dry  extract  (9.4)  is transferred with  absolute  ethanol  to a 
derivatisation vial  (7.10)  and  derivatised with  0.1  ml  BSTFA/1%  TMCS 
(6.1.21.)  by  heating  for  1 hour  at 60°C.  The  reagent  is evaporated  with  a 
stream  of  nitrogen  at 50°C  and  the  residue  dissolved  in  25  ~L  isooctane. 
Concurrently run  chloramphenicol  standards  through  the  derivatisation 
steps. 
9.6.  GC-MS  Analysis  ,  chemical  ionisation. 
For  the  determination  and  identification of  residues  of  CAP  with  mass 
spectrometry,  either electron capture  negative  ion  chemical  ionisation 
(ECNICI)  or  electron  impact  (EI)  ionisation can  be  used 
9.6.1  GC-ECNICI(MS) 
The  GC-MS  system  (7.16)  was  used  with:  A CP-Sil-19CB  fused  Silica cgpillary 
column,  Helium  as  carrier gas  at a  column  head  pressure of  1.1  x 10  Pa, 
Splitless  injections at an  injection  port  temperature  of  260°C, 
ballistically increasing  the  oven  temperature  from  its initial  temperature 
of  150°C  to  270°C  1 minute  after injection,  GC  and  separator oven  at 260 
and  270°C  respectively,  source  temperature  of  140°C,  filament  emission 
current  200  uA,  methane  as  reagent  gas  with  an  ion-source  pressure of  50 
Pa,  the  electron energy  optimized  between  70  and  90  eV,  dwell  time  of  0.052 
s.  Analysis  is performed  in  the  SIM  mode  recording  the  abundances  of  the 
ions  at m/z  = 376,  378,  466,  468,  470  (internal  standard) 
9.6.2  GC-EI(MS) 
The  GC-MS  system  (7.16)  was  used  with:  A SE-52  fused  Silica  capil~ary 
column,  Helium  as  carrier gas  at a  column  head  pressure of  1 x 10  ,  dwell 
time  0.05  s,  Analysis  is performed  in  the  SIM  mode  recording  the  abundance 
of  the  ions  at m/z/  225,  242,  361  and  451. 
9.7.  Procedure  for  Spiking  (Quantitation  and  recovery) 
9.7.1  Test  samples  of  10  g or  10  ml  of  the  homogenate  are  spiked with 
0.1  ml  solution of  the  internal  standard  (6.1.2).  The  amount  of 
added  CAP  corresponds  with  approximately  half the  maximum 
concentration expected.  The  test sample  is mixed  thoroughly  and 
stood  for  30  min  at room  temperature  or  overnight  at 4°C. 
Cy  3.5/6 10.  CALCULATION  OF  RESULTS 
The  presence  of  chloramphenicol  in  a  sample  is confirmed  if the  GC-MS  data 
agree  with  the  following  criteria:  (see  also  Section  5 of  Manual) 
1.  The  peak  has  the  same  retention time  on  GC  as  the  standards. 
2.  All  the  selected  ions  are  present  in  the  mass  spectrum  of  that peak 
after subtraction of  the  background. 
3.  GC-ECNICI(MS).  The  selected  ions  are  present  in  the  same  ratio 
to  one  another  as  seen  in  the  standard.  Effectively the  following  criteria 
are  used;  the  ratio A468/466  (r1 )  has  to  be  within  10%  of  the  theoretical 
value  of  0.76,  the  ratio A378/376  (r2)  has  to  be  within  10%  of  the 
theoretical  value  0.70  and  the  ratio A376/A466  (r3)  has  to  be  within  10%  of 
the  corresponding  standard,  experimentally determined  under  the  same 
conditions  as  for  the  sample. 
3.  GC-EI(MS).  The  selected  ions  are  present  in  the  same  ratio to one 
another  as  seen  in  the  standard.  Effectively the  following  criteria are 
used;  the  ratios A242/225  (r1),  A361/225  (r2)  and  A451/A225  (r3)  have  to 
be  within  10%  of  the  corresponding  standard,  experimentally determined 
under  the  same  conditions  as  for  the  sample. 
If chloramphenicol  is present  in  a  sample  and  satisfies the  above  criteria, 
then  an  estimate of  the  quantity present  may  be  calculated; 
For  quantification  (ECNICI(MS))  the  ratio A466/Ac470  is calculated  in  which 
Ac470  is the  corrected  value  of  A470  according  to: 
Ac470  =  A470  - 0.184  A466. 
This  correction  is necessary  since  the  chlorine  isotope  peak  of  ion  m/z  466 
contributes  to  the  response  at m/z  470.  Linearity over  the  range  from  0-
20  ~g per  kg  or  L is good  (r  =  0.9992,  intercept not  deviating 
significantly from  zero). 
For  quantification after EI(MS)  a  similar procedure  can  be  followed. 
Limit  of  detection:  0.1  ~g per  L of  urine or  milk  and  0.1  ~g per  kg  meat 
or  egg. 
10.1.  PRECISION 
Repeatability and  reproducibility were  calculated at  RIVM  and  determined 
for  urine  in  three  separate experiments,  five  replicates each  time  (GC-MS 
method) 
The  values  were;-
Concentration 
(ug  per  L) 
2.83 
12.0 
within  assay 
variability 
cv 
8.0% 
2.3% 
11.  SPECIAL  CASES 
12.  NOTES  ON  PROCEDURE 
Cy  3.5/7 
between  assay 
cv 
8.7% 
9.9% 13.  QUALITY  CONTROL.  STANDARDS  AND  REFERENCE  MATERIALS. 
RMs  will  be  available  under  the  BCR  programme  for  meat,  milk  and  eggs  (see 
Section  8 of  manual). 
The  internal  standard  is  37Cl 2-CAP 
Note;  05-CAP  is  used  by  BGA  as  internal  standard. 
14.  TEST  REPORT. 
To  give  the  indications  necessary  for  the  identification of  the  sample,  the 
reference  to  the  method  employed,  the  results and  the  form  in  which  these 
are  expressed,  any  particular points  observed  in  the  course  of  the  test and 
any  operations  not  specified  in  the  method  or  regarded  as  optional  which 
might  affect the  results. 
15.  LIST  OF  ABBREVIATIONS 
A list of  the  most  important  abbreviations  is given  in  Annex  I  section 12. 
16.  FLOW  DIAGRAM. 
enzyme  hydrolysis  EtAc  eluate 
URINE  ---------------------> EXTRELUT  COLUMN  --------------> DRY  ---> 
elute 
----> Water/MeOH  -----------> SEP-PAK  Cl8  ------> Water/MeOH  -----> HPLC 
COLUMN 
or 
homogenise/EtAc  elute 
MUSCLE,  EGGS  -----------------> DRY  ---> SEP-PAK  Si  ----------------> 
Acetonitrile/water 
----->Extract  into  EtAc  --------> DRY  ------>  HPLC 
EtOH/isooctane 
-----> HPLC  CLEAN  UP  ---------------> DERIVATISE  WITH  BSTFA/TMCS  --> 
----> GCMS  OF  TMS  DERIVATIVES  -----------------> CALCULATE  RESULTS 
Cy  3.5/8 Cy  3.6.  CHLORAMPHENICOL  - CONFIRMATION  OF  CHLORAMPHENICOL  IN  MEAT  BY  GAS 
CHROMATOGRAPHY-MASS  SPECTROMETRY. 
WARNING  AND  SAFETY  PRECAUTIONS 
0.  INTRODUCTION 
Chloramphenicol  (CAP)  is a  bacteriostatic with  a  broad  spectrum  of 
activity,  frequently  used  for  therapeutic  and  prophylolactic  purposes  in 
veterinary medicine.  In  several  countries  the  use  of  CAP  is prohibited  in 
laying  hens  and  lactating cattle.  MRLs  in  meat  products  are  set by  many 
countries  between  zero  and  10  ~g per  kg. 
1.  SCOPE 
The  use  of  CAP  is restricted throughout  the  EEC.  This  is a method  for  the 
quantitative determination  and  for  the  confirmation  of  the  presence  of  CAP 
residues  in  meat  samples.  This  work  is carried out  in  compliance  with  the 
Residues  Directive  (86/469/EEC). 
2.  FIELD  OF  APPLICATION. 
This  method  is used  for  confirmation  of  the  presence  of  chloramphenicol  in 
meat  at the  quantitative determination  of  10  ~g per  kg.  The  limit of 
detection  is 1.0  ~g per  kg  for  chloramphenicol. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  Ng 
L.118,  14.4.93.  pp  64-74] 
2052/VI/84  File 6.11  II-4,  Scientific Veterinary Committee,  Working 
Group-
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EEC  Document:  2406/VI/85-EN  File 6.21  II-4 
11Draft  Reference  Method  for  the 
detection  of  residues  of  chloramphenicol  in  meat.
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ISO  Standard  78/2-1982  Layout  for  standards  - Part  2:  Standard  for  Chemical 
Analysis 
Arnold.  D.,  Berg,  D.  van,  Boertz,  A.K.,  Mallick,  U and  Somogyi,  A., 
(1984),Eine  Radioimmunologische  Bestimmung  von  Chloramphenicol-Ruckstanden 
in  Muskulatur,  Milch  und  Eiern.  Arch.  Lebensmittelhyg.  35,  131-136. 
Arnold,  D.  and  Somogyi,  A.  (1985),  Trace  analysis  of  chloramphenicol 
residues  in  Eggs,  Milk  and  Meat:  Comparison  of  gas  chromatography  and 
radioimmunoassay.  J.A.O.A.C.,  68,  984-990 
Balizs,  G.  and  Arnold,  D.  (1989),  Reference  Standards  for  residue  analysis 
of  chloramphenicol  in  meat  and  milk:  A critical  study.  Chromatographia, 
27,  489-493. 
Van  Ginkel,  L.A.,  van  Rossum,  H.J.,  Zoontjes,  P.W.,  van  Blitterswijk,  H., 
Ellen,  G.,  van  der  Heeft,  E.,  de  Jong,  A.P.J.M.  and  Zomer,  G.  (1990), 
Development  and  validation of  a gas  chromatographic  spectrometric  procedure 
Cy  3.6/1 for  the  quantitation  and  identification of  residues  of  chloramphenicol. 
Anal.  Chim.  Acta.  237,,  61-69. 
4.  DEFINITIONS. 
Chloramphenicol  content  is taken  to  mean  the  amount  of  Chloramphenicol  in 
the  matrix  in  question,  regardless  of  the  chemical  form,  determined 
according  to  the  described  method  and  expressed  as  ~g Chloramphenicol  per 
kg  of  test sample. 
5.  PRINCIPLE. 
The  method  of  analysis  comprises  six  stages: 
(1)  Homogenisation 
(2)  Extract  into ethyl  acetate  (EtAc) 
(3)  Sep-Pak  C18  reverse  phase  column  purification 
(4)  Extract with  ethyl  acetate 
(5)  Derivatisation. 
(6)  Analysis  by  gas  chromatography/mass  spectrometry  (GC/MS). 
6.  MATERIALS 
During  the  analysis,  unless  otherwise  stated use  only  reagents  of 
recognised  analytical  grade  and  only  distilled water  or water  of  equivalent 
purity. 
6.1.1. 
6.1.2. 
6.1.3. 
6.1.4. 
6.1.5. 
6.1.6. 
6.1.7. 
6.1.8. 
6.1.9. 
6.1.10 
6.1.11 
6.1.12 
6.1.13 
6.1.14 
6.1.15 
6.1.16 
6.1.17. 
6.2. 
Chloramphenicol,  Cas  No.  56-75-7;  C 11H 12Cl2N 205 ,  Mol.  Wt. 
323.1;(Sigma  C-0378))  or  Sigma  drug  standard  solution,  1 mg  per 
mL  (C-9028) 
Chloramphenicol  - meta  isomer  donated  by  Parke  Davis,  Freiburg, 
Germany 
Internal  standard  - deuterated  chloramphenicol  (98%)  CAP-ring-D4-
benzyl--D1  (Promochem  GmbH,  Wesel,  Germany). 
Pyridine  - dried  (Merck  7463) 
Hexamethyldisilazine  (Baker  8788) 
Chlorotrimethylsilane  (Aldrich  C7,285-4) 
Methanol  p.a.  (Merck  6009) 
Chloroform  p.a.  (Merck  2445) 
Acetonitrile  (Merck  3) 
Ethylacetate  p.a.  (Merck  9623) 
n-Hexane  p.a.  (Merck  4371) 
Sodium  chloride p.a.  (Merck  6404) 
Solid  phase  extraction cartridge  (Sep-Pak,  C18)  (Water-Millipore, 
art.  no.  51910) 
Heptacosafluorotributylamine  (Fluka  77299) 
Methyl  iodide  for  synthesis  (Merck  806064) 
Nitrogen  (Linde) 
Ethanol  abs.  p.a.  (Merck  983) 
Solutions. 
6.2.1.  Solutions  of  standards,  concentration  and  storage. 
6.2.1.1.  It is recommended  to  use  a commercially  available standard 
solution  (6.1.1),  1 mg  per  mL;  transfer 600  ~L to a  100  mL 
volumetric  flask  and  make  up  to  volume  with  ethanol  (6.1.17). 
Cy  3.6/2 6.2.1.2. 
6.2.1.3. 
6.2.2. 
7. 
7.1 
7.2 
7.3 
7.4 
7.5 
7.6 
7.7 
7.8 
7.9 
7.10 
7.11 
7.12 
7.13 
7.14 
7.14.1. 
7.14.2. 
8. 
This  stock  solution  can  be  stored for  six months  at +4°C. 
Transfer  1 ml  stock  solution  (6.2.1.1)  (10  ~g per  mL)  to  a  10  mL 
volumetric  flask  and  make  up  volume  with  ethanol.  For  a 
calibration curve  ranging  from  240  pg  to  1200  pg  CAP  (equivalent 
to 4 to  20  ~g per  kg  meat)  per  2  ~L injection take  20  to  100  ~L, 
derivatise and  dissolve  in  1000  ~L n-hexane.  The  standard 
solution  should  be  prepared  monthly,  stored at +4°C  and  silylated 
daily for  the  analysis. 
CAP  internal  standard  solution.  (D5-CAP). 
Take  5 mL  of  the  D 5-CAP  stock  solution  (10  mg  per  100  mL  ethanol 
and  make  up  to  100  mL  with  ethanol  (Solution  I).  Transfer  10  mL 
of  solution  I  to  a volumetric  flask  and  make  up  to  100  mL  with 
ethanol  (Solution  II).  Add  60  ~L solution  II  to  the  sample 
(equivalent  to  30  ng  per  3 g meat). 
These  solutions  can  be  stored for  six months  at +4°C. 
Silylating reagent.  Mix  pyridine  (9  parts),  hexamethyldisilazine 
(3  parts)  and  chlorotrimethylsilazine  (1  part). 
EQUIPMENT 
Mincer  or  other  device  for mincing  meat 
Vortex  mixer 
Centrifuge  (e.g Sorvall,  USA) 
Sample  concentrator with  heating  block 
Speed-vac  concentrator  (Savant  Instruments,  Hicksville,  N.Y., 
USA) 
UNIVAPO  150H  (UniEquipe,  Martinsried,  Germany) 
Dispensets  - 3 mL  and  5 mL  (Brand,  Germany) 
Pipettes  - 20  ~L,  200  ~L,  1000  ~L 
Tubes  - 15  mL,  113  mm  x 17  mm 
Tubes  25  mL,  100  mm  x 24  mm 
GC-micro  sample  vials -200  ~L (Chrompack,  Netherlands) 
5 mL  syringe  (Hamilton) 
5  ~L syringe  (SGE,  Australia) 
GC-MS  System 
GC  - HP  5890  with  direct capillary interface  (Hewlett-Packard) 
MS- SSQ  710  (Finnigan  MAT,  San  Jose,  Ca.,  USA) 
SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section 6.3.1  and  ISO  document  78/2-1982  and 
the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection of  residues  in  meat  as  defined  in  Directive  64/433/EEC. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to 
allow  the  reference  method  to  be  carried out  and  to allow  repeat 
analysis where  required.  Not  less  than  200  g should  be 
collected. 
This  method  for  Chloramphenicol  uses  3 g of  meat  for  a single 
determination. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to allow 
proper  identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain 
Cy  3.6/3 the  integrity of  the  sample  and  not  prejudice  the  result of  the 
examination. 
Samples  for  the  analysis of  CAP  must  be  stored  and  transported at 
temperatures  below  -18°C. 
9.  PROCEDURE 
9.1.  Sample  Clean-up 
9.1.2 
9.1.2.1 
9.1.2.2 
9.1.2.3 
9.1.2.4 
9.1.2.5 
9.1.2.6 
9.1.2.7 
9.1.2.8 
9.1.2.9 
9.1.2.10 
9.1.2.11 
9.1.2.12 
9.1.3. 
Take  a coherent  part of  muscle  tissue and  mince  at 0°C  to 4°C. 
In  the  case  of  frozen  meat  add  the  excess  liquid,  produced  when 
the  meat  is thawed,  quantitatively to  the  minced  meat  and  mix 
well.  The  sample  can  now  be  stored  at ooc  to  4°C  for  analysis 
within  48  hours.  For  prolonged  storage,  freeze  aliquots at <  -
20°C  preferably at -80°C  to  ensure  stability. 
First Extraction 
Weigh  3 g of  minced  tissue  in  a centrifuge tube  (7.9)  and  add  the 
internal  standard  (30  ng  D 5-CAP  or  meta-isomer  per  100  ~L 
ethanol). 
Add  8 ml  acetonitrile - 4%  aqueous  sodium  chloride  (1:1,  v/v)  and 
mix  well 
Centrifuge  10  min  at 4000  x g. 
Decant  supernatant  liquid  into  a centrifuge tube  (7.10) 
Add  5 ml  n-hexane,  mix  well,  centrifuge 5 min  at 1700  x g. 
Discard  upper  layer 
Repeat  the  hexane  extraction  (9.1.2.5 - 9.1.2.6) 
Add  5 ml  ethyl  acetate  (water  saturated)  to  lower  aqueous  phase, 
mix,  centrifuge 5 min  at 1700  x g. 
Take  off upper  layer 
Repeat  the  ethyl  acetate extraction  (9.1.2.8 - 9.1.2.9) 
Evaporate  collected organic  phase  (9.1.2.9)  to  dryness 
Dissolve  dry  residue  in  3 ml  acetonitrile:water  (5:95,  v/v) 
Sep-Pak  C18  Purification 
The  Sep-Pak  cartridges  (6.1.13)  are  prepared  by  washing  sequentially with  5 
ml  of methanol  (6.1.7),  5 ml  of  chloroform  (6.1.8),  5 ml  methanol  and  10  ml 
water.  Add  the  extract and  wash  with  5 ml  acetonitrile:water::5:95 v/v. 
The  CAP  is eluted with  3 ml  acetonitrile:water::50:50 v/v. 
9.1.4. 
9.1.4.1 
9.1.4.2 
9.1.4.3 
9.1.4.4. 
9.1.5. 
9.1.5.1 
9.1.5.2 
9.1.5.3 
Second  Extraction 
Extract  the  CAP  from  the  eluted fluid with  5  ml  ethyl  acetate 
(water  saturated),  and  centrifuge at 1700  x g. 
Take  off the  upper  layer. 
Repeat  the ethyl  acetate extraction  (9.1.4.1  - 9.1.4.2) 
Evaporate  the  combined  collected organic  phase  to dryness. 
Silylation 
Add  50  ~L silylating agent  (6.2.2)  to  the  sample  and  standard. 
Evaporate  immediately  under  a  gentle  stream  of  dry  nitrogen. 
Dissolve  immediately  in  1000  ~L n-hexane  (6.1.11). 
Cy  3.6/4 9.2  Instrumental  Conditions. 
GC  Column 
Carrier Gas 
Flow  Rate 
Injection System 
Injection  volume 
Injector Temperature 
Temperature  Programme 
Transfer  line 
Retention  times. 
DB5,  26m  x 0.25  mm  i.d. 
0.1  urn  stationary phase  thickness. 
Helium  5.0 
ca.  40  mL  per  min 
split/splitless 
1  J.LL 
280°C 
splitless time,  1 minute 
70°C  to  250°C  (25°C  per  min),  final  temp.  for 
8 min. 
270°C 
CAP  meta-isomer  9.12  min 
CAP  and  deut.  CAP  9.26  min 
9.2.2  MS  Parameters 
Operating  in  Negative  CI  mode. 
Ion  source  parameters 
Reactant  Gas 
pressure 
Calibration 
Resolution  Parameters 
Dwell  time 
Dynode 
Ions  to  be  measured 
Source  temp.  100°C 
Emission  current;  300  uA 
Electron  energy;  50  eV 
Ammonia 
3 x 10-6  torr 
Perfluorotributylamine  (FC  43) 
masses  169,  283,  414,  514,  557,  595,  633 
Resolution;  300 
100  msec  per  ion 
20  kV 
Para-CAP;  466  468  470  378  376 
Meta-CAP;  466  468  470 
deut-CAP;  471  473  475 
10.  CALCULATION  OF  RESULTS 
The  presence  of  chloramphenicol  in  a  sample  is confirmed  if the  GC-MS  data 
agree  with  the  following  criteria:  (see  also Section  5 of  Manual) 
1.  The  peak  has  the  same  retention time  on  GC  as  the  standards. 
2.  All  the  selected  ions  are  present  in  the  mass  spectrum  of  that peak 
after subtraction of  the  background. 
3.  The  selected  ions  are  present  in  the  same  ratio to one  another  as  seen 
in  the  standard. 
If chloramphenicol  is present  in  a  sample  and  satisfies the  above  criteria, 
then  the  quantity present  may  be  calculated; 
For  quantification the  results are  calculated using  the  ratio of  the  peak 
areas  of  CAP  and  the  internal  standard.  The  quality of  the  standard  curve 
is  judged  by  linear regression. 
Cy  3.6/5 10.1.  PRECISION 
The  method  was  validated  by  comparison  to  the  results obtained with 
(I)  pig  muscle  incurred with  CAP  and  prepared  as  reference  material 
at  BGA. 
(II)  two  independent  methods;  RIA  and  GC  with  ECD. 
Results  for  incurred  samples. 
RIA 
GC  with  ECD 
GC-NCI-MS 
9.45  ~g per  kg;  n =  44 
9.92  ~g per  kg;  n =  10 
9.53  ~g per  kg;  n = 8 
* value  is corrected  by  a random  factor 
11.  SPECIAL  CASES 
12.  NOTES  ON  PROCEDURE 
* 
13.  QUALITY  CONTROL.  STANDARDS  AND  REFERENCE  MATERIALS. 
RMs  will  be  available under  the  BCR  programme  for  meat,  milk  and  eggs  (see 
Section  8 of  manual). 
D 5-CAP  is used  by  BGA  as  internal  standard. 
Note;  The  internal  standard  used  at  RIVM  is  37Cl 2-CAP 
14.  TEST  REPORT. 
To  give  the  indications  necessary  for  the  identification of  the  sample,  the 
reference  to  the  method  employed,  the  results and  the  form  in  which  these 
are  expressed,  any  particular points  observed  in  the  course  of  the  test and 
any  operations  not  specified  in  the  method  or  regarded  as  optional  which 
might  affect the  results. 
15.  LIST  OF  ABBREVIATIONS 
A list of  the  most  important  abbreviations  is given  in  Annex  I  section  12. 
16.  FLOW  DIAGRAM. 
homogenise  elute 
MUSCLE  ------------------>  SOLVENT  EXTRACTION  ----->  SEP-PAK  C18  ------> 
EXTRACT  WITH  ETHYL  ACETATE  ---------->  DERIVATISE  AS  TMS  ETHERS  -----> 
GC-MS  (NCI)  ------->  CALCULATE  RESULTS 
Cy  3.6/6 Cy  3.7.  CHLORAMPHENICOL  - HPLC  ANALYSIS  OF  CHLORAMPHENICOL  IN  MILK. 
WARNING  AND  SAFETY  PRECAUTIONS 
SAFETY 
Organic  solvents  - all  organic  solvents  must  be  treated as  potentially 
hazardous  and  all  procedures  using  them  must  be  performed  in  a  fume 
cupboard. 
0.  INTRODUCTION 
Chloramphenicol  (CAP)  is a bacteriostatic with  a  broad  spectrum  of 
activity,  frequently  used  for  therapeutic  and  prophylolactic purposes  in 
veterinary medicine.  The  EEC,  through  the  CVMP,  specifically does  not 
recommend  the  use  of  CAP  in  laying  hens  and  lactating cattle (see  section 
2). 
1.  SCOPE 
The  use  of  CAP  is restricted throughout  the  EEC.  To  ensure  that farmers 
are  not  continuing  to  use  chloramphenicol  in  laying  hens  or  lactating 
cattle,  and  to  control  the  use  in  meat  producing  animals  samples  are 
collected on  farms  and  at slaughterhouses  and  screened  for  the  presence  of 
this compound  using  a  number  of  techniques  (see  Section  4).  Whenever  there 
is a  positive screening  result,  this must  be  confirmed. 
2.  FIELD  OF  APPLICATION. 
This  method  is used  for  confirmation  of  the  presence  of  chloramphenicol  in 
milk.  The  detection  limit with  UHT  sterilised milk  is  <1  ~g/litre or  kg  of 
matrix  for  Chloramphenicol. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
ISO  Standard  78/2-1982  Layout  for  standards  - Part  2:  Standard  for  Chemical 
Analysis 
ISO  Standard  5725  (1986) 
Determination  of  chloramphenicol  in  milk  by  high  performance  liquid 
chromatography.  CNEVA,  Lab.  des  Medicaments  Veterinaires,  Fougeres, 
Document  no.  UCM/90/04 
4.  DEFINITIONS. 
Chloramphenicol  content  is taken  to  mean  the  amount  of  chloramphenicol  in 
milk  determined  according  to  the  described  method  and  expressed  as  ~g 
chloramphenicol  per  L test sample. 
5.  PRINCIPLE. 
The  method  comprises  three  stages 
- Samples  of  milk  are  extracted using  ethyl  acetate. 
Cy  3.7/1 - purification of  the  extract with  a mixture  of  chloroform-hexane 
- quantification  by  high  performance  liquid chromatography  (HPLC)  on 
silica coated  column  type  C-18  with  UV  detection at 278  nm. 
6.  MATERIALS 
6.1.  Chemicals 
6.1.1 
6.1.2 
6.1.3 
6.1.4 
6.1.5 
6.1.6 
6.1.7 
6.1.8 
6.1.9 
6.1.10 
Ethyl  acetate,  Analytical  grade  (Merck  9623)  distilled  in  a 
rotary evaporator  (7.2.6)  before  use 
Methanol,  Analytical  grade  (Merck  6009) 
Chloroform,  Analytical  grade  (Merck  2445) 
Hexane,  Analytical  grade  for  analysis  (Merck  4367) 
Acetonitrile,  HPLC  grade  (Prolabo  20059326) 
37%  HCl,  analytical  grade  (Merck  317).  Make  5 mol  per  L 
solution. 
Di-ammonium  hydrogenphosphate  (Merck  1207):  prepare  0.005  mol  per 
L solution,  (0.66  g per  L) 
Demineralised  water,  resistivity above  18  MO.cm,  filtered on 
active carbon  and  a 0.45  urn  filter. 
Chloramphenicol  >99%  pure,  Crystalline  (Sigma  Chemicals  Ltd) 
Control  milk  free of  any  trace of  CAP. 
6.1.11.  Solutions  see  6.1.6.,  6.1.7. 
6.1.13.  Chloramphenicol  Standards 
6.1.13.1  Standard  solution;  500  ~g/mL chloramphenicol  in  methanol. 
Store  at 4°C.  Stable for  at  least three months. 
6.1.13.2  Intermediate  Standards;  Dilute  stock  standard with  water  (6.1.8) 
to  make  5 and  50  ~g per  mL  solutions.  Store  at 4°C.  Stable for 
maximum  period  of  2 weeks. 
6.1.13.3  Working  Standards  On  day  of  use,  dilute  intermediate 
solutions with  water  to  give  a  set of  9 standards  with 
concentrations  in  ng  per  mL  equal  to  10,  25,  50,  100,  125,  250, 
500,  1250,  2500. 
7.  EQUIPMENT 
7.1.  Glassware 
7.1.1  Graduated  pipettes,  1 mL,  5 mL  and  25  mL 
7.1.2  50  mL  glass  centrifuge tubes  with  screw  caps. 
7.1.3  5 mL  glass  haemolysis  tubes. 
7.1.4  Round  bottomed  stoppered  flasks,  25  mL  or  50  mL. 
7.1.5  Volumetric  stoppered  flasks,  20  mk,  25  mL,  50  mL  and  100  mL 
7.1.6  Silicone  stoppers,  type  Rhodorsil  which  fit the  centrifuge and 
haemolysis  tubes. 
7.1.7  Polyethylene  stoppers  to fit stoppered  glassware 
7.1.8  Glass  pipettes 
7.2.  Apparatus 
7.2.1  Rubber  pear-shaped  sucking  up  system  type  PROLABO 
11Propipette
11
, 
fittable to  glass pipettes. 
7.2.2  Automatic  pipettes,  100  ~L,  1000  ul  and  5000  ~L  (type  Gilson 
11Pipetman
11
) 
7.2.3  5 to  25  mL  automatic  dispenser,  type  BRAND 
11Dispensette
11
• 
Cy  3.7/2 7.2.4. 
7.2.5. 
7.2.6. 
7.2.7. 
7.2.8. 
7.2.9. 
7.2.10. 
7.2.11. 
7.2.12 
7.2.13. 
8. 
Stirrer for  tubes,  type  HEIDOLPH 
11Top-mix
11 
Rotary  stirrer with  rotating plates,  type  HEIDOLPH 
11Reax  2
11 
Rotary  evaporator,  type  BUCHLI,  linked  to  vacuum  pump. 
Agitation water  bath,  type  BIOBLOCK 
11Polytest  20
11 
Analytical  balance 
Refrigerated  centrifuge,  type  JOUAN  E 96,  set at  15°C 
Ultrasonic water  bath,  type  BIOBLOCK  B72  401 
HPLC  equipment 
Kratos  spectroflow 400  pump  with  Kratos  Spectroflow  773 
absorbance  detector set at 278  nm  with  Spectra-Physics  SP  4290 
integrator.  Waters  4  urn  C-18  Novapak  column  (150  x 3.9  mm). 
Rheodyne  injector  (7125)  fitted with  200  ~L loop. 
250  ~L Glass  syringe  for  chromatography,  type  HAMILTON 
Filtering equipment,  Containing  0.45  urn  filter  (Millipore  -
Waters) 
SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section  6.3.1  and  ISO  document  78/2-1982  and 
the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN  and  eec  93/256. 
8.1.  Nature  of  the  Sample;  Samples  of  milk  shall  be  such  as  to enable  the 
detection of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to  allow 
the  reference method  to  be  carried out  and  to  allow  repeat  analysis where 
required. 
In  this method  for  chloramphenicol  the  sizes  shall  not  be  less  than  30  mL 
milk. 
8.3.  The  milk  must  be  cooled  after collection and  stored  at~ -20°C 
pending  analysis. 
9. 
9.1. 
9.2. 
9.3. 
9.4. 
9.5. 
9.6. 
9.7. 
9.8. 
9.9. 
9.10. 
9.11. 
9.12. 
9.13. 
PROCEDURE 
Thaw  the  milk  sample  in  a water  bath  at 30°C. 
Homogenise  the milk  sample  so  as  to  blend  if necessary  the  cream 
with  the  milk. 
Transfer  5 mL  milk  into  a  50  mL  centrifuge tube  with  an  automatic 
pipette. 
Add  50  ~L 5 mol/L  HCl  solution  (6.1.6)  and  stir for  10  sec. 
Add  25  mL  distilled ethyl  acetate  (6.1.1)  using  an  automatic 
dispenser  (7.2.3)  and  plug  the  tube  with  a  silicone stopper. 
Place  the  tubes  between  the  plates of  the  rotary stirrer (7.2.5), 
perpendicularly to  the  axis  of  rotation of  the  plates.  Stir for 
10  min.  at 40  rpm. 
Centrifuge  for  5 min  at 2400  g. 
Transfer  20  mL  of  the  organic  phase  with  a  25  mL  ~lass pipette 
(7.1.1)  into  25  mL  or  50  mL  round  bottomed  flask  (7.1.4). 
Evaporate  to  dryness  using  a rotary evaporator  at 30°C. 
Resuspend  the  oily residue  in  1.6  mL  mixture  of  hexane:chloroform 
(1:1  v/v)  using  an  automatic  pipette (7.2.2). 
Stir for  15  sec  (7.2.4)  at the  highest  speed. 
Add  0.8  mL  water  with  an  automatic  pipette. 
Plug  with  a polyethylene  stopper  and  stir for  5 min  at 35  rpm 
with  the  rotary stirrer (7.2.5)  placing  the  flasks  horizontally 
Cy  3.7/3 9.14. 
9.15. 
9.16. 
9.17. 
9.17.1 
9.17.2 
9.17.3 
9.17.4 
9.18. 
9.18.1 
9.18.2 
9.18.3 
9.18.4. 
10. 
10.1 
10.2 
10.3 
so  that their axles  are  parallel  to  rotation of  the  plates. 
Transfer  the  content  of  the  flask  into  an  haemolysis  tube  and 
plug  it (7.1.6). 
Centrifuge  for  10  min  at  3300  g. 
Take  250  ~L supernatant with  a  syringe  (7.2.12)  and  inject  into 
the  chromatographic  system. 
Spiking 
Transfer  4.9  mL  control  milk  into  5 centrifuge tubes  (7.1.2)  with 
an  automatic  pipette. 
Add  0.1  mL  of  each  of  the  standard  solutions containing  100,  250, 
500,  1250  and  2500  ng  per  mL  so  as  to  obtain  5 samples  of  milk 
respectively spiked  at 2,  5,  10,  25  and  50  ng  per  mL. 
Stir the mixtures  and  allow  to  stand  for  15  min. 
Carry  out  the  extraction  steps  9.4  to  9.16. 
HPLC 
Mobile  phase  is acetonitrile,  0.005  mol/L  ammonium  hydrogen 
phosphate  (18:82,  v/v). 
Flow  rate 1 mL  per  min. 
Wavelength  278  nm 
The  retention of  CAP  is about  10  min. 
CALCULATION  OF  RESULTS 
Inject the working  standards  containing  10,  25,  50,  125  and  250 
ng  per  mL,  equivalent  to  2,  5,  10,  25  and  50  ng  per  mL  milk. 
Derive  the  calibration curve  and  check  the  linearity of  the 
detector response. 
Calculate  the  recovery  from  the  results obtained  for  the  spiked 
extracts  (see 9.17).  The  mean  recovery  is reported  in  the  range 
93.2  ~ 4.7%  for  the  concentrations  ranging  2 to  50  ng  per  mL. 
Calculate  the  concentration  of  CAP  present  in  the  samples  to  be 
analyzed  using  the  calibration curve  and  taking  into account  the 
recovery  and  the  possible dilution. 
A x Ce  x 0.8 x 25  A x Ce 
c =  = 
Ae  X  5  X  20  Ae  X  5 
where  A is area  or  height  of  CAP  in  the  sample 
Ae  is area  or  height  of  CAP  in  the  standard 
Ce  is the  concentration of  the  standard 
10.4.  Specificity;  The  chromatograms  corresponding  to  the  extracts of 
milk  used  to determine  the  limit of  detection  (see  Section  5, 
1.1.10)  do  not  reveal  significant  interference at the  retention 
time  of  CAP. 
10.5  Accuracy;  The  accuracy  was  measured  from  whole  UHT  milk  samples 
spiked  to  2,  5,  10,  25  and  50  ng  per  mL  with  four  replicates for 
each  concentration.  The  results are  shown  in  table 1. 
Cy  3.7/4 Table  1;  Accuracy  of  the  method. 
Theoretical  Found  so  cv  Recovery 
Cone,  (  ng/ml)  (ng/mL)  (ng/ml)  (%)  (%) 
2  2.01  0.09  4.46  100.3 
5  4.62  0.21  4.42  92.5 
10  9.35  0.08  0.82  93.6 
25  22.71  0.05  0.24  90.9 
50  44.45  0.55  1.23  88.9 
10.6  Limits  of  detection  and  quantification. 
10.6.1  The  limit of  detection was  assessed  on  30  either whole  or  half 
skimmed  UHT  sterilized milk  samples.  It is equal  to  the  mean  quantity 
measured  on  the  control  samples  to which  is added  three times  the  standard 
deviation  of  the  mean. 
In  experiments  at  CNEVA  this was  equal  to 0.292  +  (3  x 0.136)  =  0.7  ng  per 
mL. 
10.6.2.  The  limit of  quantification assessed  using  the  same  samples  as  in 
10.6.1,  was  the  mean  value  plus  10  times  the  SO,  i.e.  1.66  ng  per  mL. 
10.7.  Linearity;  The  regression  line was  calculated from  the  samples 
analyzed  in  10.1.  At  CNEVA  this value  was  e.g.  Y =  0.885X  + 0.355,  r  = 
0.9998 
10.8.  Precision.  Precision  data  were  obtained  at  CNEVA  in  a  study  using  3 
operators  and  4  levels of  concentrations,  5,10,25  and  50  ng  per  mL  (the  2 
ng  per  ml  concentration was  not  studied  because  some  detectors  may  not 
reach  the  required  level  of  sensitivity).  Each  level  of  concentration was 
assayed  in  quadruplicate  by  each  operator.  The  results of  repeatability 
and  reproducibility were  calculated according  to  ISO  standard  5725  (1986) 
and  are  given  in  table 2. 
Table  2.  Precision  data 
Level  Theor  mean  cone.  range  repeatability  reproducibility 
cone.  found  Sr  CVr(%)  r  SR  CVR(%)  R 
(ng/mL)  (ng/mL)  (ng/mL) 
1  5  4.83  4.50  - 5.11  0.089  1.86  0.054  0.228  4.71  0.645 
2  10  8.89  8.35  - 9.43  0.281  3.16  0.794  0.397  4.46  1.123 
3  25  23.50  22.05  - 24.80  0.337  1.44  0.959  1.078  4.59  3.051 
4  50  44.34  42.08  - 46.13  1.151  2.60  3.258  1.169  2.64  3.309 
For  each  concentration  level,  for  repeatability the  SO  is Sr,  the  CV  is 
CVr,  and  the  repeatability is r; for  reproducibility the  SO  is SR,  the  CV 
is  CVR  and  the  reproducibility is R. 
R and  r  are  the  values  below  which  the  difference  between  two  results of  a 
single trial, obtained  for  conditions  of  repeatability (r)  and 
reproducibility  (R)  can  be  expected  to occur  with  a  95%  probability. 
Note;  The  CVr  range  is 1.44%  - 3.16%  which  is well  below  the  limits  (15% 
at 10  ng  per  g)  for  CVs  set out  in  the  Criteria document  in  section  5. 
Cy  3.7/5 11.  SPECIAL  CASES. 
12.  NOTES  ON  PROCEDURE. 
13.  SAMPLE  CONTROLS.  Note  that most  of  the  working  solutions  are 
only  used  for  validation  purposes. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS. 
See  abbreviations  in  Annex  I,  Section  12  of  Manual. 
16.  FLOW  DIAGRAM 
MILK  ---------->  SOLVENT  EXTRACT  (EtAc)  ------>  EXTRACT 
(CHC1 3/HEXANE) 
---------->  EXTRACT  WITH  WATER  -------->  HPLC 
Cy  3.7/6 Cy  3.8.  TETRACYCLINES  - DETERMINATION  BY  HPLC  OF  TETRACYCLINES  AT  RESIDUE 
LEVELS  IN  ANIMAL  TISSUES. 
WARNING  AND  SAFETY  PRECAUTIONS 
0.  INTRODUCTION 
Tetracylines  are  a group  of  antibiotics  including  tetracycline, 
chlortetracycline,  and  oxytetracycline which  are  used  therapeutically and 
prophylactically  in  animal  husbandry.  Residues  of  these  substances  are 
often  found  in  animals  especially pigs.  The  residues  are  sometimes  at 
violative  levels.  The  provisional  MRLs  set  in  the  EEC  for  tetracylines  is 
10-600  ~g per  kg  meat  and  100  ~g per  L of  milk. 
1.  SCOPE 
This  method  of  analysis  describes  the  determination  of  the  total  content of 
tetracycline,  chlortetracycline and  oxytetracycline  in  samples  of  animal 
origin. 
2.  FIELD  OF  APPLICATION. 
The  method  can  be  used  for muscle,  kidney  and  milk.  The  limit of 
determination  following  the  validation of  the  method  is 10  ~g/kg or  litre 
of  sample  for  tetracyclines. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
2052/VI/84  File 6.11  II-4,  Scientific Veterinary Committee,  Working 
Group  - "Reference  Methods  for  Residues",  General  Criteria for  the 
establishment of  Reference  Methods  for  the  Detection  of  Residues. 
ISO  Standard  78/2-1982  Layout  for  standards  - Part  2:  Standard  for  Chemical 
Analysis 
MAFF,  1989,  Determination  of  tetracyclines at residue  levels  in  animal 
tissues.  Food  Science  Laboratory,  Colney  Lane,  Norwich,  UK  Standard 
Operating  Procedure. 
Farrington,  W.H.H.,  Tarbin,  J.,  Bygrave,  J.  and  Shearer,  G.  (1991). 
Analysis  of  trace residues  of  tetracyclines  in  animal  tissues using  metal 
chelate affinity chromatography/HPLC.  Food  Addit.  &  Contamin.  ~.  55-64 
4.  DEFINITIONS. 
Tetracyclines  content  is taken  to  mean  the  amount  of  tetracyclines  in  the 
substance  in  question,  regardless  of  the  chemical  form,  determined 
according  to  the  described  method  and  expressed  as  ~g or  mg  tetracyclines 
per  kg  or  litre of  test sample. 
Cy  3.8/1 5.  PRINCIPLE 
The  methods  comprises  6 stages;-
- Homogenisation  of  tissue samples  in  buffer or  diluting milk  in  buffer 
- Extraction  on  chelating Sepharose  column 
- Extraction  on  XAD-2  resin  column 
- Addition  of  5%  mercapto-propionic  acid  as  an  antioxidant 
- End  point  determination  with  HPLC  by  UV  detection at 350  nm. 
- The  amount  of  tetracyclines  is calculated  by  interpolation from  a 
standard  curve  and  taking  into  account  the  recovery  of  tetracyclines, 
especially from  tissue samples. 
6.  CHEMICALS 
6.1.1 
6.1.2 
6.1.3 
6.1.4 
6.1.5 
6.1.6 
6.1.7 
6.1.8 
6.1.9 
6.1.10 
6.1.11 
6.2. 
6.2.1 
6.2.2 
6.2.3 
6.2.4 
6.2.5 
6.3 
6.3.1 
6.3.2 
6.4. 
6.4.1 
6.4.2. 
6.4.3 
Succinic  anhydride  (BDH) 
Sodium  hydroxide  (BDH) 
EDTA  (BDH) 
Methanol,  redistilled  (BDH) 
Ethanol  (Burroughs  Ltd) 
Acetonitrile  (Romil) 
Oxalic  acid  (BDH) 
Chelating  Sepharose,  fast flow  in  20%  ethanol  (Pharmacia) 
Amberlite  XAD-2  (BDH) 
Copper  sulphate 
B-mercaptopropionic  acid 
Solutions  and  Buffers. 
Succinate  Buffer  pH  4.0;  5 g succinic anhydride  dissolved  in 
900  mL  water  adjusted  to  pH  4.0 with  0.1M  NaOH  and  made  up  to 1 L 
water. 
EDTA:Succinate  buffer;  The  succinate  buffer,  (6.2.1),  containing 
37.2  g EDTA  per  L. 
HPLC  Mobile  Phase;  0.01M oxalic acid:acetonitrile 1:1  v/v 
Copper  sulphate  solution;  0.5  g per  L water 
B-mercaptopropionic  acid;  50  g per  L Methanol 
Column  Preparations. 
Chelating  Sepharose;  5 mL  chelating  sepharose  was  thoroughly 
mixed  and  placed  in  200  mm  x 20  mm  i.d.  glass  column.  Excess 
liquid was  run  off.  Aqueous  copper  sulphate  (6.2.4),  20  mL,  was 
passed  through  the  column,  followed  by  succinate  buffer  (6.2.1). 
After  use  the  columns  can  be  stored  in  20%  aqueous  ethanol  at 4°C 
and  may  be  reused  15  times. 
Amberlite  XAD-2;  The  resin was  washed  with  acetone,  methanol  and 
water.  Glass  columns  200  mm  x 20  mm  i.d. were  packed  to  a  bed 
height  of  10  em  with  aqueous  slurry. 
After  use  the  columns  can  be  regenerated  by  washing  with  acetone, 
methanol  and  water. 
Standards 
Tetracycline  (T  3258),  chlortetracycline  (C  4881)  and 
oxytetracycline  (0  5750)  were  obtained  from  Sigma  Chemical  Co. 
Stock  standards;  1 mg  per  mL  tetracycline  in  methanol.  Store  at 
4°C  and  make  fresh  weekly. 
Intermediate  standards;  Dilute  1 mL  stock  to  100  mL  with 
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6.5. 
7. 
7.1 
7.2 
7.3 
7.4. 
7.5 
7.6 
7.7. 
7.8 
7.9 
7.10 
7.11 
8. 
distilled water.  Store  at 4°C  and  make  fresh  weekly. 
Working  standards;  Dilute  1 mL  intermediate  standard  to  10  mL 
with  distilled water.  Final  concentration  is 1 ng  per  ul.  Make 
fresh  daily. 
Spiking  Procedure 
Using  the  working  standards  (6.4.4)  spike  10  g sample  with  100  ul 
and  500  ul  standard  solution.  Allow  to  stand  for  15  minutes. 
EQUIPMENT 
Centrifuge  tubes  250  mL  and  50  mL  capacity. 
Glass  columns  200  mm  x 20  mm  i.d. fitted with  sintered glass frit 
and  stopcock 
Glass  filter funnel  250  mL 
Conical  flasks  250  mL 
Pear  shaped  flasks  50  mL 
Round  bottomed  flasks  250  mL 
Filter paper  (Whatman)  541 
Ultra-Turrax  Homogeniser 
Mixer  (Vortex) 
Rotary  evaporator  - Buchli  with  water  bath  at 40°C 
HPLC-LKB  2150  pump 
Column;  Chromsep  (Chrompack)  cartridge column  assembly  packed 
with  Lichrosorb  RP8  with  integral  (10  mm  x 2.1  mm  i.d.) guard 
column  packed  with  pellicular  (30-40  urn)  reverse  phase. 
Mobile  phase  was  pumped  at 0.4  mL  per  min. 
UV  detection  was  at 350  nm  (0.005  AUFS)  (Severn,  SA6510)  and  the 
chromatogram  recorded  and  integrated using  an  electronic 
integrator  (Spectra  Physics  4290).  10  ~L samples  were  injected 
using  a Waters  Wisp  712. 
SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section 6.3.1  and  ISO  document  78/2-1982  and 
the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection of  residues  in  meat,  as  defined  in  Directive  64/433/EEC  and  also 
in  milk. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large enough  to  allow 
the  reference method  to  be  carried out  and  to  allow  repeat analysis where 
required. 
In  this method  for  tetracyclines the  sizes  shall  not  be  less than 
50  g muscle,  kidney;  50  mL  milk 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to allow 
proper  identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice  the  result of  the  examination. 
Samples  for  the  analysis  of  tetracyclines must  be  stored  and  transported at 
temperatures  below  -18°C. 
Cy  3.8/3 9.  PROCEDURE 
9.1.  10  g milk  or  finely sliced tissue and  40  mL  succinate  buffer were 
placed  in  an  ultrasonic bath  (3  min)  homogenised  (2  min)  and 
centrifuged  (5  min)  at 12,000  r.c.f. 
9.2  Supernatant  was  filtered through  Whatman  541  filter paper. 
9.3  The  stages  9.1  and  9.2  were  repeated  using  the  sediment  instead 
of  tissue. 
9.4.  The  stages  9.1  and  9.2 were  again  repeated  using  the  sediment 
instead  of  tissue and  with  only  20  mL  buffer. 
9.5  The  combined  filtrates were  loaded  onto  the  prepared  chelating 
Sepharose  column  which  was  subsequently washed  with  water  (10 
mL),  methanol  (30  mL)  and  water  (2  x 10  mL).  The  flow  should 
not  exceed  4  mL  per  min. 
9.6  The  tetracyclines were  eluted with  EDTA-succinate  buffer  (40  mL) 
followed  by  a further  10  mL  of  this buffer.  Flow  ca.  4 ml  per 
min. 
9.7  The  combined  eluates were  loaded  directly onto  the  XAD-2  column. 
9.8  The  column  was  washed  with  water  (2  x 100  mL)  and  eluted with 
redistilled methanol  (100  mL  at 4  mL  per  min). 
9.9  The  methanol  was  reduced  to a  small  volume  by  rotary evaporation 
and  the  residue  transferred to a  pear  shaped  flask with 
redistilled methanol  (3  x 2 mL) 
9.10  5%  B-mercaptopropionic  acid  (0.1  mL)  was  added  and  the  methanol 
removed  by  rotary evaporation. 
9.11  The  residue was  dissolved  in  the  HPLC  mobile  phase  (500  ~L) with 
vortexing  and  ultrasonication before  transfer to  a  WISP  vial. 
9.12  HPLC  was  performed  using  10  ul. 
10.  CALCULATION  OF  RESULTS 
10.1.  A calibration curve  is constructed of  peak  height  against 
concentration for a  range  of  standards  from  1 to  20  ng.  The  quantity of 
each  of  the  tetracylines  in  each  sample  injection  is then  calculated from 
the  measured  peak  height.  This  figure  is then  corrected  for  injection 
volume  and  mean  % recovery  (calculated from  spiked  samples)  to  give  a 
concentration  in  mg/kg  (ppm).  The  standard  injection of  10  ul  is 
equivalent  to 0.2  g of  extracted sample. 
Retention  times  are  normally  of  the  order;  oxytetracyline,  6 min, 
tetracycline,  8 min,  chlortetracycline 10  min. 
amount  of  tetracycline found  x 100 
% recovery  = ---------------
amount  of  Spike  added 
Concentration  of  tetracycline  in  sample  (mg/kg)  = 
~g tetracycline  (from  calibration curve)  1  100 
--------------------------- X --- X ---------
1000  0. 05  % recovery 
For  samples  containing  tetracyclines at concentrations  beyond  the  range  of 
the  standard  curve,  a dilution of  the  extract  is prepared  and 
chromatographed,  and  the  appropriate  volumetric  correction  is  applied. 
Cy  3.8/4 10.2.  SENSITIVITY 
The  minimum  limit of  determination  of  tetracyclines  by  this method  is 
0.01  mg/kg. 
10.3.  RECOVERIES 
Recoveries  determined  at MAFF,  Norwich  (mean±  SO)  of  added  tetracyclines 
to  twelve  pig  kidneys  were;-
Spike 
0.01  mg  per  kg 
0.05  mg  per  kg 
Oxytetracyline 
80  ±  7 
75  ±  7 
11.  SPECIAL  CASES. 
12.  NOTES  ON  PROCEDURE. 
13.  SAMPLE  CONTROLS 
Tetracycline  Chlortetracycline 
72  ±  7  87  ±  15 
63  ± 6  73  ±  8 
It is convenient  to  analyze  5 or  7 tissue samples  plus  1 spiked  quality 
control  blank  sample  in  each  batch.  The  sample  numbers  depend  on  the 
centrifuge  head  capacity. 
*The  blank  sample  was  obtained  from  a  sample  previously analyzed  and  found 
to  contain  no  tetracyclines. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS. 
See  abbreviations  in  Annex  I,  Section  12  of  Manual. 
16.  FLOW  DIAGRAM 
Tissue  --~ add  buffer  ---------------~ Homogenise 
I 
Milk 
I 
I 
! 
I 
I 
I 
I 
I 
I 
I 
! 
add  buffer ---------------------->  Sepharose  chelating  column 
I 
I 
I 
I 
! 
Calculate  ~----- HPLC  <---- B-mercapto  <----XAD-2  column 
results  propionic  acid 
Cy  3.8/5 Cy  3.9.  NITROFURANS  - HPLC  ANALYSIS  WITH  A DIALYSIS  METHOD  FOR 
DETERMINING  RESIDUES  OF  NITROFURANS  IN  EGGS,  MILK  AND  MEAT. 
WARNING  AND  SAFETY  PRECAUTIONS 
SAFETY 
Organic  solvents  - all organic  solvents  must  be  treated as  potentially 
hazardous  and  all  procedures  using  them  must  be  performed  in  a  fume 
cupboard. 
0.  INTRODUCTION 
Nitrofurans  (here  furazolidone,  nitrofurazone,  nitrofurantoin  and 
furaltadone)  are  antibacterial  agents  used  in  pigs  and  poultry. 
1.  SCOPE 
This  work  is carried out  in  compliance  with  the  Residues  Directive 
(86/469/EEC). 
2.  FIELD  OF  APPLICATION. 
This  method  is used  for  determining  the  presence  of  nitrofurans  in  eggs, 
meat  or  milk.  The  method  is operated  at RIKILT  in  the  Netherlands,  as  a 
routine monitoring  method  analyzing  about  30  samples  per  day.  It can  be 
used  as  a confirmatory method.  The  limits of  determinations  range  from  1-
10  ~g per  kg  of  matrix  for  Nitrofurans. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
2052/VI/84  File 6.11  11-4,  Scientific Veterinary Committee,  Working 
Group-
11Reference  Methods  for Residues .. ,  General  Criteria for  the 
establishment  of  Reference  Methods  for  the  Detection  of  Residues. 
ISO  Standard  78/2-1982  Layout  for  standards  - Part  2:  Standard  for Chemical 
Analysis 
ISO  Standard  5725  (1986) 
Aerts,  M.M.L.,  Beek,W.M.J.  and  Brinkman,  U.A.Th.,  (1990),  On-line 
combination  of  dialysis and  column-switching  liquid  chromatography  as  a 
fully automated  sample  preparation  technique  for  biological  samples. 
Determination  of  nitrofuran  residues  in  edible products.  J.Chromatogr. 
500,  453-468 
4.  DEFINITIONS. 
Nitrofurans  content  is taken  to mean  the  amount  of  nitrofurans  in  eggs, 
milk  or  meat  determined  according  to  the  described  method  and  expressed  as 
~g nitrofurans  per  kg  test sample. 
Cy  3.9/1 5.  PRINCIPLE. 
The  method  comprises  four  stages  all  carried out  in  the  absence  of  daylight 
or  white  light. 
- Samples  of  decreamed-milk  are  mixed  in  saline.  Meat  and  eggs  are 
homogenised  in  saline 
- Centrifugation 
- purification of  the  supernatant extract by  dialysis 
- quantification  by  high  performance  liquid chromatography  (HPLC)  with  UV 
detection  at 365  nm. 
6. 
6.1. 
6.1.1 
6.1.2 
6.1.3 
6.1.4 
6.1.5 
6.1.6. 
6.1.7. 
6.1.8. 
6.2. 
6.2.1. 
6.2.2. 
6.2.3. 
6.2.4. 
6.2.5. 
6.3. 
6.3.1. 
6.3.2. 
7. 
7.1. 
7.1.1 
7.1.2 
7.1.3 
7.1.4 
7.2. 
7.2.1. 
MATERIALS 
Chemicals 
Sodium  chloride 
Methanol,  Analytical  grade 
Acetone,  Analytical  grade 
Acetonitrile,  HPLC  grade 
Sodium  azide 
Sodium  acetate 
Glacial  acetic acid 
Demineralised  water,  filtered on  Milli-Q  purification system 
(Millipore,  Milford,  USA) 
Solutions 
0.9%  NaCl  in  water  (6.1.8). 
1%  sodium  azide  in  water  (6.1.8.) 
10%  sodium  azide  in  water  (6.1.8.) 
0.1M  sodium  acetate - acetic acid  buffer;  pH  5.0. 
HPLC  eluent;  Mix  800  mL  of  acetate buffer  (6.2.4)  with  200  mL 
acetonitrile (6.1.4.) 
Nitrofuran  Standards 
Furazolidone,  nitrofurazone,  nitrofurantoin  and  furaltadone  were 
obtained  from  Sigma,  USA. 
Standard  solution;  100  ~g/mL nitrofurans  in  acetone:methanol, 
1:1  v/v. 
Store  at 4°C  in  the  dark.  Stable for  maximum  period  of  at least 
one  month. 
Working  Standards  are  10  ~g nitrofuran  per  mL  saline  (6.2.1). 
They  should  be  prepared  fresh  daily. 
EQUIPMENT 
Glassware 
Graduated  pipettes, 
Glass  centrifuge tubes 
Glass  test tubes  to take  6 mL  samples. 
Normal  laboratory glassware 
Apparatus 
Automatic  pipettes, 
Cy  3.9/2 7.2.2.  Analytical  balance 
7.2.3.  Refrigerated  centrifuge 
7.2.4.  Refrigerator at <-18°C 
7.2.5.  Vibromixer 
7.3.  Dialysis  Equipment 
An  autosampler-dialysis  module  is a modified  Gilson  ASTED  system  consisting 
of  a Model  231  autosampling  injector,  two  Model  401  diluters equipped  with 
5 mL  and  1 mL  syringes  and  two  poly(methyl  methacrylate)  flat-plate 
dialyser blocks  and  fitted with  a Cuprophan  membrane  (10,000-15,000  Daltons 
cut-off)  having  donor  volumes  of  100  ~L and  370  ~L and  acceptor  volumes  of 
175  ~L and  650  ~L,  respectively. 
The  selection and  arrangement  of  the  blocks  depends  on  the  volume  of 
material  available for  analysis. 
7.4  HPLC  equipment 
A constant  pulseless-flow  pump  (Gilson  Medical  Electronics,  Model  302/5), 
with  a Kratos  Spectroflow  783  absorbance  detector set at 365  nm,  0.001 
a.u.f.s.,  a rise time  of  5 sec  and  an  automatic  six-port valve  (Model  7010, 
Rheodyne,  USA)  mounted  either on  a  switching-valve module  (Must,  Spark, 
Emmen,  NL)  or  on  an  autosampling  injector  (Model  231,  Gilson). 
Chromatographic  peaks  are  recorded  with  an  integrator  (Chromatopac  C-R2A, 
Shimadzu,  Japan)  or  a  Kipp  DD-U1  recorder.  All  timed  events  are  controlled 
by  the  ASTED  controller.  The  precolumn  used  is 60  mm  x 4.6  mm  i.d.  column 
fitted with  20  urn  frits and  containing  37-50  urn  Bondapak  C 18/Corasil 
(Millipore).  The  column  is a  250  mm  x 4.6  mm  i.d.  column  containing  5  urn 
Hypersil  ODS  (Chrompack,  Middelburg,  NL).  The  flow  rate of  the  eluent 
(6.2.5)  was  1 mL  per  min. 
7.5.  Homogeniser,  Model  400  Stomacher  laboratory blender,  (Lameris, 
NL) 
7.6.  Light  sealed  room  lit by  yellow  light. 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is  drawn  to  section  6.3.1  and  ISO  document  78/2-1982  and 
the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  of  meat,  milk  and  eggs  shall  be  such 
as  to  enable  the  detection of  residues.  Only  samples  which  are  not  spoiled 
by  bacteria may  be  examined. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large enough  to allow 
the  reference  method  to  be  carried out  and  to  allow  repeat  analysis where 
required. 
8.3.  The  samples  must  be  cooled  after collection and  stored  at~ -20°C 
pending  analysis. 
9.  PROCEDURE 
9.1.  Thaw  the  sample. 
9.2.  Raw  milk  - samples  are  decreamed  by  centrifugation  (10  min,  2000 
g}  and  subsequent  freezing  (15  min  at -20°C).  An  aliquot  (10  mL) 
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9.4. 
9.5. 
[Note; 
9.5.1 
9.6. 
10. 
10.1 
10.2 
is diluted with  10  ml  of  saline solution  (6.2.1)  and  2 ml  of  1% 
sodium  azide  (6.2.2). 
Meat  - 10  g of  homogenised  meat  is blended  for  3 min  in  a 
Stomacher  (7.5)  with  30  mL  saline  (6.2.1).  After  centrifugation 
(2000  g),  20  mL  of  the  clear upper  phase  are  isolated and  mixed 
with  2 mL  1%  sodium  azide  (6.2.2). 
Eggs  - 10  g of  homogenised  whole  egg  is diluted with  10  mL  saline 
(6.2.1)  and  3 mL  of  10%  sodium  azide  solution  (6.2.3). 
Dialysis  - Aliquots  of  diluted  solutions  9.2,  9.3 or  9.4  are 
injected  into  the  dialysis module.  The  maximum  of  about  4  mL  of 
sample  can  be  introduced either as  a  continuously flowing 
injection or  divided  into multiple  pulsed  injections.  During  the 
dialysis the  dialyser acceptor  stream  (water)  is continuously 
transported with  a  second,  1  mL  syringe,  diluter and  successive  1 
mL  volumes  of  the  dialysate are  led  to  the  trace enrichment 
column.  After  application of  the  total  dialysate,  the  enrichment 
column  can  be  flushed  with  acceptor  stream  solvent  and,  after 
switching  of  the  automatic  six-port valve,  back-flushed  to  he 
analytical  column  with  the  HPLC  eluent  (6.2.5). 
The  dialyser donor  and  acceptor  channels  are  then  flushed  with 
water  (6.1.8.),  the  six port valve  returned  to  its original 
position  and  the  enrichment  column  is regenerated with  water.] 
Configuration  of  Dialysis  Blocks. 
RIKILT  uses  a  pulsed  dialysis mode  in  which  two  dialyser blocks 
are fitted  in  series having  donor  volumes  of  2 x 370  ~L and 
acceptor  volumes  of  2 x 650  ~L.  A 4 mL  sample  is  injected as 
five  750  ~L pulses  and  one  250  ~L pulse.  The  final  pulse 
consisted of  500  ~L of  the  already dialysed fifth pulse  and  the 
remaining  250  ~L sample  extract.  The  first five  samples  are 
statically dialysed for  3 min  at an  acceptor  flow-rate  of  0.36  mL 
per  min,  giving  a  dialyser efficiency of  about  30%.  The  final 
pulse  is dialysed for  9 min  at the  same  acceptor  flow-rate. 
Using  this prolonged  dialysis time,  the  last 2 mL  of  acceptor 
solvent  are  essentially free from  matrix  components,  and  can  be 
used  to flush  the  precolumn.  The  total  acceptor  volume  that  is 
led  over  the  precolumn  is about  8.6 mL.  After  application of 
this volume,  the  precolumn  is backflushed  for  about  5 min  with 
HPLC  eluent  (6.2.5)  and  the  enriched  analytes  are  separated  on 
the  analytical  column. 
Blank  samples  and  spiked  blank  samples  are  run  as  quality 
controls  and  to  provide  a  standard  curve.  The  spiked  samples  are 
prepared  by  injecting 1 - 100  ~L of  aqueous  standard  solutions 
(6.1.13.2)  into  the  raw  samples. 
CALCULATION  OF  RESULTS 
Derive  the  calibration curve  using  the  results for  the  spiked 
blank  samples  (9.6)  and  check  the  linearity of  the  detector 
response. 
The  mean  recoveries  observed  at RIKILT  are measured  for  spiked  (5 
~g per  kg)  samples  compared  with  the  same  spikes  in  saline.  The 
results are  shown  in  table 1. 
Cy  3.9/4 Table  1.  Limits  of  Determination  (LD)  and  Recoveries. 
Drug  Meat  (veal,  chicken) 
LD  Recovery 
(ug/kg)  %  CV% 
Nitrofurazone  2  76  1.7 
Nitrofurantoin  2  75  2.6 
Furazolidone  2  89  2.2 
Furaltadone  5  86  4.0 
(data  from  Aerts  et al., 1990.) 
LD 
(ug/kg) 
1 
1 
1 
3 
Eggs 
Recovery 
%  CV% 
85  4.1 
76  2.0 
88  4.8 
86  6.5 
10.3  Calculate  the  concentration  of  nitrofuran  present  in  the  samples  to 
be  analyzed  using  the  calibration curve  obtained  for  spiked  blank 
samples  and  taking  into  account  the  possible dilution. 
10.4.  Specificity;  The  chromatograms  corresponding  to  the  extracts of 
blank  samples  of  eggs,milk  and  meat  do  not  reveal  significant 
interference at the  retention  time  of  the  four  nitrofurans. 
Furthermore  the  most  common  used  antimicrobials  and  cocccidiostats  do 
not  interfere. 
10.5  Limits  of  detection  and  determination. 
Limit  of  detection  (ug/kg)  Limit  of  determination 
(ug/kg) 
eggs  meat  eggs  meat 
Nitrofurazone  0.5  1.0  1  2 
Nitrofurantoin  0.5  1.0  1  2 
Furazolidone  0.5  1.0  1  2 
Furaltadone  1.5  2.5  3  5 
(Data  from  H.  Keukens,  RIKILT) 
10.6.  Precision.  The  CVs  for  the  recoveries  of  spikes  from  eggs,  milk  and 
meat  are  shown  in  table 1. 
11.  SPECIAL  CASES. 
12.  NOTES  ON  PROCEDURE. 
NITROFURANS  DECOMPOSE  IN  WHITE/DAY  LIGHT.  IT  IS  ESSENTIAL  THAT  ALL 
PROCEDURES  ARE  CARRIED  OUT  IN  THE  ABSENCE  OF  DAYLIGHT  AND  WHITE  LIGHT. 
13.  SAMPLE  CONTROLS 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS. 
See  abbreviations  in  Annex  I,  Section  12  of  Manual. 
16.  FLOW  DIAGRAM 
MILK,  EGGS,  MEAT  ---------->  SALINE  EXTRACT  ------>  DIALYSIS 
-------->  HPLC  ------->  CALCULATE  RESULTS 
Cy  3.9/5 Cy  4.1.  BENZIMIDAZOLES  - DETERMINATION  OF  BENZIMIDAZOLES  AT  RESIDUE  LEVELS 
IN  ANIMAL  TISSUES  AND  MILK. 
WARNING  AND  SAFETY  PRECAUTIONS 
0.  INTRODUCTION 
The  benzimidazoles  are  a  group  of  substances  with  the  common  benzimidazole 
structure,  they  include  Oxfendazole,  Fenbendazole,  Cambendazole, 
Thiabendazole,  and  Albendazole.  Febantel  is a  pro-drug  which  is rapidly 
cyclised  in  the  animal  to  benzimidazole  type  compounds.  Benzimidazoles  are 
anthelmintics  used  for  the  protection  and  cure  of  internal  worm  parasites 
in  food  producing  animals.  Benzimidazoles  are  administered  orally as 
solutions,  suspensions  or  pellets. 
The  MRL  set  in  the  EEC  for  Benzimidazoles  are  listed  in  section  2. 
1.  SCOPE 
This  method  of  analysis  describes  the  determination  of  the  content  of 
Benzimidazoles  in  samples  of  animal  origin. 
2.  FIELD  OF  APPLICATION. 
The  method  was  developed  for monitoring  milk  and  liver tissue.  The  limit of 
determination  following  validation of  the  method  is 0.02  mg/kg  of  sample  or 
0.02  mg  per  L milk  for  Benzimidazoles. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  N 2 
L.118,  14.4.93.  pp  64-74] 
ISO  Standard  78/2-1982  Layout  for  standards  - Part 2:  Standard  for Chemical 
Analysis 
MAFF,  1989,  Determination  of  Benzimidazoles  at residue  levels  in  animal 
tissues and  milk.  Food  Science  Laboratory,  Colney  Lane,  Norwich.  Standard 
Operating  Procedure. 
Marti,  A.M.,  Mooser,  A.E.  and  Koch,  H.  (1990),  Determination  of 
benzimidazoles  anthelmintics  in  meat  samples.  J.  Chromatogr.  498,  145-157 
4.  DEFINITIONS. 
Benzimidazoles  content  is taken  to mean  the  amount  of  Benzimidazoles  in  the 
substance  in  question,  regardless of  the  chemical  form,  determined 
according  to  the  described  method  and  expressed  as  ~g or  mg  Benzimidazoles 
per  kg  or  L of  test sample. 
5.  PRINCIPLE 
The  methods  comprises  6 stages;-
Homogenisation  of  tissue samples  in  buffer 
- Extraction with  organic  solvent 
- Clean-up  on  solid phase  Silica column. 
Cy  4.1/1 - Extraction  on  reverse  phase  C18  column 
- End  point  determination  with  HPLC  by  fluorescent  UV  detection  (see  note 
on  GC-MS  verification) 
- The  amount  of  Benzimidazoles  is calculated  by  interpolation from  a 
standard  curve  and  taking  into  account  the  recovery of  Benzimidazoles, 
especially from  tissue samples. 
Note;  In  the  method  developed  at the  Swiss  Federal  Veterinary Office, 
Berne,  by  Marti  et al,  (1990),  positive results obtained  by  HPLC  were 
verified using  GC-MS  after forming  the  methyl  or  pentaflourobenzyl 
derivatives of  the  benzimidazoles. 
6.  CHEMICALS 
6.1.1 
6.1.2 
6.1.3 
6.1.4 
6.1.5 
6.1.6 
6.1.7 
6  .1.8 
6.1.9 
6.1.10 
6.1.11 
6.2. 
6.2.1 
6.2.2. 
6.2.3 
6.2.4. 
6.3. 
6.3.1. 
6.3.2. 
6.3.3. 
6.3.4. 
6.3.5. 
6.3.6 
6.3.6.1 
6.3.6.2 
6.5. 
Chloroform  (BDH) 
Acetone  (BDH) 
Sodium  hydroxide  0.1N  AVS  (BDH) 
Methanol,  redistilled  (BDH) 
Acetic  anhydride  (Sigma) 
Acetonitrile  HPLC  Grade  (Romil) 
Ethyl  acetate  (May  &  Baker) 
Hexane  (BDH), 
Toluene  (BDH) 
Potassium  dihydrogen  orthophoshate  (BDH) 
Ammonium  carbonate  (BDH) 
Solutions 
0.25M  phosphate  buffer,  pH  7.0  ;  34  g potassium  dihydrogen 
orthophoshate  was  dissolved  in  900  mL  water.  The  pH  was  adjusted 
to  7.0  with  0.1M  sodium  hydroxide  and  the  volume  made  up  to 1 L. 
0.1M  ammonium  carbonate;  15.7  g of  ammonium  carbonate  was 
dissolved  in  1 L water. 
60%  hexane  in  chloroform;  Mix  60  mL  of  hexane  and  40  mL 
chloroform. 
HPLC  Mobile  Phase;  400  mL  methanol  was  added  to  600  ml  0.1M 
ammonium  carbonate.  The  solution was  mixed  and  passed  through  a 
"Durapore  ..  filter,  assisted by  vacuum.  The  mobile  phase  was 
degassed  using  ultrasonication  and  with  reduced  pressure. 
Standards 
Benzimidazoles  reference  standards were  -
Thiabendazole  (Merck,  Sharpe  and  Dohme  Ltd.) 
Albendazole  (Smith,  Kline  and  French) 
Oxfendazole  (Syntex) 
Cambendazole  (Merck,  Sharpe  and  Dohme  Ltd.) 
Stock  standards;  5 mg  Benzimidazoles  in  100  mL  methanol.  Store 
at 4°C  and  make  fresh  monthly. 
Working  standards; 
Dilute 1  mL  stock  to  100  ml  with  methanol.  Final  concentration  is 
0.5  ~g per  mL.  Store at 4°C  and  make  fresh  weekly. 
Dilute 0.5  ml  stock  to  100  ml  with  methanol.  Final  concentration 
is 0.25  ~g per  ml.  Make  fresh weekly 
Spiking  Procedure 
Using  separately the working  standards  (6.3.6.1  &  6.3.6.2)  spike 
5 g sample  with  1 mL  of  solution.  Allow  to  stand  for  15  minutes. 
Cy  4.1/2 7. 
7.1 
7.2 
7.3 
7.4. 
7.5 
7.6 
7.7. 
7.8 
7.9 
7.10 
7.11. 
7.12. 
7.13. 
7.14. 
7.15. 
7.16. 
7.17. 
7.18. 
7.19. 
7.19.1. 
7.19.2. 
7.19.3. 
7.19.4. 
7.19.5. 
7.20 
8. 
EQUIPMENT 
Centrifuges  tubes  100  mL  capacity,  plastic. 
Glass  filter funnel  - 77  mm  diameter 
All  glass filter holder,  47  mm  - Millipore. 
Glass  sample  bottles,  5 mL  & 25  mL 
Pear  shaped  flasks  50  mL  and  100  mL 
Glass  reactivials 3 mL  with  PTFE  lined  screw  caps. 
Glass  syringes,  1 mL  and  10  mL 
Ultra-Turrax  Homogeniser 
Mixer  (Vortex) 
Rotary  evaporator  - Buchli  with  water  bath  at 40°C 
Vials,  low  volume  for  autosampler 
Syringes  1 mL  plastic disposable 
Centrifuge  - IEC  Centra-7R  or  equivalent 
Ultrasonic  bath- L&R  140S  or  equivalent 
Adjustable  pipettes 5 mL 
Filter paper,  15  em,  phase  separation  - Whatman  PS-1 
Membrane  filter holder  - Millipore  Swinney  Stainless,  13  mm 
Membrane  filters,  13  mm  and  47  mm  - Millipore  Ltd. 
Solid  Phase  Extraction 
Vacuum  Manifold  - Vac-Elut 
C18/500  mg  cartridges - Bond-Elut,  Jones  Chromatography  Ltd. 
Silica 500  mg  cartridges  - Bond-Elut,  Jones  Chromatography  Ltd. 
Cartridge  taps  - Jones  Chromatography  Ltd. 
Reservoirs  50  mL  for  cartridges - Jones  Chromatography  Ltd. 
HPLC  LKB  2150  pump 
Column;  20  em  x 3 mm  i.d.  Chromsep  (Chrompack)  cartridge column 
assembly  packed  with  Chromspher  C8  with  integral  (10  mm  x 2.1  mm 
i.d.) guard  column  packed  with  pellicular  (30-40  urn)  reverse 
phase. 
Mobile  phase  was  pumped  at 0.4  mL  per  min. 
The  fluorescence  detector was  a Perkin  Elmer  LS4  with  the 
excitation wavelength  312  nm,  slit width  10  nm,  and  the  emission 
wavelength  at 355  nm,  slit width  10  nm. 
The  chromatogram  was  recorded  and  integrated using  an  electronic 
integrator  (Spectra  Physics  4290).  20  ~L samples  were  injected 
using  a Waters  Wisp  712. 
SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section  6.3.1  and  ISO  document  78/2-1982  and 
the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to  enable  the 
detection of  residues  in  meat,  as  defined  in  Directive  64/433/EEC  and  also 
in  milk. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to  allow 
the  reference method  to  be  carried out  and  to allow  repeat  analysis where 
required. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to  allow 
proper  identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice  the  result of  the  examination. 
Cy  4.1/3 Samples  for  the  analysis  of  Benzimidazoles  must  be  stored  and  transported 
at temperatures  below  -18°C. 
9.  PROCEDURE 
9.1.  5 g finely sliced tissue or  5  mL  milk  and  15  mL  acetonitrile were 
placed  into a  centrifuge tube. 
9.2.  25  mL  ethyl  acetate were  added  and  the  mixture  was  homogenised  (4 
min)  and  centrifuged  (5  min)  at 2,500  rpm. 
9.3  The  supernatant  was  filtered through  the  phase  separating  paper 
containing  sodium  sulphate,  into  a  100  mL  pear  shaped  flask. 
9.4  Steps  9.2  and  9.3 were  repeated. 
9.5.  The  pooled  filtrates were  reduced  to about  1 mL  by  rotary 
evaporation  (7.10). 
9.6.  The  residue was  transferred to  a  pre-conditioned  Bond-Elut  Silica 
cartridge using  3 x 2  mL  60%  hexane  in  chloroform. 
The  Silica  Bond-Elut  columns  were  conditioned  by  drawing  through 
5  mL  60%  hexane  in  chloroform.acetonitrile. 
9.7.  The  cartridge was  allowed  to  dry  and  then  washed  through  with  2 
mL  toluene  and  air dried. 
9.8.  The  benzimidazoles  were  eluted with  10  mL  acetone. 
9.9.  The  acetone  was  removed  by  rotary evaporation  and  the  residue 
transferred  in  10%  methanol  in  water  (3  x 2 mL). 
9.10.  After  allowing  the  column  to  dry  the  benzimidazoles  were  eluted 
with  10  mL  acetonitrile  into  glass  sample  bottles  (7.4). 
9.11  The  eluate was  transferred to a  50  mL  pear-shaped  flask  using  2 x 
2  mL  acetonitrile rinses. 
9.12  The  organic  phase  was  evaporated  to  dryness  using  a rotary 
evaporator with  a water  bath  set at 40°C. 
9.13  The  residue was  redissolved  in  1 mL  HPLC  mobile  phase. 
9.14  Standards  for  Calibration Curve. 
The  standard  additions  are  done  at this stage  (9.7)  for  the 
preparation  of  a  standard  curve  over  the  range  0 - 5  ~g per  kg. 
9.15  HPLC  was  performed  using  20  ~L. 
10.  CALCULATION  OF  RESULTS 
10.1.  A calibration curve,  0 - 5  ~g,  is constructed  of  peak  height 
against concentration  for  a  range  of  standards.  The  quantity of  each  of 
the  Benzimidazoles  in  each  sample  injection  is  then  calculated from  the 
measured  peak  height.  This  figure  is then  corrected for  injection  volume 
and  mean  % recovery  (calculated from  spiked  samples)  to  give  a 
concentration  in  mg/kg  (ppm).  The  standard  injection of  20  ~L  is 
equivalent  to  100  mg  or  mL  of  extracted  sample. 
% recovery  =  amount  of  Benzimidazoles  found  x 100 
amount  of  Spike  added 
Concentration  of  Benzimidazoles  in  sample  (mg/kg)  = 
ug  Benzimidazoles  (from  calibration curve)  x _1  ___  x  100 
1000  0.05  % recovery 
For  samples  containing  Benzimidazoles  at concentrations  beyond  the  range  of 
the  standard  curve,  a dilution of  the  extract  is prepared  and 
chromatographed, 
and  the  appropriate  volumetric  correction  is applied. 
Cy  4.1/4 10.2.  SENSITIVITY 
The  minimum  limit of  determination  of  Benzimidazoles  by  this method  is 
0.02  mg/kg  for  all  four  benzimidazoles  in  all  tissue types. 
10.3.  QUALITY  ASSURANCE  PROCEDURES. 
10.3.1.  Validation;  Batches  of  up  to  six blank  samples  are  spiked  at the 
0.05  or  0.1  mg  per  kg  level  for all  the  four  benzimidazoles  and  extractions 
are  performed  on  each  of  three consecutive  days.  Each  batch  comprised  the 
following  samples;-
2 blanks;  2 standard  additions  at 0.05  mg  per  kg; 
2 standard  additions  at 0.1  mg  per  kg;  6 spikes  at 0.05  or  0.1  mg  per  kg. 
Recovery  of  the  analyte  should  fall  within  60-90%.  CV  values  should  fall 
within  the range  5-15%  for  inter and  intra batch  precision. 
10.3.2.  Examples  of  quality assurance  data  obtained  at MAFF,  Norwich. 
MILK; 
Recovery  of  benzimidazoles  from  milk  measured  at  level  of  10  ~g per  L in  3 
samples  on  day  1,  5 samples  on  day  2 and  4 samples  on  day  3 
Albendazole  sulphone, 
Oxfendazole, 
LIVER; 
77  ~ 3%  CV=4%,  Thiabendazole, 
70  ~  4%  CV=6%,  Cambendazole, 
53  +  6%  CV=11% 
52  ~  6%  CV=12% 
Recovery  of  benzimidazoles  from  liver measured  at  level  of  20  ~g per  kg  in 
6 samples  per  day  for  3 consecutive  days. 
Albendazole  sulphone,  90  ~ 10% 
Oxfendazole,  71  ~ 9% 
11.  SPECIAL  CASES. 
CV=11%, 
CV=13%, 
Thiabendazole, 
Cambendazole, 
77  +  5%  CV=7% 
82  ~ 13%  CV=13% 
In  samples  in  which  a positive  is suspected,  further  confirmatory evidence 
may  be  obtained  by  comparison  of  the  stopped-flow  analysis of  the  emission 
spectra of  the  suspect  peaks. 
For  bovine  milk  samples  thiabendazole  is not  excreted  as  the  parent  drug 
and  can  be  used  as  an  internal  standard. 
12.  NOTES  ON  PROCEDURE. 
It is convenient  to analyze  up  to  ten  samples  per  batch  per  day  with  HPLC 
overnight.  A batch  would  include  unknowns,  plus  spiked  quality control 
samples. 
13.  SAMPLE  CONTROLS 
The  blank  samples  were  obtained  from  a sample  previously analyzed  and  found 
to  contain  no  Benzimidazoles. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS. 
See  abbreviations  in  Annex  I,  section  12  of  Manual. 
16.  FLOW  DIAGRAM 
Tissue  --~ add  ethyl  acetate---------~ Homogenise  ------>  Si  column 
I 
I 
! 
Calculate results <---- HPLC  <------- C18  column 
Cy  4.1/5 Cy  4.2.  LASALOCID  - DETERMINATION  OF  LASALOCID  AT  RESIDUE  LEVELS  IN 
POULTRY  MUSCLE  AND  POULTRY  EGGS. 
WARNING  AND  SAFETY  PRECAUTIONS 
0.  INTRODUCTION 
Lasalocid  is an  ionophore  antibiotic that  is used  as  a  growth  promoter  in 
cattle and  as  a coccidiostat  in  poultry. 
1.  SCOPE 
This  method  of  analysis  describes  the  determination  of  the  total  content  of 
Lasalocid  in  samples  of  poultry origin. 
2.  FIELD  OF  APPLICATION. 
The  method  can  be  used  for  poultry muscle  and  poultry eggs.  The  limit of 
determination  following  validation of  the  method  when  confirmed  by  stop-
flow  analysis of  the emission  spectra  is 10  ~g/kg of  sample  for  Lasalocid. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
2052/VI/84  File 6.11  II-4,  Scientific Veterinary Committee,  Working 
Group- "Reference  Methods  for  Residues",  General  Criteria for  the 
establishment of  Reference  Methods  for  the  Detection  of  Residues. 
ISO  Standard  78/2-1982  Layout  for  standards  - Part  2:  Standard  for  Chemical 
Analysis 
MAFF,  1989,  Determination  of  Lasalocid  at residue  levels  in  poultry muscle 
and  eggs.  Food  Science  Laboratory,  Colney  Lane,  Norwich.  Standard 
Operating  Procedure. 
4.  DEFINITIONS. 
Lasalocid  content  is taken  to  mean  the  amount  of  Lasalocid  in  the  substance 
in  question,  regardless of  the  chemical  form,  determined  according  to the 
described  method  and  expressed  as  ~g or  mg  Lasalocid  per  kg  of  test sample. 
5.  PRINCIPLE 
The  methods  comprises  6 stages;-
- Homogenisation  of  tissue samples  in  buffer 
- Extraction with  organic  solvent 
- Extraction  on  Solid  phase  Silica column 
- End  point  determination  with  HPLC  by  fluorescent  UV  detection 
- The  amount  of  Lasalocid  is calculated  by  interpolation from  a  standard 
curve  and  taking  into  account  the  recovery  of  Lasalocid,  especially from 
tissue samples. 
6.  CHEMICALS 
Cy  4.2/1 6.1.1 
6.1.2 
6.1.3 
6.1.4 
6.1.5 
6.1.6 
6.1.7 
6.1.8 
6.2. 
6.2.1 
6.2.2. 
6.2.3. 
6.3. 
6.3.1 
6.3.2. 
6.3.3 
6.3.4 
6.3.4.1 
6.3.4.2 
6.5. 
7. 
7.1 
7.2 
7.3 
7.4. 
7.5 
7.6 
7.7. 
7.8 
7.9 
7.10 
7.11. 
7.12. 
7.13. 
7.14. 
7.15. 
7.16. 
7.17. 
7.18. 
7.19. 
7.20. 
7.20.1. 
Chloroform  - redistilled  (May  & Baker) 
Carbon  Tetrachloride  - Glass  distilled grade  (Rathburn) 
Sodium  chloride  (BDH) 
Methanol,  redistilled  (FSA) 
Sodium  sulphate  anhydrous  (BDH) 
Acetonitrile  (Rathburn  HPLC  Grade) 
Hexane  (Rathburn) 
1,1,3,3-tetramethylguanidine - redistilled  (Aldrich) 
Solutions 
Saturated  sodium  chloride;- Sodium  chloride dissolved  in  water  to 
saturation. 
5%  methanol  in  chloroform;- 5 ml  methanol  made  to  100  mL  with 
chloroform 
HPLC  Mobile  Phase;  5 ml  1,1,3,3-tetramethylguanidine diluted to 
1 L with  acetonitrile. 
Standards 
Lasalocid  reference  standard  was  obtained  from  Sigma  Chern  Co. 
Stock  standards;  50  mg  Lasalocid  in  250  ml  methanol.  Store  at 
4°C  and  make  fresh  monthly. 
Intermediate  standards;  Dilute  1 mL  stock  to  10  ml  with 
methanol.  Store  at 4°C  and  make  fresh  daily. 
Working  standards; 
Dilute 0.2  ml  intermediate  standard  to  10  ml  with  HPLC  mobile 
phase.  Final  concentration  is 0.4  ~g per  ml.  Make  fresh  daily. 
Dilute  1 ml  working  standard  (6.3.4.1)  to  10  ml  with  HPLC  mobile 
phase.  Final  concentration  is 0.04  ~g per  ml.  Make  fresh  daily. 
Spiking  Procedure 
Using  the working  standards  (6.3.4)  spike  5 g sample  with  50  ul 
and  125  ul  standard  solution.  Allow  to  stand  for  15  minutes. 
EQUIPMENT 
Centrifuges  tubes  100  ml  capacity 
Separating funnels,  250  ml  capacity 
All  glass filter holder,  47  mm  - Millipore. 
Test  tubes  - 125  x 16  mm  (  to fit vacuum  Manifold) 
Pear  shaped  flasks  25  ml 
Round  bottomed  flasks,  250  ml  capacity 
Glass  pipettes,  1 ml  and  10  ml  graduated 
Ultra-Turrax  Homogeniser 
Mixer  (Vortex) 
Rotary  evaporator  - Buchli  with  water  bath  at 50°C 
Vials  2 ml  and  0.3  ml  volume  for  autosampler 
Disposable  syringes  1 ml  capacity 
Centrifuge  - IEC  Centra-7R  or  equivalent 
Ultrasonic  bath- L&R  140S  or  equivalent 
Adjustable  pipettes 200  ~L and  1000  ~L 
Multipart  nitrogen  evaporator with  heater  block  (40°C)  for 
reactivials. 
Membrane  filter holder  - Millipore  Swinney  Stainless,  13  mm 
Membrane  filters,  13  mm  and  47  mm  - Millipore  Ltd. 
Filter paper  15  em,  type  PS-1  Whatman 
Solid  Phase  Extraction 
Vacuum  Manifold  - Spe-ed  mate  30  (Applied  Separations) 
Cy  4.2/2 7.20.2.  Bond-Elut  Silica cartridges,  500  mg/2.8  mL  - (Jones 
Chromatography  Ltd.) 
7.20.3  Bond-Elut  adaptors  (Jones  Chromatography  Ltd.) 
7.20.4  Bond-Elut  Reservoirs  75  mL  for  cartridges - (Jones  Chromatography 
Ltd.) 
7.20.5  The  columns  were  washed  with  5 mL  hexane  before  use. 
7.21  HPLC-Waters  590  pump 
Column;  10  em  x 4.6  mm  i.d.  packed  with  Hypercarb  7 ~m (porous 
Graphite  Carbon)  (Shandon) 
Mobile  phase  was  pumped  at 0.5  mL  per  min. 
The  fluorescence  detector was  a Philips  PU  4027  with  the 
excitation wavelength  310  nm  and  the  emission  wavelength  at 420 
nm. 
The  chromatogram  was  recorded  and  integrated  using  an  electronic 
integrator  (Spectra  Physics  4400).  25  ~L samples  were  injected 
using  a Waters  Wisp  712. 
The  column  and  mobile  phase  were  maintained  at 35°C  using  a Jones 
model  7962  oven. 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section 6.3.1  and  to  ISO  document  78/2-1982  and 
also  the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN  and  EEC 
93/256. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection of  residues  in  meat,  as  defined  in  Directive 64/433/EEC  and  also 
in  milk. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to allow 
the  reference method  to  be  carried out  and  to  allow  repeat  analysis where 
required. 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to allow  proper 
identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice  the  result of  the  examination. 
Samples  for  the  analysis  of  Lasalocid  must  be  stored  and  transported at 
temperatures  below  -18°C. 
Samples  for  analysis  of  muscle  should  be  obtained  by  removing  thin slices 
from  the  frozen  tissue.  The  bulk  sample  should  not  be  allowed  to thaw. 
9.  PROCEDURE 
9.1.  2 g finely sliced tissue or  homogenised  egg  were  homogenised  in 
25  mL  acetonitrile.  The  homogenate  was  placed  in  an  ultrasonic 
bath  (5  min)  and  centrifuged  (5  min)  at 3,000  rpm. 
9.2  The  supernatant was  transferred to  250  mL  separating funnel. 
9.3  The  residue was  reextracted with  25  mL  acetonitrile and  the 
supernatants  combined  in  the  separating funnel. 
9.3  The  supernatant  was  shaken  for  one  minute  with  50  mL  carbon 
tetrachloride and  20  mL  saturated  sodium  chloride. 
9.4  The  lower  organic  phase  was  filtered through  anhydrous  sodium 
Cy  4.2/3 sulphate  and  Whatman  PS-1  paper  into  250  mL  round  bottomed  flask. 
9.5.  The  filtrate was  evaporated  to dryness  by  rotary evaporation 
(7.10) 
9.6  The  residue was  transferred quantitatively to a Silica Cartridge 
using  3 x 2 mL  hexane. 
9.3  The  C8  Bond-Elut  columns  were  conditioned  by  drawing  through  5 mL 
acetonitrile followed  by  5 mL  aqueous  acetonitrile/triethylamine 
mixture  (6.2.1). 
9.5  The  column  was  washed  with  5 mL  chloroform 
9.6  The  lasalocid was  eluted with  10  mL  5%  methanol  in  chloroform. 
9.7.  The  eluate was  transferred to  a  25  mL  pear-shaped  flask  and 
evaporated  to  dryness  by  rotary evaporation  (7.10). 
9.8.  The  residue was  redissolved  in  0.5  mL  HPLC  mobile  phase  by  Vortex 
mixing  (15  sec)  and  ultrasonication  (3  minutes). 
9.9.  The  extract was  transferred to  a  1 mL  disposable  syringe  and 
filtered through  a Millipore  HVLP  0.45  ~m disc  into  an  HPLC  vial. 
9.10.  Standards  for  Calibration Curve. 
The  standard  additions  are  done  at this stage  (9.7)  for  the 
preparation  of  a  standard  curve  over  the  range  0 - 100  ~g per  kg. 
Each  point  is  done  in  triplicate. 
9.14  HPLC  was  performed  using  25  ~L. 
10.  CALCULATION  OF  RESULTS 
10.1.  A calibration curve  is constructed of  peak  height  against 
concentration for  a range  of  standards.  The  quantity of  each  of  the 
Lasalocids  in  each  sample  injection  is then  calculated from  the measured 
peak  height.  This  figure  is  corrected for  injection  volume  and  mean  % 
recovery  (calculated from  spiked  samples)  to  give  a concentration  in  mg/kg 
(ppm).  The  standard  injection of  25  ~L is equivalent  to  100  mg  of 
extracted sample. 
% recovery  =  amount  of  Lasalocid  found  x 100 
amount  of  Spike  added 
Concentration  of  Lasalocid  in  sample  (mg/kg)  = 
ug  Lasalocid  (from  calibration curve)  x _1  __  x  100 
1000  0.05  % recovery 
For  samples  containing  Lasalocids  at concentrations  beyond  the  range  of  the 
standard  curve,  a dilution of  the  extract  is prepared  and  chromatographed, 
and  the  appropriate  volumetric  correction  is applied. 
10.2.  SENSITIVITY 
The  minimum  limit of  determination  of  Lasalocids  by  this method  is 
10  ~g/kg when  confirmed  by  stop-flow analysis of  the  emission  spectra. 
10.3.  QUALITY  ASSURANCE  PROCEDURES. 
10.3.1.  Validation;  Batches  of  up  to  eight blank  samples  are  spiked  at 
the  10  or  100  ~g per  kg  level  and  extractions are  performed  on  each  of 
three consecutive  days.  Each  batch  should  include  blanks  and  spiked 
samples. 
Cy  4.2/4 Recovery  of  the  analyte  in  the  100  ~g per  kg  spike  should  fall  within  the 
range  65-90%.  CV  values  should  be  less  than  15%  for  inter and  intra batch 
precision. 
11.  SPECIAL  CASES. 
In  samples  in  which  a  positive  is suspected,  further confirmatory evidence 
may  be  obtained  by  comparison  of  the  stopped-flow  analysis of  the  emission 
spectra of  the  suspect  peaks. 
12.  NOTES  ON  PROCEDURE. 
13.  SAMPLE  CONTROLS 
It is convenient  to analyze  16-20  samples  per  batch  per  day.  A batch  would 
include  9-13  unknowns,  plus  spiked  quality control  samples. 
The  blank  samples  were  obtained  from  a  sample  previously analyzed  and  found 
to  contain  no  Lasalocid. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS. 
See  abbreviations  in  Annex  I,  section  12  of  Manual. 
16.  FLOW  DIAGRAM 
Tissue  --~ add  acetonitrile----------~ Homogenise  ------> solvent 
extract 
I 
I 
I 
I 
I 
I 
I 
I 
l 
Calculate <---- HPLC  <------- Filter <------------- Sep-pak  Si  column 
results 
Cy  4.2/5 Cy  4.3.  CARBADOX  AS  QCA  - DETERMINATION  BY  GC-MS  OF  QUINOXALINE  CARBOXYLIC 
ACID  (QCA)  IN  LIVER  TISSUE. 
WARNING  AND  SAFETY  PRECAUTIONS 
SAFETY 
1.  Organic  solvents  - all  organic  solvents must  be  treated as 
potentially hazardous  and  all  procedures  using  them  must  be 
performed  in  a fume  cupboard. 
2.  Ammonia  - use  only  in  a fume  cupboard  and  wear  safety glasses. 
3.  Homogenising  - perform  in  a fume  cupboard  to  avoid  aerosols. 
4.  Dry  ice  - wear  thick  hide  gloves  and  face  shield.  Dry  ice  can 
cause  burns  and  frostbite  if in  contact with  the  skin. 
5.  Do  not  carry out  the  methylation  using  diazomethane  unless  you 
have  been  trained to  do  so. 
ALL  REACTIONS  INVOLVING  THE  PREPARATION  AND  USE  OF  DIAZOMETHANE  MUST  BE 
CARRIED  OUT  IN  A FUME  CUPBOARD.  PROTECTIVE  CLOTHING  MUST  BE  WORN. 
DO  NOT  USE  EQUIPMENT  WITH  GROUND  GLASS  JOINTS  - THERE  IS  A POTENTIAL 
EXPLOSION  HAZARD! 
You  should  ensure  that you  and  anyone  else  in  the  room  are  aware  of  the 
potential  explosion  hazards  associated with  diazomethane.  All  diazomethane 
generated  MUST  be  destroyed  immediately  if it is not  being  used  for  direct 
methylation.  This  is achieved  by  bubbling  through  dilute HCl.  All 
glassware  used  should  be  rinsed  in  HCl  before  it leaves  the  fume  cupboard. 
FIRST  AID 
1.  Solvents,  acids  and  alkalis  in  contact with  skin  - wash  with 
copious  amounts  of  cold  water.  Splashes  in  the  eye  - irrigate 
with  water  and  seek  medical  attention  immediately. 
2.  Cuts  - seek  assistance of  first aider  immediately. 
3.  Burns  and  frostbite  - run  affected  part under  cold water  (burns) 
or  tepid water  (frostbite) for  10  minutes  and  seek  medical 
attention. 
0.  INTRODUCTION 
Purpose 
The  confirmation  of  the  presence  of  QCA  in  samples  taken  from  farm  animals 
in  compliance  with  the  Residues  Directive 86/469/EEC. 
Background 
Carbadox  is an  animal  drug  used  to  increase  the  rate of  weight  gain, 
improve  feed  efficiency and  control  swine  dysentery  and  bacterial 
enteritis.  Carbadox  is a  suspected  carcinogen  but  is  itself not  normally 
found  as  a residue  in  edible tissues.  The  major  metabolite  quinoxaline-2-
carboxylic  acid  (QCA)  is found  as  a residue  and  may  also  be  produced  as  an 
artefact during  the  assay  for  QCA.  QCA  is not  a  carcinogen. 
1.  SCOPE 
This  method  of  analysis  in  use  at CVL,  UK,  describes  the  determination  of 
the total  content of  QCA  in  pig  liver. 
Cy  4.3/1 2.  FIELD  OF  APPLICATION. 
The  method  is described  to  be  used  for  porcine  liver.  The  detection  limit 
has  not  yet  been  defined. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
2052/VI/84  File 6.11  II-4,  Scientific Veterinary Committee,  Working 
Group- "Reference  Methods  for Residues",  General  Criteria for  the 
establishment  of  Reference  Methods  for  the  Detection  of  Residues. 
ISO  Standard  78/2-1982  Layout  for  standards  - Part  2:  Standard  for  Chemical 
Analysis 
Standard  operating  procedure- Central  Vet  Lab.,  UK.  Confirmation  of  a 
metabolite  of  Carbadox  in  tissues  by  GC-MS.  (1988) 
4.  DEFINITIONS. 
QCA  content  is taken  to  mean  the  amount  of  QCA  in  liver determined 
according  to  the  described  method  and  expressed  as  ~g QCA  per  kg  test 
sample. 
5.0  PRINCIPLE 
Dried  extracts of  liver cleaned  up  by  an  ion-exchange  system  are methylated 
with  diazomethane  and  the  methylated  extracts are  subjected  to  analysis  by 
gas  chromatography-mass  spectrometry  (GC-MS)  by  selected  ion  monitoring. 
6. 
6.1. 
6.1.1. 
6.1.2. 
6.1.3. 
6.1.4. 
6.1.5. 
6.1.6. 
6.1.7. 
6.1.8 
6.1.9. 
6.1.10 
6.1.11 
6.1.12 
6.1.13 
6.2. 
MATERIALS 
Chemicals 
Diazald  Aldrich  Chemical  Co  Ltd 
Potassium  hydroxide  AR  grade 
Sodium  hydroxide  3M  BDH 
Ethyl  digol  (carbitol)  Technical  grade,  BDH 
Hydrochloric  acid  1M  AR  grade  May  &  Baker 
Methanol  Distal  grade,  Fisons 
Acetone  Distal  grade,  Fisons 
Ethyl  acetate  Distal  Grade,  Fisons 
Chloroform  Distal  Grade,  Fisons 
Hexane  Distal  Grade,  Rathburns 
Perfluorotributylamine  (PFTBA)  Finnigan  MAT 
Macroporous  cation  resin  (AF  MP-50),  AR  grade,  Bio-Rad 
Citric acid  buffer,  pH  6,  0.5M;  Adjust  pH  of  100  mL  citric acid 
to  pH  6 with  5M  sodium  hydroxide.  Make  up  to  200  mL  with  water 
and  readjust  pH  to  6. 
Standards 
Solid  QCA  may  be  obtained  from  Pfizer. 
A standard  of  concentration  =  1 mg/mL  of  QCA  in  methanol  should  be  prepared 
Cy  4.3/2 using  available  QCA. 
Working  standards  of  concentrations  =  0.01  ~g/mL, 0.1  ~g/mL,  1  ~g/mL, 
5  ~g/mL,  10  ~g/mL should  be  prepared  by  dilution from  the  stock. 
7.  Equipment 
7.1.  Mini  diazald  apparatus  (Aldrich  Chemical  Co  Ltd) 
7.2.  Separating  funnels  with  teflon  stopcock  100  mL,  250  mL 
7.3.  Stoppered  centrifuge tubes,  10  mL 
7.4.  Boiling  Water  bath 
7.5.  Buchner  funnel  and  Whatman  No  1 filter paper. 
7.6  Glass  chromatography  column,  10.5  mm  diameter 
7.7  Ice  bath 
7.8  Round  bottomed  flask,  250  mL 
7.9.  Rotary  evaporator 
7.10.  Mass  spectrometer,  Finnigan  MAT,  coupled  to  a gas  chromatograph 
and  linked  to  an  INCOS  data  system 
7.11  Preparation  of  Resin  and  Ion-exchange  column; 
Set  up  a  Buchner  funnel  with  a filter paper  and  filter flask 
attached  to  suction.  Place  100  g resin  (6.1.12)  in  the funnel. 
Wash  the  resin with  a)  1 L methanol,  b)  1 L water,  c)  500  mL  1M 
HCl. 
Stir the  resin  and  maintain  a moderate  filter rate. 
Store  the filter cake  in  a  capped  amber  jar. 
Mix  7 g washed  resin with  1M  HCl  and  transfer to  a chromatography 
column.  Pack  the  resin to  a height  of  100  mm  and  maintain  the 
level  of  HCl  just above  the  resin  bed. 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to section  6.3.1  and  ISO  document  78/2-1982  and 
the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection of  residues  in  meat  as  defined  in  Directive  64/433/EEC.  Failing 
this biological  fluids or  faeces  may  constitute the  samples  for  the 
detection of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to allow 
the  reference method  to  be  carried out  and  to  allow  repeat  analysis where 
required. 
In  this method  for  QCA  the  sizes shall  not  be  less  than  20  g liver  • 
9.0. 
9.1. 
9.1.1. 
9.1.2. 
9.1.3. 
9.1.4 
PROCEDURE 
Sample  preparation 
5 g thawed  sample  is minced  and  placed  into a  50  ml  centrifuge 
tube. 
10  mL  of  3M  sodium  hydroxide  is added,  the  tube  stoppered  lightly 
and  placed  in  a boiling water  bath  for  30  minutes. 
After  cooling  the  hydrolysate  in  an  ice  bath  the  pH  is adjusted 
to  <  1 using  4 mL  cone.  HCl.  15  mL  ethyl  acetate  is added  and 
the mixture  shaken  for  20  seconds  before  centrifuging at 1500  rpm 
to clarify the  organic  phase. 
The  ethyl  acetate phase  is transferred with  a Pasteur  pipette to 
Cy  4.3/3 9.1.5 
9.1.6 
9.1.7. 
9.1.8. 
9.2. 
a  100  ml  separating funnel. 
The  aqueous  phase  is re-extracted with  2 additional  15  ml  of 
ethyl  acetate as  above  and  the  ethyl  acetate phases  combined. 
5 ml  citric acid  buffer  (6.1.13)  is added  and  the mixture  shaken 
for  1 minute.  After  allowing  the  lower  phase  to clarify the 
aqueous  phase  is run  into a beaker.  This  step  is repeated  twice 
with  further 5 ml  portions of  buffer.  The  combined  aqueous 
phases  are  acidified with  2 ml  cone.  HCl. 
The  acidified extract is transferred to  the  ion-exchange  column 
(7.11)  and  the  column  drained  to  the  top  of  the  bed.  The  resin 
is washed  with  40  ml  1M  HCl  and  the eluent discarded.  A 250  ml 
separating funnel  is placed  beneath  the  column  and  the  column 
eluted with  75  ml  10%  methanol  in  water  (v/v)  until  the  column  is 
dry. 
1 ml  cone  HCl  is added  to the  eluate.  The  eluate  is extracted 
with  3 x 50  ml  chloroform  into a round  bottomed  flask.  The 
chloroform  extract  is evaporated  to dryness  using  a rotary 
evaporator at 45-50°C.  The  residue  is transferred to a  10  ml 
centrifuge tube  with  10  ml  methanol.  The  volume  is reduced  to 1 
ml  under  a  stream  of  nitrogen  at 45-50°C. 
Derivatisation 
DO  NOT  CARRY  OUT  THIS  METHYLATION  UNLESS  YOU  HAVE  BEEN  TRAINED  TO  DO  SO. 
READ  THE  SECTION  ON  SAFETY  AND  FOLLOW  THE  ADVICE  GIVEN  CAREFULLY. 
9.2.1. 
9.2.2. 
9.2.3. 
9.2.4. 
9.2.5. 
9.2.6. 
9.2.7. 
9.2.8. 
9.2.9 
The  following  reagents  are  prepared: 
(a)  2 g diazald  in  20  ml  diethyl  ether. 
(b)  3 g potassium  hydroxide  in  3 ml  distilled water  added  to 
10  ml  ethyl  digol. 
(c)  10%  hydrochloric  acid,  100  ml. 
The  Mini-diazald  kit  is set up  according  to  the  maker's 
instructions. 
Until  ready  to methylate  the  samples,  the  diazomethane  generated 
must  be  passed  through  the  10%  HCl,  which  will  neutralise it. 
Ensure  that the  kit  is set up  for  this. 
Reagent  (b)  (KOH  in  H 20  +  ethyl  digol)  is placed  in  the  reaction 
vessel. 
A separating funnel  is positioned  over  the  reaction  vessel. 
Reagent  (a)  (diazald  in  ether)  is placed  in  this funnel. 
The  reaction  vessel  is placed  in  a water  bath  at 50-60°C  and  the 
diazald  solution added  slowly  and  carefully over  a period  of 
approximately  20  minutes.  Once  the  reaction  has  started,  the 
diazomethane  is bubbled  through  the  sample  and  standards  until 
the  solution  is coloured  yellow.  Whenever  the  diazomethane  is 
not  bubbling  through  a sample  or  standard  it is  important  that it 
is passed  through  the  HCl  to  neutralise  it. 
Once  all  of  the  standards  and  samples  have  been  derivatised,  the 
diazomethane  generated  is passed  through  the  HCl  solution,  and 
the  reaction  continued  until  all of  the  reagents  have  been  used 
up. 
The  derivatives  are  taken  to  dryness  under  nitrogen  and 
resuspended  in  100  ~l  hexane. 
At  the  same  time  a  series of  standards  at different 
concentrations  should  be  run  through  the  derivatization stages. 
Cy  4.3/4 9.3. 
9.3.1. 
GC-MS  Analysis 
The  GC  parameters  are 
COLUMN:  J&W  fused  silica capillary column, 
INJECTIONS:  0.5  ~1  manual  injections. 
TEMPERATURES:  Interface:  270°C 
SE-54,  15  m x 0.25  mm. 
Injector:  260°C 
OVEN  TEMPERATURES: 
from  temp  to  temp 
(oc)  (oc) 
55  55 
55  240 
240  240 
CARRIER  GAS:  Helium 
rate 
(°C/min) 
20 
flow  rate  = 1 mL/min 
injector pressure= 10  psi. 
time 
(min) 
1.0 
9.2 
10.0 
9.3.2  The  mass  spectrometry  parameters  are 
IONISER: 
Mode:  EI  positive  ion 
Temperature:  150°C 
MANIFOLD  TEMPERATURE:  90  (±  5)  °C 
ELECTRON  MULTIPLIER:  1.2  kV 
ELECTRON  ENERGY:  70  electron  volts. 
total  time 
(min) 
1.0 
10.2 
20.2 
Other  parameters  should  be  set up  by  adjusting the  instrument  controls to 
give  the  optimum  peak  height  and  shape  for  a suitable calibration compound. 
The  CVL  uses  perfluorotributylamine  (PFTBA). 
9.3.3.  The  MS  is operated  in  EI  mode  and  scanned  between  m/z  = 50  and 
400. 
9.3.4.  The  following  are  analyzed; 
a)  hexane 
b)  10  ~g per  mL  derivatised  QCA  standard  in  a  volume  of  100  ~L 
1000  scans  were  collected.  After  4 minutes  the  filament  is 
turned  off. 
9.3.5  The  QCA  derivative  peak  elutes between  6-7  minutes  after 
injection.  This  peak  is examined  and  the  exact masses  to  3 
decimal  places were  found  for  at  least the  ions 
m/z  = 102,  130,  158,  188 
9.3.6  These  ions  are  used  to  set up  or  modify  and  then  create a 
multiple  ion  detection  (MID)  scan  list. 
9.3.7  Hexane  is rerun  through  the  system  to  check  that there  is no 
carry over  of  QCA  derivative. 
9.3.8.  The  remaining  samples  and  standards  are  analyzed  using  0.5  ~L. 
It is advisable  to: 
a)  Analyze  1 ~g Qf  QCA  derivative first to  ensure  that the  MID 
is set up  correctly.  This  is followed  by  hexane. 
b)  Analyze  standards  in  order  of  increasing  concentration. 
c)  Switch  the  filament  on  100  scans  before  the  QCA  derivative 
elutes from  the  column  and  switch  it off 100  scans  afterwards. 
d)  Inject hexane  between  each  injection. 
Cy  4.3/5 10.0.  RESULTS 
The  presence  of  a  QCA  in  a  sample  is confirmed  if the  GC-MS  data  satisfy 
the following  criteria: 
1.  The  peak  in  the  sample  has  the  same  GC  retention time  as  that  in 
the  standard. 
2.  The  ions  present  in  the  mass  spectrum  of  the  sample  GC  peak  are 
identical  to  those  in  the  mass  spectrum  of  the  standard. 
3.  The  ratios of  the  ions  to  one  another  are  the  same  as  those  in 
the  standard. 
The  limit of  detection for  this method  has  not  yet been  assessed. 
11.  SPECIAL  CASES. 
12.  NOTES  ON  PROCEDURE. 
13.  SAMPLE  CONTROLS 
The  blank  sample  was  obtained  from  a  sample  previously analyzed  and  found 
to contain  no  QCA. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS. 
See  abbreviations  in  Annex  I,  section  12  of  Manual. 
16.  FLOW  DIAGRAM 
SAMPLE  -------->Homogenise------> alkaline digestion  ----~ 
I 
I 
! 
derivatise <------- ion-exchange  column  <--- solvent extraction 
I 
I 
! 
GC-MS  ------>  Calculate results 
Cy  4.3/6 Cy  4.4  IVERMECTIN  - DETERMINATION  OF  IVERMECTIN  AT  RESIDUE  LEVELS  IN 
ANIMAL  TISSUES. 
WARNING  AND  SAFETY  PRECAUTIONS 
0.  INTRODUCTION 
Ivermectin  is a potent endo- and  ectoparasitic agent  with  a broad  spectrum 
of  activity in  several  animal  species  including  cattle,  sheep,  pigs,  horses 
and  humans.  Ivermectin  may  be  administered  orally,  parentally or  as  a 
pour  on  preparation.  The  dose  is usually  in  the  range  0.2  - 0.6  mg/kg 
body  weight  (B.W.). 
The  MRL  set  in  the  EEC  for  Ivermectins  is 15  ~g per  kg  liver and  0  ~g per  L 
of  milk. 
1.  SCOPE 
This  method  of  analysis  describes  the  determination  of  the  total  content  of 
Ivermectin  in  samples  of  animal  origin. 
2.  FIELD  OF  APPLICATION. 
The  method  can  be  used  for  bovine  muscle  and  bovine  and  porcine  kidney.  The 
limit of  determination  following  the  validation of  the  method  is 2  ~g/kg of 
sample  for  Ivermectin. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
2052/VI/84  File 6.11  II-4,  Scientific Veterinary Committee,  Working 
Group-
11Reference  Methods  for  Residues .. ,  General  Criteria for  the 
establishment of  Reference  Methods  for  the  Detection  of  Residues. 
ISO  Standard  78/2-1982  Layout  for  standards  - Part  2:  Standard  for  Chemical 
Analysis 
MAFF,  1989,  Determination  of  Ivermectin  at residue  levels  in  animal 
tissues.  Food  Science  Laboratory,  Colney  Lane,  Norwich.  Standard 
Operating  Procedure. 
Nordlander,  I.  and  Johnsson,  H.  (1990).  Determination  of  Ivermectin 
residues  in  swine  tissues - An  improved  clean-up  procedure  using  solid 
phase  extraction.  Food  Addit.  Contamin.  l, 79-82 
Tway,  P.C.,  Wood,  J.S.  and  Downing,  G.V.  (1981)  Determination  of 
ivermectin  in  cattle and  sheep  tissues using  high  performance  liquid 
chromatography  with  fluorescence  detection.  J.Agric.  Food  Chern.  29,  1059-
1063 
4.  DEFINITIONS. 
Ivermectin  content  is taken  to  mean  the  amount  of  Ivermectin  in  the 
substance  in  question,  regardless of  the  chemical  form,  determined 
according  to  the  described  method  and  expressed  as  ~g or  mg  Ivermectin  per 
kg  of  test sample. 
Cy  4.4/1 5.  PRINCIPLE 
The  methods  comprises  6 stages;-
Homogenisation  of  tissue samples  in  buffer 
Extraction with  organic  solvent 
Extraction  on  reverse  phase  CB  column 
Derivatisation 
Clean-up  on  solid phase  column. 
End  point  determination  with  HPLC  by  fluorescent  UV  detection 
The  amount  of  Ivermectin  is calculated  by  interpolation from  a 
standard  curve  and  taking  into  account  the  recovery  of 
Ivermectin,  especially from  tissue samples. 
6.  CHEMICALS 
6.1.1 
6.1.2 
6.1.3 
6.1.4 
6.1.5 
6.1.6 
6.1.7 
Chloroform  (BDH) 
Triethylamine  (Sigma) 
Methylimidazole  (Sigma) 
Methanol,  redistilled  (BDH) 
Acetic  anhydride  (Sigma) 
Acetonitrile  (Romil) 
Dimethylformamide  (Sigma) 
6.2.  Solutions 
6.2.1  Aqueous  acetonitrile with  triethylamine;  1 mL  triethylamine  is 
added  to  300  mL  acetonitrile and  made  up  to 1 L with  water. 
6.2.2.  Derivatisation mixture;  Mix  methylimidazole,  acetic anhydride 
and  dimethylformamide  in  the  ratio 2:6:9  v/v.  Prepare 
immediately  before  use.  Use  100  ~L per  derivatisation. 
6.2.3.  HPLC  Mobile  Phase;  30  mL  methanol  was  added  to 970  mL  water, 
mixed  and  passed  through  a  Durapore  ..  filter,  assisted by  vacuum. 
The  mobile  phase  was  degassed  using  ultrasonication and  with 
reduced  pressure. 
6.3. 
6.3.1 
6.3.2. 
6.3.3 
6.3.4 
6.5. 
7. 
7.1 
7.2 
7.3 
7.4. 
7.5 
7.6 
Standards 
Ivermectin  reference  standards  were  obtained  from  Merck,  Sharpe 
and  Dohme  Ltd. 
Stock  standards;  10  mg  Ivermectin  in  100  ml  methanol.  Store at 
4°C  and  make  fresh  fortnightly. 
Intermediate  standards;  Dilute 4 mL  stock  to  100  mL  with 
methanol.  Store  at 4°C  and  make  fresh  fortnightly. 
Working  standards;  Dilute  5  mL  intermediate  standard  to  100  mL 
with  methanol.  Final  concentration  is 0.2  ng  per  ul.  Make  fresh 
daily. 
Spiking  Procedure 
Using  the working  standards  (6.3.4)  spike  5 g sample  with  50  ul 
and  125  ul  standard  solution.  Allow  to  stand  for  15  minutes. 
EQUIPMENT 
Centrifuges  tubes  50  mL  capacity,  plastic. 
100  mL  glass beakers 
All  glass filter holder,  47  mm- Millipore. 
Glass  sample  bottles,  25  mL 
Pear  shaped  flasks  50  mL 
Glass  reactivials 3 ml  with  PTFE  lined  screw  caps. 
Cy  4.4/2 7.7. 
7.8 
7.9 
7.10 
7.11. 
7.12. 
7.13. 
7.14. 
7.15. 
7.16. 
7.17. 
7.18. 
7.19. 
7.19.1. 
7.19.2. 
7.19.3. 
7.19.4. 
7.19.5. 
7.20 
8. 
Glass  syringes,  1 mL  and  10  mL 
Ultra-Turrax  Homogeniser 
Mixer  (Vortex) 
Rotary  evaporator  - Buchli  with  water  bath  at 40°C 
Vials  low  volume  for  autosampler 
Glass  vials 2 mL 
Centrifuge  - MSE  High  Speed  18  or  equivalent 
Ultrasonic  bath- L&R  140S  or  equivalent 
Adjustable  pipettes 200  ~L and  1000  ~L 
Multipart  nitrogen  evaporator with  heater  block  (40°C)  for 
reactivials. 
Membrane  filter holder  - Millipore  Swinney  Stainless,  13  mm 
Membrane  filters,  13  mm  and  47  mm- Millipore  Ltd. 
Solid  Phase  Extraction 
Vacuum  Manifold  - Vac-Elut 
C8/500  mg  cartridges - Bond-Elut,  Jones  Chromatography  Ltd. 
Silica cartridges - Sep-pak,  Waters  Associates. 
Cartridge  taps  - Jones  Chromatography  Ltd. 
Reservoirs  50  mL  for  cartridges  - Jones  Chromatography  Ltd. 
HPLC-LKB  2150  pump 
Column;  10  em  x 3 mm  i.d.  Chromsep  (Chrompack)  cartridge column 
assembly  packed  with  5 urn  Hypersil  CDS  with  integral  (10  mm  x 2.1 
mm  i.d.)  guard  column  packed  with  pellicular  (30-40  urn)  reverse 
phase. 
Mobile  phase  was  pumped  at 0.4  mL  per  min. 
The  fluorescence  detector was  a Perkin  Elmer  LS4  with  the 
excitation wavelength  364  nm,  slit width  10  nm,  and  the  emission 
wavelength  at 470  nm,  slit width  10  nm.  The  scale expansion  was 
4.0  units. 
The  chromatogram  was  recorded  and  integrated  using  an  electronic 
integrator  (Spectra  Physics  4290).  25  ~L samples  were  injected 
using  a Waters  Wisp  712. 
SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section 6.3.1  and  ISO  document  78/2-1982  and 
the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection  of  residues  in  meat,  as  defined  in  Directive  64/433/EEC  and  also 
in  milk. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to  allow 
the  reference method  to  be  carried out  and  to  allow  repeat  analysis where 
required. 
In  this method  for  Ivermectins  the  sizes  shall  not  be  less  than  30  g 
muscle,  kidney 
8.3.  The  samples  must  be  taken  and  packed  in  such  a way  as  to allow 
proper  identification  in  the  laboratory. 
8.4.  The  method  of  packing,  preservation  and  transport must  maintain  the 
integrity of  the  sample  and  not  prejudice  the  result of  the  examination. 
Samples  for  the  analysis  of  Ivermectins  must  be  stored  and  transported at 
temperatures  below  -18°C. 
Cy  4.4/3 9.  PROCEDURE 
9.1.  5 g finely sliced tissue and  15  mL  acetonitrile were  placed  in  an 
ultrasonic bath  (3  min)  homogenised  (2  min)  and  centrifuged  (5 
min)  at 5,000  rpm. 
9.2  The  Supernatant  was  transferred to  beaker  containing  40  mL  water 
and  0.05  mL  triethylamine.  The  contents were  mixed  by  stirring. 
9.3  The  CB  Bond-Elut  columns  were  conditioned  by  drawing  through  5 mL 
acetonitrile followed  by  5 mL  aqueous  acetonitrile/triethylamine 
mixture  (6.2.1). 
9.4.  The  extract was  transferred to  the  Bond-Elut  column  which  was 
fitted with  a  tap  and  a reservoir.  After  allowing  the  column  to 
drain  but  not  dry  the  column  was  eluted with  5 mL  acetonitrile 
into  glass  sample  bottles  (7.4). 
9.5  The  eluate was  transferred to a  50  mL  pear-shaped  flask  using  2 x 
2 mL  acetonitrile rinses. 
9.6  The  organic  phase  was  evaporated  to  dryness  using  a rotary 
evaporator with  a water  bath  set at 40°C. 
9.7  The  residue was  redissolved  in  1 mL  methanol. 
9.8.  Standards  for Calibration Curve. 
The  standard  additions  are  done  at this stage  (9.7)  for  the 
preparation of  a  standard  curve  over  the  range  0 - 5  ~g per  kg. 
Vol.  Working  Standard 
(6.3.4)  ~L 
0 
25 
50 
75 
100 
125 
Vol.  Methanol 
~L 
1000 
975 
950 
925 
900 
875 
Equiv.  Cone.  Ivermectin 
~g per  kg 
0 
1 
2 
3 
4 
5 
9.9  A 500  ~L aliquot of  extract  (9.7)  was  transferred to a 
reactivial.  Samples  may  be  stored at -20°C  at this point. 
Otherwise  remove  methanol  by  evaporating  to dryness  under  a 
stream  of  nitrogen. 
9.10  100  ~L derivatisation mixture  (6.2.2.)  was  added.  The  vial  was 
capped  tightly and  the  contents  gently swirled.  The  reactivials 
were  placed  in  an  oven  at 95°C  for  1 hour. 
9.11  After  cooling  the  vials the  contents were  transferred 
quantitatively with  3-4  mL  chloroform  to  a  10  mL  glass syringe 
attached  to a silica Sep-pak  cartridge  (7.19.3).  The  sample  was 
passed  through  the  cartridge and  the  eluate collected  in  a  50  mL 
pear-shaped  flask.  A further 9 mL  chloroform was  passed  through 
the  cartridge and  the  eluate also  collected  in  the  pear-shaped 
flask. 
9.12  The  chloroform  was  removed  by  rotary evaporation  at 40°C. 
9.13.  The  viscous  residue was  taken  up  in  0.50  mL  methanol  and  filtered 
through  a 0.45  urn  Millipore filter attached  to a  1 mL  syringe. 
The  sample  was  collected  in  a glass  autosampler  vial  (7.11). 
9.14  HPLC  was  performed  using  25  ~L. 
10.  CALCULATION  OF  RESULTS 
10.1.  A calibration curve  is constructed of  peak  height  against 
concentration for  a range  of  standards  The  quantity of  each  of  the 
Ivermectins  in  each  sample  injection  is then  calculated from  the measured 
Cy  4.4/4 peak  height.  This  figure  is then  corrected for  injection  volume  and  mean  % 
recovery  (calculated from  spiked  samples)  to give  a concentration  in  mg/kg 
(ppm).  The  standard  injection of  25  ~L  is equivalent  to  0.25  g of 
extracted sample. 
The  retention  time  of  ivermectin  is approximately  7 minutes. 
% recovery = amount  of  Ivermectin  found  x 100 
amount  of  Spike  added 
Concentration  of  Ivermectin  in  sample  (mg/kg)  = 
ug  Ivermectin  (from  calibration curve)  x  1  x  100 
1000  0.05  % recovery 
For  samples  containing  Ivermectins  at concentrations  beyond  the  range  of 
the  standard  curve,  a dilution of  the  extract  is prepared  and 
chromatographed,  and  the  appropriate  volumetric  correction  is applied. 
10.2.  SENSITIVITY 
The  minimum  limit of  determination  of  Ivermectins  by  this method  is 
0.002  mg/kg. 
10.3.  QUALITY  ASSURANCE  PROCEDURES. 
10.3.1.  Validation;  Batches  of  up  to  six blank  samples  are  spiked  at the 
2 or  5  ~g per  kg  level  and  extractions  are  performed  on  each  of  three 
consecutive  days.  Each  batch  comprised  the  following  samples;-
2  blanks 
2  standard  additions  at 2  ~g per  kg 
2 standard  additions  at 5  ~g per  kg 
6 spikes  at 2 or  5  ~g per  kg. 
Recovery  of  the  analyte  should  fall  within  70-110%.  Cv  values  should  fall 
within  the  range  5-15%  for  inter and  intra batch  precision. 
11.  SPECIAL  CASES. 
12.  NOTES  ON  PROCEDURE. 
13.  SAMPLE  CONTROLS 
It is convenient  to  analyze  16-20  samples  per  batch  per  day.  A batch  would 
include  9-13  unknowns,  plus  spiked  quality control  samples. 
The  blank  samples  were  obtained  from  a  sample  previously analyzed  and  found 
to  contain  no  Ivermectin. 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS. 
See  abbreviations  in  Annex  I,  Section  12  of  Manual. 
16.  FLOW  DIAGRAM 
Tissue  --~ add  acetonitrile----------~ Homogenise  ------> CB  column 
I 
I 
! 
Calculate <---- HPLC  <------- Sep-pak  Si  column  <------ Derivatise 
results 
Cy  4.4/5 Cy  4.5.  TRANQUILLIZERS  AND  CARAZOLOL  - AN  HPLC  METHOD  WITH  ON-LINE  UV 
SPECTRUM  IDENTIFICATION  AND  OFF-LINE  TLC  CONFIRMATION  FOR  RESIDUES  IN  PIG 
KIDNEYS. 
WARNING  AND  SAFETY  PRECAUTIONS 
SAFETY 
Organic  solvents  - all  organic  solvents  must  be  treated as  potentially 
hazardous  and  all  procedures  using  them  must  be  performed  in  a  fume 
cupboard. 
0.  INTRODUCTION 
Tranquillizers  and  the  B-blocker  carazolol  are  used  to  aid  the  management 
of  stress  in  many  veterinary practices.  Of  particular  interest for 
residues  is the  treatment  of  pigs  to  prevent  mortality and  loss  of  meat 
quality during  transport to  the  slaughterhouse.  The  time  between  drug 
administration  and  slaughter  is usually not  more  than  a few  hours  and  this 
can  result  in  high  residues  in  the  edible tissues. 
1.  SCOPE 
The  use  of  many  of  the  tranquillizers and  carazolol  varies  throughout  the 
EEC.  To  ensure  that farmers  are  not  using  these  drugs  in  non-approved 
situations  and  to  control  the  use  in  meat  producing  animals  samples  of 
kidneys  are  taken  at slaughterhouses  and  screened  for the  presence  of  these 
compounds  using  a  number  of  techniques  (see  Section  4).  Whenever  there  is 
a  positive screening  result,  this must  be  confirmed.  This  work  is carried 
out  in  compliance  with  the  Residues  Directive  (86/469/EEC). 
2.  FIELD  OF  APPLICATION. 
This  method  is used  for  confirmation  of  the  presence  of  six tranquillizers 
and  carazolol  in  pig  kidney.  The  limits of  identification ranges  from  1 to 
2.5  ug  per  kg  kidney  for  the  tranquillizers and  carazolol.  Azaperone  forms 
a major  metabolite,  azaperol,  and  the  two  compounds  appear  together  as 
residues. 
3.  REFERENCES. 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  [OJ.  ~ 
L.118,  14.4.93.  pp  64-74] 
2052/VI/84  File 6.11  II-4,  Scientific Veterinary Committee,  Working 
Group- .. Reference  Methods  for  Residues .. ,  General  Criteria for  the 
establishment  of  Reference  Methods  for  the  Detection  of  Residues. 
ISO  Standard  78/2-1982  Layout  for  standards  - Part  2:  Standard  for  Chemical 
Analysis 
ISO  Standard  5725  (1986) 
Van  Ginkel,  L.A .. Schwillens,  P.L.W.J.  and  Olling,  M.,  (1989),  Liquid 
chromatographic  method  with  on-line  UV  spectrum  identification and  off-line 
thin-layer chromatographic  confirmation  for  the  detection  of  tranquillizers 
and  carazolol  in  pig  kidneys.  Anal.  Chim.  Acta.  225,  137-146 
Cy  4.5/1 Haagsma,  N.,  Bathelt,  E.R.  and  Engelsma,  J.W.  (1988),  Thin-layer 
chromatographic  method  for  the  tranquillizers azaperone,  propiopromazine 
and  carazolol  in  pig  tissues.  J.Chrom.  436,  73-79. 
4.  DEFINITIONS. 
Tranquillizers  and  carazolol  content  is taken  to  mean  the  amount  of 
tranquillizers and  carazolol  in  kidney  determined  according  to the 
described  method  and  expressed  as  ug  tranquillizers or  carazolol  per  kg 
test sample. 
5.  PRINCIPLE. 
The  method  comprises  four  stages 
Samples  of  kidney  are  extracted from  an  alkaline homogenate  using 
diethylether. 
clean-up with  silica-based dial  cartridges 
analysis  and  fractionation  of  eluate with  HPLC  using  a diode-
array detector 
confirmation  of  tranquillizers and  carazolol  by  TLC  of  selected 
HPLC  fractions. 
6.  MATERIALS 
6.1.  Chemicals 
Note:  The  chemicals  were  all of  analytical  grade  and  obtained  from  Merck 
unless  stated otherwise. 
6.1.1 
6.1.2 
6.1.3 
6.1.4 
6.1.5 
6.1.6 
6.1.7 
6.1.8 
6.1.9 
6.1.10 
6.1.11 
6.1.12 
6.1.13. 
6.1.14. 
6.1.15. 
6.1.16. 
6.1.17. 
6.1.18. 
6.1.19. 
6.2 
6.2.1. 
6.2.2. 
6.2.3 
6.2.4. 
Ethyl  acetate 
Ethanol 
Chloroform 
Hexane 
Acetonitrile,  HPLC  grade 
Sodium  hydroxide 
Diethyl  ether 
Anhydrous  sodium  sulphate 
Light  petroleum,  B.Pt.  40-60°C 
Cone.  sulphuric  acid 
Ammonium  acetate 
Acetone 
Dichloromethane 
Ammonia 
Bismuth(III)  nitrate 
Glacial  acetic acid 
Potassium  iodide 
Vanillin 
85%  Phosphoric  acid 
Solutions 
Acetonitrile  :  water  (80:20  v/v) 
Acetonitrile  :  water  (60:40  v/v) 
Acetonitrile  :  water  (60:40  v/v)  containing 0.1  mol  per  L 
ammonium  acetate 
Acetonitrile  :  water  1 mol  per  L ammonium  acetate 
(44.5:54.5:1,  v/v/v) 
Cy  4.5/2 6.2.5. 
6.2.5.1. 
6.2.5.2 
6.2.5.3. 
6.2.6. 
6.2.6.1. 
6.2.6.2 
6.2.6.3. 
6.3. 
6.3.1. 
6.3.2. 
6.3.3. 
7. 
7.1. 
7.2. 
7.2.1. 
7.2.2. 
7.2.3. 
7.2.4. 
7.2.5. 
7.2.6 
7.2.7. 
TLC  solvents 
Mobile  phase  I;  acetone  :  dichloromethane  :  25%  ammonia 
(40:60:1,  v/v/v) 
Mobile  phase  II;  acetone  :  25%  ammonia  (100:0.1,  v/v) 
Mobile  phase  III;  acetone 
Colour  reagents  for  TLC. 
Dragendorff  reagent;  Mix  a  solution of  0.8  g bismuth(III) 
nitrate in  10  ml  glacial  acetic acid  and  40  ml  distilled water 
with  a solution  containing 8 g potassium  iodide  in  20  ml 
distilled water.  Store  this solution  in  the  dark  and  prepare  the 
working  reagent  fresh  by  mixing  6 ml  of  the  above-described 
solution with  12  ml  glacial  acetic acid,  100  ml  ethanol  (96%  v/v) 
and  100  ml  diethyl  ether. 
Vanillin-Phosphoric  acid  reagent;  dissolve  3 g vanillin  in  100  ml 
ethanol  (96%  v/v)  and  subsequently  add,  with  stirring,  75  ml  of 
85%  phosphoric  acid,  50  ml  distilled water  and  50  ml  diethyl 
ether. 
Sulphuric  acid  reagent;  Add  20  ml  concentrated  sulphuric acid  to 
100  ml  ethanol  (96%  v/v),  cool  the  mixture  and  add  20  ml  of 
diethyl  ether. 
STANDARDS;  Azaperone  and  Haloperidol  (Janssen  Pharmaceutica); 
acepromazine  (Clin  Midy);  Chlorpromazine  (Sigma);  Propiopromazine 
and  xylazine  (Bayer). 
Fraction  I  was  a  solution  in  chloroform  of  azaperone  and  azaperol 
at concentrations  2 ug  per  L 
Fraction  II  was  a solution  in  chloroform  of  carazolol, 
haloperidol  and  xylazine  at concentrations  1 ug  per  L 
Fraction  III was  a solution  in  chloroform  of  acepromazine, 
propiopromazine  and  chlorpromazine  at concentrations  1 ug  per  L 
EQUIPMENT 
Glassware 
The  normal  range  of  minor  laboratory glassware  is needed. 
Apparatus 
Ultra-Turrax  homogeniser 
Rotary  evaporator,  type  Buchli  linked  to  vacuum  pump. 
water  bath  at 95°C 
water  bath  at 45°C  with  nitrogen  dispensing  tubes  for  evaporating 
solvents. 
Glass  syringes  for  chromatography,  type  HAMILTON 
Silica based  diol  based  cartridges  (Baker  70-9403)  washed  with  3 
ml  ethanol  and  3 ml  diethyl  ether before  applying  extract. 
Baker  10  SPE  system 
7.3.  HPLC  equipment 
The  system  consisted of  an  LKB  2150  pump  with  LKB  2152  controller,  an  LKB 
2212  fraction  collector,  a Hewlett  Packard  1040A  diode-array detector,  a 
Chromguard  replacement  column  and  holder  as  a reversed-phase  pre-column  (10 
mm  x 3 mm  i.d.)  and  an  analytical  column  (150  mm  x 4.6  mm  i.d.)packed with 
SAS-Hypersil  (5  urn)  (Shandon),  and  solvent  6.2.4.  as  the  eluent at a flow 
rate of  2 ml  per  min.  The  eluent was  monitored  at 235  nm  and  collected as 
three  separate fractions  so  as  to  contain  azaperone  and  azaperol  in 
fraction one,  carazolol,  xylazine  and  haloperidol  in  fraction  two  and 
azopromazine,  propiopromazine  and  chlorpromazine  in  the  third fraction. 
Cy  4.5/3 7.4. 
7.4.1 
7.4.2. 
TLC  equipment.  e.g.  tanks,  sprayers,  applicators 
TLC  plates,  type  HPTLC-Fertigplatten  Kieselgel-60  (Merck). 
Purchased  as  20  em  x 20  em  and  cut  into four  plates of  5 em  x 5 
em. 
Oven  at 70°C  or  120°C  for  TLC  plates 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is drawn  to  section  6.3.1  and  ISO  document  78/2-1982  and 
the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1.  Nature  of  the  Sample;  Samples  of  kidneys  shall  be  such  as  to enable 
the  detection  of  residues. 
8.2.  Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to  allow 
the  reference  method  to  be  carried out  and  to allow  repeat  analysis where 
required. 
8.3.  The  kidney  must  be  cooled  after collection and  stored  at~ -20°C 
pending  analysis. 
9. 
9.1. 
9.2. 
9.3. 
9.4. 
9.5. 
9.6. 
9.7. 
9.8. 
9.9. 
9.9.1 
9.9.2 
9.9.3 
9.10. 
9.11. 
9.12. 
9.13. 
9.14. 
PROCEDURE 
Thaw  the  kidneys  and  remove  parts of  the  marrow. 
Homogenise  50  g of  the  remaining  material  in  an  Ultra-Turrax 
homogeniser. 
To  20  g homogenate  add  4 mL  of  5 mol  per  L NaOH. 
For  the  quality controls  add  a mixture  of  standards  to  kidneys 
from  pigs  untreated with  Tranquillizers  and  carazolol  (control 
pigs  - blank  samples).  Allow  to  stand  for  at least 30  min  at 
room  temperature  or  at +4°C  overnight. 
The  resulting suspensions  was  incubated  for  1  hour  at 95°C  in  a 
water  bath. 
Cool  to  room  temperature  and  extract with  70  mL  diethyl  ether. 
Add  10  g anhydrous  sodium  sulphate  and  filter. 
Add  20  mL  light petroleum  (6.1.9). 
Solid  Phase  Extraction. 
Add  crude  extract to  column  (7.2.6) with  the  aid  of  a  50  mL 
funnel. 
Wash  with  3 mL  diethyl  ether,  3 mL  ethanol,  1 ml  acetonitrile 
water  (80:20  v/v}  (6.2.1),  3 mL  acetonitrile  :  water  (60:40 
v/v}  (6.2.2). 
The  cartridges are  eluted with  1.5  mL  of  acetonitrile  :  water 
(60  :40  v/v)  containing 0.1  mol  per  L ammonium  acetate.  The 
eluate  is collected  in  a glass  tube  containing  0.025  mL  of  5 mol 
per  L NaOH. 
The  solvent was  evaporated  after the  addition  of  1 mL  acetone. 
The  dry  residue  is dissolved  in  0.1  mL  water  and  extracted with 
2.5  mL  hexane.  The  hexane  extract  is evaporated  to  dryness  and 
redissolved  in  0.07  mL  of  HPLC  eluent  (6.2.4). 
HPLC.  0.055  ml  of  extract 9.11  was  injected  into  the  HPLC 
system. 
3 tubes  containing  0.05  mL  of  5 mol  per  L NaOH  are  used  to 
collect the  fractions  as  outlined  in  7.3. 
The  volume  of  the  fractions  is reduced  under  a stream  of  nitrogen 
to  half  the  original  volume. 
The  fractions were  extracted with  2 x 2 mL  diethyl  ether.  After 
drying  with  0.5  g of  anhydrous  sodium  sulphate  the  ether  is 
evaporated  to  dryness. 
Cy  4.5/4 9.15.  0.4  mL  of  ethanol  is added  to  the  extracts which  may  be  stored  in 
the  dark  at -20°C  until  TLC  analysis. 
9.16.  TLC.  The  detection  systems  are  based  on  the  work  of  Haagsma  et., 
(1988) 
9.16.1  The  extracts 9.15.  are evaporated  to  dryness,  dissolved  in  0.05 
mL  chloroform  and  0.015  mL  spotted onto  two  separate  TLC  plates 
(a  &  B)  for each  fraction.  0.005  mL  of  the  corresponding 
standards  (6.3)  were  spotted onto  plate B. 
9.16.2  The  extract from  fraction  one  (see  7.3)  is run  in  mobile  phase  I 
(6.2.5.1),  dried,  developed  in  mobile  phase  III  (6.2.5.3),  dried 
and  dipped  for  a  few  seconds  in  Dragendorff  reagent  (6.2.6.1). 
After  drying  for  2-5  min  the  spots  of  azaperone  and  azaperol 
become  visible.  If the  detectability was  insufficient,  the 
following  procedure  is followed:  Heat  the  plates for  5 min  at 
70°C,  cool  to  room  temperature  and  place  in  the  vanillin-
phosphoric  acid  solution.  After  drying  for  10  min  inspect  the 
plates at 365  nm  on  a  transilluminator.  The  tranquillizers 
become  visible as  red  spots.  Heating  the  plates for  5 min  at 
70°C  accelerates this process. 
9.16.3  The  extract from  fraction  two  is  treated  in  the  same  way,  except 
that  instead of  mobile  phase  III,  mobile  phase  11(6.2.5.2)  is 
used.  However  for  the  detection  of  carazolol,  heating after 
treatment with  the  vanillin-phosphoric  acid  is essential. 
Sometimes  heating  at 120°C  for 5 min  is needed. 
9.16.4.  The  extracts from  fraction  three are developed  in  mobile  phase 
I,dried,  developed  in  mobile  phase  II,  dried  again  and  heated  for 
1 min  at 120°C.  The  plates are  dipped  in  the  sulphuric  acid 
reagent  (6.2.6.3)  for a  few  seconds  and  heated  for  4 min  at 
120°C.  After  cooling  the  plates are  placed  in  Dragendorff 
reagent  for  a few  seconds  and  then  dried.  The  tranquillizers 
become  visible as  dark  brown  spots. 
10.  CALCULATION  OF  RESULTS 
10.1  The  limit of  detection  for  the  tranquillizers and  carazolol  on 
HPLC  measured  at 235  nm  was  determined  using  the criteria  in 
section  5 of  this manual,  i.e.  the  limit of  detection was  the 
mean  of  the  measured  content  of  a  representative blank  plus  three 
time  the  standard  deviation  of  the  mean. 
The  limit of  identification based  on  the  diode-array detection 
system  was  defined  as:  the  maximum  absorption  wavelength  in  the 
spectrum  of  the  analyte  should  be  the  same  as  that of  the 
standard material  within  a margin  determined  by  the  resolution of 
the  detection  system;  for  diode-array detection  this  is typically 
within  ~ 2  nm;  and  the  spectrum  of  the  analyte  should  not  be 
different from  that of  the  standard  material  for  those  parts of 
the  spectrum  with  a relative absorbance  >10%  of  the  absorbance  of 
the  standard  material;  this criterium is met  when  the  same  maxima 
are  present  and  at  no  point  is the  difference  between  the  two 
spectra more  than  10%  of  the  absorbance  of  the  standard  material. 
The  values  for  the  limits of  detection  by  both  HPLC  and  TLC  and 
the  limits of  identification by  HPLC  diode-array are  given  in 
table 1 taken  from  the  paper  by  Van  Ginkel  et al.,  (1989). 
Cy  4.5/5 Table  1. 
Compound  Limit  of  Detection  Limit  of 
Azaperol 
Azaperone 
Carazolol 
Xylazine 
Haloperidol 
Acepromazine 
Propiopromazine 
Chlorpromazine 
(ug  per  kg) 
HPLC  TLC 
<1  1 
<1  1 
<1  0.3 
2.5  3 
2.5  6 
5  0.3 
5  0.3 
10  0.3 
Identification 
(ug  per  kg) 
2.5 
2.5 
1 
10 
10 
10 
10 
25 
Recovery 
n = 6 
%  so  (%) 
64  4.4 
60  2.3 
56  7.5 
31  7.0 
59  6.0 
55  3.9 
61  11 
59  11 
10.2.  RECOVERIES; 
The  recoveries  of  tranquillizers and  carazolol  from  spiked 
samples  at concentration  ranges  1-5  times  the  limit of  detection 
was  reported  by  Van  Ginkel  et al.,  (1989)(see  table 1).  The 
recoveries  are  calculated from  their relative  UV  absorbances. 
These  values  correspond  to  the  actual  recovery  in  the  HPLC 
fractions  and  are  not  corrected for  aliquot factors.  With  the 
exception  of  xylazine  all  recoveries  are  between  55  and  64%.  The 
lower  recovery  of  xylazine  is caused  by  incomplete  elution from 
the  SPE  cartridge. 
11.  SPECIAL  CASES. 
12.  NOTES  ON  PROCEDURE. 
13.  SAMPLE  CONTROLS 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS. 
See  abbreviations  in  Annex  I,  Section  12  of  Manual. 
16.  FLOW  DIAGRAM 
Homogenise  kidney  ----->alkaline digest ----->extract with  diethyl  ether 
------> SPE  clean-up  ------> HPLC  ------> TLC  -----> Results. 
Cy  4.5/6 Cy  4.6.  TRANQUILLIZERS  - IDENTIFICATION  USING  GC-MS  CONFIRMATION  FOR 
RESIDUES  OF  TRANQUILLIZERS  IN  PIG  KIDNEYS. 
WARNING  AND  SAFETY  PRECAUTIONS 
SAFETY 
Organic  solvents  - all organic  solvents  must  be  treated as  potentially 
hazardous  and  all  procedures  using  them  must  be  performed  in  a  fume 
cupboard. 
Dilute  the  concentrated  sulphuric with  care. 
0.  INTRODUCTION 
Tranquillizers  and  the  B-blocker  carazolol  are  used  to  aid  the  management 
of  stress  in  many  veterinary practices.  Of  particular  interest for 
residues  is the  treatment  of  pigs  to  prevent  mortality and  loss  of  meat 
quality during  transport to  the  slaughterhouse.  The  time  between  drug 
administration  and  slaughter  is usually not  more  than  a  few  hours  and  this 
can  result  in  high  residues  in  the  edible tissues. 
1.  SCOPE 
The  use  of  many  of  the  tranquillizers and  carazolol  varies  throughout  the 
EEC.  To  ensure  that farmers  are  not  using  these  drugs  in  non-approved 
situations  and  to  control  the  use  in  meat  producing  animals  samples  of 
kidneys  are  taken  at slaughterhouses  and  screened  for  the  presence  of  these 
compounds  using  a  number  of  techniques  (see  Section  4)  and  method  Sg  4.1. 
Whenever  there  is a  positive screening  result,  this must  be  confirmed. 
This  work  is carried out  in  compliance  with  the  Residues  Directive 
(86/469/EEC). 
2.  FIELD  OF  APPLICATION. 
This  method  is  used  for  confirmation  of  the  presence  of  five  tranquillizers 
in  pig  kidney.  The  limits of  identification are  50  ug  per  kg  kidney  for 
the  tranquillizers.  Azaperone  forms  a major  metabolite,  azaperol,  and  the 
two  compounds  appear  together  as  residues.  The  method  is operated  at 
RIKILT-DLO  in  the  Netherlands. 
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4.  DEFINITIONS. 
Tranquillizers  content  is taken  to  mean  the  amount  of  tranquillizers  in 
kidney  determined  according  to  the  described  method  and  expressed  as  ug 
tranquillizers per  kg  test sample. 
5.  PRINCIPLE. 
The  method  comprises  four  stages 
- Samples  of  kidney  are extracted with  acetonitrile 
- clean-up with  Sep-Pak  C18  cartridges 
- solvent/solvent partition 
- confirmation  of  tranquillizers by  GC-MS  of  selected  HPLC  fractions. 
6.  MATERIALS 
6.1.  Chemicals 
Note:  The  chemicals  were  all  of  analytical  grade  and  obtained  from  Merck 
unless  stated otherwise.  Reagents  of  similar quality may  be  used  from 
other  sources. 
6.1.1 
6.1.2 
6.1.3 
6.1.4 
6.1.5 
6.1.6 
6.1.7 
6.1.8 
6.1.9 
6.1.10 
6.1.11 
6.1.12 
6.2 
6.2.1 
6.2.2 
6.2.3 
Acetone  (Merck-14) 
Methanol  (Merck-6009) 
25%  ammonia  solution  (Merck-5432) 
n-Hexane  (Merck-714) 
Acetonitrile,  HPLC  grade  (Merck-3) 
Sodium  chloride  (Merck-6404) 
Acetic  acid  (Merck-63) 
Anhydrous  sodium  acetate  (Merck-6268) 
Cone.  sulphuric  acid  (Merck-714) 
Sodium  hydroxide 
Tert-butyl  methyl  ether 
Ethyl  acetate  (Uvasol  grade)  (Merck-863) 
Solutions 
Sodium  chloride  solution;  Dissolve  100  g sodium  chloride  in 
water  and  make  up  to  1 L. 
Sulphuric  acid  solution,  0.01  - 0.05M;  Mix  28  mL  of  sulphuric 
acid  (6.1.9)  in  a beaker  with  500  mL  water.  Allow  the  solution 
to  reach  room  temperature.  Transfer  20  to  100  mL  of  this 
solution  to  250  mL  water  in  a  1 L beaker.  Fill  the  beaker  with 
more  water. 
Acidic  Acetonitrile  :  Add  1 mL  of  0.05M sulphuric  acid  solution 
(6.2.2)  to  100  mL  acetonitrile. 
Cy  4.6/2 6.2.4 
6.3. 
6.3.1. 
6.3.2. 
6.3.3. 
6.3.4 
6.4 
7. 
7.1 
7.2 
7.3 
7.3.1 
7.4 
7.5 
7.6 
7.7 
7.8 
7.9 
7.10 
7.11 
7.11.1 
7.11.2 
0.5M sodium  hydroxide.  Dissolve  20  g sodium  hydroxide  in  600  ml 
water  and  make  up  to 1 L with  water. 
Standards;  Acepromazine,  Azaperol  and  Haloperidol  (RIVM) 
Chlorpromazine  hydrochloride,  Propionylpromazine  and  xylazine 
(Sigma).  Azaperone;  (Janssen  Pharm- Beerse,  Belgium) 
Stock  Standards.  Weigh  accurately  10  ±  1 mg  of  each  individual 
standard  (6.3)  into a  100  ml  graduated  flask.  Make  up  to  100  ml 
with  methanol.  The  solution  is stored  in  the  dark  at 4-8°C  and 
is stable for  up  to one  year. 
Working  Standards.  Pipette 1 ml  of  stock  standard for 
acepromazine  and  haloperidol,  chlorpromazine  hydrochloride, 
propionylpromazine  and  azaperone  into  a  100  ml  graduated  flask 
and  make  up  to  100  ml  with  sulphuric  acid  solution,  0.01  - 0.05M, 
(6.2.2).  The  concentration  of  each  standard  is 1 mg  per  L. 
Working  Standard  for  azaperone  and  azaperol;  Pipette 1 ml  of 
stock  standard  for  azaperol  and  azaperone  into a  100  ml  graduated 
flask  and  make  up  to  100  ml  with  0.01M sulphuric  acid  solution, 
(6.2.2).  Transfer  20  ml  of  this solution  into  another  100  ml 
graduated  flask  and  make  up  to  100  ml  with  sulphuric  acid 
solution,  0.01M,  (6.2.2).  The  concentration  of  each  standard  is 
0.2  mg  per  L. 
Internal  standard  for  GC-MS.  Make  up  a  solution of  2 ng  per  ~L 
of  2,3,4-2,4' ,5'-hexachlorobiphenyl  (PCB)  (Promochem,  Wesel, 
Germany)  in  ethyl  acetate  (6.1.12). 
Control  Samples;  Certified blank  samples  of  pig  kidneys  should 
be  spiked  with  the  standards  at concentrations  of  20  and  50  ~g 
per  kg.  Do  this  by  pipetting  100  or  250  ~L of  the working 
standard  6.3.2 and/or  6.3.3  into  an  80  ml  centrifuge tube 
containing  5 g homogenised  sample  and  allow  to  stand  for  10  min. 
before  extraction. 
EQUIPMENT 
Analytical  balances 
Normal  laboratory glassware  including  graduated  volumetric 
flasks,  100  ml  capacity 
Centrifuge  (MSE-Coolspin) 
Polypropylene  centrifuge tubes,  capacity 80  ml 
Ultrasonic  bath 
Sep-Pak  C18  cartridges  (Waters  art.  51910) 
Heating  block  with  thermostat  and  evaporation  system  with 
nitrogen  (Pierce Reacti  Therm  Module  ~ 18790  and  Pierce  Reacti 
Vap  ~ 18780) 
Vibromixer 
Food  Processor  (Moulinette) 
Syringes,  50  ml  (Terumo) 
pH  meter 
GC-MS 
GC-MS  is Hewlett  Packard  HP-MSD  equipped  with  a  HP5890A  gas 
chromatograph,  a model  HP5970B  mass  selective detector,  a  model 
HP7673A  autosampler  and  a model  HP59970C  chemstation. 
Conditions 
GC  column 
Carrier gas 
Fused  silica capillary column,  25  x 0.22 
mm.  i.d.  coated  with  0.12  ~m layer  of  CP  Sil-5 
Helium,  linear velocity,  30  em  per  sec 
Cy  4.6/3 Split 
Septum  flush 
T-injector 
Injection 
T-oven 
MS  interface 
T interface 
Mass  range 
Ion  source 
t-measuring 
20  mL  per  min,  opened  4 min  after  injection 
3 mL  per  min,  opened  4 min  after  injection 
260°C 
5  ~L splitless 
80-260°C;  rate  10°C  per  min; 
initial  hold  2 min;  final  hold  2 min. 
direct coupling  of  column  to  ion  source 
260°C 
m/z  40-800 
Electron  impact  (EI),  70  eV 
50  ms 
8.  SAMPLES  AND  SAMPLING  PROCEDURE. 
N.B.  Attention  is  drawn  to  section 6.3.1  and  to  ISO  document  78/2-1982  and 
also  the  following  notes  derived  from  Annex  II  of  2052/VI/84-EN. 
8.1. 
8.2. 
8.3. 
8.4. 
9.0 
9.1 
9.2 
9.3 
9.4 
9.4.1 
9.4.2 
9.4.3 
9.4.4 
9.4.5 
9.4.6 
9.5 
9.6 
Nature  of  the  Sample;  Samples  shall  be  such  as  to enable  the 
detection of  residues  in  meat  as  defined  in  Directive 64/433/EEC. 
Size  of  Sample;  The  size of  the  sample  must  be  large  enough  to 
allow  the  method  to  be  carried out  and  to allow  repeat analysis 
where  required. 
The  samples  must  be  taken  and  packed  in  such  a way  as  to allow 
proper  identification  in  the  laboratory. 
The  method  of  packing,  preservation  and  transport must  maintain 
the  integrity of  the  sample  and  not  prejudice  the  result of  the 
examination. 
Samples  for  the  analysis of  tranquillizers must  be  stored  and 
transported  at temperatures  below  -18°C. 
PROCEDURE 
Homogenise  the  kidney  sample  in  a food  processor  (7.8) 
Weigh  10  g of  the  homogenised  sample  into  an  80  mL  centrifuge 
tube  (7.3.1). 
Pipette  20  mL  acetonitrile  into  the  tube.  During  the  addition 
the  sample  is mixed  gently  on  a Vibromixer.  Increase  the  speed 
to  1500  rpm  for  45  sec.  Transfer  the  tubes  to an  ultrasonic bath 
for  2 min.  Centrifuge  for  5 min  at 4000  g. 
Clean  up  with  Sep-Pak  cartridges; 
Activate  the  cartridges  (7.5)  with  5 mL  methanol  and  5 mL  water. 
Drain  the  cartridges using  a  syringe  (7.9). 
Add  50  mL  10%  sodium  chloride  solution  (6.2.1)  and  7.5  mL 
supernatant  from  the  sample  extract  (9.3)  together,  mix  and  flush 
through  the  column. 
Pass  through  the  column  1 mL  0.01M sulphuric  acid  (6.2.2)  and 
then  2 mL  of  air. 
Prepare  calibrated 10  mL  test tubes  by  washing  with  ammonia 
solution  (6.1.3),  water,  methanol  and  acetone. 
Elute  the  analytes with  2 mL  acidic acetonitrile solution  (6.2.3) 
into the  prepared  test tubes  (9.4.5). 
Reduce  the  volume  of  the  eluate to  300  ~L by  evaporation with 
nitrogen  on  a  heating  block  at 70°C.  Do  not  dry. 
Add  immediately  1 mL  n-hexane.  Mix  for  30  sec  on  a Vibromixer  at 
Cy  4.6/4 700  rpm  and  centrifuge at 2000  g for  5 min. 
9.7  Discard  the  hexane  fraction  and  repeat  step 9.6.  and  discard  the 
hexane  fraction. 
9.8  Adjust  the  pH  to  10  by  the  addition  of  150  ~L of  0.5M sodium 
hydroxide. 
9.9  After  gentle mixing  add  1 mL  tert-butyl  methyl  ether.  Vortex  for 
30  sec.  Centrifuge.  Transfer  the  upper  organic  phase  into a  4  mL 
vial. 
9.10  Repeat  9.9  two  times. 
9.11  Evaporate  the  combined  organic  phases  to  dryness  using  a  stream 
of  nitrogen  and  at 30°C. 
9.12  Dissolve  the  residue  in  25  ~L of  the  PCB  internal  standard 
solution  (6.3.4)  with  Vortex  mixing. 
9.13  Inject 5  ~L into  the  GC-MS  system. 
9.14  With  each  series of  samples  standard  solutions of  the  standards 
of  interest over  the  range  0 - 10  ng  per  ~L were  analyzed. 
10.0  CALCULATION  OF  RESULTS 
10.1  The  MS  spectra were  evaluated  according  to  the criteria  in  EC 
93/256  (see  section  5).  The  reproducibility for  four  ions  is 
good  for all  the  tranquillizers except  xylazine  and  haloperidol 
and  also carazolol.  These  latter compounds  have  to  be  excluded 
from  the  test. 
10.2  Data  on  repeatability of  retention times. 
The  retention times  in  minutes  and  their percentage  coefficients 
of  variation  (in  parenthesis)  for  10  analyses  were;-
PCB  138  (IS),  16.125  (1.5%);  xylazine,  12.731  (4.2%); 
chlorpromazine,  17.593  (2.0%);  azaperone,  19.152  (2.3%); 
acepromazine,  19.238  (1.3%);  azaperol,  19.599  (2.6%); 
propionylpromazine,  19.817  (2.0%);  haloperidol,  20.993  (2.5%) 
10.3  Repeatability of  Ion  intensity.  n =  10,  CV  in  parenthesis 
C  t  t•  .  5  L  oncen  ra  1on  lS  ng  per  ~ . 
Analyte  Base  Ion  Ion  Ion 
Peak  m/z  (CV%)  m/z  (CV%)  m/z  (CV%) 
PCB  138  (IS)  360 
Xylazine  205  220  (19.0)u  177  (13.8)u  145  (16.0)u 
Chlorpromazine  318  272  (  1.1)  86  (3.3)  233  (2.6) 
Azaperone  107  233  (3.6)  165  (3.6)  309  (4.6) 
Acepromazine  326  280  (0.9)  241  (4.2)  197  (7.0) 
Azaperol  107  235  (7.0)  121  (4.2)  222  (5.9) 
Prop i ony  l_promaz i ne  340  294  (3.8)  255  (3.3)  197  (5.0) 
Haloperidol  224  237  (6.0)u  123  (12.2)u  206  (11.7)u 
Superscr1pt  u means  result does  not  meet  cr1ter1a  1n  EC  93/256. 
Ions  are  in  order  of  intensity. 
Data  in  10.2  and  10.3  are  from  Hoogland  et al,  (1991). 
All  four  ions  can  be  reliably detected  at concentrations  of  50  ~g per  kg 
kidney. 
Cy  4.6/5 10.4  Recoveries;  No  data  available. 
The  percentage  recoveries  must  be  in  the  following  ranges; 
Carazolol,  84-113;  xylazine,  24-80;  azaperone,  74-124;  haloperidol,  75-115; 
acepromazine,  78-124;  propionylpromazine,  77-113;  chlorpromazine,  58-128. 
11.  SPECIAL  CASES. 
Interference;  The  presence  of  the  compounds;  promazine,  diazepam, 
oxazepam,  amitryptyline,  lorazepam,  prochlorperazine,  nefofam,  cyclizine, 
perphenazine  and  hydroxizine  in  kidney  samples  did  not  interfere with  the 
SIM  analysis of  the  compounds  investigated. 
12.  NOTES  ON  PROCEDURE. 
The  analytes  are  unstable  in  light.  Keep  all  samples  in  the  dark  and  work 
only  under  an  amber  light. 
13.  SAMPLE  CONTROLS 
14.  TEST  REPORT 
15.  LIST  OF  ABBREVIATIONS. 
See  abbreviations  in  Annex  I,  Section  12  of  Manual. 
16.  FLOW  DIAGRAM 
Homogenise  kidney  ----->  extract with  acetonitrile ----->  C18  Sep-Pak 
I 
I 
I 
I 
l 
Identify &  Quantify  <------- GC-MS  <-------- Solvent/solvent partition 
(EI-mode) 
Cy  4.6/6 7.0  THE  CONCENTRATION  OF  RESIDUES  OF  VETERINARY  DRUGS  AND  LEVELS  OF 
NATURALLY  OCCURRING  STEROIDS  IN  FARM  ANIMALS. 
This  section  provides  information  on  the  residues  and  in  the  case  of 
naturally occurring  substances  found  in  farm  animals  the  physiological 
levels of  substances  of  interest  in  the  control  of  residues  in  farm  animals 
and  their products. 
Part  7.1.  is a copy  of  report produced  for  the  EEC  by  Professor  Hoffmann, 
Veterinary Faculty,  University of  Giessen,  Germany.  None  of  the  data  is 
changed  but  the  report  has  been  edited to  conform  with  the  style of  the 
manual. 
For  the  purposes  of  the  report  by  Hoffmann,  naturally occurring  steroids 
are  considered  to  be  testosterone,  epitestosterone,  oestradiol-17a, 
oestradiol-17B,  oestrone  and  progesterone.  19-nortestosterone  is covered 
in  section  7.2.  as  a  xenobiotic  compound  but  it has  to  be  noted  that this 
compound  occurs  naturally  in  pigs  and  horses. 
Part  7.2.  gives  information  on  the  residues  of  some  key  xenobiotic 
substances  of  special  interest for  residue  control.  It is planned  to 
expand  this section  in  future  editions.  The  drugs  covered  so  far are 
7.2.1. 
7.2.1.1. 
7.2.1.2 
7.2.1.3 
7.2.1.4. 
7.2.2. 
7.2.2.1 
7.2.2.2. 
7.2.2.3. 
7.2.3. 
7.2.3.1. 
7.2.3.2. 
7.2.3.3. 
7.2.4. 
ANABOLIC  AGENTS 
TRENBOLONE 
ZERANOL 
STILBENES,  DES,  HEX,  DE 
19-NORTESTOSTERONE 
ANTIBIOTICS 
SULPHONAMIDES,  (Sulphadimidine,  sulphathiazole) 
B-LACTAMS  (Benzylpenicillin,  penicillin-V) 
CHLORAMPHENICOL 
ANTHELMINTHIC$  AND  PARASITICIDE$ 
BENZIMIDAZOLE$  (Albendazole,  Febantel,  Fenbendazole, 
Flubendazole,  Oxfendazole,  Thiabendazole,  Triclabendazole) 
IVERMECTIN 
CLOSANTEL 
B-AGONISTS 
7/1 7.1.  LEVELS  OF  NATURALLY  OCCURRING  SEX  STEROIDS  IN  EDIBLE  BOVINE  TISSUES 
Reference  Levels  of  naturally occurring  hormones;  report of  Professor 
B.Hoffmann  as  requested with  letter of  October  6,  1987,  Directorate-General 
for Agriculture,  VI/B/II.2;  and  submitted  to  the  Scientific Veterinary 
Committee. 
1.  SCOPE  OF  THE  REPORT 
Among  the  mechanisms  controlling physiology  and  pathophysiology  of  higher 
organisms  autocrine,  paracrine  and  endocrine  regulatory factors  are  of 
utmost  importance.  Hence  their presence  in  all edible animal  and  plant 
products  has  to  be  expected. 
With  this paper  it is  intended  to  present  information  on  the  occurrence  of 
endogenous  sex  hormones  in  edible animal  tissues and  products.  Reference 
will  only  be  made  to  those  data  which  have  been  obtained  by  applying 
adequate  methodology  according  to  presently accepted  reliability criteria. 
Where  possible  suggestions will  be  made  for  upper  tissue concentration 
which  might  serve  as  preliminary aids  to discriminating  between  treated and 
untreated animals. 
2.  INTRODUCTION 
Endogenous  sex  hormones  are  defined  as  substance  of  steroidal  nature 
produced  by  the  male  and  female  gonad.  However,  other endocrine  active 
organs  like the  placenta or  adrenal  gland  may  similarly produce  these 
compounds  in  respectable amounts.  Characteristic of  the  female  animal  is 
the  production  of  oestrogens  (C18-steroids)  and  of  progesterone 
(C21-steroid),  while  sex  steroid production  in  the  male  animal  is 
characterized  by  the  release of  testosterone  (C19-steroid)  from  the  testis. 
In  the female  oestradiol-17B  is the main  product  coming  from  the  ovary 
while  other oestrogens,  like for  example  oestrone  and  oestrone-sulphate, 
represent  the  main  oestrogens  coming  from  the  placenta. 
It should  be  noted  that differences  between  males  and  females  in  respect to 
the  production  of  sex  hormones  are  not  qualitative but  quantitative and 
that within  sexes  production  rates  and  hence  tissue  levels  vary  depending 
on  age  and  physiological  status of  the  animal  (16). 
When  reviewing  the  literature it becomes  evident  that the  only  animal 
species  investigated  in  some  detail  is cattle.  Thus  all  data  presented  in 
this report refer to this species. 
All  the  data  presented  have  been  obtained  by  competitive  protein  binding 
analysis;  in  most  studies,  however,  highly  specific antisera were  used, 
while  only  few  papers  refer to  the  use  of  receptor  proteins.  It should 
further  be  noted  that prior to  protein  binding  analysis additional 
extraction  and  purification steps  had  been  included,  like high  performance 
liquid chromatography,  thin  layer  chromatography  or  column  chromatography. 
As  stated above  the  data  quoted  have  been  obtained with  validated methods. 
7/2 3.  CONCENTRATIONS  IN  EDIBLE  PRODUCTS 
3.1  TESTOSTERONE 
The  levels of  free,  unconjugated  testosterone determined  in  various  tissues 
of  veal  calves,  heifers,  pregnant  cattle and  slaughter bulls are  summarized 
in  Table  1.  Obviously  highest  levels  are  found  in  slaughter bulls with 
fatty tissue showing  maximal  concentrations;  in  the  other animals  highest 
concentrations were  determined  in  the  kidney.  Levels  of  conjugated 
testosterone,  expressed  as  percent  of  total  testosterone,  are  presented  in 
Table  2.  Conjugated  testosterone  is very  low  in  muscle  while  it dominates 
in  the  liver and  is about  equal  to  the  percentage  of  free  testosterone  in 
the  kidney. 
The  cumulation  of  testosterone  in  fat of  bulls can  be  explained  by  the 
ongoing  and  rather continuous  production  of  testosterone  (about  50mg/24h) 
and  the  lipophilic properties of  this steroid.  The  cumulation  of 
testosterone  in  kidneys  of  the  other animals  examined  may  be  due  to the 
presence  of  specific testosterone binding  sites.  In  female  veal  calves 
testosterone  is of  ovarian  and  adrenal  origin  (16). 
Based  on  the  levels  determined  for free  testosterone Table  3 shows  the 
ranking  of  organs  and  tissues  in  cattle subpopulations.  The  fact,  that 
testosterone  is  highest  in  fat of  slaughter  bulls  is well  demonstrated. 
Testosterone  has  also  been  determined  in  milk  of  cattle with  lower  levels 
at oestrus  (50pg/ml)  compared  to  the  luteal  phase  of  the  cycle  (122pg/ml) 
(1).  The  ratio of  free  to  conjugated  testosterone has  been  determined  to  be 
1:1  (3).  Also  the  presence  of  5a-androstane-3,17-dione  (1ng/ml)  and  some  of 
its  isomers  has  been  shown  in  milk  (2). 
3.2  PROGESTERONE 
Tissue  levels of  progesterone  for  female  cattle are  given  in  Table  4.  The 
ongoing  progesterone  production  during  pregnancy  expresses  itself  in  the 
relatively high  levels measurable  in  pregnant  cattle.  The  accumulation  of 
progesterone  in  fatty tissue of  all  types  of  cattle examined  is explained 
by  the  lipophilic properties of  this  steroid hormone.  Hence  also  in  milk 
and  in  milk  products  progesterone  levels  are  correlated with  the  percentage 
of  fat as  shown  in  Table  5. 
In  milk  itself progesterone  levels relate to  the  stage of  oestrous  cycle, 
with  minimal  concentrations at oestrus  and  highest  levels  during  the  luteal 
phase  and  pregnancy  (see  Table  5). 
3.3  OESTROGENS 
Tables  6 - 9 show  data  for  oestradiol-17B,  oestrone  and  total  oestrogens. 
The  term  "total  oestrogens"  refers  to  the  application of  an  assay  using  an 
antiserum with  a  high  cross  reactivity between  oestrone,  oestradiol-17a and 
oestradiol-17B;  other oestrogens  are  less cross  reactive. 
The  levels for oestradiol-17B  are  presented  in  Table  6.  Lowest  levels  have 
been  determined  in  steers,  followed  by  veal  calves  and  heifers;  highest 
levels were  found  in  pregnant  cattle  (as  a result of  placental  oestrogen 
7/3 production).  The  concentrations  determined  in  pregnant  cattle increase with 
the  length  of  pregnancy  and  are  highest  in  liver followed  by  kidney,  fat 
and  muscle.  The  low  levels observed  in  steers show  no  significant 
differences  between  the  various  tissues examined. 
Table  7 gives  the  data  established for  oestrone  .  Since  oestrone  is the 
primary  product  of  placental  oestrogen  production  there  is a dramatic 
increase  during  pregnancy  with  highest  levels measurable  in  fat. 
Total  oestrogens  have  been  determined  in  tissues of  6 female  and  17  male 
veal  calves.  The  results are  presented  in  Table  8 and  figure  1.  There  are 
striking differences  between  the  concentrations  determined  in  liver and 
kidney,  compared  to muscle. 
Figure  1.  Total  oestrogens  in  Calves. 
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Oestrogen  concentrations  in  milk  have  also  been  determined.  Total 
oestrogens  (0.64  - 2.14  ng  per  ml)  were  highest  in  milk  sampled  in  the  five 
day  period  immediately  before  parturition and  fall  below  0.2  ng  per  ml 
after one  day  post-partum  (13),  the  levels obtained  during  other  stages  of 
the  reproductive  phase  are  presented  in  Table  9.  Obviously  there are  only 
small  variations  in  oestradiol-17B  and  oestrone  concentrations,  however,  as 
determined  between  days  205  and  209  of  pregnancy,  oestrone  sulphate  levels 
are  somewhat  higher  than  oestradiol-17B  (13). 
7/4 4.  TENTATIVE  RECOMMENDATIONS  FOR  PRELIMINARY  LEVELS  AS  AIDS  TO 
DISCRIMINATE  BETWEEN  TREATED  AND  UNTREATED  CATTLE 
To  our  present  knowledge  up  to  now  distinctions  between  untreated  animals 
and  those  treated with  oestradiol-17B,  testosterone or  progesterone  can 
only  be  made  on  a quantitative and  not  a qualitative  basis.  This  statement 
is based  on  the  fact  that the  three  steroids mentioned  above 
(oestradiol-17B,  testosterone,  progesterone)  will  enter the  same  metabolic 
pathways,  regardless of  whether  they are  of  endogenous  or  exogenous  origin. 
Thus,  treated animals  can  only  be  identified  if their tissue  levels 
significantly exceed  those  of  untreated  animals;  if such  a  situation  is 
detected  it further  has  to  be  verified that the  particular animal  showing 
this  levels was  clinically sound  and  that no  reproductive  problems,  such  as 
cystic ovaries  or  tumours  of  sex  hormone  producing  organs  had  been  present 
at slaughter. 
Under  practical  conditions,  i.e. when  being  exposed  to  carcasses  or  parts 
of  carcasses  only,  it seems  unrealistic to  distinguish  between  carcasses 
from  steers,  bulls or  heifers.  It might,  however,  be  possible  to  identify 
carcasses  from  veal  calves.  Thus  the  levels for discrimination  to  be  set 
have  to  relate to cattle  in  general  on  one  side  (steers,  bulls,  heifers, 
and  cows,  either pregnant  or  non-pregnant)  and  - where  feasible  - to  veal 
calves  on  the  other  side. 
When  trying to  establish preliminary  levels for  discrimination  the  in  some 
respects  limited  data  base  has  to  be  considered.  Thus  in  order  to account 
for  the  biological  variation  and  following  generally accepted  procedures,  3 
standard-deviations  (SD)  were  added  to  the  calculated mean  values.  The 
resulting figures  were  further rounded  up  to  an  even  number  by  allowing  for 
another  correction  around  10%. 
4.1  TESTOSTERONE 
4.1.1  Female,  sexually  immature  veal  calves 
By  applying  the  above  mentioned  procedure  the  following  figures were 
obtained  from  the  data  presented  for  5 female  veal  calves: 
Tissue  Metabolites  estimated  Mean  value  rounded 
plus  3  SD  up  to 
(  ng  I  g  ) 
Muscle  free  testosterone  0.06  0.07 
Liver  free  and  conj.  testosterone  (3:7)  0.31  0.35 
Kidney  free  and  conj.  testosterone  (1:1)  1.17  1.30 
Fat  free  testosterone  0.53  0.60 
4.1.2  Cattle  including male  veal  calves 
No  special  data  for male  veal  calves  are  available.  However,  as  has  been 
shown  from  determining  testosterone  in  plasma,  testicular function  is well 
expressed  even  right after parturition and  many  bull  calves  may  have 
entered  the  process  of  puberty  at the  time  of  slaughter.  Hence  they  have  to 
be  considered with  the  other  types  of  cattle.  There  in  respect  to  the 
classification of  carcasses,  preliminary  levels for discrimination  have  to 
be  delineated  from  the  bull. 
7/5 Tissue  Metabolites  estimated  Mean  Value  rounded 
Muscle 
Liver 
Kidney 
Fat 
free  testosterone 
free  and  conj.  testosterone  (3:7) 
free  and  conj.  testosterone  (1:1) 
free  testosterone 
4.2  PROGESTERONE 
plus  3SD  up  to 
2.97 
6.55 
18.63 
37.00 
(  ng  I  g ) 
3.20 
7.00 
20.00 
40.00 
4.2.1  Sexually  immature  male  and  female  veal  calves 
Since  it can  be  assumed  that ovarian  progesterone  production  has  not  yet 
started  in  female  veal  calves  going  to  slaughter,  the  available data  for 
5(4)  male  veal  calves  can  be  taken  to  set preliminary  levels of 
discrimination  for  the whole  group  of  veal  calves. 
Tissue  Metabolite  estimated  Mean  value  rounded  up  to 
plus  3  SD 
(  ng  I  g  ) 
Muscle  progesterone  0.51  0.55 
Liver  progesterone  0.60  0.70 
Kidney  progesterone  1.09  1.20 
Fat  progesterone  13.30  15.00 
4.2.2  C a  t  t  1 e 
With  respect  to  the  frequent  slaughtering  of  pregnant  cattle,  levels of 
discrimination  must  be  based  on  the  progesterone  concentration  determined 
in  tissues obtained  from  this type  of  animal. 
The  figures  given  below  (preliminary  levels of  discrimination)  are  derived 
from  3 animals  for  muscle,  liver and  kidney  and  10  animals  for fat. 
Tissue  Metabolite  estimated  Mean  value  rounded  up  to 
plus  3 SD 
(  ng  I  g  ) 
Muscle  progesterone  29.90  32.00 
Liver  progesterone  7.53  8.50 
Kidney  progesterone  11.77  13.00 
Fat  progesterone  656.40  700.00 
4.3  OESTROGENS 
As  is obvious  from  Tables  6,  7,  and  8 the  data  obtained  so  far for 
oestrogens  are  less coherent  than  those  obtained  for  testosterone and 
progesterone.  This  may  be  due  to  slight methodological  differences  between 
the  various  laboratories particularly in  relation to  purification steps or 
other  types  of  antisera used.  The  most  homogeneous  pool  has  been  obtained 
for  oestrone,  which  is a major  metabolite  of  oestrogen  metabolism  in  cattle 
(16).  Thus  it is suggested  to  use  oestrone  as  the  marker  compound  for 
distinction  between  treated and  untreated  animals 
716 It must  further  be  assumed,  that  liver and  kidney  particularly contain 
conjugated  oestrone.  However,  no  data  in  relation to the occurrence  of  this 
steroid  in  tissue of  untreated cattle have  been  reported. 
Hence  for  the  time  being  only  free oestrone  can  be  used  as  a marker 
compound;  yet  it is strongly recommended  to  carry out  extra work  to  allow 
the  inclusion of  conjugated  oestrone  and  to  possibly establish a firm  data 
base  for oestradiol-17B. 
4.3.1  Sexually  immature  male  and  female  veal  calves 
Tissue  Metabolite  estimated  Mean  value  rounded  up  to 
plus  3  SD 
(  ng  I  g  ) 
Muscle  oestrone  0.19  0.20 
Liver  oestrone  0.47  0.50 
Kidney  oestrone  0.16  0.20 
Fat  oestrone  0.53  0.60 
4.3.2  C a  t  t  1 e 
In  respect  to the  frequent  slaughtering of  pregnant  cattle,  levels  of 
discrimination  must  be  based  on  the  oestrone  concentration  determined  in 
tissues obtained  form  this type  of  animal. 
Tissue  Metabolite  estimated  Mean  Value  rounded  up  to 
plus  3  SD 
(  ng  I  g  ) 
Muscle  oestrone  1.24  1.30 
Liver  oestrone  0.38  0.40 
Kidney  oestrone  0.77  0.90 
Fat  oestrone  8.42  9.00 
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7/8 Table  1:  Levels  of  free endogenous  testosterone  in  edible animal  tissues 
(ng/kg  mean  ± SD). 
muscle  1  iver  kidney  fat 
female  veal  16  ± 13  39  ± 18  256  ± 110  178  ±  118 
calves  (1)  n = 5  n = 5  n = 5  n = 5 
heifers  (1)  92  ± 29  193  ± 101  595  ±  650  250  ± 64 
n = 5  n = 5  n = 5  n = 5 
(2)  20  ± 7  13  ± 2  189  ± 92  26  ±  7 
n = 15  n = 10  n = 15  n = 35 
pregnant  cattle 
day  120  (5)  302  ± 163  39  ± 13  1930  ± 453  406  ± 101 
n = 15  n = 8  n = 5  n = 7 
day  180  (5)  343  ± 117  121  ± 19  3505  ± 1537  751  ± 174 
n = 11  n = 11  n = 6  n = 11 
day  240  (5)  418  ± 180  274  ±  69  4014  ± 2269  694  ±  231 
n = 4  n = 4  n = 4  n = 4 
bu 11  (1)  776  ±730  749  ± 405  2738  ± 2192  10950  ± 8683 
n = 4  n = 4  n = 3  n = 5 
(1)  294  ± 319 
n = 4 
Values  in  parentheses  are  number  of  animals. 
Table.  2:  Conjugated  testosterone as  % of  total  testosterone 
in  tissues of  2 female  veal  calves  and 
slaughter  bulls  (1) 
% of  conj.  testosterone 
Animal  muscle  liver  kidney 
Female  veal  calves  below  detection  74  38 
level  70  44 
Bulls  17  76  35 
below  detection  80  40 
level 
7/9 Table  3:  Ranking  of  organ  and  tissue concentration  according 
to  the  presence  of  free  testosterone  in  cattle sub-
populations  (1) 
ranking  factor  and  tissues 
Animal  muscle  liver  kidney  fat 
Female  veal  calf  1  2.4  16.0  11.1 
Heifer  1  2.1  6.5  2.7 
Slaughter  bull  1  1.4  5.2  20.5 
Table  4:  Levels  of  free endogenous  progesterone  in  edible animal  tissues 
(ng/kg  mean  ±  SD). 
muscle  liver 
veal  calves  247  ±  87  269  ±  110 
calves  (4)  n = 5  n = 5 
(14) 
heifers  (14) 
steer  (5)  270  ±  330  260  ±  70 
n = 16  n = 17 
pregnant  cattle 
(5)  10100  ±  6600  3420  ±  1370 
n  =  3  n  =  3 
(14) 
kidney  fat 
456  ±  211 
n = 5 
5800  ±  2500 
n = 4 
16700  ±  16800 
n = 5 
170  ±  140  2480  ±  1610 
n = 18  n = 21 
6190  ±  1860  239000  ±  116000 
n = 3  n = 3 
336000  ±  106700 
n  =  10 
The  values  in  parentheses  are  the  reference  numbers,  n is the  number  of 
animals. 
7/10 Table  5:  Levels  of  free  endogenous  progesterone  in  milk  and  milk  products 
(ug/1  mean  ±  SD). 
Product  fat %  [6]  [7]  [15] 
Skim  milk  0.1  1.4  4.6  ±  0.4  (12)  0.17  ±  0.04e  (10) 
2.1  ±  0.6  (4)  0.84  ±  1.0cl  (10) 
1.1  ±  0.1P  (10) 
Buttermilk  1.0  6.5  4.7  ±  0.8  (?) 
Homogenised  1.5  6.0 
Heated  milk  3.5  11.8 
Normal  milk  3.5  12.5  11.3  ±  0.6  (12)  0.92  ±  0.19e  (8) 
9.5  ±  0.5  (4)  23.1  ±  3.6cl  (8) 
35.7  ±  5.6P  (8) 
Milk  powder  25  98.4 
Cream  32  43  58.7  ±  5.3  (12) 
72.7  ±  5.8  (4) 
Butter  82  300  133  ±  5  (?) 
Butter fat  13  ±  14e  f?) 
360  ±  110c  (?) 
360  ±  110P  (?) 
The  values  in  [  ]  are  reference  numbers,  those  in  (  ) are  the  number  of 
animals. 
e  is oestrus,  cl  is  luteal  phase,  p is pregnancy. 
7/11 Table  6:  Levels  of  free endogenous  oestradiol-178  in  edible animal  tissues 
(ng/kg  mean  ±  SD). 
muscle  liver  kidney  fat 
veal  calves  113  ±  143  73  ±  163  11  ±  10  129  ±  57 
(8)  n = 5  n = 5  n = 5  n = 5 
heifers  (9)  12  ±  18  38  ±  2  40  ±  4  10  ±  3a 
n = 9  n = 9  n = 9  n = 8 
8  ±  1b 
n = 6 
(5)  6  ±  9  2 ±  1  3 ±  3  13  ±  14 
n = 15  n = 10  n = 15  n = 35 
pregnant  cattle 
day  120  (5)  16  ±  12  58  ±  50  127  ±  46  31  ±  13 
n = 8  n = 8  n = 5  n = 7 
day  180  (5)  27  ±  14  380  ±  280  230  ±  100  72  ±  37 
n = 11  n = 11  n = 6  n = 11 
day  240  (5)  33  ±  16  1027  ±  365  274  ±  85  68  ±  35 
n = 4  n = 4  n = 4  n = 4 
month  4  (8)  860  n = 1 
month  9  (8)  370  n = 1 
months  1-3  (9)  5  ±  1 
n = 3 
months  3-6  (9)  22  ±  9 
n = 4 
months  6-9  (9)  163  ±  74 
n = 5 
steer  (9)  14  ±  1  12  ±  1  13  ±  1  10 
n = 14  n = 14  n = 14  n = 1 
(9)  6  [max  13]  4  [max  9]  7 [max14]  7 [max  21] 
n = 43  n = 43  n = 43  n = 43 
(5)  1 ±  0.3  1 ±  0.4  2  ±  2  2  ±  1 
n = 16  n = 18  n = 18  n = 21 
Values  in  (  )  are  the  reference  numbers,n  is  number  of  animals. 
a  is follicular phase  of  cycle;  b is  luteal  phase. 
7/12 Table  7:  Levels  of  free  endogenous  oestrone  in  edible animal  tissues  (ng/kg 
mean  ±  SD). 
veal  calves 
(8) 
heifers  (9) 
(5) 
(12) 
pregnant  cattle 
day  120  (5  ) 
day  180  (5) 
day  240  (5) 
month  4  (8) 
months  1-3  (12) 
(9) 
months  3-6  (12) 
(9) 
months  6-9  (12) 
(9) 
steer  (9) 
(5) 
muscle 
75  ±  38 
n  = 5 
3  ±  1 
n  =  15 
31  ±  4 
n =  8 
203  ±  170 
n  =  8 
482  ±  301 
n  =  11 
523  ±  240 
n  =  4 
120  n  =  1 
13  ±  3 
n  = 5 
186  ±  13 
n  =  9 
208  ±  53 
n  =  9 
5  [max  11] 
n  =  192 
2  ±  0.7 
n  =  16 
1  iver 
204  ±  88 
n = 5 
2  ±  1 
n  =  10 
23  ±  3 
n  =  8 
30  ±  33 
n  =  8 
115  ±  83 
n  =  11 
145  ±  56 
n  =  4 
25  ±  8 
n  =  5 
125  ±  26 
n  =  9 
252  ±  43 
n  =  9 
9  [max  14] 
n  =  192 
0.7  ±  0.2 
n  =  18 
kidney 
47  ±  38 
n  =  5 
1  ±  1 
n =  15 
14  ±  2 
n  =  8 
fat 
275  ±  84 
n  =  5 
40  ±  12a 
n =  8 
48  ±  24b 
n = 6 
11  ±  6 
n  =  35 
28  ±  3 
n =  8 
84  ±  2(?)  780  ±  641 
n  =  5  n  =  7 
166  ±  94 
n  =  6 
142  ±  41 
n  =  4 
10  ±  4 
n  =  5 
262  ±  67 
n  =  9 
550  ±  72 
n = 9 
2717  ±  1259 
n = 11 
2765  ±  1497 
n  =  4 
18  ±  3 
n  =  5 
40  ±  25 
n  =  3 
462  ±  55 
n  =  9 
964  ±  353 
n  =  4 
3687  ±  549 
n  =  9 
3874  ±  1516 
n  =  16 
8  [max  15]  11  [max  26] 
n = 192  n = 192 
1  ±  0.5 
n  =  18 
8  ±  5 
n =  21 
bull  (12)  15  ±  2  13  ±  1  3  ±  0.4  36  ±  5 
n = 7  n = 7  n = 7  n = 7 
Values  in  (  )  are  the  reference  numbers,n  is  number  of  animals. 
a  is follicular phase  of  cycle;  b is  luteal  phase. 
7/13 Tab.  8:  Levels  of  total  oestrogens  in  tissues of  veal  calves  {pg/g;  ±  SO) 
muscle  liver  kidney  fat 
Female  veal  calves  1.8  ±  1.5  600  ±  339  270  ±  227 
Male  veal  calves  35  ±  23  2200  ±  1300  630  ±  310  198  ±  177 
Table.  9:  Oestradiol-17B  and  oestrone  concentrations milk  {pg/ml,  mean± 
SE) 
oestradiol-17B  oestrone 
Oestrus  84  ±  41  58  ±  6 
n = 6  n = 6 
Cl-phase  29  ±  4  45  ±  7 
n = 6  n = 6 
pregnancy  day  55-81  85  ±  9  57  ±  20 
n = 5  n = 5 
day  107-145  52  ±  14  35  ±  13 
n = 4  n = 4 
day  205-209  48  ±  21  97  ± 21 
n =  4  n = 4 
7/14 7.2.  RESIDUES  OF  XENOBIOTIC  VETERINARY  DRUGS. 
7.2.1. 
7.2.1.1. 
7.2.1.2 
7.2.1.3 
7.2.1.4. 
7.2.2. 
7.2.2.1 
7.2.2.2. 
7.2.2.3. 
7.2.3. 
7.2.3.1. 
7.2.3.2. 
7.2.3.3. 
7.2.4. 
ANABOLIC  AGENTS 
TRENBOLONE 
ZERANOL 
STILBENES,  DES,  HEX,  DE 
19-NORTESTOSTERONE 
ANTIBIOTICS 
SULPHONAMIDES,  (Sulphadimidine,  sulphathiazole) 
B-LACTAMS  (Benzylpenicillin,  penicillin-V) 
CHLORAMPHENICOL 
ANTHELMINTHICS  AND  PARASITICIDES 
BENZIMIDAZOLES  (Albendazole,  Febantel,  Fenbendazole, 
Flubendazole,  Oxfendazole,  Thiabendazole,  Triclabendazole) 
IVERMECTIN 
CLOSANTEL 
B-AGONISTS  (Clenbuterol,  Salbutamol) 
This  section  provides  information  on  the  levels of  residues  of  some  of  the 
veterinary drugs.  Importance  is given  to situations where  the 
concentrations  of  residues  are  those  which  are found  when  the  drugs  are 
used  according  to recommended  doses  for  good  veterinary practice  in  those 
situations where  the  drug  is  licensed.  In  countries where  the  drugs  are 
specifically prohibited  the  information  may  be  useful  in  providing  a  guide 
to the  concentrations of  residues which  might  be  encountered  if the  drugs 
are  used  illegally.  There  is also  information  on  residues  of  substances 
which  have  been  used  in  high  dosage  and  at shorter than  recommended 
withdrawal  times. 
Many  drugs  and  particulary antimicrobials  are  administered  in  the feed  or 
drinking water.  The  resultant  absorption  from  the  enteric system  is 
partly dependant  on  the  size of  the molecule.  Thus  with  large  M.Wt 
compounds  (>  500  daltons)  they  are  not  readily absorbed.  This  results  in 
the  drug  being  most  active  in  the  gut  and  not  much  use  for  systemic 
activity.  Also  there  is not  much  of  a residue  problem  for  the  tissues 
since most  of  the  drug  is eliminated  through  the  faeces  or  the  bile. 
With  drugs  of  M.Wt.  <  500  daltons  then  they  are  absorbed  and  can  exert a 
whole  animal  antimicrobial  therapeutic effect and  also  cause  residues  in 
all  the  tissues.  The  residues  are  excreted  in  the  urine  as  well  as  the 
faeces. 
Thus  there are  few  residue  problems  with  most  of  the  high  molecular  weight 
antimicrobial  feed  additives,  and  problems  occur,  especially in  pigs,  with 
the  low  M.Wt.  drugs  namely,  sulphonamides,  tetracylines and  penicillins. 
7/15 7.2.1.  RESIDUES  OF  XENOBIOTIC  ANABOLIC  AGENTS. 
During  the  period  1970  to  the  early 1980's  when  anabolic  agents  were  being 
widely  used  in  several  countries  a  large  amount  of  scientific data  was 
collected on  the  levels of  residues  found  in  animals.  Much  of  the  original 
information  was  for  the  stilbene compounds  and  later for  trenbolone, 
zeranol  and  19-nortestosterone.  Since  the  introduction  by  way  of  the  EEC 
Directive 85/649  of  a  complete  ban  on  the  use  of  xenobiotic  anabolic  agents 
as  growth  promoters  there  has  been  a  number  of  incidences  where  not  only 
the  compounds  mentioned  above  but  also  several  other anabolic  agents  e.g. 
MPA,  MGA,  EE2,  boldenone,  MT,  and  the  B-agonists,  have  been  used  illegally. 
Methods  were  developed  to  detect these  substances  and  to  determine  the 
concentrations  of  residues  which  occur  in  animals  treated with  the  drugs. 
A general  guide  (based  on  published  results)  to  the  concentrations  of 
residues which  might  be  found  following  the  use  of  anabolic  agents  in 
cattle and  sheep  is  shown  in  table 1.  There  will  be  concentrations  outside 
of  these  ranges  which  will  be  lower  with  either the  use  of  very  low  doses 
or  very  long  periods  between  sampling  and  treatment or  high  if very  large 
doses  are  used  e.g.  >  1 gramme,  and  sampled  within  a few  days  of  drug 
administration. 
Table  1.  Concentrations  of Anabolic  Agents  in  Food-producing  Animals. 
Tissue/sample  Concentration  range  ~g per  kg  or  L 
Site of  administration  105  - 108 
Muscle  0.05  - 0.5 
Liver  0.1  - 5 
Kidney  0.05 - 2 
Fat  0.05  - 1 
Urine  0.2  - 100 
Bile  1  - 1000 
Faeces  1  - 500 
Blood  0.01  - 0.5 
7.2.1.1.  TRENBOLONE 
Trenbolone  is the  active component  of  the  veterinary preparation  containing 
trenbolone  acetate.  It is a  steroid with  a  structure similar to other C 18-
androgens.  In  ruminants  trenbolone  is metabolised  from  the  17B-OH  to  the 
17a-OH  form  namely,  epi-trenbolone. 
The  use  of  trenbolone  is prohibited within  the  EEC  but  is allowed  in  other 
countries  including  the  USA.  Some  typical  residue  levels  are  shown  in 
table 2. 
7/16 Table  2.  RESIDUES  OF  IMPLANTS  OF  TRENBOLONE  ACETATE  OUTSIDE  INJECTION  SITE 
(~g per  kg  or  ~g per  L). 
SPECIES  DOSE  DAYS  MUSCLE  LIVER  KIDNEY  FAT  BILE  URINE  Ref. 
(mg)  POST 
DOSE 
cow  300  10  0.13B  0.30B  1 
0.32a 
30  0.17B  0.45B  1 
0.40a 
60  0.03B  0.16B  1 
0.22a 
cow  300  63  1.7a  10.9a  0.13  2 
STEER  300  63  0.30  0.39  0.11  0.24  3 
140E  63  0.25  0.21  0.06  0.18  3 
300Z  60  0.06B  0.09B  0.21B  0.10B  4 
300Z  60  0.03  0.08  0.25  0.07  4 
STEER  200E  60  0.23  0.05  0.08  6 
CALF  140E  78  0.19  0.47  0.19  0.44  5 
CALF  140E  70  0.13  0.52  0.39  6 
1400E  70  0.80  3.45  2.58  6 
RESIDUES  AT  IMPLANT  SITE. 
ANIMAL  DOSE  DAYS  WEIGHT  % DOSE  Ref. 
(mg)  post  dose  (mg  TBA) 
STEER  140  100  8.4  6  7 
300  150  54  18  7 
a  is residue of  alB,  B is residue  of  BTB,  all  other cone.  are  unresolved 
mixture  of  both  isomers.  E is  TBA  in  admixture  with  20-40  mg  E 2-B 
Z is zeranol  implanted  in  same  animal. 
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7.2.1.2.  ZERANOL 
The  use  of  zeranol  is prohibited within  the  EEC  but  is allowed  in  some 
countries  including  the  USA.  Typical  residue  levels  are  shown  in  table 3. 
Table  3.  RESIDUES  OF  IMPLANTS  OF  ZERANOL  OUTSIDE  INJECTION  SITE  (~g per  kg  or 
~g per  L). 
SPECIES  DOSE 
(mg) 
DAYS  MUSCLE  LIVER  KIDNEY  FAT  BILE  URINE  FAECES  Ref. 
POST 
DOSE 
STEER  36  7  0  0.37  0  14  6  3  1 
14  0.28  0.63  0.11  22  5  5 
30  0  0.71  0.03  16  3  3 
70  0  0.1  0.03  0  5  1  0.7 
>90  0  0  0  0  2.5  <1  <0.5 
36  67  0.01  0.35  0.08  0.06  2 
SHEEP  12  2  7  3 
14  2-19 
42  25-78 
70  10 
RESIDUES  AT  IMPLANT  SITE. 
ANIMAL  IMPLANT  DOSE  DAYS  WEIGHT  % DOSE  Ref. 
(mg)  post  dose  (mg  Z) 
STEER  3H-Z  72  65  11  15 
3H-Z  72  125  8.6  12 
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4.  Sharp,  G.D.  and  Dyer,  I.A.  (1972),  Zearalenol  metabolism  in  steers. 
J.Anim.  Sci,  34,  176-179 
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4 7.2.1.3.  THE  STILBENES,  DES,  HEX  AND  DE. 
The  stilbenes were  used  legally for  more  than  20  years,  especially in  the 
USA  and  the  UK.  Drug  disposition  studies using  radiolabelled  DES  provide 
information  on  the  maximum  concentrations  of  residues  in  animals  which  were 
either fed,  implanted  or  injected with  DES.  Residue  data  is also  provided 
where  residues were  measured  in  situations where  the  stilbenes were 
administered  both  legally and  where  misuse  of  the  drugs  was  simulated. 
Table  4.  RESIDUES  OF  IMPLANTS  OF  DES  AND  HEX  OUTSIDE  INJECTION  SITE  (~g per 
kg  or  ~g per  L). 
SPECIES  DRUG  ROUTE  DAYS  MUSCLE  LIVER  KIDNEY  FAT  BILE  URINE  FAECES  Ref 
/DOSE  POST 
(mg)  DOSE 
SHEEP  DES*  0,3-100  7  <1 
STEER 
STEER 
CALF 
CALF 
DES*  0,  20  1 
10 
DES*  I,  28  30 
120 
DES  Inj,100  4 
DES  Inj,200  7 
-DP 
DES  Inj,150  28 
-DP 
DES  Inj,150  90 
-DP 
0.09 
0.04 
0.03 
0.03 
0.09 
0.54 
0.21 
0.05 
<1 
3.9 
0.08 
0.4 
0.7 
0.3 
18.9 
2.3 
0.2 
<1 
3.7 
0.09 
0.3 
0.5 
0.8 
8.9 
1.5 
0.2 
<1 
0.2 
0.1 
<0.05 
8.3 
119 
0.08 
13 
5 
1 
2 
3,4 
5 
5 
5 
5 
CALF 
CALF 
CALF  DES  lnj,200  1-50 
-DP 
>10  >10  6 
STEER  HEX  I,  60 
SHEEP  HEX  I,  15 
POULTRY  HEX  I,  12 
90  0.03 
60  0.08 
44  0.5 
0.1 
1.0 
6.2 
0.5 
3.0 
3.2  0.2  2.4  7,8 
<0.05 
1.3 
4.9  8 
DES*  is radiolabelled  DES  and  values  are  for  total  residues. 
DES-DP  is DES-dipropionate. 
The  following  points  are  relevant; 
Data  is only  available for  residues  of  DES  and  HEX. 
Oral  administration  of  DES  results  in  high  residues  if samples  are 
taken  within  one  or  two  days  of  the  last treatment. 
Implantation  or  injection of  stilbenes  is readily detected  in  faeces, 
bile or  urine. 
Residues  in  muscle  or fat are  extremely  low  and  difficult to detect 
but  residues  are  detectable  in  liver and  kidney. 
High  concentrations  of  parent  drug  may  be  found  at the  injection 
sites. 
REFERENCES; 
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2.  Aschbacher,  P.W.  and  Thacker,  E.J.  (1974),  Metabolic  fate of  oral 
diethylstilbestrol  in  steers.  J.  Anim.  Sci.,  39,1185-1192 
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6.  Karg,  H.,  Meyer,  H.H.D.,  Vogt,  K.,  Landwehr,  M.,  Hoffmann,  B.  and 
Schopper,  D.,  (1984),  In  .. Manipulation  of  growth  in  farm  animals .. ,  Eds. 
J.F.  Roche  and  D.  o•callaghan,  Martius  Nijhoff,  pp.  34-60 
7.  Harwood,  D.J.,  Heitzman,  R.J.  and  Jouquey,  A.  (1980),  A 
radioimmunoassay  method  for  the  measurement  of  residues of  the  anabolic 
agent,  hexoestrol  in  tissues of  cattle and  sheep.  J.  vet,  Pharmacal. 
Therap., l, 245-254 
8.  Heitzman,  R.J.  and  Harwood,  D.J.  (1983),  The  radioimmunoassay  (RIA)  of 
hexoestrol  residues  in  faeces,  tissues and  body  fluids of  bulls and  steers. 
Vet.  Rec.,  112,  120-123 
9.  Herriman,  I.D.,  Harwood,D.J.,  Blandford,  T.  and  Lindsay,  D.,  (1982), 
Distribution of  hexoestrol  residues  in  caponised  chickens.  Vet.  Rec.,  111, 
435-436. 
See  also for methods;  Covey,  T.R.,  Silvestre,  D.,  Hoffman,  M.K.  and  Henion, 
J.D.  (1988),  A GCMS  screening,  confirmation  and  quantification method  for 
oestrogenic  compounds.  Biomed.  &  Environ.  MS.  ~, 45-46. 
7.2.1.4.  19-NORTESTOSTERONE 
Structure and  Metabolites  (Cattle) 
19-nortestosterone 
(NT) 
OH  OH 
epi-19-nortestosterone 
(epi-NT) 
OH 
HO 
H 
5a-oestrane-3B,17a-diol 
NT  is an  androgenic  steroid with  an  anabolic  to androgenic  activity ratio 
greater than  that of  testosterone. 
Metabolism 
Cattle - The  major  metabolite  is epi-19-nortestosterone  (the 17a-ol). 
Minor  metabolites  are  19-norepiandrosterone  and  5a-oestrane-3B,17a-diol. 
All  the  metabolites  and  the  parent  compound  are mostly  in  the  conjugated 
7/20 form  in  urine,  bile,  kidney  and  liver. 
Pigs  - 19-nortestosterone  is a major  metabolite  in  the  urine of  boars 
and  also  cryptorchid  pigs  (Vandenbroek  et al.,  1991).  Epi-19-
nortestosterone was  not  identified as  a urinary metabolite  (Debruyckere  et 
al.,  1990). 
Horses  - The  major  metabolites  are  5a-oestrane-3B,17a-diol  and  5a-oestrane-
3B,17B-diol.  There  are  several  other minor  metabolites  including  19-
norepiandrosterone. 
Natural  Occurrence 
NT  occurs  naturally  in  male  pigs  (Maghuin-Rogister  et al.,  1988; 
Debruyckere  et al.,  1990)  and  stallions  (Houghton  et al,  1984;  Benoit  et 
al.  1985).  The  detection  of  epi-NT  in  urine of  peripartum  cows  provided 
evidence  of  endogenous  production  of  NT  in  late-pregnant  cows  (Vandenbroeck 
et al.,  1991).  More  recent studies report that  NT  is endogenous  in  late-
pregnant  cows  and  new  born  calves  (Meyer  et al.,  1992)  and  also  in  cows  at 
other times  during  pregnancy  (Meyer,  private communication).  NT  was  found 
in  both  uterine  vein  blood  and  jugular vein  blood  of  peripartum  cows. 
During  the first few  days  after parturition the  levels of  NT  fall  below  the 
detection  limit of  the  assay  (40  ng/L).  Epi-19-nortestosterone  (epi-NT) 
was  readily detected  in  the  urine of  peripartum  cows  and  new  born  calves 
(Meyer  et al;  1992)  and  the  result has  been  confirmed  in  other  EC 
laboratories using  the  same  urine  samples  from  the  pregnant  cows  at the 
Munich  laboratory.  Daeseleire et al.,  (1993)  found  no  evidence  of  epi-NT 
in  the  urine of  late pregnant  cows. 
Concentrations  of  NT  and  Metabolites  in  Farm  Animals 
Animal  Tissue  NT  epi-NT  Other 
(~g/L or  (~g/L or  me tabs 
kg)  kg)  I 
Cow  Urine  +ve  up  to  35  +ve 
(late  Blood  (Uterine)  0.6 - 4.4 
pregnant)  Blood  (jugular vein)  0.2  - 0.9 
Calf  Urine  0.2  - 32 
(1-6d) 
Pig  Urine  ca  300  -ve 
(Boar) 
Horse  Urine  +ve  +ve  +ve 
(Stallion) 
A study  in  Belgium  (Daeseleire et al,  1992)  examined  the  urine  of  one 
pregnant  cow  (gestation time  not  stated),  three  non-pregnant  cows  and  six 
steers.  There  was  no  evidence  of  NT  or  epi-NT  but  the  metabolite  5a-
oestrane-3B,17a-diol  was  detected  in  the  pregnant  animal. 
No  measurements  have  been  made  of  naturally occurring  levels  in  bile 
although  the metabolites  of  NT  (e.g.  epi-NT)  should  be  easily detectable  in 
bile if they  are  present  in  any  other tissue or fluid. 
7/21 Exogenous  Nortestosterone 
Nortestosterone  (NT)  is the  active component  of  several  veterinary 
preparations  containing  nortestosterone esterified at the  17B  position 
as  either propionate,  decanoate,  laurate or  phenylpropionate. 
Haasnoot  et al,  (1989)  measured  the  residues  of  both  NT  and  epi-NT  in  the 
urine of  a male  veal  calf weighing  183  kg  injected  intramuscularly with  200 
mg  NT-laurate  and  20  mg  oestradiol-benzoate.  They  recorded  half  lives of 
2 days  for  NT  and  15  days  for epi-NT  with  the  maximum  concentrations  in 
urine  about  7 days  after treatment. 
Most  of  the  data  in  the  literature refers to residues  in  urine  but  some 
values  are  reported for other tissues.  Haasnoot  et al.  (1989)  found  high 
concentrations  of  epi-NT  in  bile samples  and  the  concentration  (55  ~g per 
L)  was  much  higher  than  that found  in  urine  (3.1  ~g per  L)  of  the  same 
calf.  They  also  reported  residues  in  meat  of  three  calves  treated with 
NT-laurate  (as  above)  and  slaughtered  14  days  after treatment.  The 
residues  in  ~g per  kg  were;-
Calf  MUSCLE  LIVER  KIDNEY 
NT  epi-NT  NT  epi-NT  NT  epi-NT 
I  0.1  - 0.2  nd  0.1  0.8  0.5  0.5 
II  0.1  - 0.2  nd  0.1  0.5  0.5  0.6 
III  0.9  - 1.6  nd  <0.05  0.9  0.4  1.2 
The  residues  of  NT  and  epi-NT  were  measured  in  bile and  urine  samples  of 
treated calves  (van  Ginkel  et al.,  1989)(see  figure  2). 
Figure  2. 
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7/22 They  reported that epi-NT  was  the  most  suitable substance  to measure  and 
bile was  better than  urine  because  the  concentrations were  higher  in  bile 
(6  - 18  ~g per  L).  The  ratio of  NT  to  epi-NT  in  the  urine  of  calves 
treated with  the  drug  varies  between  animals  and  time  after treatment  (see 
figure  2).  In  most  cases  the  concentration  of  epi-NT  was  greater than  that 
of  NT. 
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Throughout  the  Community  the  common  methods  for  screening  for  the  presence 
of  antimicrobial  substances  are  those  based  on  the  antimicrobial  activity. 
A widely  used  test for  screening  residues  in  meat  and  offal  is the  Four 
Plate Test  (Bogaerts  and  Wolf,  1980)  and  there  are  several  suitable 
screening  tests available for  milk  (for Review  see  Bulletin of  the 
International  Dairy  Federation  N 2258/1991).  Because  of  the  aspecific nature 
of  these  screening  methods  more  specific methods  (e.g.  the  methods  in 
section  6)  are  needed  to  identify and  quantify the  antimicrobial  residue. 
The  data  given  below  was  mostly  derived  from  such  specific methods. 
7.2.2.1.  SULPHONAMIDES 
INTRODUCTION. 
The  sulphonamides  are  antibiotic substances  used  for  therapeutic and 
prophylactic  purposes  in  all  species  of  farm  animals.  The  most  commonly 
used  sulphonamide  is sulphadimidine  (sulphamethazine).  The  MRL  for 
sulphonamides  used  throughout  the  EEC  is 0.1  mg  of  parent  drug  per  kg 
tissue.  Residues  are  monitored  by  Member  States  and  violations  are  often 
detected especially  in  pigs. 
There  are  many  similarities  in  the  metabolism  and  residue  patterns of 
sulphonamides  and  many  of  the  analytical  methods  are  common  to  the  class of 
drugs.  Because  the  sulphonamides  have  been  widely  used  for more  than  forty 
years  the  information  on  residues  was  mostly  not  determined  by  the  modern 
and  more  acceptable  techniques  used  today.  One  major  study  using  C-14 
radiolabelled  sulphadimidine  in  pigs  was  commissioned  by  the  Food  and  Drug 
Administration,  USA,  (study  No.  224-81-0007)  and  carried out  in  1981.  The 
full  report of  the  study  was  published  in  1984,  FDA  224-81-005.  This 
radiometric  study  of  the  residues  provides  the  most  comprehensive 
information  on  sulphonamide  residues.  Radiometric  studies  using 
sulphadimidine  in  other  species  or  using  sulphathiazole  in  any  species  have 
not  been  reported. 
The  general  metabolism  of  sulphonamides  includes  the  acetylation of  the 
aromatic  amino  group  in  the  reticuloendothelial  cells of  the  liver and  in 
other  tissues yields  N-acetyl- derivatives,  which  are  major  metabolites  of 
sulphadimidine  and  sulphathiazole.  The  desamino-sulphonamides  have  also 
been  identified as  residues  of  the  parent  drug  in  cattle (Woolley  &  Siegel, 
1982)  and  may  be  the  preferred route of  metabolism  in  poultry  (Kietzmann, 
1981)  but  do  not  seem  to  be  an  important  metabolic  product  in  humans.  The 
desamino-metabolite  is thought  to  be  formed  by  bacteria  in  the  gut 
following  oral  administration of  the  drug.  Because  it is  less polar  than 
the  other metabolites  the  desamino-metabolite  is cleared more  slowly  and 
this possibly explains  why  desamino-sulphadimidine  is present  as  a  higher 
percentage  of  the  residues  as  withdrawal  time  increases.  Small  amounts 
(<5%  of  total  residues)  of  polar metabolites  are  produced  but  have  not  been 
identified  in  most  studies,  but  it is thought  that they  are  produced  by  the 
hydroxylation  of  the  aromatic  ring which  may  be  further conjugated  with 
glucuronic  acid.  A complication  is that residues  of  sulphadimidine  in 
liver and  muscle  of  pigs  are  converted  either chemically or  enzymatically 
to  N-glucose-sulphadimidine  during  storage at -20  C.  Thus  the  ratio of 
sulphadimidine  to N-glucose-sulphadimidine  in  pig  meat  will  depend  to  some 
extent  on  how  long  the  meat  is stored  before  eating. 
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The  data  from  six studies give  information  on  residues  of  sulphadimidine  in 
edible tissues of  pigs  and  sheep  and  also  residues  in  milk  and  eggs.  The 
conditions  of  use  are  similar to those  which  might  be  observed  in  practice. 
RESIDUES  IN  PIGS. 
The  radiometric  study  gives  the  only  complete  information  on  total  residues 
because  all  of  the other analytical  methods  miss  one  or  more  of  the 
metabolites.  Other  studies  (Ashworth  et al,  1986;  Samuelson  et al.,  1979) 
are  referenced  at the  end  of  this section. 
RADIOMETRIC  STUDY  OF  SULPHADIMIDINE  IN  PIGS. 
Pigs  were  administered  feed  containing  1lg  mg  sulphadimidine  per  ton  and  76 
~Ci Carbon-14  labelled sulphadimidine  (C  -sulphadimidine)  in  a residue 
depletion  experiment.  The  nature  and  quantity of  residues  in  tissues  and 
excreta were  measured  using  combinations  of  radiometry with  modern  methods 
of  separation  and  identification.  The  results  showed  that sulphadimidine 
is converted  in  the  live pig  to  three major  metabolites,  N-acetyl-
sulphadimidine,  N-glucose-sulphadimidine  and  desamino-sulphadimidine. 
Sulphadimidine  was  also converted  to  N-glucose-sulphadimidine  in  stored 
deep  frozen  liver and  muscle  tissues.  The  major  residues  in  all  tissues 
were  a mixture  of  parent  drug  and  the  three metabolites.  The 
concentrations of  residues were  highest  in  the  blood,  GI  tract plus 
contents,  liver and  kidney  and  depleted  in  all  tissues to  levels  below  0.1 
mg  per  kg  10  days  after drug  withdrawal  (see  table 5). 
TABLE  5.  COMPARISON  OF  SULPHADIMIDIN~ 4
RESIDUES AND  TOTAL  RESIDUES  IN  PIGS 
AFTER  WITHDRAWAL  OF  FEED  CONTAINING  C  -SULPHADIMIDINE. 
TISSUE  Withdrawal  TOTAL  14C  SULPHADIMIDINE 
Time  mg/kg  mg/kg  %TOTAL 
MUSCLE 
8  hours  3.2  1.13  35 
2 days  0.93  0.31  33 
5 days  0.06  0.02  34 
10  days  0.004  0.0006  15 
LIVER 
8  hours  7.0  1.78  25 
2 days  2.4  0.50  21 
5 days  0.23  0.04  18 
10  days  0.06  0.004  8 
KIDNEY 
8 hours  9.3  4.38  46 
2 days  2.8  1.34  48 
5 days  0.18  0.07  40 
10  days  0.03  0.003  10 
FAT 
8  hours  1.2  0.29  24 
2 days  0.38  0.09  23 
5 days  0.02  0.002  12 
10  days  0.003  0.0001  5 
Each  value  is the  mean  for three pigs  •  Data  from  FDA  224-81-005  &  USDA 
SEA-12-14-3001-064  (1984) 
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Lactating  dairy cattle were  administered  therapeutic doses  of 
sulphadimidine  by  either the  intravenous  or  intramammary  routes  and  the 
residues  in  the milk  determined  by  an  HPLC  method,  see  table 6,  (Boisseau, 
1988). 
TABLE  6.  Residues  of  sulphadimidine  in  bovine  milk  treated with  either an 
i.v.  injection of  sulphadimidine-Na  (100  mg  per  kg)  or  after 3 
administrations  of  200  mg  sulphadimidine  and  40  mg  Trimethoprim  in  each 
quarter. 
TREATMENT 
Intravenous  Intramammary 
WITHDRAWAL  TIME  OF  RESIDUES  mg/L  RESIDUES  mg/L 
TIME  (DAYS)  MILKING  MEAN  SD  WT  MEAN  SD 
1st  inj  -1  AM 
2nd  inj -1  PM  9.97  6.54 
3rd  inj  0  AM  3.04  1.29 
0.4  PM  24.6  5.1  0  PM  13.9  3.01 
1  AM  5.74  1.32  1 AM  0.46  0.53 
PM  2.26  0.73  1  PM  0.17  0.16 
2  AM  0.55  0.31  2 AM  0.08  0.05 
PM  0.22  0.12  2  PM  0.02  0.01 
3  AM  0.12  0.07  3 AM  <0.01 
PM  0.06  0.04  3  PM  <0.01 
4  AM  0.04  0.02  4  AM  ND 
PM  0.03  0.02 
5  AM  0.03  0.02 
PM  0.02  0.01 
6  AM  <0.01 
PM  ND  ND 
The  mean  values  are  taken  for five  cows.  ND  is not  detectable  (<0.01  ppm) 
Residues  measured  by  HPLC  method.  Data  provided  by  Boisseau,  1988. 
The  concentrations of  sulphadimidine  in  whole  eggs  after oral 
administration  for 5 days  at the  dose  of  either 1 g or  2 g 
sulphadimidine-Na  per  L in  the  drinking  water  of  laying  hens  are  shown  in 
figure  3.  After withdrawal  of  the  drug  for  a period  of  10  days  the 
concentrations  of  sulphadimidine  were  much  less  than  0.1  mg  per  kg. 
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Each  value  is the  mean  (a)  or  maxima  of  6 birds  laying  a total  of  2 - 6 
eggs  per  day.  Residues  were  measured  by  an  HPLC  method  (Boisseau,  1988). 
RESIDUES  OF  SULPHATHIAZOLE  IN  FARM  ANIMALS  AND  TISSUES. 
There  is  no  definitive radiometric  study  and  only  one  study where 
sulphathiazole  is administered  orally in  pig  feed.  Residues  in  tissues of 
pigs  (see  table  7)  fed  330  mg  sulphathiazole  per  ton  feed  were  highest  in 
liver  (maximum  20  ppm)  and  kidney  (maximum  74  ppm)  12  hours  after 
withdrawal  of  the  drug.  The  concentrations  declined  very  quickly  and  in 
all  tissues were  <0.18  ppm  3 days  after withdrawal  and  only  detectable  in 
one  muscle  sample  (0.01  ppm)  after 10  days  withdrawal  time.  The  residues 
following  large  intravenous  injections of  sulphathiazole  into  both  pigs 
(Bourne  et al.;  1978)  and  sheep  (Bevill  et al.;  1977b)  produced  very  high 
residues  for  the first few  hours  after administration  but  then  the  drug  was 
rapidly excreted  and  the  residues were  ca.  0-0.3  ppm  24  hours  after dosing. 
TABLE  7.  RESIDUES  OF  SULPHATHIAZOLE  IN  PIG  TISSUES  AND  URINE  AFTER  A THREE 
DAILY  ORAL  DOSES  OF  SODIUM-SULPHATHIAZOLE  AT  330  MG  PER  KG  LIVE  WEIGHT. 
Withdrawal  N  RESIDUES  (  mg  per  kg  or  L) 
(days)  Muscle  liver  kidney  fat  urine 
0.5  2  2.8  17  60  3.0 
3  2  0.06  0.06  0.04  0.1 
5  3  0.03  0.01  0.06a  0.06 
7  3  0.11  0.02  0.04  0.13 
10  3  0.00  0.00  0.00  0.00 
12  3  0.00  0.00  0.00  0.00 
1405a 
87.3a 
33.2a 
6.0 
N is number  of  pigs  and  values  are  the  means  except  those  marked 
11a
11  which 
are  results for  only  one  pig.  The  values  in  parentheses  are  the  maximum 
values.  Residues  determined  by  method  of  Annino,  (1961).  (Righter et al., 
(1971). 
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7.2.2.2.  RESIDUES  OF  B-LACTAM  ANTIBIOTICS,  BENZYLPENICILLIN  AND  PENICILLIN 
v. 
SUMMARY 
Benzylpenicillin  is one  of  the  oldest and  most  widely  used  antibiotics.  It 
is used  to  treat bacterial  infections  in  all farm  animals  and  is 
administered  either orally or  parentally.  The  drug  is much  used  in  the 
treatment  of  bovine  mastitis  and  this use  is a major  concern  for  residues 
in  milk. 
RESIDUES  IN  MILK. 
The  persistence of  residues  in  milk  depends  on  the  formulation  and 
administration  of  the  drug,  but  in  the  examples  cited does  not  persist 
beyond  five  days  after the  end  of  treatment.  In  many  countries  there are 
more  than  50  separate  preparations  containing  a penicillin for  the 
treatment  of  bovine  mastitis and  each  formulation  produces  a different 
residue  pattern  in  milk.  Since  all  preparations  cannot  be  covered  some 
studies  recently done  in  France  are  cited  (Moretain  &  Boisseau  1984,  1989) 
as  illustrations of  the  residues  in  milk. 
The  residues  of  benzylpenicillin  in  milk  following  the  administration of 
i.m.  and  intramammary  injections of  benzylpenicillin and/or  procaine 
benzylpenicillin are  shown  in  table 8.  Above  all  they  show  that the 
persistence of  the  residues  depends  on  the  formulation  of  the  commercial 
product. 
7/28 Table  8.  Residues  (~g equiv  to  sodium  benzylpenicillin/L)  in  milk 
Milking  [ •.  INTRAMUSCULAR  •....  ]  [ .••.  INTRAMAMMARY  .... ] 
Number  A  B  c  D  E  F  G 
-2  126  90  72  126  29100  174600  34800 
-1  21  22  41  40  1590  109380  420 
1  114  120  90  120  51650  173400  20520 
2  23  34  38  29  3096  5556  184 
3  7  16  20  11  329  331  15 
4  2  5  8  13  48  26  1 
5  nd  4  2  2  7  4  <1 
6  nd  2  2  1  1  1  <1 
7  nd  1  <1  <1  <1  <1  nd 
8  nd  <1  nd  <1  <1  nd  nd 
9  nd  nd  nd  nd  <1  nd  nd 
10  nd  nd  nd  nd  nd  nd  nd 
Each  value  is the  mean  of  five animals. 
Treatments;  Procaine  benzylpenicillin  (PBP),  benzylpenicillin  (BP) 
A is  40%BP,  60%  PBP  in  aqueous  solution. 
B is  PBP  and  dihydrostreptomycin  in  aqueous  solution with 
polyvinylpyrrolidone. 
C is B plus  lecithin. 
D is B plus  carboxymethylcellulose. 
E is  PBP  plus  neomycin  sulphate  in  fatty alcohols  and  petrolatum. 
F is  PBP  plus  dihydrostreptomycin,  polysorbate-SO  and  colloidal 
propylene  glycolesters of  saturated fatty acids. 
G is PBP  and  glycerolmonostearate  in  peanut  oil. 
Penicillin dosage: 
A,  two  injections  i.m.  of  16.8 mg/kg  B.W.  24  hours  apart. 
B,C,D;  two  injections  i.m.  of  20  mg/kg  B.W.  24  hours  apart. 
E;  two  administrations  of  450  mg/quarter  24  hours  apart 
silica in 
F;  three  administrations  of  1 g/quarter after three  consecutive milkings. 
G;  two  administrations  of  100  mg/quarter  24  hours  apart. 
Data  from  Moretain  &  Boisseau,  1984,  1989. 
RESIDUES  IN  MEAT. 
SUMMARY.  Definitive studies of  residues  of  benzylpenicillin  in  meat  are 
hard  to find  but  there  is evidence  that benzylpenicillin  therapy  in  meat 
producing  animals  leaves  residues  in  meat  even  though  there  is a rapid 
absorbtion  of  the  drug  and  fast clearance from  the  blood.  Residues  persist 
in  meat  for  at  least 24  hours  following  parental  administration.  Because 
procaine  penicillin  is absorbed  more  slowly  the  residues  may  persist 
longer. 
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Guillot  (1983)  injected  intramuscularly a  cow  weighing  450  kg  with  250  ~Ci 
14C-labelled  benzylpenicillin at a dose  of  6.7  mg/kg  B.W.  The  cow  was 
sacrificed two  hours  after the  injection and  the  radioactivity as 
benzylpenicillin equivalents was  measured  by  combustion  analysis  in  a 
number  of  tissues and  fluids.  The  results are  shown  in  table 9.  Moats 
(1984)  injected  intramuscularly a  cow  weighing  600  kg  with  benzylpenicillin 
at a  dose  of  6 mg/kg  B.W.  The  cow  was  slaughtered  two  hours  after the 
injection and  the  concentrations  of  benzylpenicillin  in  tissues and  fluids 
measured  by  both  bioassay  and  HPLC.  There  is a  lack  of  agreement  most 
probably  the  result of  better more  efficient extraction of  benzylpenicillin 
from  cells using  organic  solvents.  Moats  found  that about  90%  of 
benzylpenicillin was  recovered  from  tissues during  the  HPLC  assay. 
Table  9.  Residues  in  mg/kg  of  benzylpenicillin  in  bovine  tissues  and 
fluids  2 hours  after  i.m.  administration. 
[Guillot]  [ •••.••  Moats  .........  ] 
Tissue  14C-activity  Bioassay  HPLC 
Plasma  or  serum  2.7  0.79  0.95 
Bile  117  nm  nm 
Liver  14  0.58  22 
Kidney  30a,  46b  0.55  6.1 
Adrenals  2.4  nm  nm  (4) 
Muscle  0.37-0.76  (5)  0.03-0.05  (4)  0.06-0.18 
Spleen  0.7  nm  nm 
Tongue  0.8  nm  nm 
nm  is not  measured;  a  is cortex;  b is medulla.  The  numbers  in  brackets 
are  the  number  of  different types  of  muscles  examined. 
McCracken  et al.  (1976)  injected calves  with  10  mg/kg  B.W.  benzylpenicillin 
and  slaughtered  the  animals  24  hours  later.  Residues  of  benzylpenicillin 
were  measured  by  bioassay  and  were  >40  ~g/kg in  muscle  and  kidney  and  >40 
~g/1  in  urine. 
McCracken  &  O'Brien  (1976)  injected six calves  twice  i.m.  with  3 mg/kg  B.W. 
benzylpenicillin  24  hours  apart  and  sacrificed the  animals  24  hours  after 
the  last  injection.  The  residues  were  declared  positive when  they 
exceeded  40  ~g/kg,  the  lower  limit of  detection  of  the  bioassay.  All 
calves  were  positive  in  the  following  tissues;  injection site (gluteus 
muscle),  the  gluteus muscle  opposite  to  the  injection site,  pectoral 
muscle,  diaphragm  muscle,  longissimus  dorsi  muscle,  Masseter  muscle, 
kidney,  liver,  heart,  serum.  Positive results were  also observed  for  urine 
5/5,  psoas  muscle  5/6  and  oblique muscle  3/6. 
PIGS. 
Penicillin V is a semi-synthetic penicillin.  The  residues  pattern 
illustrates the  type  of  situation which  may  arise when  penicillins are  used 
as  in-feed  additives.  Forty  pigs  aged  six weeks  were  fed  feed  for  six 
weeks  containing  2 kg  penicillin V per  tonne  feed.  This  dose  is equivalent 
to about  10  mg/kg  B.W.  The  pigs  were  then  fed  drug  free diet.  Pigs  were 
sacrificed  in  groups  of  six at 0,  1,  5,  7 and  84  days  after drug 
withdrawal.  The  tissue residues were  measured  by  a  bioassay  method  with  a 
lower  limit of  detection of  50ug/kg. 
7/30 No  residues were  detected  at any  sampling  point  for  muscle,  liver,skin and 
fat.  In  the  kidneys  residues  were  detected  in  3/6  pigs  in  the  group 
sacrificed at day  0 of  drug  withdrawal.  The  values  of  the  positives was 
54,  60  and  62  ~g/kg which  are  only  just above  the  limit of  the  assay.  No 
residues were  found  in  kidneys  sampled  at  later time  points  (FAO 
Monograph,  36th  JECFA  1990). 
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RESIDUES  IN  EGGS. 
Eggs  from  laying  hens  treated orally at a dose  of  50  mg  per  kg  BW  every  12 
hours  for  3 days  with  a  10%  solution of  CAP  contained  residues  of  CAP  of 
8000  ~g per  kg  at day  5 withdrawal  period,  15  ~g per  kg  at day  10  and  3  ~g 
per  kg  at day  15  in  egg  whites.  Concentrations  in  the  egg  yokes  were  1500 
~g per  kg  at day  1,  8  ~g per  kg  at day  5 and  <1  ~g per  kg  at day  7 
(Boisseau,  1987). 
RESIDUES  IN  CALVES 
Calves  were  injected  intravenously  (i.v.) or  intramuscularly  (i.m.) with 
CAP  and  residues  determined  in  meat  and  at the  injection site.  A summary 
of  the  results  is  shown  in  table 10. 
Table  10.  RESIDUES  OF  CAP  (MG  per  KG)  IN  CALVES. 
TREATMENT  WITHDRAWAL  INJECTION  MUSCLE  MUSCLE 
TIME  (HOURS)  SITE  SHOULDER  GLUTEAL 
33  mg/kg  BW  2  915  5.2  2.2 
i.  m.  6  663  6.1  7.3 
24  288  2.1  2.5 
48  11.6  0.5  0.5 
72  10.6  0.9  0.8  ? 
66  mg/kg  BW  2  2820  6.6  7.9 
i.  m.  4  1123  10.9  7.1 
24  389  7.3  8.2 
48  265  0.2  0.6 
72  12.8  0.7  0.6 
66  mg/kg  BW  2  75.9  68.2  74.4 
i.  v.  4  33.6  33.6  32.6 
24  0.3  0.2  0.4 
48  0.1  0.4  0.1 
The  values  for  the  i.  m.  injections are  the  mean  values  for  two  animals, 
the  values  for  the  i.v.  data  are  for  single animals  {Epstein  et al,  1986). 
RESIDUES  IN  MILK 
During  the  preparation  of  Reference  materials  (RMs  see  section 8) 
containing  CAP  in  milk  samples  it was  necessary  to follow  the  depletion  of 
CAP  in  the  milk  of  two  cows  treated with  two  injections  (15  hours  apart)  of 
CAP  at a dose  of  20  mg  per  kg  body  weight  (PreiB  et al,  1993).  The 
depletion  curves  are  shown  in  figure  4. 
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7.2.3.1. 
ANTHELMINTHICS  AND  PARASITICIDES 
BENZIMIDAZOLES 
The  benzimidazoles  are  characterised  by  a  broad  spectrum  of  anthelminthic 
activity and  low  mammalian  toxicity.  They  are  not  normally  allowed  for  use 
in  lactating or  pregnant  animals.  Among  the  benzimidazoles  most  widely 
used  in  farm  animals  are  albendazole,  fenbendazole,  oxfendazole  and 
thiabendazole.  Also  used  is febantel,  a  pro-benzimidazole  which  readily 
breaks  down  in  the  gut  of  the  animal  to  form  fenbendazole,  oxfendazole  and 
their metabolites.  The  benzimidazoles  are  readily metabolised  by  oxidation 
of  the  sulphur  bridge  to form  the  sulphone  and  sulphoxide  derivatives  and 
these metabolites  are  normally  major  fractions of  the  residues. 
7.2.3.1.1.  ALBENDAZOLE 
JECFA  assessed  Albendazole  at their 34th  meeting,  1989,  and  reported  their 
findings  on  the  residues  in  FAO  Food  and  Nutrition  Paper  41/2  (1990). 
The  residue  data  clearly indicate that high  (up  to  30  mg  per  kg) 
concentrations  of  total  residues  are  present  during  the first few  days 
after administration of  drug.  These  residues  are  readily extractable and 
could  be  considered  bioavailable.  The  total  residues  are  highest  in  the 
liver and  kidney  and  fall  gradually  in  cattle to about  1 mg  per  kg  after 20 
days  withdrawal  time.  However  by  about  day  10  most  of  the  residues  are  not 
extractable with  ethyl  acetate suggesting  a  large  percentage  of  bound 
residues of which  less  than  10%  are  bioavailable.  The  total  residues  in  the 
main  edible tissues,  muscle  and  fat are  high  on  day  1 but  fall  very  rapidly 
to  levels <0.1  mg  per  kg  by  day  4. 
The  parent  drug,  albendazole,  is only  found  as  a  residue  in  edible tissues 
during  the first few  days  after drug  administration  and  should  not  be 
detected  in  farm  animals  treated according  to the  recommended  withdrawal 
periods  observed  for  albendazole  by  most  countries.  Of  the  three main 
metabolites,  albendazole  sulphone,  albendazole  sulphoxide  and  2-amino-
albendazole  sulphone,  the  metabolite  2-amino-albendazole  sulphone  can  be 
considered  a  good  "Marker  Residue"  in  liver tissue since  it represents 
about  18%  of  the  total  residues  at withdrawal  times  extending  beyond  4 
days. 
The  levels of  the marker  residue,  2-amino-albendazole  sulphone,  under  four 
different conditions of  use  at a  normal  dosage  are  shown  in  table 11. 
Table  11.  Concentrations  of  2-amino-albendazole  sulphone  in  liver of 
cattle treated with  different formulations  of  albendazole  at a  single dose 
of  10  mg  per  kg  body  weight. 
Withdrawal 
Time  (days) 
12 
16 
20 
24 
28 
32 
Bolus  Suspension  Premix  Paste 
-----------------(ug/kg)-----------------
364  nm  307  nm 
227  nm  273  nm 
146  131  201  148 
146  113  137  100 
115  78  101  81 
79  52  86  64 
Data  from  FAO  Food  and  Nutrition  Paper  41/2  (1990),  pp  8. 
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Fenbendazole,  oxfendazole  and  Febantel  are  considered  together  because  they 
have  interconnected  metabolism.  Febantel  is a  pro-benzimidazole  which 
readily breaks  down  in  the  gut  of  the  animal  to  form  fenbendazole, 
oxfendazole  and  their metabolites.  The  metabolites  are  formed  by  the 
oxidation  of  the  sulphur  to  the  sulphone  or  sulphoxide  and  the  loss  of  the 
acetyl  group  to  yield the  amine.  The  main  pathways  are;-
Febantel  ---> Fenbendazole  ---> Oxfendazole  ---> Oxfendazole  sulphone 
(fenbendazole  sulphone) 
The  MRLs  set by  the  CVMP  and  the  JECFA  are  the  same  for  all  three  compounds 
and  expressed  as  the  sum  of  the  residues  of  fenbendazole,  oxfendazole  and 
oxfendazole  sulphone.  They  are  1000  mg  per  kg  for  liver and  10  mg  per  kg 
for  muscle,  kidney,  fat  and  milk.  Using  the  recommended  doses  and 
withdrawal  times  for  all  three drugs  the  MRLs  should  not  be  exceeded  in 
practice.  It is noteworthy  that the  MRLs  set by  the  CVMP  are  lower  than 
those  suggested  by  JECFA  (see  section  2.2). 
7.2.3.1.3.  FLUBENDAZOLE. 
Flubendazole  is  an  anthelmintic for  use  in  pigs  and  poultry.  In  both 
species  the  major  metabolite  is  (2-amino-1H-benzimidazol-5-yl)-4-
fluorophenyl-methanone.  The  highest  concentrations  of  residues were  found 
in  the  liver and  egg  yolks.  The  residues  persisted for at  least 30  days  in 
pigs  and  for  about  two  weeks  in  poultry  (40th  JECFA).  The  MRLs  for 
Flubendazole  are  given  in  table 1,  section  2. 
7.2.3.1.4.  THIABENDAZOLE, 
Thiabendazole  is rapidly metabolised  and  excreted  in  all  animal  studies. 
The  major  metabolite  is  5-hydroxythiabendazole,  usually found  as  its 
glucuronide  or  sulphate ester.  After  oral  dosing  at the  recommended  rates 
it was  not  possible  to  find  residues  in  edible  tissues of  cattle,  sheep  and 
pigs  at withholding  times  of  3 and  7 days  respectively  (40th  JECFA,  1992). 
JECFA  recommended  MRLs  for  thiabendazole  of  0.1  mg  per  kg  for all  edible 
tissues of  cattle,  pigs  and  sheep  and  milk  of  cattle and  goats.  The  marker 
residue  id  the  sum  of  the  parent  compound  and  5-hydroxythiabendazole. 
7.2.3.1.5.  TRICLABENDAZOLE. 
The  absorption,  metabolism,  distribution and  excretion of  Triclabendazole 
is qualitatively similar  in  cattle and  sheep.  A large  proportion  of  the 
residues  in  edible  tissues are  in  the  bound  form.  The  40th  JECFA  selected 
the  marker  residue  as  5-chloro-6-(2• ,3
1-dichlorophenoxy)-benzimidazole-2-
one.  This  compound  is formed  when  common  fragments  of  Triclabendazgle-
related residues  are  hydrolysed  under  alkaline conditions  at 90-100  C.  The 
MRL  for  this marker  residue  are  given  in  table 1,  Section  2. 
7.2.3.2.  IVERMECTIN 
Ivermectin  is a  broad-spectrum  antiparasitic drug  against  nematodes  and 
arthropods  in  food  producing  animals.  It is a mixture  of  two  homologous 
compounds,  H 2B1a  and  H 2B1b,  derived  from  abermectin  and  differing  by  a 
7/35 methylene  group  at C-26.  Ivermectin  was  evaluated  by  the  36th  and  40th 
JECFA  meeting  and  their report  showed  that there was  full  information  on 
the  residues  in  all  the  species  (cattle [not  lactating],  sheep  and  pigs) 
for  which  use  was  recommended. 
The  drug  is almost  exclusively excreted  in  the  faeces,  with  <1%  eliminated 
via  the  urine.  The  metabolism  was  similar  in  the  ruminants  but  slightly 
different from  that  in  the  pig.  Very  little residues  are  in  the  bound 
form.  The  highest  concentrations  of  residues  are  found  in  the  liver and 
fat and  these  tissues are  the  most  suitable for  residue  control.  The 
parent  drug  accounts  for  a major  proportion  of  the  total  residues  and  H 2B1a 
is a  suitable marker  residue.  There  are  good  HPLC  methods  for  monitoring 
the  residues. 
The  depletion  of  the  total  residues  of  Ivermectin  in  liver and  fat of 
cattle,  sheep  and  pigs  is plotted  in  figure  5.  The  residues  are  below  the 
MRLs  (see  section  2)  at 28  days  withdrawal  time. 
Figure  5.  Total  Residues  of  Ivermectin  in  Liver  and  Fat. 
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.. Evaluation  of  certain veterinary drug  residues  in  food ...  1990. 
7.2.3.3.  CLOSANTEL 
Closantel  is an  anthelminthic  drug  used  in  cattle and  sheep.  The  residues 
were  evaluated  at the  36th  and  40th  JECFA  meetings.  The  residue  depletion 
patterns are  similar  in  cattle and  sheep  with  half-lives  in  tissues of  2-3 
weeks.  The  residues  are  parent  drug  with  the  remaining  residues  being  3-
and  5- monoiodoclosantel.  The  highest  concentrations  of  residues  are  found 
in  the  kidney  and  fat with  slightly lower  levels  in  the  muscle  and  liver. 
The  residues  persist  in  most  tissues for  at  least 42  days.  JECFA 
recommended  MRLs  (see  section  2)  which  should  be  met  if the  recommended 
treatments  are  used  with  withdrawal  times  of  at  least 28  days. 
7/36 7.2.4.  B-AGONISTS 
B 2-agonist  have  a  high  affinity for  the  B 2-adrenergic receptors  such  as 
occur  in  lung  tissue and  possess  a  lower  affinity for  the  B 1-receptors of 
other tissues.  They  are  substituted phenylethanolamines  that share  some 
structural  and  pharmacological  similarities with  the  catecholamines.  When 
these  compounds  are  included  in  the  diet of  growing  animals,  they  promote 
lean  tissue accretion  and  cause  a marked  reduction  of  fat deposition.  In 
meat  the  percentage  of  protein  is  increased  and  that of  fat reduced. 
The  list of  B-agonists  which  may  be  giving  rise to  residues  in  animals  and 
animal  feeds  is  increasing  and  the  following  substances  have  caused  residue 
problems  in  many  Member  States;-
Clenbuterol,  salbutamol,  cimaterol,  mabuterol,  terbutaline,  tulobuterol, 
carbuterol,  mapenterol,  clenpenterol,  clenhexerol  and  cimbuterol.  The  last 
four  were  detected for  the first time  during  1991. 
7.2.4.1.  CLENBUTEROL. 
Clenbuterol  is possibly the  most  widely  used  B-agonist  in  farm  animals. 
The  highest  levels of  residues  are  found  in  the eyes,  lungs,  liver,  kidney, 
brain,  thymus  and  spinal  chord,  with  lower  levels  in  muscle  and  fat.  The 
disposition of  clenbuterol  relative to  the  concentrations  in  plasma  for 
tissues  and  fluids of  twelve  calves  treated orally with  clenbuterol  is 
shown  in  table 12.  The  dose  and  duration  of  the  treatment  and  the  time  of 
slaughter during/after drug  administration  are  not  stated by  Girault and 
Fourtillan,  (1990). 
Table12. 
Tissue  clenbuterol  Tissue/Fluid  clenbuterol 
Liver  5.2  Lung  7.8 
Kidney  5.0  Thymus  2.2 
Muscle  0.7  - 0.8  Spinal  chord  1.8 
Heart  1.8  Brain  2.7 
Suet  0.3  Plasma  1 
Urine  9.5 
Meyer  (1991)  states that the  anabolic  dosages  of  clenbuterol  are  5 to 10-
fold  higher  than  the  therapeutic doses  for  calves  and  these  high  doses  will 
lead  to accumulation  of  residues  into most  tissues.  Calves  were 
administered  in  the feed  10  ~g clenbuterol  per  kg  body  weight  daily for  21 
days.  The  calves were  slaughtered  and  the  residues of  clenbuterol  measured 
in  tissue samples  as  shown  in  table 13.  An  important  observation  is the 
high  and  persistent concentration  of  residues  in  the  eyes.  It is possible 
that this organ  may  be  useful  for  screening  farm  animals  for  residues of  B-
agonists. 
7/37 Table  13.  Clenbuterol  residues  in  calves  (mean  values  in  ~g per  kg)  after 
feeding  10  ~g clenbuterol  per  kg  body  weight  daily for  21  days. 
Tissue  Withdrawal  time  (days) 
Lungs 
Liver 
Kidney 
Spleen 
Brain 
Masseter  muscle 
Trapezius  muscle 
Fat 
Eye 
Ovary 
Uterus 
Blood 
Urine 
0 
(3) 
76 
39 
29 
24 
12 
8.6 
4.8 
4.4 
118 
13 
8.2 
1.1 
47 
3.5 
(2) 
2.4 
1.6 
1.2 
1.2 
0.4 
0.3 
0.2 
0.3 
58 
0.4 
0.4 
0.05 
0.5 
The  number  of  calves  is  shown  in  parenthesis. 
14 
(2) 
<0.08 
0.6 
<0.08 
<0.08 
<0.08 
<0.08 
<0.08 
0.2 
15 
<0.08 
<0.08 
<0.04 
<0.05 
Schilt et al  (1991)  measured  the  residues  of  clenbuterol  in  five week-old 
broilers fed  at a rate of  1 mg  drug  per  kg  body  weight  for five days.  Five 
broilers were  slaughtered  directly after the  last feed  containing drug  and 
five more  were  killed 1 day  later.  Residues  in  the  tissues were  measured 
by  IAC\SPE\  EIA  and  checked  with  HPLC.  The  results are  shown  in  table 14. 
Table  14.  Residues  of  clenbuterol  (~g per  kg)  in  broilers. 
Time  after withdrawing  Meat  Liver  Kidney  Caecal  Gizzard 
clenbuterol  (days)  contents 
0  3  22  20  83  46 
1  1  7  3  23  5 
Clenbuterol  is readily excreted  into  the  urine.  Three  cows  were 
administered  clenbuterol  daily for  12  days  as  an  additive to their morning 
feed.  Urine,  plasma  and  faeces  were  collected  immediately  after each  feed 
and  then  8  hours  later during  the  period  of  administration  and  for  6 days 
after ceasing  treatment.  Each  cow  was  administered  a different daily dose, 
namely  2,5  or  10  ~g clenbuterol  per  kg  body  weight.  The  results for  the 
concentrations  of  clenbuterol  in  urine  are  shown  in  figure  6.  In  general 
the  levels are  much  higher  at 8  hours  after feeding  than  at the time  of 
feeding.  When  the  drug  is withdrawn  there  is a  near  exponential  decline  in 
the  concentrations  in  each  of  the  cows  reaching  the  values  for  untreated 
control  animals  after 5 days  withdrawal  time  (Delahaut  et al.,  1991). 
The  levels  in  the  plasma  and  faeces  were  also measured  in  the  above  study 
and  followed  a  somewhat  similar pattern to the  urine,  except  there was  a 
much  clearer relationship between  the  levels  and  dose.  The  highest  levels 
(1.5  - 4 ng  per  ml  plasma  and  ca  3 - 9 ng  per  g faeces)  were  observed  in 
the  animal  given  the  highest  dose  and  the  lowest  levels  (<1  ng  per  ml  or g) 
in  the  lowest  dosed  cow.  All  the  levels declined  to  control  values  within 
5 days  of  withdrawing  the  drug.  (Delahaut  et al.  1991) 
7/38 Figure  6 
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Legend;  The  clenbuterol  was  withdrawn  on  day  12,  the  treatments  for each 
cow  were;  in  ~g per  kg  body  weight  per  day  ;  2 (-1-);  5  (-+-);  10  (-*-). 
7.2.4.2.  SALBUTAMOL 
Salbutamol  enjoys  a  leading  position  in  the  sales of  human  medicines, 
especially as  a  treatment  for  asthma.  Residues  of  the  drug  have  also  been 
found  in  farm  animals.  Only  recently was  it shown  that salbutamol  is 
mostly  in  the  conjugated  form  in  the  liver and  therefore a  hydrolysis  step 
is necessary  to measure  the  residues. 
Two  calves were  fed  32  mg  of  salbutamol  hemisulphate  twice  daily for five 
days  and  the  concentration of  salbutamol  in  the  urine measured  during  after 
the  period  of  administration,see figure  7  (Van  Ginkel  et al.,  1991). 
Figure  7. 
Salbutamol (ug/L urine) 
1000 = 
~  ~  ~  ~  0  1  2  3  7  M 
DAYS  FROM  DRUG  WITHDRAWAL 
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7/40 8.  REFERENCE  MATERIALS  (RMs)  AND  SOURCES  OF  STANDARDS/REAGENTS. 
8.1.  MEASUREMENTS  AND  TESTING  PROGRAMME  (MAT)  [previously The  Community 
Bureau  of  Refererence  (BCR)]. 
The  Measurements  and  Testing  Programme  of  the  BCR  is a  research  programme 
of  the  Commission  of  the  European  Communities  having  the  broad  aim  of 
improving  accuracy  and  measurement  harmony  in  areas  of  concern  at Community 
level.  An  overview  of  the  activities of  BCR  was  presented  by  Wagstaffe  and 
Belliardo  (1990). 
The  role of  RMs  in  analytical  chemistry  is well  established especially for 
the  calibration and  verification of  the  accuracy  of  methods  (Griepink, 
1990)  and  also  in  the  biomedical  sciences  (Colinet,  1992)  and  the  assay  of 
biological  materials  (Marchandise  (1987).  The  major  problem  facing  the 
producers  of  RMs  results from  the  virtually unlimited  variety of  analyses 
obtained  in  combining  analytes,  concentrations  and  matrices.  More  than 
4000  methods  of  analysis  have  been  counted  in  the  field of  food  and 
agriculture and  the  choice  of  RMs  depends  on  priority needs. 
The  priorities for  the  production  of  RMs  for  residues were  established at a 
BCR  meeting  in  April,  1989,  and  the  resulting programme  is outlined  in 
table 8.I.  The  RMs  will  be  stored  by  the  CRLs  and  made  available for  the 
NRLs  and  commercially  available  by  the  BCR. 
The  production  of  RMs  with  the  BCR  programme  expanded  greatly and  more  than 
twenty  are  under  preparation.  In  deciding  the  target values  for  the 
residues  in  the  incurred  lyophilised  samples,  the  MAT/BCR  takes  into 
account  the  legislation from  DGVI,  the  Maximum  Residue  Limits  (MRL)  set by 
DGIII  (see  section  2)  and  the  quality of  the  analytical  methods.  Thus  for 
those  substances  which  are  not  allowed,  RMs  are  prepared  which  are  suitable 
for  positive  identification by  the  routine methods.  For  allowed  drugs  at 
least one  of  the  RMs  for  a  particular drug  will  have  a  target value  close 
to  the  MRL. 
The  purpose  of  the  RMs  is to  provide  a  unique  collection of  RMs  for  a 
particular veterinary drug  analyte.  They  are  expensive  to  produce  and  are 
limited  in  numbers  (usually 200  - 500).  Because  they  are Certified  RMs 
(CRM)  they  should  be  by  virtue of  their traceability the  reference  standard 
for measurements  in  the  Community  and  used  only  for  specific problems  and 
with  careful  consideration  of  the  materials  available. 
Their  use  is recommended  for; 
1.  Allocation  to  and  use  by  the  CRLs  and  NRLs  to  perform  quality control 
measurements  and  to  validate  new  methodology. 
2.  Controlling  and  validating the  content  and/or  concentration  of  the 
same  analyte  in  a comparable  matrix  in-house  or  so-called secondary 
materials.  These  secondary  materials  should  be  used  on  a  regular 
basis  as  the  internal  quality control  for  the methods  used  to 
determine  residues  in  tissues and  fluids. 
They  should  also  be  used  by  the  CRLs  to fulfil  their responsibilities 
under  EC  Decision  89/187  which  includes  the  quality control  of  the 
NRLs  through  ring testing  (proficiency testing schemes)  of  methods. 
These  secondary  materials  can  easily be  prepared  on  the  basis of  the 
knowledge  provided  through  the  certified reference materials  (CRMs) 
if the  comparibility of  the  matrix  characteristics are  confirmed. 
8/1 [Note;  Essential  information  useful  for  the  preparation of  secondary 
materials  is given  in  the  report which  accompanies  the  CRMs  (preparation of 
materials,  stability,  homogeneity,  storage,  shipment  and  methodology  for 
characterization.] 
8.2.  RMs  FOR  RESIDUE  ANALYSIS. 
8.2.1  REQUIREMENTS 
1.  Representative. 
incurred  material,  i.e.  samples  obtained  from  animals 
administered  parent  drug  or  contaminant.  The  sample  will  contain  the 
total  residues  including  all metabolites. 
prepared  as  lyophilised  products  which  on  reconstitution  simulate  as 
near  as  possible  the  samples  obtained  from  animals. 
contain  concentrations  of  residues  applicable  to  control  regulations 
and  practice,  i.e.  levels  close  to  the  MRLs  and  the  lower  limits of 
detection  (LLD)  of  the  reference methods. 
available  in  appropriate matrices  including  muscle  and  urine. 
2.  Homogeneous. 
within  the  variability of  the methods  of  analysis. 
within  a  single sample 
within  a  complete  batch  of  RMs  for  a  single analyte. 
3.  Stable. 
with  respect  to agreed  time  and  temperature. 
ideal  long  term  stability would  be  over  5 years  at 4°C 
short term  stability must  include  transport at ambient  and 
other selected temperature. 
4.  Sterile. 
samples  must  be  obtained  from  animals  certified  in  good  health  and  of 
known  health  history. 
samples  may  be  made  sterile by  procedures  which  do  not  degrade  the 
analyte or  significantly alter the  blank  value  (matrix  effect). 
8.3.  GENERAL  SCHEME  FOR  PRODUCTION  OF  RMs 
The  RMs  are  produced  in  farm  animals  which  are  in  good  health  and  have  a 
known  health  history. 
Scheme  of  production. 
Approved  MAT/BCR  project for  selected residue/analyte 
Project proposals  from  EEC  laboratories 
Appointed  laboratory  and  investigators. 
Select animals  and  parent  drug/contaminant 
Agreed  target concentrations  of  residues 
Pilot study  of  stability of  spiked  analyte  in  animal  samples 
Agreed  dosage  and  route of  administration 
Animal  treatments  including  non-treated  animals  (blanks) 
Monitor  residue  levels  in  live animal 
Collect urine,  faeces  and  blood  from  live animal 
Collect  samples  of  fluids,  faeces  and  tissues from  slaughtered  animal 
Determine  concentration  of  analyte(s)  in  incurred  and  blank  samples. 
Blend  samples  of  incurred  and  blank  material  to achieve  correct 
levels for  RMs. 
8/2 Lyophilise  small  batch  and  measure  concentration  for  content  and  to 
check  for  any  losses  due  to  lyophilisation. 
If  levels  are  correct check  independently  by  second  laboratory. 
Sterilise and  check  stability 
Lyophilise  main  sample 
Fluids  are  dispensed  into  vials/ampoules  and  lyophilised  and  sealed 
under  vacuum  or  an  inert gas. 
Tissues  are  lyophilised as  a  large  batch,  the  powder  thoroughly  mixed 
by  tumbling  and  then  dispensed  to  vials for  sealing under  an  inert 
gas 
Sterilise 
Label 
Check  homogeneity 
Check  stability for one  year  at temperatures  between  -40°C  and  +37°C. 
and  long  term  stability over  2 years  at selected  temperatures. 
Organise  certification programme  including  ring  testing of  material 
in  at  least eight  laboratories. 
Examine  results and  approve  certification. 
CRMs  and/or  RMs  available  by  information  from  BCR. 
These  procedures  are described  in  a  little more  detail  by  Heitzman  (1992), 
Heitzman  et al.  (1993),  Marchandise  and  Colinet  (1983),  Maier  et al.  (1992) 
and  in  ISO/REMCO  N263  (1992). 
8/3 Table  S.I.  RMs  AVAILABLE  OR  UNDER  PRODUCTION  in  1993 
ANALYTE  MATRIX  WTa  CONC  SOURCE  START 
SPECIES  g  ug/kg  DATE 
ug/L  - STATUS 
AMPICILLIN  Mk  cow  10  15-20  CNEVA  1993  On 
BETA-AGONISTS 
SALBUTAMOL  u  calf  5  2-5  UNIV  LIEGE  1991  On 
CLENBUTEROL  u  calf  5  2-5  UNIV  LIEGE  1991  On 
CHLORAMPHENICOL  M  calf  25  10  BGA  1990  RC 
Eg  poultry  3  1  BGA  1990  RC 
Mk  cow  25  1  BGA  1990  RC 
DIENOESTROL  u  steer  2  34  ±  7  RIVM  1990  c 
M  steer  RIVM  1989  RC 
DIETHYLSTILBOESTROL  U  steer  2  12.8  ±  2.5  RIVM  1990  c 
M  steer  RIVM  1989  RC 
NEOMYCIN  Mk  cow  10  3000  CNEVA  1993  On 
HEXOESTROL  u  steer  2  13.3  ±  3.1  RIVM  1990  c 
M  steer  RIVM  1989  RC 
19-NORTESTOSTERONE  u  calf  5  1-5  RIKILT  1990  RC 
M  calf  5  0.5-2  RIKILT  1990  On 
OXYTETRACYCLINE  Mk  cow  10  300  CNEVA  1991  On 
SULPHAMETHAZINE  M  pig  5  0.5  -1.0  VRL  1990  RC 
L  pig  5  0.75-1.5  VRL  1990  RC 
K  pig  5  0.75-1.5  VRL  1990  RC 
TRENBOLONE  u  calf  5  1-5  RIVM  1989  On 
ZERANOL  u  steer  5  5b  NFC-DUBLIN  1991  On 
M  steer  10  2  NFC-DUBLIN  1991  On 
L  steer  10  2  NFC-DUBLIN  1991  On 
a = equivalent  to weight  of  fresh  sample.  Cert  = material  certified. 
b = spiked  material 
On  = ongoing,  RC  = ready  for  certification,  C = certified and  available. 
8/4 8.2.2 
ANALYTE 
MATRIX 
RMs  CERTIFIED  AT  1 OCTOBER  1993 
DIETHYLSTILBOESTROL  (DES) 
Lyophilised  bovine  URINE 
Certification  No  EUR  EN  CRM  389 
Summary:  The  animals  used  were  certified in  good  health  and  had  not 
previously received  veterinary drugs.  The  RM  was  prepared  by  lyophilising 
a mixture  of  the  urine  from  a steer  injected  intramuscularly with  DES  and 
the  urine  from  untreated  steers.  The  latter was  used  to dilute the 
incurred  urine  samples  to  the  appropriate  concentration  of  DES.  DES 
occurs  as  a mixture  of  the  cis and  trans  isomers.  The  total  content of 
both  isomers  and  the  content  of  the  trans  isomer  were  determined  after 
separation  of  the  isomers  by  HPLC  and  determining  the  individual  or  summed 
concentrations  on  GCMS.  There  was  good  agreement  in  the  ring tests between 
the  values  obtained  for  total  DES  by  either the  GCMS  or  RIA  methods. 
The  vials contents  are; 
equivalent  to  2 ml  fresh  urine 
- stored  under  nisrogen 
- stable at s  +20  C 
The  results of  the  certification tests were: 
Mean  concentration 
Mean  concentration 
Mean  concentration 
Standard  Deviation 
Standard  Deviation 
Standard  Deviation 
12.8  ~g total-DES  per  L fresh  urine 
7.7  ~g trans-DES  per  L fresh  urine 
6.6  ~g cis-DES  per  L fresh  urine 
2.4  ~g total-DES  per  L 
1.3  ~g trans-DES  per  L 
1.1  ~g cis-DES  per  L 
Number  of  Laboratories  7 (total-DES);  6 (trans-DES);  4  (cis-DES) 
Date  of  certification by  BCR;  1993 
Place  of  Manufacture 
Bilthoven,  NL. 
AFRC;  Inst.  Animal  Health,  Compton,  UK  and  RIVM, 
Stored  at;  RIVM,  Bilthoven,  NL. 
Certified Blank  Materials 
Lyophilised  blank  materials equivalent  to  2 ml  blank  (control)  urine were 
prepared  from  untreated  steers.  The  materials were  prepared  under  the  same 
contract at the  same  institutes  by  the  same  personnel.  The  blank  RMs  are 
stored at RIVM.  The  blanks  are  specific for  the  three  stilbenes,  DES,HEX 
and  DE. 
8/5 ANALYTE 
MATRIX 
HEXOESTROL  (HEX) 
Certification  No 
Lyophilised  bovine  URINE 
EUR  EN  CRM  391) 
Summary:  The  animals  used  were  certified  in  good  health  and  had  not 
previously received  veterinary drugs.  The  RM  was  prepared  by  lyophilising 
a mixture  of  the  urine  from  a  steer  injected  intramuscularly with  HEX  and 
the  urine  from  untreated  steers.  The  latter was  used  to  dilute the 
incurred  urine  samples  to  the  appropriate  concentration  of  HEX.  The 
total  content  of  HEX  was  determined  after separation  by  HPLC  and  measuring 
the  concentration  on  GCMS.  There  was  good  agreement  in  the  ring tests 
between  the  values  obtained  for  the  content of  HEX  by  either the  GCMS  or 
RIA  methods. 
The  vials contents  are; 
equivalent  to  2 ml  fresh  urine 
- stored  under  ni0 rogen 
- stable at s  +20  C 
The  results of  the  certification tests were: 
Mean  concentration  13.3  ~g HEX  per  L fresh  urine 
Standard  Deviation  3.0  ~g per  L 
Number  of  Laboratories  8 
Date  of  certification by  BCR;  1993 
Place  of  Manufacture 
Bilthoven,  NL. 
AFRC;  Inst.  Animal  Health,  Compton,  UK  and  RIVM, 
Stored  at;  RIVM,  Bilthoven,  NL. 
Certified Blank  Materials 
Lyophilised  blank  materials equivalent  to  2 ml  blank  (control)  urine were 
prepared  from  untreated  steers.  The  materials were  prepared  under  the  same 
contract at the  same  institutes by  the  same  personnel.  The  blank  RMs  are 
stored at RIVM.  The  blanks  are  specific for  the  three stilbenes,  DES,HEX 
and  DE. 
8/6 ANALYTE 
MATRiX 
DIENOESTROL  (DE) 
Lyophilised  bovine  URINE 
Certification  No  EUR  EN  RM  390  (Indicative value) 
Summary:  The  animals  used  were  certified  in  good  health  and  had  not 
previously received  veterinary drugs.  The  RM  was  prepared  by  lyophilising 
a mixture  of  the  urine  from  a steer  injected  intramuscularly with  DE  and 
the  urine  from  untreated  steers.  The  latter was  used  to  dilute the 
incurred  urine  samples  to  the  appropriate  concentration  of  DE.  The  total 
content  of  DE  was  determined  after separation  by  HPLC  and  measuring  the 
concentration  on  GCMS.  The  ring  tests showed  poor  comparison  between  the 
GCMS  method  and  the  RIA  methods. 
The  vials contents  are; 
equivalent  to  2 mL  fresh  urine 
- stored  under  nisrogen 
- stable at s  +20  C 
The  results of  the  certification tests were: 
Mean  concentration  33.5  ~g DE  per  L fresh  urine 
Standard  Deviation  6.1  ~g per  L 
Number  of  Laboratories  8 
Date  of  certification by  BCR;  1993  (Indicative value  only) 
Place  of  Manufacture 
Bilthoven,  NL. 
AFRC;  Inst.  Animal  Health,  Compton,  UK  and  RIVM, 
Stored  at:  RIVM,  Bilthoven,  NL. 
Certified Blank  Materials 
Lyophilised  blank  materials equivalent  to  2 ml  blank  (control)  urine were 
prepared  from  untreated  steers.  The  materials were  prepared  under  the  same 
contract at the  same  institutes by  the  same  personnel.  The  blank  RMs  are 
stored  at RIVM.  The  blanks  are  specific for  the  three  stilbenes,  DES,HEX 
and  DE. 
8/7 8.3  SOURCES  OTHER  THAN  BCR 
8.3.1  ANAREF  COLLECTION  IN  THE  BENELUX  COUNTRIES. 
The  ANAREF  project  is  a Benelux  Public  Health  Reference  Project  involving 
RIVM  (Project  387914)and  RIKILT,  NL;  IHE,  Belgium;  and  Institute of  Hygiene 
and  Public  Health,  Luxembourg. 
The  RMs  prepared  are  listed  in  table 8.II. 
Table  8.II.  RMs  AVAILABLE  OR  UNDER  PRODUCTION 
ANALYTE  Code  MATRIX  WTa  CONC  No.  Vials  LAB 
SPECIES 
CHLORAMPHENICOL  88M0044  Ly-U  CATTLE 
88M0045  Ly-U  CATTLE 
87M1541  Ly-U  CATTLE 
88M0046  Ly-U  CATTLE 
BLANKS  u  CATTLE 
20  sets of  4 x 25  different 1 ml  samples  - RIVM 
TABLE  8.III.  PURE  STANDARDS  HELD  AT  RIVM 
g  ~g/kg  produced. 
~g/L 
2  0  200 
2  5  200 
2  10  200 
2  20  200 
1  0 
RIVM 
RIVM 
RIVM 
RIVM 
COMPOUND  RIVM  Code  No.  COMPOUND  RIVM  Code  No. 
a-NT  87M0334  d3-NT  87M1252 
Zearalenone  87M1036  a-Zearalenol  87M1037 
Zearalenone  87M1038  Zeranol  (Z)  87M1039 
B-Zearalenol  87M1040  Taleranol  87M1041 
DES  88M1733  d6-DES  88M1734 
d4-HEX  88M1768  DE  88M1736 
d2-DE  88M1769 
The  supply  is  limited  and  available only  to  approved  laboratories against 
payment.  The  standards  are  in  100  ~g portions  in  amber  glass  ampoules, 
sealed  under  nitrogen. 
FTIR  and  GCMS  (after derivatization)  and  data  sheets  are  available. 
(see  reference  Stephany,  R.W.,  and  Van  Ginkel,  L.A.  (1989), 
8.3.2 
The  two  references  below  list a  selection of  reference materials  and  their 
sources.  There  are  some  materials  of  animal  origin  although  most  of  them 
are  residue free materials  and  very  few  contain  residues  of  veterinary 
drugs. 
AOAC,  (1990),  Certified Reference  Material.  In  AOAC,  Official  Methods  of 
Analysis.  1220-1221. 
Roelandts,  I.,  (1989),  News  on  Reference  Materials.  Additional  biological 
reference materials.  Spectrochimica,  44B,  985-988. 
8/8 8.3.3  WHO  INTERNATIONAL  CHEMICAL  REFERENCE  SUBSTANCES. 
This  collection of  reference  drugs  is held  by  the  WHO  Collaborating Centre 
for Chemical  Reference  Substances  at APOTEKSBOLAT  AB,  Centrallaboritoriet, 
S-105  14,  Stockholm,  Sweden.  They  cost about  $40  +  $10  p&p  per  package. 
The  following  drugs  of  veterinary  interest are  included  in  the  list; for 
those  labelled with  *  Infrared  spectra are  available at a  small  charge. 
Substance 
Ampicillin  (anhydrous) 
Ampicillin  sodium 
*  Ampicillin  trihydrate 
Anhydrotetracycline  hydrochloride 
Bacitracin zinc 
*  Benzylpenicillin potassium 
Benzylpenicillin  sodium 
Chloramphenicol 
Chloramphenicol  palmitate 
Chlortetracycline hydrochloride 
*  Cloxacillin  sodium 
Colecalciferol  (Vitamin  D 3) 
Dapsone 
Ethinyloestradiol 
*  Haloperidol 
Methyltestosterone 
*  Metronidazole 
Norethisterone 
Norethisterone  acetate 
Oestradiol  benzoate 
Oestrone 
Oxacillin  sodium 
Oxytetracycline  dihydrate 
Oxytetracycline  hydrochloride 
Prednisolone 
Procaine  hydrochloride 
Progesterone 
Propylthiouracil 
*  Sulphamethoxazole 
*  Sulphamethoxypyridazine 
Sulphanilamide 
Testosterone  propionate 
Tetracycline  hydrochloride 
Tolbutamide 
*  Trimethoprim 
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Size  (mg) 
200 
200 
200 
25 
200 
200 
200 
200 
1000 
200 
200 
500 
100 
100 
100 
100 
100 
100 
100 
100 
100 
200 
200 
200 
100 
100 
100 
100 
100 
100 
100 
100 
200 
100 
100 
Cat.  N2 
390001 
388002 
274003 
180096 
192174 
180099 
280047 
486004 
286072 
187138 
274005 
190146 
183115 
291016 
172063 
167023 
183118 
186132 
185123 
167014 
279015 
382027 
189142 
189141 
389029 
183119 
167033 
185126 
179092 
178079 
179094 
167036 
180095 
179086 
179093 8.4  COMMERCIAL  SOURCES  OF  IMMUNOASSAY  MATERIALS  FOR  VETERINARY  DRUG 
ANALYSES. 
8.4.1  EURO-DIAGNOSTICA  B.V.  Wilmersdorf  24,  P.O.Box  2820,  7303  GC 
Apeldoom,  The  Netherlands. 
The  company  market  the  following  EIA  kits;-
Beta-agonist  kit for  screening  clenbuterol,  salbutamol,  mabuterol  and 
mapenterol  directly in  urine  samples. 
Chloramphenicol  in  urine  (LOD  50  ~g per  L)  and  meat  (LOD  10  ~g per  kg). 
19-Nortestosterone  in  urine.  The  test also  detects epi-19-nortestosterone 
and  19-norandrostenedione. 
8.4.2  GENEGO,  34170  Gorizia,  Italy - This  company  market  three multi-
analyte  columns  claiming  a capacity of  at  least 20  ng  or  100  ng  (high 
capacity column)  per  analyte.  The  products  are  -
Multi-Prep  I  for  DES,  HEX,  DE,  Z,  Taleranol  B-E2 ,  NT,  T,  MT,  and  TB 
Multi-Prep  II  for  DES,  HEX,  DE,  Z,  NT,  MT,T,  TB  and  Taleranol 
Multi-Prep  III  for Clenbuterol,  salbutamol,  terbutaline,  carbuterol 
and  marbuterol  all  B-agonists. 
These  columns  are  marketed  as  a complete  kit,  comprising  the  enzyme  and  the 
buffer for  the  digestion  of  samples,  extraction  and  washing  buffers  and 
detailed  instructions. 
The  company  markets  the  following  immunoassay  kits for  veterinary drug 
residues;-
RIA 
ELISA 
Stilbenes,  Zeranol,  Trenbolone. 
Zeranol,  DES,  19-Nortestosterone,  Progesterone, 
Chloramphenicol,  Sulphadimidine,  Penicillin-G. 
B-agonists  in  serum,  urine,  liver,  feeds,  milk  powders  and 
milk.  The  kit  is  intended  for  the  B-agonists,  with  the  lower 
limit of  detection  (LLD)  in  ~g per  L in  parenthesis; 
clenbuterol  (0.6),  mabuterol  (0.6),  salbutamol  (2),  mapenterol 
(2)  and  terbutaline  (3). 
8.4.3  LABORATORY  OF  HORMONOLOGY  - MARLOIE,  Rue  du  Point  de  Jour,  8,  B-
6900,  Marloie,  Belgium. 
Antibodies  are  avajlable against; 
testosterone  ,  oestradiol  ,  oestrone,  androstenedione, 
* 
dehydroepiandrosterone,  cortisol,  desoxycorticosterone,  17a-
hydroxyprogesterone  and  progesterone,  trenbolone  ,  zeranol, 
diethylstilboestrol,  19-nortestosterone*,  methyltestosterone, 
ethinyloestradiol*,  medroxyprogesterone  acetate,  dexamethasone 
either the  17a- or  the  17B- hydroxy  compounds. 
B-agonists  (salbutamol,  clenbuterol,  mabuterol  and  others) 
Gels  for  immunoaffinity  chromatography  are available  (minimum  quantity 1 
mL)  prepared  from  high  affinity antisera and  with  a minimum  capacity of  50 
ng  per  ml  for; 
8/10 Anabolics;  Nortestosterone,  methyltestosterone,  trenbolone, 
ethinyloestradiol,  diethylstilboestrol 
B 2-agonists;  Clenbuterol,  Salbutamol  (single or  combined) 
Antibiotics;  Chloramphenicol,  sulphadimidine 
Enzyme  conjugates;  Salbutamol-horse  radish  peroxidase. 
8.4.4  RANDOX  LABORATORIES  LTD,  Ardmore,  Diamond  Road,  Crumlin,  Co.  Antrim, 
BT29  4QY,  UK 
Antisera  are  available against  the  following  antigens;-
Avoparcin-HSA,  Chloramphenicol-HSA,  Chloramphenicol-hemi-BTG, 
Cimaterol-BTG,  Clenbuterol-HSA,  DES-gluc-BTG,  Dexamethazone-hemi-BTG, 
Flavomycin-BTG,  Flavomycin-HSA,  Hexoestrol-CPE-BTG,  Hexoestrol-CPE-
HSA,  Hexoestrol-gluc-KLH,  19-Nortestosterone-3CMO-HSA,  19-
Nortestosterone-17-hemi-HSA,  Oestradiol-17a-hemi-HSA,  Oestradiol-
17a/B-hemi-HSA,  Progesterone-CMO-BSA,  Progesterone-hemi-HSA,  Mixed 
sulpha-HSA,  Sulphadoxine-HSA,  Sulphadiazine-HSA,  Sulphadimidine-
diazo-HSA,  Sulphadimidine-HSA,  Testosterone-3CMO-BSA,  Testosterone-
3CMO-HSA,  Testosterone-17-hemi-HSA,  Trenbolone-3CMO-HSA,  Trenbolone-
hemi-BTG,  Tylosin-HBA-HSA,  Tylosin-HSA,  Zeranol-6CMO-HSA,  Zeranol-
16CPE-HSA,  Zeranol-hemi-HSA. 
The  company  markets  the  following  ELISA  kits;-
Clenbuterol,  19-Nortestosterone,  Testosterone,  Trenbolone, 
Sulpha  drugs. 
Immunoaffinity  columns  for  sale are;-
Clenbuterol,  Chloramphenicol,Dexamethazone, 
As  Multi-columns;-
Trenbolone  and  19-Nortestosterone, 
Trenbolone,  19-Nortestosterone,testosterone and  oestradiol. 
8.4.5  R-BIOPHARM  GmbH,  RoBlerstraBe  94,  6100  Darmstadt,  Germany. 
UK  agent,  Digen  Ltd,  28,  Crown  Road,  Wheatley,  Oxford,  OX33  1UL. 
The  company  markets  ELISA  kits  (Ridascreen®-ELISA)  for  the  following 
veterinary drug  residues;-
Clenbuterol  (B-agonists),  Acetylgestagenes,  17B-oestradiol, 
Testosterone,  19-Nortestosterone,  Ethinyloestradiol,  Trenbolone, 
Diethylstilboestrol,  Zeranol. 
Chloramphenicol,  Sulphadimidine,  Streptomycin,  Tetracycline. 
8.4.6  RIEDEL-DE-HAEN  Aktiengeellschaft,  WunstorferstraBe-40,  D-3016 
Seelze,  Germany. 
The  company  markets  ELISA  kits  (Ridascreen®-ELISA)  for  the  following 
veterinary drug  residues;-
B-agonists  in  serum  and  urine.  The  company  claims  that 40  samples 
can  be  screened  in  2 hours.  The  kit is  intended  for  the  B-agonists, 
with  the  lower  limit of  detection  (LLD)  in  ~g per  L in  parenthesis; 
clenbuterol  (0.6),  mabuterol  (0.6),  salbutamol  (2),  mapenterol  (2) 
and  terbutaline  (3). 
DES  in  bovine  urine,  bile,  liver,  faeces  and  meat.  LLD  <1  ppb 
19-nortestosterone  in  urine,  serum  and  meat.  LLD  0.2  ppb 
Zeranol  and  taleranol  in  urine,  serum  and  meat.  LLD  0.37  ppb 
8/11 Progesterone  in  plasma  and  meat.  LLD  1 ppb 
Trenbolone  in  urine,  faeces,  bile,  liver &  meat.  LLD  0.1  ppb 
Ethinyleostradiol  in  urine.  LLD  0.2  ~g per  L. 
Acetylgestegenes  in  fat.  LLD  0.005  - 0.06  ~g per  kg 
17B-oestradiol  in  plasma.  LLD  0.02  ~g per  L 
Testosterone  in  plasma.  LLD  0.02  ~g per  L. 
8.4.7  RHONE-POULENC  DIAGNOSTICS  LTD.  Montrose  House,  187,  George  St., 
Glasgow  G1  1YT,  Scotland. 
This  company  supplies  easy  to  use  rapid  EIA  card  tests for  the  antibiotics, 
chloramphenicol,  sulphadimidine,  sulphamethoxine  and  gentamicin. 
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8/12 9.  CHEMICAL  AND  PHYSICAL  DATA  FOR  RESIDUE  SUBSTANCES. 
INTRODUCTION. 
The  information  about  the  availability and  quality of  the  RMs  and  Reference 
Compounds  is given  in  section 8.  This  section provides  additional  chemical 
and  physical  data  about  the  analytes  measured  as  probable  residue 
substances.  Additional  information  may  be  found  in  The  Merck  Index,  the 
reports of  the  JECFA  meetings,  The  Handbook  of  Chemistry  and  the  RIKILT 
reports 86.48 &  86.49 
List; 
Group 
A I; 
A II; 
A III, 
B I; 
B II; 
Boldenone,  Chlorotestosterone,  Dienoestrol  (DEN), 
Diethylstilboestrol  (DES),  Ethinyloestradiol,  Hexoestrol  (HEX), 
Medroxyprogesterone  acetate  (MPA),  Megestrol  acetate, 
Melengestrol,  Methyltestosterone  (MT),  19-Nortestosterone 
(NT), 
Tapazole  (TAP),  Trenbolone  (TB), 
2-Thiouracil  (2-TU),  Zeranol  (Z), 
17B-Oestradiol  (BE2),  Progesterone  (P),  Testosterone  (T), 
Ampicillin,  Benzylpenicillin,  Chloramphenicol  (CAP), 
Chlortetracycline,  Dihydrostreptomycin,  Furazolidone, 
Gentamicin,  Neomycin,  Nitrofurazone,  Oxolinic  acid, 
Oxytetracyline,  Spiromycin,  Sulphadimidine,  Sulphaquinoxaline, 
Trimethoprim,  Tylosin 
Albendazole,  Azaperone,  Carazolol,  Carbadox,  Chlorpromazine, 
Cimaterol,  Clenbuterol,  Closantel,  Dimetridazole,  Febantel, 
Fenbendazole,  Flubendazole,  Haloperidol, 
Ipronidazole,Isometamidium  chloride,  Ivermectin,  Lasalocid, 
Levamisole,  Metronidazole,  Monensin,  Narasin,  Nitroxynil, 
Oxfendazole,  Propionylpromazine,  Ractopamine,  Ronidazole, 
Salbutamol,  Salinomycin,  Thiabendazole,  Triclabendazole, 
Xylazine 
Adequate  peaks  for  Infra-red analysis. 
Report  86.48  RIKILT 
Adequate  peaks  are  absorption  maxima  in  the  IR  spectrum,  1800  -500  cm-1  of 
a reference  compound,  that fulfil  the  following  requirements. 
1.  A relative  intensity of  absorbance  of  not  less  than 
- 12.5%  of  the  absorbance  of  the  most  intense  peak  when  both  peaks  are 
measured  with  respect  to zero  absorbance 
- or  5%  of  the  absorbance  of  the  most  intense  peak  ,  when  both  peaks  are 
measured  with  respect  to  their peak  baseline 
2.  An  intensity of  absorbance  of  not  less than 
- a  specific molar  absorbance  of  40  with  respect  to zero  absorbance 
- a  specific molar  absorbance  of  20  with  respect  to  the  peak  base  line. 
9/1 BOLDENONE 
RM 
Reference  Compound. 
Merck  Index  No.  1311 
JECFA  reference. 
GROUP  A I 
CAS  No;  846-48-0 
Analytical  methods  in  Section  6;  Cy  1.1,  Cy  1.2 
Species  in  which  residues  are  most  likely to occur;  cattle,  horses 
Parent  drug.  boldenone 
Therapeutic  category.  androgen,  growth  promoter 
KEY  Metabolites; 
Structure. 
OH 
0 
Molecular  Weight;  286.4 
UV; 
Melting  Point;  164-166°C 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS;  TMS-enol-TMS 
EI  TMS-enol-TMS,  430,  206,  415,  325,  299,  431 
Selected  peaks  and  relative  intensity for  identification by  IR. 
Source  of  compound  for  IR; 
lAC  column(s)  developed  or  available  . 
9/2 4u-CHLORO-TESTOSTERONE 
RM 
Reference  Compound; 
Merck  Index  No.  2371 
JECFA  reference. 
CAS  No;  1093-58-9 
Analytical  methods  in  Section  6;  Cy  1.2;  Sg  1.2. 
Species  in  which  residues  may  occur;  Cattle 
Parent  drug;  4u-chloro-testosterone or  as  an  ester;  e.g.  acetate. 
Therapeutic  category;  androgenic,  growth  promoter  in  cattle,  sheep,  pigs 
Metabolites; 
Structure; 
0 
I 
I 
Cl 
Molecular  Formula;  C 19H 27Cl02 
Molecular  Weight;  322.9 
UV  maximum  at 256  nm  in  95%  ethanol 
Melting  Point;  188-190°C 
Derivatives  for  GCMS;  TMS-enol-TMS 
OH 
Selected  ions  for  identification  in  GCMS; 
EI,  TMS-enol-TMS,  466,  468,  431,  451 
Selected  peaks  for  identification  by  IR; 
lAC  column(s)  developed  or  available;  ? 
9/3 DIENOESTROL  (DEN) 
RM  Eur  No.  RM  390  for  Urine;  Muscle  in  preparation  at RIVM,  NL. 
Reference  Compound.  Yes,  also  deuterated-DEN 
Merck  Index  No.  3085  CAS  No;  84-17-3 
JECFA  reference. 
Analytical  methods  in  Section  6;  Cy  1.1;  Cy  1.2;  Cy  1.3;  Cy  1.7; 
Sg  1.1;  Sg  1.2. 
Species  in  which  residues  are  most  likely to occur;  calves,  poultry 
Parent  drug.  DEN 
Therapeutic  category.  oestrogen,  for endocrine  control  and  as  growth 
promoter 
KEY  Metabolites;  none 
Structure. 
Molecular  Weight;  266.3 
UV; 
Melting  Point;  227-228°C 
Derivatives for  GCMS;  TMS,  HFB  and  PFB 
Selected  ions  for  identification  in  GCMS; 
EI  TMS  410,  395,  381,  217,  193 
EI  HFB  658,  629,  445,  341 
NI-CI  PFB2  445,  425 
EI  PFB2  626,  445,  249,  181 
PI-CI  ?  676,  480,  462 
Selected peaks  and  relative  intensity for  identification by  IR. 
520,  30;  620,  52;  649,  16;  775,  45;  826,  55;  834,  56;  853,  51, 
1102,  28;  1171,  53;  1205,  100;  1247,  57;  1333,  61;  1426,  34; 
1513,  98;  1592,  36;  1606,  28;  1619,  18 
Source  of  compound  for  IR;  Sigma;  Ref  No;  D-3253 
lAC  column(s)  developed  or  available  .  Yes  several 
9/4 DIETHYLSTILBOESTROL  (DES) 
RM  Eur  No.  CRM  389  for  Urine;  Muscle  in  preparation  at RIVM,  NL. 
Reference  Compound.  Yes,  also deuterated-DES 
Merck  Index  No.  3115  CAS  No.  56-53-1 
JECFA  reference. 
Analytical  methods  in  Section  6;  Cy  1.1;  Cy  1.2;  Cy  1.3;  Cy  1.7; 
Sg  1.1;  Sg  1.2;  Sg  1.3. 
Species  in  which  residues  are  most  likely to occur;  calves,  poultry 
Parent  drug.  DES  or  as  DES-dipropionate 
Therapeutic  category.  oestrogen,  for  endocrine  control  and  as  growth 
promoter 
KEY  Metabolites;  none 
Structure.  Exists  in  the  cis and  trans forms 
OH 
Molecular  Formula;  C 18H 2002 
Molecular  Weight;  268.3 
UV; 
Melting  Point;  169-172°C 
Derivatives  for  GCMS;  TMS,  HFB  and  PFB 
Selected 
EI 
NI-CI 
EI 
PI-CI 
EI 
ions  for  identification  in  GCMS; 
TMS  412,  387,  383,  397 
PFB2  447,  427 
PFB2  628,  447,  238,  181 
HFB  661,  465,  464 
HFB  660,  631,  447,  341 
OH 
Selected  peaks  and  relative  intensity for  identification by  IR. 
586,  26;  646,  18;  721,  18;  805,  21;  831,  65;  851,  32;  1012,  13; 
1114,  22;  1173,  86;  1204,  100;  1247,  63;  1282,  16;  1337,  35; 
1427,  39;  1462,  15;  1514,  99;  1590,  28;  1609,  36 
Source  of  compound  for  IR.  Interpharm;  Ref.  No.  P-4186 
lAC  column(s)  developed  or  available  .  Yes  several 
9/5 ETHINYLOESTRADIOL 
RM 
Reference  Compound; 
Merck  Index  No.  3683 
JECFA  reference. 
CAS  No;  57-63-6 
Species  in  which  residues  may  occur;  Calves,  cattle,  poultry,  pigs 
Analytical  methods  in  Section  6;  Cy  1.1;  Cy  1.2;  Cy  1.8;  Sg  1.1;  Sg  1.2. 
Parent  drug;  Ethinyloestradiol 
Therapeutic  category;  oestrogen,  growth  promoter 
Metabolites;  17a-OH  EE  in  ruminants 
Structure; 
Molecular  Formula;  C 20H 2402 
Molecular  Weight;  296.39 
UV  maximum  in  EtOH  281  nm 
OH 
Melting  Point;  182-184°C  EE-hemihydrate  141-146°C 
Derivatives  for  GCMS;  HFB,  TMS 
Selected  ions  for  identification  in  GCMS; 
EI  HFB  474,  459,  446,  353 
EI  TMS  425,  440,  300,  285 
Selected  peaks  for  identification  by  IR; 
Source  of  compound  for  IR; 
lAC  column(s)  developed  or  available;  Gel  available from  Marloie. 
9/6 HEXOESTROL  (HEX) 
RM  Eur  No.  CRM  391  for  Urine;  Muscle  in  preparation  at RIVM,  NL. 
Reference  Compound.  Yes,  also deuterated-HEX 
Merck  Index  No.  4593  CAS  No;  14188-82-0 
JECFA  reference. 
Analytical  methods  in  Section  6;  Cy  1.1;  Cy  1.2;  Cy  1.3;  Cy  1.7; 
Sg  1.1;  Sg  1.2. 
Species  in  which  residues  are  most  likely to occur;  calves,  poultry 
Parent  drug.  HEX 
Therapeutic  category.  oestrogen,  for  endocrine  control  and  as  growth 
promoter 
KEY  Metabolites;  none 
Structure. 
Molecular  Formula;  C 18H 2202 
Molecular  Weight;  270.4 
UV; 
Melting  Point;  185-188°C 
Derivatives  for  GCMS;  TMS,  HFB  and  PFB 
Selected 
EI 
NI-CI 
PI-CI 
EI 
ions  for  identification  in  GCMS; 
TMS  207,  414,  206,  399,  191,  179 
PFB2  449,  429  EI  - 315,  181 
HFB  680,  484,  466 
HFB  332,  331,  304,  303 
Selected  peaks  and  relative  intensity for  identification  by  IR. 
510,  20;  574,  41;  646,  19;  716,  23;  804,  22;  830,  41;  847,  45; 
1107,  17;  1174,  86;  1218,  63;  1440,  33;  1458,  22;  1516,  100; 
1598,  30;  1613,  32; 
Source  of  compound  for  IR;  INC;  Ref.  No.;  15529 
lAC  column(s)  developed  or  available  .  Yes  several 
9/7 MEDROXYPROGESTERONE 
RM 
Reference  Compound; 
Merck  Index  No.  5614 
JECFA  reference. 
CAS  No;  520-85-4 
Species  in  which  residues  may  occur;  Calves,  cattle,  ewe  sheep. 
Analytical  methods  in  Section  6;  Cy  1.1;  Cy  1.2;  Sg  1.1;  Sg  1.2 
Parent  drug;  Medroxyprogesterone  acetate  (MPA) 
Therapeutic  category;  Progestin,  Growth  promoter 
Metabolites;  11  in  urine,  MPA  not  found  in  urine 
Structure; 
0 
CH 
I  a 
C•O 
Molecular  Formula;  C 22H 3203  MPA  C 24H 3404 
Molecular  Weight;  344.5  MPA  386.5 
UV  maximum  in  EtOH  241  nm  MPA  maximum  in  EtOH  at 240  nm 
Melting  Point;  220-223.5°C  MPA  207-209°C 
Derivatives  for  GCMS;  MOX-TMS,  MOX  (MPA),  TMS-enol-TMS 
Selected  ions  for  identification  in  GCMS; 
EI  MOX-TMS  474,  459,  443,  353 
EI  MOX  (MPA)  415,  330,  312,  287 
EI  TMS-enol-TMS  560,  330,  315,  545,  455 
Selected  peaks  for  identification by  IR; 
MP  597,  13;  871,  18;  1093,  13;  1123,  16;  1186,  17;  1233,  23; 
1271,  23;  1349,  24;  1448,  18;  1603,  32;  1664,  93;  1696,  100; 
Source  of  compound  for  IR;  Sigma;  Ref.  No.;  M-6013 
MPA  965,  16;  1056,  13;  1080,  13;  1187,  15;  1253,  57;  1261,  58;  1365, 
29;  1607,  22;  1673,  83;  1717,  33;  1732,  100; 
Source  of  compound  for  IR;  Sigma;  Ref.  No.  M-1629 
lAC  column(s)  developed  or  available;  no 
9/8 MEGESTROL  ACETATE 
RM 
Reference  Compound; 
Merck  Index  No.  5623 
JECFA  reference. 
CAS  No;  595-33-5 
Analytical  methods  in  Section  6;  Cy  1.1;  Cy  1.2;  Sg  1.1;  Sg  1.2. 
Species  in  which  residues  may  occur;  cattle 
Parent  drug;  Megestrol  acetate 
Therapeutic  category;  Progestagen,  Might  be  used  as  growth  promoter 
Metabolites;  megestrol 
Structure; 
0 
Molecular  Weight;  384.5 
CH 
I  3 
~0 
UV  maximum  at 287  nm  in  ethanol 
Melting  Point;  214-216°C 
Derivatives  for  GCMS;  megestrol  di-TMS 
Selected  ions  for  identification  in  GCMS; 
EI  diTMS  558,  453,  543,  353,  231 
Selected  peaks  for  identification by  IR; 
lAC  column(s)  developed  or  available; 
9/9 MELENGESTROL 
RM 
Reference  Compound; 
Merck  Index  No.  5636  (melengestrol) 
JECFA  reference. 
CAS  No;  5633-18-1 
Species  in  which  residues  may  occur;  Calves,  cattle 
Analytical  methods  in  Section  6;  Cy  1.1;  Cy  1.2;  Sg  1.1. 
Parent  drug;  Melengestrol  acetate  (MPA) 
Therapeutic  category;  Progestin,  Used  as  growth  promoter 
Metabolites;  melengestrol 
Structure; 
0 
CH 
I  3 
C•O 
Molecular  Weight;  354.5  MGA  416.5 
UV  of  MGA,  maximum  in  EtOH  at 287  nm 
Melting  Point;  MPA  224-226°C 
Derivatives  for  GCMS;  HFB  (MGA) 
Selected  ions  for  identification  in  GCMS; 
EI  HFB- 477,  421,  381,  211 
Selected  peaks  for  identification  by  IR; 
lAC  column(s)  developed  or  available;  no 
9/10 17a-METHYLTESTOSTERONE  (MT) 
RM 
Reference  Compound; 
Merck  Index  No.  6000 
JECFA  reference. 
CAS  No;  58-18-4 
Species  in  which  residues  may  occur;  Calves,  cattle,  pigs 
Analytical  methods  in  Section  6;  Cy  1.1;  Cy  1.2;  Sg  1.1;  Sg  1.2 
Parent  drug;  17a-methyltestosterone 
Therapeutic  category;  androgenic,  growth  promoter 
Metabolites; 
Structure; 
0 
Molecular  Formula;  C 20H 3002 
Molecular  Weight;  302.4 
UV  maximum  in  EtOH  about  241  nm 
Melting  Point;  161-166°C 
Derivatives  for  GCMS;  TMS,  MOX-TMS,  TMS-enol-TMS 
Selected  ions  for  identification  in  GCMS; 
El  TMS  359,  317,  304,  284 
EI  MOX-TMS  403,  313,  298,  282 
EI  TMS-enol-TMS  446,  301,  431,  356 
Selected  peaks  for  identification by  IR; 
873,  15;  950,  19;  1091,  17;  1156,  28;  1190,  13;  1234,  20;  1278,  14; 
1297,  14;  1374,  25;  1450,  18;  1611,  16;  1664;  100; 
Source  of  compound  for  IR;  Sigma;  M-7252 
lAC  column(s)  developed  or  available;  Gel  available from  Marloie. 
9/11 19-NORTESTOSTERONE  (NT)  (NANDROLONE) 
RM  In  preparation  at RIKILT  - bovine  urine  and  muscle 
Reference  Compound 
Merck  Index  No.  6211  CAS  No.  434-22-0 
JECFA  reference. 
Analytical  methods  in  Section  6;  Cy  1.1;  Cy  1.2;  Sg  1.1;  Sg  1.2 
Species  in  which  residues  may  occur;  calves,  cattle,  pigs,  sheep,  horses 
Note;  Occurs  naturally  in  intact male  horses  and  pigs,  perinatal  calves  and 
pregnant  cows. 
Parent  drug;  NT  or  one  of  several  esters;  propionate,  decanoate,  laurate, 
phenyl propionate 
Therapeutic  category;  androgenic  growth  promoter,  anabolic 
Metabolites;  17aOH-NT  (epi-nortestosterone) 
Structure  OH 
0 
Molecular  Formula;  C 18H 2602 
Molecular  Weight;  274.4 
UV;  maximum,  241  nm  Melting  Point;  112°C  and  124°C 
Derivatives  for  GCMS;  HFB,  TMS,  MOX-TMS,  TFA,  TMS-enol-TMS 
Selected  ions  in  GCMS  aNT  and  BNT  give  identical  m/z  values 
EI- HFB  666,  453,  306,  133 
EI  TMS  346,  331,  256,  215 
EI  MOX-TMS  375,  360,  344,  285 
EI  di-TMS  418,  403,  328,  287,  194 
EI  TFA  466,  353,  218,  206 
EI  TMS-eenol-TMS  418,  194,  403,  287,  182 
Selected  peaks  and  relative  intensity for  identification  by  IR. 
NT;  885,  25;  967,  14;  1023,  19;  1052,  28;  1075,  24;  1133,  21;1206,31; 
1227,  14;  1259,  30;  1334,  21;  1412,  19;  1619,  27;  1666,  100; 
Source  of  NT  for  IR;  Sigma;  Ref.  No.;  N-7252 
17a-NT;  880,  18;  968,  16;  1051,  17;  1136,  13;  1211,  25;  1258,  18; 
1615,  31;  1643,  86;  1662,  100; 
Source  of  aNT;  Organon 
lAC  column(s)  developed  or available  ;  Yes.  Gel  from  Marloie 
9/12 TAPAZOLE  (METHIMAZOLE) 
RM  In  preparation  in  cattle urine  and  muscle 
Reference  Compound; 
Merck  Index  No.  5844  CAS  No;  60-56-0 
JECFA  reference. 
Analytical  method  in  Section  6;  Cy  1.9;  Sg  1.4 
Species  in  which  residues  may  occur;  cattle 
Parent  drug;  Tapazole 
Therapeutic  category;  Thyreostatic 
Metabolites; 
Structure;  CH
3  I  LI[SH 
Molecular  Weight;  114.2 
UV  maximum  in  O.lN H 2S04  211,  251.5  nm 
Melting  Point;  146-148°C 
Derivatives  for  GCMS;  TMS 
Boiling  point;  280°C  (some  decamp.) 
Selected  ions  for  identification  in  GCMS; 
PI-CI 
Selected  peaks  for  identification by  IR; 
lAC  column(s)  developed  or available;  No 
9/13 THIOURACIL  (2-THIOURACIL) 
RM  In  preparation  - cattle urine  and  muscle 
Reference  Compound; 
Merck  Index  No.  9210  CAS  No;  141-90-2 
JECFA  reference. 
Analytical  method  in  Section  6;  Cy  1.9;  Sg  1.4 
Species  in  which  residues  may  occur;  cattle 
Parent  drug;  Thiouracil 
Therapeutic  category;  Thyreostatic  and  thyroid  depressant 
Metabolites; 
Structure; 
OH 
Molecular  Weight;  128.2 
uv 
Melting  Point;  no  definite point 
Derivatives  for  GCMS;  TMS 
Selected  ions  for  identification  in  GCMS; 
PI-CI  257,  273,  345 
Selected peaks  for  identification  by  IR; 
lAC  column(s)  developed  or  available; 
9/14 TRENBOLONE  (TB) 
RM  In  preparation  calf muscle  and  urine. 
Reference  Compound  ? 
Merck  Index  No.  9402  CAS  No.  10161-33-8 
JECFA  reference.  26th,  27th,  32nd  and  34th  Meetings 
Analytical  methods  in  Section  6;  Cy  1.1;  Cy  1.2;  Cy  1.4;  Sg  1.1;  Sg  1.2 
Species  in  which  residues  may  occur;  calves,  cattle,  sheep,  pigs. 
Parent  drug  Trenbolone  acetate 
Therapeutic  category,  androgenic  growth  promoter 
Metabolites;  17aOH-TB,  17BOH-TB  (active  ingredient),  trendione 
Structure, 
0 
Molecular  Formula;  C 18H 2202 
Molecular  Weight;  270.4 
UV;  Maximum  at 239  gnd  340.5  nm 
Melting  Point;  186  C 
OH 
Derivatives  for  GCMS;  TMS,  MOX-TMS  MOX  (TBA) 
Selected  ions  for  identification  in  GCMS,  a  &  B isomers 
EI-PI  TMS  342,  252,  237,  211 
EI  MOX-TMS  371,  281,  266,  253 
TBA  EI  MOX  341,  298,  281,  266 
Selected  peaks  for  identification by  IR. 
BTB,  1017,  13;  1054,  17;  1075,  21;  1101,  25;  1199,  15;  1226,  25; 
1267,  16;  1288,  17;  1322,  15;  1346,  16;  1353,  15;  1379,  14 
1438,  15;  1569,  53;  1639,  100 
Source  of  BTB  for  IR;  Roussel  Uclaf;  Ref.  No.;  3E  0657 
aTB  762,  13;  795,  17;  852,  19;  937,  17;  1011,  22;  1028,  24; 
1088,  31;  1126,  13;  1150,  20;  1198,  27;  1229,  26;  1240,  27; 
1279,  25;  1310,  23;  1321,  18;  1346,  22;  1369,  20;  1391,  20; 
1435,  22;  1450,  16;  1578,  67;  1643,  100; 
Source  of  aTB  for  IR;  ? 
TBA  987,  16;  1023,  32;  1053,  35;  1096,  15;  1245,  100;  1375,  32; 
1439,  18;  1573,  32;  1660,  66;  1737,  83; 
Source  of  TBA  for  IR;  After extraction from  Finaplix,  Hoechst 
lAC  column(s)  developed  or  available;  Yes 
9/15 ZERANOL  (Z) 
RM  in  preparation  - bovine  urine,  muscle,  liver 
Reference  Compound 
Merck  Index  No.  9923  CAS  No;  7440-66-6 
JECFA  reference.  26th,  27th  and  32nd  meetings. 
Analytical  methods  in  Section  6;  Cy  1.1;  Cy  1.5;  Cy  1.6;  Sg  1.1;  Sg  1.2. 
Species  in  which  residues  may  occur;  calves,  cattle,  sheep,  poultry 
Parent  drug  Zeranol 
Therapeutic  category;  oestrogenic  (mild)  growth  promoter 
Metabolites,  7BOH-Z,  Zeralanone 
Structure;  OH  0 
Molecular  Weight;  322.4 
UV;  No  useful  absorbance 
Melting  Point;  181-183°C 
Derivatives  for  GCMS,  HFB,  TMS 
Selected  ions  for  identification  in  GCMS 
EI-PI  HFB  536,  519,  296,  279 
EI  TMS  538,  523,  433,  307,  379 
Selected  peaks  for  identification  by  IR. 
840,  16;  989,  24;  1075,  17;  1096,  41; 
1311,  58;  1353,  32;  1381,  21;  1464,  31; 
OH 
1167,  42; 
1587,  43; 
1200,  37; 
1615,  54; 
Source  of  Zeranol  for  IR;  International  Mineral  Corp.  USA 
IAC  column(s)  developed  or  available  ;  yes 
9/16 
1259,  100; 
1644,  70; GROUP  A II 
OESTRADIOL-178  (BE2 > 
RM 
Reference  Compound; 
Merck  Index  No.  3648 
JECFA  reference. 
CAS  No;  50-28-2 
Analytical  methods  in  Section  6;  Cy  1.1;  Cy  1.2;  Sg  1.1;  Sg  1.2 
Species  in  which  residues  may  occur;  Natural  steroid 
Parent  drug;  Oestradiol  or  an  ester e.g E2-benzoate 
Therapeutic  category;  Oestrogenic,  growth  promoter 
Metabolites;  17a0H-E2,  Oestrone 
Structure;  OH 
Molecular  Formula; 
C1aHz402 
Molecular  Weight;  272.4 
UV  maximum  at 225,  280  nm 
Melting  Point;  173-179°C 
Derivatives  for  GCMS;  PFB/TMS,  TMS 
Selected  ions  for  identification  in  GCMS; 
NI-CI  PFB/TMS  343 
EI  PFB  524,  393,  348,  253 
EI  TMS  416,  285,  231,  326 
Selected  peaks  for  identification by  IR; 
BE2  733,  29;  786,  30;  820,  56;  874,  51;  905,  16;  917,  24;  930,  34; 
962,  18;  1012,  55;  1021,  28;  1056,  83;  1102,  19;  1118,  22; 
1130,  30;  1156,  27;  1231,  78;  1250,  100;  1283,  69;  1302,  36; 
1320,  29;  1357,  44;  1382,  26;  1416,  27;  1449,  68;  1498,  74; 
1586,  47;  1610,  45; 
Source  of  BE2 for  IR;  Merck;  Ref.  No.;  8984,  Charge  No.  9007942 
aE2  573,  18;  787,  28;  821,  27;  866,  40;  919,  51;  945,  27;  970,  35; 
994,  17;  1013,  30;  1036,  41;  1054,  31;  1074,  31;  1101,  21; 
1118,  16;  1154,  33;  1234,  100;  1253,  97;  1284,  78;  1352,  39; 
1379,  47;  1443,  75;  1500,  88;  1586,  31;  1610,  64; 
Source  of  aE2 for  IR;  Sigma;  Ref.  No.;  E-8750 
lAC  column(s)  developed  or  available;  ? 
9/17 PROGESTERONE 
RM 
Reference  Compound; 
Merck  Index  No.  7678 
JECFA  reference. 
Analytical  methods  in  Section  6;  Cy  1.2; 
CAS  No;  57-83-0 
Species  in  which  residues  may  occur;  Natural  steroid 
Parent  drug;  Progesterone 
Therapeutic  category;  Progestagen,  Growth  promoter 
Metabolites; 
Structure; 
0 
Molecular  Weight;  314.5 
UV  maximum  at 240  nm 
Melting  Point;  127-131°C 
Derivatives  for  GCMS;  TMS,  TMS-enol-TMS 
Selected  ions  for  identification  in  GCMS; 
TMS  314,  272 
EI  TMS-enol-TMS  458,  353,  443 
Selected  peaks  for  identification  by  IR; 
871,  28;  948,  18;  1162,  25;  1204,  28;  1228,  26;  1237,  23;  1279,  18; 
1327,  19;  1358,  35;  1386,  22;  1439,  23;  1616,  35;  1663,  100; 
1699,  91 
Source  of  P for  IR;  Sigma;  Ref.  No.;  P-0130,  Charge  No.  13F-0838 
lAC  column(s)  developed  or  available;  probably 
9/18 TESTOSTERONE 
RM 
Reference  Compound; 
Merck  Index  No.  9000 
JECFA  reference. 
CAS  No;  58-22-0 
Analytical  methods  in  Section  6;  Cy  1.1;  Cy  1.2;  Sg  1.1;  Sg  1.2. 
Species  in  which  residues  may  occur;  Natural  steroid 
Parent  drug;  Testosterone  or  as  an  ester;  e.g.  acetate,  propionate, 
isocaproate,  decanoate,  undecanoate,  phenylpropionate,  benzoate 
Therapeutic  category;  androgenic,  growth  promoter  in  cattle,  sheep,  pigs 
Metabolites;  17aOH-T  (aT)  in  liver,  kidney,  urine,  bile,  faeces 
Structure;  oH 
0 
Molecular  Formula;  C 19H 2802 
Molecular  Weight;  288.4 
UV  maximum  at 238  nm 
Melting  Point;  155°C 
Derivatives  for  GCMS;  HFB,  TMS,  TMS-enol-TMS 
Selected  ions  for  identification  in  GCMS; 
EI,  HFB,  680,  467,  355,  220 
TMS,  360,  270,  226,  345 
EI  TMS-enol-TMS  432,  417,  301,  209 
Selected  peaks  for  identification by  IR; 
BT  870,  25;  943,  13;  957,  13;  1017,  16;  1056,  31;  1067,  31;  1114, 
13;  1131,  14;  1199,  16;  1233,  29;  1277,  18;  1360,  19;  1378,  18; 
1432,  20;  1470,  15;  1612,  29;  1658,  94;  1666,  100 
Source  of  BT  for  IR;  Sigma;  Ref.  No.;  T-1500;  Charge  No.  63F-0616 
aT  1189,  15;  1231,  16;  1276,  13;  1380,  14;  1432,  14;  1610,  25; 
1654,  100; 
Source  of  aT  for  IR;  Organon 
lAC  column(s)  developed  or  available;  ? 
9/19 GROUP  A III 
AMPICILLIN 
RM  In  preparation,  milk  and  bovine  muscle. 
Reference  Compound 
Merck  Index  No.  612  CAS  No;  69-53-4 
JECFA  reference. 
Analytical  method  in  Section  6;  Sg  1.3. 
Species  in  which  residues  may  occur;  all  especially dairy cows, 
Parent  drug;  anhydrous  form,  mono-,  Sesqui- and  tri-hydrates,  Na  &  K salts 
Therapeutic  category;  antibacterial 
Metabolites; 
Structure; 
o--
Molecular  Weight;  349.4 
uv 
Melting  Point;  dec  202°C 
Derivatives  for  GCMS 
J
CH
3 
CHCONH-p 
I  CH 
NH  N  3 
2  0  ',cOOH 
Selected  ions  for  identification  in  GCMS 
Selected  peaks  for  identification by  IR. 
IAC  column(s)  developed  or  available 
9/20 BENZYLPENICILLIN  (PEN-G) 
RM 
Reference  Compound 
Merck  Index  No.  1149 
JECFA  reference.  36th  meeting 
Analytical  method  in  Section  6;  Sg  1.3 
Species  in  which  residues  may  occur;  all 
CAS  No;  61-33-6 
Parent  drug;  Pen-G,  Na  salt  (Merck  1150),  procaine  penicillin 
Therapeutic  category;  antibacterial 
Metabolites;  penicilloic acid 
Structure; 
Molecular  Weight;  334.4 
UV  maxima  of  Na  salt  in  water  at 252.5,  258.6,  264.4  nm 
Melting  Point;  ? 
Derivatives  for  GCMS 
Selected  ions  for  identification  in  GCMS 
Selected  peaks  for  identification  by  IR. 
IAC  column(s)  developed  or  available 
9/21 CHLORAMPHENICOL  (CAP) 
RM  in  preparation  milk,  eggs  and  calf muscle 
Reference  Compound; 
Merck  Index  No.  2035  CAS  No;  56-75-7 
JECFA  reference.  12th,  32nd,  44th  meetings. 
Analytical  methods  in  Section  6;  Cy  3.6;  Cy  3.7;  Sg  3.3. 
Species  in  which  residues  may  occur;  calf,  cattle,  pig?,  poultry 
Parent  drug;  Chloramphenicol 
Therapeutic  category;  antimicrobial,  not  recommended  by  EEC  (CVMP)  in 
laying  hens  and  lactating cows 
Metabolites 
Structure 
H  H 
--o--
1  I 
~-~- CH20H 
Molecular  Weight;  323.1 
UV  maximum  at 278  nm 
Melting  Point;  150.5-151.5°C 
Derivatives  for  GCMS;  TMS 
OH  HN-COCHCI 2 
Selected  ions  for  identification  in  GCMS 
TMS  NCI  - 470,  468,  466,  378,  376  (reactant gas  methane) 
TMS  EI  - 224,  225,  242,  244,  246 
Selected  peaks  for  identification by  IR. 
lAC  column(s)  developed  or  available 
9/22 CHLORTETRACYCLINE  (CTC) 
RM 
Reference  Compound 
Merck  Index  No.  2170 
JECFA  reference. 
CAS  No;  57-62-5 
Analytical  method  in  Section  6;  Cy  3.8;  Sg  3.1 
Species  in  which  residues  may  occur;  all  especially pigs 
Parent  drug;  CTC  and  CTC  hydrochloride 
Therapeutic  category;  antimicrobial 
Metabolites 
Structure 
OH  0 
Molecular  Formula;  C 22H 23ClN208 
Molecular  Weight;478.9 
N(CH  ) 
3  2 
UV  maximum  in  0.1N HCl,  230,  262.5,  367.5  nm;  in  0.1N  NaOH,  255,  285,  345 
nm 
Melting  Point;  168-169°C 
Derivatives  for  GCMS,  parent 
Selected  ions  for  identification  in  GCMS,  [M+1]+ 
Thermospray,  [M+1]+,  479 
Extensive  fragmentation  in  EI-mode 
Selected  peaks  for  identification by  IR. 
lAC  column(s)  developed  or  available 
9/23 DIHYDROSTREPTOMYCIN 
RM  In  preparation,  milk 
Reference  Compound 
Merck  Index  No.  3161  CAS  No;  128-46-1 
JECFA  reference. 
Analytical  method  in  Section  6;  Sg  3.1 
Species  in  which  residues  may  occur;  all  especially dairy  cows 
Parent  drug;  dihydrostreptomycin  and  as  pantothenate  (Merck  No.  3162) 
Therapeutic  category;  antibacterial 
Metabolites; 
Structure;  NH 
0 
H :[i~:~H  NH~NH  2 
OH  H 
H  H 
H  OH 
H 
H~o 
R  H 
H~~  0  R'  R~H 
H  H 
OH 
Molecular  Weight;  583.6 
uv 
Melting  Point;  dec  255-256°C 
Derivatives  for  GCMS 
Selected  ions  for  identification  in  GCMS 
Selected  peaks  for  identification by  IR. 
lAC  column(s)  developed  or  available;  no 
9/24 
R  •  CH 
3 
R
1 
•  CH 2oH FURAZOLIDONE 
RM 
Reference  Compound. 
Merck  Index  No.  4175 
JECFA  reference.  40th  Meeting 
CAS  No;  67-45-8 
Analytical  methods  in  Section  6;  Cy  3.9;  Sg  3.4. 
Species  in  which  residues  are  most  likely to  occur;  All,  especially pigs 
and  poultry 
Parent  drug.  Furazolidone 
Therapeutic  category.  Antibacterial;  As  in-feed antibiotic. 
KEY  Metabolites;  Intensive metabolism,  parent  drug  either absent  or  is 
unstable  in  samples. 
Structure. 
0  NDO  CH:N 
2  I 
Lro 
Molecular  Weight;  225.2 
UV;  Maxima  at 262  nm  and  356  nm 
Melting  Point; 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  and  relative  intensity for  identification by  IR. 
Source  of  compound  for  IR; 
lAC  column(s)  developed  or  available  . 
9/25 GENTAMICIN 
Reference  Compound. 
Merck  Index  No.  4251  CAS  Nos;1403-66-3 
JECFA  reference. 
Analytical  methods  in  Section  6;  Sg  3.6 
Species  in  which  residues  are  most  likely to occur;  ALL 
Parent  drug.  Gentamicin  mixture  of  three  components;  C 1 ,  C 2 ,  C 1a 
Therapeutic  category.  Antibacterial 
KEY  Metabolites; 
Structure. 
Exists  in  four  forms  A,C1 ,  C 2,  C 1a. 
Molecular  Formula;  A,  C 18H326N 4010; 
C 1 ,  C 21H 43N 507;  C 2 ,  C 20H 41N 507;  C 1a,  C 19H 39N 507  (also  known  as  D) 
Molecular  Weight;  A, 
UV; 
'Melting  Point;  A,  194-209°C; 
C 1 ,  94-100°C;  C 2 ,  107-124°C,  C 1a,  ? 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  and  relative  intensity for  identification by  IR. 
Source  of  compound  for  IR; 
lAC  column(s)  developed  or  available  . 
9/26 NEOMYCIN 
Reference  Compound. 
Merck  Index  No.  6300(8  &  C),  6238  (Neamine);  CAS  Nos;  A,  3947-65-7 
B &  C;  1404-04-2 
JECFA  reference. 
Analytical  methods  in  Section  6;  Sg  3.6. 
Species  in  which  residues  are  most  likely to occur;  ALL 
Parent  drug.  Neomycin  mixture  of  A (Neamine),  B &  C 
Therapeutic  category.  Antibacterial 
KEY  Metabolites; 
Structure. 
Exists  in  three forms  A (Neamine),  B &  C. 
Molecular  Weight;  A,  322.4;  B &  C,  614.7 
UV; 
Melting  Point;  A,  225-226°C; 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  and  relative  intensity for  identification by  IR. 
Source  of  compound  for  IR; 
IAC  column(s)  developed  or  available  • 
9/27 NITROFURAZONE 
RM 
Reference  Compound. 
Merck  Index  No.  6446 
JECFA  reference.  40th  Meeting 
CAS  No;  58-87-0 
Analytical  methods  in  Section  6;  Cy  3.9;  Sg  3.4. 
Species  in  which  residues  are  most  likely to  occur;  All  especially pigs 
and  poultry. 
Parent  drug.  Nitrofurazone 
Therapeutic  category.  Antibacterial;  Used  as  in-feed  antibiotic. 
KEY  Metabolites;  Extensive  metabolism. 
Structure. 
2  2 
0  N UO  CH=N- NHCONH 
Molecular  Weight;  198.14 
UV;  Maxima  at 264  nm  and  367  nm 
Melting  Point;  236-240°C 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  and  relative  intensity for  identification by  IR. 
Source  of  compound  for  IR; 
lAC  column(s)  developed  or  available  • 
9/28 OXOLINIC  ACID 
RM 
Reference  Compound. 
Merck  Index  No.  6814 
JECFA  reference. 
CAS  No.  14698-29-4 
Analytical  method;  see  Takatsuki,  K.  (1991),  J.  Chromatog.  538,  259-267 
Limit  of  detection  1~g per  kg  fish  by  GC-MS. 
Species  in  which  residues  are  most  likely to  occur;  Farmed  fish 
Parent  drug.  Oxolinic  acid 
Therapeutic  category.  Antibiotic for  treating diseases  of  fish. 
KEY  Metabolites; 
Structure. 
COOH 
Molecular  Weight;  261 
UV; 
Melting  Point;  314-316°C 
Derivatives  for  GCMS;  Reduction  product 
after treatment with  sodium  tetraborate 
Selected  ions  for  identification  in  GCMS; 
204,  219,  176  Tatatsuki.  K.,  J.Chrom.  1991,  538,  259-267 
Selected  peaks  and  relative  intensity for  identification by  IR. 
Source  of  compound  for  IR; 
lAC  column(s)  developed  or  available  .  No 
9/29 OXYTETRACYLINE  (  OTC) 
RM 
Reference  Compound 
Merck  Index  No.  6846 
JECFA  reference. 
CAS  No;  79-57-2 
Analytical  method  in  Section  6;  Cy  3.8,  Sg  3.1 
Species  in  which  residues  may  occur;  all 
Parent  drug,  OTC  as  dihydrate  or  hydrochloride 
Therapeutic  category;  antimicrobial 
Metabolites 
Structure; 
OH  0  OH 
Molecular  Weight;  460.4 
N(CH  ) 
3  2 
I 
OH 
UV  in  pH  4.5  0.01M  phosphate  buffer  - 249,  276,  353  nm 
Melting  Point;  181°C  (decamp.) 
Derivatives  for  GCMS;  parent 
Selected  ions  for  identification  in  GCMS,  [M+1]+ 
CAD-MIKE  using  MS-MS  in  EI  mode;  M+.,  460.  442  416 
Thermospray  [M+1]+,  461 
Selected  peaks  for  identification by  IR. 
lAC  column(s)  developed  or  available 
9/30 SPIRAMYCIN 
RM 
Reference  Compound. 
Merck  Index  No.  8597  CAS  No;  8025-81-8 
JECFA  reference.  12th  &  38th  meetings 
Analytical  methods  in  Section  6; 
Species  in  which  residues  are  most  likely to occur;  all 
Parent  drug.  Spiramycin  I,  II  & III 
Therapeutic  category.  Antibacterial 
KEY  Metabolites;  Neospiramycin  (limited evidence) 
Structure. 
Molecular  Formula;  I,  C43H 74N2014;  II,  C45H76N2015; 
Molecular  Weight;  I, 843.1;  II, 885.2 
UV; 
III,  C46H7aN2015; 
III, 899.2 
Melting  Point;  I,  134-137°C;  II,  130-133°C;  III,  128-131°C 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  and  relative  intensity for  identification  by  IR. 
Source  of  compound  for  IR; 
lAC  column(s)  developed  or  available  . 
9/31 SULPHADIMIDINE  (SULPHAMETHAZINE) 
RM  IN  PREPARATION  - muscle,  liver and  urine of  pig 
Reference  Compound; 
Merck  Index  No.  8786  CAS  No.  57-68-1 
JECFA  reference.  34th  meeting 
Analytical  methods  in  Section  6;  Cy  3.1;  Cy  3.2;  Cy  3.3;  Cy  3.4;  Sg  3.2 
Species  in  which  residues  may  occur;  pigs,  cattle,  poultry 
Parent  drug;  Sulfamethazine 
Therapeutic  category;  antibacterial 
Metabolites;  N-acetyl-SMZ,  N-glucose-SMZ,  desamino-SMZ 
Structure;  CH 
H N~  SO  NH-{N---<:.
3 
2 ~  2  N~ 
Molecular  Weight;  278.3 
CH 
3 
UV;  241  nm  in  water,  243  &  257  nm  in  0.01N  NaOH,  241  &  297  in  0.01N  HCl 
Melting  Point;176°C 
Derivatives  for  GCMS;  parent,  methyl  ester 
Selected  ions  for  identification  in  GCMS  + 
Thermospray  [M+1]  279  (parent);  [M+1]  321  (N-4-acetyl-SMZ) 
EI-?  see;  Siegert,  K.  (1985)  Nachweis  von  Sulfonamiden  und  Antibiotica 
mit  Methoden  der  gekoppelten  GCMS.  Fleischwirtsch.  65,  1496-1497 
Selected  peaks  for  identification by  IR. 
lAC  column(s)  developed  or  available;  yes 
9/32 SULPHAQUINOXALINE 
RM 
Reference  Compound; 
Merck  Index  No.  8815 
JECFA  reference. 
CAS  No;  59-40-5 
Analytical  method  in  Section  6;  Cy  3.1;  Sg  3.2. 
Species  in  which  residues  may  occur; 
Parent  drug;  Sulphaquinoxaline 
Therapeutic  category; 
Metabolites; 
Structure; 
Antimicrobial 
Molecular  Formula;  C 14H12N402S 
Molecular  Weight;  300.3 
UV  maximum,  pH  6.6  in  water  252  nm,  360  nm 
Melting  Point;  247-248°C 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  for  identification by  IR; 
IAC  column(s)  developed  or  available;  ? 
9/33 TRIMETHOPRIM 
RM 
Reference  Compound; 
Merck  Index  No.  9516 
JECFA  reference. 
Analytical  method  in  Section  6; 
Species  in  which  residues  may  occur;  All 
Parent  drug;  Trimethoprim 
CAS  No;  738-70-5 
Therapeutic  category;  Antibacterial;  usually mixed  with  a  sulphonamide. 
Metabolites; 
Structure; 
CH  0 
3 
CH  0 
3 
Molecular  Weight;  290.3 
uv 
Melting  Point;  199-203°C 
Derivatives  for  GCMS; 
OCH 
3 
N 
NH 
2 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  for  identification by  IR; 
lAC  column(s)  developed  or  available;  No 
9/34 TYLOSIN 
RM 
Reference  Compound. 
Merck  Index  No.  9631 
JECFA  reference.  12th  &  38th  meetings 
Analytical  methods  in  Section  6; 
CAS  No;  1401-69-0 
Species  in  which  residues  are  most  likely to  occur;  Cattle,  pigs,  poultry 
Parent  drug.  Tylosin 
Therapeutic  category.  Antibacterial 
KEY  Metabolites;  Extensive  metabolism 
Structure. 
Molecular  Formula;  C45H77N017 
Molecular  Weight;  916.1 
UV;  Maximum  at 282  nm 
Melting  Point;  128-132°C 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  and  relative  intensity for  identification by  IR. 
Source  of  compound  for  IR; 
lAC  column(s)  developed  or  available  • 
9/35 ALBENDAZOLE 
RM 
Reference  Compound; 
GROUP  B I 
Merck  Index  No.  197  CAS  No;  54965-21-8 
JECFA  reference.  34th  meeting 
Analytical  method  in  Section  6;  Cy  4.1; 
Species  in  which  residues  may  occur;  cattle,  sheep, 
Parent  drug;  Albendazole 
Therapeutic  category;  Anthelmintic 
Metabolites;  2-amino-albendazole  sulphone  (Marker  substance  - JECFA) 
Structure;  H 
~N1rNHCOOCH 3 
CH  CH  CH S~ 
3  2  2 
Molecular  Formula;  C 12H 15N 302S 
Molecular  Weight;  265.3 
Melting  Point;  208-210°C  UV  maximum  297  nm 
Derivatives  for  GCMS;  methyl  or  pentafluorobenzyl  of  albendazole 
t-butyldimethylsilyl  of  2-amino-albendazole  sulphone 
Selected  ions  for  identification  in  GCMS; 
Albendazole  (ABZ);  EI  - 265,  236,  234,  233,  191,  190,  178 
ABZ-2-amino  sulphone;  EI  - 239,  197,  196,  180,  148,  133,  132,  105 
Methyl- ABZ;  EI  - 293,  234,  192,  72,  59 
Pentafluorobenzyl-ABZ;  EI  - 625,  566,  444,  181 
Pentafluorobenzyl-ABZ;  PICI  - 654,  626,  446,  182,  181 
(Ref;  Gyurik  et al.,  (1981),  Drug  Metab.  &  Disposition,~. 503-508) 
t-butyldimethylsilyl-2-amino-ABZ-sulphone;  ?  - 467,  410,  354,  189 
Ref;  FAO  Food  and  Nutrition  Paper  41/2  (1990), 
Selected  peaks  for  identification by  IR; 
lAC  column(s)  developed  or  available;  none 
9/36 AZAPERONE 
RM 
Reference  Compound; 
Merck  Index  No.  903 
JECFA  reference.  38th  meeting 
CAS  No;  1649-18-9 
Analytical  method  in  Section  6;  Cy  4.5;  Cy  4.6.;  Sg  4.1 
Species  in  which  residues  may  occur;  pigs 
Parent  drug;  Azaperone 
Therapeutic  category;  Tranquilizer 
Metabolites;  Azaperol 
Structure; 
Molecular  Weight;  327.4 
uv 
Melting  Point;  73-75°C 
Derivatives  for  GCMS;  Parent  and  azaperol. 
Selected  ions  for  identification  in  GCMS; 
Azaperone  EI  107  (base  peak),  233,  165,  309 
Azaperol  EI  107  (base  peak),  235,  121,  222 
Selected  peaks  for  identification by  IR; 
lAC  column(s)  developed  or  available;  no 
9/37 CARAZOLOL 
RM 
Reference  Compound; 
Merck  Index  No.  1753 
JECFA  reference.  38th  meeting 
CAS  No;  57775-83-2 
Analytical  method  in  Section  6;  Cy  4.5;  Cy  4.6;  Sg  4.1 
Species  in  which  residues  may  occur;  pigs,  cattle 
Parent  drug;  Carazolol 
Therapeutic  category;  Tranquillizer,  B-andrenergic  blocker 
Metabolites;  as  glucuronide,  lactate and  acetate. 
Structure;  H 
cto 
0  CH 
I  I  3 
CH- CH- C~- NH-CH 
I  I  I 
H  OH  CH
3 
Molecular  Formula;  C 18H 22N 202 
Molecular  Weight;  298.4 
UV  maximum  at 286  nm 
Melting  Point;135-138°C 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  for  identification by  IR; 
lAC  column(s)  developed  or  available;  no 
9/38 CARBADOX 
RM 
Reference  Compound 
Merck  Index  No.  1757 
JECFA  reference.  36th  meeting 
CAS  No;  6804-07-5 
Analytical  method  in  Section  6;  Cy  4.3  (as  QCA); 
Sg  4.2  (as  QCA);  Sg  4.3  (as  Desoxycarbadox) 
Species  in  which  residues  may  occur;  pigs,  poultry? 
Parent  drug;  Cardadox 
Therapeutic  category;  antimicrobial 
Metabolites;  quinolinic acid  (QCA),  Desoxycarbadox. 
Structure;  o 
t 
0:  r  CH -NNHCOOCH3 
1 
0 
Molecular  Weight;  262.2 
UV  maximum  in  water  236,  251,  303,  366,  373  nm 
Melting  Point;239.5-240°C 
Derivatives  for  GCMS;  Prepare  methyl  ester of  QCA 
Selected  ions  for  identification  in  GCMS 
EI  QCA-methyl  ester  188,  158,  130,  102 
Selected  peaks  for  identification by  IR. 
lAC  column(s)  developed  or  available 
9/39 CHLORPROMAZINE 
RM 
Reference  Compound; 
Merck  Index  No.  2163 
JECFA  reference.  38th  meeting 
CAS  No;  50-53-3 
Analytical  method  in  Section  6;  Cy  4.5;  Cy  4.6.;  Sg  4.1. 
Species  in  which  residues  may  occur;  pigs 
Parent  drug;  Chlorpromazine 
Therapeutic  category;  tranquillizer 
Metabolites; 
Structure; 
~H 
2
cH
2
CH
2
N(CH
3
)
2 
N  Cl 
8 
Molecular  Formula;  C 17H 19ClN2S 
Molecular  Weight;  318.9 
uv 
Boiling  Point;  200-205°C 
Derivatives  for  GCMS;  parent 
Selected  ions  for  identification  in  GCMS; 
EI  318  (base  peak),  272,  86,  233 
Selected  peaks  for  identification by  IR; 
lAC  column(s)  developed  or  available;  no 
9/40 CIMATEROL 
RM 
Reference  Compound;  In  preparation  in  bovine  urine,  pig  muscle  and  liver 
Merck  Index  No.  CAS  No;  54239-37-1 
JECFA  reference. 
Analytical  method  in  Section  6;  Cy  2.1;  Cy  2.3; 
Sg  2.1;  Sg  2.2;  Sg  2.3;  Sg  2.4 
Species  in  which  residues  may  occur;  Cattle,  pigs,  chickens. 
Parent  drug;  Cimaterol 
Therapeutic  category;  B-agonist,  bronchodilator,  alters partition of 
nutrients on  favour  of  increased  protein  to fat ratios. 
Metabolites;  -CN  grup  oxidised  to  -CONH2  or  -COOH 
Structure;  Ni!!C  CH 
O
H  H  H  I  3 
I  I  I 
HN  C-C-N-C-H 
2  I  I  I 
OH  H  CH 
3 
Molecular  Formula; 
Molecular  Weight;  219.3 
uv 
Melting  Point; 
Derivatives  for  GCMS;  Mono-TMS  {M.W.=  291);  Di-TMS  (M.W.=  363) 
Selected  ions  for  identification  in  GCMS; 
Mono-TMS  EI  276,  234,  219,  186,  72 
Di-TMS  EI  348,  291,  258,  72 
Mono-TMS  PI-CI  292,  276,  202 
Selected  peaks  for  identification by  IR; 
9/41 CLENBUTEROL 
RM  in  preparation  - calf urine 
Reference  Compound;  ?  RIVM 
Merck  Index  No.  2316  CAS  No;  37148-27-9 
JECFA  reference. 
Analytical  methods  in  Section  6;  Cy  2.1;  Cy  2.2;  Cy  2.3. 
Sg  2.1;  Sg  2.2;  Sg  2.3;  Sg  2.4 
Species  in  which  residues  may  occur;  pigs,  calves,  poultry 
Parent  drug;  clenbuterol,  clenbuterol  hydrochloride 
Therapeutic  category;  B-agonist,  bronchodilator,  tocolytic effects  in 
parturient cattle,  aid  in  embryo  transfer  in  cattle,  alters partition of 
nutrients  on  favour  of  increased  protein to fat ratios. 
Metabolites; 
Structure;  Cl 
0
H  H  H  CH 
I  I  I  I 
3 
H2N  c-c-N-C-CH 
I  I  I  3 
OH  H  CH 
Cl  3 
Molecular  Formula; 
Molecular  Weight;  277.2 
uv 
Melting  Point;  174-175.5°C  (hydrochloride) 
Derivatives for  GCMS;  Mono-TMS  (M.W.=348), 
cyclic 2(dimethyl)silamorpholine  (D.M.S)  (M.W.=  346) 
Selected  ions  for  identification  in  GCMS 
Mono-TMS  EI  333,  277,  262,  243,  187,  86 
Cyclic-OMS  346,  331,  283,  128,  100 
Mono-TMS  PI-CI  349,  333,  259 
Selected  peaks  for  identification by  IR. 
lAC  column(s)  developed  or  available  ;  yes 
9/42 CLOSANTEL 
RM 
Reference  Compound. 
Merck  Index  No.  CAS  No; 
JECFA  reference.  40th  meeting 
Analytical  methods  in  Section  6; 
Species  in  which  residues  are  most  likely to occur;  Cattle and  sheep 
Parent  drug.  Closantel 
Therapeutic  category.  Anthelminthic 
KEY  Metabolites;  3-monoiodoclosantel 
Structure. 
I  0  Cl  CN  Q8-NH-o-(;H-o-CI 
I  OH  CHa 
Molecular  Formula;  C 22H 14Cl 2I2N 202 
Molecular  Weight;  663.1 
UV; 
Melting  Point;  215-235°C  with  decomposition 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  and  relative  intensity for  identification by  IR. 
Source  of  compound  for  IR; 
lAC  column(s)  developed  or  available  • 
9/43 DIMETRIDAZOLE 
RM 
Reference  Compound; 
Merck  Index  No.  3262 
JECFA  reference.  34th  meeting 
Analytical  method  in  Section  6; 
Species  in  which  residues  may  occur; 
Parent  drug;  Dimetridazole 
CAS  No;  551-92-8 
Therapeutic  category;  Antiprotozoal;  Control  of  histomoniasis  in  poultry 
and  swine  dysentery  caused  by  Treponema  hyodysenteriae 
Metabolites;  extensive metabolism 
Molecular  Weight;  141.1 
uv 
Melting  Point;  138-139°C 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  for  identification  by  IR; 
lAC  column(s)  developed  or  available;  no 
9/44 FEBANTEL 
RM 
Reference  Compound; 
Merck  Index  No.  3879 
JECFA  reference.  38th  meeting 
Analytical  method  in  Section  6;  Cy  4.1; 
CAS  No;  58306-30-2 
Species  in  which  residues  may  occur;  cattle,  sheep 
Parent  drug;  Febantel 
Therapeutic  category;  Anthelmintic 
Metabolites;  Converted  to  fenbendazole  and  oxfendazole  in  host. 
Structure; 
0 O
N•C/NHCOOCH3 
'NHCOOCH 
S  NHCOCH  OCH 
3 
2  3 
Molecular  Weight;  446.5 
uv 
Melting  Point;  129-130°C 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  for  identification by  IR; 
lAC  column(s)  developed  or  available;  no 
9/45 FENBENDAZOLE 
RM 
Reference  Compound; 
Merck  Index  No.  3891 
JECFA  reference.  38th  meeting 
Analytical  method  in  Section  6;  Cy  4.1; 
CAS  No;  43210-67-9 
Species  in  which  residues  may  occur;  cattle,  sheep,  horses,  pigs 
Parent  drug;  Fenbendazole 
Therapeutic  category;  anthelmintic 
Metabolites; 
Structure;  H 
I 
NY  NHCOOCH3 
Molecular  Weight;  299.4 
UV  maximum  at 297  nm 
Melting  Point;  dec.  233°C 
N 
Derivatives for  GCMS;  methyl  or  pentafluorobenzyl 
Selected  ions  for  identification  in  GCMS; 
Methyl-fenbendazole;  EI  - 327,  268,  59 
Pentafluorobenzyl-fenbendazole;  EI  - 659,  600,  478,  181,  59 
Pentafluorobenzyl-fenbendazole;  PICI  - 688,  660,  480,  182,  181 
Selected  peaks  for  identification by  IR; 
lAC  column(s)  developed  or available;  no 
9/46 FLUBENDAZOLE 
RM 
Reference  Compound. 
Merck  Index  No.  4030 
JECFA  reference. 
Analytical  methods  in  Section  6; 
CAS  No;  31430-15-6 
Species  in  which  residues  are  most  likely to  occur;  pigs  and  poultry 
Parent  drug.  Flubendazole 
Therapeutic  category.  Anthelmintic 
Key  Metabolites;  (2-amino-lH-benzimidazol-5-yl)-4-fluorophenyl-methanone. 
Structure. 
Molecular  Weight;  313.3 
UV; 
Melting  Point;  260°C 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  and  relative  intensity for  identification  by  IR. 
Source  of  compound  for  IR; 
lAC  column(s)  developed  or  available  • 
9/47 HALOPERIDOL 
RM 
Reference  Compound; 
Merck  Index  No.  4480 
JECFA  reference. 
CAS  No;  52-86-8 
Analytical  method  in  Section  6;  Cy  4.5;  Cy  4.6.;  Sg  4.1. 
Species  in  which  residues  may  occur;  pigs 
Parent  drug;  Haloperidol 
Therapeutic  category;  tranquillizer 
Metabolites; 
Structure; 
Molecular  Formula;  C 21H 23ClFN02 
Molecular  Weight;  375.9 
UV  maximum  at 247nm  &  241  nm  in  0.1M  HCl  MeOH  (9:1,  v/v) 
Melting  Point;  148-149.4°C 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
EI  224.  Ions  237,  123  and  206  do  not  meet  criteria  (EEC  93/256) 
Selected  peaks  for  identification by  IR; 
lAC  column(s)  developed  or  available;  no 
9/48 IPRONIDAZOLE 
RM 
Reference  Compound; 
Merck  Index  No.  4934 
JECFA  reference.  34th  meeting 
Analytical  method  in  Section  6; 
CAS  No;  14885-29-1 
Species  in  which  residues  may  occur;  pigs  and  poultry 
Parent  drug;  Ipronidazole 
Therapeutic  category;  Antiprotozoal;  Control  of  histomoniasis  in  poultry 
and  swine  dysentery  caused  by  Treponema  hyodysenteriae 
Metabolites;  Extensive  metabolism  including  2-hydroxy-ipronidazole 
Structure;  CH 3 
I 
0  N LN  VCH(CH  ) 
2  ~  32 
N 
Molecular  Weight;  169.2 
uv 
Melting  Point;  60°C 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  for  identification by  IR; 
lAC  column(s)  developed  or  available;  no 
9/49 ISOMETAMIDIUM  CHLORIDE 
RM 
Reference  Compound. 
Merck  Index  No.  5028 
JECFA  reference.  34th  &  40th  Meetings 
Analytical  methods  in  Section  6; 
CAS  No;  34301-55-8 
Species  in  which  residues  are  most  likely to occur;  All  ruminants 
Parent  drug.  Isometamidium  chloride 
Therapeutic  category.  Antitrypanosomal  agent 
KEY  Metabolites;  Parent  drug  is main  residue 
Structure. 
Molecular  Weight;  496.0 
UV; 
Melting  Point;  244-245°C 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  and  relative  intensity for  identification by  IR. 
Source  of  compound  for  IR; 
lAC  column(s)  developed  or  available  . 
9/50 IVERMECTIN 
RM 
Reference  Compound; 
Merck  Index  No.  5089 
JECFA  reference.  36th  meeting 
Analytical  method  in  Section  6;  Cy  4.4; 
Species  in  which  residues  may  occur;  all 
CAS  No;  70288-86-7 
Parent  drug;  Ivermectin  is a chemically modified  fermentation  product 
consisting of  two  compounds  differing from  each  other by  only one 
methylene  (-CH2-)  group.  The  two  compounds  are  designated  22,23-
dihydroavermectin-B1a  and  22,23-dihydroavermectin-B1b. 
Ivermectin  is a mixture  of  the  2 Avermectins,  H 2B 1a &  H 2B 1b 
containing  no  less than  80%  H 2B 1a and  no  more  than  20%  H 2B 1b 
Therapeutic  category;  Antiparasitic 
Metabolites;24-hydroxy methyl  ivermectin  in  sheep,  cattle and  rats; 
3
11-0-desmethyl  derivatives  in  pigs 
Molecular  Formula;  H 2B 1a;  C 48H 74014:  H 2B1b;  C47H72014 
Molecular  Weight;  H 2B 1a 875.1,  H 2B 1b  861.1 
UV  maximum  in  methanol  238,  245  nm 
Melting  Point;  H 2B 1a  155-157°C 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  for  identification  by  IR; 
lAC  column(s)  developed  or  available;  no 
9/51 LASALOCID 
RM 
Reference  Compound; 
Merck  Index  No.  5204 
JECFA  reference. 
Analytical  method  in  Section  6;  Cy  4.2; 
Species  in  which  residues  may  occur; 
Parent  drug;  Lasalocid 
CAS  No;  25999-31-9 
Therapeutic  category;  Coccidiostat  in  poultry,  Ionophore,  Feed  additive, 
growth  promoter 
Metabolites; 
Structure; 
HO 
Molecular  Weight;  590.8 
UV  maximum  in  50%  isopranol  248,  348  nm 
Melting  Point;  110-ll4°C 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  for  identification  by  IR; 
lAC  column(s)  developed  or  available;  no 
9/52 
I 
I 
I 
,CH CH 
,  2  3 
' 
OH 
'cH CH 
'  2  3  'cH 
3 LEVAMISOLE  (TETRAMISOLE) 
RM 
Reference  Compound; 
Merck  Index  No.  9055 
JECFA  reference.  36th  and  44th  meetings. 
Analytical  method  in  Section  6;  Sg  4.5 
CAS  No;  5036-02-2 
Species  in  which  residues  may  occur;  cattle,  sheep,  goats,  pigs  &  poultry 
Parent  drug;  Levamisole  hydrochloride 
Therapeutic  category;  anthelmintic,  immunopotentiater 
Metabolites;  Extensive 
Structure; 
Molecular  Formula;  C 11H1zNzS 
Molecular  Weight;  204.3 
uv 
Melting  Point;  87-89°C,  hydrochloride;  264-265°C 
Derivatives  for  GCMS;  parent 
Selected  ions  for  identification  in  GCMS; 
EI-PI  148,  121,  203,  204 
Selected  peaks  for  identification by  IR; 
lAC  column(s)  developed  or  available;  no 
9/53 METRONIDAZOLE 
RM 
Reference  Compound; 
Merck  Index  No.  6033 
JECFA  reference.  34th  meeting 
Analytical  method  in  Section  6; 
CAS  No;  443-48-1 
Species  in  which  residues  may  occur;  pigs,  poultry 
Parent  drug;  Metronidazole 
Therapeutic  category;  Antiprotozoal;  Control  of  histomoniasis  in  poultry 
and  swine  dysentery  caused  by  Treponema  hyodysenteriae 
Metabolites;  Extensive  metabolism 
Structure;  CH  CH  OH 
I  2  2  o2NLrcH3 
Molecular  Weight;  171.2 
uv 
Melting  Point;  158-160°C 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  for  identification by  IR; 
lAC  column(s)  developed  or  available;  no 
9/54 MONENSIN 
RM 
Reference  Compound; 
Merck  Index  No.  6100 
JECFA  reference. 
Analytical  method  in  Section  6;  Sg  4.4. 
CAS  No;  17090-79-8 
Species  in  which  residues  may  occur;  Poultry,  cattle, 
Parent  drug;  Monensin,  or  sodium  salt 
Therapeutic  category;  Ionophore,  antibacterial,  antifungal,  antiprotozoal, 
coccidiostat  in  poultry,  feed  additive,  growth  promoter 
Metabolites; 
Structure; 
H  C 
3 
Molecular  Weight;  670.9 
UV  no  major  absorbance 
Melting  Point;  Na  salt - 267-269°C 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  for  identification by  IR; 
lAC  column(s)  developed  or  available;  no 
9/55 
HC -CH 
I  3 
COOH 
CH 
3 NARASIN 
RM 
Reference  Compound; 
Merck  Index  No.  6271 
JECFA  reference. 
Analytical  method  in  Section  6;  Sg  4.4 
CAS  No;  55134-13-9 
Species  in  which  residues  may  occur;  poultry,  cattle,  sheep 
Parent  drug;  Narasin 
Therapeutic  category;  Coccidiostat  in  poultry,  Ionophore,  Feed  additive, 
growth  promoter 
Metabolites; 
Structure; 
(4-Me-salinomycin) 
Molecular  Weight;  765.1 
UV  maximum  in  Ethanol  285  nm 
Melting  Point;  98-100°C 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  for  identification by  IR; 
lAC  column(s)  developed  or  available;  no 
9/56 NITROXYNIL 
RM 
Reference  Compound; 
Merck  Index  No.6504 
JECFA  reference. 
Analytical  method  in  Section  6; 
CAS  No;  1689-89-0 
Species  in  which  residues  may  occur;  cattle,  sheep 
Parent  drug;  Nitroxynil 
Therapeutic  category;  anthelmintic  (fasciliocide) 
Metabolites; 
Structure; 
Molecular  Formula;  C 7H 3IN203 
Molecular  Weight;  290.03 
OH 
/NO 
CN 
UV  maximum  at 
Melting  Point; 
?  nm,  (HPLC  used  at 273  nm.) 
137-138°C 
Derivatives  for  GCMS; 
2 
Selected  ions  for  identification  in  GCMS;  parent  drug 
EI  - 290,  273,  244,  117,  88 
Selected  peaks  for  identification by  IR; 
lAC  column(s)  developed  or  available;  no 
9/57 OXFENDAZOLE 
RM 
Reference  Compound; 
Merck  Index  No.6808 
JECFA  reference.  38th  meeting 
Analytical  method  in  Section  6;  Cy  4.1; 
CAS  No;  53716-50-0 
Species  in  which  residues  may  occur;  cattle,  sheep,  pigs? 
Parent  drug;  Oxfendazole 
Therapeutic  category;  anthelmintic 
Metabolites; 
Structure;  H 
0 
S ~  r  NHCOOCHS 
Molecular  Weight;  315.4 
UV  maximum  at 295  nm 
Melting  Point;  dec.  253°C 
A 
Derivatives for  GCMS;  Methyl  or  pentafluorobenzyl, 
Selected  ions  for  identification  in  GCMS; 
Methyl  oxfendazole;  EI  - 343,  327,  295,  266,  250,  236,  159,  72,  59 
Pentafluorobenzyl-oxfendazole;  EI  - 675,  659,  627,  600,  181,  59 
Pentafluorobenzyl-oxfendazole;  PICI  - 701,  676,  660,  85,  71,  57 
Selected  peaks  for  identification  by  IR; 
lAC  column(s)  developed  or  available;  no 
9/58 PROPIONYLPROMAZINE 
RM 
Reference  Compound; 
Merck  Index  No.  7730 
JECFA  reference.  38th  meeting 
CAS  No;  3568-24-9 
Analytical  method  in  Section  6;  Cy  4.5;  Cy  4.6;  Sg  4.1. 
Species  in  which  residues  may  occur;  pigs 
Parent  drug;  Propionylpromazine  and  as  hydrochloride 
Therapeutic  category;  Tranquillizer 
Metabolites;  none  identified 
Structure;  CH  CH  CH  N(CH  ) 
o~dOCH2~=3 
Molecular  Formula;  C 20H 24N 20S 
Molecular  Weight;  340.6 
uv 
Melting  Point;  69-70°C 
Derivatives  for  GCMS;  parent 
Selected  ions  for  identification  in  GCMS; 
EI  340  (base  peak),  294,255,  197 
Selected  peaks  for  identification by  IR; 
lAC  column(s)  developed  or  available;  no 
9/59 RACTOPAMINE 
RM 
Reference  Compound. 
Merck  Index  No.  CAS  No; 
JECFA  reference.  40th  Meeting 
Analytical  methods  in  Section  6;  Cy  2.3;  Sg  2.1;  Sg  2.4 
Species  in  which  residues  are  most  likely to  occur;  pigs 
Parent  drug.  Ractopamine  hydrochloride 
Therapeutic  category.  B-agonist;  In-feed  repartitioning agent 
KEY  Metabolites;  Ractopamine-glucuronides 
Structure. 
Cl 
HO-o-C
1
H  -CH  -~H  -CH -CH -cH ~-OH 
2  21  2  2~ 
OH  CH 
3 
Molecular  Weight;  337.5 
UV; 
Melting  Point;  °C 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  and  relative intensity for  identification by  IR. 
Source  of  compound  for  IR; 
lAC  column(s)  developed  or  available  . 
9/60 RONIDAZOLE 
RM 
Reference  Compound; 
Merck  Index  No.  8128 
JECFA  reference.  34th  meeting 
Analytical  method  in  Section  6; 
CAS  No;  7681-76-7 
Species  in  which  residues  may  occur;  pigs,  poultry 
Parent  drug;  Ronidazole 
Therapeutic  category;  Antiprotozoal;  Control  of  histomoniasis  in  poultry 
and  swine  dysentery  caused  by  Treponema  hyodysenteriae 
Metabolites;  extensive metabolism 
Structure;  CH 
I  3 
0  N LN  YCH  OOCNH  2  2  2 
N 
Molecular  Weight;  200.2 
uv 
Melting  Point;  167-169°C 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  for  identification by  IR; 
lAC  column(s)  developed  or  available;  no 
9/61 SALBUTAMOL  (ALBUTEROL) 
RM  In  preparation  - calf urine  and  pig  muscle  and  liver 
Reference  Compound 
Merck  Index  No.  206  CAS  No;  18559-94-9 
JECFA  reference. 
Analytical  method  in  Section  6;  Cy  2.1;  Cy  2.3. 
Sg  2.1;  Sg  2.2;  Sg  2.3;  Sg  2.4 
Species  in  which  residues  may  occur;  pigs,  calves,  poultry 
Parent  drug;  Salbutamol 
Therapeutic  category;  8-agonist,  bronchodilator,  tocolytic effects  in 
parturient cattle,  possible aid  in  embryo  transfer  in  cattle,  alters 
partition of  nutrients on  favour  of  increased  protein  to  fat ratios. 
Metabolites;  The  sulphate  conjugate  is the main  residue  in  bovine  and 
porcine  liver. 
Structure; 
HO 
Molecular  Weight;  239.3 
uv 
Melting  Point;  151°C 
H  H  H  CH 
I  I  I  I 
3 
c-C-N- C -CH 
I  I  I  3 
OH  H  CH
3 
Derivatives  for  GCMS;  Tri-TMS  (M.W.  =  455) 
Selected  ions  for  identification  in  GCMS 
Tri-TMS  EI  426,  370,  356,  336,  280,  (86  or  72  for  screening) 
Tri-TMS  PI-CI  456,  440,  366,  also  394,  369,  350 
Tri-TMS  EI  86,  369,  455  (Method  Sg  2.1,  Sg  2.3) 
Selected  peaks  for  identification by  IR. 
lAC  column(s)  developed  or  available  ;  yes 
9/62 SALINOMYCIN 
RM 
Reference  Compound; 
Merck  Index  No.  8193 
JECFA  reference. 
Analytical  method  in  Section  6;  Sg  4.4. 
CAS  No;  53003-10-4 
Species  in  which  residues  may  occur;  Poultry,  cattle,  sheep 
Parent  drug;  Salinomycin 
Therapeutic  category;  Anticoccidial,  ionophore 
Metabolites; 
Structure; 
Molecular  Formula;  C 42H 70011 
Molecular  Weight;  751.0 
UV  maximum  in  ethanol;water  (2/1)  284  nm 
Melting  Point;  112.5-113.5°C 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  for  identification by  IR; 
IAC  column(s)  developed  or  available;  no 
9/63 
OH THIABENDAZOLE 
RM 
Reference  Compound; 
Merck  Index  No.  9126 
JECFA  reference.  40th  meeting 
Analytical  method  in  Section  6;  Cy  4.1; 
CAS  No;  148-79-8 
Species  in  which  residues  may  occur;  cattle,  sheep 
Parent  drug;  Thiabendazole 
Therapeutic  category;  Anthelmintic,  fungicide 
Metabolites; 
Structure;  Ho 
~N 
Molecular  Formula; 
Molecular  Weight;  201.3 
UV  maximum  at 301  nm 
Melting  Point;  304-305°C 
Derivatives  for  GCMS;  Methyl  or  pentafluorobenzyl, 
Selected  ions  for  identification  in  GCMS; 
Methyl-thiabendazole;  EI  - 215,  187,  156,  155,  77 
Pentafluorbenzyl-thiabendazole;  EI  - 381,  362,  303,  214,  181,  90 
Pentafluorbenzyl-thiabendazole;  PICI  - 410,  382,  202,  182,  181 
lAC  column(s)  developed  or available;  no 
9/64 TRICLABENDAZOLE 
RM 
Reference  Compound. 
Merck  Index  No.  CAS  No;  68786-66-3 
JECFA  reference.  40th  meeting 
Analytical  methods  in  Section  6; 
Species  in  which  residues  are  most  likely to occur;  all  ruminants 
Parent  drug.  Triclabendazole 
Therapeutic  category.  Anthelmintic 
KEY  Metabolites;  Oxidation  to sulphoxide  and  sulphone. 
Structure.  CI:(XN 
Q-
I  }s-cH3 
0  ~  N 
H 
Cl  Cl 
Molecular  Weight;  359.7 
UV; 
Melting  Point;  175°C  (a- modification),  162°C  (B- modification) 
Derivatives  for  GCMS; 
Selected  ions  for  identification  in  GCMS; 
Selected  peaks  and  relative  intensity for  identification by  IR. 
Source  of  compound  for  IR; 
lAC  column(s)  developed  or  available  . 
9/65 XYLAZINE 
RM 
Reference  Compound; 
Merck  Index  No.  9889 
JECFA  reference. 
CAS  No;  7361-61-7 
Analytical  method  in  Section  6;  Cy  4.5;  Sg  4.1 
Species  in  which  residues  may  occur;  pigs 
Parent  drug;  Xylazine 
Therapeutic  category;  tranquillizer 
Metabolites; 
Structure; 
Molecular  Weight;  220.3 
uv 
Melting  Point;  140-142°C 
Derivatives  for  GCMS;  parent 
Selected  ions  for  identification  in  GCMS; 
EI  205  (base  peak),  Ions  220,  177  and  145  do  not  meet  criteria  (EEC 
93/256) 
Selected  peaks  for  identification by  IR; 
lAC  column(s)  developed  or  available;  no 
9/66 10.  IMPORTANT  EEC  LEGISLATION  CONCERNING  RESIDUES. 
10.1  EEC  PUBLISHED  LIST 
64/433 
70/373 
70/524 
72/462 
81/602 
81/851 
81/852 
83/90 
84/425 
85/358 
85/397 
85/591 
85/649 
Council  Directive  on  health  problems  affecting  intra-Community 
trade  in  fresh  meat.  Several  amendments.  [OJ  ~ L 121, 
29.7.1964,  pp.2012-64] 
Council  Directive establishing Community  methods  for  the 
official  control  of  feedingstuffs.  [OJ  ~ L 170,  3.8.1970,  pp. 
2- ]  >10  amendments. 
Council  Directive concerning  additives  in  feedstuffs.  c.  50 
amendments.  e.g.  90/167  relating to medicated  feedingstuffs. 
[OJ  ~ L 270,  14.12.1970,  pp.l-20] 
Council  Directive  on  health  and  veterinary  inspection  problems 
upon  importation  of  of  bovine  animals  and  swine  and  fresh  meat 
from  third countries.  (several  amendments).  [OJ  ~ L 302, 
31.12.1972,  p.28] 
Council  Directive concerning  the  prohibition of  certain 
substances  having  a  hormonal  action  and  of  any  substances 
having  a  thyreostatic action.  [OJ~ L 222,  7.8.1981,  pp.  32-33] 
Council  Directive  on  the  approximation  of  the  laws  of  Member 
States relating to  veterinary medicinal  products.  [OJ~ L 317, 
6.11.1981,  pp.  1-17].  Amended  in  Directives  90/676  and  90/677. 
Council  Directive  on  the  approximation  of  the  laws  of  the 
Member  States  relating to  analytical,  pharmaco-toxicological 
and  clinical  standards  and  protocols  in  respect of  the  testing 
of  veterinary medicinal  products.  [OJ~ L 317,  6.11.81,  pp.  18-
28] 
amends  64/433  [OJ  ~ L 59,  5.3.83,  pp  10-33] 
lOth  Commission  Directive establishing Community  methods  for 
the  official  control  of  feedingstuffs.  [OJ  ~ L 238,  6.9.84, 
pp.34-38] 
Council  Directive  supplementing  Directive 81/602/EEC  concerning 
the  prohibition of  certain substances  having  a  hormonal  action 
and  of  any  substances  having  a thyreostatic action.  [OJ  ~ L 
191,  23.7.1985,  pp.46-49] 
Council  Directive  on  health  and  animal  health  problems 
affecting  intra-Community  trade  in  heat-treated milk.  [OJ  ~ L 
226,  24.8.1985,  pp.  13-18] 
Concerning  the  introducton  of  Community  methods  of  sampling  and 
analysis for  the monitoring  of  foodstuffs  intended  for  human 
consumption.  [OJ  ~ L 372,  331.12.85,  pp  50-52] 
Council  Directive  prohibiting the  use  in  livestock  farming  of 
certain substances  having  a  hormonal  action.  [OJ  ~ L 382, 
31.12.1985,  pp.  228-231] 
10/1 86/363 
86/469 
87/410 
88/146 
Note;  Declared  invalid.  Replaced  by  88/146/EEC. 
Council  Directive  on  the  fixing  of  maximum  levels for  pesticide 
residues  of  substances  in  and  on  foodstuff  of  animal  origin. 
[OJ  ~ L 221,  7.8.1986,  pp.  43-47] 
Council  Directive  concerning  the  examination  of  animals  and 
fresh  meat  for  the  presence  of  residues.  [OJ  ~ L  275, 
26.9.1986,  36-46] 
Commission  Decision  of  14th  July  1987  laying  down  the  methods 
to  be  used  for  detecting  residues  of  substances  having  a 
hormonal  action  and  of  substances  having  a thyreostatic action. 
[OJ~ L  223,  11.8.1987,  pp.18-36] 
Council  Directive  prohibiting the  use  in  livestock  farming  of 
certain substances  having  a  hormonal  action.  [OJ  ~ L 70, 
16.3.1988,  p.16] 
88/196-206,  88/240,  Commission  Decisions  approving  the  plan  relating to 
the  examination  for  hormone  residues  submitted  by  each  of  the 
Member  States.  [OJ  ~ L  94,  12.4.1988,  pp.  22-32;  OJ  ~ L  105, 
26.4.1988,  p.28] 
88/299 
89/15 
89/153 
89/187 
Council  Directive  on  trade  in  animals  treated with  certain 
substances  having  a  hormonal  action  and  their meat,  as  referred 
to  in  article 7 of  Directive 88/146/EEC.  [OJ  ~ L  128, 
21.5.1988,  p.36] 
Commission  Decision  on  the  importation  of  live animals  and 
fresh  meat  from  certain third countries.  [OJ  ~ L 8,  11.1.1989, 
pp.11-12] 
Commission  Decision  concerning  the  correlation of  samples  taken 
for  residue examination  with  animals  and  their farms  of  origin. 
[OJ  ~ L 59,  2.3.89,  33-34] 
Council  Decision  determining  the  powers  and  conditions of 
operation  of  Community  reference  laboratories  provided  for  by 
directive 86/469  EEC  concerning  the  examination  of  animals  and 
fresh  meat  for  the  presence  of  residues.  [OJ  ~ L 66,  10.3.1989, 
pp.37-38] 
89/265-276  Council  Decisions  approving  the  plan  relating to the 
examination  for  residues  other than  those  having  a  hormonal 
action  submitted  by  each  of  the  Member  States.  LOJ  ~ L  108, 
19.4.89,  pp.  20-31] 
89/397 
89/610 
Council  Directive  on  the  official control  of  foodstuffs.  [OJ  ~ 
L 186,  30.6.89,  pp.  23-26] 
Commission  Decision  of  14th  November  1989  laying  down  the 
reference methods  and  the  list of  national  reference 
laboratories for  detecting  residues.  [OJ  ~ L  351,  2.12.1989, 
pp.  39-50] 
10/2 89/662 
90/135 
90/167 
90/424 
90/515 
90/675 
90/676 
90/677 
90/2377 
91/61 
91/398 
91/486 
91/508 
91/664 
Council  Directive concerning  veterinary checks  in  intra-
Community  trade with  a  view  to the  completion  of  the  internal 
market.  LOJ  ~ L 395,  30.12.89.  pp.13-22] 
Commission  Decision  which  deals with  the  plans  of third 
countries for  residue examination  of  fresh  meat  and  animals  for 
substances  other than  those  having  a  hormonal  action. 
Amended  by  Commission  Decision  90/262.  [OJ  ~ L 76,  22.3.1990, 
pp.24-25] 
Laying  down  the  conditions  governing  the  preparation,  placing 
on  the market  and  use  of  medicated  feedingstuffs  in  the 
Community.  [OJ~ L 92,  7.4.1990,  pp.  42-48] 
Council  Decision  on  expenditure  in  the  veterinary field  [OJ  ~ 
L 224,  18.8.1990,  pp.  19-28] 
Commission  Decision  laying  down  the  reference methods  for 
detecting residues of  heavy  metals  and  arsenic.  [OJ  ~ L 286, 
18.10.1990,  pp.  33-39] 
Council  Directive  laying  down  the  principles governing  the 
organisation of  veterinary checks  on  products  entering the 
Community  from  third countries.  [OJ  ~ L 373,  31.12.90,  pp.  1-
14] 
Amendment  to Directives 81/851.  (Veterinary Medicines)  [OJ  ~ L 
373,  31.12.90,  pp.  15-25] 
Amendment  to Directives 81/851.  (Veterinary Medicines)  [OJ  ~ L 
373,  31.12.90,  pp.  26-28] 
Regulation  laying  down  a Community  procedure  for the 
establishment of  maximum  residue  limits of  veterinary medicinal 
products  in  foodstuffs  of  animal  origin.  OJ  ~  L 224, 
18.1.1990,  pp.1-8] 
Council  Decision  amending  Decision  90/218/EEC  [OJ  ~ L 116, 
8.5.1990,  p.27]  concerning  the  administration of  Bovine 
Somatotropin  (BST).  [OJ~ L 37,  9.2.1991,  p.39] 
Commission  Decision  on  a computerized  network  linking 
veterinary authorities  (Animo).  [OJ' L 221,  9.8.1991,  p.30] 
Commission  Decision  amending  Decision  90/135/EEC  relating to 
the  plans  of  third countries concerning  examination  of  residues 
of  fresh  meat  for  substances  other than  those  having  a  hormonal 
action.  [OJ~ L 260,  17.9.91,  pp.13-16] 
Commission  Directive amending  the  annexes  to Council  Directive 
70/524/EEC  concerning  additives  in  feeding  stuffs.  [OJ  ~ L 271, 
27.9.1991,  pp.67-69] 
Council  Decision  designating  the  Community  reference 
laboratories for testing certain substances  for residues.  [OJ  ~ 
, L 368,  31.12.1991,  17-18] 
10/3 92/18 
92/183 
92/675 
93/256 
93/257 
Commission  Directive modifying  the  Annex  to  Council  Directive 
81/852/EEC  on  the  approximation  of  the  laws  of  Member  States 
relating to  the  analytical,  pharmacotoxicological  and  clinical 
standards  and  protoco;s  in  respect of  the  testing of  veterinary 
medicinal  products.  [O.J.  ~ L.97.,  10.4.92.,  pp  1-12] 
Commission  Decision  laying  down  the  general  conditions  to  be 
complied  with  for  the  import  of  certain raw  materials for  the 
pharmaceutical  processing  industry,  coming  from  third 
countries,  which  appear  on  the  list established  by  Council 
Decision  79/542/EEC.  [OJ  ~ L 84,  31.3.1992,  pp.  33-37] 
Commission  Regulation  amending  annexes  I  and  III  of  Council 
Regulation  (EEC)  No.  2377/90  laying  down  a Community  procedure 
for  the  establishment of  maximum  residue  limits of  veterinary 
medicinal  products  in  foodstuffs  of  animal  origin.  [OJ  ~ L 73, 
19.3.1992,  pp.  8-14] 
Commission  Decision,  93/256/EEC,  laying  down  the  methods  for 
detecting residues  of  substances  having  a  hormonal  or 
thyrostatic action.  [OJ.  ~ L.118,  14.4.93.  pp  64-74] 
Commission  Decision,  93/257/EEC,  laying  down  the  reference 
methods  and  the  list of  national  reference  laboratories for 
detecting residues.  [OJ.  ~ L.118,  14.5.93,  pp  75-79] 
10.2.  SUMMARY  OF  EEC  LEGISLATION  FOR  THE  CONTROL  OF  RESIDUES. 
10.2.1.  DEFINITION 
The  term  residue  is used  in  this context  according  to  Directive 86/469 
which  says  that  .. residue  means  residue  of  substances  having  a 
pharmacological  action  and  of  conversion  products  thereof  and  other 
substances  transmitted  to  meat  and  which  are  likely to  be  dangerous  to 
human  health
11
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10.2.2.  LEGISLATION  GIVING  GENERAL  RULES. 
64/433  was  the first Directive  on  health  problems  affecting  Intra-Community 
trade  in  fresh  meat.  The  Directive 83/90  amended  64/433  and  lays  down  the 
ground  rules  as  regards  the  examination  of  animals  or meat  for  residues 
that the  Council  shall  adopt.  In  particular-
- the  detailed arrangements  for  controls. 
- the  frequency  of  sampling. 
It states that every  Member  State shall  ensure  that the  following  meat  is 
not  sent  from  it•s territory to  that of  another  Member  State 
- fresh  meat  from  animals  to  which  stilbenes or  stilbene derivatives  have 
been  administered,  and  meat  containing  residues  of  these  substances. 
- fresh  meat  containing  residues  of  other  substances  having  a  hormonal 
action,  antibiotics,  antimony,  arsenic  ,  pesticides,  or  other  substances 
which  are  harmful  to  human  health.  If such  residues  exceed  the  permitted 
level  or,  where  no  permitted  level  has  been  laid  down,  the  quantity which 
has  been  proved  scientifically to  be  safe  and  on  which  the  Scientific 
Veterinary Committee  (SVC)  has  expressed  its opinion. 
- fresh  meat  from  animals  to which  substances  likely to  make  the  meat 
dangerous  or  harmful  to  human  health  have  been  administered  and  on  which 
10/4 the  SVC  has  expressed  its opinion. 
86/469  is a  Directive concerning  the  examination  of  animals  and  fresh  meat 
for  the  presence  of  residues.  It consists of  19  articles and  2 annexes. 
The  articles give  definitions for  the  terms  used,  oblige  Member  States to 
assign  to a central  body  the  coordination  and  implementation  of  the 
inspections  provided  for  and  to  submit  plans  to achieve  the  objectives of 
the  Directive.  It ensures  that veterinary experts  from  the  Commission  may 
make  on-the-spot  checks.  The  minimum  frequency  of  inspections  is 
specified.  The  import  from  third countries  is allowed  only  in  those  cases, 
where  these  countries  have  a  legislation on  the  use  of  substances  matching 
the  EEC  legislation.  The  taking  of  samples  is regulated  in  detail  and  the 
procedure  for  treating cases  of  infringements. 
In  Annex  I  the  residues  are  grouped  as  detailed  in  Section  2 of  manual. 
In  Annex  II  the  sampling  levels  and  frequency  and  the  residue  testing under 
reference  to  the  grouping  in  Annex  I  are  regulated. 
72/462  is a  Directive concerning  the  health  and  veterinary  inspection 
problems  upon  importation  of  bovine  animals  and  swine  and  fresh  meat  from 
third countries.  It prohibits the  importation  to  the  Community  of  meat 
containing  levels of  substances  which  are  judged  harmful  or  likely to 
render  consumption  thereof dangerous  or  injurious  to  human  health. 
10.2.3.  DETAILED  LEGISLATION. 
Following  on  from  the  basic  Directives  above  there are  many  Directives  and 
Decisions  which  add  detail.  Hormones  were  initially a major  problem  and 
there  is a  specific batch  of  legislation for  these  substances  (see 
12.2.4.). 
Other  Decisions  of  special  interest to  the  control  of  residues  are 
- 87/410  which  deals with  the  correlation of  samples  taken  for residue 
examination  with  animals  and  their farm  of  origin.  Lays  down  the  routine 
methods  to  be  used  for  the  detecting of  residues  of  substances  having  a 
hormonal  action  and  of  substances  having  a  thyreostatic action. 
- 89/153  which  fixes  the  conditions  of  working  for  the  Reference 
laboratories. 
- 89/610  revoked  and  replaced  by  93/257  which  fixes  the  reference methods 
and  lists the  National  Reference  Laboratories  (NRL  see  Section  3 of  manual) 
for  detecting residues.  Council  Decision  91/664  designates  the  four 
national  reference  laboratories  (NRL). 
- 90/135  which  deals with  the  plans  of  third countries for  residue 
examination  of  fresh  meat  and  animals  for  substances  other  than  those 
having  a  hormonal  action. 
- 92/18  The  Commission  Directive  92/18/EEC  sets out  an  approximation  of 
the  laws  of  Member  States relating to analytical,  pharmacotoxicological  and 
clinical  standards  and  protocols  in  respect of  the  testing of  veterinary 
medicinal  products.  Part  B is  on  Residue  Testing  and  requests  information 
on  the  nature  and  persistence of  residues  in  order  to  establish practical 
withdrawal  times  and  also  asks  for  a  practical  analytical  method  suitable 
for  routine  use  to  verify compliance  with  the withdrawal  period. 
92/675  A Commission  Regulation  amending  annexes  I  and  III  of  Council 
Regulation  (EEC)  No.  2377/90  laying  down  a Community  procedure  for  the 
establishment  of  maximum  residue  limits of  veterinary medicinal  products  in 
foodstuffs  of  animal  origin. 
10/5 10.2.4.  LEGISLATION  SPECIALLY  FOR  HORMONAL  SUBSTANCES. 
-81/602  a Directive which  prohibits  stilbenes and  thyreostats.  The 
therapeutic use  of  other  hormonal  substances  is regulated. 
-85/358  a Directive which  supplements  81/602  by  introducing  Community 
control  measures  covering  farm  animals  in  their farms  of  origin and  at the 
slaughterhouses,  and  the  meat  of  such  animals  and  the  meat  products 
obtained  therefrom. 
-85/649  a directive prohibiting  hormonal  substances  for fattening  purposes 
whereas  the  use  of  certain substances  for  therapeutic  purposes  may  be 
authorised  but  must  be  strictly controlled  in  order  to  prevent  any  misuse 
of  them.  The  therapeutic  treatment with  substances  having  a  hormonal 
action  is  prohibited for  animals  intended  for fattening.  The  import  of 
animals  and  meat  to  which  have  been  administered  in  any  way  whatsoever 
substances  with  a thyreostatic,  oestrogenic,  androgenic  or  gestagenic 
action  is  prohibited. 
A programme  establishing the  frequency  of  controls  on  imports  from  third 
countries  is set up. 
-87/470  a Council  Decision  laying  down  the  methods  to  be  used  for 
detecting residues  of  substances  having  a  hormonal  action  and  of  substances 
having  a thyreostatic action. 
-88/146  a Directive  on  prohibiting the  use  in  livestock  of  certain 
substances  having  a  hormonal  action  is regulating the  use  of  these 
substances  further  by  claiming  from  Member  States 
- a  list of  products  containing  as  active substances,  oestradiol-17B, 
testosterone and  progesterone  and  those  derivatives which  readily yield the 
parent  compound  on  hydrolysis. 
- the  conditions  of  use  of  these  products,  in  particular the waiting 
period  necessary  and  detailed provisions  concerning  the  control  of  these 
conditions  of  use. 
- the  means  of  identification of  use. 
-88/196  &  88/200  are  Commission  Decisions  approving  the  plans  relating to 
the  examination  of  hormone  residues  submitted  by  Member  States under 
reference  to  Directive 86/469 
-93/256  is a Commission  Decision  laying  down  the  methods  for  detecting 
residues  of  substances  having  a  hormonal  or  thyrostatic action.  However 
the  criteria are  to  be  regarded  as  covering  the  analytical  methods  used  for 
all  veterinary drugs  and  substances. 
10.2.5.  FUTURE  LEGISLATION. 
The  Council  is working  on  a Regulation  laying  down  a Community  procedure 
for  the establishment  of  residue  limits of  veterinary medicine  products  in 
foodstuff  of  animal  origin. 
Directive 86/469  is being  modified  to  cover  fish  and  may  be  extended  to 
cover  poultry. 
10/6 11.  GENERAL  REFERENCES. 
The  references  listed are  aimed  at giving  an  overview  of  the whole  subject 
of  residues  of  veterinary drugs.  Specific references  for each  section are 
included  in  that section.  Also  each  of  the  methods  in  section  6 contains 
selected references. 
Anabolic  agents  in  animal  production.  FAO/WHO  Symposium,  Rome,  March  1975, 
EQS,  (1976)  Suppl  V.  Ed.  by  Lu,  F.C.  and  Rendel,  J.  Georg  Thieme, 
Stuttgart,  ISBN  3-13-536101-2 
Anabolics  in  Animal  Production.  Public  health  aspects,  analytical  methods 
and  regulation.  Symposium  held  at OlE,  Paris  Feb.  1983.  Ed.  by 
Meissonnier,  E.  Soreograph,  France.  ISBN  92-9044-118-6 
Analysis  of  food  contaminants.  Ed.  by  Gilbert,  J.  Elsevier Appl.  Sc. 
London  and  New  York,  (1984)  ISBN  0-85334-255-5 
Chemistry  Quality  and  Assurance  Hanbooks.  Vol.  I.  Principles.  Vol.  II. 
Specific Methods.  USDA  Food  Safety  and  Quality Service.  USDA  and  FSIS 
Handbooks  - continuously updated. 
Drug  residues  in  animals.  Ed.  by  Rico,  A.  Academic  Press  Inc.  (1986) 
Euroresidues  II.  Conference  on  residues  of  veterinary drugs  in  food  at 
Veldhoven,  The  Netherlands,  May  1993,  Edited  by  Haagsma,  N.,  Ruiter,  A. 
and  Czedik-Eysenberg,  P.B.  ISBN  90-6159-016-7.  volumes  1 &  2. 
Immunoassays  in  food  analysis.  Ed.  by  Morris,  B.A.  and  Clifford,  M.N. 
Elsevier Appl.  Sc.  London  and  New  York,  (1985)  ISBN  0-85334-321-7 
Immunoassays  for  Veterinary  and  food  analysis- 1.  Ed.  by  Morris,  B.A., 
Clifford,  M.N.  and  Jackman,  R.  Elsevier Appl.  Sc.  London  and  New  York, 
(1988)  ISBN  1-85166-138-7 
Manipulation  of  growth  in  farm  animals.  A seminar  in  the  CEC  programme  of 
coordination  of  research  on  beef  production,  Brussels,  Dec.,  1982.  Ed.  by 
Roche,  J.F.  and  o•callaghan  D.  Matinus  Nijhoff  for  the  EEC,  (1984),  ISBN  0-
89838-617-6,  EUR  8919  EN 
Pharmacological  basis of  large  animal  medicine.  Ed.  by  Bogan,  J.A.,  Lees, 
P.  and  Yoxall,  A.T.  Blackwell  Scientific,  Oxford,  (1983),  ISBN  0-632-
01055-X 
Second  international  symposium  on  the  analysis  of  anabolizing  and  doping 
agents  in  biosamples.  May  1990,  Ghent,  Belgium,  Ed.  by  Van  Peteghem,  C. 
J.  Chromatog.  (1991),  564,  No.2,  361-583 
International  symposium  on  hormone  and  veterinary drug  analysis,  Ghent, 
Belgium,  May,  1992.  Eds.  Pardue  et al.  Anal.  Chim.  Acta.  275,  1-362 
Van  Ginkel,  L.A.  and  Stephany,  R.S.  (1991)  New  trends  in  strategies for 
residue  analysis of  growth  promoting  agents.  Microbiol.-Ailments-
Nutrition,  ~,  89-94 
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ANNEX  I  LIST  OF  ABBREVIATIONS  AND  SYMBOLS 
AA 
Ac 
approx. 
B 
b.pt.  bp? 
BCR 
Bi 
B 0/T 
Bo 
c 
C-18 
C-Ac 
C-diol 
C-Si 
C-S03H 
ca. 
cc 
CGE 
CI 
Ci 
em 
cone 
CPM 
csx 
D 
Dens 
detn 
Di .A 
Dial 
DPM 
e.g. 
ECD 
EDTA 
EEC 
Eg 
EI 
EIA 
equiv. 
Et 
EtOH 
F 
F 
FAO 
Fe 
Fig. 
Fl 
FPT 
G 
g 
g 
GC 
GIB 
=  atomic  absorption 
=  acetate 
= approximately 
=  Belgium 
=  boiling  point 
=  Community  Bureau  of  Reference,  EEC. 
= bile 
=  fraction of  the  radioactivity of  the  bound  fraction 
=  radioactivity of  the  bound  fraction of  a  blank  sample 
=  chromatography 
=  CC  on  C-18  cartridges 
=  acetylated chromatography  cartridge 
=  dihydroxylated  chromatography  cartridges 
=  silica chromatograpy  cartridges 
=  sulphite chromatography  cartridge 
=  circa,  about,  approximately 
=  column  C 
=  capillary gel  electrophoresis 
=  chemical  ionization 
=  Curie 
=  centimetre 
=  concentration 
=  counts  per  minute 
=  ? chromatography  cartridge 
=  Denmark 
= densiometric 
=  determination 
=  diode  array 
=  dialysis 
=  disintegrations  per  minute 
=  for example 
=  electro-chemical  detector 
=  Ethylenediaminetetraacetic acid 
=  European  Economic  Community 
=  eggs 
=  electron  impact  ionization 
=  enzyme  immunoassay 
=  equivalent 
=  ethyl 
=  ethyl  alcohol  or  ethanol 
=  fat 
=  France 
= Food  and  Agriculture  Organisation 
=  faeces 
=  figure 
=  fluorescence 
=  four  plate test 
=  Germany 
=  grams 
=  gravity 
=  gas  chromatography 
=  growth  inhibition of  bacteria 
12/1 Gr  = Greece 
Grav  = gravimetric 
h  = hour 
HFBA  = heptafluorobutyric  anhydride 
H 20  = water 
HPLC  = high  pressure  liquid chromatography 
HPTLC  =high performance  thin-layer chromatography 
HRMS  = high  resolution mass  spectrometry 
I.S.  = injection site - normally  muscle 
lA  = immunoassay 
lAC  = immunoaffinity  chromatography 
IMG  = immunogram 
Ir  = Ireland 
IR  = infrared 
ISO  = International  Organisation  for  Standardisation 
It  = Italy 
K  = kidney 
kg  = kilogram(s) 
L  = liver 
L  = litre(s) 
L  = Luxembourg; 
LC  = liquid chromatography 
LLD  = lower  limit of  detection  of  system 
LRMS  = low  resolution mass  spectrometry 
M  = muscle 
m  = metre(s)  or  milli  prefix or  mass 
M  = molar 
MAFF  = Ministry of  Agriculture,  Fisheries  and  Food,  United  Kingdom 
MAT  = Measurements  &  Testing  Programme,  DG12. 
Me  = methyl 
MeOH  = methyl  alcohol  or  methanol 
mg  = milligram(s) 
min  = minute(s) 
Mk  = milk 
ml  = millilitre(s) 
mm  = millimetre(s) 
mp  = melting  point 
MOX  = methoxylamine  hydrochloride 
MS  = mass  spectrometry 
MSPD  =matrix solid-phase  dispersion 
MW  = molecular  weight 
ng  = nanogram(s) 
NH2  = amino 
NL  = Netherlands  (Holland) 
nm  = nanometre(s) 
NMR  = nuclear  magnetic  resonance 
No.  = number 
~SB  = non-specific  binding  = aspecific binding  (ASB) 
C  = degrees  Celsius  (Centigrade) 
P  = Portugal 
PFB  = pentafluorobenzene-
pg  = picogram(s) 
Pl  = plasma 
ppb  = parts  per  billion  (1/109 ) 
ppm  = parts  per  million 
ppt  =parts per  trillion (1/1012) 
12/2 Pr 
ref. 
Rf 
RIA 
rpm 
s 
s 
Se 
sec 
soln 
SP 
T 
Th 
TLC 
TMS(i) 
u 
ug  or  J.L9 
UK 
UK-NI 
ul or  J.LL 
USDA 
uv 
v/v 
Vis 
w/w 
WHO 
wt 
z 
= propyl 
= reference 
= distance  spot  moved/distance  solvent  moved  in  TLC 
= radioimmunoassay 
= revolutions  per  minute 
= solvent  extraction 
= Spain 
= Serum 
= second(s) 
= solution 
= spectrometry,  e.g.  Diode  array 
= total  radioactivity  (CPM  OR  DPM)  added  to  a  sample 
= Thyroid 
=thin-layer chromatography 
= trimethylsilyl-
= urine 
= microgram(s) 
= United  Kingdom 
= UK-Northern  Ireland 
= microlitre(s) 
= United  States  Department  of  Agriculture 
= ultraviolet 
= both  components  measured  by  volume 
= visible  (either by  eye  or  in  visible spectrum 
= both  compoents  measured  by  weight 
= World  Health  Organisation 
= weight 
= charge 
EEC  Member  States. 
B  = Belgium 
D  = Denmark 
F  = France 
G  = Germany 
Gr  = Greece 
Ir  = Ireland 
It  = Italy 
L  = Luxembourg 
NL  = Netherlands  (Holland) 
P  = Portugal 
S  = Spain 
UK  = United  Kingdom 
UK-NI  = UK-Northern  Ireland 
Samples 
Bi 
Eg 
F 
Fe 
= bile 
= eggs 
= fat 
= faeces 
I.S. 
K 
= injection site - normally  muscle 
= kidney 
L  = liver 
M  = muscle 
Mk  = milk 
Pl  = plasma 
12/3 Se 
Th 
u 
R 
I 
!?.:::  0 
> 
< 
I 
= Serum 
= Thyroid 
= urine 
= retina 
= per 
= percentage,  parts  per  hundred 
= more  than 
= less than 
=off-line hyphenated  techniques 
=on-line hyphenated  techniques 
E.g.  HPLCIGC-MS  = HPLC  off-line followed  by  GC  with  on-line  MS 
Compounds 
aE2 
aTB 
Bol 
CAP 
DE  or  DEN 
DES 
El 
E3 
EE 
HEX 
MT 
MTU 
NT 
SMZ 
BE2 
T 
BTB 
TAP 
TB  or  TbOH 
TBA 
TU 
z 
= oestradiol-17a 
= trenbolone-17a 
=  boldenone 
= chloramphenicol 
=  dienoestrol 
=  diethylstilboestrol 
=  oestrone 
= oestriol 
= ethinyloestradiol 
= hexoestrol 
= methyltestosterone 
= methylthiouracil 
= 19-nortestosterone 
= sulphamethazine  or  sulphadimidine 
= oestradiol-17B 
= testosterone 
= trenbolone-17B 
= tapazole 
= trenbolone 
trenbolone  acetate 
= thiouracil 
= zeranol 
Reference  Laboratories. 
RL  = Reference  laboratories 
BGA  = Bundesgesundamptseit,  Berlin 
CNEVAILMV  =  Centre  National  d'Etudes  Veterinaires et Alimentaires, 
Laboratoire  des  Medicaments  Veterinaires,  Fougeres 
CVL  = Central  Veterinary  Labor~tory,  Weybridge 
IHE  = Institut d'Hygiene  et d'Epidemiologie,  Brussels 
ISS  = Institute Superiore  di  Sanita,  Rome 
NFC  = National  Food  Centre,  Dublin 
RIKILT(-DLO)=  Rijkskwaliteitsinstituut voor  Land- en  Tuinbouwprodukten, 
Wageningen 
RIVM  = Rijksinstitut voor  Volksgezondheid  en  Milieuhygiene, 
Bilthoven 
VRL  = Veterinary Research  Laboratories,  Belfast.· 
12/4 12.2.  ANNEX  II.  CALCULATIONS  OF  LIMITS 
12.2.1.  Calculating  the  values  for  the  lower  limits of  sensitivity, 
detection,  determination  (quantitation or reliable measurement)  and 
decision  (regulatory action)  are  a mix  of  statistics (  at what  confidence 
level  or  how  many  standard  deviations)  and  political  decision.  The 
criteria document  in  section  5 and  expressly covers  the  limit of  detection 
and  the  limit of  determination. 
Different values  for  the  lower  limit of  decision  and  the  lower  limit of 
detection were  first suggested  by  Heitzman  and  Harwood  (1983).  They  tried 
to  take  into  account  the  problem  of  non-specific  interference  in 
immunoassays  which  gives  rise to  high  values  for  blank  materials.  They 
calculated the  lower  limit of  detection  as  the  mean  value  for  the  blank 
samples  plus  2  SD  and  suggested  a  lower  limit of  decision  as  an  arbitrary 
value  higher  than  the  lower  limit of  detection which  took  into account  the 
practicality of  the  method  and  the  values  found  in  animals  (cattle)  known 
to  have  been  treated with  drug  (HEX).  In  a  later paper  on  residues of 
monensin  in  cattle,  Heitzman  et al.,  (1986)  suggested  that the  lower  limit 
of  detection was  the  mean  +  2  SD  and  the  lower  limit of  decision  was  the 
mean  +  3 SD. 
12.2.2.  Lower  limit of  detection/determination  in  Section  4 
As  can  be  seen  in  the  tables  in  section 4 for  the  routine methods  used  in 
different Member  States there  are wide  variations  in  the  limits for  the 
measurement  of  residues  of  a particular analyte  even  though  essentially 
similar methods  are  used.  However  there  is  increasing  agreement  between 
the  Member  States on  the  lower  limit of  decision  for  particular analytes. 
For  Reference  methods  the  limits  are  more  clearly defined  in  the  Criteria 
Document,  EEC  93/256  (see  section  5). 
In  the  simplest  situation; 
lower  limit of  detection  is mean  of  20  blank  values  +  3 times  SD. 
lower  limit of  decision  is mean  of  20  blank  values  +  6 times  SD. 
In  other situations,  e.g.  where  peak  noise  has  to  taken  into  account  or 
identifying a  spot  on  a  TLC  other approaches  are outlined  in  section 5. 
References; 
Heitzman,  R.J.  and  Harwood,  D.J.  (1983)  The  radioimmunoassay  (RIA)  of 
hexoestrol  residues  in  faeces,  tissues and  body  fluids of  bulls and  steers. 
Vet.  Rec.  112,  120-123. 
Heitzman,  R.J.,  Carter,  A.C.  and  Cottingham,  J.D.  (1986)  An  enzyme  linked 
immunosorbent  assay  (ELISA)  for  residues  of  monensin  in  plasma  of  cattle. 
Br.  vet.  J.  142,  516-523. 
12/5 12.2.3.  GRAPHICAL  METHOD  FOR  THE  CALCULATION  OF  LIMITS  USING  RECOVERIES 
Where  spiked  material  is used  to  construct a  calibration curve  of  added 
amount  of  spike  versus  the  amount  of  spike  recovered  (determined  from  a 
standard  curve  obtained without  the  matrix)  the  limits of  detection  and 
determination  can  be  calculated from  the  curve. 
Matrix  material  is spiked  in  at  least quadruplicate  at 5 or  more  levels 
and  the  recovery  determined  by  interpolation with  a  standard  curve  obtained 
without  the  matrix.  The  confidence  limits  (e.g  95%,  99%  or  99.9%)  for  the 
curve  are  drawn.  The  limits  are  calculated from  the  graph  as  described  in 
the  schematic  graph  below.  The  individual  values  and  the  best fit linear 
regression  line are  drawn  and  the  confidence  limits.  The  99%  confidence 
limits are  used  in  this graph  and  are for  illustration purposes. 
4 
3 
2 
Mass of Spike 
Recovered 
0  I  1 
LL Detection 
LL Determination 
I 
2  3 
Mass of Spike 
4  5  6 
A more  detailed approach  to  the  statistical evaluation of  results can  be 
found  in 
11Statische Methoden  in  der  Wasseranalytik.  Begriffe,  Strategien, 
Anwendungen
11
•  Edited  by  Funk,  W.,  Damman,  V.,  Vonderheid,  C.  and  Oehlmann, 
G.  publ.  VCH,  Weinheim,  D-6940.  ISBN  3-527-26307-1,  Chapter  4. 
11Nachweis-
und  Bestimmungsgrenze ... 
12/6 12.2.4.  CALCULATION  OF  CONFIDENCE  LIMITS  (INTERVALS). 
Data  needed;  mean,  x;  SD,  number  of  values,  n; 
t  value  (see  table)  using  degrees  freedom  °F  =  n - 1 at 
confidence  required,  e.g.  95%  (P<0.05); 
Confidence  limits  =  x ±  SD  X t 
v'(n  - 1) 
Table  of  critical  t  values  for  comparison  of  averages  (two  tailed). 
Degrees  of  Confidence  Interval 
Freedom  90%  95%  99% 
1  6.31  12.71  63.66 
2  2.92  4.30  9.93 
3  2.35  3.18  5.84 
4  2.13  2.78  4.60 
5  2.02  2.57  4.03 
6  1.94  2.45  3.71 
7  1.90  2.37  3.50 
8  1.86  2.31  3.36 
9  1.83  2.26  3.25 
10  1.81  2.23  3.17 
11  1.80  2.20  3.11 
12  1.78  2.18  3.06 
13  1.77  2.16  3.01 
14  1.76  2.15  2.98 
15  1.73  2.09  2.95 
20  1.73  2.09  2.85 
25  1.71  2.06  2.79 
30  1.70  2.04  2.75 
12/7 13.0.  INDEX 
[Note:  The  pages  are  numbered  separately for each  section,  e.g.  section 3 
page  5  is 3/5.  The  analytical  methods  in  section 6 are  numbered  separately 
for each  method,  e.g.  page  3 of  routine method  Cy  1.2  is  Cy  1.2/3.] 
ADI  2/4 
Albendazole  2/3,  7/1,  7/15,  7/34,  9/1,  9/36,  Cy  4.1/1,  Cy  4.1/2,  Cy  4.1/5 
Ampicillin  2/5,  8/4,  8/9,  9/20 
Anabolic  agents  2/7,  6/7,  6/11,  7/1,  7/8,  7/15,  7/16,  7/18,  8/12,  11/1, 
Cy  1.1/1,  Cy  1.1/8-9,  Cy  1.1/12-13,  Cy  1.2/1,  Cy  1.2/5,  Cy  1.2/8, 
Cy  1.8/1,  Sg  1.1/1,  Sg  1.2/6 
Androgens  7/16,  Cy  1.2/1-2,  Cy  1.2/6-7,  Cy  1.2/9,  Sg  1.2/10 
Anthelmintics  4/14,  Cy  4.1/1 
Antibacterial  6/4,  9/20,  9/21,  9/24-28,  9/31,  9/32,  9/34,  9/35,  9/55, 
Cy  3.9/1,  Sg  3.1/7-8,  Sg  3.1/11,  Sg  3.1/14,  3.4/1,  Sg  3.5/1,  Sg  3.6/1 
Antibiotics  2/1,  6/2-4,  7/1,  7/15,  7/28,  8/10,  8/11,  10/4,  Cy  3.8/1, 
Sg  3.1/7,  Sg  3.2/1 
Antibody  5/11,  Cy  1.6/3,  Cy  1.6/7-9,  Cy  1.7/3,  Cy  1.7/8-9,  Sg  1.3/3-5, 
Sg  2.2/2,  Sg  2.3/1 
Antimicrobial  2/1,  6/3-5,  7/15,  7/24,  9/22,  9/23,  9/30,  9/33,  9/39, 
Cy  3.1/1 
Azaperone  2/3,  2/6,  9/1,  9/37,  Cy  4.5/1-3,  Cy  4.5/5-6,  Cy  4.6/1,  Cy  4.6/3, 
Cy  4.6/5-6,  Sg  4.1/1,  Sg  4.1/3,  Sg  4.1/6 
BCR  6/7,  7/33,  8/1-3,  8/5-8,  8/12,  Cy  2.1/2,  Cy  3.5/7,  Cy  3.6/6 
Benzimidazoles  2/3,  4/14,  6/1,  7/1,  7/15,  7/34,  Cy  4.1/1-2,  Cy  4.1/4-5 
Benzylpenicillin  2/2,  2/5,  7/1,  7/15,  7/28-30,  8/9,  9/1,  9/21,  Sg  3.1/7 
B-lactam  6/4,  7/28 
BGA  3/1,  5/1,  6/6,  7/33,  8/4,  Cy  3.5/8,  Cy  3.6/6,  Sg  3.3/2-3,  Sg  3.3/6, 
Sg  4.3/8 
Bile  7/16-19,  7/22,  7/30,  Cy  1.2/12,  Cy  1.2/15,  Cy  1.4/3,  Cy  1.4/6, 
Cy  1.5/3,  Cy  1.5/6,  Cy  1.6/4-5,  Cy  1.7/5 
Blank  5/2-6,  5/17,  5/21,  8/2,  8/5-7 
Blood  2/7,  6/8,  7/8,  7/16,  7/21,  7/25,  7/28,  7/29,  7/38,  8/2,  Cy  1.4/1, 
Cy  1.6/4,  Cy  1.7/5, 
Bound  residues  7/34,  Cy  1.1/10 
CAP  7/32,  7/33,  Cy  3.4/4,  Cy  3.5/8,  Cy  3.6/3,  Cy  3.6/6,  Sg  3.3/2 
Carazolol  2/3,  2/6,  4/11,  9/1,  9/38,  Sg  4.1/1-6 
Carbadox  2/3,  4/14,  9/1,  9/39,  Cy  4.3/1-2,  Sg  4.2/1-2,  Sg  4.3/1-6 
Certified Reference  Material  8/8 
Chemical  ionization  5/15,  7/40,  Cy  1.1/2,  Cy  2.2/1,  Cy  2.2/5 
Chloramphenicol  2/1,  2/2,  2/6,  4/10,  6/2-6,  7/1,  7/15,  7/32,  7/33,  8/4, 
8/8-11,  9/1,  9/22,  Cy  3.5/1-7,  Cy  3.6/1-3,  Cy  3.6/5,  Cy  3.7/1-3, 
Sg  3.1/7,  Sg  3.3/1-2 
Chlorotestosterone  9/1,  Cy  1.2/1,  Cy  1.2/7,  Sg  1.2/6-7,  Sg  1.2/12 
Chlorpromazine  2/3,  9/1,  9/40,  Cy  4.5/3,  Cy  4.5/6,  Cy  4.6/3,  Cy  4.6/5-6, 
Sg  4.1/3,  Sg  4.1/6 
Chlortetracycline  2/2,  8/9,  9/1,  9/23,  Cy  3.8/1,  Cy  3.8/2,  Cy  3.8/4, 
Cy  3.8/5,  Sg  3.1/7 
Cimaterol  2/3,  4/9,  6/3,  7/37,  8/11,  9/1,  9/41,  Cy  2.1/1-2,  Cy  2.1/6-7, 
Cy  2.3/1-2,  Cy  2.3/6,  Sg  2.1/1-2,  Sg  2.1/5,  Sg  2.3/1-2,  Sg  2.4/1-4 
Clenbuterol  2/3,  4/9,  6/3,  7/15,  7/37-40,  8/4,  8/10,  8/11,  9/1,  9/42, 
Cy  1.1/8,  Cy  2.1/1-2,  Cy  2.1/6-9,  Cy  2.2/1-6,  Cy  2.3/1-2,  Cy  2.3/6, 
Sg  2.1/1-2,  Sg  2.1/5,  Sg  2.2/1-3,  Sg  2.3/1-4,  Sg  2.4/1-4 
Closantel  2/3,  7/1,  7/15,  7/36,  9/1,  9/43 
CNEVA  8/4 
Community  Bureau  of Reference  8/1,  Sg  3.1/7 
13/1 Confirmatory  method  5/13,  Sg  1.4/2 
Conjugates  6/10,  8/10,  Cy  1.1/4,  Cy  1.1/10,  Cy  1.2/2,  Cy  1.6/2,  Cy  1.7/2, 
Cy  1.8/1,  Cy  2.1/9,  Cy  2.3/2,  Cy  2.3/3,  Sg  1.2/8,  Sg  1.3/2,  Sg 
2.1/1-2,  Sg  2.4/1-2 
CRL  3/1,  4/1,  5/17,  6/1,  6/4 
Decision  2/7,  3/1,  4/1,  5/1,  5/3,  5/5,  5/6,  5/8,  5/17,  5/23,  6/1,  6/8, 
6/11,  6/13,  8/1,  10/2-6 
Desoxycarbadox  9/39,  Sg  4.3/1-6 
DGVI  4/1,  5/1,  6/6,  8/1 
Dienoestrol  2/2,  8/4,  8/7,  9/1,  9/4,  Cy  1.1/1-2,  Cy  1.2/1,  Cy  1.2/7, 
Cy  1.2/10,  Cy  1.2/12,  Cy  1.2/14,  Cy  1.7/1,  Sg  1.1/1-2,  Sg  1.2/6-7, 
Sg  1.3/1,  Sg  1.1/1-2,  Sg  1.2/6-7,  Sg  1.2/12,  Sg  1.3/2 
Diethylstilboestrol  2/2,  8/4,  8/5,  8/10,  8/11,  9/1,  9/5,  Cy  1.1/1-2, 
Cy  1.1/8,  Cy  1.1/16,  Cy  1.2/1,  Cy  1.2/10,  Cy  1.7/1 
Dihydrostreptomycin  2/2,  7/29,  9/1,  9/24,  Sg  3.1/7,  Sg  3.1/9,  Sg  3.1/13 
Dimetridazole  2/3,  2/6,  9/1,  9/44,  3.4/1-2,  3.4/5 
Directive  2/1,  2/4,  2/6,  2/7,  3/1,  4/1,  5/1,  5/4,  5/6,  5/23,  6/1,  6/8, 
7/16,  10/1-6 
Edible  tissues  7/18,  7/25,  7/34,  7/35,  Cy  1.1/1,  Cy  1.2/1,  Cy  4.3/1, 
Cy  4.5/1,  Cy  4.6/1,  Sg  1.1/1,  Sg  1.2/6,  Sg  3.6/1,  Sg  4.1/1,  Sg  4.2/1, 
Sg  4.3/1,  Sg  4.5/1 
EEC  2/1-7,  3/1,  4/1,  5/1,  5/4,  5/6,  5/17,  5/23,  6/1,  6/6,  6/11,  6/13,  7/1, 
7/16,  7/18,  7/24,  8/2,  9/22,  9/48,  9/66,  10/1-5,  11/1 
Eggs  2/3,  2/5,  2/6,  4/15,  6/8,  7/25,  7/26,  7/27,  7/32,  9/22,  Cy  3.5/1-2, 
Cy  3.5/5,  Cy  3.5/7-8,  Cy  3.6/1,  Cy  3.6/6,  Cy  3.9/1-5,  Cy  4.2/1, 
Sg  3.3/1-6,  3.4/4 
EIA  4/2-7,  4/9-10,  4/12,  4/15,  6/2-3,  6/11,  7/38,  8/10-11,  Sg  2.2/1-2, 
Sg  2.3/1-6 
Electron  impact  ionization  5/15 
Ethinyloestradiol  4/6,  6/2,  8/9-11,  9/1,  9/6,  Cy  1.1/1,  Cy  1.1/8, 
Cy  1.1/13,  Cy  1.1/16,  Cy  1.2/1,  Cy  1.2/7,  Cy  1.8/1-4,  Sg  1.1/1-2, 
Sg  1.2/6-7,  Sg  1.2/12 
Faeces  2/7,  4/15,  6/8,  7/15-16,  7/18-20,  7/36,  7/38,  8/2,  9/19,  Cy  1.1/1, 
Cy  1.1/9,  Cy  1.2/5,  Cy  1.2/12,  Cy  1.4/1,  Cy  1.4/3,  Cy  1.5/3, 
Cy  1.6/1-2,  Cy  1.6/4,  Cy  1.6/6-7,  Cy  1.7/1-2,  Cy  1.7/4-6,  Cy  1.7/8-9, 
Cy  1.9/3,  Cy  2.1/4,  Cy  3.1/3,  Cy  3.2/10,  Cy  3.3/3,  Cy  3.4/4, 
Cy  3.5/4,  Cy  4.3/3,  Sg  1.3/1,  Sg  1.4/4,  Sg  2.3/3 
FAO  2/2,  2/4,  7/31,  7/33-34,  9/36,  11/1 
Fat  2/6,  4/6,  4/15,  6/8,  6/10,  7/3-19,  7/25,  7/27,  7/31,  7/34-38,  9/41-42, 
9/62,  Cy  1.1/3-4,  Cy  1.1/10,  Cy  1.2/5,  Cy  1.6/2-4,  Cy  1.6/7, 
Cy  1.7/5,  Cy  2.2/1,  Cy  3.4/1,  Sg  1.1/1-5,  Sg  3.6/1,  Sg  3.6/3-4, 
Sg  3.6/6 
Febantel  2/3,  2/6,  7/1,  7/15,  7/34-35,  9/1,  9/45,  Cy  4.1/1 
Feedstuffs  10/1,  Cy  3.1/1 
Fenbendazole  2/3,  2/6,  4/14,  7/1,  7/15,  7/34-35,  9/1,  9/45-46,  Cy  4.1/1 
Flubendazole  2/3,  7/1,  7/15,  7/35,  9/1,  9/47 
Four  plate test  6/1,  6/4,  7/24,  Sg  3.1/7-8,  Sg  3.1/11 
FPT  4/15 
Furazolidone  2/2,  4/13,  6/4,  6/5,  9/1,  9/25,  Cy  3.9/1-2,  Cy  3.9/5, 
3.4/1-2,  3.4/5 
Gas  chromatography  4/15,  5/1,  5/15,  7/40,  Cy  1.1/2,  Cy  1.1/12,  Cy  1.1/14, 
Cy  1.2/6,  Cy  1.2/10-11,  Cy  1.4/1-2,  Cy  1.5/1-2,  Cy  1.8/1,  Cy  1.9/1, 
Cy  2.1/2,  Cy  2.2/1,  Cy  2.3/1,  Cy  3.1/1-3,  Cy  3.5/1-2,  Cy  3.6/1-2, 
Cy  4.3/2,  Sg  1.2/6,  Sg  2.1/1,  Sg  2.4/1,  Sg  4.5/1 
GC-MS  4/2-12,  4/14,  5/7,  5/12,  5/15,  6/1,  6/4-7,  9/29,  Cy  1.1/2,  Cy  1.1/4, 
Cy  1.1/7-9,  Cy  1.1/12,  Cy  1.1/14-15,  Cy  1.2/1,  Cy  1.2/4,  Cy  1.2/6-7, 
Cy  1.2/9-11,  Cy  1.2/13-15,  Cy  1.4/1-5,  Cy  1.5/1-5,  Cy  1.8/1-5, 
13/2 Cy  1.9/1-4,  Cy  2.1/1-3,  Cy  2.1/10,  Cy  2.2/1-6,  Cy  2.3/1-7,  Cy  3.1/2-
6,  Cy  3.3/1,  Cy  3.5/4,  Cy  3.5/6-7,  Cy  3.6/3,  Cy  3.6/5-6,  Cy  4.1/2, 
Cy  4.3/1-2,  Cy  4.3/4,  Cy  4.3/6,  Cy  4.6/1-6 
Gel  6/7,  9/6,  9/11,  9/12,  Cy  1.1/8,  Cy  1.1/11-12,  Cy  1.1/16,  Cy  1.9/3, 
Cy  2.1/9,  Cy  2.3/2,  Cy  3.4/2,  Cy  3.4/4,  Sg  1.2/6-11,  Sg  1.4/1, 
Sg  2.1/1,  Sg  2.1/3,  Sg  2.1/5-6,  Sg  2.4/1-3,  Sg  2.4/6,  Sg  4.1/2, 
Sg  4.2/2,  Sg  4.5/1,  Sg  4.5/3-6 
Growth  inhibition of bacteria  4/15 
Growth  promoters  7/16,  Cy  1.1/1,  Cy  1.2/10-11,  Cy  1.5/1,  Cy  1.6/1, 
Cy  1.7/1,  Sg  1.3/1 
Haloperidol  8/9,  9/1,  9/48,  Cy  4.5/3,  Cy  4.5/6,  Cy  4.6/3,  Cy  4.6/5-6, 
Sg  4.1/3,  Sg  4.1/6 
Hexoestrol  2/2,  7/20,  8/4,  8/6,  8/11,  9/1,  9/7,  Cy  1.1/1-2,  Cy  1.2/1, 
Cy  1.2/6-7,  Cy  1.2/10,  Cy  1.2/12,  Cy  1.2/14-15,  Cy  1.7/1,  Cy  1.7/8, 
Sg  1.1/1-2,  Sg  1.2/6-7,  Sg  1.2/12,  Sg  1.3/1-3 
HPLC  4/2-15,  5/20,  6/1,  6/3-7,  6/11,  7/23,  7/26-27,  7/30,  7/36,  7/38, 
8/5-7,  9/57,  Cy  1.1/2-5,  Cy  1.1/9-13,  Cy  1.1/16,  Cy  1.4/2,  Cy  1.6/1-
7,  Cy  1.6/10,  Cy  1.7/1-10,  Cy  1.8/1-5,  Cy  2.1/1,  Cy  3.1/2,  Cy  3.2/7-
12,  Cy  3.3/1-5,  Cy  3.4/1-6,  Cy  3.5/2-8,  Cy  3.7/1,  Cy  3.7/2-6, 
Cy  3.8/1-5,  Cy  3.9/1-5,  Cy  4.1/2-5,  Cy  4.2/1-5,  Cy  4.4/2-5,  Cy  4.5/1-
6,  Cy  4.6/2,  Sg  1.1/1-5,  3.4/1-5,  Sg  3.5/1-6,  Sg  3.6/1-6,  Sg  4.1/1-6, 
Sg  4.2/1-6,  Sg  4.3/1-8,  Sg  4.5/2 
HPTLC  4/2-4,  4/5-9,  4/12,  Cy  1.9/1-4,  Cy  4.5/4,  Sg  1.1/1-5,  Sg  1.4/1-6, 
Sg  3.2/1-5,  Sg  4.3/7-11 
Hydrolysis  6/10,  7/39,  10/6,  Cy  1.1/6,  Cy  1.1/11,  Cy  1.2/2,  Cy  1.2/5, 
Cy  1.2/11-12,  Cy  1.2/15,  Cy  1.4/2-3,  Cy  1.4/6,  Cy  1.5/2-3,  Cy  1.5/6, 
Cy  1.6/2,  Cy  1.6/6,  Cy  1.7/2,  Cy  1.8/1,  Cy  2.1/5,  Cy  2.1/9-10, 
Cy  2.3/2-3,  Cy  2.3/7,  Cy  3.5/2,  Cy  3.5/4,  Cy  3.5/8,  Sg  1.2/7-8, 
Sg  1.3/2,  Sg  2.1/1-2,  Sg  2.1/6,  Sg  2.4/1-2,  Sg  4.2/2 
lAC  4/2-5,  4/7,  4/9,  4/10,  5/15,  Cy  2.1/7,  Cy  2.1/10 
Immunoaffinity  chromatography  4/15,  5/15,  6/7,  6/11,  8/10,  Cy  1.1/2, 
Cy  1.1/8,  Cy  1.1/11,  Cy  1.1/16,  Cy  2.1/5,  Cy  2.1/9 
Immunoassay  4/15,  5/1,  5/15,  6/4-6,  6/11,  8/10,  Cy  2.1/2,  Sg  2.2/1, 
Sg  2.3/1 
Immunogram  5/6,  5/15 
Infrared  5/15,  6/13,  8/9 
Injection site  4/15,  7/17-19,  7/30,  7/32 
Internal  standard  5/10,  5/13,  5/21,  5/22,  6/8,  6/9,  6/12 
Ipronidazole  2/3,  9/1,  9/49 
Isometamidium  2/3 
Ivermectin  2/3,  2/6,  4/14,  6/11,  7/1,  7/15,  7/35-36,  9/1,  9/51, 
Cy  4.4/1-5, 
Kidney  2/5-6,  4/15,  6/8,  7/3-7,  7/9-10,  7/12-14,  7/16-20,  7/22,  7/25, 
7/27,  7/30,  7/34-38,  9/19,  Cy  1.1/10,  Cy  1.2/8,  Cy  1.6/2-7, 
Cy  1.7/5,Cy 2.2/1,  Cy  2.2/6,  Cy  3.1/2,  Cy  3.1/3,  Cy  3.2/7-8, 
Cy  3.2/11,  Cy  3.3/1-5,  Cy  3.4/1,  Cy  3.4/5-6,  Cy  3.8/1,  Cy  3.8/3, 
Cy  4.4/1,  Cy  4.4/3,  Cy  4.5/1-6,  Cy  4.6/1-6,  Sg  2.4/1,  Sg  2.4/4-6, 
Sg  3.6/1-2,  Sg  3.6/6,  Sg  4.1/1-2,  Sg  4.1/4,  Sg  4.1/6,  Sg  4.2/1-2, 
Sg  4.2/6,  Sg  4.3/1-2,  Sg  4.3/6-7,  Sg  4.3/10 
Kit(s)  6/1,  6/2,  8/10,  8/11,  Cy  1.1/8,  Cy  2.1/9,  Cy  3.1/4,  Cy  4.3/4, 
Sg  2.2/1-3,  Sg  2.3/1,  Sg  3.2/3 
Lasalocid  2/3,  9/1,  9/52,  Cy  4.2/1-5, 
Levamisole  2/3,  2/6,  4/14,  9/1,  9/53,  Sg  4.5/1-6 
Liquid  chromatography  4/15,  5/1,  5/15,  6/13,  7/2,  7/31,  Cy  1.1/11-12, 
Cy  1.7/1,  Cy  2.1/1,  Cy  3.2/7,  Cy  3.3/2,  Cy  3.4/1,  Cy  3.7/1-2, 
Cy  3.9/1-2,  Cy  4.6/2,  Sg  1.3/1,  3.4/1,  Sg  4.1/2,  Sg  4.3/2 
Low  resolution mass  spectrometry  5/15 
13/3 Lower  limit of  detection  4/15,  7/30,  8/11,  Sg  2.3/1 
Mass  spectrometry  4/15,  5/1,  5/15,  Cy  1.1/2,  Cy  1.1/12,  Cy  1.1/14, 
Cy  1.2/6,  Cy  1.2/10-11,  Cy  1.2/14,  Cy  1.4/1-2,  Cy  1.5/1-2,  Cy  1.8/1, 
Cy  1.9/1,  Cy  2.1/2,  Cy  2.2/1,  Cy  2.3/1,  Cy  3.1/1-5,  Cy  3.5/1-2, 
Cy  3.5/6,  Cy  3.6/1-2,  Cy  4.3/2,  Cy  4.3/5,  Sg  1.2/6,  Sg  2.1/1, 
Sg  2.4/1,  Sg  4.5/1,  Sg  4.5/4 
Maximum  Residue  Limit  5/4-7,  5/9,  Cy  3.1/6,  Cy  3.3/5 
Measurement  and  Testing  Programme  6/7,  8/1,  Cy  1.5/6,  Cy  2.3/2,  Sg  3.3/6 
Meat  2/5-6,  3/1,  3/3,  6/1,  6/3-4,  6/8,  6/13,  7/22,  7/24,  7/29,  7/32, 
7/37-38,  7/40,  8/10-11,  10/1-6,  Cy  1.1/1-2,  Cy  1.1/9,  Cy  1.2/5, 
Cy  1.2/9,  Cy  1.2/11-12,  Cy  1.4/3,  Cy  1.5/3,  Cy  1.6/1,  Cy  1.6/4, 
Cy  1.7/1,  Cy  1.7/4,  Cy  1.9/1,  Cy  1.9/3-4,  Cy  2.1/1,  Cy  2.1/4, 
Cy  2.2/3,  Cy  2.3/1,  Cy  3.1/1-3,  Cy  3.2/7,  Cy  3.2/10,  Cy  3.3/2-3, 
Cy  3.4/1,  Cy  3.4/4,  Cy  3.5/1-2,  Cy  3.5/4,  Cy  3.5/7,  Cy  3.6/1, 
Cy  3.6/3-4,  Cy  3.6/6,  Cy  3.7/1,  Cy  3.8/1,  Cy  3.8/3,  Cy  3.9/1-4, 
Cy  3.9/5,  Cy  4.1/1,  Cy  4.1/3,  Cy  4.2/3,  Cy  4.3/3,  Cy  4.4/3,  Cy  4.5/1, 
Cy  4.6/1,  Cy  4.6/4,  Sg  1.3/1,  Sg  1.3/4-5,  Sg  1.4/1-6,  Sg  2.1/1-3, 
Sg  2.4/1,  Sg  2.4/4-6,  Sg  3.1/7-8,  Sg  3.1/11,  Sg  3.1/13-14,  Sg  3.2/1-
5,  Sg  3.3/1-6,  3.4/1-5,  Sg  3.5/4,  Sg  3.6/4,  Sg  4.1/1,  Sg  4.1/4, 
Sg  4.2/4,  Sg  4.3/1-7,  Sg  4.3/10,  Sg  4.5/3 
Medroxyprogesterone  acetate  2/2,  8/10,  9/1,  9/8,  Cy  1.1/1,  Cy  1.1/8, 
Sg  1.1/1-5 
Megestrol  acetate  2/7,  4/6,  9/1,  9/9,  Cy  1.1/1,  Sg  1.1/1-5 
Melengestrol  2/7,  4/6,  9/1,  9/10,  Sg  1.1/1-5 
Member  States  2/1,  2/3,  4/1,  4/15,  5/1,  6/1,  6/4,  6/6,  7/24,  7/37,  10/1, 
10/2,  10/4,  10/5,  10/6 
Methyltestosterone  2/2,  8/9-10,  9/1,  9/11,  Cy  1.1/1,  Cy  1.1/8,  Cy  1.1/16, 
Cy  1.2/1,  Cy  1.2/7-8,  Sg  1.1/1-2,  Sg  1.1/4,  Sg  1.2/6-7,  Sg  1.2/12 
Metronidazole  2/3,  8/9,  9/1,  9/54 
Milk  2/5-6,  4/15,  6/3-4,  6/8,  6/10,  7/3-4,  7/7-8,  7/11,  7/14,  7/24-26, 
7/28-29,  7/31-33,  7/35,  9/20,  9/22,  9/24,  10/1,  Cy  1.9/3-4,  Cy 
3.2/7,  Cy  3.3/2,  Cy  3.4/1,  Cy  3.5/1-7,  Cy  3.6/1,  Cy  3.6/6,  Cy  3.7/1-
6,  Cy  3.8/1-5,  Cy  3.9/1-5,  Cy  4.1/1-5,  Cy  4.2/3,  Cy  4.4/1,  Cy  4.4/3, 
Sg  1.4/4-6,  Sg  2.2/1,  Sg  2.2/3,  Sg  3.3/1-6,  3.4/4,  Sg  4.5/3 
Monensin  2/3,  9/1,  9/55,  Sg  4.3/7-8 
Monitoring  7/8,  7/18,  7/23,  7/36,  10/1,  Cy  1.2/11,  Cy  2.2/5,  Cy  2.3/3, 
Cy  3.1/1,  Cy  3.1/2,  Cy  3.2/7,  Cy  3.3/2,  Cy  3.4/1,  Cy  3.9/1,  Cy  4.1/1, 
Cy  4.3/2,  Sg  1.2/10,  Sg  2.1/3,  Sg  2.1/5,  Sg  2.4/3,  Sg  2.4/6, 
Sg  3.1/11,  3.4/1,  Sg  4.5/1 
MRL  2/2-5,  5/21,  7/24,  7/35,  8/1,  Cy  1.1/1,  Cy  1.2/1,  Cy  1.6/1,  Cy  1.7/1, 
Cy  1.9/1,  Cy  3.1/6,  Cy  3.3/5,  Cy  4.1/1,  Cy  4.4/1,  Sg  1.4/1,  Sg  3.2/1, 
Sg  3.4/1,  Sg  4.5/1-3 
Multiresidue  6/1,  6/7,  6/12,  7/40,  Cy  1.2/1,  Sg  4.1/1 
Muscle  2/5-6,  4/15,  6/4,  6/8,  7/3-7,  7/9-10,  7/12-14,  7/16-19,  7/22, 
7/24-25,  7/27,  7/30-32,  7/34-38,  8/2,  9/4-5,  9/7,  9/12-16,  9/20, 
9/22,  9/32,  9/41,  9/62,  Cy  1.1/1-2,  Cy  1.1/4,  Cy  1.1/10,  Cy  1.4/1-2, 
Cy  1.6/2-9,  Cy  1.7/2-3,  Cy  1.7/5,  Cy  1.7/7-9,  Cy  1.9/1,  Cy  2.1/6, 
Cy  2.2/1,  Cy  3.1/3,  Cy  3.2/7,  Cy  3.2/11,  Cy  3.4/1,  Cy  3.4/6, 
Cy  3.5/2,  Cy  3.5/5,  Cy  3.5/8,  Cy  3.6/4,  Cy  3.6/6,  Cy  3.8/1,  Cy  3.8/3, 
Cy  4.2/1,  Cy  4.2/3,  Cy  4.4/1,  Cy  4.4/3,  Sg  1.1/1,  Sg  1.4/1,  Sg  3.3/1, 
Sg  3.3/4,  Sg  3.3/6,  Sg  3.5/1-2,  Sg  3.5/6,  Sg  3.6/1-2,  Sg  3.6/6 
Narasin  2/3,  9/1,  9/56,  Sg  4.3/7-8 
Neomycin  7/29,  8/4,  9/1,  9/27,  Sg  3.6/1-5 
Nitrofurans  2/2,  2/6,  3/2,  4/13,  5/20,  6/3,  6/4,  Cy  3.9/1-2,  Cy  3.9/5, 
Sg  3.4/1-2,  3.4/5 
Nitrofurazone  2/2,  9/1,  9/28,  Cy  3.9/1-2,  Cy  3.9/5,  Sg  3.4/2 
Nitroxynil  4/14,  9/1,  9/57 
13/4 Nortestosterone  2/2,  2/7,  3/2,  4/3,  6/2,  7/1,  7/15-16,  7/20-23,  8/4,  8/10, 
8/11,  9/1,  9/12,  Cy  1.1/1-2,  Cy  1.1/8,  Cy  1.1/10,  Cy  1.1/16, 
Cy  1.2/1,  Cy  1.2/7,  Sg  1.1/1-2,  Sg  1.1/4,  Sg  1.2/6-7,  Sg  1.2/12 
NRL  3/1,  5/17,  10/5 
Oestradiol  2/2,  2/7,  6/2,  7/1,  7/2-5,  7/7,  7/12,  7/14,  7/17,  7/22,  8/9-11, 
9/1,  9/17,  10/6,  Cy  1.1/1,  Cy  1.1/5,  Cy  1.1/8,  Cy  1.1/13,  Cy  1.2/1, 
Cy  1.2/7-8,  Sg  1.1/1-2,  Sg  1.1/4,  Sg  1.2/6-7,  Sg  1.2/12 
Oxfendazole  2/3,  2/6,  4/14,  7/1,  7/15,  7/34,  7/35,  9/1,  9/45,  9/58, 
Cy  4.1/1-2,  Cy  4.1/5 
Oxytetracyline  2/2,  9/1,  9/30,  Cy  3.8/4-5 
Penicillin  6/2,  7/1,  7/15,  7/28-31,  8/10,  9/21,  Sg  3.1/8-9,  Sg  3.1/13 
Pharmacokinetics  7/28 
Plasma  2/7,  4/15,  6/8,  6/10,  7/5,  7/17,  7/30,  7/37-38,  7/40,  8/11, 
Cy  1.1/1,  Cy  1.1/16,  Cy  1.6/1,  Cy  1.6/10,  Cy  1.7/10,  Cy  1.9/3-4, 
Cy  2.1/2,  Cy  2.1/10,  Cy  2.2/1-6,  Sg  1.1/1,  Sg  1.4/4-6 
Precision  5/3-7,  5/20,  6/5,  Cy  1.1/4,  Cy  1.1/15,  Cy  1.6/9,  Cy  1.9/4, 
Cy  2.2/5,  Cy  3.5/7,  Cy  3.6/6,  Cy  3.7/5,  Cy  3.9/5,  Cy  4.1/5,  Cy  4.2/5, 
Cy  4.4/5,  Sg  1.3/5,  Sg  1.4/6,  Sg  2.2/3,  Sg  3.3/6,  Sg  3.5/5,  Sg  3.6/6, 
Sg  4.5/6 
Pregnant  2/7,  7/3-9,  7/10,  7/12,  7/13,  7/21,  7/34,  9/12 
Progesterone  2/2,  6/2,  7/1-3,  7/5,  7/6,  7/8,  7/10-11,  8/9-11,  9/1,  9/18, 
10/6,  Cy  1.1/8,  Cy  1.2/1,  Cy  1.2/7 
Propionylpromazine  2/3,  9/1,  9/59,  Cy  4.6/3,  Cy  4.6/5-6,  Sg  4.1/3, 
Sg  4.1/6 
Quality control  5/8,  5/10,  5/17,  5/21,  6/12,  8/1,  8/12,  Sg  3.5/6 
Ractopamine  2/3,  9/1,  9/60,  Cy  2.3/1-6,  Sg  2.1/1-5,  Sg  2.4/1-5 
Radioimmunoassay  4/15,  6/13,  7/8,  7/17,  7/18,  7/20,  7/23,  7/40,  Cy  1.2/10, 
Cy  1.5/1,  Cy  1.6/1,  Cy  1.6/7,  Cy  1.7/1,  Cy  1.7/8,  Cy  3.5/2,  Cy  3.6/1, 
Sg  1.3/1,  Sg  1.3/4,  Sg  3.3/1,  Sg  3.3/5 
Reference  Laboratories  3/1,  4/1,  5/17,  6/1,  10/2-5,  Cy  1.7/10,  Sg  1.3/6 
Reference  Material  5/2,  5/3,  5/10,  8/8,  Cy  3.4/1,  Cy  3.4/5-6,  Cy  3.6/6 
RIA  4/2-7,  4/9,  4/10,  4/15,  6/2,  6/6,  6/10-11,  7/20,  8/5-7,  8/10, 
Cy  1.6/1-10,  Cy  1.7/1-10,  Cy  3.6/6,  Sg  1.3/1-6,  Sg  2.2/2,  Sg  2.3/1, 
Sg  3.3/1-2,  Sg  3.3/5-6 
RIKILT  3/4,  5/1,  6/6,  8/4,  8/8,  9/1,  9/12,  Cy  2.1/9,  Cy  2.3/2,  Cy  3.9/1, 
Cy  3.9/4-5,  Sg  3.2/5,  3.4/1-2,  Sg  4.3/1,  Sg  4.3/6-7 
RIVM  3/1,  3/3-4,  4/15,  5/1,  6/6-7,  6/12,  8/4-8,  8/12,  9/4-5,  9/7,  9/42, 
Cy  1.1/3,  Cy  1.1/5,  Cy  1.1/8-16,  Cy  2.1/4,  Cy  2.1/6,  Cy  2.1/9, 
Cy  3.5/2,  Cy  3.5/7,  Cy  3.6/6,  Cy  4.6/3,  Sg  4.1/3 
RMs  5/23,  6/7,  6/12,  7/32,  8/1-8,  9/1,  Cy  1.1/3,  Cy  1.7/10,  Cy  1.9/4, 
Cy  2.3/7,  Cy  3.4/6,  Cy  3.5/7,  Cy  3.6/6,  Sg  1.1/5,  Sg  1.2/11, 
Sg  1.3/6,  Sg  1.4/6,  Sg  2.1/6,  Sg  2.2/3,  Sg  2.3/5,  Sg  2.4/6 
Ronidazole  2/3,  2/6,  9/1,  9/61,  3.4/1-2,  3.4/5 
Routine  method  2/7,  Sg  1.1/1,  Sg  1.2/6,  Sg  4.3/7 
Salbutamol  2/3,  4/9,  6/3,  7/15,  7/37,  7/39,  8/4,  8/10-11,  9/1,  9/62, 
Cy  1.1/8,  Cy  2.1/1-2,  Cy  2.1/6-9,  Cy  2.3/1-2,  Cy  2.3/6,  Sg  2.1/1-2, 
Sg  2.1/5,  Sg  2.2/1-3,  Sg  2.3/1-5,  Sg  2.4/1-4 
Salinomycin  2/3,  9/1,  9/56,  9/63,  Sg  4.3/7-8 
Serum  4/15,  6/8,  6/10,  7/30,  8/11,  Cy  1.1/16,  Cy  1.6/10,  Cy  1.7/10, 
Cy  2.1/2,Cy 2.1/10,  Cy  4.4/1,  Sg  2.2/1,  Sg  2.3/1-2 
Spiramycin  2/3,  2/5,  9/31,  Sg  3.1/7 
Standard  5/2,  5/4,  5/6,  5/9,  5/10,  5/11,  5/12,  5/13,  5/14,  5/18,  5/20, 
5/21,  5/22,  5/23,  6/3,  6/8,  6/9,  6/12,  7/5,  7/28,  8/1,  8/5,  8/6,  8/7 
Stilbenes  2/1,  2/7,  3/2,  4/2,  6/2,  6/6,  7/1,  7/15,  7/19,  8/5-7,  8/10, 
10/4,  10/6,  Cy  1.1/2,  Cy  1.2/10-14,  Cy  1.7/1-5,  Cy  1.7/10,  Sg  1.2/10, 
Sg  1.3/1-6 
Sulphadimidine  2/2,  6/2,  7/1,  7/15,  7/24-27,  8/10-11,  9/1,  9/32, 
13/5 Cy  3.1/2-6,  Cy  3.2/7-8,  Cy  3.2/10-12,  Cy  3.3/1-5,  Cy  3.4/1-6, 
Sg  3.1/8-9,  Sg  3.1/13,  Sg  3.2/5 
Sulphaquinoxaline  2/2,  9/1,  9/33,  Cy  3.1/3,  Cy  3.2/12,  Sg  3.2/5 
Tapazole  2/2,  9/1,  9/13,  Cy  1.9/1,  Sg  1.4/1 
Testosterone  2/2,  2/7,  6/2,  7/1-3,  7/5-6,  7/7,  7/9-10,  7/20,  8/9,  8/10-11, 
9/1,  9/3,  9/19,  10/6,  Cy  1.1/1-2,  Cy  1.1/5,  Cy  1.1/8,  Cy  1.2/1-2, 
Cy  1.2/6-7,  Sg  1.1/1-2,  Sg  1.1/4,  Sg  1.2/6-7,  Sg  1.2/12 
Thiabendazole  2/3-4,  4/14,  7/1,  7/15,  7/34-35,  9/1,  9/64,  Cy  4.1/1-2, 
Cy  4.1/5 
Thiouracil  2/2,  9/1,  9/14,  Cy  1.9/1,  Sg  1.4/1-2 
Trenbolone  2/2,  2/7,  3/2,  4/4,  6/2,  7/1,  7/15-18,  8/4,  8/10-11,  9/1,  9/15, 
Cy  1.1/1-2,  Cy  1.1/8,  Cy  1.1/11,  Cy  1.1/13,  Cy  1.1/16,  Cy  1.2/7, 
Cy  1.2/9,  Cy  1.4/1-6,  Cy  1.5/5,  Cy  2.1/1,  Sg  1.1/1-2,  Sg  1.1/4, 
Sg  1.2/6-7,  Sg  1.2/12 
Triclabendazole  2/3,  7/1,  7/15,  7/35,  9/1,  9/65 
Trimethoprim  2/3,  2/5,  6/4,  7/26,  8/9,  9/1,  9/34 
Tylosin  2/3,  8/11,  9/1,  9/35,  Sg  3.1/7 
Urine  2/7,  4/15,  6/8,  6/10,  6/12-13,  7/8,  7/15-23,  7/27,  7/30,  7/36-40, 
8/2,  8/5-7,  8/10-11,  9/4-5,  9/7-8,  9/12-16,  9/19,  9/32,  9/41-42, 
9/62,  Cy  1.1/1-2,  Cy  1.1/10,  Cy  1.1/12,  Cy  1.1/14,  Cy  1.1/16, 
Cy  1.4/1,  Cy  1.6/1-2,  Cy  1.6/4-5,  Cy  1.6/7,  Cy  1.6/9-10,  Cy  1.7/1-2, 
Cy  1.7/5,  Cy  1.7/8 Cy  1.7/10,  Cy  1.8/1,  Cy  1.8/3,  Cy  1.8/5,  Cy  1.9/3, 
Cy  2.1/1-2,  Cy  2.1/4-5,  Cy  2.1/7-8,  Cy  2.1/10,  Cy  2.2/1,  Cy  2.3/1-4, 
Cy  2.3/7,  Cy  3.5/1-8,  Sg  1.1/1,  Sg  1.2/6-7,  Sg  1.2/9-11,  Sg  1.3/1, 
Sg  1.3/4,  Sg  1.3/6,  Sg  1.4/4,  Sg  2.1/1,  Sg  2.1/3,  Sg  2.1/6,  Sg  2.2/1-
3,  Sg  2.3/1-6,  Sg  2.4/1,  Sg  3.2/1,  Sg  4.1/1 
USDA  5/17,  5/21,  5/23,  7/25,  7/28,  11/1,  Sg  3.2/1 
VRL  3/4,  8/4,  Cy  3.2/12 
Withdrawal  time  7/24,  7/27,  7/34,  7/36,  7/38 
Xenobiotic  2/7,  7/1,  7/15-16,  Cy  1.1/1,  Cy  1.2/1,  Cy  1.8/1,  Sg  1.1/1, 
Sg  1.2/6,  Sg  1.2/11 
Xylazine  9/1,  9/66,  Cy  4.5/3,  Cy  4.5/6,  Cy  4.6/3,  Cy  4.6/5-6,  Sg  4.1/3, 
Sg  4.1/6 
Zeranol  2/2,  4/5,  7/18,  8/4,  8/8,  9/1,  9/16,  Cy  1.1/13,  Cy  1.5/1-2, 
Cy  1.6/1,  Cy  1.6/8,  Sg  1.2/12 
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C  0  R  D  I  S 
consult 
CORDIS 
The Community Research 
and Development 
Information Service 
CORDIS is an on-line service set up under the VALUE programme to give quick and easy 
access to information on European Community research programmes. 
The CORDIS service is at present offered free-of-charge by the European Commission Host 
Organisation (ECHO). A menu-based interface makes CORDIS simple to use even if you are 
not familiar with on-line information services. For experienced users, the standard Common 
Command Language (CCL) method of extracting data is also available. 
CORDIS comprises eight databases: 
RTD-News: short announcements of Calls for Proposals, publications and events in the 
R&D field 
RTD-Programmes: details of all EC programmes in R&D and related areas 
RTD-Projects: containing 14,000 entries on individual activities within the programmes 
RTD-Publications: bibliographic details and summaries of more than 50,000 scientific 
and technical publications arising from EC activities 
RTD-Results: provides valuable leads and hot tips on prototypes ready for industrial 
exploitation and areas of research ripe for collaboration 
RTD-Comdocuments: details of  Commission communications to  the Council of  Ministers 
and the European Parliament on research topics 
RTD-Acronyms: explains the thousands of acronyms and abbreviations current in the 
Community research area 
RTD-Partners: helps bring organisations and research centres together  for collaboration 
on project proposals, exploitation of results, or marketing agreements. 
I"  For more information and CORDIS registration forms, contact 
ECHO Customer Service 
CORDIS Operations 
BP 23.73 
L-1 02J Luxembourg 
Tel.: (+352) 34 9811  Fax: (+J52} 34 9812 34 
If you are already an ECHO user, please indicate your customer number. European Communities - Commission 
EUR 15127- Residues in food-producing animals and their 
products: 
Reference materials and methods - 2nd edition 
R. J.  Heitzman 
Luxembourg: Office for Official Publications of the European Communities 
1994- Nos, 512 pp, num. tab., fig- 21.0  x  29.7 em 
ISBN 0-632-03786-5 
Food quality, especially public concern about residues in meat, is one of 
the important issues in Europe. This is the first revision of a book whose 
purpose is to bring together and update the activities in residues of 
veterinary drugs within the Community. The increasing vigilance and 
control of residues of veterinary drugs in farm animals and their primary 
products relies on effective control of residues. This is only made 
possible by having adequate technical resources to carry out relevant 
legislation. The analytical methodology used must have an acceptable 
quality assurance supported by good quality control criteria, sufficient 
reference materials and technical data. 
This book addresses each of these needs in detail. There is a summary of 
relevant EEC legislation including a selection of Maximum Residue Limits 
(MRLs). The methods used in each Member State for the examination of 
residues of a large number of drugs is summarised and a selection of the 
methods are described in detail. There is supporting information on 
residues and chemical/physical data of the most important veterinary drugs. 
Also one section of the book covers quality assurance and gives the 
criteria for the methods to be used in routine analysis of residues. VETERINARY 
DRUG 
RESIDUES 
ISBN  0-632-03786-5 
Ill I I 
9  780632 037865  > 
Veterinary Drug Residues is recognised 
as the standard reference manual for 
analytical residue technology and has 
become an essential resource for all 
testing laboratories involved in the 
international meat trade. 
The second edition brings together the 
current rapid developments and 
activities il1 residues of veterinary drugs 
within the European Community. 
Legislation is summarised and there is 
information on the Reference 
Laboratories, the maximum residues 
limits (MRL) and the criteria for the 
methods to be used for routine analysis 
of residues by Member States and other 
countries wishing to export meat to the 
EC. Current examination techniques and 
the analytical methods used in Member 
States are described in detail. Quality 
assurance in the laboratory is described 
and supporting information on residues 
and chemical/physical data of the most 
important veterinary drugs is also 
included. 
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